doi,PMID,section,ITC num,Ind studies num,questions,reviewer 1,reviewer 2,decision,identical,Notes reviewer 1,Notes reviewer 2,reviewer
10.1111/j.1743-7563.2011.01400.x,21585706,general_information,NA,NA,Medical Condition of Interest Name,non-small cell lung cancer,non-squamous non-small cell lung cancer,XXXX,FALSE,NA,NA,NA
10.1111/j.1743-7563.2011.01400.x,21585706,general_information,NA,NA,Countries of first author affiliations,NA,NA,taiwan,TRUE,NA,NA,NA
10.1111/j.1743-7563.2011.01400.x,21585706,general_information,NA,NA,Countries of last author affiliations,NA,NA,switzerland,TRUE,NA,NA,NA
10.1111/j.1743-7563.2011.01400.x,21585706,general_information,NA,NA,"Positions of study investigators (for any authors of the article, any that applies)",NA,NA,"Academic, Pharmaceutical Industry, Private Data Analysis Company",TRUE,NA,NA,NA
10.1111/j.1743-7563.2011.01400.x,21585706,general_information,NA,NA,"At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company",NA,NA,Yes,TRUE,NA,NA,NA
10.1111/j.1743-7563.2011.01400.x,21585706,general_information,NA,NA,Mentioned sources of funding,NA,NA,Pharmaceutical Industry,TRUE,NA,NA,NA
10.1111/j.1743-7563.2011.01400.x,21585706,general_information,NA,NA,"Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article",NA,NA,Yes,TRUE,NA,NA,NA
10.1111/j.1743-7563.2011.01400.x,21585706,general_information,NA,NA,Mention of a systematic review to find the studies to compare treatments of interest,NA,NA,Yes,TRUE,NA,NA,NA
10.1111/j.1743-7563.2011.01400.x,21585706,study_information,NA,1,Patient-level data used,NA,NA,Yes,TRUE,NA,NA,NA
10.1111/j.1743-7563.2011.01400.x,21585706,study_information,NA,1,Clinical Trial,NA,NA,Yes,TRUE,NA,NA,NA
10.1111/j.1743-7563.2011.01400.x,21585706,study_information,NA,1,NCT (only for clinical trial registered on clinicaltrials.gov),NA,NA,NCT00451906,TRUE,NA,NA,NA
10.1111/j.1743-7563.2011.01400.x,21585706,study_information,NA,1,Country where the clinical trial/observational study was conducted (international if more than one),NA,NA,international,TRUE,NA,NA,NA
10.1111/j.1743-7563.2011.01400.x,21585706,study_information,NA,1,Phase of the clinical trial (clinical trial only),NA,NA,4,TRUE,NA,NA,NA
10.1111/j.1743-7563.2011.01400.x,21585706,study_information,NA,1,Number of treatment arms (clinical trial only),NA,NA,1,TRUE,NA,NA,NA
10.1111/j.1743-7563.2011.01400.x,21585706,study_information,NA,2,Patient-level data used,NA,NA,No,TRUE,NA,NA,NA
10.1111/j.1743-7563.2011.01400.x,21585706,study_information,NA,2,Clinical Trial,NA,NA,Yes,TRUE,NA,NA,NA
10.1111/j.1743-7563.2011.01400.x,21585706,study_information,NA,2,Data source name (only if observational study or clinical trial without NCT),NA,NA,yang et al. (2010),TRUE,NA,NA,NA
10.1111/j.1743-7563.2011.01400.x,21585706,study_information,NA,2,Country where the clinical trial/observational study was conducted (international if more than one),NA,international,XXXX,FALSE,NA,NA,NA
10.1111/j.1743-7563.2011.01400.x,21585706,study_information,NA,2,Phase of the clinical trial (clinical trial only),NA,NA,3,TRUE,NA,NA,NA
10.1111/j.1743-7563.2011.01400.x,21585706,study_information,NA,2,Number of treatment arms (clinical trial only),NA,NA,2 or more,TRUE,NA,NA,NA
10.1111/j.1743-7563.2011.01400.x,21585706,methodology,1,NA,Treatment name 1,bevacizumab + cisplatin,bevacizumab + cisplatin-based chemotherapy,bevacizumab + cisplatin,FALSE,Median difference calculted from the 2 point estimates reported,"Is this a MAIC ? (weights has not been calculated)

Method : A matching algorithm was developed whereby 1000 samples of the pre-matched analysis set of the SAiL data were selected that resulted in equal distributions of the ECOG PS and gender-matching variables selected. A distribution of survival outcomes was derived by calculating the median PFS estimate from each of the 1000 matched sets. The mean of this distribution provided the PFS point estimates, while a 95% CI was defined by the 2.5 and 97.5 percentiles.

HR has not been calculated
",NA
10.1111/j.1743-7563.2011.01400.x,21585706,methodology,1,NA,Study 'number(s)' for treatment 1,NA,NA,1,TRUE,NA,NA,NA
10.1111/j.1743-7563.2011.01400.x,21585706,methodology,1,NA,Treatment name 2,NA,NA,pemetrexed + cisplatin,TRUE,NA,NA,NA
10.1111/j.1743-7563.2011.01400.x,21585706,methodology,1,NA,Study 'number(s)' for treatment 2,NA,NA,2,TRUE,NA,NA,NA
10.1111/j.1743-7563.2011.01400.x,21585706,methodology,1,NA,Type of population-adjusted indirect comparisons performed,"Other kind of ""Matching-Adjusted Indirect Comparison""",MAIC,"Other kind of ""Matching-Adjusted Indirect Comparison""",FALSE,NA,NA,NA
10.1111/j.1743-7563.2011.01400.x,21585706,methodology,1,NA,Anchored comparison?,Yes,No,No,FALSE,NA,NA,NA
10.1111/j.1743-7563.2011.01400.x,21585706,methodology,1,NA,Form of the indirect comparison,NA,NA,Simple (ie treatments effects extracted from two studies),TRUE,NA,NA,NA
10.1111/j.1743-7563.2011.01400.x,21585706,methodology,1,NA,Definition of a single primary outcome for the indirect comparison,Yes,"No primary outcome defined, or multiple primary outcomes without any clear distinction between them",Yes,FALSE,NA,NA,NA
10.1111/j.1743-7563.2011.01400.x,21585706,methodology,1,NA,Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined),NA,NA,progression-free survival,TRUE,NA,NA,NA
10.1111/j.1743-7563.2011.01400.x,21585706,methodology,1,NA,Primary outcome: variable type,NA,NA,Time-to-event,TRUE,NA,NA,NA
10.1111/j.1743-7563.2011.01400.x,21585706,methodology,1,NA,Justification for selecting variables to be included in the adjustment model (in the main text),"Nothing mentioned, not reported",Statistical imbalanced between treatment groups (independently of the status of prognostic/effect modifier),Statistical imbalanced between treatment groups (independently of the status of prognostic/effect modifier),FALSE,NA,NA,NA
10.1111/j.1743-7563.2011.01400.x,21585706,methodology,1,NA,Inclusion of prognostic factors in the adjustment/matching model,NA,NA,Yes,TRUE,NA,NA,NA
10.1111/j.1743-7563.2011.01400.x,21585706,methodology,1,NA,Inclusion of treatment-effect modifiers in the adjustment/matching model,NA,NA,No discussion (in the main text) of the status of treatment-effect modifiers of the variables,TRUE,NA,NA,NA
10.1111/j.1743-7563.2011.01400.x,21585706,methodology,1,NA,"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)",NA,No,No,FALSE,NA,NA,NA
10.1111/j.1743-7563.2011.01400.x,21585706,methodology,1,NA,Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale),NA,NA,No,TRUE,NA,NA,NA
10.1111/j.1743-7563.2011.01400.x,21585706,results,1,NA,Sample size of the population of interest in the non IPD treatment arm,NA,NA,67,TRUE,NA,NA,NA
10.1111/j.1743-7563.2011.01400.x,21585706,results,1,NA,Initial sample size of the population of interest in the IPD treatment arm,NA,NA,72,TRUE,NA,NA,NA
10.1111/j.1743-7563.2011.01400.x,21585706,results,1,NA,"Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC",NA,NA,46,TRUE,NA,NA,NA
10.1111/j.1743-7563.2011.01400.x,21585706,results,1,NA,Reporting of a weights' distribution evaluation (MAIC),NA,NA,Not mentioned,TRUE,NA,NA,NA
10.1111/j.1743-7563.2011.01400.x,21585706,results,1,NA,Reporting of the list of the covariates adjusted for/matched on,NA,NA,Yes,TRUE,NA,NA,NA
10.1111/j.1743-7563.2011.01400.x,21585706,results,1,NA,Number of covariates adjusted for/matched on,NA,NA,2,TRUE,NA,NA,NA
10.1111/j.1743-7563.2011.01400.x,21585706,results,1,NA,Covariates adjusted for/matched on in the indirect comparison,NA,NA,"Sex, Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...)",TRUE,NA,NA,NA
10.1111/j.1743-7563.2011.01400.x,21585706,results,1,NA,Primary outcome: treatment effect contrast,Median difference,HR has not been calculated,Median difference,FALSE,NA,NA,NA
10.1111/j.1743-7563.2011.01400.x,21585706,results,1,NA,Direction of the treatment effect contrast: IPD treatment is:,"Numerator if ratio, or left side if difference",NA,"Numerator if ratio, or left side if difference",FALSE,NA,NA,NA
10.1111/j.1743-7563.2011.01400.x,21585706,results,1,NA,Primary outcome: adjusted treatment effect,1,NA,1,FALSE,NA,NA,NA
10.1007/bf03261873,23113551,general_information,NA,NA,Medical Condition of Interest Name,NA,NA,attention-deficit/hyperactivity disorder,TRUE,NA,NA,NA
10.1007/bf03261873,23113551,general_information,NA,NA,Countries of first author affiliations,NA,NA,usa,TRUE,NA,NA,NA
10.1007/bf03261873,23113551,general_information,NA,NA,Countries of last author affiliations,NA,NA,usa,TRUE,NA,NA,NA
10.1007/bf03261873,23113551,general_information,NA,NA,"Positions of study investigators (for any authors of the article, any that applies)",NA,NA,"Pharmaceutical Industry, Private Data Analysis Company",TRUE,NA,NA,NA
10.1007/bf03261873,23113551,general_information,NA,NA,"At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company",NA,NA,Yes,TRUE,NA,NA,NA
10.1007/bf03261873,23113551,general_information,NA,NA,Mentioned sources of funding,NA,NA,Pharmaceutical Industry,TRUE,NA,NA,NA
10.1007/bf03261873,23113551,general_information,NA,NA,"Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article",NA,NA,Yes,TRUE,NA,NA,NA
10.1007/bf03261873,23113551,general_information,NA,NA,Mention of a systematic review to find the studies to compare treatments of interest,NA,NA,Yes,TRUE,NA,NA,NA
10.1007/bf03261873,23113551,study_information,NA,1,Patient-level data used,NA,NA,Yes,TRUE,NA,NA,NA
10.1007/bf03261873,23113551,study_information,NA,1,Clinical Trial,NA,NA,Yes,TRUE,NA,NA,NA
10.1007/bf03261873,23113551,study_information,NA,1,NCT (only for clinical trial registered on clinicaltrials.gov),NA,NA,NCT00152009,TRUE,NA,NA,NA
10.1007/bf03261873,23113551,study_information,NA,1,Phase of the clinical trial (clinical trial only),NA,NA,3,TRUE,NA,NA,NA
10.1007/bf03261873,23113551,study_information,NA,1,Number of treatment arms (clinical trial only),NA,NA,2 or more,TRUE,NA,NA,NA
10.1007/bf03261873,23113551,study_information,NA,1,Country where the clinical trial/observational study was conducted (international if more than one),unknown,NA,unknown,FALSE,NA,NA,NA
10.1007/bf03261873,23113551,study_information,NA,2,Patient-level data used,NA,NA,Yes,TRUE,NA,NA,NA
10.1007/bf03261873,23113551,study_information,NA,2,Clinical Trial,NA,NA,Yes,TRUE,NA,NA,NA
10.1007/bf03261873,23113551,study_information,NA,2,NCT (only for clinical trial registered on clinicaltrials.gov),NA,NCT00150618,NCT00150618,FALSE,NA,NA,NA
10.1007/bf03261873,23113551,study_information,NA,2,Phase of the clinical trial (clinical trial only),NA,3,3,FALSE,NA,NA,NA
10.1007/bf03261873,23113551,study_information,NA,2,Number of treatment arms (clinical trial only),NA,NA,2 or more,TRUE,NA,NA,NA
10.1007/bf03261873,23113551,study_information,NA,2,Data source name (only if observational study or clinical trial without NCT),sallee et al. (2009),NA,NA,FALSE,NA,NA,NA
10.1007/bf03261873,23113551,study_information,NA,2,Country where the clinical trial/observational study was conducted (international if more than one),usa,NA,unknown,FALSE,NA,NA,NA
10.1007/bf03261873,23113551,study_information,NA,3,Patient-level data used,NA,NA,No,TRUE,NA,NA,NA
10.1007/bf03261873,23113551,study_information,NA,3,Clinical Trial,NA,NA,Yes,TRUE,NA,NA,NA
10.1007/bf03261873,23113551,study_information,NA,3,Data source name (only if observational study or clinical trial without NCT),NA,NA,michelson et al. (2001),TRUE,NA,NA,NA
10.1007/bf03261873,23113551,study_information,NA,3,Country where the clinical trial/observational study was conducted (international if more than one),NA,NA,usa,TRUE,NA,NA,NA
10.1007/bf03261873,23113551,study_information,NA,3,Number of treatment arms (clinical trial only),NA,NA,2 or more,TRUE,NA,NA,NA
10.1007/bf03261873,23113551,methodology,1,NA,Treatment name 1,NA,NA,guanfacine extended-release low dose,TRUE,"not Bucher ITC, so not anchored, but use the mean placebo efficacy which has been added to the weighting model
other = placebo effect","Guanfacine Low Dose

Cost-effectivness (economic) analysis

Adjust for placebo outcome ==> Anchored-MAIC ???
Placebo outcome = other covariate

Mean changes in the ADHD-RS-IV total score :
non IPD = -17.3
adjusted IPD = -13.6
p = 0.07",NA
10.1007/bf03261873,23113551,methodology,1,NA,Study 'number(s)' for treatment 1,NA,NA,1;2,TRUE,NA,NA,NA
10.1007/bf03261873,23113551,methodology,1,NA,Treatment name 2,NA,NA,atomoxetine,TRUE,NA,NA,NA
10.1007/bf03261873,23113551,methodology,1,NA,Study 'number(s)' for treatment 2,NA,NA,3,TRUE,NA,NA,NA
10.1007/bf03261873,23113551,methodology,1,NA,Type of population-adjusted indirect comparisons performed,NA,NA,MAIC,TRUE,NA,NA,NA
10.1007/bf03261873,23113551,methodology,1,NA,Anchored comparison?,NA,NA,No,TRUE,NA,NA,NA
10.1007/bf03261873,23113551,methodology,1,NA,Form of the indirect comparison,NA,NA,"Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate)",TRUE,NA,NA,NA
10.1007/bf03261873,23113551,methodology,1,NA,Definition of a single primary outcome for the indirect comparison,NA,NA,Yes,TRUE,NA,NA,NA
10.1007/bf03261873,23113551,methodology,1,NA,Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined),adhd-rs-iv total score,change in the adhd-rs-iv total score from baseline to end-point,change in the adhd-rs-iv total score from baseline to end-point,FALSE,NA,NA,NA
10.1007/bf03261873,23113551,methodology,1,NA,Primary outcome: variable type,NA,NA,"Continuous (count, mean, ...)",TRUE,NA,NA,NA
10.1007/bf03261873,23113551,methodology,1,NA,Justification for selecting variables to be included in the adjustment model (in the main text),NA,NA,"Nothing mentioned, not reported",TRUE,NA,NA,NA
10.1007/bf03261873,23113551,methodology,1,NA,Inclusion of prognostic factors in the adjustment/matching model,NA,NA,No discussion (in the main text) of the status of prognostic factors of the variables,TRUE,NA,NA,NA
10.1007/bf03261873,23113551,methodology,1,NA,Inclusion of treatment-effect modifiers in the adjustment/matching model,NA,NA,No discussion (in the main text) of the status of treatment-effect modifiers of the variables,TRUE,NA,NA,NA
10.1007/bf03261873,23113551,methodology,1,NA,"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)",Yes,No,Yes,FALSE,NA,NA,NA
10.1007/bf03261873,23113551,methodology,1,NA,Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale),NA,NA,No,TRUE,NA,NA,NA
10.1007/bf03261873,23113551,methodology,2,NA,Treatment name 1,NA,NA,guanfacine extended-release mid dose,TRUE,other = placebo effect,"Guanfacine Mid Dose

Cost-effectivness (economic) analysis

Adjust for placebo outcome ==> Anchored-MAIC ???
Placebo outcome = other covariate

Mean changes in the ADHD-RS-IV total score :
non IPD = -19.6 
adjusted IPD = -13.6
p = 0.02",NA
10.1007/bf03261873,23113551,methodology,2,NA,Study 'number(s)' for treatment 1,NA,NA,1;2,TRUE,NA,NA,NA
10.1007/bf03261873,23113551,methodology,2,NA,Treatment name 2,NA,NA,atomoxetine,TRUE,NA,NA,NA
10.1007/bf03261873,23113551,methodology,2,NA,Study 'number(s)' for treatment 2,NA,NA,3,TRUE,NA,NA,NA
10.1007/bf03261873,23113551,methodology,2,NA,Type of population-adjusted indirect comparisons performed,NA,NA,MAIC,TRUE,NA,NA,NA
10.1007/bf03261873,23113551,methodology,2,NA,Anchored comparison?,NA,NA,No,TRUE,NA,NA,NA
10.1007/bf03261873,23113551,methodology,2,NA,Form of the indirect comparison,NA,NA,"Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate)",TRUE,NA,NA,NA
10.1007/bf03261873,23113551,methodology,2,NA,Definition of a single primary outcome for the indirect comparison,NA,NA,Yes,TRUE,NA,NA,NA
10.1007/bf03261873,23113551,methodology,2,NA,Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined),adhd-rs-iv total score,change in the adhd-rs-iv total score from baseline to end-point,change in the adhd-rs-iv total score from baseline to end-point,FALSE,NA,NA,NA
10.1007/bf03261873,23113551,methodology,2,NA,Primary outcome: variable type,NA,NA,"Continuous (count, mean, ...)",TRUE,NA,NA,NA
10.1007/bf03261873,23113551,methodology,2,NA,Justification for selecting variables to be included in the adjustment model (in the main text),NA,NA,"Nothing mentioned, not reported",TRUE,NA,NA,NA
10.1007/bf03261873,23113551,methodology,2,NA,Inclusion of prognostic factors in the adjustment/matching model,NA,NA,No discussion (in the main text) of the status of prognostic factors of the variables,TRUE,NA,NA,NA
10.1007/bf03261873,23113551,methodology,2,NA,Inclusion of treatment-effect modifiers in the adjustment/matching model,NA,NA,No discussion (in the main text) of the status of treatment-effect modifiers of the variables,TRUE,NA,NA,NA
10.1007/bf03261873,23113551,methodology,2,NA,"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)",Yes,No,Yes,FALSE,NA,NA,NA
10.1007/bf03261873,23113551,methodology,2,NA,Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale),NA,NA,No,TRUE,NA,NA,NA
10.1007/bf03261873,23113551,methodology,3,NA,Treatment name 1,NA,NA,guanfacine extended-release high dose,TRUE,other = placebo effect,"Guanfacine High Dose

Cost-effectivness (economic) analysis

Adjust for placebo outcome ==> Anchored-MAIC ???
Placebo outcome = other covariate

Mean changes in the ADHD-RS-IV total score :
non IPD = -20.6 
adjusted IPD = -13.6
p<0.01",NA
10.1007/bf03261873,23113551,methodology,3,NA,Study 'number(s)' for treatment 1,NA,NA,1;2,TRUE,NA,NA,NA
10.1007/bf03261873,23113551,methodology,3,NA,Treatment name 2,NA,NA,atomoxetine,TRUE,NA,NA,NA
10.1007/bf03261873,23113551,methodology,3,NA,Study 'number(s)' for treatment 2,NA,NA,3,TRUE,NA,NA,NA
10.1007/bf03261873,23113551,methodology,3,NA,Type of population-adjusted indirect comparisons performed,NA,NA,MAIC,TRUE,NA,NA,NA
10.1007/bf03261873,23113551,methodology,3,NA,Anchored comparison?,NA,NA,No,TRUE,NA,NA,NA
10.1007/bf03261873,23113551,methodology,3,NA,Form of the indirect comparison,NA,NA,"Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate)",TRUE,NA,NA,NA
10.1007/bf03261873,23113551,methodology,3,NA,Definition of a single primary outcome for the indirect comparison,NA,NA,Yes,TRUE,NA,NA,NA
10.1007/bf03261873,23113551,methodology,3,NA,Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined),adhd-rs-iv total score,change in the adhd-rs-iv total score from baseline to end-point,change in the adhd-rs-iv total score from baseline to end-point,FALSE,NA,NA,NA
10.1007/bf03261873,23113551,methodology,3,NA,Primary outcome: variable type,NA,NA,"Continuous (count, mean, ...)",TRUE,NA,NA,NA
10.1007/bf03261873,23113551,methodology,3,NA,Justification for selecting variables to be included in the adjustment model (in the main text),NA,NA,"Nothing mentioned, not reported",TRUE,NA,NA,NA
10.1007/bf03261873,23113551,methodology,3,NA,Inclusion of prognostic factors in the adjustment/matching model,NA,NA,No discussion (in the main text) of the status of prognostic factors of the variables,TRUE,NA,NA,NA
10.1007/bf03261873,23113551,methodology,3,NA,Inclusion of treatment-effect modifiers in the adjustment/matching model,NA,NA,No discussion (in the main text) of the status of treatment-effect modifiers of the variables,TRUE,NA,NA,NA
10.1007/bf03261873,23113551,methodology,3,NA,"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)",Yes,No,Yes,FALSE,NA,NA,NA
10.1007/bf03261873,23113551,methodology,3,NA,Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale),NA,NA,No,TRUE,NA,NA,NA
10.1007/bf03261873,23113551,results,1,NA,Sample size of the population of interest in the non IPD treatment arm,NA,NA,84,TRUE,NA,NA,NA
10.1007/bf03261873,23113551,results,1,NA,Initial sample size of the population of interest in the IPD treatment arm,NA,NA,147,TRUE,NA,NA,NA
10.1007/bf03261873,23113551,results,1,NA,"Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC",NA,NA,49,TRUE,NA,NA,NA
10.1007/bf03261873,23113551,results,1,NA,Reporting of a weights' distribution evaluation (MAIC),NA,NA,Not mentioned,TRUE,NA,NA,NA
10.1007/bf03261873,23113551,results,1,NA,Reporting of the list of the covariates adjusted for/matched on,NA,NA,Yes,TRUE,NA,NA,NA
10.1007/bf03261873,23113551,results,1,NA,Number of covariates adjusted for/matched on,NA,NA,6,TRUE,NA,NA,NA
10.1007/bf03261873,23113551,results,1,NA,Covariates adjusted for/matched on in the indirect comparison,NA,NA,"Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Other(s)",TRUE,NA,NA,NA
10.1007/bf03261873,23113551,results,1,NA,Primary outcome: treatment effect contrast,NA,NA,Means difference,TRUE,NA,NA,NA
10.1007/bf03261873,23113551,results,1,NA,"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])",<0.001,0.07,0.07,FALSE,NA,NA,NA
10.1007/bf03261873,23113551,results,1,NA,Direction of the treatment effect contrast: IPD treatment is:,"Numerator if ratio, or left side if difference",NA,"Numerator if ratio, or left side if difference",FALSE,NA,NA,NA
10.1007/bf03261873,23113551,results,1,NA,Primary outcome: adjusted treatment effect,-6,NA,-3.7,FALSE,NA,NA,NA
10.1007/bf03261873,23113551,results,2,NA,Sample size of the population of interest in the non IPD treatment arm,NA,NA,84,TRUE,NA,NA,NA
10.1007/bf03261873,23113551,results,2,NA,Initial sample size of the population of interest in the IPD treatment arm,NA,NA,46,TRUE,NA,NA,NA
10.1007/bf03261873,23113551,results,2,NA,"Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC",NA,NA,16,TRUE,NA,NA,NA
10.1007/bf03261873,23113551,results,2,NA,Reporting of a weights' distribution evaluation (MAIC),NA,NA,Not mentioned,TRUE,NA,NA,NA
10.1007/bf03261873,23113551,results,2,NA,Reporting of the list of the covariates adjusted for/matched on,NA,NA,Yes,TRUE,NA,NA,NA
10.1007/bf03261873,23113551,results,2,NA,Number of covariates adjusted for/matched on,NA,NA,6,TRUE,NA,NA,NA
10.1007/bf03261873,23113551,results,2,NA,Covariates adjusted for/matched on in the indirect comparison,NA,NA,"Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Other(s)",TRUE,NA,NA,NA
10.1007/bf03261873,23113551,results,2,NA,Primary outcome: treatment effect contrast,NA,NA,Means difference,TRUE,NA,NA,NA
10.1007/bf03261873,23113551,results,2,NA,"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])",NA,NA,0.02,TRUE,NA,NA,NA
10.1007/bf03261873,23113551,results,2,NA,Direction of the treatment effect contrast: IPD treatment is:,"Numerator if ratio, or left side if difference",NA,"Numerator if ratio, or left side if difference",FALSE,NA,NA,NA
10.1007/bf03261873,23113551,results,2,NA,Primary outcome: adjusted treatment effect,-6,NA,-6,FALSE,NA,NA,NA
10.1007/bf03261873,23113551,results,3,NA,Sample size of the population of interest in the non IPD treatment arm,NA,NA,84,TRUE,NA,NA,NA
10.1007/bf03261873,23113551,results,3,NA,Initial sample size of the population of interest in the IPD treatment arm,NA,NA,82,TRUE,NA,NA,NA
10.1007/bf03261873,23113551,results,3,NA,"Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC",NA,NA,38,TRUE,NA,NA,NA
10.1007/bf03261873,23113551,results,3,NA,Reporting of a weights' distribution evaluation (MAIC),NA,NA,Not mentioned,TRUE,NA,NA,NA
10.1007/bf03261873,23113551,results,3,NA,Reporting of the list of the covariates adjusted for/matched on,NA,NA,Yes,TRUE,NA,NA,NA
10.1007/bf03261873,23113551,results,3,NA,Number of covariates adjusted for/matched on,NA,NA,6,TRUE,NA,NA,NA
10.1007/bf03261873,23113551,results,3,NA,Covariates adjusted for/matched on in the indirect comparison,NA,NA,"Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Other(s)",TRUE,NA,NA,NA
10.1007/bf03261873,23113551,results,3,NA,Primary outcome: treatment effect contrast,NA,NA,Means difference,TRUE,NA,NA,NA
10.1007/bf03261873,23113551,results,3,NA,"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])",0.07,<0.01,<0.01,FALSE,NA,NA,NA
10.1007/bf03261873,23113551,results,3,NA,Direction of the treatment effect contrast: IPD treatment is:,"Numerator if ratio, or left side if difference",NA,"Numerator if ratio, or left side if difference",FALSE,NA,NA,NA
10.1007/bf03261873,23113551,results,3,NA,Primary outcome: adjusted treatment effect,-3.7,NA,-7,FALSE,NA,NA,NA
10.1007/s40263-013-0102-x,23975660,general_information,NA,NA,Medical Condition of Interest Name,attention-deficit/hyperactivity disorder in children and adolescents,attention-deficit/hyperactivity disorder,attention-deficit/hyperactivity disorder in children and adolescents,FALSE,NA,NA,NA
10.1007/s40263-013-0102-x,23975660,general_information,NA,NA,Countries of first author affiliations,NA,NA,usa,TRUE,NA,NA,NA
10.1007/s40263-013-0102-x,23975660,general_information,NA,NA,Countries of last author affiliations,NA,NA,usa,TRUE,NA,NA,NA
10.1007/s40263-013-0102-x,23975660,general_information,NA,NA,"Positions of study investigators (for any authors of the article, any that applies)",NA,NA,"Academic, Pharmaceutical Industry, Private Data Analysis Company",TRUE,NA,NA,NA
10.1007/s40263-013-0102-x,23975660,general_information,NA,NA,"At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company",NA,NA,Yes,TRUE,NA,NA,NA
10.1007/s40263-013-0102-x,23975660,general_information,NA,NA,Mentioned sources of funding,NA,NA,Pharmaceutical Industry,TRUE,NA,NA,NA
10.1007/s40263-013-0102-x,23975660,general_information,NA,NA,"Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article",NA,NA,Yes,TRUE,NA,NA,NA
10.1007/s40263-013-0102-x,23975660,general_information,NA,NA,Mention of a systematic review to find the studies to compare treatments of interest,NA,NA,Yes,TRUE,NA,NA,NA
10.1007/s40263-013-0102-x,23975660,study_information,NA,1,Patient-level data used,NA,NA,Yes,TRUE,NA,NA,NA
10.1007/s40263-013-0102-x,23975660,study_information,NA,1,Clinical Trial,NA,NA,Yes,TRUE,NA,NA,NA
10.1007/s40263-013-0102-x,23975660,study_information,NA,1,NCT (only for clinical trial registered on clinicaltrials.gov),NA,NA,NCT00152009,TRUE,NA,NA,NA
10.1007/s40263-013-0102-x,23975660,study_information,NA,1,Phase of the clinical trial (clinical trial only),NA,NA,3,TRUE,NA,NA,NA
10.1007/s40263-013-0102-x,23975660,study_information,NA,1,Number of treatment arms (clinical trial only),NA,NA,2 or more,TRUE,NA,NA,NA
10.1007/s40263-013-0102-x,23975660,study_information,NA,1,Country where the clinical trial/observational study was conducted (international if more than one),unknown,NA,unknown,FALSE,NA,NA,NA
10.1007/s40263-013-0102-x,23975660,study_information,NA,2,Patient-level data used,NA,NA,Yes,TRUE,NA,NA,NA
10.1007/s40263-013-0102-x,23975660,study_information,NA,2,Clinical Trial,NA,NA,Yes,TRUE,NA,NA,NA
10.1007/s40263-013-0102-x,23975660,study_information,NA,2,NCT (only for clinical trial registered on clinicaltrials.gov),NA,NCT00150618,NCT00150618,FALSE,NA,NA,NA
10.1007/s40263-013-0102-x,23975660,study_information,NA,2,Phase of the clinical trial (clinical trial only),NA,3,3,FALSE,NA,NA,NA
10.1007/s40263-013-0102-x,23975660,study_information,NA,2,Number of treatment arms (clinical trial only),NA,NA,2 or more,TRUE,NA,NA,NA
10.1007/s40263-013-0102-x,23975660,study_information,NA,2,Data source name (only if observational study or clinical trial without NCT),sallee et al. (2009),NA,NA,FALSE,NA,NA,NA
10.1007/s40263-013-0102-x,23975660,study_information,NA,2,Country where the clinical trial/observational study was conducted (international if more than one),usa,NA,unknown,FALSE,NA,NA,NA
10.1007/s40263-013-0102-x,23975660,study_information,NA,3,Patient-level data used,NA,NA,No,TRUE,NA,NA,NA
10.1007/s40263-013-0102-x,23975660,study_information,NA,3,Clinical Trial,NA,NA,Yes,TRUE,NA,NA,NA
10.1007/s40263-013-0102-x,23975660,study_information,NA,3,Data source name (only if observational study or clinical trial without NCT),NA,NA,spencer et al. (2002),TRUE,NA,NA,NA
10.1007/s40263-013-0102-x,23975660,study_information,NA,3,Number of treatment arms (clinical trial only),NA,NA,2 or more,TRUE,NA,NA,NA
10.1007/s40263-013-0102-x,23975660,methodology,1,NA,Treatment name 1,NA,NA,guanfacine extended release,TRUE,NA,"Comparison of the total ADHD-RS-IV score, GXR 0.09â€“0.12 mg/kg/day, base case analysis

""Individual patients in the GXR trials were assigned weightings such that their  average placebo outcomes exactly matched those reported for the ATX trial.""
==> anchored-MAIC ?
==> placebo outcome = a covariate ? 3 covariates (1 total + 2 subscales) ???

weighting Method ?",NA
10.1007/s40263-013-0102-x,23975660,methodology,1,NA,Study 'number(s)' for treatment 1,NA,NA,1;2,TRUE,NA,NA,NA
10.1007/s40263-013-0102-x,23975660,methodology,1,NA,Treatment name 2,NA,NA,atomoxetine,TRUE,NA,NA,NA
10.1007/s40263-013-0102-x,23975660,methodology,1,NA,Study 'number(s)' for treatment 2,NA,NA,3,TRUE,NA,NA,NA
10.1007/s40263-013-0102-x,23975660,methodology,1,NA,Type of population-adjusted indirect comparisons performed,NA,NA,MAIC,TRUE,NA,NA,NA
10.1007/s40263-013-0102-x,23975660,methodology,1,NA,Anchored comparison?,Yes,No,Yes,FALSE,NA,NA,NA
10.1007/s40263-013-0102-x,23975660,methodology,1,NA,Form of the indirect comparison,Simple (ie treatments effects extracted from two studies),"Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate)",Simple (ie treatments effects extracted from two studies),FALSE,NA,NA,NA
10.1007/s40263-013-0102-x,23975660,methodology,1,NA,Definition of a single primary outcome for the indirect comparison,"No primary outcome defined, or multiple primary outcomes without any clear distinction between them",Yes,Yes,FALSE,NA,NA,NA
10.1007/s40263-013-0102-x,23975660,methodology,1,NA,Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined),change in adhd rating scale iv total score,the mean change from baseline in the adhd-rs-iv total score at the final on-treatment assessment prior to down-titration,the mean change from baseline in the adhd-rs-iv total score at the final on-treatment assessment prior to down-titration,FALSE,NA,NA,NA
10.1007/s40263-013-0102-x,23975660,methodology,1,NA,Primary outcome: variable type,NA,NA,"Continuous (count, mean, ...)",TRUE,NA,NA,NA
10.1007/s40263-013-0102-x,23975660,methodology,1,NA,Justification for selecting variables to be included in the adjustment model (in the main text),NA,NA,"Nothing mentioned, not reported",TRUE,NA,NA,NA
10.1007/s40263-013-0102-x,23975660,methodology,1,NA,Inclusion of prognostic factors in the adjustment/matching model,NA,NA,No discussion (in the main text) of the status of prognostic factors of the variables,TRUE,NA,NA,NA
10.1007/s40263-013-0102-x,23975660,methodology,1,NA,Inclusion of treatment-effect modifiers in the adjustment/matching model,NA,NA,No discussion (in the main text) of the status of treatment-effect modifiers of the variables,TRUE,NA,NA,NA
10.1007/s40263-013-0102-x,23975660,methodology,1,NA,"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)",NA,NA,Yes,TRUE,NA,NA,NA
10.1007/s40263-013-0102-x,23975660,methodology,1,NA,Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale),NA,NA,No,TRUE,NA,NA,NA
10.1007/s40263-013-0102-x,23975660,results,1,NA,Sample size of the population of interest in the non IPD treatment arm,NA,NA,84,TRUE,NA,NA,NA
10.1007/s40263-013-0102-x,23975660,results,1,NA,Initial sample size of the population of interest in the IPD treatment arm,NA,NA,82,TRUE,NA,NA,NA
10.1007/s40263-013-0102-x,23975660,results,1,NA,Reporting of a weights' distribution evaluation (MAIC),NA,NA,Not mentioned,TRUE,NA,NA,NA
10.1007/s40263-013-0102-x,23975660,results,1,NA,Reporting of the list of the covariates adjusted for/matched on,NA,NA,Yes,TRUE,NA,NA,NA
10.1007/s40263-013-0102-x,23975660,results,1,NA,Number of covariates adjusted for/matched on,8,10,8,FALSE,NA,NA,NA
10.1007/s40263-013-0102-x,23975660,results,1,NA,Covariates adjusted for/matched on in the indirect comparison,NA,NA,"Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Race/ethnicity, Other(s)",TRUE,NA,NA,NA
10.1007/s40263-013-0102-x,23975660,results,1,NA,Primary outcome: treatment effect contrast,NA,NA,Means difference,TRUE,NA,NA,NA
10.1007/s40263-013-0102-x,23975660,results,1,NA,Direction of the treatment effect contrast: IPD treatment is:,NA,NA,"Numerator if ratio, or left side if difference",TRUE,NA,NA,NA
10.1007/s40263-013-0102-x,23975660,results,1,NA,Primary outcome: unadjusted treatment effect,NA,NA,-9.2,TRUE,NA,NA,NA
10.1007/s40263-013-0102-x,23975660,results,1,NA,"p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])",NA,NA,<0.01,TRUE,NA,NA,NA
10.1007/s40263-013-0102-x,23975660,results,1,NA,Primary outcome: adjusted treatment effect,NA,NA,-7,TRUE,NA,NA,NA
10.1007/s40263-013-0102-x,23975660,results,1,NA,"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])",NA,NA,<0.01,TRUE,NA,NA,NA
10.1007/s40263-013-0102-x,23975660,results,1,NA,"If anchored comparison, sample size of the population of interest in the non IPD treatment anchor arm",83,NA,83,FALSE,NA,NA,NA
10.1007/s40263-013-0102-x,23975660,results,1,NA,"If anchored comparison, initial sample size of the population of interest in the IPD anchor arm",136,NA,136,FALSE,NA,NA,NA
10.1185/03007995.2014.977992,25356603,general_information,NA,NA,Medical Condition of Interest Name,chronic myeloid leukemia in chronic phase,chronic myeloid leukemia,XXXX,FALSE,NA,NA,NA
10.1185/03007995.2014.977992,25356603,general_information,NA,NA,Countries of first author affiliations,NA,NA,usa,TRUE,NA,NA,NA
10.1185/03007995.2014.977992,25356603,general_information,NA,NA,Countries of last author affiliations,NA,NA,usa,TRUE,NA,NA,NA
10.1185/03007995.2014.977992,25356603,general_information,NA,NA,"Positions of study investigators (for any authors of the article, any that applies)",NA,NA,"Academic, Pharmaceutical Industry, Private Data Analysis Company",TRUE,NA,NA,NA
10.1185/03007995.2014.977992,25356603,general_information,NA,NA,"At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company",NA,NA,Yes,TRUE,NA,NA,NA
10.1185/03007995.2014.977992,25356603,general_information,NA,NA,Mentioned sources of funding,NA,NA,Pharmaceutical Industry,TRUE,NA,NA,NA
10.1185/03007995.2014.977992,25356603,general_information,NA,NA,"Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article",NA,NA,Yes,TRUE,NA,NA,NA
10.1185/03007995.2014.977992,25356603,general_information,NA,NA,Mention of a systematic review to find the studies to compare treatments of interest,NA,NA,No,TRUE,NA,NA,NA
10.1185/03007995.2014.977992,25356603,study_information,NA,1,Patient-level data used,NA,NA,Yes,TRUE,NA,NA,NA
10.1185/03007995.2014.977992,25356603,study_information,NA,1,Clinical Trial,NA,NA,Yes,TRUE,NA,NA,NA
10.1185/03007995.2014.977992,25356603,study_information,NA,1,NCT (only for clinical trial registered on clinicaltrials.gov),NA,NA,NCT00471497,TRUE,NA,NA,NA
10.1185/03007995.2014.977992,25356603,study_information,NA,1,Country where the clinical trial/observational study was conducted (international if more than one),NA,NA,international,TRUE,NA,NA,NA
10.1185/03007995.2014.977992,25356603,study_information,NA,1,Phase of the clinical trial (clinical trial only),NA,NA,3,TRUE,NA,NA,NA
10.1185/03007995.2014.977992,25356603,study_information,NA,1,Number of treatment arms (clinical trial only),NA,NA,2 or more,TRUE,NA,NA,NA
10.1185/03007995.2014.977992,25356603,study_information,NA,2,Patient-level data used,NA,NA,No,TRUE,NA,NA,NA
10.1185/03007995.2014.977992,25356603,study_information,NA,2,Clinical Trial,NA,NA,Yes,TRUE,NA,NA,NA
10.1185/03007995.2014.977992,25356603,study_information,NA,2,NCT (only for clinical trial registered on clinicaltrials.gov),NA,NA,NCT00481247,TRUE,NA,NA,NA
10.1185/03007995.2014.977992,25356603,study_information,NA,2,Country where the clinical trial/observational study was conducted (international if more than one),NA,NA,international,TRUE,NA,NA,NA
10.1185/03007995.2014.977992,25356603,study_information,NA,2,Phase of the clinical trial (clinical trial only),NA,NA,3,TRUE,NA,NA,NA
10.1185/03007995.2014.977992,25356603,study_information,NA,2,Number of treatment arms (clinical trial only),NA,NA,2 or more,TRUE,NA,NA,NA
10.1185/03007995.2014.977992,25356603,methodology,1,NA,Treatment name 1,NA,NA,nilotinib,TRUE,matching treatment arms separately,NA,NA
10.1185/03007995.2014.977992,25356603,methodology,1,NA,Study 'number(s)' for treatment 1,NA,NA,1,TRUE,NA,NA,NA
10.1185/03007995.2014.977992,25356603,methodology,1,NA,Treatment name 2,NA,NA,dasatinib,TRUE,NA,NA,NA
10.1185/03007995.2014.977992,25356603,methodology,1,NA,Study 'number(s)' for treatment 2,NA,NA,2,TRUE,NA,NA,NA
10.1185/03007995.2014.977992,25356603,methodology,1,NA,Type of population-adjusted indirect comparisons performed,NA,NA,MAIC,TRUE,NA,NA,NA
10.1185/03007995.2014.977992,25356603,methodology,1,NA,Anchored comparison?,NA,NA,Yes,TRUE,NA,NA,NA
10.1185/03007995.2014.977992,25356603,methodology,1,NA,Form of the indirect comparison,NA,NA,Simple (ie treatments effects extracted from two studies),TRUE,NA,NA,NA
10.1185/03007995.2014.977992,25356603,methodology,1,NA,Definition of a single primary outcome for the indirect comparison,NA,NA,"No primary outcome defined, or multiple primary outcomes without any clear distinction between them",TRUE,NA,NA,NA
10.1185/03007995.2014.977992,25356603,methodology,1,NA,Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined),molecular response,major molecular response by 12 months,major molecular response by 12 months,FALSE,NA,NA,NA
10.1185/03007995.2014.977992,25356603,methodology,1,NA,Primary outcome: variable type,NA,NA,Binary (eg rates),TRUE,NA,NA,NA
10.1185/03007995.2014.977992,25356603,methodology,1,NA,Justification for selecting variables to be included in the adjustment model (in the main text),NA,NA,"Nothing mentioned, not reported",TRUE,NA,NA,NA
10.1185/03007995.2014.977992,25356603,methodology,1,NA,Inclusion of prognostic factors in the adjustment/matching model,NA,NA,No discussion (in the main text) of the status of prognostic factors of the variables,TRUE,NA,NA,NA
10.1185/03007995.2014.977992,25356603,methodology,1,NA,Inclusion of treatment-effect modifiers in the adjustment/matching model,NA,NA,No discussion (in the main text) of the status of treatment-effect modifiers of the variables,TRUE,NA,NA,NA
10.1185/03007995.2014.977992,25356603,methodology,1,NA,"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)",NA,NA,No,TRUE,NA,NA,NA
10.1185/03007995.2014.977992,25356603,methodology,1,NA,Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale),NA,NA,No,TRUE,NA,NA,NA
10.1185/03007995.2014.977992,25356603,results,1,NA,Sample size of the population of interest in the non IPD treatment arm,NA,NA,259,TRUE,NA,NA,NA
10.1185/03007995.2014.977992,25356603,results,1,NA,"If anchored comparison, sample size of the population of interest in the non IPD treatment anchor arm",NA,NA,260,TRUE,NA,NA,NA
10.1185/03007995.2014.977992,25356603,results,1,NA,Initial sample size of the population of interest in the IPD treatment arm,NA,NA,278,TRUE,NA,NA,NA
10.1185/03007995.2014.977992,25356603,results,1,NA,"If anchored comparison, initial sample size of the population of interest in the IPD anchor arm",NA,NA,282,TRUE,NA,NA,NA
10.1185/03007995.2014.977992,25356603,results,1,NA,Reporting of a weights' distribution evaluation (MAIC),NA,NA,Not mentioned,TRUE,NA,NA,NA
10.1185/03007995.2014.977992,25356603,results,1,NA,Reporting of the list of the covariates adjusted for/matched on,NA,NA,Yes,TRUE,NA,NA,NA
10.1185/03007995.2014.977992,25356603,results,1,NA,Number of covariates adjusted for/matched on,6,5,5,FALSE,NA,NA,NA
10.1185/03007995.2014.977992,25356603,results,1,NA,Covariates adjusted for/matched on in the indirect comparison,"Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Race/ethnicity, Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...)","Age, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...)","Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Race/ethnicity, Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...)",FALSE,NA,NA,NA
10.1185/03007995.2014.977992,25356603,results,1,NA,Primary outcome: treatment effect contrast,NA,NA,Rate difference,TRUE,NA,NA,NA
10.1185/03007995.2014.977992,25356603,results,1,NA,Direction of the treatment effect contrast: IPD treatment is:,NA,NA,"Numerator if ratio, or left side if difference",TRUE,NA,NA,NA
10.1185/03007995.2014.977992,25356603,results,1,NA,Primary outcome: adjusted treatment effect,11.7,11.70%,11.70%,FALSE,NA,NA,NA
10.1185/03007995.2014.977992,25356603,results,1,NA,"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])",NA,NA,0.045,TRUE,NA,NA,NA
10.2217/cer.15.33,26159375,general_information,NA,NA,Medical Condition of Interest Name,chronic genotype 1b hepatitis c,genotype 1b hepatitis c virus infection,XXXX,FALSE,NA,NA,NA
10.2217/cer.15.33,26159375,general_information,NA,NA,Countries of first author affiliations,NA,NA,usa,TRUE,NA,NA,NA
10.2217/cer.15.33,26159375,general_information,NA,NA,Countries of last author affiliations,NA,NA,usa,TRUE,NA,NA,NA
10.2217/cer.15.33,26159375,general_information,NA,NA,"Positions of study investigators (for any authors of the article, any that applies)",NA,NA,"Pharmaceutical Industry, Private Data Analysis Company",TRUE,NA,NA,NA
10.2217/cer.15.33,26159375,general_information,NA,NA,"At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company",NA,NA,Yes,TRUE,NA,NA,NA
10.2217/cer.15.33,26159375,general_information,NA,NA,Mentioned sources of funding,NA,NA,Pharmaceutical Industry,TRUE,NA,NA,NA
10.2217/cer.15.33,26159375,general_information,NA,NA,"Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article",NA,NA,Yes,TRUE,NA,NA,NA
10.2217/cer.15.33,26159375,general_information,NA,NA,Mention of a systematic review to find the studies to compare treatments of interest,NA,NA,Yes,TRUE,NA,NA,NA
10.2217/cer.15.33,26159375,study_information,NA,1,Patient-level data used,NA,NA,Yes,TRUE,NA,NA,NA
10.2217/cer.15.33,26159375,study_information,NA,1,Clinical Trial,NA,NA,Yes,TRUE,NA,NA,NA
10.2217/cer.15.33,26159375,study_information,NA,1,NCT (only for clinical trial registered on clinicaltrials.gov),NA,NA,NCT01497834,TRUE,NA,NA,NA
10.2217/cer.15.33,26159375,study_information,NA,1,Country where the clinical trial/observational study was conducted (international if more than one),NA,NA,japan,TRUE,NA,NA,NA
10.2217/cer.15.33,26159375,study_information,NA,1,Phase of the clinical trial (clinical trial only),NA,NA,3,TRUE,NA,NA,NA
10.2217/cer.15.33,26159375,study_information,NA,1,Number of treatment arms (clinical trial only),NA,NA,1,TRUE,NA,NA,NA
10.2217/cer.15.33,26159375,study_information,NA,10,Patient-level data used,NA,NA,No,TRUE,NA,NA,NA
10.2217/cer.15.33,26159375,study_information,NA,10,Clinical Trial,NA,NA,Yes,TRUE,NA,NA,NA
10.2217/cer.15.33,26159375,study_information,NA,10,NCT (only for clinical trial registered on clinicaltrials.gov),NA,NA,NCT01289782,TRUE,NA,NA,NA
10.2217/cer.15.33,26159375,study_information,NA,10,Country where the clinical trial/observational study was conducted (international if more than one),NA,NA,international,TRUE,NA,NA,NA
10.2217/cer.15.33,26159375,study_information,NA,10,Phase of the clinical trial (clinical trial only),NA,NA,3,TRUE,NA,NA,NA
10.2217/cer.15.33,26159375,study_information,NA,10,Number of treatment arms (clinical trial only),NA,NA,2 or more,TRUE,NA,NA,NA
10.2217/cer.15.33,26159375,study_information,NA,11,Patient-level data used,NA,NA,No,TRUE,NA,NA,NA
10.2217/cer.15.33,26159375,study_information,NA,11,Clinical Trial,NA,NA,Yes,TRUE,NA,NA,NA
10.2217/cer.15.33,26159375,study_information,NA,11,NCT (only for clinical trial registered on clinicaltrials.gov),NA,NA,NCT01290679,TRUE,NA,NA,NA
10.2217/cer.15.33,26159375,study_information,NA,11,Country where the clinical trial/observational study was conducted (international if more than one),NA,NA,international,TRUE,NA,NA,NA
10.2217/cer.15.33,26159375,study_information,NA,11,Phase of the clinical trial (clinical trial only),NA,NA,3,TRUE,NA,NA,NA
10.2217/cer.15.33,26159375,study_information,NA,11,Number of treatment arms (clinical trial only),NA,NA,2 or more,TRUE,NA,NA,NA
10.2217/cer.15.33,26159375,study_information,NA,12,Patient-level data used,NA,NA,No,TRUE,NA,NA,NA
10.2217/cer.15.33,26159375,study_information,NA,12,Clinical Trial,NA,NA,Yes,TRUE,NA,NA,NA
10.2217/cer.15.33,26159375,study_information,NA,12,NCT (only for clinical trial registered on clinicaltrials.gov),NA,NA,NCT01281839,TRUE,NA,NA,NA
10.2217/cer.15.33,26159375,study_information,NA,12,Country where the clinical trial/observational study was conducted (international if more than one),NA,NA,international,TRUE,NA,NA,NA
10.2217/cer.15.33,26159375,study_information,NA,12,Phase of the clinical trial (clinical trial only),NA,NA,3,TRUE,NA,NA,NA
10.2217/cer.15.33,26159375,study_information,NA,12,Number of treatment arms (clinical trial only),NA,NA,2 or more,TRUE,NA,NA,NA
10.2217/cer.15.33,26159375,study_information,NA,13,Patient-level data used,NA,NA,No,TRUE,NA,NA,NA
10.2217/cer.15.33,26159375,study_information,NA,13,Clinical Trial,NA,NA,Yes,TRUE,NA,NA,NA
10.2217/cer.15.33,26159375,study_information,NA,13,NCT (only for clinical trial registered on clinicaltrials.gov),NA,NA,NCT01641640,TRUE,NA,NA,NA
10.2217/cer.15.33,26159375,study_information,NA,13,Country where the clinical trial/observational study was conducted (international if more than one),international,usa,XXXX,FALSE,NA,NA,NA
10.2217/cer.15.33,26159375,study_information,NA,13,Phase of the clinical trial (clinical trial only),NA,NA,3,TRUE,NA,NA,NA
10.2217/cer.15.33,26159375,study_information,NA,13,Number of treatment arms (clinical trial only),NA,NA,1,TRUE,NA,NA,NA
10.2217/cer.15.33,26159375,study_information,NA,2,Patient-level data used,NA,NA,Yes,TRUE,NA,NA,NA
10.2217/cer.15.33,26159375,study_information,NA,2,Clinical Trial,NA,NA,Yes,TRUE,NA,NA,NA
10.2217/cer.15.33,26159375,study_information,NA,2,NCT (only for clinical trial registered on clinicaltrials.gov),NA,NA,NCT01581203,TRUE,NA,NA,NA
10.2217/cer.15.33,26159375,study_information,NA,2,Country where the clinical trial/observational study was conducted (international if more than one),NA,NA,international,TRUE,NA,NA,NA
10.2217/cer.15.33,26159375,study_information,NA,2,Phase of the clinical trial (clinical trial only),NA,NA,3,TRUE,NA,NA,NA
10.2217/cer.15.33,26159375,study_information,NA,2,Number of treatment arms (clinical trial only),2 or more,1,2 or more,FALSE,NA,NA,NA
10.2217/cer.15.33,26159375,study_information,NA,3,Patient-level data used,NA,NA,Yes,TRUE,NA,NA,NA
10.2217/cer.15.33,26159375,study_information,NA,3,Clinical Trial,NA,NA,Yes,TRUE,NA,NA,NA
10.2217/cer.15.33,26159375,study_information,NA,3,NCT (only for clinical trial registered on clinicaltrials.gov),NA,NA,NCT01718145,TRUE,NA,NA,NA
10.2217/cer.15.33,26159375,study_information,NA,3,Country where the clinical trial/observational study was conducted (international if more than one),NA,NA,japan,TRUE,NA,NA,NA
10.2217/cer.15.33,26159375,study_information,NA,3,Phase of the clinical trial (clinical trial only),NA,NA,3,TRUE,NA,NA,NA
10.2217/cer.15.33,26159375,study_information,NA,3,Number of treatment arms (clinical trial only),NA,NA,2 or more,TRUE,NA,NA,NA
10.2217/cer.15.33,26159375,study_information,NA,4,Patient-level data used,NA,NA,No,TRUE,NA,NA,NA
10.2217/cer.15.33,26159375,study_information,NA,4,Clinical Trial,NA,NA,Yes,TRUE,NA,NA,NA
10.2217/cer.15.33,26159375,study_information,NA,4,NCT (only for clinical trial registered on clinicaltrials.gov),NA,NA,NCT00627926,TRUE,NA,NA,NA
10.2217/cer.15.33,26159375,study_information,NA,4,Country where the clinical trial/observational study was conducted (international if more than one),NA,NA,international,TRUE,NA,NA,NA
10.2217/cer.15.33,26159375,study_information,NA,4,Phase of the clinical trial (clinical trial only),NA,NA,3,TRUE,NA,NA,NA
10.2217/cer.15.33,26159375,study_information,NA,4,Number of treatment arms (clinical trial only),NA,NA,2 or more,TRUE,NA,NA,NA
10.2217/cer.15.33,26159375,study_information,NA,5,Patient-level data used,NA,NA,No,TRUE,NA,NA,NA
10.2217/cer.15.33,26159375,study_information,NA,5,Clinical Trial,NA,NA,Yes,TRUE,NA,NA,NA
10.2217/cer.15.33,26159375,study_information,NA,5,NCT (only for clinical trial registered on clinicaltrials.gov),NA,NA,NCT01241760,TRUE,NA,NA,NA
10.2217/cer.15.33,26159375,study_information,NA,5,Country where the clinical trial/observational study was conducted (international if more than one),NA,NA,international,TRUE,NA,NA,NA
10.2217/cer.15.33,26159375,study_information,NA,5,Phase of the clinical trial (clinical trial only),NA,NA,3,TRUE,NA,NA,NA
10.2217/cer.15.33,26159375,study_information,NA,5,Number of treatment arms (clinical trial only),1,2 or more,2 or more,FALSE,NA,NA,NA
10.2217/cer.15.33,26159375,study_information,NA,6,Patient-level data used,NA,NA,No,TRUE,NA,NA,NA
10.2217/cer.15.33,26159375,study_information,NA,6,Clinical Trial,NA,NA,Yes,TRUE,NA,NA,NA
10.2217/cer.15.33,26159375,study_information,NA,6,NCT (only for clinical trial registered on clinicaltrials.gov),NA,NA,NCT00758043,TRUE,NA,NA,NA
10.2217/cer.15.33,26159375,study_information,NA,6,Country where the clinical trial/observational study was conducted (international if more than one),NA,NA,international,TRUE,NA,NA,NA
10.2217/cer.15.33,26159375,study_information,NA,6,Phase of the clinical trial (clinical trial only),NA,NA,3,TRUE,NA,NA,NA
10.2217/cer.15.33,26159375,study_information,NA,6,Number of treatment arms (clinical trial only),1,2 or more,2 or more,FALSE,NA,NA,NA
10.2217/cer.15.33,26159375,study_information,NA,7,Patient-level data used,NA,NA,No,TRUE,NA,NA,NA
10.2217/cer.15.33,26159375,study_information,NA,7,Clinical Trial,NA,NA,Yes,TRUE,NA,NA,NA
10.2217/cer.15.33,26159375,study_information,NA,7,NCT (only for clinical trial registered on clinicaltrials.gov),NA,NA,NCT00703118,TRUE,NA,NA,NA
10.2217/cer.15.33,26159375,study_information,NA,7,Country where the clinical trial/observational study was conducted (international if more than one),NA,NA,international,TRUE,NA,NA,NA
10.2217/cer.15.33,26159375,study_information,NA,7,Phase of the clinical trial (clinical trial only),NA,NA,3,TRUE,NA,NA,NA
10.2217/cer.15.33,26159375,study_information,NA,7,Number of treatment arms (clinical trial only),NA,NA,2 or more,TRUE,NA,NA,NA
10.2217/cer.15.33,26159375,study_information,NA,8,Patient-level data used,NA,NA,No,TRUE,NA,NA,NA
10.2217/cer.15.33,26159375,study_information,NA,8,Clinical Trial,NA,NA,Yes,TRUE,NA,NA,NA
10.2217/cer.15.33,26159375,study_information,NA,8,NCT (only for clinical trial registered on clinicaltrials.gov),NA,NA,NCT00705432,TRUE,NA,NA,NA
10.2217/cer.15.33,26159375,study_information,NA,8,Phase of the clinical trial (clinical trial only),NA,NA,3,TRUE,NA,NA,NA
10.2217/cer.15.33,26159375,study_information,NA,8,Number of treatment arms (clinical trial only),NA,NA,2 or more,TRUE,NA,NA,NA
10.2217/cer.15.33,26159375,study_information,NA,8,Country where the clinical trial/observational study was conducted (international if more than one),unknown,NA,unknown,FALSE,NA,NA,NA
10.2217/cer.15.33,26159375,study_information,NA,9,Patient-level data used,NA,NA,No,TRUE,NA,NA,NA
10.2217/cer.15.33,26159375,study_information,NA,9,Clinical Trial,NA,NA,Yes,TRUE,NA,NA,NA
10.2217/cer.15.33,26159375,study_information,NA,9,NCT (only for clinical trial registered on clinicaltrials.gov),NA,NA,NCT00708500,TRUE,NA,NA,NA
10.2217/cer.15.33,26159375,study_information,NA,9,Phase of the clinical trial (clinical trial only),NA,NA,3,TRUE,NA,NA,NA
10.2217/cer.15.33,26159375,study_information,NA,9,Number of treatment arms (clinical trial only),2 or more,3 or more,2 or more,FALSE,NA,NA,NA
10.2217/cer.15.33,26159375,study_information,NA,9,Country where the clinical trial/observational study was conducted (international if more than one),unknown,NA,international,FALSE,NA,NA,NA
10.2217/cer.15.33,26159375,methodology,1,NA,Treatment name 1,NA,NA,daclatasvir + asunaprevir,TRUE,Supplemental materials unavailable   treatment naive patients,"Treatment-naive patients
N non IPD are taken from Table 2 (The sum of N in each arm)
No access to supplementary materials",NA
10.2217/cer.15.33,26159375,methodology,1,NA,Study 'number(s)' for treatment 1,NA,NA,2;3,TRUE,NA,NA,NA
10.2217/cer.15.33,26159375,methodology,1,NA,Treatment name 2,NA,NA,telaprevir + peginterferon-Î± + ribavirin,TRUE,NA,NA,NA
10.2217/cer.15.33,26159375,methodology,1,NA,Study 'number(s)' for treatment 2,NA,NA,4;5;6,TRUE,NA,NA,NA
10.2217/cer.15.33,26159375,methodology,1,NA,Type of population-adjusted indirect comparisons performed,NA,NA,MAIC,TRUE,NA,NA,NA
10.2217/cer.15.33,26159375,methodology,1,NA,Anchored comparison?,NA,NA,No,TRUE,NA,NA,NA
10.2217/cer.15.33,26159375,methodology,1,NA,Form of the indirect comparison,NA,NA,"Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate)",TRUE,NA,NA,NA
10.2217/cer.15.33,26159375,methodology,1,NA,Definition of a single primary outcome for the indirect comparison,NA,NA,Yes,TRUE,NA,NA,NA
10.2217/cer.15.33,26159375,methodology,1,NA,Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined),sustained virologic response,proportion of genotype 1b patients achieving svr at week 12 or week 24 post-treatment,sustained virologic response,FALSE,NA,NA,NA
10.2217/cer.15.33,26159375,methodology,1,NA,Primary outcome: variable type,NA,NA,Binary (eg rates),TRUE,NA,NA,NA
10.2217/cer.15.33,26159375,methodology,1,NA,Justification for selecting variables to be included in the adjustment model (in the main text),NA,NA,"Nothing mentioned, not reported",TRUE,NA,NA,NA
10.2217/cer.15.33,26159375,methodology,1,NA,Inclusion of prognostic factors in the adjustment/matching model,NA,NA,No discussion (in the main text) of the status of prognostic factors of the variables,TRUE,NA,NA,NA
10.2217/cer.15.33,26159375,methodology,1,NA,Inclusion of treatment-effect modifiers in the adjustment/matching model,NA,NA,No discussion (in the main text) of the status of treatment-effect modifiers of the variables,TRUE,NA,NA,NA
10.2217/cer.15.33,26159375,methodology,1,NA,"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)",NA,NA,No,TRUE,NA,NA,NA
10.2217/cer.15.33,26159375,methodology,1,NA,Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale),NA,NA,No,TRUE,NA,NA,NA
10.2217/cer.15.33,26159375,methodology,2,NA,Treatment name 1,NA,NA,daclatasvir + asunaprevir,TRUE,treatment naive patients,"Treatment-naive patients
N non IPD are taken from Table 2
No access to supplementary materials",NA
10.2217/cer.15.33,26159375,methodology,2,NA,Study 'number(s)' for treatment 1,NA,NA,2;3,TRUE,NA,NA,NA
10.2217/cer.15.33,26159375,methodology,2,NA,Treatment name 2,NA,NA,boceprevir + peginterferon-Î± + ribavirin,TRUE,NA,NA,NA
10.2217/cer.15.33,26159375,methodology,2,NA,Study 'number(s)' for treatment 2,NA,NA,8,TRUE,NA,NA,NA
10.2217/cer.15.33,26159375,methodology,2,NA,Type of population-adjusted indirect comparisons performed,NA,NA,MAIC,TRUE,NA,NA,NA
10.2217/cer.15.33,26159375,methodology,2,NA,Anchored comparison?,NA,NA,No,TRUE,NA,NA,NA
10.2217/cer.15.33,26159375,methodology,2,NA,Form of the indirect comparison,NA,NA,"Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate)",TRUE,NA,NA,NA
10.2217/cer.15.33,26159375,methodology,2,NA,Definition of a single primary outcome for the indirect comparison,NA,NA,Yes,TRUE,NA,NA,NA
10.2217/cer.15.33,26159375,methodology,2,NA,Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined),sustained virologic response,proportion of genotype 1b patients achieving svr at week 12 or week 24 post-treatment,sustained virologic response,FALSE,NA,NA,NA
10.2217/cer.15.33,26159375,methodology,2,NA,Primary outcome: variable type,NA,NA,Binary (eg rates),TRUE,NA,NA,NA
10.2217/cer.15.33,26159375,methodology,2,NA,Justification for selecting variables to be included in the adjustment model (in the main text),NA,NA,"Nothing mentioned, not reported",TRUE,NA,NA,NA
10.2217/cer.15.33,26159375,methodology,2,NA,Inclusion of prognostic factors in the adjustment/matching model,NA,NA,No discussion (in the main text) of the status of prognostic factors of the variables,TRUE,NA,NA,NA
10.2217/cer.15.33,26159375,methodology,2,NA,Inclusion of treatment-effect modifiers in the adjustment/matching model,NA,NA,No discussion (in the main text) of the status of treatment-effect modifiers of the variables,TRUE,NA,NA,NA
10.2217/cer.15.33,26159375,methodology,2,NA,"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)",NA,NA,No,TRUE,NA,NA,NA
10.2217/cer.15.33,26159375,methodology,2,NA,Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale),NA,NA,No,TRUE,NA,NA,NA
10.2217/cer.15.33,26159375,methodology,3,NA,Treatment name 1,NA,NA,daclatasvir + asunaprevir,TRUE,treatment naive patients,"Treatment-naive patients
N non IPD are taken from Table 2 (The sum of N in each arm)
No access to supplementary materials",NA
10.2217/cer.15.33,26159375,methodology,3,NA,Study 'number(s)' for treatment 1,NA,NA,2;3,TRUE,NA,NA,NA
10.2217/cer.15.33,26159375,methodology,3,NA,Treatment name 2,NA,NA,simeprevir + peginterferon-Î± + ribavirin,TRUE,NA,NA,NA
10.2217/cer.15.33,26159375,methodology,3,NA,Study 'number(s)' for treatment 2,NA,NA,10;11,TRUE,NA,NA,NA
10.2217/cer.15.33,26159375,methodology,3,NA,Type of population-adjusted indirect comparisons performed,NA,NA,MAIC,TRUE,NA,NA,NA
10.2217/cer.15.33,26159375,methodology,3,NA,Anchored comparison?,NA,NA,No,TRUE,NA,NA,NA
10.2217/cer.15.33,26159375,methodology,3,NA,Form of the indirect comparison,NA,NA,"Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate)",TRUE,NA,NA,NA
10.2217/cer.15.33,26159375,methodology,3,NA,Definition of a single primary outcome for the indirect comparison,NA,NA,Yes,TRUE,NA,NA,NA
10.2217/cer.15.33,26159375,methodology,3,NA,Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined),sustained virologic response,proportion of genotype 1b patients achieving svr at week 12 or week 24 post-treatment,sustained virologic response,FALSE,NA,NA,NA
10.2217/cer.15.33,26159375,methodology,3,NA,Primary outcome: variable type,NA,NA,Binary (eg rates),TRUE,NA,NA,NA
10.2217/cer.15.33,26159375,methodology,3,NA,Justification for selecting variables to be included in the adjustment model (in the main text),NA,NA,"Nothing mentioned, not reported",TRUE,NA,NA,NA
10.2217/cer.15.33,26159375,methodology,3,NA,Inclusion of prognostic factors in the adjustment/matching model,NA,NA,No discussion (in the main text) of the status of prognostic factors of the variables,TRUE,NA,NA,NA
10.2217/cer.15.33,26159375,methodology,3,NA,Inclusion of treatment-effect modifiers in the adjustment/matching model,NA,NA,No discussion (in the main text) of the status of treatment-effect modifiers of the variables,TRUE,NA,NA,NA
10.2217/cer.15.33,26159375,methodology,3,NA,"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)",NA,NA,No,TRUE,NA,NA,NA
10.2217/cer.15.33,26159375,methodology,3,NA,Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale),NA,NA,No,TRUE,NA,NA,NA
10.2217/cer.15.33,26159375,methodology,4,NA,Treatment name 1,NA,NA,daclatasvir + asunaprevir,TRUE,treatment naive patients,"Treatment-naive patients
N non IPD are taken from Table 2
No access to supplementary materials",NA
10.2217/cer.15.33,26159375,methodology,4,NA,Study 'number(s)' for treatment 1,NA,NA,2;3,TRUE,NA,NA,NA
10.2217/cer.15.33,26159375,methodology,4,NA,Treatment name 2,NA,NA,sofosbuvir + peginterferon-Î± + ribavirin,TRUE,NA,NA,NA
10.2217/cer.15.33,26159375,methodology,4,NA,Study 'number(s)' for treatment 2,NA,NA,13,TRUE,NA,NA,NA
10.2217/cer.15.33,26159375,methodology,4,NA,Type of population-adjusted indirect comparisons performed,NA,NA,MAIC,TRUE,NA,NA,NA
10.2217/cer.15.33,26159375,methodology,4,NA,Anchored comparison?,NA,NA,No,TRUE,NA,NA,NA
10.2217/cer.15.33,26159375,methodology,4,NA,Form of the indirect comparison,NA,NA,"Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate)",TRUE,NA,NA,NA
10.2217/cer.15.33,26159375,methodology,4,NA,Definition of a single primary outcome for the indirect comparison,NA,NA,Yes,TRUE,NA,NA,NA
10.2217/cer.15.33,26159375,methodology,4,NA,Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined),sustained virologic response,proportion of genotype 1b patients achieving svr at week 12 or week 24 post-treatment,sustained virologic response,FALSE,NA,NA,NA
10.2217/cer.15.33,26159375,methodology,4,NA,Primary outcome: variable type,NA,NA,Binary (eg rates),TRUE,NA,NA,NA
10.2217/cer.15.33,26159375,methodology,4,NA,Justification for selecting variables to be included in the adjustment model (in the main text),NA,NA,"Nothing mentioned, not reported",TRUE,NA,NA,NA
10.2217/cer.15.33,26159375,methodology,4,NA,Inclusion of prognostic factors in the adjustment/matching model,NA,NA,No discussion (in the main text) of the status of prognostic factors of the variables,TRUE,NA,NA,NA
10.2217/cer.15.33,26159375,methodology,4,NA,Inclusion of treatment-effect modifiers in the adjustment/matching model,NA,NA,No discussion (in the main text) of the status of treatment-effect modifiers of the variables,TRUE,NA,NA,NA
10.2217/cer.15.33,26159375,methodology,4,NA,"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)",NA,NA,No,TRUE,NA,NA,NA
10.2217/cer.15.33,26159375,methodology,4,NA,Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale),NA,NA,No,TRUE,NA,NA,NA
10.2217/cer.15.33,26159375,methodology,5,NA,Treatment name 1,NA,NA,daclatasvir + asunaprevir,TRUE,treatment naive patients,"Treatment-naive patients
N non IPD are taken from Table 2 (The sum of N in each arm)
No access to supplementary materials",NA
10.2217/cer.15.33,26159375,methodology,5,NA,Study 'number(s)' for treatment 1,NA,NA,2;3,TRUE,NA,NA,NA
10.2217/cer.15.33,26159375,methodology,5,NA,Treatment name 2,NA,NA,peginterferon-Î± + ribavirin,TRUE,NA,NA,NA
10.2217/cer.15.33,26159375,methodology,5,NA,Study 'number(s)' for treatment 2,NA,NA,4;8;10;11,TRUE,NA,NA,NA
10.2217/cer.15.33,26159375,methodology,5,NA,Type of population-adjusted indirect comparisons performed,NA,NA,MAIC,TRUE,NA,NA,NA
10.2217/cer.15.33,26159375,methodology,5,NA,Anchored comparison?,NA,NA,No,TRUE,NA,NA,NA
10.2217/cer.15.33,26159375,methodology,5,NA,Form of the indirect comparison,NA,NA,"Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate)",TRUE,NA,NA,NA
10.2217/cer.15.33,26159375,methodology,5,NA,Definition of a single primary outcome for the indirect comparison,NA,NA,Yes,TRUE,NA,NA,NA
10.2217/cer.15.33,26159375,methodology,5,NA,Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined),sustained virologic response,proportion of genotype 1b patients achieving svr at week 12 or week 24 post-treatment,sustained virologic response,FALSE,NA,NA,NA
10.2217/cer.15.33,26159375,methodology,5,NA,Primary outcome: variable type,NA,NA,Binary (eg rates),TRUE,NA,NA,NA
10.2217/cer.15.33,26159375,methodology,5,NA,Justification for selecting variables to be included in the adjustment model (in the main text),NA,NA,"Nothing mentioned, not reported",TRUE,NA,NA,NA
10.2217/cer.15.33,26159375,methodology,5,NA,Inclusion of prognostic factors in the adjustment/matching model,NA,NA,No discussion (in the main text) of the status of prognostic factors of the variables,TRUE,NA,NA,NA
10.2217/cer.15.33,26159375,methodology,5,NA,Inclusion of treatment-effect modifiers in the adjustment/matching model,NA,NA,No discussion (in the main text) of the status of treatment-effect modifiers of the variables,TRUE,NA,NA,NA
10.2217/cer.15.33,26159375,methodology,5,NA,"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)",NA,NA,No,TRUE,NA,NA,NA
10.2217/cer.15.33,26159375,methodology,5,NA,Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale),NA,NA,No,TRUE,NA,NA,NA
10.2217/cer.15.33,26159375,methodology,6,NA,Treatment name 1,NA,NA,daclatasvir + asunaprevir,TRUE,treatment experienced patients,"Treatment-experienced patients
N non IPD are taken from Table 2
No access to supplementary materials",NA
10.2217/cer.15.33,26159375,methodology,6,NA,Study 'number(s)' for treatment 1,NA,NA,1;2;3,TRUE,NA,NA,NA
10.2217/cer.15.33,26159375,methodology,6,NA,Treatment name 2,NA,NA,telaprevir + peginterferon-Î± + ribavirin,TRUE,NA,NA,NA
10.2217/cer.15.33,26159375,methodology,6,NA,Study 'number(s)' for treatment 2,NA,NA,7,TRUE,NA,NA,NA
10.2217/cer.15.33,26159375,methodology,6,NA,Type of population-adjusted indirect comparisons performed,NA,NA,MAIC,TRUE,NA,NA,NA
10.2217/cer.15.33,26159375,methodology,6,NA,Anchored comparison?,NA,NA,No,TRUE,NA,NA,NA
10.2217/cer.15.33,26159375,methodology,6,NA,Form of the indirect comparison,NA,NA,"Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate)",TRUE,NA,NA,NA
10.2217/cer.15.33,26159375,methodology,6,NA,Definition of a single primary outcome for the indirect comparison,NA,NA,Yes,TRUE,NA,NA,NA
10.2217/cer.15.33,26159375,methodology,6,NA,Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined),sustained virologic response,proportion of genotype 1b patients achieving svr at week 12 or week 24 post-treatment,sustained virologic response,FALSE,NA,NA,NA
10.2217/cer.15.33,26159375,methodology,6,NA,Primary outcome: variable type,NA,NA,Binary (eg rates),TRUE,NA,NA,NA
10.2217/cer.15.33,26159375,methodology,6,NA,Justification for selecting variables to be included in the adjustment model (in the main text),NA,NA,"Nothing mentioned, not reported",TRUE,NA,NA,NA
10.2217/cer.15.33,26159375,methodology,6,NA,Inclusion of prognostic factors in the adjustment/matching model,NA,NA,No discussion (in the main text) of the status of prognostic factors of the variables,TRUE,NA,NA,NA
10.2217/cer.15.33,26159375,methodology,6,NA,Inclusion of treatment-effect modifiers in the adjustment/matching model,NA,NA,No discussion (in the main text) of the status of treatment-effect modifiers of the variables,TRUE,NA,NA,NA
10.2217/cer.15.33,26159375,methodology,6,NA,"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)",NA,NA,No,TRUE,NA,NA,NA
10.2217/cer.15.33,26159375,methodology,6,NA,Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale),NA,NA,No,TRUE,NA,NA,NA
10.2217/cer.15.33,26159375,methodology,7,NA,Treatment name 1,NA,NA,daclatasvir + asunaprevir,TRUE,treatment experienced patients,"Treatment-experienced patients
N non IPD are taken from Table 2
No access to supplementary materials",NA
10.2217/cer.15.33,26159375,methodology,7,NA,Study 'number(s)' for treatment 1,NA,NA,1;2;3,TRUE,NA,NA,NA
10.2217/cer.15.33,26159375,methodology,7,NA,Treatment name 2,NA,NA,boceprevir + peginterferon-Î± + ribavirin,TRUE,NA,NA,NA
10.2217/cer.15.33,26159375,methodology,7,NA,Study 'number(s)' for treatment 2,NA,NA,9,TRUE,NA,NA,NA
10.2217/cer.15.33,26159375,methodology,7,NA,Type of population-adjusted indirect comparisons performed,NA,NA,MAIC,TRUE,NA,NA,NA
10.2217/cer.15.33,26159375,methodology,7,NA,Anchored comparison?,NA,NA,No,TRUE,NA,NA,NA
10.2217/cer.15.33,26159375,methodology,7,NA,Form of the indirect comparison,NA,NA,"Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate)",TRUE,NA,NA,NA
10.2217/cer.15.33,26159375,methodology,7,NA,Definition of a single primary outcome for the indirect comparison,NA,NA,Yes,TRUE,NA,NA,NA
10.2217/cer.15.33,26159375,methodology,7,NA,Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined),sustained virologic response,proportion of genotype 1b patients achieving svr at week 12 or week 24 post-treatment,sustained virologic response,FALSE,NA,NA,NA
10.2217/cer.15.33,26159375,methodology,7,NA,Primary outcome: variable type,NA,NA,Binary (eg rates),TRUE,NA,NA,NA
10.2217/cer.15.33,26159375,methodology,7,NA,Justification for selecting variables to be included in the adjustment model (in the main text),NA,NA,"Nothing mentioned, not reported",TRUE,NA,NA,NA
10.2217/cer.15.33,26159375,methodology,7,NA,Inclusion of prognostic factors in the adjustment/matching model,NA,NA,No discussion (in the main text) of the status of prognostic factors of the variables,TRUE,NA,NA,NA
10.2217/cer.15.33,26159375,methodology,7,NA,Inclusion of treatment-effect modifiers in the adjustment/matching model,NA,NA,No discussion (in the main text) of the status of treatment-effect modifiers of the variables,TRUE,NA,NA,NA
10.2217/cer.15.33,26159375,methodology,7,NA,"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)",NA,NA,No,TRUE,NA,NA,NA
10.2217/cer.15.33,26159375,methodology,7,NA,Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale),NA,NA,No,TRUE,NA,NA,NA
10.2217/cer.15.33,26159375,methodology,8,NA,Treatment name 1,NA,NA,daclatasvir + asunaprevir,TRUE,treatment experienced patients,"Treatment-experienced patients
N non IPD are taken from Table 2
No access to supplementary materials",NA
10.2217/cer.15.33,26159375,methodology,8,NA,Study 'number(s)' for treatment 1,NA,NA,1;2;3,TRUE,NA,NA,NA
10.2217/cer.15.33,26159375,methodology,8,NA,Treatment name 2,NA,NA,simeprevir + peginterferon-Î± + ribavirin,TRUE,NA,NA,NA
10.2217/cer.15.33,26159375,methodology,8,NA,Study 'number(s)' for treatment 2,NA,NA,12,TRUE,NA,NA,NA
10.2217/cer.15.33,26159375,methodology,8,NA,Type of population-adjusted indirect comparisons performed,NA,NA,MAIC,TRUE,NA,NA,NA
10.2217/cer.15.33,26159375,methodology,8,NA,Anchored comparison?,NA,NA,No,TRUE,NA,NA,NA
10.2217/cer.15.33,26159375,methodology,8,NA,Form of the indirect comparison,NA,NA,"Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate)",TRUE,NA,NA,NA
10.2217/cer.15.33,26159375,methodology,8,NA,Definition of a single primary outcome for the indirect comparison,NA,NA,Yes,TRUE,NA,NA,NA
10.2217/cer.15.33,26159375,methodology,8,NA,Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined),sustained virologic response,proportion of genotype 1b patients achieving svr at week 12 or week 24 post-treatment,sustained virologic response,FALSE,NA,NA,NA
10.2217/cer.15.33,26159375,methodology,8,NA,Primary outcome: variable type,NA,NA,Binary (eg rates),TRUE,NA,NA,NA
10.2217/cer.15.33,26159375,methodology,8,NA,Justification for selecting variables to be included in the adjustment model (in the main text),NA,NA,"Nothing mentioned, not reported",TRUE,NA,NA,NA
10.2217/cer.15.33,26159375,methodology,8,NA,Inclusion of prognostic factors in the adjustment/matching model,NA,NA,No discussion (in the main text) of the status of prognostic factors of the variables,TRUE,NA,NA,NA
10.2217/cer.15.33,26159375,methodology,8,NA,Inclusion of treatment-effect modifiers in the adjustment/matching model,NA,NA,No discussion (in the main text) of the status of treatment-effect modifiers of the variables,TRUE,NA,NA,NA
10.2217/cer.15.33,26159375,methodology,8,NA,"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)",NA,NA,No,TRUE,NA,NA,NA
10.2217/cer.15.33,26159375,methodology,8,NA,Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale),NA,NA,No,TRUE,NA,NA,NA
10.2217/cer.15.33,26159375,methodology,9,NA,Treatment name 1,NA,NA,daclatasvir + asunaprevir,TRUE,treatment experienced patients,"Treatment-experienced patients
N non IPD are taken from Table 2 (The sum of N in each arm)
No access to supplementary materials",NA
10.2217/cer.15.33,26159375,methodology,9,NA,Study 'number(s)' for treatment 1,NA,NA,1;2;3,TRUE,NA,NA,NA
10.2217/cer.15.33,26159375,methodology,9,NA,Treatment name 2,NA,NA,peginterferon-Î± + ribavirin,TRUE,NA,NA,NA
10.2217/cer.15.33,26159375,methodology,9,NA,Study 'number(s)' for treatment 2,NA,NA,9;12,TRUE,NA,NA,NA
10.2217/cer.15.33,26159375,methodology,9,NA,Type of population-adjusted indirect comparisons performed,NA,NA,MAIC,TRUE,NA,NA,NA
10.2217/cer.15.33,26159375,methodology,9,NA,Anchored comparison?,NA,NA,No,TRUE,NA,NA,NA
10.2217/cer.15.33,26159375,methodology,9,NA,Form of the indirect comparison,NA,NA,"Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate)",TRUE,NA,NA,NA
10.2217/cer.15.33,26159375,methodology,9,NA,Definition of a single primary outcome for the indirect comparison,NA,NA,Yes,TRUE,NA,NA,NA
10.2217/cer.15.33,26159375,methodology,9,NA,Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined),sustained virologic response,proportion of genotype 1b patients achieving svr at week 12 or week 24 post-treatment,sustained virologic response,FALSE,NA,NA,NA
10.2217/cer.15.33,26159375,methodology,9,NA,Primary outcome: variable type,NA,NA,Binary (eg rates),TRUE,NA,NA,NA
10.2217/cer.15.33,26159375,methodology,9,NA,Justification for selecting variables to be included in the adjustment model (in the main text),NA,NA,"Nothing mentioned, not reported",TRUE,NA,NA,NA
10.2217/cer.15.33,26159375,methodology,9,NA,Inclusion of prognostic factors in the adjustment/matching model,NA,NA,No discussion (in the main text) of the status of prognostic factors of the variables,TRUE,NA,NA,NA
10.2217/cer.15.33,26159375,methodology,9,NA,Inclusion of treatment-effect modifiers in the adjustment/matching model,NA,NA,No discussion (in the main text) of the status of treatment-effect modifiers of the variables,TRUE,NA,NA,NA
10.2217/cer.15.33,26159375,methodology,9,NA,"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)",NA,NA,No,TRUE,NA,NA,NA
10.2217/cer.15.33,26159375,methodology,9,NA,Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale),NA,NA,No,TRUE,NA,NA,NA
10.2217/cer.15.33,26159375,results,1,NA,Sample size of the population of interest in the non IPD treatment arm,1643,1630,1643,FALSE,NA,NA,NA
10.2217/cer.15.33,26159375,results,1,NA,Reporting of a weights' distribution evaluation (MAIC),NA,NA,Not mentioned,TRUE,NA,NA,NA
10.2217/cer.15.33,26159375,results,1,NA,Reporting of the list of the covariates adjusted for/matched on,NA,NA,No,TRUE,NA,NA,NA
10.2217/cer.15.33,26159375,results,1,NA,Primary outcome: treatment effect contrast,NA,NA,Rate difference,TRUE,NA,NA,NA
10.2217/cer.15.33,26159375,results,1,NA,Direction of the treatment effect contrast: IPD treatment is:,NA,NA,"Numerator if ratio, or left side if difference",TRUE,NA,NA,NA
10.2217/cer.15.33,26159375,results,1,NA,Primary outcome: adjusted treatment effect,NA,NA,8.7,TRUE,NA,NA,NA
10.2217/cer.15.33,26159375,results,1,NA,"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])",[0.2;17.3],[0.2;17.3] p<0.05,[0.2;17.3],FALSE,NA,NA,NA
10.2217/cer.15.33,26159375,results,1,NA,Initial sample size of the population of interest in the IPD treatment arm,324,NA,324,FALSE,NA,NA,NA
10.2217/cer.15.33,26159375,results,2,NA,Sample size of the population of interest in the non IPD treatment arm,NA,NA,368,TRUE,NA,NA,NA
10.2217/cer.15.33,26159375,results,2,NA,Reporting of a weights' distribution evaluation (MAIC),NA,NA,Not mentioned,TRUE,NA,NA,NA
10.2217/cer.15.33,26159375,results,2,NA,Reporting of the list of the covariates adjusted for/matched on,NA,NA,No,TRUE,NA,NA,NA
10.2217/cer.15.33,26159375,results,2,NA,Primary outcome: treatment effect contrast,NA,NA,Rate difference,TRUE,NA,NA,NA
10.2217/cer.15.33,26159375,results,2,NA,Direction of the treatment effect contrast: IPD treatment is:,NA,NA,"Numerator if ratio, or left side if difference",TRUE,NA,NA,NA
10.2217/cer.15.33,26159375,results,2,NA,Primary outcome: adjusted treatment effect,NA,NA,16.5,TRUE,NA,NA,NA
10.2217/cer.15.33,26159375,results,2,NA,"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])",[2.5;30.5],[2.5;30.5] p<0.05,[2.5;30.5],FALSE,NA,NA,NA
10.2217/cer.15.33,26159375,results,2,NA,Initial sample size of the population of interest in the IPD treatment arm,324,NA,324,FALSE,NA,NA,NA
10.2217/cer.15.33,26159375,results,3,NA,Sample size of the population of interest in the non IPD treatment arm,NA,NA,521,TRUE,NA,NA,NA
10.2217/cer.15.33,26159375,results,3,NA,Reporting of a weights' distribution evaluation (MAIC),NA,NA,Not mentioned,TRUE,NA,NA,NA
10.2217/cer.15.33,26159375,results,3,NA,Reporting of the list of the covariates adjusted for/matched on,NA,NA,No,TRUE,NA,NA,NA
10.2217/cer.15.33,26159375,results,3,NA,Primary outcome: treatment effect contrast,NA,NA,Rate difference,TRUE,NA,NA,NA
10.2217/cer.15.33,26159375,results,3,NA,Direction of the treatment effect contrast: IPD treatment is:,NA,NA,"Numerator if ratio, or left side if difference",TRUE,NA,NA,NA
10.2217/cer.15.33,26159375,results,3,NA,Primary outcome: adjusted treatment effect,NA,NA,0.4,TRUE,NA,NA,NA
10.2217/cer.15.33,26159375,results,3,NA,"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])",NA,NA,[-8.9;9.7],TRUE,NA,NA,NA
10.2217/cer.15.33,26159375,results,3,NA,"If anchored comparison, sample size of the population of interest in the non IPD treatment anchor arm",NA,NA,XXXX,FALSE,NA,NA,NA
10.2217/cer.15.33,26159375,results,3,NA,Initial sample size of the population of interest in the IPD treatment arm,324,NA,324,FALSE,NA,NA,NA
10.2217/cer.15.33,26159375,results,4,NA,Sample size of the population of interest in the non IPD treatment arm,NA,NA,327,TRUE,NA,NA,NA
10.2217/cer.15.33,26159375,results,4,NA,Reporting of a weights' distribution evaluation (MAIC),NA,NA,Not mentioned,TRUE,NA,NA,NA
10.2217/cer.15.33,26159375,results,4,NA,Reporting of the list of the covariates adjusted for/matched on,NA,NA,No,TRUE,NA,NA,NA
10.2217/cer.15.33,26159375,results,4,NA,Primary outcome: treatment effect contrast,NA,NA,Rate difference,TRUE,NA,NA,NA
10.2217/cer.15.33,26159375,results,4,NA,Direction of the treatment effect contrast: IPD treatment is:,NA,NA,"Numerator if ratio, or left side if difference",TRUE,NA,NA,NA
10.2217/cer.15.33,26159375,results,4,NA,Primary outcome: adjusted treatment effect,NA,NA,3,TRUE,NA,NA,NA
10.2217/cer.15.33,26159375,results,4,NA,"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])",NA,NA,[-21.2;27.1],TRUE,NA,NA,NA
10.2217/cer.15.33,26159375,results,4,NA,Initial sample size of the population of interest in the IPD treatment arm,324,NA,324,FALSE,NA,NA,NA
10.2217/cer.15.33,26159375,results,5,NA,Sample size of the population of interest in the non IPD treatment arm,NA,NA,988,TRUE,NA,NA,NA
10.2217/cer.15.33,26159375,results,5,NA,Reporting of a weights' distribution evaluation (MAIC),NA,NA,Not mentioned,TRUE,NA,NA,NA
10.2217/cer.15.33,26159375,results,5,NA,Reporting of the list of the covariates adjusted for/matched on,NA,NA,No,TRUE,NA,NA,NA
10.2217/cer.15.33,26159375,results,5,NA,Primary outcome: treatment effect contrast,NA,NA,Rate difference,TRUE,NA,NA,NA
10.2217/cer.15.33,26159375,results,5,NA,Direction of the treatment effect contrast: IPD treatment is:,NA,NA,"Numerator if ratio, or left side if difference",TRUE,NA,NA,NA
10.2217/cer.15.33,26159375,results,5,NA,Primary outcome: adjusted treatment effect,NA,NA,39.6,TRUE,NA,NA,NA
10.2217/cer.15.33,26159375,results,5,NA,"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])",[30.3;48.9],[30.3;48.9] p<0.05,[30.3;48.9],FALSE,NA,NA,NA
10.2217/cer.15.33,26159375,results,5,NA,Initial sample size of the population of interest in the IPD treatment arm,324,NA,324,FALSE,NA,NA,NA
10.2217/cer.15.33,26159375,results,6,NA,Sample size of the population of interest in the non IPD treatment arm,540,266,266,FALSE,NA,NA,NA
10.2217/cer.15.33,26159375,results,6,NA,"Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC",NA,NA,XXXX,FALSE,NA,NA,NA
10.2217/cer.15.33,26159375,results,6,NA,Reporting of a weights' distribution evaluation (MAIC),NA,NA,Not mentioned,TRUE,NA,NA,NA
10.2217/cer.15.33,26159375,results,6,NA,Reporting of the list of the covariates adjusted for/matched on,NA,NA,No,TRUE,NA,NA,NA
10.2217/cer.15.33,26159375,results,6,NA,Primary outcome: treatment effect contrast,NA,NA,Rate difference,TRUE,NA,NA,NA
10.2217/cer.15.33,26159375,results,6,NA,Direction of the treatment effect contrast: IPD treatment is:,NA,NA,"Numerator if ratio, or left side if difference",TRUE,NA,NA,NA
10.2217/cer.15.33,26159375,results,6,NA,Primary outcome: adjusted treatment effect,NA,NA,17,TRUE,NA,NA,NA
10.2217/cer.15.33,26159375,results,6,NA,"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])",[5.3;28.7],[5.3;28.7] p<0.05,[5.3;28.7],FALSE,NA,NA,NA
10.2217/cer.15.33,26159375,results,6,NA,Initial sample size of the population of interest in the IPD treatment arm,314,NA,314,FALSE,NA,NA,NA
10.2217/cer.15.33,26159375,results,7,NA,Sample size of the population of interest in the non IPD treatment arm,NA,NA,162,TRUE,NA,NA,NA
10.2217/cer.15.33,26159375,results,7,NA,Reporting of a weights' distribution evaluation (MAIC),NA,NA,Not mentioned,TRUE,NA,NA,NA
10.2217/cer.15.33,26159375,results,7,NA,Reporting of the list of the covariates adjusted for/matched on,NA,NA,No,TRUE,NA,NA,NA
10.2217/cer.15.33,26159375,results,7,NA,Primary outcome: treatment effect contrast,NA,NA,Rate difference,TRUE,NA,NA,NA
10.2217/cer.15.33,26159375,results,7,NA,Direction of the treatment effect contrast: IPD treatment is:,NA,NA,"Numerator if ratio, or left side if difference",TRUE,NA,NA,NA
10.2217/cer.15.33,26159375,results,7,NA,Primary outcome: adjusted treatment effect,NA,NA,22.8,TRUE,NA,NA,NA
10.2217/cer.15.33,26159375,results,7,NA,"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])",[6.9;38.7],[6.9;38.7] p<0.05,[6.9;38.7],FALSE,NA,NA,NA
10.2217/cer.15.33,26159375,results,7,NA,Initial sample size of the population of interest in the IPD treatment arm,314,NA,314,FALSE,NA,NA,NA
10.2217/cer.15.33,26159375,results,8,NA,Sample size of the population of interest in the non IPD treatment arm,NA,NA,260,TRUE,NA,NA,NA
10.2217/cer.15.33,26159375,results,8,NA,Reporting of a weights' distribution evaluation (MAIC),NA,NA,Not mentioned,TRUE,NA,NA,NA
10.2217/cer.15.33,26159375,results,8,NA,Reporting of the list of the covariates adjusted for/matched on,NA,NA,No,TRUE,NA,NA,NA
10.2217/cer.15.33,26159375,results,8,NA,Primary outcome: treatment effect contrast,NA,NA,Rate difference,TRUE,NA,NA,NA
10.2217/cer.15.33,26159375,results,8,NA,Direction of the treatment effect contrast: IPD treatment is:,NA,NA,"Numerator if ratio, or left side if difference",TRUE,NA,NA,NA
10.2217/cer.15.33,26159375,results,8,NA,Primary outcome: adjusted treatment effect,NA,NA,10.3,TRUE,NA,NA,NA
10.2217/cer.15.33,26159375,results,8,NA,"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])",[1.1;19.5],[1.1;19.5] p<0.05,[1.1;19.5],FALSE,NA,NA,NA
10.2217/cer.15.33,26159375,results,8,NA,Initial sample size of the population of interest in the IPD treatment arm,314,NA,314,FALSE,NA,NA,NA
10.2217/cer.15.33,26159375,results,9,NA,Sample size of the population of interest in the non IPD treatment arm,NA,NA,213,TRUE,NA,NA,NA
10.2217/cer.15.33,26159375,results,9,NA,Reporting of a weights' distribution evaluation (MAIC),NA,NA,Not mentioned,TRUE,NA,NA,NA
10.2217/cer.15.33,26159375,results,9,NA,Reporting of the list of the covariates adjusted for/matched on,NA,NA,No,TRUE,NA,NA,NA
10.2217/cer.15.33,26159375,results,9,NA,Primary outcome: treatment effect contrast,NA,NA,Rate difference,TRUE,NA,NA,NA
10.2217/cer.15.33,26159375,results,9,NA,Direction of the treatment effect contrast: IPD treatment is:,NA,NA,"Numerator if ratio, or left side if difference",TRUE,NA,NA,NA
10.2217/cer.15.33,26159375,results,9,NA,Primary outcome: adjusted treatment effect,NA,NA,57.7,TRUE,NA,NA,NA
10.2217/cer.15.33,26159375,results,9,NA,"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])",[44.0;71.4],[44.0;71.4] p<0.05,[44.0;71.4],FALSE,NA,NA,NA
10.2217/cer.15.33,26159375,results,9,NA,Initial sample size of the population of interest in the IPD treatment arm,314,NA,314,FALSE,NA,NA,NA
10.1185/03007995.2015.1106934,26455472,general_information,NA,NA,Medical Condition of Interest Name,genotype 4 hcv,genotype 4 hepatitis c virus (hcv) infection,genotype 4 hepatitis c virus (hcv) infection,FALSE,NA,NA,NA
10.1185/03007995.2015.1106934,26455472,general_information,NA,NA,Countries of first author affiliations,NA,NA,belgium,TRUE,NA,NA,NA
10.1185/03007995.2015.1106934,26455472,general_information,NA,NA,Countries of last author affiliations,NA,NA,uk,TRUE,NA,NA,NA
10.1185/03007995.2015.1106934,26455472,general_information,NA,NA,"Positions of study investigators (for any authors of the article, any that applies)",NA,NA,"Pharmaceutical Industry, Private Data Analysis Company",TRUE,NA,NA,NA
10.1185/03007995.2015.1106934,26455472,general_information,NA,NA,"At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company",NA,NA,Yes,TRUE,NA,NA,NA
10.1185/03007995.2015.1106934,26455472,general_information,NA,NA,Mentioned sources of funding,NA,NA,Pharmaceutical Industry,TRUE,NA,NA,NA
10.1185/03007995.2015.1106934,26455472,general_information,NA,NA,"Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article",NA,NA,Yes,TRUE,NA,NA,NA
10.1185/03007995.2015.1106934,26455472,general_information,NA,NA,Mention of a systematic review to find the studies to compare treatments of interest,NA,NA,Yes,TRUE,NA,NA,NA
10.1185/03007995.2015.1106934,26455472,study_information,NA,1,Patient-level data used,NA,NA,Yes,TRUE,NA,NA,NA
10.1185/03007995.2015.1106934,26455472,study_information,NA,1,Clinical Trial,NA,NA,Yes,TRUE,NA,NA,NA
10.1185/03007995.2015.1106934,26455472,study_information,NA,1,NCT (only for clinical trial registered on clinicaltrials.gov),NA,NA,NCT01567735,TRUE,NA,NA,NA
10.1185/03007995.2015.1106934,26455472,study_information,NA,1,Country where the clinical trial/observational study was conducted (international if more than one),NA,NA,international,TRUE,NA,NA,NA
10.1185/03007995.2015.1106934,26455472,study_information,NA,1,Phase of the clinical trial (clinical trial only),NA,NA,3,TRUE,NA,NA,NA
10.1185/03007995.2015.1106934,26455472,study_information,NA,1,Number of treatment arms (clinical trial only),NA,NA,1,TRUE,NA,NA,NA
10.1185/03007995.2015.1106934,26455472,study_information,NA,2,Patient-level data used,NA,NA,No,TRUE,NA,NA,NA
10.1185/03007995.2015.1106934,26455472,study_information,NA,2,Clinical Trial,NA,NA,Yes,TRUE,NA,NA,NA
10.1185/03007995.2015.1106934,26455472,study_information,NA,2,Data source name (only if observational study or clinical trial without NCT),NA,NA,varghese et al. (2009),TRUE,NA,NA,NA
10.1185/03007995.2015.1106934,26455472,study_information,NA,2,Country where the clinical trial/observational study was conducted (international if more than one),NA,NA,kuwait,TRUE,NA,NA,NA
10.1185/03007995.2015.1106934,26455472,study_information,NA,2,Number of treatment arms (clinical trial only),NA,NA,1,TRUE,NA,NA,NA
10.1185/03007995.2015.1106934,26455472,study_information,NA,3,Patient-level data used,NA,NA,No,TRUE,NA,NA,NA
10.1185/03007995.2015.1106934,26455472,study_information,NA,3,Clinical Trial,NA,NA,Yes,TRUE,NA,NA,NA
10.1185/03007995.2015.1106934,26455472,study_information,NA,3,Data source name (only if observational study or clinical trial without NCT),NA,NA,rumi et al. (2010),TRUE,NA,NA,NA
10.1185/03007995.2015.1106934,26455472,study_information,NA,3,Country where the clinical trial/observational study was conducted (international if more than one),NA,NA,italy,TRUE,NA,NA,NA
10.1185/03007995.2015.1106934,26455472,study_information,NA,3,Number of treatment arms (clinical trial only),NA,NA,2 or more,TRUE,NA,NA,NA
10.1185/03007995.2015.1106934,26455472,study_information,NA,4,Patient-level data used,NA,NA,No,TRUE,NA,NA,NA
10.1185/03007995.2015.1106934,26455472,study_information,NA,4,Clinical Trial,NA,NA,Yes,TRUE,NA,NA,NA
10.1185/03007995.2015.1106934,26455472,study_information,NA,4,Data source name (only if observational study or clinical trial without NCT),NA,NA,el makhzangy et al. (2009),TRUE,NA,NA,NA
10.1185/03007995.2015.1106934,26455472,study_information,NA,4,Country where the clinical trial/observational study was conducted (international if more than one),NA,NA,egypt,TRUE,NA,NA,NA
10.1185/03007995.2015.1106934,26455472,study_information,NA,4,Number of treatment arms (clinical trial only),NA,NA,1,TRUE,NA,NA,NA
10.1185/03007995.2015.1106934,26455472,study_information,NA,5,Patient-level data used,NA,NA,No,TRUE,NA,NA,NA
10.1185/03007995.2015.1106934,26455472,study_information,NA,5,Clinical Trial,NA,NA,Yes,TRUE,NA,NA,NA
10.1185/03007995.2015.1106934,26455472,study_information,NA,5,NCT (only for clinical trial registered on clinicaltrials.gov),NA,NA,NCT00421434,TRUE,NA,NA,NA
10.1185/03007995.2015.1106934,26455472,study_information,NA,5,Country where the clinical trial/observational study was conducted (international if more than one),unknown,egypt,egypt,FALSE,NA,NA,NA
10.1185/03007995.2015.1106934,26455472,study_information,NA,5,Phase of the clinical trial (clinical trial only),4,"2, 3","2, 3",FALSE,NA,NA,NA
10.1185/03007995.2015.1106934,26455472,study_information,NA,5,Number of treatment arms (clinical trial only),NA,NA,2 or more,TRUE,NA,NA,NA
10.1185/03007995.2015.1106934,26455472,study_information,NA,6,Patient-level data used,NA,NA,No,TRUE,NA,NA,NA
10.1185/03007995.2015.1106934,26455472,study_information,NA,6,Clinical Trial,NA,NA,Yes,TRUE,NA,NA,NA
10.1185/03007995.2015.1106934,26455472,study_information,NA,6,NCT (only for clinical trial registered on clinicaltrials.gov),NA,NA,NCT00502099,TRUE,NA,NA,NA
10.1185/03007995.2015.1106934,26455472,study_information,NA,6,Country where the clinical trial/observational study was conducted (international if more than one),NA,NA,egypt,TRUE,NA,NA,NA
10.1185/03007995.2015.1106934,26455472,study_information,NA,6,Phase of the clinical trial (clinical trial only),"2, 3",4,4,FALSE,NA,NA,NA
10.1185/03007995.2015.1106934,26455472,study_information,NA,6,Number of treatment arms (clinical trial only),NA,NA,2 or more,TRUE,NA,NA,NA
10.1185/03007995.2015.1106934,26455472,methodology,1,NA,Treatment name 1,simeprevir + peginterferon alfa-2a + ribavirin,simÃ©prÃ©vir + peginterferon alpha 2a + ribavirin,simeprevir + peginterferon alfa-2a + ribavirin,FALSE,"undertaken in the context of Health Technology Approval   BMI as other
Considering that they adjusted on both prognostic and treatment effect modifiers variables 
Sample size given after matching is likely not an ESS, but still reported in the form","

BMI = others covariates",NA
10.1185/03007995.2015.1106934,26455472,methodology,1,NA,Study 'number(s)' for treatment 1,NA,NA,1,TRUE,NA,NA,NA
10.1185/03007995.2015.1106934,26455472,methodology,1,NA,Treatment name 2,peginterferon alfa-2a + ribavirin,peginterferon alfa- 2a + ribavirin,peginterferon alfa-2a + ribavirin,FALSE,NA,NA,NA
10.1185/03007995.2015.1106934,26455472,methodology,1,NA,Study 'number(s)' for treatment 2,NA,NA,2,TRUE,NA,NA,NA
10.1185/03007995.2015.1106934,26455472,methodology,1,NA,Type of population-adjusted indirect comparisons performed,NA,NA,MAIC,TRUE,NA,NA,NA
10.1185/03007995.2015.1106934,26455472,methodology,1,NA,Anchored comparison?,NA,NA,No,TRUE,NA,NA,NA
10.1185/03007995.2015.1106934,26455472,methodology,1,NA,Form of the indirect comparison,NA,NA,Simple (ie treatments effects extracted from two studies),TRUE,NA,NA,NA
10.1185/03007995.2015.1106934,26455472,methodology,1,NA,Definition of a single primary outcome for the indirect comparison,NA,NA,Yes,TRUE,NA,NA,NA
10.1185/03007995.2015.1106934,26455472,methodology,1,NA,Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined),sustained viral response,percentage of patients achieving sustained viral response (svr,sustained viral response,FALSE,NA,NA,NA
10.1185/03007995.2015.1106934,26455472,methodology,1,NA,Primary outcome: variable type,NA,NA,Binary (eg rates),TRUE,NA,NA,NA
10.1185/03007995.2015.1106934,26455472,methodology,1,NA,Justification for selecting variables to be included in the adjustment model (in the main text),A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion),"Nothing mentioned, not reported",A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion),FALSE,NA,NA,NA
10.1185/03007995.2015.1106934,26455472,methodology,1,NA,Inclusion of prognostic factors in the adjustment/matching model,Yes,No discussion (in the main text) of the status of prognostic factors of the variables,No,FALSE,NA,NA,NA
10.1185/03007995.2015.1106934,26455472,methodology,1,NA,Inclusion of treatment-effect modifiers in the adjustment/matching model,Yes,No discussion (in the main text) of the status of treatment-effect modifiers of the variables,Yes,FALSE,NA,NA,NA
10.1185/03007995.2015.1106934,26455472,methodology,1,NA,"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)",NA,NA,No,TRUE,NA,NA,NA
10.1185/03007995.2015.1106934,26455472,methodology,1,NA,Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale),NA,NA,No,TRUE,NA,NA,NA
10.1185/03007995.2015.1106934,26455472,methodology,2,NA,Treatment name 1,simeprevir + peginterferon alfa-2a + ribavirin,simÃ©prÃ©vir + peginterferon alpha 2a + ribavirin,simeprevir + peginterferon alfa-2a + ribavirin,FALSE,NA,BMI = others covariates,NA
10.1185/03007995.2015.1106934,26455472,methodology,2,NA,Study 'number(s)' for treatment 1,NA,NA,1,TRUE,NA,NA,NA
10.1185/03007995.2015.1106934,26455472,methodology,2,NA,Treatment name 2,peginterferon alfa-2a + ribavirin,peginterferon alpha 2a + ribavirin,peginterferon alfa-2a + ribavirin,FALSE,NA,NA,NA
10.1185/03007995.2015.1106934,26455472,methodology,2,NA,Study 'number(s)' for treatment 2,2,3,3,FALSE,NA,NA,NA
10.1185/03007995.2015.1106934,26455472,methodology,2,NA,Type of population-adjusted indirect comparisons performed,NA,NA,MAIC,TRUE,NA,NA,NA
10.1185/03007995.2015.1106934,26455472,methodology,2,NA,Anchored comparison?,NA,NA,No,TRUE,NA,NA,NA
10.1185/03007995.2015.1106934,26455472,methodology,2,NA,Form of the indirect comparison,NA,NA,Simple (ie treatments effects extracted from two studies),TRUE,NA,NA,NA
10.1185/03007995.2015.1106934,26455472,methodology,2,NA,Definition of a single primary outcome for the indirect comparison,NA,NA,Yes,TRUE,NA,NA,NA
10.1185/03007995.2015.1106934,26455472,methodology,2,NA,Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined),sustained viral response,percentage of patients achieving sustained viral response (svr,sustained viral response,FALSE,NA,NA,NA
10.1185/03007995.2015.1106934,26455472,methodology,2,NA,Primary outcome: variable type,NA,NA,Binary (eg rates),TRUE,NA,NA,NA
10.1185/03007995.2015.1106934,26455472,methodology,2,NA,Justification for selecting variables to be included in the adjustment model (in the main text),A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion),"Nothing mentioned, not reported",A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion),FALSE,NA,NA,NA
10.1185/03007995.2015.1106934,26455472,methodology,2,NA,Inclusion of prognostic factors in the adjustment/matching model,Yes,No discussion (in the main text) of the status of prognostic factors of the variables,No,FALSE,NA,NA,NA
10.1185/03007995.2015.1106934,26455472,methodology,2,NA,Inclusion of treatment-effect modifiers in the adjustment/matching model,Yes,No discussion (in the main text) of the status of treatment-effect modifiers of the variables,Yes,FALSE,NA,NA,NA
10.1185/03007995.2015.1106934,26455472,methodology,2,NA,"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)",NA,NA,No,TRUE,NA,NA,NA
10.1185/03007995.2015.1106934,26455472,methodology,2,NA,Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale),NA,NA,No,TRUE,NA,NA,NA
10.1185/03007995.2015.1106934,26455472,methodology,3,NA,Treatment name 1,simeprevir + peginterferon alfa-2a + ribavirin,simÃ©prÃ©vir + peginterferon alpha 2a + ribavirin,simeprevir + peginterferon alfa-2a + ribavirin,FALSE,NA,NA,NA
10.1185/03007995.2015.1106934,26455472,methodology,3,NA,Study 'number(s)' for treatment 1,NA,NA,1,TRUE,NA,NA,NA
10.1185/03007995.2015.1106934,26455472,methodology,3,NA,Treatment name 2,peginterferon alfa-2a + ribavirin,peginterferon alpha 2a + ribavirin,peginterferon alfa-2a + ribavirin,FALSE,NA,NA,NA
10.1185/03007995.2015.1106934,26455472,methodology,3,NA,Study 'number(s)' for treatment 2,NA,NA,4,TRUE,NA,NA,NA
10.1185/03007995.2015.1106934,26455472,methodology,3,NA,Type of population-adjusted indirect comparisons performed,NA,NA,MAIC,TRUE,NA,NA,NA
10.1185/03007995.2015.1106934,26455472,methodology,3,NA,Anchored comparison?,NA,NA,No,TRUE,NA,NA,NA
10.1185/03007995.2015.1106934,26455472,methodology,3,NA,Form of the indirect comparison,NA,NA,Simple (ie treatments effects extracted from two studies),TRUE,NA,NA,NA
10.1185/03007995.2015.1106934,26455472,methodology,3,NA,Definition of a single primary outcome for the indirect comparison,NA,NA,Yes,TRUE,NA,NA,NA
10.1185/03007995.2015.1106934,26455472,methodology,3,NA,Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined),sustained viral response,percentage of patients achieving sustained viral response (svr,sustained viral response,FALSE,NA,NA,NA
10.1185/03007995.2015.1106934,26455472,methodology,3,NA,Primary outcome: variable type,NA,NA,Binary (eg rates),TRUE,NA,NA,NA
10.1185/03007995.2015.1106934,26455472,methodology,3,NA,Justification for selecting variables to be included in the adjustment model (in the main text),A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion),"Nothing mentioned, not reported",A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion),FALSE,NA,NA,NA
10.1185/03007995.2015.1106934,26455472,methodology,3,NA,Inclusion of prognostic factors in the adjustment/matching model,Yes,No discussion (in the main text) of the status of prognostic factors of the variables,No,FALSE,NA,NA,NA
10.1185/03007995.2015.1106934,26455472,methodology,3,NA,Inclusion of treatment-effect modifiers in the adjustment/matching model,Yes,No discussion (in the main text) of the status of treatment-effect modifiers of the variables,Yes,FALSE,NA,NA,NA
10.1185/03007995.2015.1106934,26455472,methodology,3,NA,"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)",NA,NA,No,TRUE,NA,NA,NA
10.1185/03007995.2015.1106934,26455472,methodology,3,NA,Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale),NA,NA,No,TRUE,NA,NA,NA
10.1185/03007995.2015.1106934,26455472,methodology,4,NA,Treatment name 1,simeprevir + peginterferon alfa-2a + ribavirin,simÃ©prÃ©vir + peginterferon alpha 2a + ribavirin,simeprevir + peginterferon alfa-2a + ribavirin,FALSE,NA,NA,NA
10.1185/03007995.2015.1106934,26455472,methodology,4,NA,Study 'number(s)' for treatment 1,NA,NA,1,TRUE,NA,NA,NA
10.1185/03007995.2015.1106934,26455472,methodology,4,NA,Treatment name 2,peginterferon alfa-2a + ribavirin,peginterferon alpha 2a + ribavirin,peginterferon alfa-2a + ribavirin,FALSE,NA,NA,NA
10.1185/03007995.2015.1106934,26455472,methodology,4,NA,Study 'number(s)' for treatment 2,NA,NA,5,TRUE,NA,NA,NA
10.1185/03007995.2015.1106934,26455472,methodology,4,NA,Type of population-adjusted indirect comparisons performed,NA,NA,MAIC,TRUE,NA,NA,NA
10.1185/03007995.2015.1106934,26455472,methodology,4,NA,Anchored comparison?,NA,NA,No,TRUE,NA,NA,NA
10.1185/03007995.2015.1106934,26455472,methodology,4,NA,Form of the indirect comparison,NA,NA,Simple (ie treatments effects extracted from two studies),TRUE,NA,NA,NA
10.1185/03007995.2015.1106934,26455472,methodology,4,NA,Definition of a single primary outcome for the indirect comparison,NA,NA,Yes,TRUE,NA,NA,NA
10.1185/03007995.2015.1106934,26455472,methodology,4,NA,Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined),sustained viral response,percentage of patients achieving sustained viral response (svr,sustained viral response,FALSE,NA,NA,NA
10.1185/03007995.2015.1106934,26455472,methodology,4,NA,Primary outcome: variable type,NA,NA,Binary (eg rates),TRUE,NA,NA,NA
10.1185/03007995.2015.1106934,26455472,methodology,4,NA,Justification for selecting variables to be included in the adjustment model (in the main text),A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion),"Nothing mentioned, not reported",A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion),FALSE,NA,NA,NA
10.1185/03007995.2015.1106934,26455472,methodology,4,NA,Inclusion of prognostic factors in the adjustment/matching model,Yes,No discussion (in the main text) of the status of prognostic factors of the variables,No,FALSE,NA,NA,NA
10.1185/03007995.2015.1106934,26455472,methodology,4,NA,Inclusion of treatment-effect modifiers in the adjustment/matching model,Yes,No discussion (in the main text) of the status of treatment-effect modifiers of the variables,Yes,FALSE,NA,NA,NA
10.1185/03007995.2015.1106934,26455472,methodology,4,NA,"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)",NA,NA,No,TRUE,NA,NA,NA
10.1185/03007995.2015.1106934,26455472,methodology,4,NA,Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale),NA,NA,No,TRUE,NA,NA,NA
10.1185/03007995.2015.1106934,26455472,methodology,5,NA,Treatment name 1,simeprevir + peginterferon alfa-2a + ribavirin,simÃ©prÃ©vir + peginterferon alpha 2a + ribavirin,simeprevir + peginterferon alfa-2a + ribavirin,FALSE,NA,NA,NA
10.1185/03007995.2015.1106934,26455472,methodology,5,NA,Study 'number(s)' for treatment 1,NA,NA,1,TRUE,NA,NA,NA
10.1185/03007995.2015.1106934,26455472,methodology,5,NA,Treatment name 2,peginterferon alfa-2a + ribavirin,peginterferon alpha 2a + ribavirin,peginterferon alfa-2a + ribavirin,FALSE,NA,NA,NA
10.1185/03007995.2015.1106934,26455472,methodology,5,NA,Study 'number(s)' for treatment 2,NA,NA,6,TRUE,NA,NA,NA
10.1185/03007995.2015.1106934,26455472,methodology,5,NA,Type of population-adjusted indirect comparisons performed,NA,NA,MAIC,TRUE,NA,NA,NA
10.1185/03007995.2015.1106934,26455472,methodology,5,NA,Anchored comparison?,NA,NA,No,TRUE,NA,NA,NA
10.1185/03007995.2015.1106934,26455472,methodology,5,NA,Form of the indirect comparison,NA,NA,Simple (ie treatments effects extracted from two studies),TRUE,NA,NA,NA
10.1185/03007995.2015.1106934,26455472,methodology,5,NA,Definition of a single primary outcome for the indirect comparison,NA,NA,Yes,TRUE,NA,NA,NA
10.1185/03007995.2015.1106934,26455472,methodology,5,NA,Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined),sustained viral response,percentage of patients achieving sustained viral response (svr,sustained viral response,FALSE,NA,NA,NA
10.1185/03007995.2015.1106934,26455472,methodology,5,NA,Primary outcome: variable type,NA,NA,Binary (eg rates),TRUE,NA,NA,NA
10.1185/03007995.2015.1106934,26455472,methodology,5,NA,Justification for selecting variables to be included in the adjustment model (in the main text),A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion),"Nothing mentioned, not reported",A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion),FALSE,NA,NA,NA
10.1185/03007995.2015.1106934,26455472,methodology,5,NA,Inclusion of prognostic factors in the adjustment/matching model,Yes,No discussion (in the main text) of the status of prognostic factors of the variables,No,FALSE,NA,NA,NA
10.1185/03007995.2015.1106934,26455472,methodology,5,NA,Inclusion of treatment-effect modifiers in the adjustment/matching model,Yes,No discussion (in the main text) of the status of treatment-effect modifiers of the variables,Yes,FALSE,NA,NA,NA
10.1185/03007995.2015.1106934,26455472,methodology,5,NA,"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)",NA,NA,No,TRUE,NA,NA,NA
10.1185/03007995.2015.1106934,26455472,methodology,5,NA,Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale),NA,NA,No,TRUE,NA,NA,NA
10.1185/03007995.2015.1106934,26455472,results,1,NA,Sample size of the population of interest in the non IPD treatment arm,NA,NA,30,TRUE,NA,NA,NA
10.1185/03007995.2015.1106934,26455472,results,1,NA,Initial sample size of the population of interest in the IPD treatment arm,30,35,35,FALSE,NA,NA,NA
10.1185/03007995.2015.1106934,26455472,results,1,NA,"Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC",NA,NA,29,TRUE,NA,NA,NA
10.1185/03007995.2015.1106934,26455472,results,1,NA,Reporting of a weights' distribution evaluation (MAIC),NA,NA,Not mentioned,TRUE,NA,NA,NA
10.1185/03007995.2015.1106934,26455472,results,1,NA,Reporting of the list of the covariates adjusted for/matched on,NA,NA,Yes,TRUE,NA,NA,NA
10.1185/03007995.2015.1106934,26455472,results,1,NA,Number of covariates adjusted for/matched on,NA,NA,5,TRUE,NA,NA,NA
10.1185/03007995.2015.1106934,26455472,results,1,NA,Covariates adjusted for/matched on in the indirect comparison,NA,NA,"Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Other(s)",TRUE,NA,NA,NA
10.1185/03007995.2015.1106934,26455472,results,1,NA,Primary outcome: treatment effect contrast,NA,NA,OR,TRUE,NA,NA,NA
10.1185/03007995.2015.1106934,26455472,results,1,NA,Direction of the treatment effect contrast: IPD treatment is:,NA,NA,"Numerator if ratio, or left side if difference",TRUE,NA,NA,NA
10.1185/03007995.2015.1106934,26455472,results,1,NA,Primary outcome: adjusted treatment effect,NA,NA,3.28,TRUE,NA,NA,NA
10.1185/03007995.2015.1106934,26455472,results,2,NA,Sample size of the population of interest in the non IPD treatment arm,NA,NA,18,TRUE,NA,NA,NA
10.1185/03007995.2015.1106934,26455472,results,2,NA,Initial sample size of the population of interest in the IPD treatment arm,30,35,35,FALSE,NA,NA,NA
10.1185/03007995.2015.1106934,26455472,results,2,NA,"Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC",NA,NA,15,TRUE,NA,NA,NA
10.1185/03007995.2015.1106934,26455472,results,2,NA,Reporting of a weights' distribution evaluation (MAIC),NA,NA,Not mentioned,TRUE,NA,NA,NA
10.1185/03007995.2015.1106934,26455472,results,2,NA,Reporting of the list of the covariates adjusted for/matched on,NA,NA,Yes,TRUE,NA,NA,NA
10.1185/03007995.2015.1106934,26455472,results,2,NA,Number of covariates adjusted for/matched on,NA,NA,5,TRUE,NA,NA,NA
10.1185/03007995.2015.1106934,26455472,results,2,NA,Covariates adjusted for/matched on in the indirect comparison,NA,NA,"Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Other(s)",TRUE,NA,NA,NA
10.1185/03007995.2015.1106934,26455472,results,2,NA,Primary outcome: treatment effect contrast,NA,NA,OR,TRUE,NA,NA,NA
10.1185/03007995.2015.1106934,26455472,results,2,NA,Direction of the treatment effect contrast: IPD treatment is:,NA,NA,"Numerator if ratio, or left side if difference",TRUE,NA,NA,NA
10.1185/03007995.2015.1106934,26455472,results,2,NA,Primary outcome: adjusted treatment effect,NA,NA,4.26,TRUE,NA,NA,NA
10.1185/03007995.2015.1106934,26455472,results,3,NA,Sample size of the population of interest in the non IPD treatment arm,NA,NA,95,TRUE,NA,NA,NA
10.1185/03007995.2015.1106934,26455472,results,3,NA,Initial sample size of the population of interest in the IPD treatment arm,30,31,30,FALSE,NA,NA,NA
10.1185/03007995.2015.1106934,26455472,results,3,NA,"Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC",NA,NA,14,TRUE,NA,NA,NA
10.1185/03007995.2015.1106934,26455472,results,3,NA,Reporting of a weights' distribution evaluation (MAIC),NA,NA,Not mentioned,TRUE,NA,NA,NA
10.1185/03007995.2015.1106934,26455472,results,3,NA,Reporting of the list of the covariates adjusted for/matched on,NA,NA,Yes,TRUE,NA,NA,NA
10.1185/03007995.2015.1106934,26455472,results,3,NA,Number of covariates adjusted for/matched on,NA,NA,2,TRUE,NA,NA,NA
10.1185/03007995.2015.1106934,26455472,results,3,NA,Covariates adjusted for/matched on in the indirect comparison,NA,NA,"Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease)",TRUE,NA,NA,NA
10.1185/03007995.2015.1106934,26455472,results,3,NA,Primary outcome: treatment effect contrast,NA,NA,OR,TRUE,NA,NA,NA
10.1185/03007995.2015.1106934,26455472,results,3,NA,Direction of the treatment effect contrast: IPD treatment is:,NA,NA,"Numerator if ratio, or left side if difference",TRUE,NA,NA,NA
10.1185/03007995.2015.1106934,26455472,results,3,NA,Primary outcome: adjusted treatment effect,NA,NA,10.02,TRUE,NA,NA,NA
10.1185/03007995.2015.1106934,26455472,results,4,NA,Sample size of the population of interest in the non IPD treatment arm,NA,NA,40,TRUE,NA,NA,NA
10.1185/03007995.2015.1106934,26455472,results,4,NA,Initial sample size of the population of interest in the IPD treatment arm,30,35,35,FALSE,NA,NA,NA
10.1185/03007995.2015.1106934,26455472,results,4,NA,"Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC",NA,NA,26,TRUE,NA,NA,NA
10.1185/03007995.2015.1106934,26455472,results,4,NA,Reporting of a weights' distribution evaluation (MAIC),NA,NA,Not mentioned,TRUE,NA,NA,NA
10.1185/03007995.2015.1106934,26455472,results,4,NA,Reporting of the list of the covariates adjusted for/matched on,NA,NA,Yes,TRUE,NA,NA,NA
10.1185/03007995.2015.1106934,26455472,results,4,NA,Number of covariates adjusted for/matched on,NA,NA,2,TRUE,NA,NA,NA
10.1185/03007995.2015.1106934,26455472,results,4,NA,Covariates adjusted for/matched on in the indirect comparison,NA,NA,"Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease)",TRUE,NA,NA,NA
10.1185/03007995.2015.1106934,26455472,results,4,NA,Primary outcome: treatment effect contrast,NA,NA,OR,TRUE,NA,NA,NA
10.1185/03007995.2015.1106934,26455472,results,4,NA,Direction of the treatment effect contrast: IPD treatment is:,NA,NA,"Numerator if ratio, or left side if difference",TRUE,NA,NA,NA
10.1185/03007995.2015.1106934,26455472,results,4,NA,Primary outcome: adjusted treatment effect,NA,NA,6.69,TRUE,NA,NA,NA
10.1185/03007995.2015.1106934,26455472,results,4,NA,"If anchored comparison, sample size of the population of interest in the non IPD treatment anchor arm",NA,NA,XXXX,FALSE,NA,NA,NA
10.1185/03007995.2015.1106934,26455472,results,5,NA,Sample size of the population of interest in the non IPD treatment arm,NA,NA,109,TRUE,NA,NA,NA
10.1185/03007995.2015.1106934,26455472,results,5,NA,Initial sample size of the population of interest in the IPD treatment arm,30,19,19,FALSE,NA,NA,NA
10.1185/03007995.2015.1106934,26455472,results,5,NA,"Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC",NA,NA,17,TRUE,NA,NA,NA
10.1185/03007995.2015.1106934,26455472,results,5,NA,Reporting of a weights' distribution evaluation (MAIC),NA,NA,Not mentioned,TRUE,NA,NA,NA
10.1185/03007995.2015.1106934,26455472,results,5,NA,Reporting of the list of the covariates adjusted for/matched on,NA,NA,Yes,TRUE,NA,NA,NA
10.1185/03007995.2015.1106934,26455472,results,5,NA,Number of covariates adjusted for/matched on,NA,NA,2,TRUE,NA,NA,NA
10.1185/03007995.2015.1106934,26455472,results,5,NA,Covariates adjusted for/matched on in the indirect comparison,NA,NA,"Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease)",TRUE,NA,NA,NA
10.1185/03007995.2015.1106934,26455472,results,5,NA,Primary outcome: treatment effect contrast,NA,NA,OR,TRUE,NA,NA,NA
10.1185/03007995.2015.1106934,26455472,results,5,NA,Direction of the treatment effect contrast: IPD treatment is:,NA,NA,"Numerator if ratio, or left side if difference",TRUE,NA,NA,NA
10.1185/03007995.2015.1106934,26455472,results,5,NA,Primary outcome: adjusted treatment effect,NA,NA,5.43,TRUE,NA,NA,NA
10.2217/cer.15.69,26793987,general_information,NA,NA,Medical Condition of Interest Name,hepatitis c virus genotype 1b,hepatitis c genotype 1,XXXX,FALSE,NA,NA,NA
10.2217/cer.15.69,26793987,general_information,NA,NA,Countries of first author affiliations,NA,NA,usa,TRUE,NA,NA,NA
10.2217/cer.15.69,26793987,general_information,NA,NA,Countries of last author affiliations,NA,NA,usa,TRUE,NA,NA,NA
10.2217/cer.15.69,26793987,general_information,NA,NA,"Positions of study investigators (for any authors of the article, any that applies)",NA,NA,"Pharmaceutical Industry, Private Data Analysis Company",TRUE,NA,NA,NA
10.2217/cer.15.69,26793987,general_information,NA,NA,"At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company",NA,NA,Yes,TRUE,NA,NA,NA
10.2217/cer.15.69,26793987,general_information,NA,NA,Mentioned sources of funding,NA,NA,Pharmaceutical Industry,TRUE,NA,NA,NA
10.2217/cer.15.69,26793987,general_information,NA,NA,"Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article",NA,NA,Yes,TRUE,NA,NA,NA
10.2217/cer.15.69,26793987,general_information,NA,NA,Mention of a systematic review to find the studies to compare treatments of interest,Yes,No,Yes,FALSE,NA,NA,NA
10.2217/cer.15.69,26793987,study_information,NA,1,Patient-level data used,NA,NA,Yes,TRUE,NA,NA,NA
10.2217/cer.15.69,26793987,study_information,NA,1,Clinical Trial,NA,NA,Yes,TRUE,NA,NA,NA
10.2217/cer.15.69,26793987,study_information,NA,1,NCT (only for clinical trial registered on clinicaltrials.gov),NA,NA,NCT01497834,TRUE,NA,NA,NA
10.2217/cer.15.69,26793987,study_information,NA,1,Country where the clinical trial/observational study was conducted (international if more than one),NA,NA,japan,TRUE,NA,NA,NA
10.2217/cer.15.69,26793987,study_information,NA,1,Phase of the clinical trial (clinical trial only),NA,NA,3,TRUE,NA,NA,NA
10.2217/cer.15.69,26793987,study_information,NA,1,Number of treatment arms (clinical trial only),NA,NA,1,TRUE,NA,NA,NA
10.2217/cer.15.69,26793987,study_information,NA,2,Patient-level data used,Yes,NA,XXXX,FALSE,NA,NA,NA
10.2217/cer.15.69,26793987,study_information,NA,2,Clinical Trial,Yes,NA,XXXX,FALSE,NA,NA,NA
10.2217/cer.15.69,26793987,study_information,NA,2,NCT (only for clinical trial registered on clinicaltrials.gov),NCT01718145,NA,NCT01718145,FALSE,NA,NA,NA
10.2217/cer.15.69,26793987,study_information,NA,2,Country where the clinical trial/observational study was conducted (international if more than one),japan,NA,japan,FALSE,NA,NA,NA
10.2217/cer.15.69,26793987,study_information,NA,2,Phase of the clinical trial (clinical trial only),3,NA,3,FALSE,NA,NA,NA
10.2217/cer.15.69,26793987,study_information,NA,2,Number of treatment arms (clinical trial only),2 or more,NA,2 or more,FALSE,NA,NA,NA
10.2217/cer.15.69,26793987,study_information,NA,3,Patient-level data used,NA,NA,No,TRUE,NA,NA,NA
10.2217/cer.15.69,26793987,study_information,NA,3,Clinical Trial,NA,NA,Yes,TRUE,NA,NA,NA
10.2217/cer.15.69,26793987,study_information,NA,3,NCT (only for clinical trial registered on clinicaltrials.gov),NA,NA,NCT01975675,TRUE,NA,NA,NA
10.2217/cer.15.69,26793987,study_information,NA,3,Country where the clinical trial/observational study was conducted (international if more than one),NA,NA,japan,TRUE,NA,NA,NA
10.2217/cer.15.69,26793987,study_information,NA,3,Phase of the clinical trial (clinical trial only),NA,NA,3,TRUE,NA,NA,NA
10.2217/cer.15.69,26793987,study_information,NA,3,Number of treatment arms (clinical trial only),NA,NA,2 or more,TRUE,NA,NA,NA
10.2217/cer.15.69,26793987,methodology,1,NA,Treatment name 1,NA,NA,daclatasvir + asunaprevir,TRUE,"supplementary materials not available
BMI  (others)
unadjusted and adjusted rate difference confidence interval seem off, not consistent with groups estimates, neither with pvalues
rate differences calculated manually","BMI = other

Rate difference before adjustment = 1 -  0.952 = 0.048
Rate difference after adjustment = 1 -  0.993 = 0.007",NA
10.2217/cer.15.69,26793987,methodology,1,NA,Study 'number(s)' for treatment 1,1;2,1,1;2,FALSE,NA,NA,NA
10.2217/cer.15.69,26793987,methodology,1,NA,Treatment name 2,sofosbuvir + ledipasvir,ofosbuvir/ ledipasvir,sofosbuvir + ledipasvir,FALSE,NA,NA,NA
10.2217/cer.15.69,26793987,methodology,1,NA,Study 'number(s)' for treatment 2,NA,NA,3,TRUE,NA,NA,NA
10.2217/cer.15.69,26793987,methodology,1,NA,Type of population-adjusted indirect comparisons performed,NA,NA,MAIC,TRUE,NA,NA,NA
10.2217/cer.15.69,26793987,methodology,1,NA,Anchored comparison?,NA,NA,No,TRUE,NA,NA,NA
10.2217/cer.15.69,26793987,methodology,1,NA,Form of the indirect comparison,"Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate)",Simple (ie treatments effects extracted from two studies),Simple (ie treatments effects extracted from two studies),FALSE,NA,NA,NA
10.2217/cer.15.69,26793987,methodology,1,NA,Definition of a single primary outcome for the indirect comparison,NA,NA,Yes,TRUE,NA,NA,NA
10.2217/cer.15.69,26793987,methodology,1,NA,Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined),sustained virologic response at week 12 post-treatment,sustained virologic response (svr) at 12 weeks post treatment,sustained virologic response at week 12 post-treatment,FALSE,NA,NA,NA
10.2217/cer.15.69,26793987,methodology,1,NA,Primary outcome: variable type,NA,NA,Binary (eg rates),TRUE,NA,NA,NA
10.2217/cer.15.69,26793987,methodology,1,NA,Justification for selecting variables to be included in the adjustment model (in the main text),NA,NA,"Nothing mentioned, not reported",TRUE,NA,NA,NA
10.2217/cer.15.69,26793987,methodology,1,NA,Inclusion of prognostic factors in the adjustment/matching model,NA,NA,No discussion (in the main text) of the status of prognostic factors of the variables,TRUE,NA,NA,NA
10.2217/cer.15.69,26793987,methodology,1,NA,Inclusion of treatment-effect modifiers in the adjustment/matching model,NA,NA,No discussion (in the main text) of the status of treatment-effect modifiers of the variables,TRUE,NA,NA,NA
10.2217/cer.15.69,26793987,methodology,1,NA,"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)",NA,NA,No,TRUE,NA,NA,NA
10.2217/cer.15.69,26793987,methodology,1,NA,Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale),NA,NA,No,TRUE,NA,NA,NA
10.2217/cer.15.69,26793987,results,1,NA,Sample size of the population of interest in the non IPD treatment arm,NA,NA,171,TRUE,NA,NA,NA
10.2217/cer.15.69,26793987,results,1,NA,Initial sample size of the population of interest in the IPD treatment arm,NA,NA,252,TRUE,NA,NA,NA
10.2217/cer.15.69,26793987,results,1,NA,Reporting of a weights' distribution evaluation (MAIC),NA,NA,Not mentioned,TRUE,NA,NA,NA
10.2217/cer.15.69,26793987,results,1,NA,Reporting of the list of the covariates adjusted for/matched on,NA,NA,Yes,TRUE,NA,NA,NA
10.2217/cer.15.69,26793987,results,1,NA,Number of covariates adjusted for/matched on,NA,NA,11,TRUE,NA,NA,NA
10.2217/cer.15.69,26793987,results,1,NA,Covariates adjusted for/matched on in the indirect comparison,NA,NA,"Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Past treatments for the disease of interest, Other(s)",TRUE,NA,NA,NA
10.2217/cer.15.69,26793987,results,1,NA,Primary outcome: treatment effect contrast,NA,NA,Rate difference,TRUE,NA,NA,NA
10.2217/cer.15.69,26793987,results,1,NA,Direction of the treatment effect contrast: IPD treatment is:,"Numerator if ratio, or left side if difference","Denominator if ratio, or rightside if difference","Numerator if ratio, or left side if difference",FALSE,NA,NA,NA
10.2217/cer.15.69,26793987,results,1,NA,"p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])",NA,NA,0.004,TRUE,NA,NA,NA
10.2217/cer.15.69,26793987,results,1,NA,"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])",NA,NA,0.398,TRUE,NA,NA,NA
10.2217/cer.15.69,26793987,results,1,NA,Primary outcome: unadjusted treatment effect,-0.048,NA,XXXX,FALSE,NA,NA,NA
10.2217/cer.15.69,26793987,results,1,NA,Primary outcome: adjusted treatment effect,-0.007,NA,XXXX,FALSE,NA,NA,NA
10.1016/j.jtho.2016.05.029,27288979,general_information,NA,NA,Medical Condition of Interest Name,advanced or metastatic non-small cell lung cancer,advanced non-small cell lung cancer (nsclc),XXXX,FALSE,NA,NA,NA
10.1016/j.jtho.2016.05.029,27288979,general_information,NA,NA,Countries of first author affiliations,NA,NA,singapore,TRUE,NA,NA,NA
10.1016/j.jtho.2016.05.029,27288979,general_information,NA,NA,Countries of last author affiliations,NA,NA,canada,TRUE,NA,NA,NA
10.1016/j.jtho.2016.05.029,27288979,general_information,NA,NA,"Positions of study investigators (for any authors of the article, any that applies)",NA,NA,"Academic, Pharmaceutical Industry, Private Data Analysis Company",TRUE,NA,NA,NA
10.1016/j.jtho.2016.05.029,27288979,general_information,NA,NA,"At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company",NA,NA,Yes,TRUE,NA,NA,NA
10.1016/j.jtho.2016.05.029,27288979,general_information,NA,NA,Mentioned sources of funding,NA,NA,Pharmaceutical Industry,TRUE,NA,NA,NA
10.1016/j.jtho.2016.05.029,27288979,general_information,NA,NA,"Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article",NA,NA,Yes,TRUE,NA,NA,NA
10.1016/j.jtho.2016.05.029,27288979,general_information,NA,NA,Mention of a systematic review to find the studies to compare treatments of interest,NA,NA,No,TRUE,NA,NA,NA
10.1016/j.jtho.2016.05.029,27288979,study_information,NA,1,Patient-level data used,NA,NA,Yes,TRUE,NA,NA,NA
10.1016/j.jtho.2016.05.029,27288979,study_information,NA,1,Clinical Trial,NA,NA,Yes,TRUE,NA,NA,NA
10.1016/j.jtho.2016.05.029,27288979,study_information,NA,1,NCT (only for clinical trial registered on clinicaltrials.gov),NA,NA,NCT01283516,TRUE,NA,NA,NA
10.1016/j.jtho.2016.05.029,27288979,study_information,NA,1,Country where the clinical trial/observational study was conducted (international if more than one),NA,NA,international,TRUE,NA,NA,NA
10.1016/j.jtho.2016.05.029,27288979,study_information,NA,1,Phase of the clinical trial (clinical trial only),NA,NA,1,TRUE,NA,NA,NA
10.1016/j.jtho.2016.05.029,27288979,study_information,NA,1,Number of treatment arms (clinical trial only),NA,NA,1,TRUE,NA,NA,NA
10.1016/j.jtho.2016.05.029,27288979,study_information,NA,2,Patient-level data used,NA,NA,Yes,TRUE,NA,NA,NA
10.1016/j.jtho.2016.05.029,27288979,study_information,NA,2,Clinical Trial,NA,NA,Yes,TRUE,NA,NA,NA
10.1016/j.jtho.2016.05.029,27288979,study_information,NA,2,NCT (only for clinical trial registered on clinicaltrials.gov),NA,NA,NCT01685138,TRUE,NA,NA,NA
10.1016/j.jtho.2016.05.029,27288979,study_information,NA,2,Country where the clinical trial/observational study was conducted (international if more than one),NA,NA,international,TRUE,NA,NA,NA
10.1016/j.jtho.2016.05.029,27288979,study_information,NA,2,Phase of the clinical trial (clinical trial only),NA,NA,2,TRUE,NA,NA,NA
10.1016/j.jtho.2016.05.029,27288979,study_information,NA,2,Number of treatment arms (clinical trial only),NA,NA,1,TRUE,NA,NA,NA
10.1016/j.jtho.2016.05.029,27288979,study_information,NA,3,Patient-level data used,NA,NA,No,TRUE,NA,NA,NA
10.1016/j.jtho.2016.05.029,27288979,study_information,NA,3,Clinical Trial,NA,NA,Yes,TRUE,NA,NA,NA
10.1016/j.jtho.2016.05.029,27288979,study_information,NA,3,NCT (only for clinical trial registered on clinicaltrials.gov),NA,NA,NCT00585195,TRUE,NA,NA,NA
10.1016/j.jtho.2016.05.029,27288979,study_information,NA,3,Country where the clinical trial/observational study was conducted (international if more than one),NA,NA,international,TRUE,NA,NA,NA
10.1016/j.jtho.2016.05.029,27288979,study_information,NA,3,Phase of the clinical trial (clinical trial only),NA,NA,1,TRUE,NA,NA,NA
10.1016/j.jtho.2016.05.029,27288979,study_information,NA,3,Number of treatment arms (clinical trial only),NA,NA,1,TRUE,NA,NA,NA
10.1016/j.jtho.2016.05.029,27288979,study_information,NA,4,Patient-level data used,NA,NA,No,TRUE,NA,NA,NA
10.1016/j.jtho.2016.05.029,27288979,study_information,NA,4,Clinical Trial,NA,NA,Yes,TRUE,NA,NA,NA
10.1016/j.jtho.2016.05.029,27288979,study_information,NA,4,NCT (only for clinical trial registered on clinicaltrials.gov),NA,NA,NCT00932451,TRUE,NA,NA,NA
10.1016/j.jtho.2016.05.029,27288979,study_information,NA,4,Country where the clinical trial/observational study was conducted (international if more than one),NA,NA,international,TRUE,NA,NA,NA
10.1016/j.jtho.2016.05.029,27288979,study_information,NA,4,Phase of the clinical trial (clinical trial only),NA,NA,2,TRUE,NA,NA,NA
10.1016/j.jtho.2016.05.029,27288979,study_information,NA,4,Number of treatment arms (clinical trial only),NA,NA,1,TRUE,NA,NA,NA
10.1016/j.jtho.2016.05.029,27288979,study_information,NA,5,Patient-level data used,NA,NA,No,TRUE,NA,NA,NA
10.1016/j.jtho.2016.05.029,27288979,study_information,NA,5,Clinical Trial,NA,NA,Yes,TRUE,NA,NA,NA
10.1016/j.jtho.2016.05.029,27288979,study_information,NA,5,NCT (only for clinical trial registered on clinicaltrials.gov),NA,NA,NCT00932893,TRUE,NA,NA,NA
10.1016/j.jtho.2016.05.029,27288979,study_information,NA,5,Country where the clinical trial/observational study was conducted (international if more than one),NA,NA,international,TRUE,NA,NA,NA
10.1016/j.jtho.2016.05.029,27288979,study_information,NA,5,Phase of the clinical trial (clinical trial only),NA,NA,3,TRUE,NA,NA,NA
10.1016/j.jtho.2016.05.029,27288979,study_information,NA,5,Number of treatment arms (clinical trial only),NA,NA,2 or more,TRUE,NA,NA,NA
10.1016/j.jtho.2016.05.029,27288979,methodology,1,NA,Treatment name 1,ceritinib,certinib,ceritinib,FALSE,NA,NA,NA
10.1016/j.jtho.2016.05.029,27288979,methodology,1,NA,Study 'number(s)' for treatment 1,NA,NA,1;2,TRUE,NA,NA,NA
10.1016/j.jtho.2016.05.029,27288979,methodology,1,NA,Treatment name 2,NA,NA,crizotinib,TRUE,NA,NA,NA
10.1016/j.jtho.2016.05.029,27288979,methodology,1,NA,Study 'number(s)' for treatment 2,NA,NA,3;4;5,TRUE,NA,NA,NA
10.1016/j.jtho.2016.05.029,27288979,methodology,1,NA,Type of population-adjusted indirect comparisons performed,NA,NA,MAIC,TRUE,NA,NA,NA
10.1016/j.jtho.2016.05.029,27288979,methodology,1,NA,Anchored comparison?,NA,NA,No,TRUE,NA,NA,NA
10.1016/j.jtho.2016.05.029,27288979,methodology,1,NA,Form of the indirect comparison,NA,NA,"Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate)",TRUE,NA,NA,NA
10.1016/j.jtho.2016.05.029,27288979,methodology,1,NA,Definition of a single primary outcome for the indirect comparison,NA,NA,"No primary outcome defined, or multiple primary outcomes without any clear distinction between them",TRUE,NA,NA,NA
10.1016/j.jtho.2016.05.029,27288979,methodology,1,NA,Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined),NA,NA,overall survival,TRUE,NA,NA,NA
10.1016/j.jtho.2016.05.029,27288979,methodology,1,NA,Primary outcome: variable type,NA,NA,Time-to-event,TRUE,NA,NA,NA
10.1016/j.jtho.2016.05.029,27288979,methodology,1,NA,Justification for selecting variables to be included in the adjustment model (in the main text),"A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion), Literature based (clinically or methodologically relevant to adjust on these variables based on the literature search conducted for this specific purpose)","Nothing mentioned, not reported","A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion), Literature based (clinically or methodologically relevant to adjust on these variables based on the literature search conducted for this specific purpose)",FALSE,NA,NA,NA
10.1016/j.jtho.2016.05.029,27288979,methodology,1,NA,Inclusion of prognostic factors in the adjustment/matching model,NA,NA,Yes,TRUE,NA,NA,NA
10.1016/j.jtho.2016.05.029,27288979,methodology,1,NA,Inclusion of treatment-effect modifiers in the adjustment/matching model,Yes,No discussion (in the main text) of the status of treatment-effect modifiers of the variables,Yes,FALSE,NA,NA,NA
10.1016/j.jtho.2016.05.029,27288979,methodology,1,NA,"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)",NA,NA,No,TRUE,NA,NA,NA
10.1016/j.jtho.2016.05.029,27288979,methodology,1,NA,Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale),NA,NA,No,TRUE,NA,NA,NA
10.1016/j.jtho.2016.05.029,27288979,results,1,NA,Sample size of the population of interest in the non IPD treatment arm,NA,NA,557,TRUE,NA,NA,NA
10.1016/j.jtho.2016.05.029,27288979,results,1,NA,Initial sample size of the population of interest in the IPD treatment arm,NA,NA,189,TRUE,NA,NA,NA
10.1016/j.jtho.2016.05.029,27288979,results,1,NA,"Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC",NA,NA,143,TRUE,NA,NA,NA
10.1016/j.jtho.2016.05.029,27288979,results,1,NA,Reporting of a weights' distribution evaluation (MAIC),NA,NA,Not mentioned,TRUE,NA,NA,NA
10.1016/j.jtho.2016.05.029,27288979,results,1,NA,Reporting of the list of the covariates adjusted for/matched on,NA,NA,Yes,TRUE,NA,NA,NA
10.1016/j.jtho.2016.05.029,27288979,results,1,NA,Number of covariates adjusted for/matched on,NA,NA,6,TRUE,NA,NA,NA
10.1016/j.jtho.2016.05.029,27288979,results,1,NA,Covariates adjusted for/matched on in the indirect comparison,NA,NA,"Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Race/ethnicity, Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Past treatments for the disease of interest",TRUE,NA,NA,NA
10.1016/j.jtho.2016.05.029,27288979,results,1,NA,Primary outcome: treatment effect contrast,NA,NA,HR,TRUE,NA,NA,NA
10.1016/j.jtho.2016.05.029,27288979,results,1,NA,Direction of the treatment effect contrast: IPD treatment is:,NA,NA,"Numerator if ratio, or left side if difference",TRUE,NA,NA,NA
10.1016/j.jtho.2016.05.029,27288979,results,1,NA,Primary outcome: unadjusted treatment effect,NA,0.49,0.49,FALSE,NA,NA,NA
10.1016/j.jtho.2016.05.029,27288979,results,1,NA,"p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])",NA,<0.001,[0.33;0.74],FALSE,NA,NA,NA
10.1016/j.jtho.2016.05.029,27288979,results,1,NA,Primary outcome: adjusted treatment effect,NA,NA,0.59,TRUE,NA,NA,NA
10.1016/j.jtho.2016.05.029,27288979,results,1,NA,"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])",[0.46;0.75],<0.001,[0.46;0.75],FALSE,NA,NA,NA
10.1016/j.jtho.2016.05.029,27288979,results,1,NA,"If anchored comparison, initial sample size of the population of interest in the IPD anchor arm",na,NA,XXXX,FALSE,NA,NA,NA
10.1016/j.jtho.2016.05.029,27288979,results,1,NA,"If anchored comparison, effective sample size after reweighting for MAIC; or sample size used in the regression model for STC in the IPD anchor arm",na,NA,XXXX,FALSE,NA,NA,NA
10.1007/s40258-016-0271-0,27550239,general_information,NA,NA,Medical Condition of Interest Name,NA,NA,relapsed and/or refractory multiple myeloma,TRUE,NA,NA,NA
10.1007/s40258-016-0271-0,27550239,general_information,NA,NA,Countries of first author affiliations,NA,NA,the netherlands,TRUE,NA,NA,NA
10.1007/s40258-016-0271-0,27550239,general_information,NA,NA,Countries of last author affiliations,NA,NA,usa,TRUE,NA,NA,NA
10.1007/s40258-016-0271-0,27550239,general_information,NA,NA,"Positions of study investigators (for any authors of the article, any that applies)",NA,NA,"Pharmaceutical Industry, Private Data Analysis Company",TRUE,NA,NA,NA
10.1007/s40258-016-0271-0,27550239,general_information,NA,NA,"At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company",NA,NA,Yes,TRUE,NA,NA,NA
10.1007/s40258-016-0271-0,27550239,general_information,NA,NA,Mentioned sources of funding,NA,NA,Pharmaceutical Industry,TRUE,NA,NA,NA
10.1007/s40258-016-0271-0,27550239,general_information,NA,NA,"Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article",NA,NA,Yes,TRUE,NA,NA,NA
10.1007/s40258-016-0271-0,27550239,general_information,NA,NA,Mention of a systematic review to find the studies to compare treatments of interest,NA,NA,Yes,TRUE,NA,NA,NA
10.1007/s40258-016-0271-0,27550239,study_information,NA,1,Patient-level data used,NA,NA,Yes,TRUE,NA,NA,NA
10.1007/s40258-016-0271-0,27550239,study_information,NA,1,Clinical Trial,NA,NA,Yes,TRUE,NA,NA,NA
10.1007/s40258-016-0271-0,27550239,study_information,NA,1,NCT (only for clinical trial registered on clinicaltrials.gov),NA,NA,NCT01023308,TRUE,NA,NA,NA
10.1007/s40258-016-0271-0,27550239,study_information,NA,1,Country where the clinical trial/observational study was conducted (international if more than one),NA,NA,international,TRUE,NA,NA,NA
10.1007/s40258-016-0271-0,27550239,study_information,NA,1,Phase of the clinical trial (clinical trial only),NA,NA,3,TRUE,NA,NA,NA
10.1007/s40258-016-0271-0,27550239,study_information,NA,1,Number of treatment arms (clinical trial only),NA,NA,2 or more,TRUE,NA,NA,NA
10.1007/s40258-016-0271-0,27550239,study_information,NA,2,Patient-level data used,NA,NA,No,TRUE,NA,NA,NA
10.1007/s40258-016-0271-0,27550239,study_information,NA,2,Clinical Trial,NA,NA,Yes,TRUE,NA,NA,NA
10.1007/s40258-016-0271-0,27550239,study_information,NA,2,NCT (only for clinical trial registered on clinicaltrials.gov),NA,NA,NCT00056160,TRUE,NA,NA,NA
10.1007/s40258-016-0271-0,27550239,study_information,NA,2,Country where the clinical trial/observational study was conducted (international if more than one),NA,NA,international,TRUE,NA,NA,NA
10.1007/s40258-016-0271-0,27550239,study_information,NA,2,Phase of the clinical trial (clinical trial only),NA,NA,3,TRUE,NA,NA,NA
10.1007/s40258-016-0271-0,27550239,study_information,NA,2,Number of treatment arms (clinical trial only),NA,NA,2 or more,TRUE,NA,NA,NA
10.1007/s40258-016-0271-0,27550239,study_information,NA,3,Patient-level data used,NA,NA,No,TRUE,NA,NA,NA
10.1007/s40258-016-0271-0,27550239,study_information,NA,3,Clinical Trial,NA,NA,Yes,TRUE,NA,NA,NA
10.1007/s40258-016-0271-0,27550239,study_information,NA,3,NCT (only for clinical trial registered on clinicaltrials.gov),NA,NA,NCT00424047,TRUE,NA,NA,NA
10.1007/s40258-016-0271-0,27550239,study_information,NA,3,Country where the clinical trial/observational study was conducted (international if more than one),NA,NA,international,TRUE,NA,NA,NA
10.1007/s40258-016-0271-0,27550239,study_information,NA,3,Phase of the clinical trial (clinical trial only),NA,NA,3,TRUE,NA,NA,NA
10.1007/s40258-016-0271-0,27550239,study_information,NA,3,Number of treatment arms (clinical trial only),NA,NA,2 or more,TRUE,NA,NA,NA
10.1007/s40258-016-0271-0,27550239,methodology,1,NA,Treatment name 1,NA,NA,panobinostat + bortezomib + dexamethasone,TRUE,Past treatment with lenalidomide was not considered as an adjustment variable since it was used as a matching variable,NA,NA
10.1007/s40258-016-0271-0,27550239,methodology,1,NA,Study 'number(s)' for treatment 1,NA,NA,1,TRUE,NA,NA,NA
10.1007/s40258-016-0271-0,27550239,methodology,1,NA,Treatment name 2,NA,NA,lenalidomide + dexamethasone,TRUE,NA,NA,NA
10.1007/s40258-016-0271-0,27550239,methodology,1,NA,Study 'number(s)' for treatment 2,NA,NA,2;3,TRUE,NA,NA,NA
10.1007/s40258-016-0271-0,27550239,methodology,1,NA,Type of population-adjusted indirect comparisons performed,NA,NA,MAIC,TRUE,NA,NA,NA
10.1007/s40258-016-0271-0,27550239,methodology,1,NA,Anchored comparison?,NA,NA,No,TRUE,NA,NA,NA
10.1007/s40258-016-0271-0,27550239,methodology,1,NA,Form of the indirect comparison,NA,NA,"Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate)",TRUE,NA,NA,NA
10.1007/s40258-016-0271-0,27550239,methodology,1,NA,Definition of a single primary outcome for the indirect comparison,NA,NA,"No primary outcome defined, or multiple primary outcomes without any clear distinction between them",TRUE,NA,NA,NA
10.1007/s40258-016-0271-0,27550239,methodology,1,NA,Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined),NA,NA,progression-free survival,TRUE,NA,NA,NA
10.1007/s40258-016-0271-0,27550239,methodology,1,NA,Primary outcome: variable type,NA,NA,Time-to-event,TRUE,NA,NA,NA
10.1007/s40258-016-0271-0,27550239,methodology,1,NA,Justification for selecting variables to be included in the adjustment model (in the main text),NA,NA,"A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion), Literature based (clinically or methodologically relevant to adjust on these variables based on the literature search conducted for this specific purpose)",TRUE,NA,NA,NA
10.1007/s40258-016-0271-0,27550239,methodology,1,NA,Inclusion of prognostic factors in the adjustment/matching model,Yes,No discussion (in the main text) of the status of prognostic factors of the variables,Yes,FALSE,NA,NA,NA
10.1007/s40258-016-0271-0,27550239,methodology,1,NA,Inclusion of treatment-effect modifiers in the adjustment/matching model,NA,NA,No discussion (in the main text) of the status of treatment-effect modifiers of the variables,TRUE,NA,NA,NA
10.1007/s40258-016-0271-0,27550239,methodology,1,NA,"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)",NA,NA,No,TRUE,NA,NA,NA
10.1007/s40258-016-0271-0,27550239,methodology,1,NA,Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale),NA,NA,No,TRUE,NA,NA,NA
10.1007/s40258-016-0271-0,27550239,results,1,NA,Sample size of the population of interest in the non IPD treatment arm,NA,NA,220,TRUE,NA,NA,NA
10.1007/s40258-016-0271-0,27550239,results,1,NA,Initial sample size of the population of interest in the IPD treatment arm,NA,NA,142,TRUE,NA,NA,NA
10.1007/s40258-016-0271-0,27550239,results,1,NA,"Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC",NA,NA,138,TRUE,NA,NA,NA
10.1007/s40258-016-0271-0,27550239,results,1,NA,Reporting of a weights' distribution evaluation (MAIC),NA,NA,Not mentioned,TRUE,NA,NA,NA
10.1007/s40258-016-0271-0,27550239,results,1,NA,Reporting of the list of the covariates adjusted for/matched on,NA,NA,Yes,TRUE,NA,NA,NA
10.1007/s40258-016-0271-0,27550239,results,1,NA,Number of covariates adjusted for/matched on,3,4,4,FALSE,NA,NA,NA
10.1007/s40258-016-0271-0,27550239,results,1,NA,Covariates adjusted for/matched on in the indirect comparison,NA,NA,"Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Past treatments for the disease of interest",TRUE,NA,NA,NA
10.1007/s40258-016-0271-0,27550239,results,1,NA,Primary outcome: treatment effect contrast,NA,NA,HR,TRUE,NA,NA,NA
10.1007/s40258-016-0271-0,27550239,results,1,NA,Direction of the treatment effect contrast: IPD treatment is:,NA,NA,"Numerator if ratio, or left side if difference",TRUE,NA,NA,NA
10.1007/s40258-016-0271-0,27550239,results,1,NA,Primary outcome: adjusted treatment effect,NA,NA,0.96,TRUE,NA,NA,NA
10.1007/s40258-016-0271-0,27550239,results,1,NA,"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])",NA,NA,[0.72;1.28],TRUE,NA,NA,NA
10.1186/s40734-017-0051-5,28265459,general_information,NA,NA,Medical Condition of Interest Name,NA,NA,huntington disease,TRUE,NA,NA,NA
10.1186/s40734-017-0051-5,28265459,general_information,NA,NA,Countries of first author affiliations,NA,NA,usa,TRUE,NA,NA,NA
10.1186/s40734-017-0051-5,28265459,general_information,NA,NA,Countries of last author affiliations,NA,NA,usa,TRUE,NA,NA,NA
10.1186/s40734-017-0051-5,28265459,general_information,NA,NA,"Positions of study investigators (for any authors of the article, any that applies)",NA,NA,"Academic, Pharmaceutical Industry, Private Data Analysis Company",TRUE,NA,NA,NA
10.1186/s40734-017-0051-5,28265459,general_information,NA,NA,"At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company",NA,NA,Yes,TRUE,NA,NA,NA
10.1186/s40734-017-0051-5,28265459,general_information,NA,NA,Mentioned sources of funding,NA,NA,Pharmaceutical Industry,TRUE,NA,NA,NA
10.1186/s40734-017-0051-5,28265459,general_information,NA,NA,"Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article",NA,NA,Yes,TRUE,NA,NA,NA
10.1186/s40734-017-0051-5,28265459,general_information,NA,NA,Mention of a systematic review to find the studies to compare treatments of interest,NA,NA,No,TRUE,NA,NA,NA
10.1186/s40734-017-0051-5,28265459,study_information,NA,1,Patient-level data used,NA,NA,Yes,TRUE,NA,NA,NA
10.1186/s40734-017-0051-5,28265459,study_information,NA,1,Clinical Trial,NA,NA,Yes,TRUE,NA,NA,NA
10.1186/s40734-017-0051-5,28265459,study_information,NA,1,NCT (only for clinical trial registered on clinicaltrials.gov),NA,NA,NCT01795859,TRUE,NA,NA,NA
10.1186/s40734-017-0051-5,28265459,study_information,NA,1,Country where the clinical trial/observational study was conducted (international if more than one),NA,NA,international,TRUE,NA,NA,NA
10.1186/s40734-017-0051-5,28265459,study_information,NA,1,Phase of the clinical trial (clinical trial only),NA,NA,3,TRUE,NA,NA,NA
10.1186/s40734-017-0051-5,28265459,study_information,NA,1,Number of treatment arms (clinical trial only),NA,NA,2 or more,TRUE,NA,NA,NA
10.1186/s40734-017-0051-5,28265459,study_information,NA,2,Patient-level data used,NA,NA,No,TRUE,NA,NA,NA
10.1186/s40734-017-0051-5,28265459,study_information,NA,2,Clinical Trial,NA,NA,Yes,TRUE,NA,NA,NA
10.1186/s40734-017-0051-5,28265459,study_information,NA,2,NCT (only for clinical trial registered on clinicaltrials.gov),NA,NA,NCT00219804,TRUE,NA,NA,NA
10.1186/s40734-017-0051-5,28265459,study_information,NA,2,Phase of the clinical trial (clinical trial only),NA,NA,3,TRUE,NA,NA,NA
10.1186/s40734-017-0051-5,28265459,study_information,NA,2,Number of treatment arms (clinical trial only),NA,NA,2 or more,TRUE,NA,NA,NA
10.1186/s40734-017-0051-5,28265459,study_information,NA,2,Country where the clinical trial/observational study was conducted (international if more than one),unknown,NA,XXXX,FALSE,NA,NA,NA
10.1186/s40734-017-0051-5,28265459,methodology,1,NA,Treatment name 1,NA,NA,deutetrabenazine,TRUE,Risk differences calculated from the data in Table 2,NA,NA
10.1186/s40734-017-0051-5,28265459,methodology,1,NA,Study 'number(s)' for treatment 1,NA,NA,1,TRUE,NA,NA,NA
10.1186/s40734-017-0051-5,28265459,methodology,1,NA,Treatment name 2,NA,NA,tetrabenazine,TRUE,NA,NA,NA
10.1186/s40734-017-0051-5,28265459,methodology,1,NA,Study 'number(s)' for treatment 2,NA,NA,2,TRUE,NA,NA,NA
10.1186/s40734-017-0051-5,28265459,methodology,1,NA,Type of population-adjusted indirect comparisons performed,NA,NA,MAIC,TRUE,NA,NA,NA
10.1186/s40734-017-0051-5,28265459,methodology,1,NA,Anchored comparison?,NA,NA,Yes,TRUE,NA,NA,NA
10.1186/s40734-017-0051-5,28265459,methodology,1,NA,Form of the indirect comparison,NA,NA,Simple (ie treatments effects extracted from two studies),TRUE,NA,NA,NA
10.1186/s40734-017-0051-5,28265459,methodology,1,NA,Definition of a single primary outcome for the indirect comparison,NA,NA,"No primary outcome defined, or multiple primary outcomes without any clear distinction between them",TRUE,NA,NA,NA
10.1186/s40734-017-0051-5,28265459,methodology,1,NA,Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined),overall adverse events,incidence rates for overall aes,overall adverse events,FALSE,NA,NA,NA
10.1186/s40734-017-0051-5,28265459,methodology,1,NA,Primary outcome: variable type,NA,NA,Binary (eg rates),TRUE,NA,NA,NA
10.1186/s40734-017-0051-5,28265459,methodology,1,NA,Justification for selecting variables to be included in the adjustment model (in the main text),A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion),"Statistical imbalanced between treatment groups (independently of the status of prognostic/effect modifier), A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion)","Statistical imbalanced between treatment groups (independently of the status of prognostic/effect modifier), A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion)",FALSE,NA,NA,NA
10.1186/s40734-017-0051-5,28265459,methodology,1,NA,Inclusion of prognostic factors in the adjustment/matching model,NA,NA,No discussion (in the main text) of the status of prognostic factors of the variables,TRUE,NA,NA,NA
10.1186/s40734-017-0051-5,28265459,methodology,1,NA,Inclusion of treatment-effect modifiers in the adjustment/matching model,NA,NA,No discussion (in the main text) of the status of treatment-effect modifiers of the variables,TRUE,NA,NA,NA
10.1186/s40734-017-0051-5,28265459,methodology,1,NA,"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)",NA,NA,No,TRUE,NA,NA,NA
10.1186/s40734-017-0051-5,28265459,methodology,1,NA,Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale),NA,NA,No,TRUE,NA,NA,NA
10.1186/s40734-017-0051-5,28265459,results,1,NA,Sample size of the population of interest in the non IPD treatment arm,NA,NA,54,TRUE,NA,NA,NA
10.1186/s40734-017-0051-5,28265459,results,1,NA,"If anchored comparison, sample size of the population of interest in the non IPD treatment anchor arm",NA,NA,30,TRUE,NA,NA,NA
10.1186/s40734-017-0051-5,28265459,results,1,NA,Initial sample size of the population of interest in the IPD treatment arm,NA,NA,45,TRUE,NA,NA,NA
10.1186/s40734-017-0051-5,28265459,results,1,NA,"If anchored comparison, initial sample size of the population of interest in the IPD anchor arm",NA,45,45,FALSE,NA,NA,NA
10.1186/s40734-017-0051-5,28265459,results,1,NA,Reporting of a weights' distribution evaluation (MAIC),NA,NA,Not mentioned,TRUE,NA,NA,NA
10.1186/s40734-017-0051-5,28265459,results,1,NA,Reporting of the list of the covariates adjusted for/matched on,NA,NA,Yes,TRUE,NA,NA,NA
10.1186/s40734-017-0051-5,28265459,results,1,NA,Number of covariates adjusted for/matched on,NA,NA,3,TRUE,NA,NA,NA
10.1186/s40734-017-0051-5,28265459,results,1,NA,Covariates adjusted for/matched on in the indirect comparison,NA,NA,"Age, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease)",TRUE,NA,NA,NA
10.1186/s40734-017-0051-5,28265459,results,1,NA,Primary outcome: treatment effect contrast,NA,NA,Risk difference,TRUE,NA,NA,NA
10.1186/s40734-017-0051-5,28265459,results,1,NA,Direction of the treatment effect contrast: IPD treatment is:,NA,NA,"Numerator if ratio, or left side if difference",TRUE,NA,NA,NA
10.1186/s40734-017-0051-5,28265459,results,1,NA,Primary outcome: unadjusted treatment effect,-20.7,-20.70%,-20.70%,FALSE,NA,NA,NA
10.1186/s40734-017-0051-5,28265459,results,1,NA,"p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])",<0.001,0.135,0.135,FALSE,NA,NA,NA
10.1186/s40734-017-0051-5,28265459,results,1,NA,Primary outcome: adjusted treatment effect,-35.3,-35.30%,-35.30%,FALSE,NA,NA,NA
10.1186/s40734-017-0051-5,28265459,results,1,NA,"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])",<0.001,0.063,0.063,FALSE,NA,NA,NA
10.1186/s40734-017-0051-5,28265459,results,1,NA,"Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC",45,NA,XXXX,FALSE,NA,NA,NA
10.1007/s12325-017-0564-1,28573505,general_information,NA,NA,Medical Condition of Interest Name,NA,NA,chronic lymphocytic leukemia,TRUE,NA,NA,NA
10.1007/s12325-017-0564-1,28573505,general_information,NA,NA,Countries of first author affiliations,NA,NA,belgium,TRUE,NA,NA,NA
10.1007/s12325-017-0564-1,28573505,general_information,NA,NA,Countries of last author affiliations,NA,NA,uk,TRUE,NA,NA,NA
10.1007/s12325-017-0564-1,28573505,general_information,NA,NA,"Positions of study investigators (for any authors of the article, any that applies)",NA,NA,Pharmaceutical Industry,TRUE,NA,NA,NA
10.1007/s12325-017-0564-1,28573505,general_information,NA,NA,"At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company",NA,NA,Not mentioned,TRUE,NA,NA,NA
10.1007/s12325-017-0564-1,28573505,general_information,NA,NA,Mentioned sources of funding,NA,NA,Pharmaceutical Industry,TRUE,NA,NA,NA
10.1007/s12325-017-0564-1,28573505,general_information,NA,NA,"Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article",NA,NA,Yes,TRUE,NA,NA,NA
10.1007/s12325-017-0564-1,28573505,general_information,NA,NA,Mention of a systematic review to find the studies to compare treatments of interest,NA,NA,No,TRUE,NA,NA,NA
10.1007/s12325-017-0564-1,28573505,study_information,NA,1,Patient-level data used,NA,NA,Yes,TRUE,NA,NA,NA
10.1007/s12325-017-0564-1,28573505,study_information,NA,1,Clinical Trial,NA,NA,Yes,TRUE,NA,NA,NA
10.1007/s12325-017-0564-1,28573505,study_information,NA,1,NCT (only for clinical trial registered on clinicaltrials.gov),NA,NA,NCT01722487,TRUE,NA,NA,NA
10.1007/s12325-017-0564-1,28573505,study_information,NA,1,Country where the clinical trial/observational study was conducted (international if more than one),NA,NA,international,TRUE,NA,NA,NA
10.1007/s12325-017-0564-1,28573505,study_information,NA,1,Phase of the clinical trial (clinical trial only),NA,NA,3,TRUE,NA,NA,NA
10.1007/s12325-017-0564-1,28573505,study_information,NA,1,Number of treatment arms (clinical trial only),NA,NA,2 or more,TRUE,NA,NA,NA
10.1007/s12325-017-0564-1,28573505,study_information,NA,2,Patient-level data used,NA,NA,No,TRUE,NA,NA,NA
10.1007/s12325-017-0564-1,28573505,study_information,NA,2,Clinical Trial,NA,NA,Yes,TRUE,NA,NA,NA
10.1007/s12325-017-0564-1,28573505,study_information,NA,2,NCT (only for clinical trial registered on clinicaltrials.gov),NA,NA,NCT01010061,TRUE,NA,NA,NA
10.1007/s12325-017-0564-1,28573505,study_information,NA,2,Country where the clinical trial/observational study was conducted (international if more than one),NA,NA,international,TRUE,NA,NA,NA
10.1007/s12325-017-0564-1,28573505,study_information,NA,2,Phase of the clinical trial (clinical trial only),NA,NA,3,TRUE,NA,NA,NA
10.1007/s12325-017-0564-1,28573505,study_information,NA,2,Number of treatment arms (clinical trial only),NA,NA,2 or more,TRUE,NA,NA,NA
10.1007/s12325-017-0564-1,28573505,methodology,1,NA,Treatment name 1,ibrutinib1,ibrutinib,ibrutinib,FALSE,"Bayesian analysis, so credible intervals reported
Sample sizes reported together for both active treatment and control arms: 
	NonIPD 589 
	IPD 191 
	ESS 35","Creatinine clearance = comorbidities

Effectif non IPD (intervention + placebo ) = 589
Initial sample size IPD (intervention + placebo ) = 115
ESS IPD (intervention + placebo ) = 35

HR for PFS by  IRC assessment :
Naive Analysis = 0.85 [0.44;1.63]
MAIC = 0.24 [0.04;1.35]",NA
10.1007/s12325-017-0564-1,28573505,methodology,1,NA,Study 'number(s)' for treatment 1,NA,NA,1,TRUE,NA,NA,NA
10.1007/s12325-017-0564-1,28573505,methodology,1,NA,Treatment name 2,NA,NA,obinutuzumab + chlorambucil,TRUE,NA,NA,NA
10.1007/s12325-017-0564-1,28573505,methodology,1,NA,Study 'number(s)' for treatment 2,NA,NA,2,TRUE,NA,NA,NA
10.1007/s12325-017-0564-1,28573505,methodology,1,NA,Type of population-adjusted indirect comparisons performed,NA,NA,MAIC,TRUE,NA,NA,NA
10.1007/s12325-017-0564-1,28573505,methodology,1,NA,Anchored comparison?,NA,NA,Yes,TRUE,NA,NA,NA
10.1007/s12325-017-0564-1,28573505,methodology,1,NA,Form of the indirect comparison,NA,NA,Simple (ie treatments effects extracted from two studies),TRUE,NA,NA,NA
10.1007/s12325-017-0564-1,28573505,methodology,1,NA,Definition of a single primary outcome for the indirect comparison,NA,NA,"No primary outcome defined, or multiple primary outcomes without any clear distinction between them",TRUE,NA,NA,NA
10.1007/s12325-017-0564-1,28573505,methodology,1,NA,Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined),progression-free survival,progression-free survival by investigator assessment,progression-free survival,FALSE,NA,NA,NA
10.1007/s12325-017-0564-1,28573505,methodology,1,NA,Primary outcome: variable type,NA,NA,Time-to-event,TRUE,NA,NA,NA
10.1007/s12325-017-0564-1,28573505,methodology,1,NA,Justification for selecting variables to be included in the adjustment model (in the main text),Literature based (clinically or methodologically relevant to adjust on these variables based on the literature search conducted for this specific purpose),A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion),Literature based (clinically or methodologically relevant to adjust on these variables based on the literature search conducted for this specific purpose),FALSE,NA,NA,NA
10.1007/s12325-017-0564-1,28573505,methodology,1,NA,Inclusion of prognostic factors in the adjustment/matching model,No,Yes,Yes,FALSE,NA,NA,NA
10.1007/s12325-017-0564-1,28573505,methodology,1,NA,Inclusion of treatment-effect modifiers in the adjustment/matching model,NA,NA,Yes,TRUE,NA,NA,NA
10.1007/s12325-017-0564-1,28573505,methodology,1,NA,"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)",NA,NA,No,TRUE,NA,NA,NA
10.1007/s12325-017-0564-1,28573505,methodology,1,NA,Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale),NA,NA,No,TRUE,NA,NA,NA
10.1007/s12325-017-0564-1,28573505,results,1,NA,Reporting of a weights' distribution evaluation (MAIC),NA,NA,Not mentioned,TRUE,NA,NA,NA
10.1007/s12325-017-0564-1,28573505,results,1,NA,Reporting of the list of the covariates adjusted for/matched on,NA,NA,Yes,TRUE,NA,NA,NA
10.1007/s12325-017-0564-1,28573505,results,1,NA,Number of covariates adjusted for/matched on,9,11,9,FALSE,NA,NA,NA
10.1007/s12325-017-0564-1,28573505,results,1,NA,Covariates adjusted for/matched on in the indirect comparison,NA,NA,"Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Comorbidities and medical history (beside pathology/disease of interest in the comparison)",TRUE,NA,NA,NA
10.1007/s12325-017-0564-1,28573505,results,1,NA,Primary outcome: treatment effect contrast,NA,NA,HR,TRUE,NA,NA,NA
10.1007/s12325-017-0564-1,28573505,results,1,NA,Direction of the treatment effect contrast: IPD treatment is:,NA,NA,"Numerator if ratio, or left side if difference",TRUE,NA,NA,NA
10.1007/s12325-017-0564-1,28573505,results,1,NA,Primary outcome: unadjusted treatment effect,0.5,0.48,0.5,FALSE,NA,NA,NA
10.1007/s12325-017-0564-1,28573505,results,1,NA,"p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])",[0.22;1.15],[0.22;1.02],[0.22;1.15],FALSE,NA,NA,NA
10.1007/s12325-017-0564-1,28573505,results,1,NA,Primary outcome: adjusted treatment effect,0.24,0.12,0.24,FALSE,NA,NA,NA
10.1007/s12325-017-0564-1,28573505,results,1,NA,"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])",[0.04;1.35],[0.02;0.97],[0.04;1.35],FALSE,NA,NA,NA
10.1007/s12325-017-0564-1,28573505,results,1,NA,Sample size of the population of interest in the non IPD treatment arm,589,NA,589,FALSE,NA,NA,NA
10.1007/s12325-017-0564-1,28573505,results,1,NA,Initial sample size of the population of interest in the IPD treatment arm,191,NA,115,FALSE,NA,NA,NA
10.1007/s12325-017-0564-1,28573505,results,1,NA,"Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC",35,NA,35,FALSE,NA,NA,NA
10.1007/s40744-017-0070-6,28762213,general_information,NA,NA,Medical Condition of Interest Name,active psoriatic arthritis,psoriatic arthritis,XXXX,FALSE,NA,NA,NA
10.1007/s40744-017-0070-6,28762213,general_information,NA,NA,Countries of first author affiliations,NA,NA,usa,TRUE,NA,NA,NA
10.1007/s40744-017-0070-6,28762213,general_information,NA,NA,Countries of last author affiliations,NA,NA,usa,TRUE,NA,NA,NA
10.1007/s40744-017-0070-6,28762213,general_information,NA,NA,"Positions of study investigators (for any authors of the article, any that applies)",NA,NA,"Academic, Pharmaceutical Industry, Private Data Analysis Company",TRUE,NA,NA,NA
10.1007/s40744-017-0070-6,28762213,general_information,NA,NA,"At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company",NA,NA,Yes,TRUE,NA,NA,NA
10.1007/s40744-017-0070-6,28762213,general_information,NA,NA,Mentioned sources of funding,NA,NA,Pharmaceutical Industry,TRUE,NA,NA,NA
10.1007/s40744-017-0070-6,28762213,general_information,NA,NA,"Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article",NA,NA,Yes,TRUE,NA,NA,NA
10.1007/s40744-017-0070-6,28762213,general_information,NA,NA,Mention of a systematic review to find the studies to compare treatments of interest,NA,NA,Yes,TRUE,NA,NA,NA
10.1007/s40744-017-0070-6,28762213,study_information,NA,1,Patient-level data used,NA,NA,Yes,TRUE,NA,NA,NA
10.1007/s40744-017-0070-6,28762213,study_information,NA,1,Clinical Trial,NA,NA,Yes,TRUE,NA,NA,NA
10.1007/s40744-017-0070-6,28762213,study_information,NA,1,NCT (only for clinical trial registered on clinicaltrials.gov),NA,NA,NCT00195689,TRUE,NA,NA,NA
10.1007/s40744-017-0070-6,28762213,study_information,NA,1,Country where the clinical trial/observational study was conducted (international if more than one),NA,NA,usa,TRUE,NA,NA,NA
10.1007/s40744-017-0070-6,28762213,study_information,NA,1,Phase of the clinical trial (clinical trial only),NA,NA,3,TRUE,NA,NA,NA
10.1007/s40744-017-0070-6,28762213,study_information,NA,1,Number of treatment arms (clinical trial only),NA,NA,2 or more,TRUE,NA,NA,NA
10.1007/s40744-017-0070-6,28762213,study_information,NA,2,Patient-level data used,NA,NA,No,TRUE,NA,NA,NA
10.1007/s40744-017-0070-6,28762213,study_information,NA,2,Clinical Trial,NA,NA,Yes,TRUE,NA,NA,NA
10.1007/s40744-017-0070-6,28762213,study_information,NA,2,NCT (only for clinical trial registered on clinicaltrials.gov),NA,NA,NCT01392326,TRUE,NA,NA,NA
10.1007/s40744-017-0070-6,28762213,study_information,NA,2,Country where the clinical trial/observational study was conducted (international if more than one),NA,NA,international,TRUE,NA,NA,NA
10.1007/s40744-017-0070-6,28762213,study_information,NA,2,Phase of the clinical trial (clinical trial only),NA,NA,3,TRUE,NA,NA,NA
10.1007/s40744-017-0070-6,28762213,study_information,NA,2,Number of treatment arms (clinical trial only),NA,NA,2 or more,TRUE,NA,NA,NA
10.1007/s40744-017-0070-6,28762213,study_information,NA,3,Patient-level data used,NA,NA,No,TRUE,NA,NA,NA
10.1007/s40744-017-0070-6,28762213,study_information,NA,3,Clinical Trial,NA,NA,Yes,TRUE,NA,NA,NA
10.1007/s40744-017-0070-6,28762213,study_information,NA,3,NCT (only for clinical trial registered on clinicaltrials.gov),NA,NA,NCT01752634,TRUE,NA,NA,NA
10.1007/s40744-017-0070-6,28762213,study_information,NA,3,Country where the clinical trial/observational study was conducted (international if more than one),NA,NA,international,TRUE,NA,NA,NA
10.1007/s40744-017-0070-6,28762213,study_information,NA,3,Phase of the clinical trial (clinical trial only),NA,NA,3,TRUE,NA,NA,NA
10.1007/s40744-017-0070-6,28762213,study_information,NA,3,Number of treatment arms (clinical trial only),NA,NA,2 or more,TRUE,NA,NA,NA
10.1007/s40744-017-0070-6,28762213,methodology,1,NA,Treatment name 1,NA,NA,adalimumab,TRUE,"Associated with an economic analysis
3 other studies used MAIC to conduct this comparison, but none where anchored, and the latter two report that secukinumab (NonIPD) has better outcomes and cost effectiveness ==> interesting to look at their justification to conduct unanchored comparisons  1 : Greenberg JD, Nikoglou E, Gunda P, Palmer J, S J. Comparison of secukinumab Vs adalimumab in a cost per responder analysis based on a matching-adjusted indirect comparison of efficacy data for the treatment of psoriatic arthritis at 48 weeks from the US perspective [abstract]. Arthritis Rheumatol. 2016;68 (suppl 10).
2 : Nash P, editor Secukinumab for the treatment of psoriatic arthritis: comparative effectiveness results versus adalimumab up to 48 weeks using a matching-adjusted indirect comparison.
3 : Nash P, McInnes IB, Mease PJ, et al. Secukinumab for the treatment of psoriatic arthritis: comparative effectiveness versus adalimumab using a matching-adjusted indirect comparison [abstract]. Arthritis Rheumatol. 2016;68 (suppl 10).",HAQ-DI = Disease severity,NA
10.1007/s40744-017-0070-6,28762213,methodology,1,NA,Study 'number(s)' for treatment 1,NA,NA,1,TRUE,NA,NA,NA
10.1007/s40744-017-0070-6,28762213,methodology,1,NA,Treatment name 2,NA,NA,secukinumab 150 mg,TRUE,NA,NA,NA
10.1007/s40744-017-0070-6,28762213,methodology,1,NA,Study 'number(s)' for treatment 2,NA,NA,2;3,TRUE,NA,NA,NA
10.1007/s40744-017-0070-6,28762213,methodology,1,NA,Type of population-adjusted indirect comparisons performed,NA,NA,MAIC,TRUE,NA,NA,NA
10.1007/s40744-017-0070-6,28762213,methodology,1,NA,Anchored comparison?,NA,NA,Yes,TRUE,NA,NA,NA
10.1007/s40744-017-0070-6,28762213,methodology,1,NA,Form of the indirect comparison,NA,NA,"Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate)",TRUE,NA,NA,NA
10.1007/s40744-017-0070-6,28762213,methodology,1,NA,Definition of a single primary outcome for the indirect comparison,NA,NA,"No primary outcome defined, or multiple primary outcomes without any clear distinction between them",TRUE,NA,NA,NA
10.1007/s40744-017-0070-6,28762213,methodology,1,NA,Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined),response rate in relative acr 20,response rates for acr 20 (american college of rheumatology) at week 24,response rates for acr 20 (american college of rheumatology) at week 24,FALSE,NA,NA,NA
10.1007/s40744-017-0070-6,28762213,methodology,1,NA,Primary outcome: variable type,NA,NA,Binary (eg rates),TRUE,NA,NA,NA
10.1007/s40744-017-0070-6,28762213,methodology,1,NA,Justification for selecting variables to be included in the adjustment model (in the main text),NA,NA,A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion),TRUE,NA,NA,NA
10.1007/s40744-017-0070-6,28762213,methodology,1,NA,Inclusion of prognostic factors in the adjustment/matching model,NA,NA,Yes,TRUE,NA,NA,NA
10.1007/s40744-017-0070-6,28762213,methodology,1,NA,Inclusion of treatment-effect modifiers in the adjustment/matching model,NA,NA,Yes,TRUE,NA,NA,NA
10.1007/s40744-017-0070-6,28762213,methodology,1,NA,"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)",NA,NA,No,TRUE,NA,NA,NA
10.1007/s40744-017-0070-6,28762213,methodology,1,NA,Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale),NA,NA,No,TRUE,NA,NA,NA
10.1007/s40744-017-0070-6,28762213,methodology,2,NA,Treatment name 1,NA,NA,adalimumab,TRUE,NA,"HAQ-DI = Disease severity

Weight = Other",NA
10.1007/s40744-017-0070-6,28762213,methodology,2,NA,Study 'number(s)' for treatment 1,NA,NA,1,TRUE,NA,NA,NA
10.1007/s40744-017-0070-6,28762213,methodology,2,NA,Treatment name 2,NA,NA,secukinumab 300 mg,TRUE,NA,NA,NA
10.1007/s40744-017-0070-6,28762213,methodology,2,NA,Study 'number(s)' for treatment 2,NA,NA,2;3,TRUE,NA,NA,NA
10.1007/s40744-017-0070-6,28762213,methodology,2,NA,Type of population-adjusted indirect comparisons performed,NA,NA,MAIC,TRUE,NA,NA,NA
10.1007/s40744-017-0070-6,28762213,methodology,2,NA,Anchored comparison?,NA,NA,Yes,TRUE,NA,NA,NA
10.1007/s40744-017-0070-6,28762213,methodology,2,NA,Form of the indirect comparison,NA,NA,"Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate)",TRUE,NA,NA,NA
10.1007/s40744-017-0070-6,28762213,methodology,2,NA,Definition of a single primary outcome for the indirect comparison,NA,NA,"No primary outcome defined, or multiple primary outcomes without any clear distinction between them",TRUE,NA,NA,NA
10.1007/s40744-017-0070-6,28762213,methodology,2,NA,Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined),response rate in relative acr 20,response rates for acr 20 (american college of rheumatology) at week 24,response rates for acr 20 (american college of rheumatology) at week 24,FALSE,NA,NA,NA
10.1007/s40744-017-0070-6,28762213,methodology,2,NA,Primary outcome: variable type,NA,NA,Binary (eg rates),TRUE,NA,NA,NA
10.1007/s40744-017-0070-6,28762213,methodology,2,NA,Justification for selecting variables to be included in the adjustment model (in the main text),NA,NA,A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion),TRUE,NA,NA,NA
10.1007/s40744-017-0070-6,28762213,methodology,2,NA,Inclusion of prognostic factors in the adjustment/matching model,NA,NA,Yes,TRUE,NA,NA,NA
10.1007/s40744-017-0070-6,28762213,methodology,2,NA,Inclusion of treatment-effect modifiers in the adjustment/matching model,NA,NA,Yes,TRUE,NA,NA,NA
10.1007/s40744-017-0070-6,28762213,methodology,2,NA,"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)",NA,NA,No,TRUE,NA,NA,NA
10.1007/s40744-017-0070-6,28762213,methodology,2,NA,Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale),NA,NA,No,TRUE,NA,NA,NA
10.1007/s40744-017-0070-6,28762213,results,1,NA,Sample size of the population of interest in the non IPD treatment arm,NA,NA,302,TRUE,NA,NA,NA
10.1007/s40744-017-0070-6,28762213,results,1,NA,"If anchored comparison, sample size of the population of interest in the non IPD treatment anchor arm",NA,NA,300,TRUE,NA,NA,NA
10.1007/s40744-017-0070-6,28762213,results,1,NA,Initial sample size of the population of interest in the IPD treatment arm,NA,NA,134,TRUE,NA,NA,NA
10.1007/s40744-017-0070-6,28762213,results,1,NA,"Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC",NA,NA,49,TRUE,NA,NA,NA
10.1007/s40744-017-0070-6,28762213,results,1,NA,"If anchored comparison, initial sample size of the population of interest in the IPD anchor arm",NA,NA,147,TRUE,NA,NA,NA
10.1007/s40744-017-0070-6,28762213,results,1,NA,"If anchored comparison, effective sample size after reweighting for MAIC; or sample size used in the regression model for STC in the IPD anchor arm",NA,NA,79,TRUE,NA,NA,NA
10.1007/s40744-017-0070-6,28762213,results,1,NA,Reporting of a weights' distribution evaluation (MAIC),NA,NA,Not mentioned,TRUE,NA,NA,NA
10.1007/s40744-017-0070-6,28762213,results,1,NA,Reporting of the list of the covariates adjusted for/matched on,NA,NA,Yes,TRUE,NA,NA,NA
10.1007/s40744-017-0070-6,28762213,results,1,NA,Number of covariates adjusted for/matched on,NA,NA,10,TRUE,NA,NA,NA
10.1007/s40744-017-0070-6,28762213,results,1,NA,Covariates adjusted for/matched on in the indirect comparison,NA,NA,"Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Race/ethnicity, Past treatments for the disease of interest, Other(s)",TRUE,NA,NA,NA
10.1007/s40744-017-0070-6,28762213,results,1,NA,Primary outcome: treatment effect contrast,Rate difference,Means difference,Rate difference,FALSE,NA,NA,NA
10.1007/s40744-017-0070-6,28762213,results,1,NA,Direction of the treatment effect contrast: IPD treatment is:,NA,NA,"Numerator if ratio, or left side if difference",TRUE,NA,NA,NA
10.1007/s40744-017-0070-6,28762213,results,1,NA,Primary outcome: adjusted treatment effect,0.095,9.50%,9.50%,FALSE,NA,NA,NA
10.1007/s40744-017-0070-6,28762213,results,1,NA,"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])",NA,NA,0.176,TRUE,NA,NA,NA
10.1007/s40744-017-0070-6,28762213,results,2,NA,Sample size of the population of interest in the non IPD treatment arm,NA,NA,100,TRUE,NA,NA,NA
10.1007/s40744-017-0070-6,28762213,results,2,NA,"If anchored comparison, sample size of the population of interest in the non IPD treatment anchor arm",NA,NA,300,TRUE,NA,NA,NA
10.1007/s40744-017-0070-6,28762213,results,2,NA,Initial sample size of the population of interest in the IPD treatment arm,NA,NA,134,TRUE,NA,NA,NA
10.1007/s40744-017-0070-6,28762213,results,2,NA,"Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC",NA,NA,76,TRUE,NA,NA,NA
10.1007/s40744-017-0070-6,28762213,results,2,NA,"If anchored comparison, initial sample size of the population of interest in the IPD anchor arm",NA,NA,147,TRUE,NA,NA,NA
10.1007/s40744-017-0070-6,28762213,results,2,NA,"If anchored comparison, effective sample size after reweighting for MAIC; or sample size used in the regression model for STC in the IPD anchor arm",NA,NA,79,TRUE,NA,NA,NA
10.1007/s40744-017-0070-6,28762213,results,2,NA,Reporting of a weights' distribution evaluation (MAIC),NA,NA,Not mentioned,TRUE,NA,NA,NA
10.1007/s40744-017-0070-6,28762213,results,2,NA,Reporting of the list of the covariates adjusted for/matched on,NA,NA,Yes,TRUE,NA,NA,NA
10.1007/s40744-017-0070-6,28762213,results,2,NA,Number of covariates adjusted for/matched on,NA,NA,10,TRUE,NA,NA,NA
10.1007/s40744-017-0070-6,28762213,results,2,NA,Covariates adjusted for/matched on in the indirect comparison,NA,NA,"Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Race/ethnicity, Past treatments for the disease of interest, Other(s)",TRUE,NA,NA,NA
10.1007/s40744-017-0070-6,28762213,results,2,NA,Primary outcome: treatment effect contrast,Rate difference,Means difference,Rate difference,FALSE,NA,NA,NA
10.1007/s40744-017-0070-6,28762213,results,2,NA,Direction of the treatment effect contrast: IPD treatment is:,NA,NA,"Numerator if ratio, or left side if difference",TRUE,NA,NA,NA
10.1007/s40744-017-0070-6,28762213,results,2,NA,Primary outcome: adjusted treatment effect,0.053,NA,5.30%,FALSE,NA,NA,NA
10.1007/s40744-017-0070-6,28762213,results,2,NA,"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])",NA,NA,0.507,TRUE,NA,NA,NA
10.1080/13696998.2018.1443111,29458286,general_information,NA,NA,Medical Condition of Interest Name,metastatic non-small cell lung cancer,anaplastic lymphoma kinase-positive metastatic non-small cell lung cancer,XXXX,FALSE,NA,NA,NA
10.1080/13696998.2018.1443111,29458286,general_information,NA,NA,Countries of first author affiliations,NA,NA,usa,TRUE,NA,NA,NA
10.1080/13696998.2018.1443111,29458286,general_information,NA,NA,Countries of last author affiliations,NA,NA,usa,TRUE,NA,NA,NA
10.1080/13696998.2018.1443111,29458286,general_information,NA,NA,"Positions of study investigators (for any authors of the article, any that applies)",NA,NA,"Pharmaceutical Industry, Private Data Analysis Company",TRUE,NA,NA,NA
10.1080/13696998.2018.1443111,29458286,general_information,NA,NA,"At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company",NA,NA,Yes,TRUE,NA,NA,NA
10.1080/13696998.2018.1443111,29458286,general_information,NA,NA,Mentioned sources of funding,NA,NA,Pharmaceutical Industry,TRUE,NA,NA,NA
10.1080/13696998.2018.1443111,29458286,general_information,NA,NA,"Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article",NA,NA,Yes,TRUE,NA,NA,NA
10.1080/13696998.2018.1443111,29458286,general_information,NA,NA,Mention of a systematic review to find the studies to compare treatments of interest,NA,NA,No,TRUE,NA,NA,NA
10.1080/13696998.2018.1443111,29458286,study_information,NA,1,Patient-level data used,NA,NA,Yes,TRUE,NA,NA,NA
10.1080/13696998.2018.1443111,29458286,study_information,NA,1,Clinical Trial,NA,NA,Yes,TRUE,NA,NA,NA
10.1080/13696998.2018.1443111,29458286,study_information,NA,1,NCT (only for clinical trial registered on clinicaltrials.gov),NA,NA,NCT01828099,TRUE,NA,NA,NA
10.1080/13696998.2018.1443111,29458286,study_information,NA,1,Country where the clinical trial/observational study was conducted (international if more than one),NA,NA,international,TRUE,NA,NA,NA
10.1080/13696998.2018.1443111,29458286,study_information,NA,1,Phase of the clinical trial (clinical trial only),NA,NA,3,TRUE,NA,NA,NA
10.1080/13696998.2018.1443111,29458286,study_information,NA,1,Number of treatment arms (clinical trial only),NA,NA,2 or more,TRUE,NA,NA,NA
10.1080/13696998.2018.1443111,29458286,study_information,NA,2,Patient-level data used,NA,NA,No,TRUE,NA,NA,NA
10.1080/13696998.2018.1443111,29458286,study_information,NA,2,Clinical Trial,NA,NA,Yes,TRUE,NA,NA,NA
10.1080/13696998.2018.1443111,29458286,study_information,NA,2,NCT (only for clinical trial registered on clinicaltrials.gov),NA,NA,NCT01154140,TRUE,NA,NA,NA
10.1080/13696998.2018.1443111,29458286,study_information,NA,2,Country where the clinical trial/observational study was conducted (international if more than one),NA,NA,international,TRUE,NA,NA,NA
10.1080/13696998.2018.1443111,29458286,study_information,NA,2,Phase of the clinical trial (clinical trial only),NA,NA,3,TRUE,NA,NA,NA
10.1080/13696998.2018.1443111,29458286,study_information,NA,2,Number of treatment arms (clinical trial only),NA,NA,2 or more,TRUE,NA,NA,NA
10.1080/13696998.2018.1443111,29458286,methodology,1,NA,Treatment name 1,ceritinib,certinib,ceritinib,FALSE,Associated with an economics analysis,"Cost-effectivness (economic) analysis

For the cost-effictivness analysis, the authors need to evaluate PFS and OS :
HR for OS = 0.82 [0.54;1.27]",NA
10.1080/13696998.2018.1443111,29458286,methodology,1,NA,Study 'number(s)' for treatment 1,NA,NA,1,TRUE,NA,NA,NA
10.1080/13696998.2018.1443111,29458286,methodology,1,NA,Treatment name 2,NA,NA,crizotinib,TRUE,NA,NA,NA
10.1080/13696998.2018.1443111,29458286,methodology,1,NA,Study 'number(s)' for treatment 2,NA,NA,2,TRUE,NA,NA,NA
10.1080/13696998.2018.1443111,29458286,methodology,1,NA,Type of population-adjusted indirect comparisons performed,NA,NA,MAIC,TRUE,NA,NA,NA
10.1080/13696998.2018.1443111,29458286,methodology,1,NA,Form of the indirect comparison,NA,NA,Simple (ie treatments effects extracted from two studies),TRUE,NA,NA,NA
10.1080/13696998.2018.1443111,29458286,methodology,1,NA,Definition of a single primary outcome for the indirect comparison,NA,NA,"No primary outcome defined, or multiple primary outcomes without any clear distinction between them",TRUE,NA,NA,NA
10.1080/13696998.2018.1443111,29458286,methodology,1,NA,Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined),progression free survival,progression-free survival,progression-free survival,FALSE,NA,NA,NA
10.1080/13696998.2018.1443111,29458286,methodology,1,NA,Primary outcome: variable type,NA,NA,Time-to-event,TRUE,NA,NA,NA
10.1080/13696998.2018.1443111,29458286,methodology,1,NA,Justification for selecting variables to be included in the adjustment model (in the main text),NA,NA,"Nothing mentioned, not reported",TRUE,NA,NA,NA
10.1080/13696998.2018.1443111,29458286,methodology,1,NA,Inclusion of prognostic factors in the adjustment/matching model,NA,NA,No discussion (in the main text) of the status of prognostic factors of the variables,TRUE,NA,NA,NA
10.1080/13696998.2018.1443111,29458286,methodology,1,NA,Inclusion of treatment-effect modifiers in the adjustment/matching model,NA,NA,No discussion (in the main text) of the status of treatment-effect modifiers of the variables,TRUE,NA,NA,NA
10.1080/13696998.2018.1443111,29458286,methodology,1,NA,"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)",NA,NA,No,TRUE,NA,NA,NA
10.1080/13696998.2018.1443111,29458286,methodology,1,NA,Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale),NA,NA,No,TRUE,NA,NA,NA
10.1080/13696998.2018.1443111,29458286,methodology,1,NA,Anchored comparison?,No,NA,No,FALSE,NA,NA,NA
10.1080/13696998.2018.1443111,29458286,results,1,NA,Reporting of a weights' distribution evaluation (MAIC),NA,NA,Not mentioned,TRUE,NA,NA,NA
10.1080/13696998.2018.1443111,29458286,results,1,NA,Reporting of the list of the covariates adjusted for/matched on,NA,NA,No,TRUE,NA,NA,NA
10.1080/13696998.2018.1443111,29458286,results,1,NA,Primary outcome: treatment effect contrast,NA,HR,HR,FALSE,NA,NA,NA
10.1080/13696998.2018.1443111,29458286,results,1,NA,Primary outcome: adjusted treatment effect,NA,NA,0.64,TRUE,NA,NA,NA
10.1080/13696998.2018.1443111,29458286,results,1,NA,"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])",NA,NA,[0.47;0.87],TRUE,NA,NA,NA
10.1080/13696998.2018.1443111,29458286,results,1,NA,Direction of the treatment effect contrast: IPD treatment is:,"Numerator if ratio, or left side if difference",NA,"Numerator if ratio, or left side if difference",FALSE,NA,NA,NA
10.1007/s40744-018-0106-6,29605841,general_information,NA,NA,Medical Condition of Interest Name,active psoriatic arthritis,psoriatic arthritis,XXXX,FALSE,NA,NA,NA
10.1007/s40744-018-0106-6,29605841,general_information,NA,NA,Countries of first author affiliations,NA,NA,australia,TRUE,NA,NA,NA
10.1007/s40744-018-0106-6,29605841,general_information,NA,NA,Countries of last author affiliations,NA,NA,switzerland,TRUE,NA,NA,NA
10.1007/s40744-018-0106-6,29605841,general_information,NA,NA,"Positions of study investigators (for any authors of the article, any that applies)",NA,NA,"Academic, Pharmaceutical Industry, Private Data Analysis Company",TRUE,NA,NA,NA
10.1007/s40744-018-0106-6,29605841,general_information,NA,NA,"At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company",NA,NA,Yes,TRUE,NA,NA,NA
10.1007/s40744-018-0106-6,29605841,general_information,NA,NA,Mentioned sources of funding,NA,NA,Pharmaceutical Industry,TRUE,NA,NA,NA
10.1007/s40744-018-0106-6,29605841,general_information,NA,NA,"Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article",NA,NA,Yes,TRUE,NA,NA,NA
10.1007/s40744-018-0106-6,29605841,general_information,NA,NA,Mention of a systematic review to find the studies to compare treatments of interest,NA,NA,Yes,TRUE,NA,NA,NA
10.1007/s40744-018-0106-6,29605841,study_information,NA,1,Patient-level data used,NA,NA,Yes,TRUE,NA,NA,NA
10.1007/s40744-018-0106-6,29605841,study_information,NA,1,Clinical Trial,NA,NA,Yes,TRUE,NA,NA,NA
10.1007/s40744-018-0106-6,29605841,study_information,NA,1,NCT (only for clinical trial registered on clinicaltrials.gov),NA,NA,NCT01752634,TRUE,NA,NA,NA
10.1007/s40744-018-0106-6,29605841,study_information,NA,1,Country where the clinical trial/observational study was conducted (international if more than one),NA,NA,international,TRUE,NA,NA,NA
10.1007/s40744-018-0106-6,29605841,study_information,NA,1,Phase of the clinical trial (clinical trial only),NA,NA,3,TRUE,NA,NA,NA
10.1007/s40744-018-0106-6,29605841,study_information,NA,1,Number of treatment arms (clinical trial only),NA,NA,2 or more,TRUE,NA,NA,NA
10.1007/s40744-018-0106-6,29605841,study_information,NA,2,Patient-level data used,NA,NA,No,TRUE,NA,NA,NA
10.1007/s40744-018-0106-6,29605841,study_information,NA,2,Clinical Trial,NA,NA,Yes,TRUE,NA,NA,NA
10.1007/s40744-018-0106-6,29605841,study_information,NA,2,NCT (only for clinical trial registered on clinicaltrials.gov),NA,NA,NCT00195689,TRUE,NA,NA,NA
10.1007/s40744-018-0106-6,29605841,study_information,NA,2,Country where the clinical trial/observational study was conducted (international if more than one),international,usa,usa,FALSE,NA,NA,NA
10.1007/s40744-018-0106-6,29605841,study_information,NA,2,Phase of the clinical trial (clinical trial only),NA,NA,3,TRUE,NA,NA,NA
10.1007/s40744-018-0106-6,29605841,study_information,NA,2,Number of treatment arms (clinical trial only),2 or more,1,1,FALSE,NA,NA,NA
10.1007/s40744-018-0106-6,29605841,methodology,1,NA,Treatment name 1,NA,NA,secukinumab 150 mg,TRUE,NA,"Anchored-MAIC of Sec 150 mg (ACR response rate at week 12)
Weight = other
ESSs for ancored and unanchored-MAIC are equals ?

""a principal analysis replicated the baseline characteristics of a previous MAIC between the same two trials"" ==> literature use for covariate selection",NA
10.1007/s40744-018-0106-6,29605841,methodology,1,NA,Study 'number(s)' for treatment 1,NA,NA,1,TRUE,NA,NA,NA
10.1007/s40744-018-0106-6,29605841,methodology,1,NA,Treatment name 2,NA,NA,adalimumab,TRUE,NA,NA,NA
10.1007/s40744-018-0106-6,29605841,methodology,1,NA,Study 'number(s)' for treatment 2,NA,NA,2,TRUE,NA,NA,NA
10.1007/s40744-018-0106-6,29605841,methodology,1,NA,Type of population-adjusted indirect comparisons performed,NA,NA,MAIC,TRUE,NA,NA,NA
10.1007/s40744-018-0106-6,29605841,methodology,1,NA,Anchored comparison?,NA,NA,Yes,TRUE,NA,NA,NA
10.1007/s40744-018-0106-6,29605841,methodology,1,NA,Form of the indirect comparison,NA,NA,Simple (ie treatments effects extracted from two studies),TRUE,NA,NA,NA
10.1007/s40744-018-0106-6,29605841,methodology,1,NA,Definition of a single primary outcome for the indirect comparison,NA,NA,"No primary outcome defined, or multiple primary outcomes without any clear distinction between them",TRUE,NA,NA,NA
10.1007/s40744-018-0106-6,29605841,methodology,1,NA,Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined),acr response rate at week 12,acr 20 response rate at week 12,acr 20 response rate at week 12,FALSE,NA,NA,NA
10.1007/s40744-018-0106-6,29605841,methodology,1,NA,Primary outcome: variable type,NA,NA,Binary (eg rates),TRUE,NA,NA,NA
10.1007/s40744-018-0106-6,29605841,methodology,1,NA,Justification for selecting variables to be included in the adjustment model (in the main text),"Status of prognostic factor/treatment effect modified assessed in the IPD dataset, A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion)","Status of prognostic factor/treatment effect modified assessed in the IPD dataset, A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion), Literature based (clinically or methodologically relevant to adjust on these variables based on the literature search conducted for this specific purpose)","Status of prognostic factor/treatment effect modified assessed in the IPD dataset, A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion)",FALSE,NA,NA,NA
10.1007/s40744-018-0106-6,29605841,methodology,1,NA,Inclusion of prognostic factors in the adjustment/matching model,NA,NA,Yes,TRUE,NA,NA,NA
10.1007/s40744-018-0106-6,29605841,methodology,1,NA,Inclusion of treatment-effect modifiers in the adjustment/matching model,NA,NA,Yes,TRUE,NA,NA,NA
10.1007/s40744-018-0106-6,29605841,methodology,1,NA,"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)",No,Yes,Yes,FALSE,NA,NA,NA
10.1007/s40744-018-0106-6,29605841,methodology,1,NA,Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale),NA,NA,No,TRUE,NA,NA,NA
10.1007/s40744-018-0106-6,29605841,methodology,2,NA,Treatment name 1,NA,NA,secukinumab 300 mg,TRUE,NA,"Anchored-MAIC of Sec 300 mg (ACR response rate at week 12)
Weight = other
ESSs for ancored and unanchored-MAIC are equals ?

""a principal analysis replicated the baseline characteristics of a previous MAIC between the same two trials"" ==> literature use for covariate selection",NA
10.1007/s40744-018-0106-6,29605841,methodology,2,NA,Study 'number(s)' for treatment 1,NA,NA,1,TRUE,NA,NA,NA
10.1007/s40744-018-0106-6,29605841,methodology,2,NA,Treatment name 2,NA,NA,adalimumab,TRUE,NA,NA,NA
10.1007/s40744-018-0106-6,29605841,methodology,2,NA,Study 'number(s)' for treatment 2,NA,NA,2,TRUE,NA,NA,NA
10.1007/s40744-018-0106-6,29605841,methodology,2,NA,Type of population-adjusted indirect comparisons performed,NA,NA,MAIC,TRUE,NA,NA,NA
10.1007/s40744-018-0106-6,29605841,methodology,2,NA,Anchored comparison?,NA,NA,Yes,TRUE,NA,NA,NA
10.1007/s40744-018-0106-6,29605841,methodology,2,NA,Form of the indirect comparison,NA,NA,Simple (ie treatments effects extracted from two studies),TRUE,NA,NA,NA
10.1007/s40744-018-0106-6,29605841,methodology,2,NA,Definition of a single primary outcome for the indirect comparison,NA,NA,"No primary outcome defined, or multiple primary outcomes without any clear distinction between them",TRUE,NA,NA,NA
10.1007/s40744-018-0106-6,29605841,methodology,2,NA,Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined),acr response rate at week 16,acr 20 response rate at week 12,acr 20 response rate at week 12,FALSE,NA,NA,NA
10.1007/s40744-018-0106-6,29605841,methodology,2,NA,Primary outcome: variable type,NA,NA,Binary (eg rates),TRUE,NA,NA,NA
10.1007/s40744-018-0106-6,29605841,methodology,2,NA,Justification for selecting variables to be included in the adjustment model (in the main text),"Status of prognostic factor/treatment effect modified assessed in the IPD dataset, A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion)","Status of prognostic factor/treatment effect modified assessed in the IPD dataset, A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion), Literature based (clinically or methodologically relevant to adjust on these variables based on the literature search conducted for this specific purpose)","Status of prognostic factor/treatment effect modified assessed in the IPD dataset, A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion)",FALSE,NA,NA,NA
10.1007/s40744-018-0106-6,29605841,methodology,2,NA,Inclusion of prognostic factors in the adjustment/matching model,NA,NA,Yes,TRUE,NA,NA,NA
10.1007/s40744-018-0106-6,29605841,methodology,2,NA,Inclusion of treatment-effect modifiers in the adjustment/matching model,NA,NA,Yes,TRUE,NA,NA,NA
10.1007/s40744-018-0106-6,29605841,methodology,2,NA,"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)",No,Yes,Yes,FALSE,NA,NA,NA
10.1007/s40744-018-0106-6,29605841,methodology,2,NA,Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale),NA,NA,No,TRUE,NA,NA,NA
10.1007/s40744-018-0106-6,29605841,methodology,3,NA,Treatment name 1,NA,NA,secukinumab 150 mg,TRUE,NA,"Unanchored-MAIC of Sec 150 mg (ACR response rate at week 16)
Weight = other
ESSs for ancored and unanchored-MAIC are equals ?

""a principal analysis replicated the baseline characteristics of a previous MAIC between the same two trials"" ==> literature use for covariate selection",NA
10.1007/s40744-018-0106-6,29605841,methodology,3,NA,Study 'number(s)' for treatment 1,NA,NA,1,TRUE,NA,NA,NA
10.1007/s40744-018-0106-6,29605841,methodology,3,NA,Treatment name 2,NA,NA,adalimumab,TRUE,NA,NA,NA
10.1007/s40744-018-0106-6,29605841,methodology,3,NA,Study 'number(s)' for treatment 2,NA,NA,2,TRUE,NA,NA,NA
10.1007/s40744-018-0106-6,29605841,methodology,3,NA,Type of population-adjusted indirect comparisons performed,NA,NA,MAIC,TRUE,NA,NA,NA
10.1007/s40744-018-0106-6,29605841,methodology,3,NA,Anchored comparison?,NA,NA,No,TRUE,NA,NA,NA
10.1007/s40744-018-0106-6,29605841,methodology,3,NA,Form of the indirect comparison,NA,NA,Simple (ie treatments effects extracted from two studies),TRUE,NA,NA,NA
10.1007/s40744-018-0106-6,29605841,methodology,3,NA,Definition of a single primary outcome for the indirect comparison,NA,NA,"No primary outcome defined, or multiple primary outcomes without any clear distinction between them",TRUE,NA,NA,NA
10.1007/s40744-018-0106-6,29605841,methodology,3,NA,Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined),acr response rate at week 16,acr 20 response rate at week 16,acr 20 response rate at week 16,FALSE,NA,NA,NA
10.1007/s40744-018-0106-6,29605841,methodology,3,NA,Primary outcome: variable type,NA,NA,Binary (eg rates),TRUE,NA,NA,NA
10.1007/s40744-018-0106-6,29605841,methodology,3,NA,Justification for selecting variables to be included in the adjustment model (in the main text),"Status of prognostic factor/treatment effect modified assessed in the IPD dataset, A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion)","Status of prognostic factor/treatment effect modified assessed in the IPD dataset, A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion), Literature based (clinically or methodologically relevant to adjust on these variables based on the literature search conducted for this specific purpose)","Status of prognostic factor/treatment effect modified assessed in the IPD dataset, A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion)",FALSE,NA,NA,NA
10.1007/s40744-018-0106-6,29605841,methodology,3,NA,Inclusion of prognostic factors in the adjustment/matching model,NA,NA,Yes,TRUE,NA,NA,NA
10.1007/s40744-018-0106-6,29605841,methodology,3,NA,Inclusion of treatment-effect modifiers in the adjustment/matching model,NA,NA,Yes,TRUE,NA,NA,NA
10.1007/s40744-018-0106-6,29605841,methodology,3,NA,"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)",No,Yes,Yes,FALSE,NA,NA,NA
10.1007/s40744-018-0106-6,29605841,methodology,3,NA,Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale),NA,NA,No,TRUE,NA,NA,NA
10.1007/s40744-018-0106-6,29605841,methodology,4,NA,Treatment name 1,NA,NA,secukinumab 300 mg,TRUE,NA,"Unanchored-MAIC of Sec 300 mg (ACR response rate at week 16)
Weight = other
ESSs for ancored and unanchored-MAIC are equals ?

""""a principal analysis replicated the baseline characteristics of a previous MAIC between the same two trials"""" ==> literature use for covariate selection",NA
10.1007/s40744-018-0106-6,29605841,methodology,4,NA,Study 'number(s)' for treatment 1,NA,NA,1,TRUE,NA,NA,NA
10.1007/s40744-018-0106-6,29605841,methodology,4,NA,Treatment name 2,NA,NA,adalimumab,TRUE,NA,NA,NA
10.1007/s40744-018-0106-6,29605841,methodology,4,NA,Study 'number(s)' for treatment 2,NA,NA,2,TRUE,NA,NA,NA
10.1007/s40744-018-0106-6,29605841,methodology,4,NA,Type of population-adjusted indirect comparisons performed,NA,NA,MAIC,TRUE,NA,NA,NA
10.1007/s40744-018-0106-6,29605841,methodology,4,NA,Anchored comparison?,No,Yes,No,FALSE,NA,NA,NA
10.1007/s40744-018-0106-6,29605841,methodology,4,NA,Form of the indirect comparison,NA,NA,Simple (ie treatments effects extracted from two studies),TRUE,NA,NA,NA
10.1007/s40744-018-0106-6,29605841,methodology,4,NA,Definition of a single primary outcome for the indirect comparison,NA,NA,"No primary outcome defined, or multiple primary outcomes without any clear distinction between them",TRUE,NA,NA,NA
10.1007/s40744-018-0106-6,29605841,methodology,4,NA,Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined),acr response rate at week 16,acr 50 response rate at week 16,acr 20 response rate at week 16,FALSE,NA,NA,NA
10.1007/s40744-018-0106-6,29605841,methodology,4,NA,Primary outcome: variable type,NA,NA,Binary (eg rates),TRUE,NA,NA,NA
10.1007/s40744-018-0106-6,29605841,methodology,4,NA,Justification for selecting variables to be included in the adjustment model (in the main text),"Status of prognostic factor/treatment effect modified assessed in the IPD dataset, A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion)","Status of prognostic factor/treatment effect modified assessed in the IPD dataset, A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion), Literature based (clinically or methodologically relevant to adjust on these variables based on the literature search conducted for this specific purpose)","Status of prognostic factor/treatment effect modified assessed in the IPD dataset, A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion)",FALSE,NA,NA,NA
10.1007/s40744-018-0106-6,29605841,methodology,4,NA,Inclusion of prognostic factors in the adjustment/matching model,NA,NA,Yes,TRUE,NA,NA,NA
10.1007/s40744-018-0106-6,29605841,methodology,4,NA,Inclusion of treatment-effect modifiers in the adjustment/matching model,NA,NA,Yes,TRUE,NA,NA,NA
10.1007/s40744-018-0106-6,29605841,methodology,4,NA,"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)",No,Yes,Yes,FALSE,NA,NA,NA
10.1007/s40744-018-0106-6,29605841,methodology,4,NA,Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale),NA,NA,No,TRUE,NA,NA,NA
10.1007/s40744-018-0106-6,29605841,results,1,NA,Sample size of the population of interest in the non IPD treatment arm,NA,NA,151,TRUE,NA,NA,NA
10.1007/s40744-018-0106-6,29605841,results,1,NA,"If anchored comparison, sample size of the population of interest in the non IPD treatment anchor arm",NA,NA,162,TRUE,NA,NA,NA
10.1007/s40744-018-0106-6,29605841,results,1,NA,Initial sample size of the population of interest in the IPD treatment arm,NA,NA,100,TRUE,NA,NA,NA
10.1007/s40744-018-0106-6,29605841,results,1,NA,"Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC",NA,NA,36,TRUE,NA,NA,NA
10.1007/s40744-018-0106-6,29605841,results,1,NA,"If anchored comparison, initial sample size of the population of interest in the IPD anchor arm",NA,NA,98,TRUE,NA,NA,NA
10.1007/s40744-018-0106-6,29605841,results,1,NA,"If anchored comparison, effective sample size after reweighting for MAIC; or sample size used in the regression model for STC in the IPD anchor arm",NA,NA,27,TRUE,NA,NA,NA
10.1007/s40744-018-0106-6,29605841,results,1,NA,Reporting of a weights' distribution evaluation (MAIC),NA,NA,Not mentioned,TRUE,NA,NA,NA
10.1007/s40744-018-0106-6,29605841,results,1,NA,Reporting of the list of the covariates adjusted for/matched on,NA,NA,Yes,TRUE,NA,NA,NA
10.1007/s40744-018-0106-6,29605841,results,1,NA,Number of covariates adjusted for/matched on,10,11,11,FALSE,NA,NA,NA
10.1007/s40744-018-0106-6,29605841,results,1,NA,Covariates adjusted for/matched on in the indirect comparison,NA,NA,"Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Race/ethnicity, Past treatments for the disease of interest, Other(s)",TRUE,NA,NA,NA
10.1007/s40744-018-0106-6,29605841,results,1,NA,Primary outcome: treatment effect contrast,NA,NA,RR,TRUE,NA,NA,NA
10.1007/s40744-018-0106-6,29605841,results,1,NA,Direction of the treatment effect contrast: IPD treatment is:,NA,NA,"Numerator if ratio, or left side if difference",TRUE,NA,NA,NA
10.1007/s40744-018-0106-6,29605841,results,1,NA,Primary outcome: adjusted treatment effect,NA,NA,0.69,TRUE,NA,NA,NA
10.1007/s40744-018-0106-6,29605841,results,1,NA,"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])",NA,NA,[0.34;1.43],TRUE,NA,NA,NA
10.1007/s40744-018-0106-6,29605841,results,2,NA,Sample size of the population of interest in the non IPD treatment arm,NA,NA,151,TRUE,NA,NA,NA
10.1007/s40744-018-0106-6,29605841,results,2,NA,"If anchored comparison, sample size of the population of interest in the non IPD treatment anchor arm",NA,NA,162,TRUE,NA,NA,NA
10.1007/s40744-018-0106-6,29605841,results,2,NA,Initial sample size of the population of interest in the IPD treatment arm,NA,NA,100,TRUE,NA,NA,NA
10.1007/s40744-018-0106-6,29605841,results,2,NA,"Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC",NA,NA,38,TRUE,NA,NA,NA
10.1007/s40744-018-0106-6,29605841,results,2,NA,"If anchored comparison, initial sample size of the population of interest in the IPD anchor arm",NA,NA,98,TRUE,NA,NA,NA
10.1007/s40744-018-0106-6,29605841,results,2,NA,"If anchored comparison, effective sample size after reweighting for MAIC; or sample size used in the regression model for STC in the IPD anchor arm",NA,NA,27,TRUE,NA,NA,NA
10.1007/s40744-018-0106-6,29605841,results,2,NA,Reporting of a weights' distribution evaluation (MAIC),NA,NA,Not mentioned,TRUE,NA,NA,NA
10.1007/s40744-018-0106-6,29605841,results,2,NA,Reporting of the list of the covariates adjusted for/matched on,NA,NA,Yes,TRUE,NA,NA,NA
10.1007/s40744-018-0106-6,29605841,results,2,NA,Number of covariates adjusted for/matched on,10,11,11,FALSE,NA,NA,NA
10.1007/s40744-018-0106-6,29605841,results,2,NA,Covariates adjusted for/matched on in the indirect comparison,NA,NA,"Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Race/ethnicity, Past treatments for the disease of interest, Other(s)",TRUE,NA,NA,NA
10.1007/s40744-018-0106-6,29605841,results,2,NA,Primary outcome: treatment effect contrast,NA,NA,RR,TRUE,NA,NA,NA
10.1007/s40744-018-0106-6,29605841,results,2,NA,Direction of the treatment effect contrast: IPD treatment is:,NA,NA,"Numerator if ratio, or left side if difference",TRUE,NA,NA,NA
10.1007/s40744-018-0106-6,29605841,results,2,NA,Primary outcome: adjusted treatment effect,NA,NA,0.61,TRUE,NA,NA,NA
10.1007/s40744-018-0106-6,29605841,results,2,NA,"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])",[0.29;127],[0.29;1.27],[0.29;1.27],FALSE,NA,NA,NA
10.1007/s40744-018-0106-6,29605841,results,3,NA,Sample size of the population of interest in the non IPD treatment arm,NA,NA,151,TRUE,NA,NA,NA
10.1007/s40744-018-0106-6,29605841,results,3,NA,Initial sample size of the population of interest in the IPD treatment arm,NA,NA,100,TRUE,NA,NA,NA
10.1007/s40744-018-0106-6,29605841,results,3,NA,"Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC",NA,NA,36,TRUE,NA,NA,NA
10.1007/s40744-018-0106-6,29605841,results,3,NA,Reporting of a weights' distribution evaluation (MAIC),NA,NA,Not mentioned,TRUE,NA,NA,NA
10.1007/s40744-018-0106-6,29605841,results,3,NA,Reporting of the list of the covariates adjusted for/matched on,NA,NA,Yes,TRUE,NA,NA,NA
10.1007/s40744-018-0106-6,29605841,results,3,NA,Number of covariates adjusted for/matched on,10,11,11,FALSE,NA,NA,NA
10.1007/s40744-018-0106-6,29605841,results,3,NA,Covariates adjusted for/matched on in the indirect comparison,NA,NA,"Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Race/ethnicity, Past treatments for the disease of interest, Other(s)",TRUE,NA,NA,NA
10.1007/s40744-018-0106-6,29605841,results,3,NA,Primary outcome: treatment effect contrast,NA,NA,RR,TRUE,NA,NA,NA
10.1007/s40744-018-0106-6,29605841,results,3,NA,Direction of the treatment effect contrast: IPD treatment is:,NA,NA,"Numerator if ratio, or left side if difference",TRUE,NA,NA,NA
10.1007/s40744-018-0106-6,29605841,results,3,NA,Primary outcome: adjusted treatment effect,NA,NA,1.34,TRUE,NA,NA,NA
10.1007/s40744-018-0106-6,29605841,results,3,NA,"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])",[0.29;1.54],0.017,[1.05;1.70],FALSE,NA,NA,NA
10.1007/s40744-018-0106-6,29605841,results,4,NA,Sample size of the population of interest in the non IPD treatment arm,NA,NA,151,TRUE,NA,NA,NA
10.1007/s40744-018-0106-6,29605841,results,4,NA,Initial sample size of the population of interest in the IPD treatment arm,NA,NA,100,TRUE,NA,NA,NA
10.1007/s40744-018-0106-6,29605841,results,4,NA,"Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC",NA,NA,38,TRUE,NA,NA,NA
10.1007/s40744-018-0106-6,29605841,results,4,NA,Reporting of a weights' distribution evaluation (MAIC),NA,NA,Not mentioned,TRUE,NA,NA,NA
10.1007/s40744-018-0106-6,29605841,results,4,NA,Reporting of the list of the covariates adjusted for/matched on,NA,NA,Yes,TRUE,NA,NA,NA
10.1007/s40744-018-0106-6,29605841,results,4,NA,Number of covariates adjusted for/matched on,10,11,11,FALSE,NA,NA,NA
10.1007/s40744-018-0106-6,29605841,results,4,NA,Covariates adjusted for/matched on in the indirect comparison,"Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Race/ethnicity, Past treatments for the disease of interest, Comorbidities and medical history (beside pathology/disease of interest in the comparison)","Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Race/ethnicity, Past treatments for the disease of interest, Other(s)","Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Race/ethnicity, Past treatments for the disease of interest, Other(s)",FALSE,NA,NA,NA
10.1007/s40744-018-0106-6,29605841,results,4,NA,Primary outcome: treatment effect contrast,NA,NA,RR,TRUE,NA,NA,NA
10.1007/s40744-018-0106-6,29605841,results,4,NA,Direction of the treatment effect contrast: IPD treatment is:,NA,NA,"Numerator if ratio, or left side if difference",TRUE,NA,NA,NA
10.1007/s40744-018-0106-6,29605841,results,4,NA,Primary outcome: adjusted treatment effect,1.18,1.54,1.18,FALSE,NA,NA,NA
10.1007/s40744-018-0106-6,29605841,results,4,NA,"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])",[0.90;1.54],0.03,[0.90;1.54],FALSE,NA,NA,NA
10.2147/cmar.s163478,29861642,general_information,NA,NA,Medical Condition of Interest Name,NA,NA,"hr+, her2âˆ’ advanced breast cancer",TRUE,NA,NA,NA
10.2147/cmar.s163478,29861642,general_information,NA,NA,Countries of first author affiliations,NA,NA,usa,TRUE,NA,NA,NA
10.2147/cmar.s163478,29861642,general_information,NA,NA,Countries of last author affiliations,NA,NA,usa,TRUE,NA,NA,NA
10.2147/cmar.s163478,29861642,general_information,NA,NA,"Positions of study investigators (for any authors of the article, any that applies)",Pharmaceutical Industry,"Pharmaceutical Industry, Private Data Analysis Company","Pharmaceutical Industry, Private Data Analysis Company",FALSE,NA,NA,NA
10.2147/cmar.s163478,29861642,general_information,NA,NA,"At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company",NA,NA,Yes,TRUE,NA,NA,NA
10.2147/cmar.s163478,29861642,general_information,NA,NA,Mentioned sources of funding,NA,NA,Pharmaceutical Industry,TRUE,NA,NA,NA
10.2147/cmar.s163478,29861642,general_information,NA,NA,"Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article",NA,Yes,Yes,FALSE,NA,NA,NA
10.2147/cmar.s163478,29861642,general_information,NA,NA,Mention of a systematic review to find the studies to compare treatments of interest,NA,NA,Yes,TRUE,NA,NA,NA
10.2147/cmar.s163478,29861642,study_information,NA,1,Patient-level data used,NA,NA,Yes,TRUE,NA,NA,NA
10.2147/cmar.s163478,29861642,study_information,NA,1,Clinical Trial,NA,NA,Yes,TRUE,NA,NA,NA
10.2147/cmar.s163478,29861642,study_information,NA,1,NCT (only for clinical trial registered on clinicaltrials.gov),NA,NA,NCT01958021,TRUE,NA,NA,NA
10.2147/cmar.s163478,29861642,study_information,NA,1,Country where the clinical trial/observational study was conducted (international if more than one),NA,NA,international,TRUE,NA,NA,NA
10.2147/cmar.s163478,29861642,study_information,NA,1,Phase of the clinical trial (clinical trial only),NA,NA,3,TRUE,NA,NA,NA
10.2147/cmar.s163478,29861642,study_information,NA,1,Number of treatment arms (clinical trial only),NA,NA,2 or more,TRUE,NA,NA,NA
10.2147/cmar.s163478,29861642,study_information,NA,2,Patient-level data used,NA,NA,No,TRUE,NA,NA,NA
10.2147/cmar.s163478,29861642,study_information,NA,2,Clinical Trial,NA,NA,Yes,TRUE,NA,NA,NA
10.2147/cmar.s163478,29861642,study_information,NA,2,NCT (only for clinical trial registered on clinicaltrials.gov),NA,NA,NCT01740427,TRUE,NA,NA,NA
10.2147/cmar.s163478,29861642,study_information,NA,2,Country where the clinical trial/observational study was conducted (international if more than one),NA,NA,international,TRUE,NA,NA,NA
10.2147/cmar.s163478,29861642,study_information,NA,2,Phase of the clinical trial (clinical trial only),NA,NA,3,TRUE,NA,NA,NA
10.2147/cmar.s163478,29861642,study_information,NA,2,Number of treatment arms (clinical trial only),NA,NA,2 or more,TRUE,NA,NA,NA
10.2147/cmar.s163478,29861642,methodology,1,NA,Treatment name 1,ribociclib + letrozole,ribociclib,ribociclib,FALSE,Sample size calculated using sample sizes percentages reduction given in the main text. Difference between post matching sample size (for inclusion criteria) and ESS is extremely small in regards of the number of variables adjusted for. Seems wrong so important to report.,"
Authors did not give the Initial sample size/ESS :
""Of the MONALEESA-2 ITT population, 334 patients were treated with RIBO and LET and 334 patients were treated with placebo and LET.""
""The MONALEESA-2 population was reduced by about 30% in each arm to fit the PALOMA-2. Compared with the ITT population, the effective sample size was 66% for RIBO and 71% for placebo (postexclusion sample sizes were 68% and 73%, respectively)""
",NA
10.2147/cmar.s163478,29861642,methodology,1,NA,Study 'number(s)' for treatment 1,1,2,1,FALSE,NA,NA,NA
10.2147/cmar.s163478,29861642,methodology,1,NA,Treatment name 2,palbociclib + letrozole,palbociclib,palbociclib,FALSE,NA,NA,NA
10.2147/cmar.s163478,29861642,methodology,1,NA,Study 'number(s)' for treatment 2,NA,NA,2,TRUE,NA,NA,NA
10.2147/cmar.s163478,29861642,methodology,1,NA,Type of population-adjusted indirect comparisons performed,NA,NA,MAIC,TRUE,NA,NA,NA
10.2147/cmar.s163478,29861642,methodology,1,NA,Anchored comparison?,NA,NA,Yes,TRUE,NA,NA,NA
10.2147/cmar.s163478,29861642,methodology,1,NA,Form of the indirect comparison,NA,NA,Simple (ie treatments effects extracted from two studies),TRUE,NA,NA,NA
10.2147/cmar.s163478,29861642,methodology,1,NA,Definition of a single primary outcome for the indirect comparison,Yes,"No primary outcome defined, or multiple primary outcomes without any clear distinction between them",Yes,FALSE,NA,NA,NA
10.2147/cmar.s163478,29861642,methodology,1,NA,Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined),NA,NA,progression-free survival,TRUE,NA,NA,NA
10.2147/cmar.s163478,29861642,methodology,1,NA,Primary outcome: variable type,NA,NA,Time-to-event,TRUE,NA,NA,NA
10.2147/cmar.s163478,29861642,methodology,1,NA,Justification for selecting variables to be included in the adjustment model (in the main text),NA,NA,"Nothing mentioned, not reported",TRUE,NA,NA,NA
10.2147/cmar.s163478,29861642,methodology,1,NA,Inclusion of prognostic factors in the adjustment/matching model,NA,NA,Yes,TRUE,NA,NA,NA
10.2147/cmar.s163478,29861642,methodology,1,NA,Inclusion of treatment-effect modifiers in the adjustment/matching model,NA,NA,No discussion (in the main text) of the status of treatment-effect modifiers of the variables,TRUE,NA,NA,NA
10.2147/cmar.s163478,29861642,methodology,1,NA,"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)",NA,NA,No,TRUE,NA,NA,NA
10.2147/cmar.s163478,29861642,methodology,1,NA,Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale),NA,NA,No,TRUE,NA,NA,NA
10.2147/cmar.s163478,29861642,results,1,NA,Sample size of the population of interest in the non IPD treatment arm,NA,NA,444,TRUE,NA,NA,NA
10.2147/cmar.s163478,29861642,results,1,NA,"If anchored comparison, sample size of the population of interest in the non IPD treatment anchor arm",NA,NA,222,TRUE,NA,NA,NA
10.2147/cmar.s163478,29861642,results,1,NA,Reporting of a weights' distribution evaluation (MAIC),NA,NA,Not mentioned,TRUE,NA,NA,NA
10.2147/cmar.s163478,29861642,results,1,NA,Reporting of the list of the covariates adjusted for/matched on,NA,NA,Yes,TRUE,NA,NA,NA
10.2147/cmar.s163478,29861642,results,1,NA,Number of covariates adjusted for/matched on,NA,NA,9,TRUE,NA,NA,NA
10.2147/cmar.s163478,29861642,results,1,NA,Covariates adjusted for/matched on in the indirect comparison,NA,NA,"Age, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Race/ethnicity, Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Past treatments for the disease of interest, Other(s)",TRUE,NA,NA,NA
10.2147/cmar.s163478,29861642,results,1,NA,Primary outcome: treatment effect contrast,NA,NA,HR,TRUE,NA,NA,NA
10.2147/cmar.s163478,29861642,results,1,NA,Direction of the treatment effect contrast: IPD treatment is:,NA,NA,"Numerator if ratio, or left side if difference",TRUE,NA,NA,NA
10.2147/cmar.s163478,29861642,results,1,NA,Primary outcome: unadjusted treatment effect,NA,NA,0.959,TRUE,NA,NA,NA
10.2147/cmar.s163478,29861642,results,1,NA,"p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])",NA,NA,[0.681;1.350],TRUE,NA,NA,NA
10.2147/cmar.s163478,29861642,results,1,NA,Primary outcome: adjusted treatment effect,NA,NA,0.904,TRUE,NA,NA,NA
10.2147/cmar.s163478,29861642,results,1,NA,"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])",NA,NA,[0.644;1.268],TRUE,NA,NA,NA
10.2147/cmar.s163478,29861642,results,1,NA,Initial sample size of the population of interest in the IPD treatment arm,227,NA,227,FALSE,NA,NA,NA
10.2147/cmar.s163478,29861642,results,1,NA,"Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC",220,NA,220,FALSE,NA,NA,NA
10.2147/cmar.s163478,29861642,results,1,NA,"If anchored comparison, initial sample size of the population of interest in the IPD anchor arm",244,NA,244,FALSE,NA,NA,NA
10.2147/cmar.s163478,29861642,results,1,NA,"If anchored comparison, effective sample size after reweighting for MAIC; or sample size used in the regression model for STC in the IPD anchor arm",237,NA,237,FALSE,NA,NA,NA
10.1093/europace/euy160,30052894,general_information,NA,NA,Medical Condition of Interest Name,NA,NA,non-valvular atrial fibrillation,TRUE,NA,NA,NA
10.1093/europace/euy160,30052894,general_information,NA,NA,Countries of first author affiliations,NA,NA,uk,TRUE,NA,NA,NA
10.1093/europace/euy160,30052894,general_information,NA,NA,Countries of last author affiliations,NA,NA,canada,TRUE,NA,NA,NA
10.1093/europace/euy160,30052894,general_information,NA,NA,"Positions of study investigators (for any authors of the article, any that applies)",NA,NA,"Academic, Pharmaceutical Industry, Private Data Analysis Company",TRUE,NA,NA,NA
10.1093/europace/euy160,30052894,general_information,NA,NA,"At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company",NA,NA,Yes,TRUE,NA,NA,NA
10.1093/europace/euy160,30052894,general_information,NA,NA,Mentioned sources of funding,NA,NA,Pharmaceutical Industry,TRUE,NA,NA,NA
10.1093/europace/euy160,30052894,general_information,NA,NA,"Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article",NA,NA,Yes,TRUE,NA,NA,NA
10.1093/europace/euy160,30052894,general_information,NA,NA,Mention of a systematic review to find the studies to compare treatments of interest,NA,NA,No,TRUE,NA,NA,NA
10.1093/europace/euy160,30052894,study_information,NA,1,Patient-level data used,NA,NA,Yes,TRUE,NA,NA,NA
10.1093/europace/euy160,30052894,study_information,NA,1,Clinical Trial,NA,NA,No,TRUE,NA,NA,NA
10.1093/europace/euy160,30052894,study_information,NA,1,NCT (only for clinical trial registered on clinicaltrials.gov),NA,NA,NCT01606995,TRUE,NA,NA,NA
10.1093/europace/euy160,30052894,study_information,NA,1,Country where the clinical trial/observational study was conducted (international if more than one),NA,NA,international,TRUE,NA,NA,NA
10.1093/europace/euy160,30052894,study_information,NA,2,Patient-level data used,NA,NA,No,TRUE,NA,NA,NA
10.1093/europace/euy160,30052894,study_information,NA,2,Clinical Trial,NA,NA,Yes,TRUE,NA,NA,NA
10.1093/europace/euy160,30052894,study_information,NA,2,NCT (only for clinical trial registered on clinicaltrials.gov),NA,NA,NCT00403767,TRUE,NA,NA,NA
10.1093/europace/euy160,30052894,study_information,NA,2,Country where the clinical trial/observational study was conducted (international if more than one),NA,NA,international,TRUE,NA,NA,NA
10.1093/europace/euy160,30052894,study_information,NA,2,Phase of the clinical trial (clinical trial only),NA,NA,3,TRUE,NA,NA,NA
10.1093/europace/euy160,30052894,study_information,NA,2,Number of treatment arms (clinical trial only),NA,NA,2 or more,TRUE,NA,NA,NA
10.1093/europace/euy160,30052894,methodology,1,NA,Treatment name 1,NA,NA,rivaroxaban,TRUE,"RCT vs RWD, to compare efficacy/safety of same treatment in different populations","To compare results from RWD and a clinical trial

""CHADS2 score and gender were selected as relevant variables for adjustment, as these encompass most of the relevant risk factors for stroke whilst also including a large enough number of patients to enable a meaningful analysis. ""  ==> risk factors and not prognostic factors ???",NA
10.1093/europace/euy160,30052894,methodology,1,NA,Study 'number(s)' for treatment 1,NA,NA,1,TRUE,NA,NA,NA
10.1093/europace/euy160,30052894,methodology,1,NA,Treatment name 2,NA,NA,rivaroxaban,TRUE,NA,NA,NA
10.1093/europace/euy160,30052894,methodology,1,NA,Study 'number(s)' for treatment 2,NA,NA,2,TRUE,NA,NA,NA
10.1093/europace/euy160,30052894,methodology,1,NA,Type of population-adjusted indirect comparisons performed,NA,NA,MAIC,TRUE,NA,NA,NA
10.1093/europace/euy160,30052894,methodology,1,NA,Anchored comparison?,NA,NA,No,TRUE,NA,NA,NA
10.1093/europace/euy160,30052894,methodology,1,NA,Form of the indirect comparison,NA,NA,Simple (ie treatments effects extracted from two studies),TRUE,NA,NA,NA
10.1093/europace/euy160,30052894,methodology,1,NA,Definition of a single primary outcome for the indirect comparison,NA,NA,"No primary outcome defined, or multiple primary outcomes without any clear distinction between them",TRUE,NA,NA,NA
10.1093/europace/euy160,30052894,methodology,1,NA,Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined),treatment-emergent adjudicated major bleeding,annualized incidence rate of major bleeding,treatment-emergent adjudicated major bleeding,FALSE,NA,NA,NA
10.1093/europace/euy160,30052894,methodology,1,NA,Primary outcome: variable type,NA,NA,Binary (eg rates),TRUE,NA,NA,NA
10.1093/europace/euy160,30052894,methodology,1,NA,Justification for selecting variables to be included in the adjustment model (in the main text),NA,NA,"Nothing mentioned, not reported",TRUE,NA,NA,NA
10.1093/europace/euy160,30052894,methodology,1,NA,Inclusion of prognostic factors in the adjustment/matching model,NA,NA,No discussion (in the main text) of the status of prognostic factors of the variables,TRUE,NA,NA,NA
10.1093/europace/euy160,30052894,methodology,1,NA,Inclusion of treatment-effect modifiers in the adjustment/matching model,NA,NA,No discussion (in the main text) of the status of treatment-effect modifiers of the variables,TRUE,NA,NA,NA
10.1093/europace/euy160,30052894,methodology,1,NA,"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)",NA,NA,No,TRUE,NA,NA,NA
10.1093/europace/euy160,30052894,methodology,1,NA,Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale),NA,NA,No,TRUE,NA,NA,NA
10.1093/europace/euy160,30052894,results,1,NA,Sample size of the population of interest in the non IPD treatment arm,NA,NA,7061,TRUE,NA,NA,NA
10.1093/europace/euy160,30052894,results,1,NA,Initial sample size of the population of interest in the IPD treatment arm,NA,NA,4020,TRUE,NA,NA,NA
10.1093/europace/euy160,30052894,results,1,NA,"Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC",NA,NA,2492,TRUE,NA,NA,NA
10.1093/europace/euy160,30052894,results,1,NA,Reporting of a weights' distribution evaluation (MAIC),NA,NA,Not mentioned,TRUE,NA,NA,NA
10.1093/europace/euy160,30052894,results,1,NA,Reporting of the list of the covariates adjusted for/matched on,NA,NA,Yes,TRUE,NA,NA,NA
10.1093/europace/euy160,30052894,results,1,NA,Number of covariates adjusted for/matched on,NA,NA,2,TRUE,NA,NA,NA
10.1093/europace/euy160,30052894,results,1,NA,Covariates adjusted for/matched on in the indirect comparison,"Age, Sex","Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease)","Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease)",FALSE,NA,NA,NA
10.1093/europace/euy160,30052894,results,1,NA,Primary outcome: treatment effect contrast,NA,NA,RR,TRUE,NA,NA,NA
10.1093/europace/euy160,30052894,results,1,NA,Direction of the treatment effect contrast: IPD treatment is:,NA,NA,"Numerator if ratio, or left side if difference",TRUE,NA,NA,NA
10.1093/europace/euy160,30052894,results,1,NA,Primary outcome: adjusted treatment effect,NA,NA,0.86,TRUE,NA,NA,NA
10.1093/europace/euy160,30052894,results,1,NA,"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])",NA,NA,[0.67;1.12],TRUE,NA,NA,NA
10.2217/cer-2018-0020,30168349,general_information,NA,NA,Medical Condition of Interest Name,advanced pancreatic neuroendocrine tumor,advanced pancreatic neuroendocrine tumors,XXXX,FALSE,NA,NA,NA
10.2217/cer-2018-0020,30168349,general_information,NA,NA,Countries of first author affiliations,NA,NA,canada,TRUE,NA,NA,NA
10.2217/cer-2018-0020,30168349,general_information,NA,NA,Countries of last author affiliations,NA,NA,uk,TRUE,NA,NA,NA
10.2217/cer-2018-0020,30168349,general_information,NA,NA,"Positions of study investigators (for any authors of the article, any that applies)",NA,NA,"Academic, Pharmaceutical Industry, Private Data Analysis Company",TRUE,NA,NA,NA
10.2217/cer-2018-0020,30168349,general_information,NA,NA,"At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company",NA,NA,Yes,TRUE,NA,NA,NA
10.2217/cer-2018-0020,30168349,general_information,NA,NA,Mentioned sources of funding,NA,NA,Pharmaceutical Industry,TRUE,NA,NA,NA
10.2217/cer-2018-0020,30168349,general_information,NA,NA,"Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article",NA,NA,Yes,TRUE,NA,NA,NA
10.2217/cer-2018-0020,30168349,general_information,NA,NA,Mention of a systematic review to find the studies to compare treatments of interest,NA,NA,No,TRUE,NA,NA,NA
10.2217/cer-2018-0020,30168349,study_information,NA,1,Patient-level data used,NA,NA,Yes,TRUE,NA,NA,NA
10.2217/cer-2018-0020,30168349,study_information,NA,1,Clinical Trial,NA,NA,Yes,TRUE,NA,NA,NA
10.2217/cer-2018-0020,30168349,study_information,NA,1,NCT (only for clinical trial registered on clinicaltrials.gov),NA,NA,NCT00428597,TRUE,NA,NA,NA
10.2217/cer-2018-0020,30168349,study_information,NA,1,Country where the clinical trial/observational study was conducted (international if more than one),NA,NA,international,TRUE,NA,NA,NA
10.2217/cer-2018-0020,30168349,study_information,NA,1,Phase of the clinical trial (clinical trial only),NA,NA,3,TRUE,NA,NA,NA
10.2217/cer-2018-0020,30168349,study_information,NA,1,Number of treatment arms (clinical trial only),NA,NA,2 or more,TRUE,NA,NA,NA
10.2217/cer-2018-0020,30168349,study_information,NA,2,Patient-level data used,NA,NA,No,TRUE,NA,NA,NA
10.2217/cer-2018-0020,30168349,study_information,NA,2,Clinical Trial,NA,NA,Yes,TRUE,NA,NA,NA
10.2217/cer-2018-0020,30168349,study_information,NA,2,NCT (only for clinical trial registered on clinicaltrials.gov),NA,NA,NCT00510068,TRUE,NA,NA,NA
10.2217/cer-2018-0020,30168349,study_information,NA,2,Country where the clinical trial/observational study was conducted (international if more than one),NA,NA,international,TRUE,NA,NA,NA
10.2217/cer-2018-0020,30168349,study_information,NA,2,Phase of the clinical trial (clinical trial only),NA,NA,3,TRUE,NA,NA,NA
10.2217/cer-2018-0020,30168349,study_information,NA,2,Number of treatment arms (clinical trial only),NA,NA,2 or more,TRUE,NA,NA,NA
10.2217/cer-2018-0020,30168349,methodology,1,NA,Treatment name 1,NA,NA,sunitinib,TRUE,"Reciprocal analysis from a MAIC published using the opposite IPD and non IPD data
Conduct both adjusted and unadjusted analysis, so report results for both
median age and proportion > 64 years counted as one variable
concurrent use of somatostatin: other
Assess the residual confounding by comparing treatment arms: although this should not have any importance in an anchored analysis, and this should not be really comparable in an unanchored one
Conclude that the changes observed between their MAIC and the one from Signorovitch is due to change in data (longer followup available), while it could theoretically due to the fact that treatment effect modifiers are not distributed the same way across populations
",NA,NA
10.2217/cer-2018-0020,30168349,methodology,1,NA,Study 'number(s)' for treatment 1,NA,NA,1,TRUE,NA,NA,NA
10.2217/cer-2018-0020,30168349,methodology,1,NA,Treatment name 2,NA,NA,everolimus,TRUE,NA,NA,NA
10.2217/cer-2018-0020,30168349,methodology,1,NA,Study 'number(s)' for treatment 2,NA,NA,2,TRUE,NA,NA,NA
10.2217/cer-2018-0020,30168349,methodology,1,NA,Type of population-adjusted indirect comparisons performed,NA,NA,MAIC,TRUE,NA,NA,NA
10.2217/cer-2018-0020,30168349,methodology,1,NA,Anchored comparison?,NA,NA,Yes,TRUE,NA,NA,NA
10.2217/cer-2018-0020,30168349,methodology,1,NA,Form of the indirect comparison,NA,NA,Simple (ie treatments effects extracted from two studies),TRUE,NA,NA,NA
10.2217/cer-2018-0020,30168349,methodology,1,NA,Definition of a single primary outcome for the indirect comparison,NA,NA,Yes,TRUE,NA,NA,NA
10.2217/cer-2018-0020,30168349,methodology,1,NA,Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined),NA,NA,progression-free survival,TRUE,NA,NA,NA
10.2217/cer-2018-0020,30168349,methodology,1,NA,Primary outcome: variable type,NA,NA,Time-to-event,TRUE,NA,NA,NA
10.2217/cer-2018-0020,30168349,methodology,1,NA,Justification for selecting variables to be included in the adjustment model (in the main text),NA,NA,"Nothing mentioned, not reported",TRUE,NA,NA,NA
10.2217/cer-2018-0020,30168349,methodology,1,NA,Inclusion of prognostic factors in the adjustment/matching model,No discussion (in the main text) of the status of prognostic factors of the variables,No,No discussion (in the main text) of the status of prognostic factors of the variables,FALSE,NA,NA,NA
10.2217/cer-2018-0020,30168349,methodology,1,NA,Inclusion of treatment-effect modifiers in the adjustment/matching model,No discussion (in the main text) of the status of treatment-effect modifiers of the variables,Yes,No discussion (in the main text) of the status of treatment-effect modifiers of the variables,FALSE,NA,NA,NA
10.2217/cer-2018-0020,30168349,methodology,1,NA,"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)",NA,NA,No,TRUE,NA,NA,NA
10.2217/cer-2018-0020,30168349,methodology,1,NA,Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale),NA,NA,No,TRUE,NA,NA,NA
10.2217/cer-2018-0020,30168349,methodology,2,NA,Treatment name 1,NA,NA,sunitinib,TRUE,NA,Predictor = prognostic factor ??,NA
10.2217/cer-2018-0020,30168349,methodology,2,NA,Study 'number(s)' for treatment 1,NA,NA,1,TRUE,NA,NA,NA
10.2217/cer-2018-0020,30168349,methodology,2,NA,Treatment name 2,NA,NA,everolimus,TRUE,NA,NA,NA
10.2217/cer-2018-0020,30168349,methodology,2,NA,Study 'number(s)' for treatment 2,NA,NA,2,TRUE,NA,NA,NA
10.2217/cer-2018-0020,30168349,methodology,2,NA,Type of population-adjusted indirect comparisons performed,NA,NA,MAIC,TRUE,NA,NA,NA
10.2217/cer-2018-0020,30168349,methodology,2,NA,Anchored comparison?,NA,NA,No,TRUE,NA,NA,NA
10.2217/cer-2018-0020,30168349,methodology,2,NA,Form of the indirect comparison,NA,NA,Simple (ie treatments effects extracted from two studies),TRUE,NA,NA,NA
10.2217/cer-2018-0020,30168349,methodology,2,NA,Definition of a single primary outcome for the indirect comparison,NA,NA,Yes,TRUE,NA,NA,NA
10.2217/cer-2018-0020,30168349,methodology,2,NA,Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined),NA,NA,overall survival,TRUE,NA,NA,NA
10.2217/cer-2018-0020,30168349,methodology,2,NA,Primary outcome: variable type,NA,NA,Time-to-event,TRUE,NA,NA,NA
10.2217/cer-2018-0020,30168349,methodology,2,NA,Justification for selecting variables to be included in the adjustment model (in the main text),NA,NA,"Nothing mentioned, not reported",TRUE,NA,NA,NA
10.2217/cer-2018-0020,30168349,methodology,2,NA,Inclusion of prognostic factors in the adjustment/matching model,No discussion (in the main text) of the status of prognostic factors of the variables,Yes,No discussion (in the main text) of the status of prognostic factors of the variables,FALSE,NA,NA,NA
10.2217/cer-2018-0020,30168349,methodology,2,NA,Inclusion of treatment-effect modifiers in the adjustment/matching model,No discussion (in the main text) of the status of treatment-effect modifiers of the variables,Yes,No discussion (in the main text) of the status of treatment-effect modifiers of the variables,FALSE,NA,NA,NA
10.2217/cer-2018-0020,30168349,methodology,2,NA,"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)",NA,NA,No,TRUE,NA,NA,NA
10.2217/cer-2018-0020,30168349,methodology,2,NA,Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale),NA,NA,No,TRUE,NA,NA,NA
10.2217/cer-2018-0020,30168349,results,1,NA,Sample size of the population of interest in the non IPD treatment arm,NA,NA,207,TRUE,NA,NA,NA
10.2217/cer-2018-0020,30168349,results,1,NA,"If anchored comparison, sample size of the population of interest in the non IPD treatment anchor arm",NA,NA,203,TRUE,NA,NA,NA
10.2217/cer-2018-0020,30168349,results,1,NA,Initial sample size of the population of interest in the IPD treatment arm,NA,NA,86,TRUE,NA,NA,NA
10.2217/cer-2018-0020,30168349,results,1,NA,"Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC",85,43,43,FALSE,NA,NA,NA
10.2217/cer-2018-0020,30168349,results,1,NA,"If anchored comparison, initial sample size of the population of interest in the IPD anchor arm",43,85,85,FALSE,NA,NA,NA
10.2217/cer-2018-0020,30168349,results,1,NA,"If anchored comparison, effective sample size after reweighting for MAIC; or sample size used in the regression model for STC in the IPD anchor arm",NA,NA,31,TRUE,NA,NA,NA
10.2217/cer-2018-0020,30168349,results,1,NA,Reporting of a weights' distribution evaluation (MAIC),NA,NA,Not mentioned,TRUE,NA,NA,NA
10.2217/cer-2018-0020,30168349,results,1,NA,Reporting of the list of the covariates adjusted for/matched on,NA,NA,Yes,TRUE,NA,NA,NA
10.2217/cer-2018-0020,30168349,results,1,NA,Number of covariates adjusted for/matched on,11,12,11,FALSE,NA,NA,NA
10.2217/cer-2018-0020,30168349,results,1,NA,Covariates adjusted for/matched on in the indirect comparison,"Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Race/ethnicity, Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Past treatments for the disease of interest, Other(s)","Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Race/ethnicity, Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Past treatments for the disease of interest","Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Race/ethnicity, Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Past treatments for the disease of interest",FALSE,NA,NA,NA
10.2217/cer-2018-0020,30168349,results,1,NA,Primary outcome: treatment effect contrast,NA,NA,HR,TRUE,NA,NA,NA
10.2217/cer-2018-0020,30168349,results,1,NA,Direction of the treatment effect contrast: IPD treatment is:,NA,NA,"Numerator if ratio, or left side if difference",TRUE,NA,NA,NA
10.2217/cer-2018-0020,30168349,results,1,NA,Primary outcome: unadjusted treatment effect,NA,NA,1.2,TRUE,NA,NA,NA
10.2217/cer-2018-0020,30168349,results,1,NA,"p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])",NA,NA,[0.72;2.01],TRUE,NA,NA,NA
10.2217/cer-2018-0020,30168349,results,1,NA,Primary outcome: adjusted treatment effect,NA,NA,0.85,TRUE,NA,NA,NA
10.2217/cer-2018-0020,30168349,results,1,NA,"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])",NA,NA,[0.39;1.89],TRUE,NA,NA,NA
10.2217/cer-2018-0020,30168349,results,2,NA,Sample size of the population of interest in the non IPD treatment arm,NA,NA,207,TRUE,NA,NA,NA
10.2217/cer-2018-0020,30168349,results,2,NA,Initial sample size of the population of interest in the IPD treatment arm,NA,NA,86,TRUE,NA,NA,NA
10.2217/cer-2018-0020,30168349,results,2,NA,Reporting of a weights' distribution evaluation (MAIC),NA,NA,Not mentioned,TRUE,NA,NA,NA
10.2217/cer-2018-0020,30168349,results,2,NA,Reporting of the list of the covariates adjusted for/matched on,NA,NA,Yes,TRUE,NA,NA,NA
10.2217/cer-2018-0020,30168349,results,2,NA,Number of covariates adjusted for/matched on,11,12,11,FALSE,NA,NA,NA
10.2217/cer-2018-0020,30168349,results,2,NA,Covariates adjusted for/matched on in the indirect comparison,"Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Race/ethnicity, Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Past treatments for the disease of interest, Other(s)","Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Race/ethnicity, Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Past treatments for the disease of interest","Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Race/ethnicity, Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Past treatments for the disease of interest",FALSE,NA,NA,NA
10.2217/cer-2018-0020,30168349,results,2,NA,Primary outcome: treatment effect contrast,NA,NA,HR,TRUE,NA,NA,NA
10.2217/cer-2018-0020,30168349,results,2,NA,Direction of the treatment effect contrast: IPD treatment is:,NA,NA,"Numerator if ratio, or left side if difference",TRUE,NA,NA,NA
10.2217/cer-2018-0020,30168349,results,2,NA,Primary outcome: unadjusted treatment effect,NA,NA,1.03,TRUE,NA,NA,NA
10.2217/cer-2018-0020,30168349,results,2,NA,"p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])",NA,NA,[0.75;1.42],TRUE,NA,NA,NA
10.2217/cer-2018-0020,30168349,results,2,NA,Primary outcome: adjusted treatment effect,NA,NA,0.82,TRUE,NA,NA,NA
10.2217/cer-2018-0020,30168349,results,2,NA,"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])",NA,NA,[0.53;1.27],TRUE,NA,NA,NA
10.2217/cer-2018-0020,30168349,results,2,NA,"Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC",43,NA,43,FALSE,NA,NA,NA
10.1183/13993003.01393-2018,30309978,general_information,NA,NA,Medical Condition of Interest Name,severe uncontrolled asthma,severe asthma,severe uncontrolled asthma,FALSE,NA,NA,NA
10.1183/13993003.01393-2018,30309978,general_information,NA,NA,Countries of first author affiliations,NA,NA,france,TRUE,NA,NA,NA
10.1183/13993003.01393-2018,30309978,general_information,NA,NA,Countries of last author affiliations,NA,NA,usa,TRUE,NA,NA,NA
10.1183/13993003.01393-2018,30309978,general_information,NA,NA,"Positions of study investigators (for any authors of the article, any that applies)",NA,NA,"Academic, Pharmaceutical Industry, Private Data Analysis Company",TRUE,NA,NA,NA
10.1183/13993003.01393-2018,30309978,general_information,NA,NA,"At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company",NA,NA,Yes,TRUE,NA,NA,NA
10.1183/13993003.01393-2018,30309978,general_information,NA,NA,Mentioned sources of funding,NA,NA,Pharmaceutical Industry,TRUE,NA,NA,NA
10.1183/13993003.01393-2018,30309978,general_information,NA,NA,"Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article",NA,NA,Yes,TRUE,NA,NA,NA
10.1183/13993003.01393-2018,30309978,general_information,NA,NA,Mention of a systematic review to find the studies to compare treatments of interest,NA,NA,Yes,TRUE,NA,NA,NA
10.1183/13993003.01393-2018,30309978,study_information,NA,1,Patient-level data used,NA,NA,Yes,TRUE,NA,NA,NA
10.1183/13993003.01393-2018,30309978,study_information,NA,1,Clinical Trial,NA,NA,Yes,TRUE,NA,NA,NA
10.1183/13993003.01393-2018,30309978,study_information,NA,1,NCT (only for clinical trial registered on clinicaltrials.gov),NA,NA,NCT01928771,TRUE,NA,NA,NA
10.1183/13993003.01393-2018,30309978,study_information,NA,1,Country where the clinical trial/observational study was conducted (international if more than one),NA,NA,international,TRUE,NA,NA,NA
10.1183/13993003.01393-2018,30309978,study_information,NA,1,Phase of the clinical trial (clinical trial only),NA,NA,3,TRUE,NA,NA,NA
10.1183/13993003.01393-2018,30309978,study_information,NA,1,Number of treatment arms (clinical trial only),NA,NA,2 or more,TRUE,NA,NA,NA
10.1183/13993003.01393-2018,30309978,study_information,NA,2,Patient-level data used,NA,NA,Yes,TRUE,NA,NA,NA
10.1183/13993003.01393-2018,30309978,study_information,NA,2,Clinical Trial,NA,NA,Yes,TRUE,NA,NA,NA
10.1183/13993003.01393-2018,30309978,study_information,NA,2,NCT (only for clinical trial registered on clinicaltrials.gov),NA,NA,NCT01914757,TRUE,NA,NA,NA
10.1183/13993003.01393-2018,30309978,study_information,NA,2,Country where the clinical trial/observational study was conducted (international if more than one),NA,NA,international,TRUE,NA,NA,NA
10.1183/13993003.01393-2018,30309978,study_information,NA,2,Phase of the clinical trial (clinical trial only),NA,NA,3,TRUE,NA,NA,NA
10.1183/13993003.01393-2018,30309978,study_information,NA,2,Number of treatment arms (clinical trial only),NA,NA,2 or more,TRUE,NA,NA,NA
10.1183/13993003.01393-2018,30309978,study_information,NA,3,Patient-level data used,NA,NA,No,TRUE,NA,NA,NA
10.1183/13993003.01393-2018,30309978,study_information,NA,3,Clinical Trial,NA,NA,Yes,TRUE,NA,NA,NA
10.1183/13993003.01393-2018,30309978,study_information,NA,3,NCT (only for clinical trial registered on clinicaltrials.gov),NA,NA,NCT01691521,TRUE,NA,NA,NA
10.1183/13993003.01393-2018,30309978,study_information,NA,3,Country where the clinical trial/observational study was conducted (international if more than one),NA,NA,international,TRUE,NA,NA,NA
10.1183/13993003.01393-2018,30309978,study_information,NA,3,Phase of the clinical trial (clinical trial only),NA,NA,3,TRUE,NA,NA,NA
10.1183/13993003.01393-2018,30309978,study_information,NA,3,Number of treatment arms (clinical trial only),NA,NA,2 or more,TRUE,NA,NA,NA
10.1183/13993003.01393-2018,30309978,study_information,NA,4,Patient-level data used,NA,NA,No,TRUE,NA,NA,NA
10.1183/13993003.01393-2018,30309978,study_information,NA,4,Clinical Trial,NA,NA,Yes,TRUE,NA,NA,NA
10.1183/13993003.01393-2018,30309978,study_information,NA,4,NCT (only for clinical trial registered on clinicaltrials.gov),NA,NA,NCT01000506,TRUE,NA,NA,NA
10.1183/13993003.01393-2018,30309978,study_information,NA,4,Country where the clinical trial/observational study was conducted (international if more than one),NA,NA,international,TRUE,NA,NA,NA
10.1183/13993003.01393-2018,30309978,study_information,NA,4,Phase of the clinical trial (clinical trial only),NA,NA,2,TRUE,NA,NA,NA
10.1183/13993003.01393-2018,30309978,study_information,NA,4,Number of treatment arms (clinical trial only),NA,NA,2 or more,TRUE,NA,NA,NA
10.1183/13993003.01393-2018,30309978,methodology,1,NA,Treatment name 1,NA,NA,benralizumab,TRUE,"Report that one of the conducted MAIC results (versus reslizumab) were not presented because of too small ESS (20, a 99% reduction). That specific ITC has been conducted in the context of a NMA, with conclusion for the superiority of reslizumab, whereas it appears that baseline characterstics, namely baseline disease severity significantly diverge between the compared studies. 
For N IPD no details (959 total) and numbers of table 1 and 2 don't add up 
ESS benralizumab + placebo = 639
","mean BMI = other covariates

Effectif Benralizumab + placebo = 959
ESS  Benralizumab + placebo = 639",NA
10.1183/13993003.01393-2018,30309978,methodology,1,NA,Study 'number(s)' for treatment 1,NA,NA,1;2,TRUE,NA,NA,NA
10.1183/13993003.01393-2018,30309978,methodology,1,NA,Treatment name 2,NA,NA,mepolizumab,TRUE,NA,NA,NA
10.1183/13993003.01393-2018,30309978,methodology,1,NA,Study 'number(s)' for treatment 2,NA,NA,3;4,TRUE,NA,NA,NA
10.1183/13993003.01393-2018,30309978,methodology,1,NA,Type of population-adjusted indirect comparisons performed,NA,NA,MAIC,TRUE,NA,NA,NA
10.1183/13993003.01393-2018,30309978,methodology,1,NA,Anchored comparison?,NA,NA,Yes,TRUE,NA,NA,NA
10.1183/13993003.01393-2018,30309978,methodology,1,NA,Form of the indirect comparison,NA,NA,"Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate)",TRUE,NA,NA,NA
10.1183/13993003.01393-2018,30309978,methodology,1,NA,Definition of a single primary outcome for the indirect comparison,NA,NA,"No primary outcome defined, or multiple primary outcomes without any clear distinction between them",TRUE,NA,NA,NA
10.1183/13993003.01393-2018,30309978,methodology,1,NA,Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined),NA,NA,annual rate of clinically significant exacerbations,TRUE,NA,NA,NA
10.1183/13993003.01393-2018,30309978,methodology,1,NA,Primary outcome: variable type,NA,NA,Binary (eg rates),TRUE,NA,NA,NA
10.1183/13993003.01393-2018,30309978,methodology,1,NA,Justification for selecting variables to be included in the adjustment model (in the main text),"Status of prognostic factor/treatment effect modified assessed in the IPD dataset, A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion), Literature based (clinically or methodologically relevant to adjust on these variables based on the literature search conducted for this specific purpose)","Statistical imbalanced between treatment groups (independently of the status of prognostic/effect modifier), Status of prognostic factor/treatment effect modified assessed in the IPD dataset, A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion)","Status of prognostic factor/treatment effect modified assessed in the IPD dataset, A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion), Literature based (clinically or methodologically relevant to adjust on these variables based on the literature search conducted for this specific purpose)",FALSE,NA,NA,NA
10.1183/13993003.01393-2018,30309978,methodology,1,NA,Inclusion of prognostic factors in the adjustment/matching model,NA,NA,No,TRUE,NA,NA,NA
10.1183/13993003.01393-2018,30309978,methodology,1,NA,Inclusion of treatment-effect modifiers in the adjustment/matching model,NA,NA,Yes,TRUE,NA,NA,NA
10.1183/13993003.01393-2018,30309978,methodology,1,NA,"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)",No,Yes,No,FALSE,NA,NA,NA
10.1183/13993003.01393-2018,30309978,methodology,1,NA,Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale),NA,NA,No,TRUE,NA,NA,NA
10.1183/13993003.01393-2018,30309978,results,1,NA,Sample size of the population of interest in the non IPD treatment arm,NA,NA,538,TRUE,NA,NA,NA
10.1183/13993003.01393-2018,30309978,results,1,NA,"If anchored comparison, sample size of the population of interest in the non IPD treatment anchor arm",NA,NA,346,TRUE,NA,NA,NA
10.1183/13993003.01393-2018,30309978,results,1,NA,Reporting of a weights' distribution evaluation (MAIC),NA,NA,Not mentioned,TRUE,NA,NA,NA
10.1183/13993003.01393-2018,30309978,results,1,NA,Reporting of the list of the covariates adjusted for/matched on,NA,NA,Yes,TRUE,NA,NA,NA
10.1183/13993003.01393-2018,30309978,results,1,NA,Number of covariates adjusted for/matched on,NA,NA,7,TRUE,NA,NA,NA
10.1183/13993003.01393-2018,30309978,results,1,NA,Covariates adjusted for/matched on in the indirect comparison,NA,NA,"Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Past treatments for the disease of interest, Other(s)",TRUE,NA,NA,NA
10.1183/13993003.01393-2018,30309978,results,1,NA,Primary outcome: treatment effect contrast,NA,NA,RR,TRUE,NA,NA,NA
10.1183/13993003.01393-2018,30309978,results,1,NA,Direction of the treatment effect contrast: IPD treatment is:,NA,NA,"Numerator if ratio, or left side if difference",TRUE,NA,NA,NA
10.1183/13993003.01393-2018,30309978,results,1,NA,Primary outcome: unadjusted treatment effect,NA,NA,1.06,TRUE,NA,NA,NA
10.1183/13993003.01393-2018,30309978,results,1,NA,"p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])",0.5533,0.5553,0.5553,FALSE,NA,NA,NA
10.1183/13993003.01393-2018,30309978,results,1,NA,Primary outcome: adjusted treatment effect,NA,NA,0.94,TRUE,NA,NA,NA
10.1183/13993003.01393-2018,30309978,results,1,NA,"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])",NA,NA,0.5207,TRUE,NA,NA,NA
10.1080/03007995.2018.1541443,30362839,general_information,NA,NA,Medical Condition of Interest Name,previously untreated advanced anaplastic lymphoma kinase (alk)-positive non-small cell lung cancer,advanced or metastatic anaplastic lymphoma kinase-positive non-small cell lung cancer,previously untreated advanced anaplastic lymphoma kinase (alk)-positive non-small cell lung cancer,FALSE,NA,NA,NA
10.1080/03007995.2018.1541443,30362839,general_information,NA,NA,Countries of first author affiliations,NA,NA,usa,TRUE,NA,NA,NA
10.1080/03007995.2018.1541443,30362839,general_information,NA,NA,Countries of last author affiliations,NA,NA,usa,TRUE,NA,NA,NA
10.1080/03007995.2018.1541443,30362839,general_information,NA,NA,"Positions of study investigators (for any authors of the article, any that applies)",NA,NA,"Pharmaceutical Industry, Private Data Analysis Company",TRUE,NA,NA,NA
10.1080/03007995.2018.1541443,30362839,general_information,NA,NA,"At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company",NA,NA,Yes,TRUE,NA,NA,NA
10.1080/03007995.2018.1541443,30362839,general_information,NA,NA,Mentioned sources of funding,NA,NA,Pharmaceutical Industry,TRUE,NA,NA,NA
10.1080/03007995.2018.1541443,30362839,general_information,NA,NA,"Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article",NA,NA,Yes,TRUE,NA,NA,NA
10.1080/03007995.2018.1541443,30362839,general_information,NA,NA,Mention of a systematic review to find the studies to compare treatments of interest,NA,NA,No,TRUE,NA,NA,NA
10.1080/03007995.2018.1541443,30362839,study_information,NA,1,Patient-level data used,NA,NA,Yes,TRUE,NA,NA,NA
10.1080/03007995.2018.1541443,30362839,study_information,NA,1,Clinical Trial,NA,NA,Yes,TRUE,NA,NA,NA
10.1080/03007995.2018.1541443,30362839,study_information,NA,1,NCT (only for clinical trial registered on clinicaltrials.gov),NA,NA,NCT01828099,TRUE,NA,NA,NA
10.1080/03007995.2018.1541443,30362839,study_information,NA,1,Country where the clinical trial/observational study was conducted (international if more than one),NA,NA,international,TRUE,NA,NA,NA
10.1080/03007995.2018.1541443,30362839,study_information,NA,1,Phase of the clinical trial (clinical trial only),NA,NA,3,TRUE,NA,NA,NA
10.1080/03007995.2018.1541443,30362839,study_information,NA,1,Number of treatment arms (clinical trial only),NA,NA,2 or more,TRUE,NA,NA,NA
10.1080/03007995.2018.1541443,30362839,study_information,NA,2,Patient-level data used,NA,NA,No,TRUE,NA,NA,NA
10.1080/03007995.2018.1541443,30362839,study_information,NA,2,Clinical Trial,NA,NA,Yes,TRUE,NA,NA,NA
10.1080/03007995.2018.1541443,30362839,study_information,NA,2,NCT (only for clinical trial registered on clinicaltrials.gov),NA,NA,NCT01154140,TRUE,NA,NA,NA
10.1080/03007995.2018.1541443,30362839,study_information,NA,2,Country where the clinical trial/observational study was conducted (international if more than one),NA,NA,international,TRUE,NA,NA,NA
10.1080/03007995.2018.1541443,30362839,study_information,NA,2,Phase of the clinical trial (clinical trial only),NA,NA,3,TRUE,NA,NA,NA
10.1080/03007995.2018.1541443,30362839,study_information,NA,2,Number of treatment arms (clinical trial only),NA,NA,2 or more,TRUE,NA,NA,NA
10.1080/03007995.2018.1541443,30362839,methodology,1,NA,Treatment name 1,NA,NA,ceritinib,TRUE,"Conduct an unanchored comparison, although say that the effect of the ""chemotherapy"" arms were similar after adjustment across arms. Include all baseline characteristics without discussing the status of TEM or prognostic factors. Conducted by the inventor of the methodology! 
Don""t provide the ESS for the treatment arm, although total ESS = 340, and said that there was a 10% reduction in sample size (so should be around 170)",Smoking status = other covariates,NA
10.1080/03007995.2018.1541443,30362839,methodology,1,NA,Study 'number(s)' for treatment 1,NA,NA,1,TRUE,NA,NA,NA
10.1080/03007995.2018.1541443,30362839,methodology,1,NA,Treatment name 2,NA,NA,crizotinib,TRUE,NA,NA,NA
10.1080/03007995.2018.1541443,30362839,methodology,1,NA,Study 'number(s)' for treatment 2,NA,NA,2,TRUE,NA,NA,NA
10.1080/03007995.2018.1541443,30362839,methodology,1,NA,Type of population-adjusted indirect comparisons performed,NA,NA,MAIC,TRUE,NA,NA,NA
10.1080/03007995.2018.1541443,30362839,methodology,1,NA,Anchored comparison?,NA,NA,No,TRUE,NA,NA,NA
10.1080/03007995.2018.1541443,30362839,methodology,1,NA,Form of the indirect comparison,NA,NA,Simple (ie treatments effects extracted from two studies),TRUE,NA,NA,NA
10.1080/03007995.2018.1541443,30362839,methodology,1,NA,Definition of a single primary outcome for the indirect comparison,"No primary outcome defined, or multiple primary outcomes without any clear distinction between them",Yes,"No primary outcome defined, or multiple primary outcomes without any clear distinction between them",FALSE,NA,NA,NA
10.1080/03007995.2018.1541443,30362839,methodology,1,NA,Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined),progression free survival,progression-free survival,progression-free survival,FALSE,NA,NA,NA
10.1080/03007995.2018.1541443,30362839,methodology,1,NA,Primary outcome: variable type,NA,NA,Time-to-event,TRUE,NA,NA,NA
10.1080/03007995.2018.1541443,30362839,methodology,1,NA,Justification for selecting variables to be included in the adjustment model (in the main text),NA,NA,"Nothing mentioned, not reported",TRUE,NA,NA,NA
10.1080/03007995.2018.1541443,30362839,methodology,1,NA,Inclusion of prognostic factors in the adjustment/matching model,No discussion (in the main text) of the status of prognostic factors of the variables,Yes,Yes,FALSE,NA,NA,NA
10.1080/03007995.2018.1541443,30362839,methodology,1,NA,Inclusion of treatment-effect modifiers in the adjustment/matching model,NA,NA,No discussion (in the main text) of the status of treatment-effect modifiers of the variables,TRUE,NA,NA,NA
10.1080/03007995.2018.1541443,30362839,methodology,1,NA,"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)",NA,NA,No,TRUE,NA,NA,NA
10.1080/03007995.2018.1541443,30362839,methodology,1,NA,Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale),NA,NA,No,TRUE,NA,NA,NA
10.1080/03007995.2018.1541443,30362839,results,1,NA,Sample size of the population of interest in the non IPD treatment arm,172,343,172,FALSE,NA,NA,NA
10.1080/03007995.2018.1541443,30362839,results,1,NA,Initial sample size of the population of interest in the IPD treatment arm,189,376,189,FALSE,NA,NA,NA
10.1080/03007995.2018.1541443,30362839,results,1,NA,"Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC",NA,340,XXXX,FALSE,NA,NA,NA
10.1080/03007995.2018.1541443,30362839,results,1,NA,Reporting of a weights' distribution evaluation (MAIC),"Yes, mentions that the weights distribution has been studied, and weights distribution reported in main article or supplemental materials","Yes, mentions that the weights distribution has been studied, but weights distribution not reported","Yes, mentions that the weights distribution has been studied, and weights distribution reported in main article or supplemental materials",FALSE,NA,NA,NA
10.1080/03007995.2018.1541443,30362839,results,1,NA,Reporting of the list of the covariates adjusted for/matched on,NA,NA,Yes,TRUE,NA,NA,NA
10.1080/03007995.2018.1541443,30362839,results,1,NA,Number of covariates adjusted for/matched on,NA,NA,8,TRUE,NA,NA,NA
10.1080/03007995.2018.1541443,30362839,results,1,NA,Covariates adjusted for/matched on in the indirect comparison,"Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Race/ethnicity, Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Comorbidities and medical history (beside pathology/disease of interest in the comparison)","Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Race/ethnicity, Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Other(s)","Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Race/ethnicity, Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Comorbidities and medical history (beside pathology/disease of interest in the comparison)",FALSE,NA,NA,NA
10.1080/03007995.2018.1541443,30362839,results,1,NA,Primary outcome: treatment effect contrast,NA,NA,HR,TRUE,NA,NA,NA
10.1080/03007995.2018.1541443,30362839,results,1,NA,Direction of the treatment effect contrast: IPD treatment is:,NA,NA,"Numerator if ratio, or left side if difference",TRUE,NA,NA,NA
10.1080/03007995.2018.1541443,30362839,results,1,NA,Primary outcome: unadjusted treatment effect,NA,NA,0.68,TRUE,NA,NA,NA
10.1080/03007995.2018.1541443,30362839,results,1,NA,"p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])",NA,NA,0.01,TRUE,NA,NA,NA
10.1080/03007995.2018.1541443,30362839,results,1,NA,Primary outcome: adjusted treatment effect,NA,NA,0.64,TRUE,NA,NA,NA
10.1080/03007995.2018.1541443,30362839,results,1,NA,"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])",NA,NA,0.004,TRUE,NA,NA,NA
10.1111/jdv.15369,30472749,general_information,NA,NA,Medical Condition of Interest Name,NA,NA,plaque psoriasis,TRUE,NA,NA,NA
10.1111/jdv.15369,30472749,general_information,NA,NA,Countries of first author affiliations,NA,NA,uk,TRUE,NA,NA,NA
10.1111/jdv.15369,30472749,general_information,NA,NA,Countries of last author affiliations,NA,NA,usa,TRUE,NA,NA,NA
10.1111/jdv.15369,30472749,general_information,NA,NA,"Positions of study investigators (for any authors of the article, any that applies)",NA,NA,"Academic, Pharmaceutical Industry, Private Data Analysis Company",TRUE,NA,NA,NA
10.1111/jdv.15369,30472749,general_information,NA,NA,"At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company",NA,NA,Yes,TRUE,NA,NA,NA
10.1111/jdv.15369,30472749,general_information,NA,NA,Mentioned sources of funding,NA,NA,Pharmaceutical Industry,TRUE,NA,NA,NA
10.1111/jdv.15369,30472749,general_information,NA,NA,"Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article",NA,NA,Yes,TRUE,NA,NA,NA
10.1111/jdv.15369,30472749,general_information,NA,NA,Mention of a systematic review to find the studies to compare treatments of interest,NA,NA,Yes,TRUE,NA,NA,NA
10.1111/jdv.15369,30472749,study_information,NA,1,Patient-level data used,NA,NA,Yes,TRUE,NA,NA,NA
10.1111/jdv.15369,30472749,study_information,NA,1,Clinical Trial,NA,NA,Yes,TRUE,NA,NA,NA
10.1111/jdv.15369,30472749,study_information,NA,1,NCT (only for clinical trial registered on clinicaltrials.gov),NA,NA,NCT02132936,TRUE,NA,NA,NA
10.1111/jdv.15369,30472749,study_information,NA,1,Country where the clinical trial/observational study was conducted (international if more than one),NA,NA,france,TRUE,NA,NA,NA
10.1111/jdv.15369,30472749,study_information,NA,1,Phase of the clinical trial (clinical trial only),NA,NA,3,TRUE,NA,NA,NA
10.1111/jdv.15369,30472749,study_information,NA,1,Number of treatment arms (clinical trial only),NA,NA,2 or more,TRUE,NA,NA,NA
10.1111/jdv.15369,30472749,study_information,NA,2,Patient-level data used,NA,NA,Yes,TRUE,NA,NA,NA
10.1111/jdv.15369,30472749,study_information,NA,2,Clinical Trial,NA,NA,Yes,TRUE,NA,NA,NA
10.1111/jdv.15369,30472749,study_information,NA,2,NCT (only for clinical trial registered on clinicaltrials.gov),NA,NA,NCT01866163,TRUE,NA,NA,NA
10.1111/jdv.15369,30472749,study_information,NA,2,Country where the clinical trial/observational study was conducted (international if more than one),NA,NA,usa,TRUE,NA,NA,NA
10.1111/jdv.15369,30472749,study_information,NA,2,Phase of the clinical trial (clinical trial only),NA,NA,3,TRUE,NA,NA,NA
10.1111/jdv.15369,30472749,study_information,NA,2,Number of treatment arms (clinical trial only),NA,NA,2 or more,TRUE,NA,NA,NA
10.1111/jdv.15369,30472749,study_information,NA,3,Patient-level data used,NA,NA,Yes,TRUE,NA,NA,NA
10.1111/jdv.15369,30472749,study_information,NA,3,Clinical Trial,NA,NA,Yes,TRUE,NA,NA,NA
10.1111/jdv.15369,30472749,study_information,NA,3,NCT (only for clinical trial registered on clinicaltrials.gov),NA,NA,NCT01536886,TRUE,NA,NA,NA
10.1111/jdv.15369,30472749,study_information,NA,3,Country where the clinical trial/observational study was conducted (international if more than one),NA,NA,usa,TRUE,NA,NA,NA
10.1111/jdv.15369,30472749,study_information,NA,3,Phase of the clinical trial (clinical trial only),NA,NA,2,TRUE,NA,NA,NA
10.1111/jdv.15369,30472749,study_information,NA,3,Number of treatment arms (clinical trial only),NA,NA,2 or more,TRUE,NA,NA,NA
10.1111/jdv.15369,30472749,study_information,NA,4,Patient-level data used,NA,NA,Yes,TRUE,NA,NA,NA
10.1111/jdv.15369,30472749,study_information,NA,4,Clinical Trial,NA,NA,Yes,TRUE,NA,NA,NA
10.1111/jdv.15369,30472749,study_information,NA,4,NCT (only for clinical trial registered on clinicaltrials.gov),NA,NA,NCT01536938,TRUE,NA,NA,NA
10.1111/jdv.15369,30472749,study_information,NA,4,Country where the clinical trial/observational study was conducted (international if more than one),NA,NA,usa,TRUE,NA,NA,NA
10.1111/jdv.15369,30472749,study_information,NA,4,Phase of the clinical trial (clinical trial only),NA,NA,2,TRUE,NA,NA,NA
10.1111/jdv.15369,30472749,study_information,NA,4,Number of treatment arms (clinical trial only),NA,NA,2 or more,TRUE,NA,NA,NA
10.1111/jdv.15369,30472749,study_information,NA,5,Patient-level data used,NA,NA,No,TRUE,NA,NA,NA
10.1111/jdv.15369,30472749,study_information,NA,5,Clinical Trial,NA,NA,Yes,TRUE,NA,NA,NA
10.1111/jdv.15369,30472749,study_information,NA,5,NCT (only for clinical trial registered on clinicaltrials.gov),NA,NA,NCT02425826,TRUE,NA,NA,NA
10.1111/jdv.15369,30472749,study_information,NA,5,Country where the clinical trial/observational study was conducted (international if more than one),NA,NA,usa,TRUE,NA,NA,NA
10.1111/jdv.15369,30472749,study_information,NA,5,Phase of the clinical trial (clinical trial only),NA,NA,4,TRUE,NA,NA,NA
10.1111/jdv.15369,30472749,study_information,NA,5,Number of treatment arms (clinical trial only),NA,NA,2 or more,TRUE,NA,NA,NA
10.1111/jdv.15369,30472749,study_information,NA,6,Patient-level data used,NA,NA,No,TRUE,NA,NA,NA
10.1111/jdv.15369,30472749,study_information,NA,6,Clinical Trial,NA,NA,No,TRUE,NA,NA,NA
10.1111/jdv.15369,30472749,study_information,NA,6,Data source name (only if observational study or clinical trial without NCT),NA,NA,"zurita et al., (2017)",TRUE,NA,NA,NA
10.1111/jdv.15369,30472749,study_information,NA,6,Country where the clinical trial/observational study was conducted (international if more than one),NA,spain,XXXX,FALSE,NA,NA,NA
10.1111/jdv.15369,30472749,study_information,NA,7,Patient-level data used,NA,NA,No,TRUE,NA,NA,NA
10.1111/jdv.15369,30472749,study_information,NA,7,Clinical Trial,NA,NA,No,TRUE,NA,NA,NA
10.1111/jdv.15369,30472749,study_information,NA,7,Data source name (only if observational study or clinical trial without NCT),NA,NA,chiricozzi et al. (2016),TRUE,NA,NA,NA
10.1111/jdv.15369,30472749,study_information,NA,7,Country where the clinical trial/observational study was conducted (international if more than one),NA,italy,XXXX,FALSE,NA,NA,NA
10.1111/jdv.15369,30472749,study_information,NA,8,Patient-level data used,NA,NA,No,TRUE,NA,NA,NA
10.1111/jdv.15369,30472749,study_information,NA,8,Clinical Trial,NA,NA,No,TRUE,NA,NA,NA
10.1111/jdv.15369,30472749,study_information,NA,8,Data source name (only if observational study or clinical trial without NCT),NA,NA,inzinger et al. (2013),TRUE,NA,NA,NA
10.1111/jdv.15369,30472749,study_information,NA,8,Country where the clinical trial/observational study was conducted (international if more than one),NA,austria,XXXX,FALSE,NA,NA,NA
10.1111/jdv.15369,30472749,methodology,1,NA,Treatment name 1,NA,NA,calcipotriol + betamethasone dipropionate aerosol foam,TRUE,NA,"Studies 1 to 5   No statistics were calculated : Authors calculated the responders rate to Cal/BD foam before and after the MAIC 
+ equality test with the comparator

BMI = others",NA
10.1111/jdv.15369,30472749,methodology,1,NA,Study 'number(s)' for treatment 1,NA,NA,1;2;3;4,TRUE,NA,NA,NA
10.1111/jdv.15369,30472749,methodology,1,NA,Treatment name 2,NA,NA,apremilast,TRUE,NA,NA,NA
10.1111/jdv.15369,30472749,methodology,1,NA,Study 'number(s)' for treatment 2,NA,NA,5,TRUE,NA,NA,NA
10.1111/jdv.15369,30472749,methodology,1,NA,Type of population-adjusted indirect comparisons performed,NA,NA,MAIC,TRUE,NA,NA,NA
10.1111/jdv.15369,30472749,methodology,1,NA,Anchored comparison?,NA,NA,No,TRUE,NA,NA,NA
10.1111/jdv.15369,30472749,methodology,1,NA,Form of the indirect comparison,NA,NA,"Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate)",TRUE,NA,NA,NA
10.1111/jdv.15369,30472749,methodology,1,NA,Definition of a single primary outcome for the indirect comparison,Yes,"No primary outcome defined, or multiple primary outcomes without any clear distinction between them",Yes,FALSE,NA,NA,NA
10.1111/jdv.15369,30472749,methodology,1,NA,Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined),hysician’s global assessment 0/1 response,physician global assessment (pga) 0/1 responders rate,physician global assessment (pga) 0/1 responders rate,FALSE,NA,NA,NA
10.1111/jdv.15369,30472749,methodology,1,NA,Primary outcome: variable type,NA,NA,Binary (eg rates),TRUE,NA,NA,NA
10.1111/jdv.15369,30472749,methodology,1,NA,Justification for selecting variables to be included in the adjustment model (in the main text),"Status of prognostic factor/treatment effect modified assessed in the IPD dataset, A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion)",Status of prognostic factor/treatment effect modified assessed in the IPD dataset,"Status of prognostic factor/treatment effect modified assessed in the IPD dataset, A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion)",FALSE,NA,NA,NA
10.1111/jdv.15369,30472749,methodology,1,NA,Inclusion of prognostic factors in the adjustment/matching model,NA,NA,No discussion (in the main text) of the status of prognostic factors of the variables,TRUE,NA,NA,NA
10.1111/jdv.15369,30472749,methodology,1,NA,Inclusion of treatment-effect modifiers in the adjustment/matching model,NA,NA,No discussion (in the main text) of the status of treatment-effect modifiers of the variables,TRUE,NA,NA,NA
10.1111/jdv.15369,30472749,methodology,1,NA,"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)",NA,NA,No,TRUE,NA,NA,NA
10.1111/jdv.15369,30472749,methodology,1,NA,Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale),NA,NA,No,TRUE,NA,NA,NA
10.1111/jdv.15369,30472749,methodology,2,NA,Treatment name 1,NA,NA,calcipotriol + betamethasone dipropionate aerosol foam,TRUE,NA,NA,NA
10.1111/jdv.15369,30472749,methodology,2,NA,Study 'number(s)' for treatment 1,NA,NA,1;2;3;4,TRUE,NA,NA,NA
10.1111/jdv.15369,30472749,methodology,2,NA,Treatment name 2,NA,NA,methotrexate,TRUE,NA,NA,NA
10.1111/jdv.15369,30472749,methodology,2,NA,Study 'number(s)' for treatment 2,NA,NA,6,TRUE,NA,NA,NA
10.1111/jdv.15369,30472749,methodology,2,NA,Type of population-adjusted indirect comparisons performed,NA,NA,MAIC,TRUE,NA,NA,NA
10.1111/jdv.15369,30472749,methodology,2,NA,Anchored comparison?,NA,NA,No,TRUE,NA,NA,NA
10.1111/jdv.15369,30472749,methodology,2,NA,Form of the indirect comparison,NA,NA,"Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate)",TRUE,NA,NA,NA
10.1111/jdv.15369,30472749,methodology,2,NA,Definition of a single primary outcome for the indirect comparison,NA,NA,Yes,TRUE,NA,NA,NA
10.1111/jdv.15369,30472749,methodology,2,NA,Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined),pasi 75 locf,psoriasis area severity index (pasi) 75 responders rate,psoriasis area severity index (pasi) 75 responders rate,FALSE,NA,NA,NA
10.1111/jdv.15369,30472749,methodology,2,NA,Primary outcome: variable type,NA,NA,Binary (eg rates),TRUE,NA,NA,NA
10.1111/jdv.15369,30472749,methodology,2,NA,Justification for selecting variables to be included in the adjustment model (in the main text),"Status of prognostic factor/treatment effect modified assessed in the IPD dataset, A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion)",Status of prognostic factor/treatment effect modified assessed in the IPD dataset,"Status of prognostic factor/treatment effect modified assessed in the IPD dataset, A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion)",FALSE,NA,NA,NA
10.1111/jdv.15369,30472749,methodology,2,NA,Inclusion of prognostic factors in the adjustment/matching model,NA,NA,No discussion (in the main text) of the status of prognostic factors of the variables,TRUE,NA,NA,NA
10.1111/jdv.15369,30472749,methodology,2,NA,Inclusion of treatment-effect modifiers in the adjustment/matching model,NA,NA,No discussion (in the main text) of the status of treatment-effect modifiers of the variables,TRUE,NA,NA,NA
10.1111/jdv.15369,30472749,methodology,2,NA,"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)",NA,NA,No,TRUE,NA,NA,NA
10.1111/jdv.15369,30472749,methodology,2,NA,Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale),NA,NA,No,TRUE,NA,NA,NA
10.1111/jdv.15369,30472749,methodology,3,NA,Treatment name 1,NA,NA,calcipotriol + betamethasone dipropionate aerosol foam,TRUE,NA,BMI = others,NA
10.1111/jdv.15369,30472749,methodology,3,NA,Study 'number(s)' for treatment 1,NA,NA,1;2;3;4,TRUE,NA,NA,NA
10.1111/jdv.15369,30472749,methodology,3,NA,Treatment name 2,NA,NA,acitretin,TRUE,NA,NA,NA
10.1111/jdv.15369,30472749,methodology,3,NA,Study 'number(s)' for treatment 2,NA,NA,7,TRUE,NA,NA,NA
10.1111/jdv.15369,30472749,methodology,3,NA,Type of population-adjusted indirect comparisons performed,NA,NA,MAIC,TRUE,NA,NA,NA
10.1111/jdv.15369,30472749,methodology,3,NA,Anchored comparison?,NA,NA,No,TRUE,NA,NA,NA
10.1111/jdv.15369,30472749,methodology,3,NA,Form of the indirect comparison,NA,NA,"Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate)",TRUE,NA,NA,NA
10.1111/jdv.15369,30472749,methodology,3,NA,Definition of a single primary outcome for the indirect comparison,NA,NA,Yes,TRUE,NA,NA,NA
10.1111/jdv.15369,30472749,methodology,3,NA,Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined),pasi 75 locf,psoriasis area severity index (pasi) 75 responders rate,psoriasis area severity index (pasi) 75 responders rate,FALSE,NA,NA,NA
10.1111/jdv.15369,30472749,methodology,3,NA,Primary outcome: variable type,NA,NA,Binary (eg rates),TRUE,NA,NA,NA
10.1111/jdv.15369,30472749,methodology,3,NA,Justification for selecting variables to be included in the adjustment model (in the main text),NA,NA,"Status of prognostic factor/treatment effect modified assessed in the IPD dataset, A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion)",TRUE,NA,NA,NA
10.1111/jdv.15369,30472749,methodology,3,NA,Inclusion of prognostic factors in the adjustment/matching model,NA,NA,No discussion (in the main text) of the status of prognostic factors of the variables,TRUE,NA,NA,NA
10.1111/jdv.15369,30472749,methodology,3,NA,Inclusion of treatment-effect modifiers in the adjustment/matching model,NA,NA,No discussion (in the main text) of the status of treatment-effect modifiers of the variables,TRUE,NA,NA,NA
10.1111/jdv.15369,30472749,methodology,3,NA,"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)",NA,NA,No,TRUE,NA,NA,NA
10.1111/jdv.15369,30472749,methodology,3,NA,Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale),NA,NA,No,TRUE,NA,NA,NA
10.1111/jdv.15369,30472749,methodology,4,NA,Treatment name 1,NA,NA,calcipotriol + betamethasone dipropionate aerosol foam,TRUE,NA,NA,NA
10.1111/jdv.15369,30472749,methodology,4,NA,Study 'number(s)' for treatment 1,NA,NA,1;2;3;4,TRUE,NA,NA,NA
10.1111/jdv.15369,30472749,methodology,4,NA,Treatment name 2,NA,NA,fumaric acid esters,TRUE,NA,NA,NA
10.1111/jdv.15369,30472749,methodology,4,NA,Study 'number(s)' for treatment 2,NA,NA,8,TRUE,NA,NA,NA
10.1111/jdv.15369,30472749,methodology,4,NA,Type of population-adjusted indirect comparisons performed,NA,NA,MAIC,TRUE,NA,NA,NA
10.1111/jdv.15369,30472749,methodology,4,NA,Anchored comparison?,NA,NA,No,TRUE,NA,NA,NA
10.1111/jdv.15369,30472749,methodology,4,NA,Form of the indirect comparison,NA,NA,"Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate)",TRUE,NA,NA,NA
10.1111/jdv.15369,30472749,methodology,4,NA,Definition of a single primary outcome for the indirect comparison,NA,NA,Yes,TRUE,NA,NA,NA
10.1111/jdv.15369,30472749,methodology,4,NA,Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined),pasi 75 locf,psoriasis area severity index (pasi) 75 responders rate,psoriasis area severity index (pasi) 75 responders rate,FALSE,NA,NA,NA
10.1111/jdv.15369,30472749,methodology,4,NA,Primary outcome: variable type,NA,NA,Binary (eg rates),TRUE,NA,NA,NA
10.1111/jdv.15369,30472749,methodology,4,NA,Justification for selecting variables to be included in the adjustment model (in the main text),NA,NA,"Status of prognostic factor/treatment effect modified assessed in the IPD dataset, A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion)",TRUE,NA,NA,NA
10.1111/jdv.15369,30472749,methodology,4,NA,Inclusion of prognostic factors in the adjustment/matching model,NA,NA,No discussion (in the main text) of the status of prognostic factors of the variables,TRUE,NA,NA,NA
10.1111/jdv.15369,30472749,methodology,4,NA,Inclusion of treatment-effect modifiers in the adjustment/matching model,NA,NA,No discussion (in the main text) of the status of treatment-effect modifiers of the variables,TRUE,NA,NA,NA
10.1111/jdv.15369,30472749,methodology,4,NA,"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)",NA,NA,No,TRUE,NA,NA,NA
10.1111/jdv.15369,30472749,methodology,4,NA,Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale),NA,NA,No,TRUE,NA,NA,NA
10.1111/jdv.15369,30472749,results,1,NA,Sample size of the population of interest in the non IPD treatment arm,NA,NA,148,TRUE,NA,NA,NA
10.1111/jdv.15369,30472749,results,1,NA,Initial sample size of the population of interest in the IPD treatment arm,NA,NA,748,TRUE,NA,NA,NA
10.1111/jdv.15369,30472749,results,1,NA,"Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC",NA,NA,640,TRUE,NA,NA,NA
10.1111/jdv.15369,30472749,results,1,NA,Reporting of a weights' distribution evaluation (MAIC),NA,NA,"Yes, mentions that the weights distribution has been studied, but weights distribution not reported",TRUE,NA,NA,NA
10.1111/jdv.15369,30472749,results,1,NA,Reporting of the list of the covariates adjusted for/matched on,NA,NA,Yes,TRUE,NA,NA,NA
10.1111/jdv.15369,30472749,results,1,NA,Number of covariates adjusted for/matched on,NA,NA,3,TRUE,NA,NA,NA
10.1111/jdv.15369,30472749,results,1,NA,Covariates adjusted for/matched on in the indirect comparison,NA,NA,"Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Past treatments for the disease of interest, Other(s)",TRUE,NA,NA,NA
10.1111/jdv.15369,30472749,results,1,NA,Primary outcome: treatment effect contrast,Proportions difference,No statistics were calculated,Proportions difference,FALSE,NA,NA,NA
10.1111/jdv.15369,30472749,results,1,NA,Direction of the treatment effect contrast: IPD treatment is:,"Numerator if ratio, or left side if difference",NA,"Numerator if ratio, or left side if difference",FALSE,NA,NA,NA
10.1111/jdv.15369,30472749,results,1,NA,Primary outcome: adjusted treatment effect,20.3,NA,22.3,FALSE,NA,NA,NA
10.1111/jdv.15369,30472749,results,1,NA,"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])",<0.001,NA,<0.001,FALSE,NA,NA,NA
10.1111/jdv.15369,30472749,results,2,NA,Sample size of the population of interest in the non IPD treatment arm,NA,NA,218,TRUE,NA,NA,NA
10.1111/jdv.15369,30472749,results,2,NA,Initial sample size of the population of interest in the IPD treatment arm,NA,NA,749,TRUE,NA,NA,NA
10.1111/jdv.15369,30472749,results,2,NA,"Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC",NA,NA,633,TRUE,NA,NA,NA
10.1111/jdv.15369,30472749,results,2,NA,Reporting of a weights' distribution evaluation (MAIC),NA,NA,"Yes, mentions that the weights distribution has been studied, but weights distribution not reported",TRUE,NA,NA,NA
10.1111/jdv.15369,30472749,results,2,NA,Reporting of the list of the covariates adjusted for/matched on,NA,NA,Yes,TRUE,NA,NA,NA
10.1111/jdv.15369,30472749,results,2,NA,Number of covariates adjusted for/matched on,2,1,2,FALSE,NA,NA,NA
10.1111/jdv.15369,30472749,results,2,NA,Covariates adjusted for/matched on in the indirect comparison,"Age, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease)",Age,"Age, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease)",FALSE,NA,NA,NA
10.1111/jdv.15369,30472749,results,2,NA,Primary outcome: treatment effect contrast,Proportions difference,No statistics were calculated,Proportions difference,FALSE,NA,NA,NA
10.1111/jdv.15369,30472749,results,2,NA,Direction of the treatment effect contrast: IPD treatment is:,"Numerator if ratio, or left side if difference",NA,"Numerator if ratio, or left side if difference",FALSE,NA,NA,NA
10.1111/jdv.15369,30472749,results,2,NA,Primary outcome: adjusted treatment effect,17.3,NA,17.3,FALSE,NA,NA,NA
10.1111/jdv.15369,30472749,results,2,NA,"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])",<0.001,NA,<0.001,FALSE,NA,NA,NA
10.1111/jdv.15369,30472749,results,3,NA,Sample size of the population of interest in the non IPD treatment arm,NA,NA,41,TRUE,NA,NA,NA
10.1111/jdv.15369,30472749,results,3,NA,Initial sample size of the population of interest in the IPD treatment arm,NA,NA,748,TRUE,NA,NA,NA
10.1111/jdv.15369,30472749,results,3,NA,"Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC",NA,NA,102,TRUE,NA,NA,NA
10.1111/jdv.15369,30472749,results,3,NA,Reporting of a weights' distribution evaluation (MAIC),NA,NA,"Yes, mentions that the weights distribution has been studied, but weights distribution not reported",TRUE,NA,NA,NA
10.1111/jdv.15369,30472749,results,3,NA,Reporting of the list of the covariates adjusted for/matched on,NA,NA,Yes,TRUE,NA,NA,NA
10.1111/jdv.15369,30472749,results,3,NA,Number of covariates adjusted for/matched on,NA,NA,4,TRUE,NA,NA,NA
10.1111/jdv.15369,30472749,results,3,NA,Covariates adjusted for/matched on in the indirect comparison,NA,NA,"Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Other(s)",TRUE,NA,NA,NA
10.1111/jdv.15369,30472749,results,3,NA,Primary outcome: treatment effect contrast,Proportions difference,No statistics were calculated,Proportions difference,FALSE,NA,NA,NA
10.1111/jdv.15369,30472749,results,3,NA,Direction of the treatment effect contrast: IPD treatment is:,"Numerator if ratio, or left side if difference",NA,"Numerator if ratio, or left side if difference",FALSE,NA,NA,NA
10.1111/jdv.15369,30472749,results,3,NA,Primary outcome: adjusted treatment effect,19.2,NA,19.2,FALSE,NA,NA,NA
10.1111/jdv.15369,30472749,results,3,NA,"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])",0.009,NA,0.009,FALSE,NA,NA,NA
10.1111/jdv.15369,30472749,results,4,NA,Sample size of the population of interest in the non IPD treatment arm,NA,NA,115,TRUE,NA,NA,NA
10.1111/jdv.15369,30472749,results,4,NA,Initial sample size of the population of interest in the IPD treatment arm,NA,NA,749,TRUE,NA,NA,NA
10.1111/jdv.15369,30472749,results,4,NA,"Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC",NA,NA,224,TRUE,NA,NA,NA
10.1111/jdv.15369,30472749,results,4,NA,Reporting of a weights' distribution evaluation (MAIC),NA,NA,"Yes, mentions that the weights distribution has been studied, but weights distribution not reported",TRUE,NA,NA,NA
10.1111/jdv.15369,30472749,results,4,NA,Reporting of the list of the covariates adjusted for/matched on,NA,NA,Yes,TRUE,NA,NA,NA
10.1111/jdv.15369,30472749,results,4,NA,Number of covariates adjusted for/matched on,NA,NA,2,TRUE,NA,NA,NA
10.1111/jdv.15369,30472749,results,4,NA,Covariates adjusted for/matched on in the indirect comparison,NA,NA,"Age, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease)",TRUE,NA,NA,NA
10.1111/jdv.15369,30472749,results,4,NA,Primary outcome: treatment effect contrast,Proportions difference,No statistics were calculated,Proportions difference,FALSE,NA,NA,NA
10.1111/jdv.15369,30472749,results,4,NA,Direction of the treatment effect contrast: IPD treatment is:,"Numerator if ratio, or left side if difference",NA,"Numerator if ratio, or left side if difference",FALSE,NA,NA,NA
10.1111/jdv.15369,30472749,results,4,NA,Primary outcome: adjusted treatment effect,-4.4,NA,-4.4,FALSE,NA,NA,NA
10.1111/jdv.15369,30472749,results,4,NA,"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])",0.451,NA,0.451,FALSE,NA,NA,NA
10.1007/s12325-019-0873-7,30758745,general_information,NA,NA,Medical Condition of Interest Name,relapsed or refractory acute lymphoblastic leukemia,relapsed/refractory acute lymphoblastic leukemia,relapsed or refractory acute lymphoblastic leukemia,FALSE,NA,NA,NA
10.1007/s12325-019-0873-7,30758745,general_information,NA,NA,Countries of first author affiliations,NA,NA,usa,TRUE,NA,NA,NA
10.1007/s12325-019-0873-7,30758745,general_information,NA,NA,Countries of last author affiliations,NA,NA,uk,TRUE,NA,NA,NA
10.1007/s12325-019-0873-7,30758745,general_information,NA,NA,"Positions of study investigators (for any authors of the article, any that applies)",NA,NA,"Academic, Pharmaceutical Industry, Private Data Analysis Company",TRUE,NA,NA,NA
10.1007/s12325-019-0873-7,30758745,general_information,NA,NA,"At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company",NA,NA,Yes,TRUE,NA,NA,NA
10.1007/s12325-019-0873-7,30758745,general_information,NA,NA,Mentioned sources of funding,NA,NA,Pharmaceutical Industry,TRUE,NA,NA,NA
10.1007/s12325-019-0873-7,30758745,general_information,NA,NA,"Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article",NA,NA,Yes,TRUE,NA,NA,NA
10.1007/s12325-019-0873-7,30758745,general_information,NA,NA,Mention of a systematic review to find the studies to compare treatments of interest,NA,NA,No,TRUE,NA,NA,NA
10.1007/s12325-019-0873-7,30758745,study_information,NA,1,Patient-level data used,NA,NA,Yes,TRUE,NA,NA,NA
10.1007/s12325-019-0873-7,30758745,study_information,NA,1,Clinical Trial,NA,NA,Yes,TRUE,NA,NA,NA
10.1007/s12325-019-0873-7,30758745,study_information,NA,1,NCT (only for clinical trial registered on clinicaltrials.gov),NA,NA,NCT02013167,TRUE,NA,NA,NA
10.1007/s12325-019-0873-7,30758745,study_information,NA,1,Country where the clinical trial/observational study was conducted (international if more than one),NA,NA,international,TRUE,NA,NA,NA
10.1007/s12325-019-0873-7,30758745,study_information,NA,1,Phase of the clinical trial (clinical trial only),NA,NA,3,TRUE,NA,NA,NA
10.1007/s12325-019-0873-7,30758745,study_information,NA,1,Number of treatment arms (clinical trial only),NA,NA,2 or more,TRUE,NA,NA,NA
10.1007/s12325-019-0873-7,30758745,study_information,NA,2,Patient-level data used,NA,NA,No,TRUE,NA,NA,NA
10.1007/s12325-019-0873-7,30758745,study_information,NA,2,Clinical Trial,NA,NA,Yes,TRUE,NA,NA,NA
10.1007/s12325-019-0873-7,30758745,study_information,NA,2,NCT (only for clinical trial registered on clinicaltrials.gov),NA,NA,NCT01564784,TRUE,NA,NA,NA
10.1007/s12325-019-0873-7,30758745,study_information,NA,2,Country where the clinical trial/observational study was conducted (international if more than one),NA,NA,international,TRUE,NA,NA,NA
10.1007/s12325-019-0873-7,30758745,study_information,NA,2,Phase of the clinical trial (clinical trial only),NA,NA,3,TRUE,NA,NA,NA
10.1007/s12325-019-0873-7,30758745,study_information,NA,2,Number of treatment arms (clinical trial only),NA,NA,2 or more,TRUE,NA,NA,NA
10.1007/s12325-019-0873-7,30758745,methodology,1,NA,Treatment name 1,NA,NA,blinatumomab,TRUE,"opposite MAIC carried out by 10.1007/s12325-019-00991-w, with different conclusions",NA,NA
10.1007/s12325-019-0873-7,30758745,methodology,1,NA,Study 'number(s)' for treatment 1,NA,NA,1,TRUE,NA,NA,NA
10.1007/s12325-019-0873-7,30758745,methodology,1,NA,Treatment name 2,NA,NA,inotuzumab ozogamicin,TRUE,NA,NA,NA
10.1007/s12325-019-0873-7,30758745,methodology,1,NA,Study 'number(s)' for treatment 2,NA,NA,2,TRUE,NA,NA,NA
10.1007/s12325-019-0873-7,30758745,methodology,1,NA,Type of population-adjusted indirect comparisons performed,NA,NA,MAIC,TRUE,NA,NA,NA
10.1007/s12325-019-0873-7,30758745,methodology,1,NA,Anchored comparison?,NA,NA,Yes,TRUE,NA,NA,NA
10.1007/s12325-019-0873-7,30758745,methodology,1,NA,Form of the indirect comparison,NA,NA,Simple (ie treatments effects extracted from two studies),TRUE,NA,NA,NA
10.1007/s12325-019-0873-7,30758745,methodology,1,NA,Definition of a single primary outcome for the indirect comparison,NA,NA,"No primary outcome defined, or multiple primary outcomes without any clear distinction between them",TRUE,NA,NA,NA
10.1007/s12325-019-0873-7,30758745,methodology,1,NA,Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined),restricted mean survival time at 12 months,overall survival,restricted mean survival time,FALSE,NA,NA,NA
10.1007/s12325-019-0873-7,30758745,methodology,1,NA,Primary outcome: variable type,NA,NA,Time-to-event,TRUE,NA,NA,NA
10.1007/s12325-019-0873-7,30758745,methodology,1,NA,Justification for selecting variables to be included in the adjustment model (in the main text),NA,NA,Status of prognostic factor/treatment effect modified assessed in the IPD dataset,TRUE,NA,NA,NA
10.1007/s12325-019-0873-7,30758745,methodology,1,NA,Inclusion of prognostic factors in the adjustment/matching model,NA,NA,No,TRUE,NA,NA,NA
10.1007/s12325-019-0873-7,30758745,methodology,1,NA,Inclusion of treatment-effect modifiers in the adjustment/matching model,NA,NA,Yes,TRUE,NA,NA,NA
10.1007/s12325-019-0873-7,30758745,methodology,1,NA,"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)",NA,NA,No,TRUE,NA,NA,NA
10.1007/s12325-019-0873-7,30758745,methodology,1,NA,Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale),Yes,No,No,FALSE,NA,NA,NA
10.1007/s12325-019-0873-7,30758745,methodology,2,NA,Treatment name 1,NA,NA,blinatumomab,TRUE,NA,NA,NA
10.1007/s12325-019-0873-7,30758745,methodology,2,NA,Study 'number(s)' for treatment 1,NA,NA,1,TRUE,NA,NA,NA
10.1007/s12325-019-0873-7,30758745,methodology,2,NA,Treatment name 2,NA,NA,inotuzumab ozogamicin,TRUE,NA,NA,NA
10.1007/s12325-019-0873-7,30758745,methodology,2,NA,Study 'number(s)' for treatment 2,NA,NA,2,TRUE,NA,NA,NA
10.1007/s12325-019-0873-7,30758745,methodology,2,NA,Type of population-adjusted indirect comparisons performed,NA,NA,MAIC,TRUE,NA,NA,NA
10.1007/s12325-019-0873-7,30758745,methodology,2,NA,Anchored comparison?,NA,NA,No,TRUE,NA,NA,NA
10.1007/s12325-019-0873-7,30758745,methodology,2,NA,Form of the indirect comparison,NA,NA,Simple (ie treatments effects extracted from two studies),TRUE,NA,NA,NA
10.1007/s12325-019-0873-7,30758745,methodology,2,NA,Definition of a single primary outcome for the indirect comparison,NA,NA,"No primary outcome defined, or multiple primary outcomes without any clear distinction between them",TRUE,NA,NA,NA
10.1007/s12325-019-0873-7,30758745,methodology,2,NA,Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined),restricted mean survival time at 12 months,overall survival,restricted mean survival time,FALSE,NA,NA,NA
10.1007/s12325-019-0873-7,30758745,methodology,2,NA,Primary outcome: variable type,NA,NA,Time-to-event,TRUE,NA,NA,NA
10.1007/s12325-019-0873-7,30758745,methodology,2,NA,Justification for selecting variables to be included in the adjustment model (in the main text),NA,NA,Status of prognostic factor/treatment effect modified assessed in the IPD dataset,TRUE,NA,NA,NA
10.1007/s12325-019-0873-7,30758745,methodology,2,NA,Inclusion of prognostic factors in the adjustment/matching model,NA,NA,No,TRUE,NA,NA,NA
10.1007/s12325-019-0873-7,30758745,methodology,2,NA,Inclusion of treatment-effect modifiers in the adjustment/matching model,NA,NA,Yes,TRUE,NA,NA,NA
10.1007/s12325-019-0873-7,30758745,methodology,2,NA,"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)",NA,NA,No,TRUE,NA,NA,NA
10.1007/s12325-019-0873-7,30758745,methodology,2,NA,Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale),Yes,No,No,FALSE,NA,NA,NA
10.1007/s12325-019-0873-7,30758745,results,1,NA,Sample size of the population of interest in the non IPD treatment arm,NA,NA,164,TRUE,NA,NA,NA
10.1007/s12325-019-0873-7,30758745,results,1,NA,"If anchored comparison, sample size of the population of interest in the non IPD treatment anchor arm",NA,NA,162,TRUE,NA,NA,NA
10.1007/s12325-019-0873-7,30758745,results,1,NA,Initial sample size of the population of interest in the IPD treatment arm,NA,NA,203,TRUE,NA,NA,NA
10.1007/s12325-019-0873-7,30758745,results,1,NA,"If anchored comparison, initial sample size of the population of interest in the IPD anchor arm",NA,107,107,FALSE,NA,NA,NA
10.1007/s12325-019-0873-7,30758745,results,1,NA,Reporting of a weights' distribution evaluation (MAIC),NA,NA,Not mentioned,TRUE,NA,NA,NA
10.1007/s12325-019-0873-7,30758745,results,1,NA,Reporting of the list of the covariates adjusted for/matched on,NA,NA,Yes,TRUE,NA,NA,NA
10.1007/s12325-019-0873-7,30758745,results,1,NA,Number of covariates adjusted for/matched on,NA,NA,9,TRUE,NA,NA,NA
10.1007/s12325-019-0873-7,30758745,results,1,NA,Covariates adjusted for/matched on in the indirect comparison,NA,NA,"Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Race/ethnicity, Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Past treatments for the disease of interest",TRUE,NA,NA,NA
10.1007/s12325-019-0873-7,30758745,results,1,NA,Primary outcome: treatment effect contrast,Means difference,RMST difference at 12 months,Means difference,FALSE,NA,NA,NA
10.1007/s12325-019-0873-7,30758745,results,1,NA,Direction of the treatment effect contrast: IPD treatment is:,NA,NA,"Numerator if ratio, or left side if difference",TRUE,NA,NA,NA
10.1007/s12325-019-0873-7,30758745,results,1,NA,Primary outcome: unadjusted treatment effect,NA,NA,1.02,TRUE,NA,NA,NA
10.1007/s12325-019-0873-7,30758745,results,1,NA,"p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])",NA,NA,0.16,TRUE,NA,NA,NA
10.1007/s12325-019-0873-7,30758745,results,1,NA,Primary outcome: adjusted treatment effect,NA,NA,1.62,TRUE,NA,NA,NA
10.1007/s12325-019-0873-7,30758745,results,1,NA,"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])",NA,NA,0.04,TRUE,NA,NA,NA
10.1007/s12325-019-0873-7,30758745,results,1,NA,"Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC",107,NA,107,FALSE,NA,NA,NA
10.1007/s12325-019-0873-7,30758745,results,2,NA,Sample size of the population of interest in the non IPD treatment arm,NA,NA,164,TRUE,NA,NA,NA
10.1007/s12325-019-0873-7,30758745,results,2,NA,Initial sample size of the population of interest in the IPD treatment arm,NA,NA,203,TRUE,NA,NA,NA
10.1007/s12325-019-0873-7,30758745,results,2,NA,Reporting of a weights' distribution evaluation (MAIC),NA,NA,Not mentioned,TRUE,NA,NA,NA
10.1007/s12325-019-0873-7,30758745,results,2,NA,Reporting of the list of the covariates adjusted for/matched on,NA,NA,Yes,TRUE,NA,NA,NA
10.1007/s12325-019-0873-7,30758745,results,2,NA,Number of covariates adjusted for/matched on,NA,NA,9,TRUE,NA,NA,NA
10.1007/s12325-019-0873-7,30758745,results,2,NA,Covariates adjusted for/matched on in the indirect comparison,NA,NA,"Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Race/ethnicity, Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Past treatments for the disease of interest",TRUE,NA,NA,NA
10.1007/s12325-019-0873-7,30758745,results,2,NA,Primary outcome: treatment effect contrast,Means difference,RMST difference at 12 months,Means difference,FALSE,NA,NA,NA
10.1007/s12325-019-0873-7,30758745,results,2,NA,Direction of the treatment effect contrast: IPD treatment is:,NA,NA,"Numerator if ratio, or left side if difference",TRUE,NA,NA,NA
10.1007/s12325-019-0873-7,30758745,results,2,NA,Primary outcome: unadjusted treatment effect,NA,NA,-0.18,TRUE,NA,NA,NA
10.1007/s12325-019-0873-7,30758745,results,2,NA,"p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])",NA,NA,0.69,TRUE,NA,NA,NA
10.1007/s12325-019-0873-7,30758745,results,2,NA,Primary outcome: adjusted treatment effect,NA,NA,0.15,TRUE,NA,NA,NA
10.1007/s12325-019-0873-7,30758745,results,2,NA,"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])",NA,NA,0.76,TRUE,NA,NA,NA
10.2217/cer-2018-0141,30806520,general_information,NA,NA,Medical Condition of Interest Name,NA,NA,psoriatic arthritis,TRUE,NA,NA,NA
10.2217/cer-2018-0141,30806520,general_information,NA,NA,Countries of first author affiliations,NA,NA,usa,TRUE,NA,NA,NA
10.2217/cer-2018-0141,30806520,general_information,NA,NA,Countries of last author affiliations,NA,NA,uk,TRUE,NA,NA,NA
10.2217/cer-2018-0141,30806520,general_information,NA,NA,"Positions of study investigators (for any authors of the article, any that applies)",NA,NA,"Academic, Pharmaceutical Industry, Private Data Analysis Company",TRUE,NA,NA,NA
10.2217/cer-2018-0141,30806520,general_information,NA,NA,"At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company",NA,NA,Yes,TRUE,NA,NA,NA
10.2217/cer-2018-0141,30806520,general_information,NA,NA,Mentioned sources of funding,NA,NA,Pharmaceutical Industry,TRUE,NA,NA,NA
10.2217/cer-2018-0141,30806520,general_information,NA,NA,"Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article",NA,NA,Yes,TRUE,NA,NA,NA
10.2217/cer-2018-0141,30806520,general_information,NA,NA,Mention of a systematic review to find the studies to compare treatments of interest,NA,NA,Yes,TRUE,NA,NA,NA
10.2217/cer-2018-0141,30806520,study_information,NA,1,Patient-level data used,NA,NA,Yes,TRUE,NA,NA,NA
10.2217/cer-2018-0141,30806520,study_information,NA,1,Clinical Trial,NA,NA,Yes,TRUE,NA,NA,NA
10.2217/cer-2018-0141,30806520,study_information,NA,1,NCT (only for clinical trial registered on clinicaltrials.gov),NA,NA,NCT01752634,TRUE,NA,NA,NA
10.2217/cer-2018-0141,30806520,study_information,NA,1,Country where the clinical trial/observational study was conducted (international if more than one),NA,NA,international,TRUE,NA,NA,NA
10.2217/cer-2018-0141,30806520,study_information,NA,1,Phase of the clinical trial (clinical trial only),NA,NA,3,TRUE,NA,NA,NA
10.2217/cer-2018-0141,30806520,study_information,NA,1,Number of treatment arms (clinical trial only),NA,NA,2 or more,TRUE,NA,NA,NA
10.2217/cer-2018-0141,30806520,study_information,NA,2,Patient-level data used,NA,NA,Yes,TRUE,NA,NA,NA
10.2217/cer-2018-0141,30806520,study_information,NA,2,Clinical Trial,NA,NA,Yes,TRUE,NA,NA,NA
10.2217/cer-2018-0141,30806520,study_information,NA,2,NCT (only for clinical trial registered on clinicaltrials.gov),NA,NA,NCT01989468,TRUE,NA,NA,NA
10.2217/cer-2018-0141,30806520,study_information,NA,2,Country where the clinical trial/observational study was conducted (international if more than one),NA,NA,international,TRUE,NA,NA,NA
10.2217/cer-2018-0141,30806520,study_information,NA,2,Phase of the clinical trial (clinical trial only),NA,NA,3,TRUE,NA,NA,NA
10.2217/cer-2018-0141,30806520,study_information,NA,2,Number of treatment arms (clinical trial only),NA,NA,2 or more,TRUE,NA,NA,NA
10.2217/cer-2018-0141,30806520,study_information,NA,3,Patient-level data used,NA,NA,No,TRUE,NA,NA,NA
10.2217/cer-2018-0141,30806520,study_information,NA,3,Clinical Trial,NA,NA,Yes,TRUE,NA,NA,NA
10.2217/cer-2018-0141,30806520,study_information,NA,3,NCT (only for clinical trial registered on clinicaltrials.gov),NA,NA,NCT00051623,TRUE,NA,NA,NA
10.2217/cer-2018-0141,30806520,study_information,NA,3,Phase of the clinical trial (clinical trial only),NA,NA,3,TRUE,NA,NA,NA
10.2217/cer-2018-0141,30806520,study_information,NA,3,Number of treatment arms (clinical trial only),NA,NA,2 or more,TRUE,NA,NA,NA
10.2217/cer-2018-0141,30806520,study_information,NA,3,Country where the clinical trial/observational study was conducted (international if more than one),unknown,NA,XXXX,FALSE,NA,NA,NA
10.2217/cer-2018-0141,30806520,methodology,1,NA,Treatment name 1,secukinumab 150mg,secukinumab 150 mg,secukinumab 150mg,FALSE,NA,"""Weights were derived by logistic regression. The choice of matching parameters was made by consensus of all authors (who include both clinical and methodological experts). Patients were matched for key characteristics known or expected to influence clinical outcomes in individuals with psoriatic arthritis""

""The selection of baseline characteristics for matching (including prognostic variables and effect modifiers) has been described previously [20]. Two scenarios were developed that differed in the combination of included matching variables. First, a principal analysis (Table 1) included established prognostic variables reported in previous MAICs in PsA [18,20], but incorporated one additional parameter (TNFi-IR), identified by logistic regression analysis as a key effect modifier, as detailed in our previous study [20]. Previous TNFi exposure is also likely to be an effect modifier for infliximab: it has been established that patients with PsA who switch between TNFi therapies have lower ACR responses with subsequent TNFis than TNFi-naive patients""

""By using linear predictor scales such as ORs instead of comparing natural outcome scales such as ACR 20 responses, we complied with a mandatory requirement of NICEBy using linear predictor scales such as ORs instead of comparing natural outcome scales such as ACR 20 responses, we complied with a mandatory requirement of NICE""

Weight : other
HAQ-Di = pas un score de performance
Sample size before matching = 238
Non placebo-adjusted",NA
10.2217/cer-2018-0141,30806520,methodology,1,NA,Study 'number(s)' for treatment 1,NA,NA,1;2,TRUE,NA,NA,NA
10.2217/cer-2018-0141,30806520,methodology,1,NA,Treatment name 2,NA,NA,infliximab,TRUE,NA,NA,NA
10.2217/cer-2018-0141,30806520,methodology,1,NA,Study 'number(s)' for treatment 2,NA,NA,3,TRUE,NA,NA,NA
10.2217/cer-2018-0141,30806520,methodology,1,NA,Type of population-adjusted indirect comparisons performed,NA,NA,MAIC,TRUE,NA,NA,NA
10.2217/cer-2018-0141,30806520,methodology,1,NA,Anchored comparison?,NA,NA,No,TRUE,NA,NA,NA
10.2217/cer-2018-0141,30806520,methodology,1,NA,Form of the indirect comparison,NA,NA,"Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate)",TRUE,NA,NA,NA
10.2217/cer-2018-0141,30806520,methodology,1,NA,Definition of a single primary outcome for the indirect comparison,NA,NA,"No primary outcome defined, or multiple primary outcomes without any clear distinction between them",TRUE,NA,NA,NA
10.2217/cer-2018-0141,30806520,methodology,1,NA,Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined),american college of rheumatology (acr) responses rate at week 24,acr 20 (american college of rheumatology) criteria response at week 24,american college of rheumatology (acr) responses rate at week 24,FALSE,NA,NA,NA
10.2217/cer-2018-0141,30806520,methodology,1,NA,Primary outcome: variable type,NA,NA,Binary (eg rates),TRUE,NA,NA,NA
10.2217/cer-2018-0141,30806520,methodology,1,NA,Justification for selecting variables to be included in the adjustment model (in the main text),"Nothing mentioned, not reported","Status of prognostic factor/treatment effect modified assessed in the IPD dataset, A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion), Literature based (clinically or methodologically relevant to adjust on these variables based on the literature search conducted for this specific purpose)","Status of prognostic factor/treatment effect modified assessed in the IPD dataset, A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion), Literature based (clinically or methodologically relevant to adjust on these variables based on the literature search conducted for this specific purpose)",FALSE,NA,NA,NA
10.2217/cer-2018-0141,30806520,methodology,1,NA,Inclusion of prognostic factors in the adjustment/matching model,NA,NA,Yes,TRUE,NA,NA,NA
10.2217/cer-2018-0141,30806520,methodology,1,NA,Inclusion of treatment-effect modifiers in the adjustment/matching model,NA,NA,Yes,TRUE,NA,NA,NA
10.2217/cer-2018-0141,30806520,methodology,1,NA,"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)",NA,NA,No,TRUE,NA,NA,NA
10.2217/cer-2018-0141,30806520,methodology,1,NA,Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale),No,Yes,Yes,FALSE,NA,NA,NA
10.2217/cer-2018-0141,30806520,methodology,2,NA,Treatment name 1,secukinumab 300mg,secukinumab 300 mg,secukinumab 300mg,FALSE,NA,"""Weights were derived by logistic regression. The choice of matching parameters was made by consensus of all authors (who include both clinical and methodological experts). Patients were matched for key characteristics known or expected to influence clinical outcomes in individuals with psoriatic arthritis""

""The selection of baseline characteristics for matching (including prognostic variables and effect modifiers) has been described previously [20]. Two scenarios were developed that differed in the combination of included matching variables. First, a principal analysis (Table 1) included established prognostic variables reported in previous MAICs in PsA [18,20], but incorporated one additional parameter (TNFi-IR), identified by logistic regression analysis as a key effect modifier, as detailed in our previous study [20]. Previous TNFi exposure is also likely to be an effect modifier for infliximab: it has been established that patients with PsA who switch between TNFi therapies have lower ACR responses with subsequent TNFis than TNFi-naive patients""

""By using linear predictor scales such as ORs instead of comparing natural outcome scales such as ACR 20 responses, we complied with a mandatory requirement of NICEBy using linear predictor scales such as ORs instead of comparing natural outcome scales such as ACR 20 responses, we complied with a mandatory requirement of NICE""

Weight : other
HAQ-Di = pas un score de performance
Sample size before matching = 239
Non placebo-adjusted",NA
10.2217/cer-2018-0141,30806520,methodology,2,NA,Study 'number(s)' for treatment 1,NA,NA,1;2,TRUE,NA,NA,NA
10.2217/cer-2018-0141,30806520,methodology,2,NA,Treatment name 2,NA,NA,infliximab,TRUE,NA,NA,NA
10.2217/cer-2018-0141,30806520,methodology,2,NA,Study 'number(s)' for treatment 2,NA,NA,3,TRUE,NA,NA,NA
10.2217/cer-2018-0141,30806520,methodology,2,NA,Type of population-adjusted indirect comparisons performed,NA,NA,MAIC,TRUE,NA,NA,NA
10.2217/cer-2018-0141,30806520,methodology,2,NA,Anchored comparison?,NA,NA,No,TRUE,NA,NA,NA
10.2217/cer-2018-0141,30806520,methodology,2,NA,Form of the indirect comparison,NA,NA,"Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate)",TRUE,NA,NA,NA
10.2217/cer-2018-0141,30806520,methodology,2,NA,Definition of a single primary outcome for the indirect comparison,NA,NA,"No primary outcome defined, or multiple primary outcomes without any clear distinction between them",TRUE,NA,NA,NA
10.2217/cer-2018-0141,30806520,methodology,2,NA,Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined),american college of rheumatology (acr) responses at week 54,acr 20 (american college of rheumatology) criteria response at week 54/52,american college of rheumatology (acr) responses at week 54,FALSE,NA,NA,NA
10.2217/cer-2018-0141,30806520,methodology,2,NA,Primary outcome: variable type,NA,NA,Binary (eg rates),TRUE,NA,NA,NA
10.2217/cer-2018-0141,30806520,methodology,2,NA,Justification for selecting variables to be included in the adjustment model (in the main text),"Nothing mentioned, not reported","Statistical imbalanced between treatment groups (independently of the status of prognostic/effect modifier), A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion), Literature based (clinically or methodologically relevant to adjust on these variables based on the literature search conducted for this specific purpose)","Statistical imbalanced between treatment groups (independently of the status of prognostic/effect modifier), A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion), Literature based (clinically or methodologically relevant to adjust on these variables based on the literature search conducted for this specific purpose)",FALSE,NA,NA,NA
10.2217/cer-2018-0141,30806520,methodology,2,NA,Inclusion of prognostic factors in the adjustment/matching model,NA,NA,Yes,TRUE,NA,NA,NA
10.2217/cer-2018-0141,30806520,methodology,2,NA,Inclusion of treatment-effect modifiers in the adjustment/matching model,NA,NA,Yes,TRUE,NA,NA,NA
10.2217/cer-2018-0141,30806520,methodology,2,NA,"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)",NA,NA,No,TRUE,NA,NA,NA
10.2217/cer-2018-0141,30806520,methodology,2,NA,Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale),No,Yes,Yes,FALSE,NA,NA,NA
10.2217/cer-2018-0141,30806520,results,1,NA,Sample size of the population of interest in the non IPD treatment arm,NA,NA,100,TRUE,NA,NA,NA
10.2217/cer-2018-0141,30806520,results,1,NA,"Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC",NA,NA,84,TRUE,NA,NA,NA
10.2217/cer-2018-0141,30806520,results,1,NA,Reporting of a weights' distribution evaluation (MAIC),NA,NA,Not mentioned,TRUE,NA,NA,NA
10.2217/cer-2018-0141,30806520,results,1,NA,Reporting of the list of the covariates adjusted for/matched on,Yes,No,Yes,FALSE,NA,NA,NA
10.2217/cer-2018-0141,30806520,results,1,NA,Number of covariates adjusted for/matched on,NA,NA,11,TRUE,NA,NA,NA
10.2217/cer-2018-0141,30806520,results,1,NA,Covariates adjusted for/matched on in the indirect comparison,NA,NA,"Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Race/ethnicity, Past treatments for the disease of interest, Other(s)",TRUE,NA,NA,NA
10.2217/cer-2018-0141,30806520,results,1,NA,Primary outcome: treatment effect contrast,NA,NA,OR,TRUE,NA,NA,NA
10.2217/cer-2018-0141,30806520,results,1,NA,Direction of the treatment effect contrast: IPD treatment is:,NA,NA,"Numerator if ratio, or left side if difference",TRUE,NA,NA,NA
10.2217/cer-2018-0141,30806520,results,1,NA,Primary outcome: adjusted treatment effect,NA,NA,2.31,TRUE,NA,NA,NA
10.2217/cer-2018-0141,30806520,results,1,NA,"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])",NA,NA,0.008,TRUE,NA,NA,NA
10.2217/cer-2018-0141,30806520,results,1,NA,Initial sample size of the population of interest in the IPD treatment arm,238,NA,238,FALSE,NA,NA,NA
10.2217/cer-2018-0141,30806520,results,2,NA,Sample size of the population of interest in the non IPD treatment arm,NA,NA,100,TRUE,NA,NA,NA
10.2217/cer-2018-0141,30806520,results,2,NA,"Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC",NA,NA,70,TRUE,NA,NA,NA
10.2217/cer-2018-0141,30806520,results,2,NA,Reporting of a weights' distribution evaluation (MAIC),NA,NA,Not mentioned,TRUE,NA,NA,NA
10.2217/cer-2018-0141,30806520,results,2,NA,Reporting of the list of the covariates adjusted for/matched on,NA,NA,Yes,TRUE,NA,NA,NA
10.2217/cer-2018-0141,30806520,results,2,NA,Number of covariates adjusted for/matched on,NA,NA,11,TRUE,NA,NA,NA
10.2217/cer-2018-0141,30806520,results,2,NA,Covariates adjusted for/matched on in the indirect comparison,NA,NA,"Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Race/ethnicity, Past treatments for the disease of interest, Other(s)",TRUE,NA,NA,NA
10.2217/cer-2018-0141,30806520,results,2,NA,Primary outcome: treatment effect contrast,NA,NA,OR,TRUE,NA,NA,NA
10.2217/cer-2018-0141,30806520,results,2,NA,Direction of the treatment effect contrast: IPD treatment is:,NA,NA,"Numerator if ratio, or left side if difference",TRUE,NA,NA,NA
10.2217/cer-2018-0141,30806520,results,2,NA,Primary outcome: adjusted treatment effect,NA,NA,2.72,TRUE,NA,NA,NA
10.2217/cer-2018-0141,30806520,results,2,NA,"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])",NA,NA,0.006,TRUE,NA,NA,NA
10.2217/cer-2018-0141,30806520,results,2,NA,Initial sample size of the population of interest in the IPD treatment arm,239,NA,239,FALSE,NA,NA,NA
10.1080/03007995.2019.1605239,30964361,general_information,NA,NA,Medical Condition of Interest Name,chronic myeloid leukemia,chronic phase chronic myeloid leukemia,XXXX,FALSE,NA,NA,NA
10.1080/03007995.2019.1605239,30964361,general_information,NA,NA,Countries of first author affiliations,NA,NA,usa,TRUE,NA,NA,NA
10.1080/03007995.2019.1605239,30964361,general_information,NA,NA,Countries of last author affiliations,NA,NA,usa,TRUE,NA,NA,NA
10.1080/03007995.2019.1605239,30964361,general_information,NA,NA,"Positions of study investigators (for any authors of the article, any that applies)",NA,NA,"Academic, Pharmaceutical Industry, Private Data Analysis Company",TRUE,NA,NA,NA
10.1080/03007995.2019.1605239,30964361,general_information,NA,NA,"At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company",NA,NA,Yes,TRUE,NA,NA,NA
10.1080/03007995.2019.1605239,30964361,general_information,NA,NA,Mentioned sources of funding,NA,NA,Pharmaceutical Industry,TRUE,NA,NA,NA
10.1080/03007995.2019.1605239,30964361,general_information,NA,NA,"Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article",NA,NA,Yes,TRUE,NA,NA,NA
10.1080/03007995.2019.1605239,30964361,general_information,NA,NA,Mention of a systematic review to find the studies to compare treatments of interest,NA,NA,Yes,TRUE,NA,NA,NA
10.1080/03007995.2019.1605239,30964361,study_information,NA,1,Patient-level data used,NA,NA,Yes,TRUE,NA,NA,NA
10.1080/03007995.2019.1605239,30964361,study_information,NA,1,Clinical Trial,NA,Yes,XXXX,FALSE,NA,NA,NA
10.1080/03007995.2019.1605239,30964361,study_information,NA,1,NCT (only for clinical trial registered on clinicaltrials.gov),NA,NA,NCT00261846,TRUE,NA,NA,NA
10.1080/03007995.2019.1605239,30964361,study_information,NA,1,Country where the clinical trial/observational study was conducted (international if more than one),NA,NA,international,TRUE,NA,NA,NA
10.1080/03007995.2019.1605239,30964361,study_information,NA,1,Phase of the clinical trial (clinical trial only),"1, 2",2,XXXX,FALSE,NA,NA,NA
10.1080/03007995.2019.1605239,30964361,study_information,NA,1,Number of treatment arms (clinical trial only),NA,NA,1,TRUE,NA,NA,NA
10.1080/03007995.2019.1605239,30964361,study_information,NA,2,Patient-level data used,NA,NA,No,TRUE,NA,NA,NA
10.1080/03007995.2019.1605239,30964361,study_information,NA,2,Clinical Trial,NA,NA,Yes,TRUE,NA,NA,NA
10.1080/03007995.2019.1605239,30964361,study_information,NA,2,NCT (only for clinical trial registered on clinicaltrials.gov),NA,NA,NCT00123474,TRUE,NA,NA,NA
10.1080/03007995.2019.1605239,30964361,study_information,NA,2,Country where the clinical trial/observational study was conducted (international if more than one),NA,NA,international,TRUE,NA,NA,NA
10.1080/03007995.2019.1605239,30964361,study_information,NA,2,Phase of the clinical trial (clinical trial only),NA,NA,3,TRUE,NA,NA,NA
10.1080/03007995.2019.1605239,30964361,study_information,NA,2,Number of treatment arms (clinical trial only),1,2 or more,XXXX,FALSE,NA,NA,NA
10.1080/03007995.2019.1605239,30964361,study_information,NA,3,Patient-level data used,NA,NA,No,TRUE,NA,NA,NA
10.1080/03007995.2019.1605239,30964361,study_information,NA,3,Clinical Trial,NA,NA,Yes,TRUE,NA,NA,NA
10.1080/03007995.2019.1605239,30964361,study_information,NA,3,NCT (only for clinical trial registered on clinicaltrials.gov),NA,NA,NCT00109707,TRUE,NA,NA,NA
10.1080/03007995.2019.1605239,30964361,study_information,NA,3,Country where the clinical trial/observational study was conducted (international if more than one),NA,NA,international,TRUE,NA,NA,NA
10.1080/03007995.2019.1605239,30964361,study_information,NA,3,Phase of the clinical trial (clinical trial only),NA,NA,"1, 2",TRUE,NA,NA,NA
10.1080/03007995.2019.1605239,30964361,study_information,NA,3,Number of treatment arms (clinical trial only),NA,NA,1,TRUE,NA,NA,NA
10.1080/03007995.2019.1605239,30964361,methodology,1,NA,Treatment name 1,NA,NA,bosutinib,TRUE,Discuss the scale of the outcome,"""The MAICs in this analysis are unanchored indirect comparisons and therefore a general limitation, in this case, is that propensity score methods (such as the MAIC) need to adjust for all effect modifiers and prognostic variables in order to reliably predict absolute outcomes. Also, although we made an effort to reweight for all clinically relevant reported baseline characteristics considered as effect modifier of treatment effect or predictors of outcome, this was not done for all baseline characteristics that were reported in the trials.""",NA
10.1080/03007995.2019.1605239,30964361,methodology,1,NA,Study 'number(s)' for treatment 1,NA,NA,1,TRUE,NA,NA,NA
10.1080/03007995.2019.1605239,30964361,methodology,1,NA,Treatment name 2,NA,NA,dasatinib,TRUE,NA,NA,NA
10.1080/03007995.2019.1605239,30964361,methodology,1,NA,Study 'number(s)' for treatment 2,NA,NA,2,TRUE,NA,NA,NA
10.1080/03007995.2019.1605239,30964361,methodology,1,NA,Type of population-adjusted indirect comparisons performed,NA,NA,MAIC,TRUE,NA,NA,NA
10.1080/03007995.2019.1605239,30964361,methodology,1,NA,Anchored comparison?,NA,NA,No,TRUE,NA,NA,NA
10.1080/03007995.2019.1605239,30964361,methodology,1,NA,Form of the indirect comparison,NA,NA,Simple (ie treatments effects extracted from two studies),TRUE,NA,NA,NA
10.1080/03007995.2019.1605239,30964361,methodology,1,NA,Definition of a single primary outcome for the indirect comparison,NA,NA,"No primary outcome defined, or multiple primary outcomes without any clear distinction between them",TRUE,NA,NA,NA
10.1080/03007995.2019.1605239,30964361,methodology,1,NA,Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined),NA,NA,overall survival,TRUE,NA,NA,NA
10.1080/03007995.2019.1605239,30964361,methodology,1,NA,Primary outcome: variable type,NA,NA,Time-to-event,TRUE,NA,NA,NA
10.1080/03007995.2019.1605239,30964361,methodology,1,NA,Justification for selecting variables to be included in the adjustment model (in the main text),Status of prognostic factor/treatment effect modified assessed in the IPD dataset,"Status of prognostic factor/treatment effect modified assessed in the IPD dataset, A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion)",Status of prognostic factor/treatment effect modified assessed in the IPD dataset,FALSE,NA,NA,NA
10.1080/03007995.2019.1605239,30964361,methodology,1,NA,Inclusion of prognostic factors in the adjustment/matching model,No discussion (in the main text) of the status of prognostic factors of the variables,Yes,No discussion (in the main text) of the status of prognostic factors of the variables,FALSE,NA,NA,NA
10.1080/03007995.2019.1605239,30964361,methodology,1,NA,Inclusion of treatment-effect modifiers in the adjustment/matching model,No discussion (in the main text) of the status of treatment-effect modifiers of the variables,Yes,No discussion (in the main text) of the status of treatment-effect modifiers of the variables,FALSE,NA,NA,NA
10.1080/03007995.2019.1605239,30964361,methodology,1,NA,"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)",NA,NA,No,TRUE,NA,NA,NA
10.1080/03007995.2019.1605239,30964361,methodology,1,NA,Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale),Yes,No,Yes,FALSE,NA,NA,NA
10.1080/03007995.2019.1605239,30964361,methodology,2,NA,Treatment name 1,NA,NA,bosutinib,TRUE,NA,"""The MAICs in this analysis are unanchored indirect comparisons and therefore a general limitation, in this case, is that propensity score methods (such as the MAIC) need to adjust for all effect modifiers and prognostic variables in order to reliably predict absolute outcomes. Also, although we made an effort to reweight for all clinically relevant reported baseline characteristics considered as effect modifier of treatment effect or predictors of outcome, this was not done for all baseline characteristics that were reported in the trials.""

imatinib resistance/intolerance = Severity of disease history...",NA
10.1080/03007995.2019.1605239,30964361,methodology,2,NA,Study 'number(s)' for treatment 1,NA,NA,1,TRUE,NA,NA,NA
10.1080/03007995.2019.1605239,30964361,methodology,2,NA,Treatment name 2,NA,NA,nilotinib,TRUE,NA,NA,NA
10.1080/03007995.2019.1605239,30964361,methodology,2,NA,Study 'number(s)' for treatment 2,NA,NA,3,TRUE,NA,NA,NA
10.1080/03007995.2019.1605239,30964361,methodology,2,NA,Type of population-adjusted indirect comparisons performed,NA,NA,MAIC,TRUE,NA,NA,NA
10.1080/03007995.2019.1605239,30964361,methodology,2,NA,Anchored comparison?,NA,NA,No,TRUE,NA,NA,NA
10.1080/03007995.2019.1605239,30964361,methodology,2,NA,Form of the indirect comparison,NA,NA,Simple (ie treatments effects extracted from two studies),TRUE,NA,NA,NA
10.1080/03007995.2019.1605239,30964361,methodology,2,NA,Definition of a single primary outcome for the indirect comparison,NA,NA,"No primary outcome defined, or multiple primary outcomes without any clear distinction between them",TRUE,NA,NA,NA
10.1080/03007995.2019.1605239,30964361,methodology,2,NA,Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined),NA,NA,overall survival,TRUE,NA,NA,NA
10.1080/03007995.2019.1605239,30964361,methodology,2,NA,Primary outcome: variable type,NA,NA,Time-to-event,TRUE,NA,NA,NA
10.1080/03007995.2019.1605239,30964361,methodology,2,NA,Justification for selecting variables to be included in the adjustment model (in the main text),Status of prognostic factor/treatment effect modified assessed in the IPD dataset,"Status of prognostic factor/treatment effect modified assessed in the IPD dataset, A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion)",Status of prognostic factor/treatment effect modified assessed in the IPD dataset,FALSE,NA,NA,NA
10.1080/03007995.2019.1605239,30964361,methodology,2,NA,Inclusion of prognostic factors in the adjustment/matching model,No discussion (in the main text) of the status of prognostic factors of the variables,Yes,No discussion (in the main text) of the status of prognostic factors of the variables,FALSE,NA,NA,NA
10.1080/03007995.2019.1605239,30964361,methodology,2,NA,Inclusion of treatment-effect modifiers in the adjustment/matching model,No discussion (in the main text) of the status of treatment-effect modifiers of the variables,Yes,No discussion (in the main text) of the status of treatment-effect modifiers of the variables,FALSE,NA,NA,NA
10.1080/03007995.2019.1605239,30964361,methodology,2,NA,"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)",NA,NA,No,TRUE,NA,NA,NA
10.1080/03007995.2019.1605239,30964361,methodology,2,NA,Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale),Yes,No,Yes,FALSE,NA,NA,NA
10.1080/03007995.2019.1605239,30964361,results,1,NA,Sample size of the population of interest in the non IPD treatment arm,NA,NA,167,TRUE,NA,NA,NA
10.1080/03007995.2019.1605239,30964361,results,1,NA,Initial sample size of the population of interest in the IPD treatment arm,NA,NA,283,TRUE,NA,NA,NA
10.1080/03007995.2019.1605239,30964361,results,1,NA,"Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC",NA,269.7,XXXX,FALSE,NA,NA,NA
10.1080/03007995.2019.1605239,30964361,results,1,NA,Reporting of a weights' distribution evaluation (MAIC),NA,NA,Not mentioned,TRUE,NA,NA,NA
10.1080/03007995.2019.1605239,30964361,results,1,NA,Reporting of the list of the covariates adjusted for/matched on,NA,NA,Yes,TRUE,NA,NA,NA
10.1080/03007995.2019.1605239,30964361,results,1,NA,Number of covariates adjusted for/matched on,3,4,4,FALSE,NA,NA,NA
10.1080/03007995.2019.1605239,30964361,results,1,NA,Covariates adjusted for/matched on in the indirect comparison,"Age, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Other(s)","Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Past treatments for the disease of interest","Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Past treatments for the disease of interest",FALSE,NA,NA,NA
10.1080/03007995.2019.1605239,30964361,results,1,NA,Primary outcome: treatment effect contrast,NA,NA,HR,TRUE,NA,NA,NA
10.1080/03007995.2019.1605239,30964361,results,1,NA,Direction of the treatment effect contrast: IPD treatment is:,NA,NA,"Numerator if ratio, or left side if difference",TRUE,NA,NA,NA
10.1080/03007995.2019.1605239,30964361,results,1,NA,Primary outcome: adjusted treatment effect,NA,NA,0.82,TRUE,NA,NA,NA
10.1080/03007995.2019.1605239,30964361,results,1,NA,"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])",NA,NA,0.37,TRUE,NA,NA,NA
10.1080/03007995.2019.1605239,30964361,results,2,NA,Sample size of the population of interest in the non IPD treatment arm,NA,NA,321,TRUE,NA,NA,NA
10.1080/03007995.2019.1605239,30964361,results,2,NA,Initial sample size of the population of interest in the IPD treatment arm,NA,NA,283,TRUE,NA,NA,NA
10.1080/03007995.2019.1605239,30964361,results,2,NA,"Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC",NA,269.9,XXXX,FALSE,NA,NA,NA
10.1080/03007995.2019.1605239,30964361,results,2,NA,Reporting of a weights' distribution evaluation (MAIC),NA,NA,Not mentioned,TRUE,NA,NA,NA
10.1080/03007995.2019.1605239,30964361,results,2,NA,Reporting of the list of the covariates adjusted for/matched on,NA,NA,Yes,TRUE,NA,NA,NA
10.1080/03007995.2019.1605239,30964361,results,2,NA,Number of covariates adjusted for/matched on,NA,NA,3,TRUE,NA,NA,NA
10.1080/03007995.2019.1605239,30964361,results,2,NA,Covariates adjusted for/matched on in the indirect comparison,"Age, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Other(s)","Age, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease)","Age, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Past treatments for the disease of interest",FALSE,NA,NA,NA
10.1080/03007995.2019.1605239,30964361,results,2,NA,Primary outcome: treatment effect contrast,NA,NA,HR,TRUE,NA,NA,NA
10.1080/03007995.2019.1605239,30964361,results,2,NA,Direction of the treatment effect contrast: IPD treatment is:,NA,NA,"Numerator if ratio, or left side if difference",TRUE,NA,NA,NA
10.1080/03007995.2019.1605239,30964361,results,2,NA,Primary outcome: adjusted treatment effect,NA,NA,0.72,TRUE,NA,NA,NA
10.1080/03007995.2019.1605239,30964361,results,2,NA,"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])",NA,NA,0.16,TRUE,NA,NA,NA
10.5152/eurjrheum.2019.19057,31364979,general_information,NA,NA,Medical Condition of Interest Name,NA,NA,psoriatic arthritis,TRUE,NA,NA,NA
10.5152/eurjrheum.2019.19057,31364979,general_information,NA,NA,Countries of first author affiliations,NA,NA,usa,TRUE,NA,NA,NA
10.5152/eurjrheum.2019.19057,31364979,general_information,NA,NA,Countries of last author affiliations,NA,NA,uk,TRUE,NA,NA,NA
10.5152/eurjrheum.2019.19057,31364979,general_information,NA,NA,"Positions of study investigators (for any authors of the article, any that applies)",NA,NA,"Academic, Pharmaceutical Industry, Private Data Analysis Company",TRUE,NA,NA,NA
10.5152/eurjrheum.2019.19057,31364979,general_information,NA,NA,"At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company",NA,NA,Yes,TRUE,NA,NA,NA
10.5152/eurjrheum.2019.19057,31364979,general_information,NA,NA,Mentioned sources of funding,NA,NA,Pharmaceutical Industry,TRUE,NA,NA,NA
10.5152/eurjrheum.2019.19057,31364979,general_information,NA,NA,"Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article",NA,NA,Yes,TRUE,NA,NA,NA
10.5152/eurjrheum.2019.19057,31364979,general_information,NA,NA,Mention of a systematic review to find the studies to compare treatments of interest,NA,NA,Yes,TRUE,NA,NA,NA
10.5152/eurjrheum.2019.19057,31364979,study_information,NA,1,Patient-level data used,NA,NA,Yes,TRUE,NA,NA,NA
10.5152/eurjrheum.2019.19057,31364979,study_information,NA,1,Clinical Trial,NA,NA,Yes,TRUE,NA,NA,NA
10.5152/eurjrheum.2019.19057,31364979,study_information,NA,1,NCT (only for clinical trial registered on clinicaltrials.gov),NA,NA,NCT01752634,TRUE,NA,NA,NA
10.5152/eurjrheum.2019.19057,31364979,study_information,NA,1,Country where the clinical trial/observational study was conducted (international if more than one),NA,NA,international,TRUE,NA,NA,NA
10.5152/eurjrheum.2019.19057,31364979,study_information,NA,1,Phase of the clinical trial (clinical trial only),NA,NA,3,TRUE,NA,NA,NA
10.5152/eurjrheum.2019.19057,31364979,study_information,NA,1,Number of treatment arms (clinical trial only),NA,NA,2 or more,TRUE,NA,NA,NA
10.5152/eurjrheum.2019.19057,31364979,study_information,NA,2,Patient-level data used,NA,NA,Yes,TRUE,NA,NA,NA
10.5152/eurjrheum.2019.19057,31364979,study_information,NA,2,Clinical Trial,NA,NA,Yes,TRUE,NA,NA,NA
10.5152/eurjrheum.2019.19057,31364979,study_information,NA,2,NCT (only for clinical trial registered on clinicaltrials.gov),NA,NA,NCT01989468,TRUE,NA,NA,NA
10.5152/eurjrheum.2019.19057,31364979,study_information,NA,2,Country where the clinical trial/observational study was conducted (international if more than one),NA,NA,international,TRUE,NA,NA,NA
10.5152/eurjrheum.2019.19057,31364979,study_information,NA,2,Phase of the clinical trial (clinical trial only),NA,NA,3,TRUE,NA,NA,NA
10.5152/eurjrheum.2019.19057,31364979,study_information,NA,2,Number of treatment arms (clinical trial only),NA,NA,2 or more,TRUE,NA,NA,NA
10.5152/eurjrheum.2019.19057,31364979,study_information,NA,3,Patient-level data used,NA,NA,Yes,TRUE,NA,NA,NA
10.5152/eurjrheum.2019.19057,31364979,study_information,NA,3,Clinical Trial,NA,NA,Yes,TRUE,NA,NA,NA
10.5152/eurjrheum.2019.19057,31364979,study_information,NA,3,NCT (only for clinical trial registered on clinicaltrials.gov),NA,NA,NCT02404350,TRUE,NA,NA,NA
10.5152/eurjrheum.2019.19057,31364979,study_information,NA,3,Country where the clinical trial/observational study was conducted (international if more than one),NA,NA,international,TRUE,NA,NA,NA
10.5152/eurjrheum.2019.19057,31364979,study_information,NA,3,Phase of the clinical trial (clinical trial only),NA,NA,3,TRUE,NA,NA,NA
10.5152/eurjrheum.2019.19057,31364979,study_information,NA,3,Number of treatment arms (clinical trial only),NA,NA,2 or more,TRUE,NA,NA,NA
10.5152/eurjrheum.2019.19057,31364979,study_information,NA,4,Patient-level data used,NA,NA,No,TRUE,NA,NA,NA
10.5152/eurjrheum.2019.19057,31364979,study_information,NA,4,Clinical Trial,NA,NA,Yes,TRUE,NA,NA,NA
10.5152/eurjrheum.2019.19057,31364979,study_information,NA,4,NCT (only for clinical trial registered on clinicaltrials.gov),NA,NA,NCT00317499,TRUE,NA,NA,NA
10.5152/eurjrheum.2019.19057,31364979,study_information,NA,4,Phase of the clinical trial (clinical trial only),NA,NA,3,TRUE,NA,NA,NA
10.5152/eurjrheum.2019.19057,31364979,study_information,NA,4,Number of treatment arms (clinical trial only),NA,NA,2 or more,TRUE,NA,NA,NA
10.5152/eurjrheum.2019.19057,31364979,study_information,NA,4,Country where the clinical trial/observational study was conducted (international if more than one),unknown,NA,XXXX,FALSE,NA,NA,NA
10.5152/eurjrheum.2019.19057,31364979,methodology,1,NA,Treatment name 1,NA,NA,secukinumab 150 mg,TRUE,Attempt to evaluate the remaining bias as per NICE recommendations,"Secukinumab 150 mg
Placebo-adjusted analysis at week 12

weight = Other covariate",NA
10.5152/eurjrheum.2019.19057,31364979,methodology,1,NA,Study 'number(s)' for treatment 1,NA,NA,1;2;3,TRUE,NA,NA,NA
10.5152/eurjrheum.2019.19057,31364979,methodology,1,NA,Treatment name 2,NA,NA,etanercept,TRUE,NA,NA,NA
10.5152/eurjrheum.2019.19057,31364979,methodology,1,NA,Study 'number(s)' for treatment 2,NA,NA,4,TRUE,NA,NA,NA
10.5152/eurjrheum.2019.19057,31364979,methodology,1,NA,Type of population-adjusted indirect comparisons performed,NA,NA,MAIC,TRUE,NA,NA,NA
10.5152/eurjrheum.2019.19057,31364979,methodology,1,NA,Anchored comparison?,NA,NA,Yes,TRUE,NA,NA,NA
10.5152/eurjrheum.2019.19057,31364979,methodology,1,NA,Form of the indirect comparison,NA,NA,"Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate)",TRUE,NA,NA,NA
10.5152/eurjrheum.2019.19057,31364979,methodology,1,NA,Definition of a single primary outcome for the indirect comparison,NA,NA,"No primary outcome defined, or multiple primary outcomes without any clear distinction between them",TRUE,NA,NA,NA
10.5152/eurjrheum.2019.19057,31364979,methodology,1,NA,Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined),NA,NA,acr 20 (american college of rheumatology ) response rates at week 12,TRUE,NA,NA,NA
10.5152/eurjrheum.2019.19057,31364979,methodology,1,NA,Primary outcome: variable type,NA,NA,Binary (eg rates),TRUE,NA,NA,NA
10.5152/eurjrheum.2019.19057,31364979,methodology,1,NA,Justification for selecting variables to be included in the adjustment model (in the main text),NA,NA,"Status of prognostic factor/treatment effect modified assessed in the IPD dataset, A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion), Literature based (clinically or methodologically relevant to adjust on these variables based on the literature search conducted for this specific purpose)",TRUE,NA,NA,NA
10.5152/eurjrheum.2019.19057,31364979,methodology,1,NA,Inclusion of prognostic factors in the adjustment/matching model,No,Yes,Yes,FALSE,NA,NA,NA
10.5152/eurjrheum.2019.19057,31364979,methodology,1,NA,Inclusion of treatment-effect modifiers in the adjustment/matching model,NA,NA,Yes,TRUE,NA,NA,NA
10.5152/eurjrheum.2019.19057,31364979,methodology,1,NA,"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)",NA,NA,No,TRUE,NA,NA,NA
10.5152/eurjrheum.2019.19057,31364979,methodology,1,NA,Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale),NA,NA,No,TRUE,NA,NA,NA
10.5152/eurjrheum.2019.19057,31364979,methodology,2,NA,Treatment name 1,NA,NA,secukinumab 150 mg,TRUE,NA,"Secukinumab 150 mg
Non Placebo-adjusted analysis at week 24

weight = Other covariate",NA
10.5152/eurjrheum.2019.19057,31364979,methodology,2,NA,Study 'number(s)' for treatment 1,1.2.3,1;2;3,1;2;3,FALSE,NA,NA,NA
10.5152/eurjrheum.2019.19057,31364979,methodology,2,NA,Treatment name 2,NA,NA,etanercept,TRUE,NA,NA,NA
10.5152/eurjrheum.2019.19057,31364979,methodology,2,NA,Study 'number(s)' for treatment 2,NA,NA,4,TRUE,NA,NA,NA
10.5152/eurjrheum.2019.19057,31364979,methodology,2,NA,Type of population-adjusted indirect comparisons performed,NA,NA,MAIC,TRUE,NA,NA,NA
10.5152/eurjrheum.2019.19057,31364979,methodology,2,NA,Anchored comparison?,NA,NA,No,TRUE,NA,NA,NA
10.5152/eurjrheum.2019.19057,31364979,methodology,2,NA,Form of the indirect comparison,NA,NA,"Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate)",TRUE,NA,NA,NA
10.5152/eurjrheum.2019.19057,31364979,methodology,2,NA,Definition of a single primary outcome for the indirect comparison,NA,NA,"No primary outcome defined, or multiple primary outcomes without any clear distinction between them",TRUE,NA,NA,NA
10.5152/eurjrheum.2019.19057,31364979,methodology,2,NA,Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined),NA,NA,acr 20 (american college of rheumatology ) response rates at week 24,TRUE,NA,NA,NA
10.5152/eurjrheum.2019.19057,31364979,methodology,2,NA,Primary outcome: variable type,NA,NA,Binary (eg rates),TRUE,NA,NA,NA
10.5152/eurjrheum.2019.19057,31364979,methodology,2,NA,Justification for selecting variables to be included in the adjustment model (in the main text),NA,NA,"Status of prognostic factor/treatment effect modified assessed in the IPD dataset, A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion), Literature based (clinically or methodologically relevant to adjust on these variables based on the literature search conducted for this specific purpose)",TRUE,NA,NA,NA
10.5152/eurjrheum.2019.19057,31364979,methodology,2,NA,Inclusion of prognostic factors in the adjustment/matching model,No,Yes,Yes,FALSE,NA,NA,NA
10.5152/eurjrheum.2019.19057,31364979,methodology,2,NA,Inclusion of treatment-effect modifiers in the adjustment/matching model,NA,NA,Yes,TRUE,NA,NA,NA
10.5152/eurjrheum.2019.19057,31364979,methodology,2,NA,"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)",NA,NA,No,TRUE,NA,NA,NA
10.5152/eurjrheum.2019.19057,31364979,methodology,2,NA,Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale),NA,NA,No,TRUE,NA,NA,NA
10.5152/eurjrheum.2019.19057,31364979,methodology,3,NA,Treatment name 1,secukinumab 300mg,secukinumab 300 mg,secukinumab 300mg,FALSE,NA,"Secukinumab 300 mg
Placebo-adjusted analysis at week 12

weight = Other covariate",NA
10.5152/eurjrheum.2019.19057,31364979,methodology,3,NA,Study 'number(s)' for treatment 1,NA,NA,1;2;3,TRUE,NA,NA,NA
10.5152/eurjrheum.2019.19057,31364979,methodology,3,NA,Treatment name 2,NA,NA,etanercept,TRUE,NA,NA,NA
10.5152/eurjrheum.2019.19057,31364979,methodology,3,NA,Study 'number(s)' for treatment 2,NA,NA,4,TRUE,NA,NA,NA
10.5152/eurjrheum.2019.19057,31364979,methodology,3,NA,Type of population-adjusted indirect comparisons performed,NA,NA,MAIC,TRUE,NA,NA,NA
10.5152/eurjrheum.2019.19057,31364979,methodology,3,NA,Anchored comparison?,NA,NA,Yes,TRUE,NA,NA,NA
10.5152/eurjrheum.2019.19057,31364979,methodology,3,NA,Form of the indirect comparison,NA,NA,"Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate)",TRUE,NA,NA,NA
10.5152/eurjrheum.2019.19057,31364979,methodology,3,NA,Definition of a single primary outcome for the indirect comparison,NA,NA,"No primary outcome defined, or multiple primary outcomes without any clear distinction between them",TRUE,NA,NA,NA
10.5152/eurjrheum.2019.19057,31364979,methodology,3,NA,Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined),NA,NA,acr 20 (american college of rheumatology ) response rates at week 12,TRUE,NA,NA,NA
10.5152/eurjrheum.2019.19057,31364979,methodology,3,NA,Primary outcome: variable type,NA,NA,Binary (eg rates),TRUE,NA,NA,NA
10.5152/eurjrheum.2019.19057,31364979,methodology,3,NA,Justification for selecting variables to be included in the adjustment model (in the main text),NA,NA,"Status of prognostic factor/treatment effect modified assessed in the IPD dataset, A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion), Literature based (clinically or methodologically relevant to adjust on these variables based on the literature search conducted for this specific purpose)",TRUE,NA,NA,NA
10.5152/eurjrheum.2019.19057,31364979,methodology,3,NA,Inclusion of prognostic factors in the adjustment/matching model,No,Yes,Yes,FALSE,NA,NA,NA
10.5152/eurjrheum.2019.19057,31364979,methodology,3,NA,Inclusion of treatment-effect modifiers in the adjustment/matching model,NA,NA,Yes,TRUE,NA,NA,NA
10.5152/eurjrheum.2019.19057,31364979,methodology,3,NA,"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)",NA,NA,No,TRUE,NA,NA,NA
10.5152/eurjrheum.2019.19057,31364979,methodology,3,NA,Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale),NA,NA,No,TRUE,NA,NA,NA
10.5152/eurjrheum.2019.19057,31364979,methodology,4,NA,Treatment name 1,secukinumab 300mg,secukinumab 300 mg,secukinumab 300mg,FALSE,NA,"Secukinumab 300 mg
Non Placebo-adjusted analysis at week 24

weight = Other covariate",NA
10.5152/eurjrheum.2019.19057,31364979,methodology,4,NA,Study 'number(s)' for treatment 1,NA,NA,1;2;3,TRUE,NA,NA,NA
10.5152/eurjrheum.2019.19057,31364979,methodology,4,NA,Treatment name 2,NA,NA,etanercept,TRUE,NA,NA,NA
10.5152/eurjrheum.2019.19057,31364979,methodology,4,NA,Study 'number(s)' for treatment 2,NA,NA,4,TRUE,NA,NA,NA
10.5152/eurjrheum.2019.19057,31364979,methodology,4,NA,Type of population-adjusted indirect comparisons performed,NA,NA,MAIC,TRUE,NA,NA,NA
10.5152/eurjrheum.2019.19057,31364979,methodology,4,NA,Anchored comparison?,NA,NA,No,TRUE,NA,NA,NA
10.5152/eurjrheum.2019.19057,31364979,methodology,4,NA,Form of the indirect comparison,NA,NA,"Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate)",TRUE,NA,NA,NA
10.5152/eurjrheum.2019.19057,31364979,methodology,4,NA,Definition of a single primary outcome for the indirect comparison,NA,NA,"No primary outcome defined, or multiple primary outcomes without any clear distinction between them",TRUE,NA,NA,NA
10.5152/eurjrheum.2019.19057,31364979,methodology,4,NA,Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined),NA,NA,acr 20 (american college of rheumatology ) response rates at week 24,TRUE,NA,NA,NA
10.5152/eurjrheum.2019.19057,31364979,methodology,4,NA,Primary outcome: variable type,NA,NA,Binary (eg rates),TRUE,NA,NA,NA
10.5152/eurjrheum.2019.19057,31364979,methodology,4,NA,Justification for selecting variables to be included in the adjustment model (in the main text),NA,NA,"Status of prognostic factor/treatment effect modified assessed in the IPD dataset, A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion), Literature based (clinically or methodologically relevant to adjust on these variables based on the literature search conducted for this specific purpose)",TRUE,NA,NA,NA
10.5152/eurjrheum.2019.19057,31364979,methodology,4,NA,Inclusion of prognostic factors in the adjustment/matching model,No,Yes,Yes,FALSE,NA,NA,NA
10.5152/eurjrheum.2019.19057,31364979,methodology,4,NA,Inclusion of treatment-effect modifiers in the adjustment/matching model,NA,NA,Yes,TRUE,NA,NA,NA
10.5152/eurjrheum.2019.19057,31364979,methodology,4,NA,"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)",NA,NA,No,TRUE,NA,NA,NA
10.5152/eurjrheum.2019.19057,31364979,methodology,4,NA,Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale),NA,NA,No,TRUE,NA,NA,NA
10.5152/eurjrheum.2019.19057,31364979,results,1,NA,Sample size of the population of interest in the non IPD treatment arm,NA,NA,101,TRUE,NA,NA,NA
10.5152/eurjrheum.2019.19057,31364979,results,1,NA,"If anchored comparison, sample size of the population of interest in the non IPD treatment anchor arm",NA,NA,104,TRUE,NA,NA,NA
10.5152/eurjrheum.2019.19057,31364979,results,1,NA,Initial sample size of the population of interest in the IPD treatment arm,NA,NA,458,TRUE,NA,NA,NA
10.5152/eurjrheum.2019.19057,31364979,results,1,NA,"Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC",NA,NA,104,TRUE,NA,NA,NA
10.5152/eurjrheum.2019.19057,31364979,results,1,NA,"If anchored comparison, initial sample size of the population of interest in the IPD anchor arm",NA,NA,567,TRUE,NA,NA,NA
10.5152/eurjrheum.2019.19057,31364979,results,1,NA,"If anchored comparison, effective sample size after reweighting for MAIC; or sample size used in the regression model for STC in the IPD anchor arm",NA,NA,159,TRUE,NA,NA,NA
10.5152/eurjrheum.2019.19057,31364979,results,1,NA,Reporting of a weights' distribution evaluation (MAIC),NA,NA,Not mentioned,TRUE,NA,NA,NA
10.5152/eurjrheum.2019.19057,31364979,results,1,NA,Reporting of the list of the covariates adjusted for/matched on,NA,NA,Yes,TRUE,NA,NA,NA
10.5152/eurjrheum.2019.19057,31364979,results,1,NA,Number of covariates adjusted for/matched on,NA,NA,11,TRUE,NA,NA,NA
10.5152/eurjrheum.2019.19057,31364979,results,1,NA,Covariates adjusted for/matched on in the indirect comparison,NA,NA,"Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Race/ethnicity, Past treatments for the disease of interest, Other(s)",TRUE,NA,NA,NA
10.5152/eurjrheum.2019.19057,31364979,results,1,NA,Primary outcome: treatment effect contrast,NA,NA,OR,TRUE,NA,NA,NA
10.5152/eurjrheum.2019.19057,31364979,results,1,NA,Direction of the treatment effect contrast: IPD treatment is:,NA,NA,"Numerator if ratio, or left side if difference",TRUE,NA,NA,NA
10.5152/eurjrheum.2019.19057,31364979,results,1,NA,Primary outcome: adjusted treatment effect,NA,NA,0.57,TRUE,NA,NA,NA
10.5152/eurjrheum.2019.19057,31364979,results,1,NA,"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])",NA,NA,0.186,TRUE,NA,NA,NA
10.5152/eurjrheum.2019.19057,31364979,results,2,NA,Sample size of the population of interest in the non IPD treatment arm,NA,NA,101,TRUE,NA,NA,NA
10.5152/eurjrheum.2019.19057,31364979,results,2,NA,Initial sample size of the population of interest in the IPD treatment arm,NA,NA,458,TRUE,NA,NA,NA
10.5152/eurjrheum.2019.19057,31364979,results,2,NA,"Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC",NA,NA,104,TRUE,NA,NA,NA
10.5152/eurjrheum.2019.19057,31364979,results,2,NA,Reporting of a weights' distribution evaluation (MAIC),NA,NA,Not mentioned,TRUE,NA,NA,NA
10.5152/eurjrheum.2019.19057,31364979,results,2,NA,Reporting of the list of the covariates adjusted for/matched on,NA,NA,Yes,TRUE,NA,NA,NA
10.5152/eurjrheum.2019.19057,31364979,results,2,NA,Number of covariates adjusted for/matched on,NA,NA,11,TRUE,NA,NA,NA
10.5152/eurjrheum.2019.19057,31364979,results,2,NA,Covariates adjusted for/matched on in the indirect comparison,NA,NA,"Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Race/ethnicity, Past treatments for the disease of interest, Other(s)",TRUE,NA,NA,NA
10.5152/eurjrheum.2019.19057,31364979,results,2,NA,Primary outcome: treatment effect contrast,NA,NA,OR,TRUE,NA,NA,NA
10.5152/eurjrheum.2019.19057,31364979,results,2,NA,Direction of the treatment effect contrast: IPD treatment is:,NA,NA,"Numerator if ratio, or left side if difference",TRUE,NA,NA,NA
10.5152/eurjrheum.2019.19057,31364979,results,2,NA,Primary outcome: adjusted treatment effect,NA,NA,1.47,TRUE,NA,NA,NA
10.5152/eurjrheum.2019.19057,31364979,results,2,NA,"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])",NA,NA,0.173,TRUE,NA,NA,NA
10.5152/eurjrheum.2019.19057,31364979,results,2,NA,"If anchored comparison, sample size of the population of interest in the non IPD treatment anchor arm",104,NA,Non anchored comparison,FALSE,NA,NA,NA
10.5152/eurjrheum.2019.19057,31364979,results,2,NA,"If anchored comparison, initial sample size of the population of interest in the IPD anchor arm",567,NA,Non anchored comparison,FALSE,NA,NA,NA
10.5152/eurjrheum.2019.19057,31364979,results,2,NA,"If anchored comparison, effective sample size after reweighting for MAIC; or sample size used in the regression model for STC in the IPD anchor arm",159,NA,Non anchored comparison,FALSE,NA,NA,NA
10.5152/eurjrheum.2019.19057,31364979,results,3,NA,Sample size of the population of interest in the non IPD treatment arm,NA,NA,101,TRUE,NA,NA,NA
10.5152/eurjrheum.2019.19057,31364979,results,3,NA,"If anchored comparison, sample size of the population of interest in the non IPD treatment anchor arm",NA,NA,104,TRUE,NA,NA,NA
10.5152/eurjrheum.2019.19057,31364979,results,3,NA,Initial sample size of the population of interest in the IPD treatment arm,NA,NA,461,TRUE,NA,NA,NA
10.5152/eurjrheum.2019.19057,31364979,results,3,NA,"Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC",NA,NA,75,TRUE,NA,NA,NA
10.5152/eurjrheum.2019.19057,31364979,results,3,NA,"If anchored comparison, initial sample size of the population of interest in the IPD anchor arm",NA,NA,567,TRUE,NA,NA,NA
10.5152/eurjrheum.2019.19057,31364979,results,3,NA,"If anchored comparison, effective sample size after reweighting for MAIC; or sample size used in the regression model for STC in the IPD anchor arm",NA,NA,159,TRUE,NA,NA,NA
10.5152/eurjrheum.2019.19057,31364979,results,3,NA,Reporting of a weights' distribution evaluation (MAIC),NA,NA,Not mentioned,TRUE,NA,NA,NA
10.5152/eurjrheum.2019.19057,31364979,results,3,NA,Reporting of the list of the covariates adjusted for/matched on,NA,NA,Yes,TRUE,NA,NA,NA
10.5152/eurjrheum.2019.19057,31364979,results,3,NA,Number of covariates adjusted for/matched on,NA,NA,11,TRUE,NA,NA,NA
10.5152/eurjrheum.2019.19057,31364979,results,3,NA,Covariates adjusted for/matched on in the indirect comparison,NA,NA,"Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Race/ethnicity, Past treatments for the disease of interest, Other(s)",TRUE,NA,NA,NA
10.5152/eurjrheum.2019.19057,31364979,results,3,NA,Primary outcome: treatment effect contrast,NA,NA,OR,TRUE,NA,NA,NA
10.5152/eurjrheum.2019.19057,31364979,results,3,NA,Direction of the treatment effect contrast: IPD treatment is:,NA,NA,"Numerator if ratio, or left side if difference",TRUE,NA,NA,NA
10.5152/eurjrheum.2019.19057,31364979,results,3,NA,Primary outcome: adjusted treatment effect,NA,NA,0.86,TRUE,NA,NA,NA
10.5152/eurjrheum.2019.19057,31364979,results,3,NA,"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])",NA,NA,0.722,TRUE,NA,NA,NA
10.5152/eurjrheum.2019.19057,31364979,results,4,NA,Sample size of the population of interest in the non IPD treatment arm,NA,NA,101,TRUE,NA,NA,NA
10.5152/eurjrheum.2019.19057,31364979,results,4,NA,Initial sample size of the population of interest in the IPD treatment arm,NA,NA,461,TRUE,NA,NA,NA
10.5152/eurjrheum.2019.19057,31364979,results,4,NA,"Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC",NA,NA,75,TRUE,NA,NA,NA
10.5152/eurjrheum.2019.19057,31364979,results,4,NA,Reporting of a weights' distribution evaluation (MAIC),NA,NA,Not mentioned,TRUE,NA,NA,NA
10.5152/eurjrheum.2019.19057,31364979,results,4,NA,Reporting of the list of the covariates adjusted for/matched on,NA,NA,Yes,TRUE,NA,NA,NA
10.5152/eurjrheum.2019.19057,31364979,results,4,NA,Number of covariates adjusted for/matched on,NA,NA,11,TRUE,NA,NA,NA
10.5152/eurjrheum.2019.19057,31364979,results,4,NA,Covariates adjusted for/matched on in the indirect comparison,NA,NA,"Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Race/ethnicity, Past treatments for the disease of interest, Other(s)",TRUE,NA,NA,NA
10.5152/eurjrheum.2019.19057,31364979,results,4,NA,Primary outcome: treatment effect contrast,NA,NA,OR,TRUE,NA,NA,NA
10.5152/eurjrheum.2019.19057,31364979,results,4,NA,Direction of the treatment effect contrast: IPD treatment is:,NA,NA,"Numerator if ratio, or left side if difference",TRUE,NA,NA,NA
10.5152/eurjrheum.2019.19057,31364979,results,4,NA,Primary outcome: adjusted treatment effect,NA,NA,3.28,TRUE,NA,NA,NA
10.5152/eurjrheum.2019.19057,31364979,results,4,NA,"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])",NA,NA,<0.001,TRUE,NA,NA,NA
10.5152/eurjrheum.2019.19057,31364979,results,4,NA,"If anchored comparison, sample size of the population of interest in the non IPD treatment anchor arm",104,NA,Non anchored comparison,FALSE,NA,NA,NA
10.5152/eurjrheum.2019.19057,31364979,results,4,NA,"If anchored comparison, initial sample size of the population of interest in the IPD anchor arm",567,NA,Non anchored comparison,FALSE,NA,NA,NA
10.5152/eurjrheum.2019.19057,31364979,results,4,NA,"If anchored comparison, effective sample size after reweighting for MAIC; or sample size used in the regression model for STC in the IPD anchor arm",159,NA,Non anchored comparison,FALSE,NA,NA,NA
10.2147/jbm.s206806,31417326,general_information,NA,NA,Medical Condition of Interest Name,NA,NA,severe hemophilia a,TRUE,NA,NA,NA
10.2147/jbm.s206806,31417326,general_information,NA,NA,Countries of first author affiliations,NA,NA,usa,TRUE,NA,NA,NA
10.2147/jbm.s206806,31417326,general_information,NA,NA,Countries of last author affiliations,NA,NA,germany,TRUE,NA,NA,NA
10.2147/jbm.s206806,31417326,general_information,NA,NA,"Positions of study investigators (for any authors of the article, any that applies)",NA,NA,"Academic, Pharmaceutical Industry, Private Data Analysis Company",TRUE,NA,NA,NA
10.2147/jbm.s206806,31417326,general_information,NA,NA,"At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company",NA,NA,Yes,TRUE,NA,NA,NA
10.2147/jbm.s206806,31417326,general_information,NA,NA,Mentioned sources of funding,NA,NA,Pharmaceutical Industry,TRUE,NA,NA,NA
10.2147/jbm.s206806,31417326,general_information,NA,NA,"Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article",NA,NA,Yes,TRUE,NA,NA,NA
10.2147/jbm.s206806,31417326,general_information,NA,NA,Mention of a systematic review to find the studies to compare treatments of interest,NA,NA,Yes,TRUE,NA,NA,NA
10.2147/jbm.s206806,31417326,study_information,NA,1,Patient-level data used,NA,NA,Yes,TRUE,NA,NA,NA
10.2147/jbm.s206806,31417326,study_information,NA,1,Clinical Trial,NA,NA,Yes,TRUE,NA,NA,NA
10.2147/jbm.s206806,31417326,study_information,NA,1,NCT (only for clinical trial registered on clinicaltrials.gov),NA,NA,NCT01580293,TRUE,NA,NA,NA
10.2147/jbm.s206806,31417326,study_information,NA,1,Country where the clinical trial/observational study was conducted (international if more than one),NA,NA,international,TRUE,NA,NA,NA
10.2147/jbm.s206806,31417326,study_information,NA,1,Phase of the clinical trial (clinical trial only),NA,NA,"2, 3",TRUE,NA,NA,NA
10.2147/jbm.s206806,31417326,study_information,NA,1,Number of treatment arms (clinical trial only),1,2 or more,XXXX,FALSE,NA,NA,NA
10.2147/jbm.s206806,31417326,study_information,NA,2,Patient-level data used,NA,NA,No,TRUE,NA,NA,NA
10.2147/jbm.s206806,31417326,study_information,NA,2,Clinical Trial,NA,NA,Yes,TRUE,NA,NA,NA
10.2147/jbm.s206806,31417326,study_information,NA,2,NCT (only for clinical trial registered on clinicaltrials.gov),NA,NA,NCT01181128,TRUE,NA,NA,NA
10.2147/jbm.s206806,31417326,study_information,NA,2,Country where the clinical trial/observational study was conducted (international if more than one),NA,NA,international,TRUE,NA,NA,NA
10.2147/jbm.s206806,31417326,study_information,NA,2,Phase of the clinical trial (clinical trial only),NA,NA,3,TRUE,NA,NA,NA
10.2147/jbm.s206806,31417326,study_information,NA,2,Number of treatment arms (clinical trial only),NA,NA,2 or more,TRUE,NA,NA,NA
10.2147/jbm.s206806,31417326,study_information,NA,3,Patient-level data used,NA,NA,No,TRUE,NA,NA,NA
10.2147/jbm.s206806,31417326,study_information,NA,3,Clinical Trial,NA,NA,Yes,TRUE,NA,NA,NA
10.2147/jbm.s206806,31417326,study_information,NA,3,NCT (only for clinical trial registered on clinicaltrials.gov),NA,NA,NCT01736475,TRUE,NA,NA,NA
10.2147/jbm.s206806,31417326,study_information,NA,3,Country where the clinical trial/observational study was conducted (international if more than one),NA,NA,international,TRUE,NA,NA,NA
10.2147/jbm.s206806,31417326,study_information,NA,3,Phase of the clinical trial (clinical trial only),3,"2, 3",XXXX,FALSE,NA,NA,NA
10.2147/jbm.s206806,31417326,study_information,NA,3,Number of treatment arms (clinical trial only),NA,NA,2 or more,TRUE,NA,NA,NA
10.2147/jbm.s206806,31417326,study_information,NA,4,Patient-level data used,NA,NA,No,TRUE,NA,NA,NA
10.2147/jbm.s206806,31417326,study_information,NA,4,Clinical Trial,NA,NA,Yes,TRUE,NA,NA,NA
10.2147/jbm.s206806,31417326,study_information,NA,4,Data source name (only if observational study or clinical trial without NCT),NA,tarantino et al. (2004),tarantino et al. (2004),FALSE,NA,NA,NA
10.2147/jbm.s206806,31417326,study_information,NA,4,Number of treatment arms (clinical trial only),1,2 or more,XXXX,FALSE,NA,NA,NA
10.2147/jbm.s206806,31417326,study_information,NA,4,NCT (only for clinical trial registered on clinicaltrials.gov),NCT00157157,NA,XXXX,FALSE,NA,NA,NA
10.2147/jbm.s206806,31417326,study_information,NA,4,Country where the clinical trial/observational study was conducted (international if more than one),international,NA,XXXX,FALSE,NA,NA,NA
10.2147/jbm.s206806,31417326,study_information,NA,4,Phase of the clinical trial (clinical trial only),3,NA,XXXX,FALSE,NA,NA,NA
10.2147/jbm.s206806,31417326,study_information,NA,5,Patient-level data used,NA,NA,No,TRUE,NA,NA,NA
10.2147/jbm.s206806,31417326,study_information,NA,5,Clinical Trial,NA,NA,Yes,TRUE,NA,NA,NA
10.2147/jbm.s206806,31417326,study_information,NA,5,NCT (only for clinical trial registered on clinicaltrials.gov),NA,NA,NCT00243386,TRUE,NA,NA,NA
10.2147/jbm.s206806,31417326,study_information,NA,5,Country where the clinical trial/observational study was conducted (international if more than one),NA,NA,international,TRUE,NA,NA,NA
10.2147/jbm.s206806,31417326,study_information,NA,5,Phase of the clinical trial (clinical trial only),NA,NA,4,TRUE,NA,NA,NA
10.2147/jbm.s206806,31417326,study_information,NA,5,Number of treatment arms (clinical trial only),1,2 or more,XXXX,FALSE,NA,NA,NA
10.2147/jbm.s206806,31417326,methodology,1,NA,Treatment name 1,NA,NA,bay 94-9027,TRUE,NA,NA,NA
10.2147/jbm.s206806,31417326,methodology,1,NA,Study 'number(s)' for treatment 1,NA,NA,1,TRUE,NA,NA,NA
10.2147/jbm.s206806,31417326,methodology,1,NA,Treatment name 2,NA,NA,rfviiifc,TRUE,NA,NA,NA
10.2147/jbm.s206806,31417326,methodology,1,NA,Study 'number(s)' for treatment 2,NA,NA,2,TRUE,NA,NA,NA
10.2147/jbm.s206806,31417326,methodology,1,NA,Type of population-adjusted indirect comparisons performed,NA,NA,MAIC,TRUE,NA,NA,NA
10.2147/jbm.s206806,31417326,methodology,1,NA,Anchored comparison?,NA,NA,No,TRUE,NA,NA,NA
10.2147/jbm.s206806,31417326,methodology,1,NA,Form of the indirect comparison,NA,NA,Simple (ie treatments effects extracted from two studies),TRUE,NA,NA,NA
10.2147/jbm.s206806,31417326,methodology,1,NA,Definition of a single primary outcome for the indirect comparison,NA,NA,"No primary outcome defined, or multiple primary outcomes without any clear distinction between them",TRUE,NA,NA,NA
10.2147/jbm.s206806,31417326,methodology,1,NA,Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined),mean annualized bleeding rate,annualized bleeding rate,annualized bleeding rate,FALSE,NA,NA,NA
10.2147/jbm.s206806,31417326,methodology,1,NA,Primary outcome: variable type,NA,NA,"Continuous (count, mean, ...)",TRUE,NA,NA,NA
10.2147/jbm.s206806,31417326,methodology,1,NA,Justification for selecting variables to be included in the adjustment model (in the main text),NA,NA,"Nothing mentioned, not reported",TRUE,NA,NA,NA
10.2147/jbm.s206806,31417326,methodology,1,NA,Inclusion of prognostic factors in the adjustment/matching model,NA,NA,No discussion (in the main text) of the status of prognostic factors of the variables,TRUE,NA,NA,NA
10.2147/jbm.s206806,31417326,methodology,1,NA,Inclusion of treatment-effect modifiers in the adjustment/matching model,NA,NA,No discussion (in the main text) of the status of treatment-effect modifiers of the variables,TRUE,NA,NA,NA
10.2147/jbm.s206806,31417326,methodology,1,NA,"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)",NA,NA,No,TRUE,NA,NA,NA
10.2147/jbm.s206806,31417326,methodology,1,NA,Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale),NA,NA,No,TRUE,NA,NA,NA
10.2147/jbm.s206806,31417326,methodology,2,NA,Treatment name 1,NA,NA,bay 94-9027,TRUE,NA,NA,NA
10.2147/jbm.s206806,31417326,methodology,2,NA,Study 'number(s)' for treatment 1,NA,NA,1,TRUE,NA,NA,NA
10.2147/jbm.s206806,31417326,methodology,2,NA,Treatment name 2,NA,NA,bax 855,TRUE,NA,NA,NA
10.2147/jbm.s206806,31417326,methodology,2,NA,Study 'number(s)' for treatment 2,3,2,3,FALSE,NA,NA,NA
10.2147/jbm.s206806,31417326,methodology,2,NA,Type of population-adjusted indirect comparisons performed,NA,NA,MAIC,TRUE,NA,NA,NA
10.2147/jbm.s206806,31417326,methodology,2,NA,Anchored comparison?,NA,NA,No,TRUE,NA,NA,NA
10.2147/jbm.s206806,31417326,methodology,2,NA,Form of the indirect comparison,NA,NA,Simple (ie treatments effects extracted from two studies),TRUE,NA,NA,NA
10.2147/jbm.s206806,31417326,methodology,2,NA,Definition of a single primary outcome for the indirect comparison,NA,NA,"No primary outcome defined, or multiple primary outcomes without any clear distinction between them",TRUE,NA,NA,NA
10.2147/jbm.s206806,31417326,methodology,2,NA,Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined),NA,NA,annualized bleeding rate,TRUE,NA,NA,NA
10.2147/jbm.s206806,31417326,methodology,2,NA,Primary outcome: variable type,NA,NA,"Continuous (count, mean, ...)",TRUE,NA,NA,NA
10.2147/jbm.s206806,31417326,methodology,2,NA,Justification for selecting variables to be included in the adjustment model (in the main text),NA,NA,"Nothing mentioned, not reported",TRUE,NA,NA,NA
10.2147/jbm.s206806,31417326,methodology,2,NA,Inclusion of prognostic factors in the adjustment/matching model,NA,NA,No discussion (in the main text) of the status of prognostic factors of the variables,TRUE,NA,NA,NA
10.2147/jbm.s206806,31417326,methodology,2,NA,Inclusion of treatment-effect modifiers in the adjustment/matching model,NA,NA,No discussion (in the main text) of the status of treatment-effect modifiers of the variables,TRUE,NA,NA,NA
10.2147/jbm.s206806,31417326,methodology,2,NA,"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)",NA,NA,No,TRUE,NA,NA,NA
10.2147/jbm.s206806,31417326,methodology,2,NA,Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale),NA,NA,No,TRUE,NA,NA,NA
10.2147/jbm.s206806,31417326,methodology,3,NA,Treatment name 1,NA,NA,bay 94-9027,TRUE,NA,NA,NA
10.2147/jbm.s206806,31417326,methodology,3,NA,Study 'number(s)' for treatment 1,NA,NA,1,TRUE,NA,NA,NA
10.2147/jbm.s206806,31417326,methodology,3,NA,Treatment name 2,rahf-pfm 2004,rahf-pfm (2004 study),rahf-pfm 2004,FALSE,NA,NA,NA
10.2147/jbm.s206806,31417326,methodology,3,NA,Study 'number(s)' for treatment 2,NA,NA,4,TRUE,NA,NA,NA
10.2147/jbm.s206806,31417326,methodology,3,NA,Type of population-adjusted indirect comparisons performed,NA,NA,MAIC,TRUE,NA,NA,NA
10.2147/jbm.s206806,31417326,methodology,3,NA,Anchored comparison?,NA,NA,No,TRUE,NA,NA,NA
10.2147/jbm.s206806,31417326,methodology,3,NA,Form of the indirect comparison,NA,NA,Simple (ie treatments effects extracted from two studies),TRUE,NA,NA,NA
10.2147/jbm.s206806,31417326,methodology,3,NA,Definition of a single primary outcome for the indirect comparison,NA,NA,"No primary outcome defined, or multiple primary outcomes without any clear distinction between them",TRUE,NA,NA,NA
10.2147/jbm.s206806,31417326,methodology,3,NA,Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined),NA,NA,annualized bleeding rate,TRUE,NA,NA,NA
10.2147/jbm.s206806,31417326,methodology,3,NA,Primary outcome: variable type,NA,NA,"Continuous (count, mean, ...)",TRUE,NA,NA,NA
10.2147/jbm.s206806,31417326,methodology,3,NA,Justification for selecting variables to be included in the adjustment model (in the main text),NA,NA,"Nothing mentioned, not reported",TRUE,NA,NA,NA
10.2147/jbm.s206806,31417326,methodology,3,NA,Inclusion of prognostic factors in the adjustment/matching model,NA,NA,No discussion (in the main text) of the status of prognostic factors of the variables,TRUE,NA,NA,NA
10.2147/jbm.s206806,31417326,methodology,3,NA,Inclusion of treatment-effect modifiers in the adjustment/matching model,NA,NA,No discussion (in the main text) of the status of treatment-effect modifiers of the variables,TRUE,NA,NA,NA
10.2147/jbm.s206806,31417326,methodology,3,NA,"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)",NA,NA,No,TRUE,NA,NA,NA
10.2147/jbm.s206806,31417326,methodology,3,NA,Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale),NA,NA,No,TRUE,NA,NA,NA
10.2147/jbm.s206806,31417326,methodology,4,NA,Treatment name 1,NA,NA,bay 94-9027,TRUE,NA,NA,NA
10.2147/jbm.s206806,31417326,methodology,4,NA,Study 'number(s)' for treatment 1,NA,NA,1,TRUE,NA,NA,NA
10.2147/jbm.s206806,31417326,methodology,4,NA,Treatment name 2,rahf-pfm 2012,rahf-pfm (2012 study),rahf-pfm 2012,FALSE,NA,NA,NA
10.2147/jbm.s206806,31417326,methodology,4,NA,Study 'number(s)' for treatment 2,NA,NA,5,TRUE,NA,NA,NA
10.2147/jbm.s206806,31417326,methodology,4,NA,Type of population-adjusted indirect comparisons performed,NA,NA,MAIC,TRUE,NA,NA,NA
10.2147/jbm.s206806,31417326,methodology,4,NA,Anchored comparison?,NA,NA,No,TRUE,NA,NA,NA
10.2147/jbm.s206806,31417326,methodology,4,NA,Form of the indirect comparison,NA,NA,Simple (ie treatments effects extracted from two studies),TRUE,NA,NA,NA
10.2147/jbm.s206806,31417326,methodology,4,NA,Definition of a single primary outcome for the indirect comparison,NA,NA,"No primary outcome defined, or multiple primary outcomes without any clear distinction between them",TRUE,NA,NA,NA
10.2147/jbm.s206806,31417326,methodology,4,NA,Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined),NA,NA,annualized bleeding rate,TRUE,NA,NA,NA
10.2147/jbm.s206806,31417326,methodology,4,NA,Primary outcome: variable type,NA,NA,"Continuous (count, mean, ...)",TRUE,NA,NA,NA
10.2147/jbm.s206806,31417326,methodology,4,NA,Justification for selecting variables to be included in the adjustment model (in the main text),NA,NA,"Nothing mentioned, not reported",TRUE,NA,NA,NA
10.2147/jbm.s206806,31417326,methodology,4,NA,Inclusion of prognostic factors in the adjustment/matching model,NA,NA,No discussion (in the main text) of the status of prognostic factors of the variables,TRUE,NA,NA,NA
10.2147/jbm.s206806,31417326,methodology,4,NA,Inclusion of treatment-effect modifiers in the adjustment/matching model,NA,NA,No discussion (in the main text) of the status of treatment-effect modifiers of the variables,TRUE,NA,NA,NA
10.2147/jbm.s206806,31417326,methodology,4,NA,"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)",NA,NA,No,TRUE,NA,NA,NA
10.2147/jbm.s206806,31417326,methodology,4,NA,Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale),NA,NA,No,TRUE,NA,NA,NA
10.2147/jbm.s206806,31417326,results,1,NA,Sample size of the population of interest in the non IPD treatment arm,NA,NA,140,TRUE,NA,NA,NA
10.2147/jbm.s206806,31417326,results,1,NA,Initial sample size of the population of interest in the IPD treatment arm,NA,NA,103,TRUE,NA,NA,NA
10.2147/jbm.s206806,31417326,results,1,NA,"Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC",NA,NA,44.6,TRUE,NA,NA,NA
10.2147/jbm.s206806,31417326,results,1,NA,Reporting of a weights' distribution evaluation (MAIC),NA,NA,Not mentioned,TRUE,NA,NA,NA
10.2147/jbm.s206806,31417326,results,1,NA,Reporting of the list of the covariates adjusted for/matched on,Yes,No,Yes,FALSE,NA,NA,NA
10.2147/jbm.s206806,31417326,results,1,NA,Primary outcome: treatment effect contrast,NA,NA,Means difference,TRUE,NA,NA,NA
10.2147/jbm.s206806,31417326,results,1,NA,Direction of the treatment effect contrast: IPD treatment is:,NA,NA,"Numerator if ratio, or left side if difference",TRUE,NA,NA,NA
10.2147/jbm.s206806,31417326,results,1,NA,Primary outcome: unadjusted treatment effect,NA,NA,0.17,TRUE,NA,NA,NA
10.2147/jbm.s206806,31417326,results,1,NA,"p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])",NA,NA,[-1.35;1.70],TRUE,NA,NA,NA
10.2147/jbm.s206806,31417326,results,1,NA,Primary outcome: adjusted treatment effect,NA,NA,-0.12,TRUE,NA,NA,NA
10.2147/jbm.s206806,31417326,results,1,NA,"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])",NA,NA,[-1.62;1.37],TRUE,NA,NA,NA
10.2147/jbm.s206806,31417326,results,1,NA,Number of covariates adjusted for/matched on,7,NA,7,FALSE,NA,NA,NA
10.2147/jbm.s206806,31417326,results,1,NA,Covariates adjusted for/matched on in the indirect comparison,"Age, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Race/ethnicity, Past treatments for the disease of interest, Other(s)",NA,"Age, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Race/ethnicity, Past treatments for the disease of interest, Other(s)",FALSE,NA,NA,NA
10.2147/jbm.s206806,31417326,results,2,NA,Sample size of the population of interest in the non IPD treatment arm,NA,NA,101,TRUE,NA,NA,NA
10.2147/jbm.s206806,31417326,results,2,NA,Initial sample size of the population of interest in the IPD treatment arm,NA,NA,104,TRUE,NA,NA,NA
10.2147/jbm.s206806,31417326,results,2,NA,"Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC",NA,NA,78.3,TRUE,NA,NA,NA
10.2147/jbm.s206806,31417326,results,2,NA,Reporting of a weights' distribution evaluation (MAIC),NA,NA,Not mentioned,TRUE,NA,NA,NA
10.2147/jbm.s206806,31417326,results,2,NA,Reporting of the list of the covariates adjusted for/matched on,Yes,No,Yes,FALSE,NA,NA,NA
10.2147/jbm.s206806,31417326,results,2,NA,Primary outcome: treatment effect contrast,NA,NA,Means difference,TRUE,NA,NA,NA
10.2147/jbm.s206806,31417326,results,2,NA,Direction of the treatment effect contrast: IPD treatment is:,NA,NA,"Numerator if ratio, or left side if difference",TRUE,NA,NA,NA
10.2147/jbm.s206806,31417326,results,2,NA,Primary outcome: unadjusted treatment effect,NA,NA,0.35,TRUE,NA,NA,NA
10.2147/jbm.s206806,31417326,results,2,NA,"p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])",NA,NA,[-1.00;1.70],TRUE,NA,NA,NA
10.2147/jbm.s206806,31417326,results,2,NA,Primary outcome: adjusted treatment effect,NA,NA,0.25,TRUE,NA,NA,NA
10.2147/jbm.s206806,31417326,results,2,NA,"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])",NA,NA,[-1.19;1.70],TRUE,NA,NA,NA
10.2147/jbm.s206806,31417326,results,2,NA,Number of covariates adjusted for/matched on,5,NA,5,FALSE,NA,NA,NA
10.2147/jbm.s206806,31417326,results,2,NA,Covariates adjusted for/matched on in the indirect comparison,"Age, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Race/ethnicity, Past treatments for the disease of interest, Other(s)",NA,"Age, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Race/ethnicity, Past treatments for the disease of interest, Other(s)",FALSE,NA,NA,NA
10.2147/jbm.s206806,31417326,results,3,NA,Sample size of the population of interest in the non IPD treatment arm,66,107,66,FALSE,NA,NA,NA
10.2147/jbm.s206806,31417326,results,3,NA,Initial sample size of the population of interest in the IPD treatment arm,NA,NA,104,TRUE,NA,NA,NA
10.2147/jbm.s206806,31417326,results,3,NA,"Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC",78.3,25.32,25.32,FALSE,NA,NA,NA
10.2147/jbm.s206806,31417326,results,3,NA,Reporting of a weights' distribution evaluation (MAIC),NA,NA,Not mentioned,TRUE,NA,NA,NA
10.2147/jbm.s206806,31417326,results,3,NA,Reporting of the list of the covariates adjusted for/matched on,Yes,No,Yes,FALSE,NA,NA,NA
10.2147/jbm.s206806,31417326,results,3,NA,Primary outcome: treatment effect contrast,NA,NA,Means difference,TRUE,NA,NA,NA
10.2147/jbm.s206806,31417326,results,3,NA,Direction of the treatment effect contrast: IPD treatment is:,NA,NA,"Numerator if ratio, or left side if difference",TRUE,NA,NA,NA
10.2147/jbm.s206806,31417326,results,3,NA,Primary outcome: unadjusted treatment effect,NA,NA,-2.25,TRUE,NA,NA,NA
10.2147/jbm.s206806,31417326,results,3,NA,"p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])",[-3.64;-0.85],<0.01,[-3.64;-0.85],FALSE,NA,NA,NA
10.2147/jbm.s206806,31417326,results,3,NA,Primary outcome: adjusted treatment effect,NA,NA,-2.02,TRUE,NA,NA,NA
10.2147/jbm.s206806,31417326,results,3,NA,"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])",NA,NA,[-4.35;0.30],TRUE,NA,NA,NA
10.2147/jbm.s206806,31417326,results,3,NA,Number of covariates adjusted for/matched on,3,NA,3,FALSE,NA,NA,NA
10.2147/jbm.s206806,31417326,results,3,NA,Covariates adjusted for/matched on in the indirect comparison,"Age, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Race/ethnicity",NA,"Age, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Race/ethnicity",FALSE,NA,NA,NA
10.2147/jbm.s206806,31417326,results,4,NA,Sample size of the population of interest in the non IPD treatment arm,67,66,107,FALSE,NA,NA,NA
10.2147/jbm.s206806,31417326,results,4,NA,Initial sample size of the population of interest in the IPD treatment arm,NA,NA,104,TRUE,NA,NA,NA
10.2147/jbm.s206806,31417326,results,4,NA,"Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC",NA,NA,55.33,TRUE,NA,NA,NA
10.2147/jbm.s206806,31417326,results,4,NA,Reporting of a weights' distribution evaluation (MAIC),NA,NA,Not mentioned,TRUE,NA,NA,NA
10.2147/jbm.s206806,31417326,results,4,NA,Reporting of the list of the covariates adjusted for/matched on,Yes,No,Yes,FALSE,NA,NA,NA
10.2147/jbm.s206806,31417326,results,4,NA,Primary outcome: treatment effect contrast,NA,NA,Means difference,TRUE,NA,NA,NA
10.2147/jbm.s206806,31417326,results,4,NA,Direction of the treatment effect contrast: IPD treatment is:,NA,NA,"Numerator if ratio, or left side if difference",TRUE,NA,NA,NA
10.2147/jbm.s206806,31417326,results,4,NA,Primary outcome: unadjusted treatment effect,NA,NA,0.03,TRUE,NA,NA,NA
10.2147/jbm.s206806,31417326,results,4,NA,"p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])",NA,NA,[-0.32;0.37],TRUE,NA,NA,NA
10.2147/jbm.s206806,31417326,results,4,NA,Primary outcome: adjusted treatment effect,NA,NA,0.07,TRUE,NA,NA,NA
10.2147/jbm.s206806,31417326,results,4,NA,"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])",NA,NA,[-0.32;0.46],TRUE,NA,NA,NA
10.2147/jbm.s206806,31417326,results,4,NA,Number of covariates adjusted for/matched on,3,NA,3,FALSE,NA,NA,NA
10.2147/jbm.s206806,31417326,results,4,NA,Covariates adjusted for/matched on in the indirect comparison,"Age, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Race/ethnicity",NA,"Age, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Race/ethnicity",FALSE,NA,NA,NA
10.1007/s40263-019-00672-w,31642037,general_information,NA,NA,Medical Condition of Interest Name,NA,NA,postpartum depression,TRUE,NA,NA,NA
10.1007/s40263-019-00672-w,31642037,general_information,NA,NA,Countries of first author affiliations,NA,NA,uk,TRUE,NA,NA,NA
10.1007/s40263-019-00672-w,31642037,general_information,NA,NA,Countries of last author affiliations,NA,NA,usa,TRUE,NA,NA,NA
10.1007/s40263-019-00672-w,31642037,general_information,NA,NA,"Positions of study investigators (for any authors of the article, any that applies)",NA,NA,"Pharmaceutical Industry, Private Data Analysis Company",TRUE,NA,NA,NA
10.1007/s40263-019-00672-w,31642037,general_information,NA,NA,"At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company",NA,NA,Yes,TRUE,NA,NA,NA
10.1007/s40263-019-00672-w,31642037,general_information,NA,NA,Mentioned sources of funding,NA,NA,Pharmaceutical Industry,TRUE,NA,NA,NA
10.1007/s40263-019-00672-w,31642037,general_information,NA,NA,"Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article",NA,NA,Yes,TRUE,NA,NA,NA
10.1007/s40263-019-00672-w,31642037,general_information,NA,NA,Mention of a systematic review to find the studies to compare treatments of interest,NA,NA,Yes,TRUE,NA,NA,NA
10.1007/s40263-019-00672-w,31642037,study_information,NA,1,Patient-level data used,NA,NA,Yes,TRUE,NA,NA,NA
10.1007/s40263-019-00672-w,31642037,study_information,NA,1,Clinical Trial,NA,NA,Yes,TRUE,NA,NA,NA
10.1007/s40263-019-00672-w,31642037,study_information,NA,1,NCT (only for clinical trial registered on clinicaltrials.gov),NA,NA,NCT02614547,TRUE,NA,NA,NA
10.1007/s40263-019-00672-w,31642037,study_information,NA,1,Country where the clinical trial/observational study was conducted (international if more than one),NA,NA,usa,TRUE,NA,NA,NA
10.1007/s40263-019-00672-w,31642037,study_information,NA,1,Phase of the clinical trial (clinical trial only),NA,NA,2,TRUE,NA,NA,NA
10.1007/s40263-019-00672-w,31642037,study_information,NA,1,Number of treatment arms (clinical trial only),2 or more,1 or more,XXXX,FALSE,NA,NA,NA
10.1007/s40263-019-00672-w,31642037,study_information,NA,2,Patient-level data used,NA,NA,Yes,TRUE,NA,NA,NA
10.1007/s40263-019-00672-w,31642037,study_information,NA,2,Clinical Trial,NA,NA,Yes,TRUE,NA,NA,NA
10.1007/s40263-019-00672-w,31642037,study_information,NA,2,NCT (only for clinical trial registered on clinicaltrials.gov),NA,NA,NCT02942004,TRUE,NA,NA,NA
10.1007/s40263-019-00672-w,31642037,study_information,NA,2,Country where the clinical trial/observational study was conducted (international if more than one),NA,NA,usa,TRUE,NA,NA,NA
10.1007/s40263-019-00672-w,31642037,study_information,NA,2,Phase of the clinical trial (clinical trial only),NA,NA,3,TRUE,NA,NA,NA
10.1007/s40263-019-00672-w,31642037,study_information,NA,2,Number of treatment arms (clinical trial only),2 or more,1 or more,XXXX,FALSE,NA,NA,NA
10.1007/s40263-019-00672-w,31642037,study_information,NA,3,Patient-level data used,NA,NA,Yes,TRUE,NA,NA,NA
10.1007/s40263-019-00672-w,31642037,study_information,NA,3,Clinical Trial,NA,NA,Yes,TRUE,NA,NA,NA
10.1007/s40263-019-00672-w,31642037,study_information,NA,3,NCT (only for clinical trial registered on clinicaltrials.gov),NA,NA,NCT02942017,TRUE,NA,NA,NA
10.1007/s40263-019-00672-w,31642037,study_information,NA,3,Country where the clinical trial/observational study was conducted (international if more than one),NA,NA,usa,TRUE,NA,NA,NA
10.1007/s40263-019-00672-w,31642037,study_information,NA,3,Phase of the clinical trial (clinical trial only),NA,NA,3,TRUE,NA,NA,NA
10.1007/s40263-019-00672-w,31642037,study_information,NA,3,Number of treatment arms (clinical trial only),NA,NA,2 or more,TRUE,NA,NA,NA
10.1007/s40263-019-00672-w,31642037,study_information,NA,4,Patient-level data used,NA,NA,No,TRUE,NA,NA,NA
10.1007/s40263-019-00672-w,31642037,study_information,NA,4,Clinical Trial,NA,NA,Yes,TRUE,NA,NA,NA
10.1007/s40263-019-00672-w,31642037,study_information,NA,4,Data source name (only if observational study or clinical trial without NCT),NA,NA,yonkers et al. (2008),TRUE,NA,NA,NA
10.1007/s40263-019-00672-w,31642037,study_information,NA,4,Country where the clinical trial/observational study was conducted (international if more than one),NA,NA,usa,TRUE,NA,NA,NA
10.1007/s40263-019-00672-w,31642037,study_information,NA,4,Number of treatment arms (clinical trial only),NA,NA,2 or more,TRUE,NA,NA,NA
10.1007/s40263-019-00672-w,31642037,study_information,NA,5,Patient-level data used,NA,No,XXXX,FALSE,NA,NA,NA
10.1007/s40263-019-00672-w,31642037,study_information,NA,5,Clinical Trial,NA,Yes,XXXX,FALSE,NA,NA,NA
10.1007/s40263-019-00672-w,31642037,study_information,NA,5,Data source name (only if observational study or clinical trial without NCT),NA,sharp et al. (2010),sharp et al. (2010),FALSE,NA,NA,NA
10.1007/s40263-019-00672-w,31642037,study_information,NA,5,Country where the clinical trial/observational study was conducted (international if more than one),NA,uk,XXXX,FALSE,NA,NA,NA
10.1007/s40263-019-00672-w,31642037,study_information,NA,5,Number of treatment arms (clinical trial only),NA,2 or more,XXXX,FALSE,NA,NA,NA
10.1007/s40263-019-00672-w,31642037,methodology,1,NA,Treatment name 1,NA,NA,brexanolone,TRUE,"Performed in the context of a NMA, to connect to the NMA network be used with other ITC. Results extracted from supplemental Tables 4 and 6",Results and ESS from Supplementary materials,NA
10.1007/s40263-019-00672-w,31642037,methodology,1,NA,Study 'number(s)' for treatment 1,NA,NA,1;2;3,TRUE,NA,NA,NA
10.1007/s40263-019-00672-w,31642037,methodology,1,NA,Treatment name 2,NA,NA,placebo,TRUE,NA,NA,NA
10.1007/s40263-019-00672-w,31642037,methodology,1,NA,Study 'number(s)' for treatment 2,NA,NA,4,TRUE,NA,NA,NA
10.1007/s40263-019-00672-w,31642037,methodology,1,NA,Type of population-adjusted indirect comparisons performed,NA,NA,MAIC,TRUE,NA,NA,NA
10.1007/s40263-019-00672-w,31642037,methodology,1,NA,Anchored comparison?,NA,NA,No,TRUE,NA,NA,NA
10.1007/s40263-019-00672-w,31642037,methodology,1,NA,Form of the indirect comparison,NA,NA,"Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate)",TRUE,NA,NA,NA
10.1007/s40263-019-00672-w,31642037,methodology,1,NA,Definition of a single primary outcome for the indirect comparison,NA,NA,"No primary outcome defined, or multiple primary outcomes without any clear distinction between them",TRUE,NA,NA,NA
10.1007/s40263-019-00672-w,31642037,methodology,1,NA,Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined),change from baseline hamilton-depression scale,change from baseline for the hamilton rating scale for depression,change from baseline for the hamilton rating scale for depression,FALSE,NA,NA,NA
10.1007/s40263-019-00672-w,31642037,methodology,1,NA,Primary outcome: variable type,NA,NA,"Continuous (count, mean, ...)",TRUE,NA,NA,NA
10.1007/s40263-019-00672-w,31642037,methodology,1,NA,Justification for selecting variables to be included in the adjustment model (in the main text),NA,NA,"Nothing mentioned, not reported",TRUE,NA,NA,NA
10.1007/s40263-019-00672-w,31642037,methodology,1,NA,Inclusion of prognostic factors in the adjustment/matching model,NA,NA,No discussion (in the main text) of the status of prognostic factors of the variables,TRUE,NA,NA,NA
10.1007/s40263-019-00672-w,31642037,methodology,1,NA,Inclusion of treatment-effect modifiers in the adjustment/matching model,NA,NA,No discussion (in the main text) of the status of treatment-effect modifiers of the variables,TRUE,NA,NA,NA
10.1007/s40263-019-00672-w,31642037,methodology,1,NA,"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)",NA,NA,Yes,TRUE,NA,NA,NA
10.1007/s40263-019-00672-w,31642037,methodology,1,NA,Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale),NA,NA,No,TRUE,NA,NA,NA
10.1007/s40263-019-00672-w,31642037,results,1,NA,Sample size of the population of interest in the non IPD treatment arm,NA,NA,30,TRUE,NA,NA,NA
10.1007/s40263-019-00672-w,31642037,results,1,NA,"Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC",NA,NA,63.2,TRUE,NA,NA,NA
10.1007/s40263-019-00672-w,31642037,results,1,NA,Reporting of a weights' distribution evaluation (MAIC),NA,NA,Not mentioned,TRUE,NA,NA,NA
10.1007/s40263-019-00672-w,31642037,results,1,NA,Reporting of the list of the covariates adjusted for/matched on,NA,NA,Yes,TRUE,NA,NA,NA
10.1007/s40263-019-00672-w,31642037,results,1,NA,Number of covariates adjusted for/matched on,NA,NA,3,TRUE,NA,NA,NA
10.1007/s40263-019-00672-w,31642037,results,1,NA,Covariates adjusted for/matched on in the indirect comparison,NA,NA,"Age, Race/ethnicity, Past treatments for the disease of interest",TRUE,NA,NA,NA
10.1007/s40263-019-00672-w,31642037,results,1,NA,Primary outcome: treatment effect contrast,NA,NA,Means difference,TRUE,NA,NA,NA
10.1007/s40263-019-00672-w,31642037,results,1,NA,Direction of the treatment effect contrast: IPD treatment is:,NA,NA,"Numerator if ratio, or left side if difference",TRUE,NA,NA,NA
10.1007/s40263-019-00672-w,31642037,results,1,NA,Primary outcome: unadjusted treatment effect,3.8,NA,3.8,FALSE,NA,NA,NA
10.1007/s40263-019-00672-w,31642037,results,1,NA,"p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])",[1.86;5.74],NA,[1.86;5.74],FALSE,NA,NA,NA
10.1007/s40263-019-00672-w,31642037,results,1,NA,Primary outcome: adjusted treatment effect,13.9,-13.9,13.9,FALSE,NA,NA,NA
10.1007/s40263-019-00672-w,31642037,results,1,NA,"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])",[9.84;17.10],[-15.5;-12.3],[9.84;17.10],FALSE,NA,NA,NA
10.1080/10428194.2019.1675881,31686561,general_information,NA,NA,Medical Condition of Interest Name,transplant ineligible multiple myeloma,multiple myeloma,XXXX,FALSE,NA,NA,NA
10.1080/10428194.2019.1675881,31686561,general_information,NA,NA,Countries of first author affiliations,NA,NA,spain,TRUE,NA,NA,NA
10.1080/10428194.2019.1675881,31686561,general_information,NA,NA,Countries of last author affiliations,NA,NA,usa,TRUE,NA,NA,NA
10.1080/10428194.2019.1675881,31686561,general_information,NA,NA,"Positions of study investigators (for any authors of the article, any that applies)",NA,NA,"Academic, Pharmaceutical Industry, Private Data Analysis Company",TRUE,NA,NA,NA
10.1080/10428194.2019.1675881,31686561,general_information,NA,NA,"At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company",NA,NA,Yes,TRUE,NA,NA,NA
10.1080/10428194.2019.1675881,31686561,general_information,NA,NA,Mentioned sources of funding,NA,NA,Pharmaceutical Industry,TRUE,NA,NA,NA
10.1080/10428194.2019.1675881,31686561,general_information,NA,NA,"Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article",NA,NA,Yes,TRUE,NA,NA,NA
10.1080/10428194.2019.1675881,31686561,general_information,NA,NA,Mention of a systematic review to find the studies to compare treatments of interest,NA,NA,Yes,TRUE,NA,NA,NA
10.1080/10428194.2019.1675881,31686561,study_information,NA,1,Patient-level data used,NA,NA,Yes,TRUE,NA,NA,NA
10.1080/10428194.2019.1675881,31686561,study_information,NA,1,Clinical Trial,NA,NA,Yes,TRUE,NA,NA,NA
10.1080/10428194.2019.1675881,31686561,study_information,NA,1,NCT (only for clinical trial registered on clinicaltrials.gov),NA,NA,NCT00111319,TRUE,NA,NA,NA
10.1080/10428194.2019.1675881,31686561,study_information,NA,1,Country where the clinical trial/observational study was conducted (international if more than one),NA,NA,usa,TRUE,NA,NA,NA
10.1080/10428194.2019.1675881,31686561,study_information,NA,1,Phase of the clinical trial (clinical trial only),NA,NA,3,TRUE,NA,NA,NA
10.1080/10428194.2019.1675881,31686561,study_information,NA,1,Number of treatment arms (clinical trial only),NA,NA,2 or more,TRUE,NA,NA,NA
10.1080/10428194.2019.1675881,31686561,study_information,NA,2,Patient-level data used,NA,NA,No,TRUE,NA,NA,NA
10.1080/10428194.2019.1675881,31686561,study_information,NA,2,Clinical Trial,NA,NA,Yes,TRUE,NA,NA,NA
10.1080/10428194.2019.1675881,31686561,study_information,NA,2,NCT (only for clinical trial registered on clinicaltrials.gov),NA,NA,NCT02195479,TRUE,NA,NA,NA
10.1080/10428194.2019.1675881,31686561,study_information,NA,2,Country where the clinical trial/observational study was conducted (international if more than one),NA,NA,international,TRUE,NA,NA,NA
10.1080/10428194.2019.1675881,31686561,study_information,NA,2,Phase of the clinical trial (clinical trial only),NA,NA,3,TRUE,NA,NA,NA
10.1080/10428194.2019.1675881,31686561,study_information,NA,2,Number of treatment arms (clinical trial only),NA,NA,2 or more,TRUE,NA,NA,NA
10.1080/10428194.2019.1675881,31686561,study_information,NA,3,Patient-level data used,NA,NA,No,TRUE,NA,NA,NA
10.1080/10428194.2019.1675881,31686561,study_information,NA,3,Clinical Trial,NA,NA,Yes,TRUE,NA,NA,NA
10.1080/10428194.2019.1675881,31686561,study_information,NA,3,NCT (only for clinical trial registered on clinicaltrials.gov),NA,NA,NCT01063179,TRUE,NA,NA,NA
10.1080/10428194.2019.1675881,31686561,study_information,NA,3,Country where the clinical trial/observational study was conducted (international if more than one),NA,NA,italy,TRUE,NA,NA,NA
10.1080/10428194.2019.1675881,31686561,study_information,NA,3,Phase of the clinical trial (clinical trial only),NA,NA,3,TRUE,NA,NA,NA
10.1080/10428194.2019.1675881,31686561,study_information,NA,3,Number of treatment arms (clinical trial only),NA,NA,2 or more,TRUE,NA,NA,NA
10.1080/10428194.2019.1675881,31686561,methodology,1,NA,Treatment name 1,bortezomib-melphalan-prednisone,vmp (bortezomib/melphalan/prednisone),vmp (bortezomib/melphalan/prednisone),FALSE,Has access to IPD for some of the NONIPD studies,"""these variables were reported and extracted from a previous study""

MAIC's weights distribution  : Min, Max, Meand, median, Q1, Q3
Clairance créat = comorbidité
",NA
10.1080/10428194.2019.1675881,31686561,methodology,1,NA,Study 'number(s)' for treatment 1,NA,NA,1,TRUE,NA,NA,NA
10.1080/10428194.2019.1675881,31686561,methodology,1,NA,Treatment name 2,modified bortezomib-melphalan-prednisone schedules,modified vmp schedule,modified vmp schedule,FALSE,NA,NA,NA
10.1080/10428194.2019.1675881,31686561,methodology,1,NA,Study 'number(s)' for treatment 2,NA,NA,2;3,TRUE,NA,NA,NA
10.1080/10428194.2019.1675881,31686561,methodology,1,NA,Type of population-adjusted indirect comparisons performed,NA,NA,MAIC,TRUE,NA,NA,NA
10.1080/10428194.2019.1675881,31686561,methodology,1,NA,Anchored comparison?,NA,NA,No,TRUE,NA,NA,NA
10.1080/10428194.2019.1675881,31686561,methodology,1,NA,Form of the indirect comparison,NA,NA,"Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate)",TRUE,NA,NA,NA
10.1080/10428194.2019.1675881,31686561,methodology,1,NA,Definition of a single primary outcome for the indirect comparison,NA,NA,"No primary outcome defined, or multiple primary outcomes without any clear distinction between them",TRUE,NA,NA,NA
10.1080/10428194.2019.1675881,31686561,methodology,1,NA,Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined),progression free survival,progression-free survival,progression-free survival,FALSE,NA,NA,NA
10.1080/10428194.2019.1675881,31686561,methodology,1,NA,Primary outcome: variable type,NA,NA,Time-to-event,TRUE,NA,NA,NA
10.1080/10428194.2019.1675881,31686561,methodology,1,NA,Justification for selecting variables to be included in the adjustment model (in the main text),NA,NA,Literature based (clinically or methodologically relevant to adjust on these variables based on the literature search conducted for this specific purpose),TRUE,NA,NA,NA
10.1080/10428194.2019.1675881,31686561,methodology,1,NA,Inclusion of prognostic factors in the adjustment/matching model,NA,NA,Yes,TRUE,NA,NA,NA
10.1080/10428194.2019.1675881,31686561,methodology,1,NA,Inclusion of treatment-effect modifiers in the adjustment/matching model,NA,NA,Yes,TRUE,NA,NA,NA
10.1080/10428194.2019.1675881,31686561,methodology,1,NA,"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)",NA,NA,No,TRUE,NA,NA,NA
10.1080/10428194.2019.1675881,31686561,methodology,1,NA,Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale),NA,NA,No,TRUE,NA,NA,NA
10.1080/10428194.2019.1675881,31686561,results,1,NA,Sample size of the population of interest in the non IPD treatment arm,NA,NA,547,TRUE,NA,NA,NA
10.1080/10428194.2019.1675881,31686561,results,1,NA,Initial sample size of the population of interest in the IPD treatment arm,NA,NA,344,TRUE,NA,NA,NA
10.1080/10428194.2019.1675881,31686561,results,1,NA,"Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC",NA,NA,114,TRUE,NA,NA,NA
10.1080/10428194.2019.1675881,31686561,results,1,NA,Reporting of a weights' distribution evaluation (MAIC),Not mentioned,"Yes, mentions that the weights distribution has been studied, and weights distribution reported in main article or supplemental materials","Yes, mentions that the weights distribution has been studied, and weights distribution reported in main article or supplemental materials",FALSE,NA,NA,NA
10.1080/10428194.2019.1675881,31686561,results,1,NA,Reporting of the list of the covariates adjusted for/matched on,NA,NA,Yes,TRUE,NA,NA,NA
10.1080/10428194.2019.1675881,31686561,results,1,NA,Number of covariates adjusted for/matched on,NA,NA,8,TRUE,NA,NA,NA
10.1080/10428194.2019.1675881,31686561,results,1,NA,Covariates adjusted for/matched on in the indirect comparison,NA,NA,"Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Comorbidities and medical history (beside pathology/disease of interest in the comparison)",TRUE,NA,NA,NA
10.1080/10428194.2019.1675881,31686561,results,1,NA,Primary outcome: treatment effect contrast,NA,NA,HR,TRUE,NA,NA,NA
10.1080/10428194.2019.1675881,31686561,results,1,NA,Direction of the treatment effect contrast: IPD treatment is:,"Numerator if ratio, or left side if difference","Denominator if ratio, or rightside if difference","Numerator if ratio, or left side if difference",FALSE,NA,NA,NA
10.1080/10428194.2019.1675881,31686561,results,1,NA,Primary outcome: unadjusted treatment effect,NA,NA,0.911,TRUE,NA,NA,NA
10.1080/10428194.2019.1675881,31686561,results,1,NA,"p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])",NA,NA,0.326,TRUE,NA,NA,NA
10.1080/10428194.2019.1675881,31686561,results,1,NA,Primary outcome: adjusted treatment effect,NA,NA,0.991,TRUE,NA,NA,NA
10.1080/10428194.2019.1675881,31686561,results,1,NA,"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])",NA,NA,0.935,TRUE,NA,NA,NA
10.1016/j.clinthera.2019.09.012,31699438,general_information,NA,NA,Medical Condition of Interest Name,NA,NA,relapsed/refractory mantle cell lymphoma,TRUE,NA,NA,NA
10.1016/j.clinthera.2019.09.012,31699438,general_information,NA,NA,Countries of first author affiliations,NA,NA,usa,TRUE,NA,NA,NA
10.1016/j.clinthera.2019.09.012,31699438,general_information,NA,NA,Countries of last author affiliations,NA,NA,usa,TRUE,NA,NA,NA
10.1016/j.clinthera.2019.09.012,31699438,general_information,NA,NA,"Positions of study investigators (for any authors of the article, any that applies)",NA,NA,"Pharmaceutical Industry, Private Data Analysis Company",TRUE,NA,NA,NA
10.1016/j.clinthera.2019.09.012,31699438,general_information,NA,NA,"At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company",NA,NA,Yes,TRUE,NA,NA,NA
10.1016/j.clinthera.2019.09.012,31699438,general_information,NA,NA,Mentioned sources of funding,NA,NA,Pharmaceutical Industry,TRUE,NA,NA,NA
10.1016/j.clinthera.2019.09.012,31699438,general_information,NA,NA,"Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article",NA,NA,Yes,TRUE,NA,NA,NA
10.1016/j.clinthera.2019.09.012,31699438,general_information,NA,NA,Mention of a systematic review to find the studies to compare treatments of interest,NA,NA,Yes,TRUE,NA,NA,NA
10.1016/j.clinthera.2019.09.012,31699438,study_information,NA,1,Patient-level data used,NA,NA,Yes,TRUE,NA,NA,NA
10.1016/j.clinthera.2019.09.012,31699438,study_information,NA,1,Clinical Trial,NA,NA,Yes,TRUE,NA,NA,NA
10.1016/j.clinthera.2019.09.012,31699438,study_information,NA,1,NCT (only for clinical trial registered on clinicaltrials.gov),NA,NA,NCT02213926,TRUE,NA,NA,NA
10.1016/j.clinthera.2019.09.012,31699438,study_information,NA,1,Country where the clinical trial/observational study was conducted (international if more than one),NA,NA,international,TRUE,NA,NA,NA
10.1016/j.clinthera.2019.09.012,31699438,study_information,NA,1,Phase of the clinical trial (clinical trial only),NA,NA,2,TRUE,NA,NA,NA
10.1016/j.clinthera.2019.09.012,31699438,study_information,NA,1,Number of treatment arms (clinical trial only),NA,NA,1,TRUE,NA,NA,NA
10.1016/j.clinthera.2019.09.012,31699438,study_information,NA,10,Patient-level data used,NA,NA,No,TRUE,NA,NA,NA
10.1016/j.clinthera.2019.09.012,31699438,study_information,NA,10,Clinical Trial,NA,NA,Yes,TRUE,NA,NA,NA
10.1016/j.clinthera.2019.09.012,31699438,study_information,NA,10,NCT (only for clinical trial registered on clinicaltrials.gov),NA,NA,NCT01880567,TRUE,NA,NA,NA
10.1016/j.clinthera.2019.09.012,31699438,study_information,NA,10,Country where the clinical trial/observational study was conducted (international if more than one),NA,NA,usa,TRUE,NA,NA,NA
10.1016/j.clinthera.2019.09.012,31699438,study_information,NA,10,Phase of the clinical trial (clinical trial only),NA,NA,2,TRUE,NA,NA,NA
10.1016/j.clinthera.2019.09.012,31699438,study_information,NA,10,Number of treatment arms (clinical trial only),NA,NA,1,TRUE,NA,NA,NA
10.1016/j.clinthera.2019.09.012,31699438,study_information,NA,11,Patient-level data used,NA,NA,No,TRUE,NA,NA,NA
10.1016/j.clinthera.2019.09.012,31699438,study_information,NA,11,Clinical Trial,NA,NA,Yes,TRUE,NA,NA,NA
10.1016/j.clinthera.2019.09.012,31699438,study_information,NA,11,Data source name (only if observational study or clinical trial without NCT),NA,NA,czuczman 2015,TRUE,NA,NA,NA
10.1016/j.clinthera.2019.09.012,31699438,study_information,NA,11,Phase of the clinical trial (clinical trial only),NA,NA,2,TRUE,NA,NA,NA
10.1016/j.clinthera.2019.09.012,31699438,study_information,NA,11,Number of treatment arms (clinical trial only),NA,NA,1,TRUE,NA,NA,NA
10.1016/j.clinthera.2019.09.012,31699438,study_information,NA,11,Country where the clinical trial/observational study was conducted (international if more than one),unknown,NA,XXXX,FALSE,NA,NA,NA
10.1016/j.clinthera.2019.09.012,31699438,study_information,NA,12,Patient-level data used,NA,NA,No,TRUE,NA,NA,NA
10.1016/j.clinthera.2019.09.012,31699438,study_information,NA,12,Clinical Trial,NA,NA,Yes,TRUE,NA,NA,NA
10.1016/j.clinthera.2019.09.012,31699438,study_information,NA,12,NCT (only for clinical trial registered on clinicaltrials.gov),NA,NA,NCT00294632,TRUE,NA,NA,NA
10.1016/j.clinthera.2019.09.012,31699438,study_information,NA,12,Country where the clinical trial/observational study was conducted (international if more than one),NA,NA,usa,TRUE,NA,NA,NA
10.1016/j.clinthera.2019.09.012,31699438,study_information,NA,12,Phase of the clinical trial (clinical trial only),NA,NA,"1, 2",TRUE,NA,NA,NA
10.1016/j.clinthera.2019.09.012,31699438,study_information,NA,12,Number of treatment arms (clinical trial only),NA,NA,1,TRUE,NA,NA,NA
10.1016/j.clinthera.2019.09.012,31699438,study_information,NA,2,Patient-level data used,NA,NA,No,TRUE,NA,NA,NA
10.1016/j.clinthera.2019.09.012,31699438,study_information,NA,2,Clinical Trial,NA,NA,Yes,TRUE,NA,NA,NA
10.1016/j.clinthera.2019.09.012,31699438,study_information,NA,2,NCT (only for clinical trial registered on clinicaltrials.gov),NA,NA,NCT01646021,TRUE,NA,NA,NA
10.1016/j.clinthera.2019.09.012,31699438,study_information,NA,2,Country where the clinical trial/observational study was conducted (international if more than one),NA,NA,international,TRUE,NA,NA,NA
10.1016/j.clinthera.2019.09.012,31699438,study_information,NA,2,Phase of the clinical trial (clinical trial only),NA,NA,3,TRUE,NA,NA,NA
10.1016/j.clinthera.2019.09.012,31699438,study_information,NA,2,Number of treatment arms (clinical trial only),NA,NA,2 or more,TRUE,NA,NA,NA
10.1016/j.clinthera.2019.09.012,31699438,study_information,NA,3,Patient-level data used,NA,NA,No,TRUE,NA,NA,NA
10.1016/j.clinthera.2019.09.012,31699438,study_information,NA,3,Clinical Trial,NA,NA,Yes,TRUE,NA,NA,NA
10.1016/j.clinthera.2019.09.012,31699438,study_information,NA,3,NCT (only for clinical trial registered on clinicaltrials.gov),NA,NA,NCT01236391,TRUE,NA,NA,NA
10.1016/j.clinthera.2019.09.012,31699438,study_information,NA,3,Country where the clinical trial/observational study was conducted (international if more than one),NA,NA,international,TRUE,NA,NA,NA
10.1016/j.clinthera.2019.09.012,31699438,study_information,NA,3,Phase of the clinical trial (clinical trial only),NA,NA,2,TRUE,NA,NA,NA
10.1016/j.clinthera.2019.09.012,31699438,study_information,NA,3,Number of treatment arms (clinical trial only),NA,NA,1,TRUE,NA,NA,NA
10.1016/j.clinthera.2019.09.012,31699438,study_information,NA,4,Patient-level data used,NA,NA,No,TRUE,NA,NA,NA
10.1016/j.clinthera.2019.09.012,31699438,study_information,NA,4,Clinical Trial,NA,NA,Yes,TRUE,NA,NA,NA
10.1016/j.clinthera.2019.09.012,31699438,study_information,NA,4,NCT (only for clinical trial registered on clinicaltrials.gov),NA,NA,NCT01599949,TRUE,NA,NA,NA
10.1016/j.clinthera.2019.09.012,31699438,study_information,NA,4,Country where the clinical trial/observational study was conducted (international if more than one),NA,NA,international,TRUE,NA,NA,NA
10.1016/j.clinthera.2019.09.012,31699438,study_information,NA,4,Phase of the clinical trial (clinical trial only),NA,NA,2,TRUE,NA,NA,NA
10.1016/j.clinthera.2019.09.012,31699438,study_information,NA,4,Number of treatment arms (clinical trial only),NA,NA,1,TRUE,NA,NA,NA
10.1016/j.clinthera.2019.09.012,31699438,study_information,NA,5,Patient-level data used,NA,NA,No,TRUE,NA,NA,NA
10.1016/j.clinthera.2019.09.012,31699438,study_information,NA,5,Clinical Trial,NA,NA,Yes,TRUE,NA,NA,NA
10.1016/j.clinthera.2019.09.012,31699438,study_information,NA,5,Data source name (only if observational study or clinical trial without NCT),NA,NA,pinnacle,TRUE,NA,NA,NA
10.1016/j.clinthera.2019.09.012,31699438,study_information,NA,5,Country where the clinical trial/observational study was conducted (international if more than one),NA,NA,international,TRUE,NA,NA,NA
10.1016/j.clinthera.2019.09.012,31699438,study_information,NA,5,Phase of the clinical trial (clinical trial only),NA,NA,2,TRUE,NA,NA,NA
10.1016/j.clinthera.2019.09.012,31699438,study_information,NA,5,Number of treatment arms (clinical trial only),NA,NA,1,TRUE,NA,NA,NA
10.1016/j.clinthera.2019.09.012,31699438,study_information,NA,6,Patient-level data used,NA,NA,No,TRUE,NA,NA,NA
10.1016/j.clinthera.2019.09.012,31699438,study_information,NA,6,Clinical Trial,NA,NA,Yes,TRUE,NA,NA,NA
10.1016/j.clinthera.2019.09.012,31699438,study_information,NA,6,NCT (only for clinical trial registered on clinicaltrials.gov),NA,NA,NCT00875667,TRUE,NA,NA,NA
10.1016/j.clinthera.2019.09.012,31699438,study_information,NA,6,Country where the clinical trial/observational study was conducted (international if more than one),NA,NA,international,TRUE,NA,NA,NA
10.1016/j.clinthera.2019.09.012,31699438,study_information,NA,6,Phase of the clinical trial (clinical trial only),NA,NA,2,TRUE,NA,NA,NA
10.1016/j.clinthera.2019.09.012,31699438,study_information,NA,6,Number of treatment arms (clinical trial only),NA,NA,2 or more,TRUE,NA,NA,NA
10.1016/j.clinthera.2019.09.012,31699438,study_information,NA,7,Patient-level data used,NA,NA,No,TRUE,NA,NA,NA
10.1016/j.clinthera.2019.09.012,31699438,study_information,NA,7,Clinical Trial,NA,NA,Yes,TRUE,NA,NA,NA
10.1016/j.clinthera.2019.09.012,31699438,study_information,NA,7,NCT (only for clinical trial registered on clinicaltrials.gov),NA,NA,NCT00737529,TRUE,NA,NA,NA
10.1016/j.clinthera.2019.09.012,31699438,study_information,NA,7,Country where the clinical trial/observational study was conducted (international if more than one),NA,NA,international,TRUE,NA,NA,NA
10.1016/j.clinthera.2019.09.012,31699438,study_information,NA,7,Phase of the clinical trial (clinical trial only),NA,NA,2,TRUE,NA,NA,NA
10.1016/j.clinthera.2019.09.012,31699438,study_information,NA,7,Number of treatment arms (clinical trial only),NA,NA,1,TRUE,NA,NA,NA
10.1016/j.clinthera.2019.09.012,31699438,study_information,NA,8,Patient-level data used,NA,NA,No,TRUE,NA,NA,NA
10.1016/j.clinthera.2019.09.012,31699438,study_information,NA,8,Clinical Trial,NA,NA,Yes,TRUE,NA,NA,NA
10.1016/j.clinthera.2019.09.012,31699438,study_information,NA,8,NCT (only for clinical trial registered on clinicaltrials.gov),NA,NA,NCT00117598,TRUE,NA,NA,NA
10.1016/j.clinthera.2019.09.012,31699438,study_information,NA,8,Country where the clinical trial/observational study was conducted (international if more than one),NA,NA,international,TRUE,NA,NA,NA
10.1016/j.clinthera.2019.09.012,31699438,study_information,NA,8,Phase of the clinical trial (clinical trial only),NA,NA,3,TRUE,NA,NA,NA
10.1016/j.clinthera.2019.09.012,31699438,study_information,NA,8,Number of treatment arms (clinical trial only),NA,NA,2 or more,TRUE,NA,NA,NA
10.1016/j.clinthera.2019.09.012,31699438,study_information,NA,9,Patient-level data used,NA,NA,No,TRUE,NA,NA,NA
10.1016/j.clinthera.2019.09.012,31699438,study_information,NA,9,Clinical Trial,NA,NA,Yes,TRUE,NA,NA,NA
10.1016/j.clinthera.2019.09.012,31699438,study_information,NA,9,NCT (only for clinical trial registered on clinicaltrials.gov),NA,NA,NCT01180049,TRUE,NA,NA,NA
10.1016/j.clinthera.2019.09.012,31699438,study_information,NA,9,Country where the clinical trial/observational study was conducted (international if more than one),NA,NA,international,TRUE,NA,NA,NA
10.1016/j.clinthera.2019.09.012,31699438,study_information,NA,9,Phase of the clinical trial (clinical trial only),NA,NA,4,TRUE,NA,NA,NA
10.1016/j.clinthera.2019.09.012,31699438,study_information,NA,9,Number of treatment arms (clinical trial only),NA,NA,2 or more,TRUE,NA,NA,NA
10.1016/j.clinthera.2019.09.012,31699438,methodology,1,NA,Treatment name 1,NA,NA,acalabrutinib,TRUE,NA,Studies 1 to 5   Studies from 6 to 10,NA
10.1016/j.clinthera.2019.09.012,31699438,methodology,1,NA,Study 'number(s)' for treatment 1,NA,NA,1,TRUE,NA,NA,NA
10.1016/j.clinthera.2019.09.012,31699438,methodology,1,NA,Treatment name 2,NA,NA,ibrutinib,TRUE,NA,NA,NA
10.1016/j.clinthera.2019.09.012,31699438,methodology,1,NA,Study 'number(s)' for treatment 2,NA,NA,2;3;4,TRUE,NA,NA,NA
10.1016/j.clinthera.2019.09.012,31699438,methodology,1,NA,Type of population-adjusted indirect comparisons performed,NA,NA,MAIC,TRUE,NA,NA,NA
10.1016/j.clinthera.2019.09.012,31699438,methodology,1,NA,Anchored comparison?,NA,NA,No,TRUE,NA,NA,NA
10.1016/j.clinthera.2019.09.012,31699438,methodology,1,NA,Form of the indirect comparison,NA,NA,"Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate)",TRUE,NA,NA,NA
10.1016/j.clinthera.2019.09.012,31699438,methodology,1,NA,Definition of a single primary outcome for the indirect comparison,NA,NA,"No primary outcome defined, or multiple primary outcomes without any clear distinction between them",TRUE,NA,NA,NA
10.1016/j.clinthera.2019.09.012,31699438,methodology,1,NA,Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined),overall response rate,objective response rate,overall response rate,FALSE,NA,NA,NA
10.1016/j.clinthera.2019.09.012,31699438,methodology,1,NA,Primary outcome: variable type,NA,NA,Binary (eg rates),TRUE,NA,NA,NA
10.1016/j.clinthera.2019.09.012,31699438,methodology,1,NA,Justification for selecting variables to be included in the adjustment model (in the main text),NA,NA,A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion),TRUE,NA,NA,NA
10.1016/j.clinthera.2019.09.012,31699438,methodology,1,NA,Inclusion of prognostic factors in the adjustment/matching model,NA,NA,No discussion (in the main text) of the status of prognostic factors of the variables,TRUE,NA,NA,NA
10.1016/j.clinthera.2019.09.012,31699438,methodology,1,NA,Inclusion of treatment-effect modifiers in the adjustment/matching model,NA,NA,No discussion (in the main text) of the status of treatment-effect modifiers of the variables,TRUE,NA,NA,NA
10.1016/j.clinthera.2019.09.012,31699438,methodology,1,NA,"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)",NA,NA,No,TRUE,NA,NA,NA
10.1016/j.clinthera.2019.09.012,31699438,methodology,1,NA,Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale),NA,NA,No,TRUE,NA,NA,NA
10.1016/j.clinthera.2019.09.012,31699438,methodology,2,NA,Treatment name 1,NA,NA,acalabrutinib,TRUE,NA,NA,NA
10.1016/j.clinthera.2019.09.012,31699438,methodology,2,NA,Study 'number(s)' for treatment 1,NA,NA,1,TRUE,NA,NA,NA
10.1016/j.clinthera.2019.09.012,31699438,methodology,2,NA,Treatment name 2,NA,NA,bortezomib,TRUE,NA,NA,NA
10.1016/j.clinthera.2019.09.012,31699438,methodology,2,NA,Study 'number(s)' for treatment 2,NA,NA,5,TRUE,NA,NA,NA
10.1016/j.clinthera.2019.09.012,31699438,methodology,2,NA,Type of population-adjusted indirect comparisons performed,NA,NA,MAIC,TRUE,NA,NA,NA
10.1016/j.clinthera.2019.09.012,31699438,methodology,2,NA,Anchored comparison?,NA,NA,No,TRUE,NA,NA,NA
10.1016/j.clinthera.2019.09.012,31699438,methodology,2,NA,Form of the indirect comparison,NA,NA,Simple (ie treatments effects extracted from two studies),TRUE,NA,NA,NA
10.1016/j.clinthera.2019.09.012,31699438,methodology,2,NA,Definition of a single primary outcome for the indirect comparison,NA,NA,"No primary outcome defined, or multiple primary outcomes without any clear distinction between them",TRUE,NA,NA,NA
10.1016/j.clinthera.2019.09.012,31699438,methodology,2,NA,Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined),overall response rate,objective response rate,overall response rate,FALSE,NA,NA,NA
10.1016/j.clinthera.2019.09.012,31699438,methodology,2,NA,Primary outcome: variable type,NA,NA,Binary (eg rates),TRUE,NA,NA,NA
10.1016/j.clinthera.2019.09.012,31699438,methodology,2,NA,Justification for selecting variables to be included in the adjustment model (in the main text),NA,NA,A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion),TRUE,NA,NA,NA
10.1016/j.clinthera.2019.09.012,31699438,methodology,2,NA,Inclusion of prognostic factors in the adjustment/matching model,NA,NA,No discussion (in the main text) of the status of prognostic factors of the variables,TRUE,NA,NA,NA
10.1016/j.clinthera.2019.09.012,31699438,methodology,2,NA,Inclusion of treatment-effect modifiers in the adjustment/matching model,NA,NA,No discussion (in the main text) of the status of treatment-effect modifiers of the variables,TRUE,NA,NA,NA
10.1016/j.clinthera.2019.09.012,31699438,methodology,2,NA,"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)",NA,NA,No,TRUE,NA,NA,NA
10.1016/j.clinthera.2019.09.012,31699438,methodology,2,NA,Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale),NA,NA,No,TRUE,NA,NA,NA
10.1016/j.clinthera.2019.09.012,31699438,methodology,3,NA,Treatment name 1,NA,NA,acalabrutinib,TRUE,NA,NA,NA
10.1016/j.clinthera.2019.09.012,31699438,methodology,3,NA,Study 'number(s)' for treatment 1,NA,NA,1,TRUE,NA,NA,NA
10.1016/j.clinthera.2019.09.012,31699438,methodology,3,NA,Treatment name 2,NA,NA,lenalidomide,TRUE,NA,NA,NA
10.1016/j.clinthera.2019.09.012,31699438,methodology,3,NA,Study 'number(s)' for treatment 2,NA,NA,6;7,TRUE,NA,NA,NA
10.1016/j.clinthera.2019.09.012,31699438,methodology,3,NA,Type of population-adjusted indirect comparisons performed,NA,NA,MAIC,TRUE,NA,NA,NA
10.1016/j.clinthera.2019.09.012,31699438,methodology,3,NA,Anchored comparison?,NA,NA,No,TRUE,NA,NA,NA
10.1016/j.clinthera.2019.09.012,31699438,methodology,3,NA,Form of the indirect comparison,NA,NA,"Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate)",TRUE,NA,NA,NA
10.1016/j.clinthera.2019.09.012,31699438,methodology,3,NA,Definition of a single primary outcome for the indirect comparison,NA,NA,"No primary outcome defined, or multiple primary outcomes without any clear distinction between them",TRUE,NA,NA,NA
10.1016/j.clinthera.2019.09.012,31699438,methodology,3,NA,Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined),overall response rate,objective response rate,overall response rate,FALSE,NA,NA,NA
10.1016/j.clinthera.2019.09.012,31699438,methodology,3,NA,Primary outcome: variable type,NA,NA,Binary (eg rates),TRUE,NA,NA,NA
10.1016/j.clinthera.2019.09.012,31699438,methodology,3,NA,Justification for selecting variables to be included in the adjustment model (in the main text),NA,NA,A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion),TRUE,NA,NA,NA
10.1016/j.clinthera.2019.09.012,31699438,methodology,3,NA,Inclusion of prognostic factors in the adjustment/matching model,NA,NA,No discussion (in the main text) of the status of prognostic factors of the variables,TRUE,NA,NA,NA
10.1016/j.clinthera.2019.09.012,31699438,methodology,3,NA,Inclusion of treatment-effect modifiers in the adjustment/matching model,NA,NA,No discussion (in the main text) of the status of treatment-effect modifiers of the variables,TRUE,NA,NA,NA
10.1016/j.clinthera.2019.09.012,31699438,methodology,3,NA,"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)",NA,NA,No,TRUE,NA,NA,NA
10.1016/j.clinthera.2019.09.012,31699438,methodology,3,NA,Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale),NA,NA,No,TRUE,NA,NA,NA
10.1016/j.clinthera.2019.09.012,31699438,methodology,4,NA,Treatment name 1,NA,NA,acalabrutinib,TRUE,NA,NA,NA
10.1016/j.clinthera.2019.09.012,31699438,methodology,4,NA,Study 'number(s)' for treatment 1,NA,NA,1,TRUE,NA,NA,NA
10.1016/j.clinthera.2019.09.012,31699438,methodology,4,NA,Treatment name 2,NA,NA,temsirolimus,TRUE,NA,NA,NA
10.1016/j.clinthera.2019.09.012,31699438,methodology,4,NA,Study 'number(s)' for treatment 2,NA,NA,2;8;9,TRUE,NA,NA,NA
10.1016/j.clinthera.2019.09.012,31699438,methodology,4,NA,Type of population-adjusted indirect comparisons performed,NA,NA,MAIC,TRUE,NA,NA,NA
10.1016/j.clinthera.2019.09.012,31699438,methodology,4,NA,Anchored comparison?,NA,NA,No,TRUE,NA,NA,NA
10.1016/j.clinthera.2019.09.012,31699438,methodology,4,NA,Form of the indirect comparison,NA,NA,"Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate)",TRUE,NA,NA,NA
10.1016/j.clinthera.2019.09.012,31699438,methodology,4,NA,Definition of a single primary outcome for the indirect comparison,NA,NA,"No primary outcome defined, or multiple primary outcomes without any clear distinction between them",TRUE,NA,NA,NA
10.1016/j.clinthera.2019.09.012,31699438,methodology,4,NA,Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined),overall response rate,objective response rate,overall response rate,FALSE,NA,NA,NA
10.1016/j.clinthera.2019.09.012,31699438,methodology,4,NA,Primary outcome: variable type,NA,NA,Binary (eg rates),TRUE,NA,NA,NA
10.1016/j.clinthera.2019.09.012,31699438,methodology,4,NA,Justification for selecting variables to be included in the adjustment model (in the main text),NA,NA,A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion),TRUE,NA,NA,NA
10.1016/j.clinthera.2019.09.012,31699438,methodology,4,NA,Inclusion of prognostic factors in the adjustment/matching model,NA,NA,No discussion (in the main text) of the status of prognostic factors of the variables,TRUE,NA,NA,NA
10.1016/j.clinthera.2019.09.012,31699438,methodology,4,NA,Inclusion of treatment-effect modifiers in the adjustment/matching model,NA,NA,No discussion (in the main text) of the status of treatment-effect modifiers of the variables,TRUE,NA,NA,NA
10.1016/j.clinthera.2019.09.012,31699438,methodology,4,NA,"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)",NA,NA,No,TRUE,NA,NA,NA
10.1016/j.clinthera.2019.09.012,31699438,methodology,4,NA,Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale),NA,NA,No,TRUE,NA,NA,NA
10.1016/j.clinthera.2019.09.012,31699438,methodology,5,NA,Treatment name 1,NA,NA,acalabrutinib,TRUE,NA,NA,NA
10.1016/j.clinthera.2019.09.012,31699438,methodology,5,NA,Study 'number(s)' for treatment 1,NA,NA,1,TRUE,NA,NA,NA
10.1016/j.clinthera.2019.09.012,31699438,methodology,5,NA,Treatment name 2,NA,NA,ibrutinib + rituximab,TRUE,NA,NA,NA
10.1016/j.clinthera.2019.09.012,31699438,methodology,5,NA,Study 'number(s)' for treatment 2,NA,NA,10,TRUE,NA,NA,NA
10.1016/j.clinthera.2019.09.012,31699438,methodology,5,NA,Type of population-adjusted indirect comparisons performed,NA,NA,MAIC,TRUE,NA,NA,NA
10.1016/j.clinthera.2019.09.012,31699438,methodology,5,NA,Anchored comparison?,NA,NA,No,TRUE,NA,NA,NA
10.1016/j.clinthera.2019.09.012,31699438,methodology,5,NA,Form of the indirect comparison,NA,NA,Simple (ie treatments effects extracted from two studies),TRUE,NA,NA,NA
10.1016/j.clinthera.2019.09.012,31699438,methodology,5,NA,Definition of a single primary outcome for the indirect comparison,NA,NA,"No primary outcome defined, or multiple primary outcomes without any clear distinction between them",TRUE,NA,NA,NA
10.1016/j.clinthera.2019.09.012,31699438,methodology,5,NA,Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined),overall response rate,objective response rate,overall response rate,FALSE,NA,NA,NA
10.1016/j.clinthera.2019.09.012,31699438,methodology,5,NA,Primary outcome: variable type,NA,NA,Binary (eg rates),TRUE,NA,NA,NA
10.1016/j.clinthera.2019.09.012,31699438,methodology,5,NA,Justification for selecting variables to be included in the adjustment model (in the main text),NA,NA,A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion),TRUE,NA,NA,NA
10.1016/j.clinthera.2019.09.012,31699438,methodology,5,NA,Inclusion of prognostic factors in the adjustment/matching model,NA,NA,No discussion (in the main text) of the status of prognostic factors of the variables,TRUE,NA,NA,NA
10.1016/j.clinthera.2019.09.012,31699438,methodology,5,NA,Inclusion of treatment-effect modifiers in the adjustment/matching model,NA,NA,No discussion (in the main text) of the status of treatment-effect modifiers of the variables,TRUE,NA,NA,NA
10.1016/j.clinthera.2019.09.012,31699438,methodology,5,NA,"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)",NA,NA,No,TRUE,NA,NA,NA
10.1016/j.clinthera.2019.09.012,31699438,methodology,5,NA,Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale),NA,NA,No,TRUE,NA,NA,NA
10.1016/j.clinthera.2019.09.012,31699438,methodology,6,NA,Treatment name 1,NA,NA,acalabrutinib,TRUE,NA,NA,NA
10.1016/j.clinthera.2019.09.012,31699438,methodology,6,NA,Study 'number(s)' for treatment 1,NA,NA,1,TRUE,NA,NA,NA
10.1016/j.clinthera.2019.09.012,31699438,methodology,6,NA,Treatment name 2,ibrutinib + rituximab,bendamustine + rituximab,bendamustine + rituximab,FALSE,NA,NA,NA
10.1016/j.clinthera.2019.09.012,31699438,methodology,6,NA,Study 'number(s)' for treatment 2,NA,NA,11,TRUE,NA,NA,NA
10.1016/j.clinthera.2019.09.012,31699438,methodology,6,NA,Type of population-adjusted indirect comparisons performed,NA,NA,MAIC,TRUE,NA,NA,NA
10.1016/j.clinthera.2019.09.012,31699438,methodology,6,NA,Anchored comparison?,NA,NA,No,TRUE,NA,NA,NA
10.1016/j.clinthera.2019.09.012,31699438,methodology,6,NA,Form of the indirect comparison,NA,NA,Simple (ie treatments effects extracted from two studies),TRUE,NA,NA,NA
10.1016/j.clinthera.2019.09.012,31699438,methodology,6,NA,Definition of a single primary outcome for the indirect comparison,NA,NA,"No primary outcome defined, or multiple primary outcomes without any clear distinction between them",TRUE,NA,NA,NA
10.1016/j.clinthera.2019.09.012,31699438,methodology,6,NA,Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined),overall response rate,objective response rate,overall response rate,FALSE,NA,NA,NA
10.1016/j.clinthera.2019.09.012,31699438,methodology,6,NA,Primary outcome: variable type,NA,NA,Binary (eg rates),TRUE,NA,NA,NA
10.1016/j.clinthera.2019.09.012,31699438,methodology,6,NA,Justification for selecting variables to be included in the adjustment model (in the main text),NA,NA,A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion),TRUE,NA,NA,NA
10.1016/j.clinthera.2019.09.012,31699438,methodology,6,NA,Inclusion of prognostic factors in the adjustment/matching model,NA,NA,No discussion (in the main text) of the status of prognostic factors of the variables,TRUE,NA,NA,NA
10.1016/j.clinthera.2019.09.012,31699438,methodology,6,NA,Inclusion of treatment-effect modifiers in the adjustment/matching model,NA,NA,No discussion (in the main text) of the status of treatment-effect modifiers of the variables,TRUE,NA,NA,NA
10.1016/j.clinthera.2019.09.012,31699438,methodology,6,NA,"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)",NA,NA,No,TRUE,NA,NA,NA
10.1016/j.clinthera.2019.09.012,31699438,methodology,6,NA,Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale),NA,NA,No,TRUE,NA,NA,NA
10.1016/j.clinthera.2019.09.012,31699438,methodology,7,NA,Treatment name 1,NA,NA,acalabrutinib,TRUE,NA,NA,NA
10.1016/j.clinthera.2019.09.012,31699438,methodology,7,NA,Study 'number(s)' for treatment 1,NA,NA,1,TRUE,NA,NA,NA
10.1016/j.clinthera.2019.09.012,31699438,methodology,7,NA,Treatment name 2,NA,NA,lenalidomide + rituximab,TRUE,NA,NA,NA
10.1016/j.clinthera.2019.09.012,31699438,methodology,7,NA,Study 'number(s)' for treatment 2,NA,NA,12,TRUE,NA,NA,NA
10.1016/j.clinthera.2019.09.012,31699438,methodology,7,NA,Type of population-adjusted indirect comparisons performed,NA,NA,MAIC,TRUE,NA,NA,NA
10.1016/j.clinthera.2019.09.012,31699438,methodology,7,NA,Anchored comparison?,NA,NA,No,TRUE,NA,NA,NA
10.1016/j.clinthera.2019.09.012,31699438,methodology,7,NA,Form of the indirect comparison,NA,NA,Simple (ie treatments effects extracted from two studies),TRUE,NA,NA,NA
10.1016/j.clinthera.2019.09.012,31699438,methodology,7,NA,Definition of a single primary outcome for the indirect comparison,NA,NA,"No primary outcome defined, or multiple primary outcomes without any clear distinction between them",TRUE,NA,NA,NA
10.1016/j.clinthera.2019.09.012,31699438,methodology,7,NA,Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined),overall response rate,objective response rate,overall response rate,FALSE,NA,NA,NA
10.1016/j.clinthera.2019.09.012,31699438,methodology,7,NA,Primary outcome: variable type,NA,NA,Binary (eg rates),TRUE,NA,NA,NA
10.1016/j.clinthera.2019.09.012,31699438,methodology,7,NA,Justification for selecting variables to be included in the adjustment model (in the main text),NA,NA,A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion),TRUE,NA,NA,NA
10.1016/j.clinthera.2019.09.012,31699438,methodology,7,NA,Inclusion of prognostic factors in the adjustment/matching model,NA,NA,No discussion (in the main text) of the status of prognostic factors of the variables,TRUE,NA,NA,NA
10.1016/j.clinthera.2019.09.012,31699438,methodology,7,NA,Inclusion of treatment-effect modifiers in the adjustment/matching model,NA,NA,No discussion (in the main text) of the status of treatment-effect modifiers of the variables,TRUE,NA,NA,NA
10.1016/j.clinthera.2019.09.012,31699438,methodology,7,NA,"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)",NA,NA,No,TRUE,NA,NA,NA
10.1016/j.clinthera.2019.09.012,31699438,methodology,7,NA,Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale),NA,NA,No,TRUE,NA,NA,NA
10.1016/j.clinthera.2019.09.012,31699438,results,1,NA,Sample size of the population of interest in the non IPD treatment arm,NA,NA,370,TRUE,NA,NA,NA
10.1016/j.clinthera.2019.09.012,31699438,results,1,NA,Initial sample size of the population of interest in the IPD treatment arm,NA,NA,123,TRUE,NA,NA,NA
10.1016/j.clinthera.2019.09.012,31699438,results,1,NA,"Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC",NA,NA,45,TRUE,NA,NA,NA
10.1016/j.clinthera.2019.09.012,31699438,results,1,NA,Reporting of a weights' distribution evaluation (MAIC),NA,NA,Not mentioned,TRUE,NA,NA,NA
10.1016/j.clinthera.2019.09.012,31699438,results,1,NA,Reporting of the list of the covariates adjusted for/matched on,NA,NA,Yes,TRUE,NA,NA,NA
10.1016/j.clinthera.2019.09.012,31699438,results,1,NA,Number of covariates adjusted for/matched on,10,12,10,FALSE,NA,NA,NA
10.1016/j.clinthera.2019.09.012,31699438,results,1,NA,Covariates adjusted for/matched on in the indirect comparison,"Age, Sex,Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Race/ethnicity, Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Past treatments for the disease of interest","Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Race/ethnicity, Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Past treatments for the disease of interest","Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Race/ethnicity, Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Past treatments for the disease of interest",FALSE,NA,NA,NA
10.1016/j.clinthera.2019.09.012,31699438,results,1,NA,Primary outcome: treatment effect contrast,NA,NA,Rate difference,TRUE,NA,NA,NA
10.1016/j.clinthera.2019.09.012,31699438,results,1,NA,Direction of the treatment effect contrast: IPD treatment is:,NA,NA,"Numerator if ratio, or left side if difference",TRUE,NA,NA,NA
10.1016/j.clinthera.2019.09.012,31699438,results,1,NA,Primary outcome: unadjusted treatment effect,NA,NA,10.2,TRUE,NA,NA,NA
10.1016/j.clinthera.2019.09.012,31699438,results,1,NA,"p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])",NA,NA,<0.05,TRUE,NA,NA,NA
10.1016/j.clinthera.2019.09.012,31699438,results,1,NA,Primary outcome: adjusted treatment effect,NA,NA,9.3,TRUE,NA,NA,NA
10.1016/j.clinthera.2019.09.012,31699438,results,1,NA,"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])",<0.001,<0.05,<0.05,FALSE,NA,NA,NA
10.1016/j.clinthera.2019.09.012,31699438,results,2,NA,Sample size of the population of interest in the non IPD treatment arm,NA,NA,155,TRUE,NA,NA,NA
10.1016/j.clinthera.2019.09.012,31699438,results,2,NA,Initial sample size of the population of interest in the IPD treatment arm,NA,NA,124,TRUE,NA,NA,NA
10.1016/j.clinthera.2019.09.012,31699438,results,2,NA,"Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC",NA,NA,61,TRUE,NA,NA,NA
10.1016/j.clinthera.2019.09.012,31699438,results,2,NA,Reporting of a weights' distribution evaluation (MAIC),NA,NA,Not mentioned,TRUE,NA,NA,NA
10.1016/j.clinthera.2019.09.012,31699438,results,2,NA,Reporting of the list of the covariates adjusted for/matched on,NA,NA,Yes,TRUE,NA,NA,NA
10.1016/j.clinthera.2019.09.012,31699438,results,2,NA,Number of covariates adjusted for/matched on,9,12,9,FALSE,NA,NA,NA
10.1016/j.clinthera.2019.09.012,31699438,results,2,NA,Covariates adjusted for/matched on in the indirect comparison,NA,NA,"Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Race/ethnicity, Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Past treatments for the disease of interest",TRUE,NA,NA,NA
10.1016/j.clinthera.2019.09.012,31699438,results,2,NA,Primary outcome: treatment effect contrast,NA,NA,Rate difference,TRUE,NA,NA,NA
10.1016/j.clinthera.2019.09.012,31699438,results,2,NA,Direction of the treatment effect contrast: IPD treatment is:,NA,NA,"Numerator if ratio, or left side if difference",TRUE,NA,NA,NA
10.1016/j.clinthera.2019.09.012,31699438,results,2,NA,Primary outcome: unadjusted treatment effect,NA,NA,46,TRUE,NA,NA,NA
10.1016/j.clinthera.2019.09.012,31699438,results,2,NA,"p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])",NA,NA,<0.001,TRUE,NA,NA,NA
10.1016/j.clinthera.2019.09.012,31699438,results,2,NA,Primary outcome: adjusted treatment effect,NA,NA,50.6,TRUE,NA,NA,NA
10.1016/j.clinthera.2019.09.012,31699438,results,2,NA,"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])",NA,NA,<0.001,TRUE,NA,NA,NA
10.1016/j.clinthera.2019.09.012,31699438,results,3,NA,Sample size of the population of interest in the non IPD treatment arm,NA,NA,304,TRUE,NA,NA,NA
10.1016/j.clinthera.2019.09.012,31699438,results,3,NA,Initial sample size of the population of interest in the IPD treatment arm,NA,NA,122,TRUE,NA,NA,NA
10.1016/j.clinthera.2019.09.012,31699438,results,3,NA,"Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC",NA,NA,28,TRUE,NA,NA,NA
10.1016/j.clinthera.2019.09.012,31699438,results,3,NA,Reporting of a weights' distribution evaluation (MAIC),NA,NA,Not mentioned,TRUE,NA,NA,NA
10.1016/j.clinthera.2019.09.012,31699438,results,3,NA,Reporting of the list of the covariates adjusted for/matched on,Yes,No,Yes,FALSE,NA,NA,NA
10.1016/j.clinthera.2019.09.012,31699438,results,3,NA,Number of covariates adjusted for/matched on,NA,NA,12,TRUE,NA,NA,NA
10.1016/j.clinthera.2019.09.012,31699438,results,3,NA,Covariates adjusted for/matched on in the indirect comparison,"Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Past treatments for the disease of interest","Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Race/ethnicity, Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Past treatments for the disease of interest","Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Past treatments for the disease of interest",FALSE,NA,NA,NA
10.1016/j.clinthera.2019.09.012,31699438,results,3,NA,Primary outcome: treatment effect contrast,NA,NA,Rate difference,TRUE,NA,NA,NA
10.1016/j.clinthera.2019.09.012,31699438,results,3,NA,Direction of the treatment effect contrast: IPD treatment is:,NA,NA,"Numerator if ratio, or left side if difference",TRUE,NA,NA,NA
10.1016/j.clinthera.2019.09.012,31699438,results,3,NA,Primary outcome: unadjusted treatment effect,NA,NA,39.7,TRUE,NA,NA,NA
10.1016/j.clinthera.2019.09.012,31699438,results,3,NA,"p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])",NA,NA,<0.001,TRUE,NA,NA,NA
10.1016/j.clinthera.2019.09.012,31699438,results,3,NA,Primary outcome: adjusted treatment effect,NA,NA,38.1,TRUE,NA,NA,NA
10.1016/j.clinthera.2019.09.012,31699438,results,3,NA,"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])",NA,NA,<0.001,TRUE,NA,NA,NA
10.1016/j.clinthera.2019.09.012,31699438,results,4,NA,Sample size of the population of interest in the non IPD treatment arm,NA,NA,242,TRUE,NA,NA,NA
10.1016/j.clinthera.2019.09.012,31699438,results,4,NA,Initial sample size of the population of interest in the IPD treatment arm,NA,NA,123,TRUE,NA,NA,NA
10.1016/j.clinthera.2019.09.012,31699438,results,4,NA,"Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC",NA,NA,120,TRUE,NA,NA,NA
10.1016/j.clinthera.2019.09.012,31699438,results,4,NA,Reporting of a weights' distribution evaluation (MAIC),NA,NA,Not mentioned,TRUE,NA,NA,NA
10.1016/j.clinthera.2019.09.012,31699438,results,4,NA,Reporting of the list of the covariates adjusted for/matched on,NA,NA,Yes,TRUE,NA,NA,NA
10.1016/j.clinthera.2019.09.012,31699438,results,4,NA,Number of covariates adjusted for/matched on,3,12,3,FALSE,NA,NA,NA
10.1016/j.clinthera.2019.09.012,31699438,results,4,NA,Covariates adjusted for/matched on in the indirect comparison,"Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...)","Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Race/ethnicity, Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Past treatments for the disease of interest","Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...)",FALSE,NA,NA,NA
10.1016/j.clinthera.2019.09.012,31699438,results,4,NA,Primary outcome: treatment effect contrast,NA,NA,Rate difference,TRUE,NA,NA,NA
10.1016/j.clinthera.2019.09.012,31699438,results,4,NA,Direction of the treatment effect contrast: IPD treatment is:,NA,NA,"Numerator if ratio, or left side if difference",TRUE,NA,NA,NA
10.1016/j.clinthera.2019.09.012,31699438,results,4,NA,Primary outcome: unadjusted treatment effect,NA,NA,40.9,TRUE,NA,NA,NA
10.1016/j.clinthera.2019.09.012,31699438,results,4,NA,"p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])",NA,NA,<0.001,TRUE,NA,NA,NA
10.1016/j.clinthera.2019.09.012,31699438,results,4,NA,Primary outcome: adjusted treatment effect,NA,NA,40.7,TRUE,NA,NA,NA
10.1016/j.clinthera.2019.09.012,31699438,results,4,NA,"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])",NA,NA,<0.001,TRUE,NA,NA,NA
10.1016/j.clinthera.2019.09.012,31699438,results,5,NA,Sample size of the population of interest in the non IPD treatment arm,NA,NA,50,TRUE,NA,NA,NA
10.1016/j.clinthera.2019.09.012,31699438,results,5,NA,Initial sample size of the population of interest in the IPD treatment arm,NA,NA,84,TRUE,NA,NA,NA
10.1016/j.clinthera.2019.09.012,31699438,results,5,NA,"Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC",NA,NA,16,TRUE,NA,NA,NA
10.1016/j.clinthera.2019.09.012,31699438,results,5,NA,Reporting of a weights' distribution evaluation (MAIC),NA,NA,Not mentioned,TRUE,NA,NA,NA
10.1016/j.clinthera.2019.09.012,31699438,results,5,NA,Reporting of the list of the covariates adjusted for/matched on,NA,NA,Yes,TRUE,NA,NA,NA
10.1016/j.clinthera.2019.09.012,31699438,results,5,NA,Number of covariates adjusted for/matched on,8,12,8,FALSE,NA,NA,NA
10.1016/j.clinthera.2019.09.012,31699438,results,5,NA,Covariates adjusted for/matched on in the indirect comparison,"Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Past treatments for the disease of interest","Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Race/ethnicity, Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Past treatments for the disease of interest","Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Past treatments for the disease of interest",FALSE,NA,NA,NA
10.1016/j.clinthera.2019.09.012,31699438,results,5,NA,Primary outcome: treatment effect contrast,NA,NA,Rate difference,TRUE,NA,NA,NA
10.1016/j.clinthera.2019.09.012,31699438,results,5,NA,Direction of the treatment effect contrast: IPD treatment is:,NA,NA,"Numerator if ratio, or left side if difference",TRUE,NA,NA,NA
10.1016/j.clinthera.2019.09.012,31699438,results,5,NA,Primary outcome: unadjusted treatment effect,NA,NA,-14.2,TRUE,NA,NA,NA
10.1016/j.clinthera.2019.09.012,31699438,results,5,NA,"p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])",NA,NA,<0.05,TRUE,NA,NA,NA
10.1016/j.clinthera.2019.09.012,31699438,results,5,NA,Primary outcome: adjusted treatment effect,NA,NA,-10.6,TRUE,NA,NA,NA
10.1016/j.clinthera.2019.09.012,31699438,results,5,NA,"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])",NA,NA,0.09,TRUE,NA,NA,NA
10.1016/j.clinthera.2019.09.012,31699438,results,6,NA,Sample size of the population of interest in the non IPD treatment arm,145,45,45,FALSE,NA,NA,NA
10.1016/j.clinthera.2019.09.012,31699438,results,6,NA,Initial sample size of the population of interest in the IPD treatment arm,NA,NA,121,TRUE,NA,NA,NA
10.1016/j.clinthera.2019.09.012,31699438,results,6,NA,"Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC",NA,NA,56,TRUE,NA,NA,NA
10.1016/j.clinthera.2019.09.012,31699438,results,6,NA,Reporting of a weights' distribution evaluation (MAIC),NA,NA,Not mentioned,TRUE,NA,NA,NA
10.1016/j.clinthera.2019.09.012,31699438,results,6,NA,Reporting of the list of the covariates adjusted for/matched on,NA,NA,Yes,TRUE,NA,NA,NA
10.1016/j.clinthera.2019.09.012,31699438,results,6,NA,Number of covariates adjusted for/matched on,5,12,5,FALSE,NA,NA,NA
10.1016/j.clinthera.2019.09.012,31699438,results,6,NA,Covariates adjusted for/matched on in the indirect comparison,"Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease)","Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Race/ethnicity, Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Past treatments for the disease of interest","Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease)",FALSE,NA,NA,NA
10.1016/j.clinthera.2019.09.012,31699438,results,6,NA,Primary outcome: treatment effect contrast,NA,NA,Rate difference,TRUE,NA,NA,NA
10.1016/j.clinthera.2019.09.012,31699438,results,6,NA,Direction of the treatment effect contrast: IPD treatment is:,NA,NA,"Numerator if ratio, or left side if difference",TRUE,NA,NA,NA
10.1016/j.clinthera.2019.09.012,31699438,results,6,NA,Primary outcome: unadjusted treatment effect,NA,NA,-7,TRUE,NA,NA,NA
10.1016/j.clinthera.2019.09.012,31699438,results,6,NA,"p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])",NA,NA,0.31,TRUE,NA,NA,NA
10.1016/j.clinthera.2019.09.012,31699438,results,6,NA,Primary outcome: adjusted treatment effect,NA,NA,-9.8,TRUE,NA,NA,NA
10.1016/j.clinthera.2019.09.012,31699438,results,6,NA,"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])",NA,NA,0.22,TRUE,NA,NA,NA
10.1016/j.clinthera.2019.09.012,31699438,results,7,NA,Sample size of the population of interest in the non IPD treatment arm,NA,NA,44,TRUE,NA,NA,NA
10.1016/j.clinthera.2019.09.012,31699438,results,7,NA,Initial sample size of the population of interest in the IPD treatment arm,124,93,93,FALSE,NA,NA,NA
10.1016/j.clinthera.2019.09.012,31699438,results,7,NA,"Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC",NA,NA,64,TRUE,NA,NA,NA
10.1016/j.clinthera.2019.09.012,31699438,results,7,NA,Reporting of a weights' distribution evaluation (MAIC),NA,NA,Not mentioned,TRUE,NA,NA,NA
10.1016/j.clinthera.2019.09.012,31699438,results,7,NA,Reporting of the list of the covariates adjusted for/matched on,NA,NA,Yes,TRUE,NA,NA,NA
10.1016/j.clinthera.2019.09.012,31699438,results,7,NA,Number of covariates adjusted for/matched on,7,12,7,FALSE,NA,NA,NA
10.1016/j.clinthera.2019.09.012,31699438,results,7,NA,Covariates adjusted for/matched on in the indirect comparison,"Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Past treatments for the disease of interest","Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Race/ethnicity, Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Past treatments for the disease of interest","Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Past treatments for the disease of interest",FALSE,NA,NA,NA
10.1016/j.clinthera.2019.09.012,31699438,results,7,NA,Primary outcome: treatment effect contrast,NA,NA,Rate difference,TRUE,NA,NA,NA
10.1016/j.clinthera.2019.09.012,31699438,results,7,NA,Direction of the treatment effect contrast: IPD treatment is:,NA,NA,"Numerator if ratio, or left side if difference",TRUE,NA,NA,NA
10.1016/j.clinthera.2019.09.012,31699438,results,7,NA,Primary outcome: unadjusted treatment effect,NA,NA,16.3,TRUE,NA,NA,NA
10.1016/j.clinthera.2019.09.012,31699438,results,7,NA,"p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])",NA,NA,0.06,TRUE,NA,NA,NA
10.1016/j.clinthera.2019.09.012,31699438,results,7,NA,Primary outcome: adjusted treatment effect,NA,NA,14.1,TRUE,NA,NA,NA
10.1016/j.clinthera.2019.09.012,31699438,results,7,NA,"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])",NA,NA,0.13,TRUE,NA,NA,NA
10.1007/s12325-019-01156-5,31813086,general_information,NA,NA,Medical Condition of Interest Name,NA,NA,non-metastatic castration-resistant prostate cancer,TRUE,NA,NA,NA
10.1007/s12325-019-01156-5,31813086,general_information,NA,NA,Countries of first author affiliations,NA,NA,uk,TRUE,NA,NA,NA
10.1007/s12325-019-01156-5,31813086,general_information,NA,NA,Countries of last author affiliations,NA,NA,germany,TRUE,NA,NA,NA
10.1007/s12325-019-01156-5,31813086,general_information,NA,NA,"Positions of study investigators (for any authors of the article, any that applies)",NA,NA,"Academic, Pharmaceutical Industry, Private Data Analysis Company",TRUE,NA,NA,NA
10.1007/s12325-019-01156-5,31813086,general_information,NA,NA,"At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company",NA,NA,Yes,TRUE,NA,NA,NA
10.1007/s12325-019-01156-5,31813086,general_information,NA,NA,Mentioned sources of funding,NA,NA,Pharmaceutical Industry,TRUE,NA,NA,NA
10.1007/s12325-019-01156-5,31813086,general_information,NA,NA,"Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article",NA,NA,Yes,TRUE,NA,NA,NA
10.1007/s12325-019-01156-5,31813086,general_information,NA,NA,Mention of a systematic review to find the studies to compare treatments of interest,NA,NA,No,TRUE,NA,NA,NA
10.1007/s12325-019-01156-5,31813086,study_information,NA,1,Patient-level data used,NA,NA,Yes,TRUE,NA,NA,NA
10.1007/s12325-019-01156-5,31813086,study_information,NA,1,Clinical Trial,NA,NA,Yes,TRUE,NA,NA,NA
10.1007/s12325-019-01156-5,31813086,study_information,NA,1,NCT (only for clinical trial registered on clinicaltrials.gov),NA,NA,NCT01946204,TRUE,NA,NA,NA
10.1007/s12325-019-01156-5,31813086,study_information,NA,1,Country where the clinical trial/observational study was conducted (international if more than one),NA,NA,international,TRUE,NA,NA,NA
10.1007/s12325-019-01156-5,31813086,study_information,NA,1,Phase of the clinical trial (clinical trial only),NA,NA,3,TRUE,NA,NA,NA
10.1007/s12325-019-01156-5,31813086,study_information,NA,1,Number of treatment arms (clinical trial only),NA,NA,2 or more,TRUE,NA,NA,NA
10.1007/s12325-019-01156-5,31813086,study_information,NA,2,Patient-level data used,NA,NA,No,TRUE,NA,NA,NA
10.1007/s12325-019-01156-5,31813086,study_information,NA,2,Clinical Trial,NA,NA,Yes,TRUE,NA,NA,NA
10.1007/s12325-019-01156-5,31813086,study_information,NA,2,NCT (only for clinical trial registered on clinicaltrials.gov),NA,NA,NCT02003924,TRUE,NA,NA,NA
10.1007/s12325-019-01156-5,31813086,study_information,NA,2,Country where the clinical trial/observational study was conducted (international if more than one),NA,NA,international,TRUE,NA,NA,NA
10.1007/s12325-019-01156-5,31813086,study_information,NA,2,Phase of the clinical trial (clinical trial only),NA,NA,3,TRUE,NA,NA,NA
10.1007/s12325-019-01156-5,31813086,study_information,NA,2,Number of treatment arms (clinical trial only),NA,NA,2 or more,TRUE,NA,NA,NA
10.1007/s12325-019-01156-5,31813086,methodology,1,NA,Treatment name 1,NA,NA,apalutamide,TRUE,"Bayesian framework, therefore the probability associated to the treatment effect is p[HR<1] Concludes for the relative efficacy superiority of apalutamide over enzalutamide, because they are using a Bayesian framework. However, with a non informative prior, their methodology seem to be very close from frequentist approach, just the interpretation of results differs.","""Although most clinically important baseline characteristics that may bias indirect treatment comparison results through effect modification were adjusted for, matching could only be done for characteristics reported in the PROSPER study.""
 + Spartant Initial sample size = Before the exclusion of 36 patients with missing informations on matched variables, but the number of patients excluded in each arm is not specified",NA
10.1007/s12325-019-01156-5,31813086,methodology,1,NA,Study 'number(s)' for treatment 1,NA,NA,1,TRUE,NA,NA,NA
10.1007/s12325-019-01156-5,31813086,methodology,1,NA,Treatment name 2,NA,NA,enzalutamide,TRUE,NA,NA,NA
10.1007/s12325-019-01156-5,31813086,methodology,1,NA,Study 'number(s)' for treatment 2,NA,NA,2,TRUE,NA,NA,NA
10.1007/s12325-019-01156-5,31813086,methodology,1,NA,Type of population-adjusted indirect comparisons performed,NA,NA,MAIC,TRUE,NA,NA,NA
10.1007/s12325-019-01156-5,31813086,methodology,1,NA,Anchored comparison?,NA,NA,Yes,TRUE,NA,NA,NA
10.1007/s12325-019-01156-5,31813086,methodology,1,NA,Form of the indirect comparison,NA,NA,Simple (ie treatments effects extracted from two studies),TRUE,NA,NA,NA
10.1007/s12325-019-01156-5,31813086,methodology,1,NA,Definition of a single primary outcome for the indirect comparison,NA,NA,"No primary outcome defined, or multiple primary outcomes without any clear distinction between them",TRUE,NA,NA,NA
10.1007/s12325-019-01156-5,31813086,methodology,1,NA,Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined),metastasis free survival,metastasis-free survival,metastasis-free survival,FALSE,NA,NA,NA
10.1007/s12325-019-01156-5,31813086,methodology,1,NA,Primary outcome: variable type,NA,NA,Time-to-event,TRUE,NA,NA,NA
10.1007/s12325-019-01156-5,31813086,methodology,1,NA,Justification for selecting variables to be included in the adjustment model (in the main text),"Nothing mentioned, not reported",A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion),A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion),FALSE,NA,NA,NA
10.1007/s12325-019-01156-5,31813086,methodology,1,NA,Inclusion of prognostic factors in the adjustment/matching model,No,No discussion (in the main text) of the status of prognostic factors of the variables,No,FALSE,NA,NA,NA
10.1007/s12325-019-01156-5,31813086,methodology,1,NA,Inclusion of treatment-effect modifiers in the adjustment/matching model,NA,NA,Yes,TRUE,NA,NA,NA
10.1007/s12325-019-01156-5,31813086,methodology,1,NA,"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)",NA,NA,No,TRUE,NA,NA,NA
10.1007/s12325-019-01156-5,31813086,methodology,1,NA,Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale),NA,NA,No,TRUE,NA,NA,NA
10.1007/s12325-019-01156-5,31813086,results,1,NA,Sample size of the population of interest in the non IPD treatment arm,NA,NA,933,TRUE,NA,NA,NA
10.1007/s12325-019-01156-5,31813086,results,1,NA,"If anchored comparison, sample size of the population of interest in the non IPD treatment anchor arm",NA,NA,468,TRUE,NA,NA,NA
10.1007/s12325-019-01156-5,31813086,results,1,NA,Initial sample size of the population of interest in the IPD treatment arm,NA,NA,806,TRUE,NA,NA,NA
10.1007/s12325-019-01156-5,31813086,results,1,NA,"If anchored comparison, initial sample size of the population of interest in the IPD anchor arm",NA,NA,401,TRUE,NA,NA,NA
10.1007/s12325-019-01156-5,31813086,results,1,NA,Reporting of a weights' distribution evaluation (MAIC),NA,NA,Not mentioned,TRUE,NA,NA,NA
10.1007/s12325-019-01156-5,31813086,results,1,NA,Reporting of the list of the covariates adjusted for/matched on,NA,NA,Yes,TRUE,NA,NA,NA
10.1007/s12325-019-01156-5,31813086,results,1,NA,Number of covariates adjusted for/matched on,NA,NA,7,TRUE,NA,NA,NA
10.1007/s12325-019-01156-5,31813086,results,1,NA,Covariates adjusted for/matched on in the indirect comparison,NA,NA,"Age, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Past treatments for the disease of interest",TRUE,NA,NA,NA
10.1007/s12325-019-01156-5,31813086,results,1,NA,Primary outcome: treatment effect contrast,NA,NA,HR,TRUE,NA,NA,NA
10.1007/s12325-019-01156-5,31813086,results,1,NA,Direction of the treatment effect contrast: IPD treatment is:,NA,NA,"Numerator if ratio, or left side if difference",TRUE,NA,NA,NA
10.1007/s12325-019-01156-5,31813086,results,1,NA,Primary outcome: adjusted treatment effect,NA,NA,0.91,TRUE,NA,NA,NA
10.1007/s12325-019-01156-5,31813086,results,1,NA,"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])",p(hr < 1)] = 0.736,[0.68;1.22],0.736,FALSE,NA,NA,NA
10.2217/cer-2019-0145,31872771,general_information,NA,NA,Medical Condition of Interest Name,10.2217/cer-2019-0145,advanced gastric or gastroesophageal junction cancer,XXXX,FALSE,NA,NA,NA
10.2217/cer-2019-0145,31872771,general_information,NA,NA,Countries of first author affiliations,NA,NA,uk,TRUE,NA,NA,NA
10.2217/cer-2019-0145,31872771,general_information,NA,NA,Countries of last author affiliations,NA,NA,usa,TRUE,NA,NA,NA
10.2217/cer-2019-0145,31872771,general_information,NA,NA,"Positions of study investigators (for any authors of the article, any that applies)",NA,NA,"Academic, Pharmaceutical Industry, Private Data Analysis Company",TRUE,NA,NA,NA
10.2217/cer-2019-0145,31872771,general_information,NA,NA,"At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company",NA,NA,Yes,TRUE,NA,NA,NA
10.2217/cer-2019-0145,31872771,general_information,NA,NA,Mentioned sources of funding,NA,NA,Pharmaceutical Industry,TRUE,NA,NA,NA
10.2217/cer-2019-0145,31872771,general_information,NA,NA,"Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article",NA,NA,Yes,TRUE,NA,NA,NA
10.2217/cer-2019-0145,31872771,general_information,NA,NA,Mention of a systematic review to find the studies to compare treatments of interest,NA,NA,No,TRUE,NA,NA,NA
10.2217/cer-2019-0145,31872771,study_information,NA,1,Patient-level data used,NA,NA,Yes,TRUE,NA,NA,NA
10.2217/cer-2019-0145,31872771,study_information,NA,1,Clinical Trial,NA,NA,Yes,TRUE,NA,NA,NA
10.2217/cer-2019-0145,31872771,study_information,NA,1,NCT (only for clinical trial registered on clinicaltrials.gov),NA,NA,NCT01928394,TRUE,NA,NA,NA
10.2217/cer-2019-0145,31872771,study_information,NA,1,Country where the clinical trial/observational study was conducted (international if more than one),NA,NA,international,TRUE,NA,NA,NA
10.2217/cer-2019-0145,31872771,study_information,NA,1,Phase of the clinical trial (clinical trial only),NA,NA,"1, 2",TRUE,NA,NA,NA
10.2217/cer-2019-0145,31872771,study_information,NA,1,Number of treatment arms (clinical trial only),1,2 or more,XXXX,FALSE,NA,NA,NA
10.2217/cer-2019-0145,31872771,study_information,NA,2,Patient-level data used,No,Yes,No,FALSE,NA,NA,NA
10.2217/cer-2019-0145,31872771,study_information,NA,2,Clinical Trial,NA,NA,No,TRUE,NA,NA,NA
10.2217/cer-2019-0145,31872771,study_information,NA,2,Data source name (only if observational study or clinical trial without NCT),NA,NA,flatiron healthâ€™s electronic health record database,TRUE,NA,NA,NA
10.2217/cer-2019-0145,31872771,study_information,NA,2,Country where the clinical trial/observational study was conducted (international if more than one),NA,NA,usa,TRUE,NA,NA,NA
10.2217/cer-2019-0145,31872771,methodology,1,NA,Treatment name 1,NA,NA,nivolumab,TRUE,Use a STC where IPD data would have been available: propensity score reweighting seemed like a better option in this case,"Flatiron Healthâ€™s electronic health record database : the  main  analytic  cohort  was  constructed  by  randomly  selecting  cohort  entry  time  among  eligiblepatients such that the distribution of lines of therapy at cohort entry matched the frequencies observed in theCheckMate 032 trial (the â€˜random cohortâ€™). 

Hemoglobin, LDH : Autre covariables",NA
10.2217/cer-2019-0145,31872771,methodology,1,NA,Study 'number(s)' for treatment 1,NA,NA,1,TRUE,NA,NA,NA
10.2217/cer-2019-0145,31872771,methodology,1,NA,Treatment name 2,routine clinical practice,routine clinical practice (rcp),routine clinical practice,FALSE,NA,NA,NA
10.2217/cer-2019-0145,31872771,methodology,1,NA,Study 'number(s)' for treatment 2,NA,NA,2,TRUE,NA,NA,NA
10.2217/cer-2019-0145,31872771,methodology,1,NA,Type of population-adjusted indirect comparisons performed,NA,NA,STC,TRUE,NA,NA,NA
10.2217/cer-2019-0145,31872771,methodology,1,NA,Anchored comparison?,NA,NA,No,TRUE,NA,NA,NA
10.2217/cer-2019-0145,31872771,methodology,1,NA,Form of the indirect comparison,NA,NA,Simple (ie treatments effects extracted from two studies),TRUE,NA,NA,NA
10.2217/cer-2019-0145,31872771,methodology,1,NA,Definition of a single primary outcome for the indirect comparison,NA,NA,Yes,TRUE,NA,NA,NA
10.2217/cer-2019-0145,31872771,methodology,1,NA,Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined),all-cause mortality,overall survival,overall survival,FALSE,NA,NA,NA
10.2217/cer-2019-0145,31872771,methodology,1,NA,Primary outcome: variable type,NA,NA,Time-to-event,TRUE,NA,NA,NA
10.2217/cer-2019-0145,31872771,methodology,1,NA,Justification for selecting variables to be included in the adjustment model (in the main text),"Status of prognostic factor/treatment effect modified assessed in the IPD dataset, Literature based (clinically or methodologically relevant to adjust on these variables based on the literature search conducted for this specific purpose)","Status of prognostic factor/treatment effect modified assessed in the IPD dataset, A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion), Literature based (clinically or methodologically relevant to adjust on these variables based on the literature search conducted for this specific purpose)","Status of prognostic factor/treatment effect modified assessed in the IPD dataset, A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion), Literature based (clinically or methodologically relevant to adjust on these variables based on the literature search conducted for this specific purpose)",FALSE,NA,NA,NA
10.2217/cer-2019-0145,31872771,methodology,1,NA,Inclusion of prognostic factors in the adjustment/matching model,NA,NA,Yes,TRUE,NA,NA,NA
10.2217/cer-2019-0145,31872771,methodology,1,NA,Inclusion of treatment-effect modifiers in the adjustment/matching model,NA,NA,Yes,TRUE,NA,NA,NA
10.2217/cer-2019-0145,31872771,methodology,1,NA,"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)",NA,NA,Yes,TRUE,NA,NA,NA
10.2217/cer-2019-0145,31872771,methodology,1,NA,Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale),NA,NA,No,TRUE,NA,NA,NA
10.2217/cer-2019-0145,31872771,results,1,NA,Sample size of the population of interest in the non IPD treatment arm,34,42,34,FALSE,NA,NA,NA
10.2217/cer-2019-0145,31872771,results,1,NA,"Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC",42,34,42,FALSE,NA,NA,NA
10.2217/cer-2019-0145,31872771,results,1,NA,Reporting of the list of the covariates adjusted for/matched on,NA,NA,Yes,TRUE,NA,NA,NA
10.2217/cer-2019-0145,31872771,results,1,NA,Number of covariates adjusted for/matched on,NA,NA,6,TRUE,NA,NA,NA
10.2217/cer-2019-0145,31872771,results,1,NA,Covariates adjusted for/matched on in the indirect comparison,"Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Past treatments for the disease of interest","Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Past treatments for the disease of interest, Other(s)","Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Past treatments for the disease of interest, Other(s)",FALSE,NA,NA,NA
10.2217/cer-2019-0145,31872771,results,1,NA,Primary outcome: treatment effect contrast,NA,NA,HR,TRUE,NA,NA,NA
10.2217/cer-2019-0145,31872771,results,1,NA,Direction of the treatment effect contrast: IPD treatment is:,NA,NA,"Numerator if ratio, or left side if difference",TRUE,NA,NA,NA
10.2217/cer-2019-0145,31872771,results,1,NA,Primary outcome: adjusted treatment effect,NA,NA,0.5,TRUE,NA,NA,NA
10.2217/cer-2019-0145,31872771,results,1,NA,"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])",NA,NA,[0.36;0.68],TRUE,NA,NA,NA
10.2217/cer-2019-0145,31872771,results,1,NA,Initial sample size of the population of interest in the IPD treatment arm,42,NA,42,FALSE,NA,NA,NA
10.2217/cer-2019-0145,31872771,results,1,NA,Primary outcome: unadjusted treatment effect,0.46,NA,0.46,FALSE,NA,NA,NA
10.2217/cer-2019-0145,31872771,results,1,NA,"p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])",[0.36;0.59],NA,[0.36;0.59],FALSE,NA,NA,NA
10.2217/cer-2019-0169,31948278,general_information,NA,NA,Medical Condition of Interest Name,NA,NA,relapsing multiple sclerosis,TRUE,NA,NA,NA
10.2217/cer-2019-0169,31948278,general_information,NA,NA,Countries of first author affiliations,NA,NA,usa,TRUE,NA,NA,NA
10.2217/cer-2019-0169,31948278,general_information,NA,NA,Countries of last author affiliations,NA,NA,usa,TRUE,NA,NA,NA
10.2217/cer-2019-0169,31948278,general_information,NA,NA,"Positions of study investigators (for any authors of the article, any that applies)",NA,NA,"Pharmaceutical Industry, Private Data Analysis Company",TRUE,NA,NA,NA
10.2217/cer-2019-0169,31948278,general_information,NA,NA,"At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company",NA,NA,Yes,TRUE,NA,NA,NA
10.2217/cer-2019-0169,31948278,general_information,NA,NA,Mentioned sources of funding,NA,NA,Pharmaceutical Industry,TRUE,NA,NA,NA
10.2217/cer-2019-0169,31948278,general_information,NA,NA,"Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article",NA,NA,Yes,TRUE,NA,NA,NA
10.2217/cer-2019-0169,31948278,general_information,NA,NA,Mention of a systematic review to find the studies to compare treatments of interest,NA,NA,No,TRUE,NA,NA,NA
10.2217/cer-2019-0169,31948278,study_information,NA,1,Patient-level data used,NA,NA,Yes,TRUE,NA,NA,NA
10.2217/cer-2019-0169,31948278,study_information,NA,1,Clinical Trial,NA,NA,Yes,TRUE,NA,NA,NA
10.2217/cer-2019-0169,31948278,study_information,NA,1,NCT (only for clinical trial registered on clinicaltrials.gov),NA,NA,NCT02047734,TRUE,NA,NA,NA
10.2217/cer-2019-0169,31948278,study_information,NA,1,Country where the clinical trial/observational study was conducted (international if more than one),NA,NA,international,TRUE,NA,NA,NA
10.2217/cer-2019-0169,31948278,study_information,NA,1,Phase of the clinical trial (clinical trial only),NA,NA,3,TRUE,NA,NA,NA
10.2217/cer-2019-0169,31948278,study_information,NA,1,Number of treatment arms (clinical trial only),NA,NA,2 or more,TRUE,NA,NA,NA
10.2217/cer-2019-0169,31948278,study_information,NA,2,Patient-level data used,NA,NA,Yes,TRUE,NA,NA,NA
10.2217/cer-2019-0169,31948278,study_information,NA,2,Clinical Trial,NA,NA,Yes,TRUE,NA,NA,NA
10.2217/cer-2019-0169,31948278,study_information,NA,2,NCT (only for clinical trial registered on clinicaltrials.gov),NA,NA,NCT02294058,TRUE,NA,NA,NA
10.2217/cer-2019-0169,31948278,study_information,NA,2,Country where the clinical trial/observational study was conducted (international if more than one),NA,NA,international,TRUE,NA,NA,NA
10.2217/cer-2019-0169,31948278,study_information,NA,2,Phase of the clinical trial (clinical trial only),NA,NA,3,TRUE,NA,NA,NA
10.2217/cer-2019-0169,31948278,study_information,NA,2,Number of treatment arms (clinical trial only),NA,NA,2 or more,TRUE,NA,NA,NA
10.2217/cer-2019-0169,31948278,study_information,NA,3,Patient-level data used,NA,NA,No,TRUE,NA,NA,NA
10.2217/cer-2019-0169,31948278,study_information,NA,3,Clinical Trial,NA,NA,Yes,TRUE,NA,NA,NA
10.2217/cer-2019-0169,31948278,study_information,NA,3,NCT (only for clinical trial registered on clinicaltrials.gov),NA,NA,NCT00340834,TRUE,NA,NA,NA
10.2217/cer-2019-0169,31948278,study_information,NA,3,Country where the clinical trial/observational study was conducted (international if more than one),NA,NA,international,TRUE,NA,NA,NA
10.2217/cer-2019-0169,31948278,study_information,NA,3,Phase of the clinical trial (clinical trial only),NA,NA,3,TRUE,NA,NA,NA
10.2217/cer-2019-0169,31948278,study_information,NA,3,Number of treatment arms (clinical trial only),NA,NA,2 or more,TRUE,NA,NA,NA
10.2217/cer-2019-0169,31948278,study_information,NA,4,Patient-level data used,NA,NA,No,TRUE,NA,NA,NA
10.2217/cer-2019-0169,31948278,study_information,NA,4,Clinical Trial,NA,NA,Yes,TRUE,NA,NA,NA
10.2217/cer-2019-0169,31948278,study_information,NA,4,NCT (only for clinical trial registered on clinicaltrials.gov),NA,NA,NCT00289978,TRUE,NA,NA,NA
10.2217/cer-2019-0169,31948278,study_information,NA,4,Country where the clinical trial/observational study was conducted (international if more than one),NA,NA,international,TRUE,NA,NA,NA
10.2217/cer-2019-0169,31948278,study_information,NA,4,Phase of the clinical trial (clinical trial only),NA,NA,3,TRUE,NA,NA,NA
10.2217/cer-2019-0169,31948278,study_information,NA,4,Number of treatment arms (clinical trial only),NA,NA,2 or more,TRUE,NA,NA,NA
10.2217/cer-2019-0169,31948278,study_information,NA,5,Patient-level data used,NA,NA,No,TRUE,NA,NA,NA
10.2217/cer-2019-0169,31948278,study_information,NA,5,Clinical Trial,NA,NA,Yes,TRUE,NA,NA,NA
10.2217/cer-2019-0169,31948278,study_information,NA,5,NCT (only for clinical trial registered on clinicaltrials.gov),NA,NA,NCT00355134,TRUE,NA,NA,NA
10.2217/cer-2019-0169,31948278,study_information,NA,5,Country where the clinical trial/observational study was conducted (international if more than one),NA,NA,international,TRUE,NA,NA,NA
10.2217/cer-2019-0169,31948278,study_information,NA,5,Phase of the clinical trial (clinical trial only),NA,NA,3,TRUE,NA,NA,NA
10.2217/cer-2019-0169,31948278,study_information,NA,5,Number of treatment arms (clinical trial only),NA,NA,2 or more,TRUE,NA,NA,NA
10.2217/cer-2019-0169,31948278,methodology,1,NA,Treatment name 1,NA,NA,ozanimod,TRUE,"Say that: ""Of note, the directions and magnitudes of differences in outcomes were generally consistent both before and after matching, indicating that the trial findings were robust to the adjustment for multiple patient characteristics"": a potential general reason explaining the fact that usually no differences are found between adjusted and unadjusted results",First-dose cardiac monitoring outcomes.,NA
10.2217/cer-2019-0169,31948278,methodology,1,NA,Study 'number(s)' for treatment 1,NA,NA,1;2,TRUE,NA,NA,NA
10.2217/cer-2019-0169,31948278,methodology,1,NA,Treatment name 2,NA,NA,fingolimod,TRUE,NA,NA,NA
10.2217/cer-2019-0169,31948278,methodology,1,NA,Study 'number(s)' for treatment 2,NA,NA,3;4;5,TRUE,NA,NA,NA
10.2217/cer-2019-0169,31948278,methodology,1,NA,Type of population-adjusted indirect comparisons performed,NA,NA,MAIC,TRUE,NA,NA,NA
10.2217/cer-2019-0169,31948278,methodology,1,NA,Anchored comparison?,NA,NA,No,TRUE,NA,NA,NA
10.2217/cer-2019-0169,31948278,methodology,1,NA,Form of the indirect comparison,NA,NA,"Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate)",TRUE,NA,NA,NA
10.2217/cer-2019-0169,31948278,methodology,1,NA,Definition of a single primary outcome for the indirect comparison,NA,NA,"No primary outcome defined, or multiple primary outcomes without any clear distinction between them",TRUE,NA,NA,NA
10.2217/cer-2019-0169,31948278,methodology,1,NA,Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined),recorded heart rate < 45bpm,percentage of patients whose lowest hourly recorded heart rate was <45 bpm in the first 6 h after their first dose ( first-dose cardiac monitoring outcomes),percentage of patients whose lowest hourly recorded heart rate was <45 bpm in the first 6 h after their first dose ( first-dose cardiac monitoring outcomes),FALSE,NA,NA,NA
10.2217/cer-2019-0169,31948278,methodology,1,NA,Primary outcome: variable type,NA,NA,Binary (eg rates),TRUE,NA,NA,NA
10.2217/cer-2019-0169,31948278,methodology,1,NA,Justification for selecting variables to be included in the adjustment model (in the main text),NA,NA,A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion),TRUE,NA,NA,NA
10.2217/cer-2019-0169,31948278,methodology,1,NA,Inclusion of prognostic factors in the adjustment/matching model,NA,NA,No discussion (in the main text) of the status of prognostic factors of the variables,TRUE,NA,NA,NA
10.2217/cer-2019-0169,31948278,methodology,1,NA,Inclusion of treatment-effect modifiers in the adjustment/matching model,NA,NA,No discussion (in the main text) of the status of treatment-effect modifiers of the variables,TRUE,NA,NA,NA
10.2217/cer-2019-0169,31948278,methodology,1,NA,"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)",NA,NA,Yes,TRUE,NA,NA,NA
10.2217/cer-2019-0169,31948278,methodology,1,NA,Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale),NA,NA,No,TRUE,NA,NA,NA
10.2217/cer-2019-0169,31948278,methodology,2,NA,Treatment name 1,NA,NA,ozanimod,TRUE,NA,"Adjusted analyses of 1-year outcomes
Lymphocyte count at baseline = Other covariates",NA
10.2217/cer-2019-0169,31948278,methodology,2,NA,Study 'number(s)' for treatment 1,1,1;2,1;2,FALSE,NA,NA,NA
10.2217/cer-2019-0169,31948278,methodology,2,NA,Treatment name 2,NA,NA,fingolimod,TRUE,NA,NA,NA
10.2217/cer-2019-0169,31948278,methodology,2,NA,Study 'number(s)' for treatment 2,NA,NA,3,TRUE,NA,NA,NA
10.2217/cer-2019-0169,31948278,methodology,2,NA,Type of population-adjusted indirect comparisons performed,NA,NA,MAIC,TRUE,NA,NA,NA
10.2217/cer-2019-0169,31948278,methodology,2,NA,Anchored comparison?,NA,NA,Yes,TRUE,NA,NA,NA
10.2217/cer-2019-0169,31948278,methodology,2,NA,Form of the indirect comparison,Simple (ie treatments effects extracted from two studies),"Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate)","Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate)",FALSE,NA,NA,NA
10.2217/cer-2019-0169,31948278,methodology,2,NA,Definition of a single primary outcome for the indirect comparison,NA,NA,"No primary outcome defined, or multiple primary outcomes without any clear distinction between them",TRUE,NA,NA,NA
10.2217/cer-2019-0169,31948278,methodology,2,NA,Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined),any adverse event,risk of any adverse events at year 1 (1-year outcomes),risk of any adverse events at year 1 (1-year outcomes),FALSE,NA,NA,NA
10.2217/cer-2019-0169,31948278,methodology,2,NA,Primary outcome: variable type,NA,NA,Binary (eg rates),TRUE,NA,NA,NA
10.2217/cer-2019-0169,31948278,methodology,2,NA,Justification for selecting variables to be included in the adjustment model (in the main text),NA,NA,A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion),TRUE,NA,NA,NA
10.2217/cer-2019-0169,31948278,methodology,2,NA,Inclusion of prognostic factors in the adjustment/matching model,NA,NA,No discussion (in the main text) of the status of prognostic factors of the variables,TRUE,NA,NA,NA
10.2217/cer-2019-0169,31948278,methodology,2,NA,Inclusion of treatment-effect modifiers in the adjustment/matching model,NA,NA,No discussion (in the main text) of the status of treatment-effect modifiers of the variables,TRUE,NA,NA,NA
10.2217/cer-2019-0169,31948278,methodology,2,NA,"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)",NA,NA,Yes,TRUE,NA,NA,NA
10.2217/cer-2019-0169,31948278,methodology,2,NA,Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale),NA,NA,No,TRUE,NA,NA,NA
10.2217/cer-2019-0169,31948278,methodology,3,NA,Treatment name 1,NA,NA,ozanimod,TRUE,NA,Adjusted analyses of 2-year outcomes,NA
10.2217/cer-2019-0169,31948278,methodology,3,NA,Study 'number(s)' for treatment 1,1;2,1,1,FALSE,NA,NA,NA
10.2217/cer-2019-0169,31948278,methodology,3,NA,Treatment name 2,NA,NA,fingolimod,TRUE,NA,NA,NA
10.2217/cer-2019-0169,31948278,methodology,3,NA,Study 'number(s)' for treatment 2,NA,NA,4;5,TRUE,NA,NA,NA
10.2217/cer-2019-0169,31948278,methodology,3,NA,Type of population-adjusted indirect comparisons performed,NA,NA,MAIC,TRUE,NA,NA,NA
10.2217/cer-2019-0169,31948278,methodology,3,NA,Anchored comparison?,NA,NA,No,TRUE,NA,NA,NA
10.2217/cer-2019-0169,31948278,methodology,3,NA,Form of the indirect comparison,NA,NA,"Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate)",TRUE,NA,NA,NA
10.2217/cer-2019-0169,31948278,methodology,3,NA,Definition of a single primary outcome for the indirect comparison,NA,NA,"No primary outcome defined, or multiple primary outcomes without any clear distinction between them",TRUE,NA,NA,NA
10.2217/cer-2019-0169,31948278,methodology,3,NA,Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined),any adverse event,risk of any adverse effect at 2 years,risk of any adverse effect at 2 years,FALSE,NA,NA,NA
10.2217/cer-2019-0169,31948278,methodology,3,NA,Primary outcome: variable type,NA,NA,Binary (eg rates),TRUE,NA,NA,NA
10.2217/cer-2019-0169,31948278,methodology,3,NA,Justification for selecting variables to be included in the adjustment model (in the main text),NA,NA,A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion),TRUE,NA,NA,NA
10.2217/cer-2019-0169,31948278,methodology,3,NA,Inclusion of prognostic factors in the adjustment/matching model,NA,NA,No discussion (in the main text) of the status of prognostic factors of the variables,TRUE,NA,NA,NA
10.2217/cer-2019-0169,31948278,methodology,3,NA,Inclusion of treatment-effect modifiers in the adjustment/matching model,NA,NA,No discussion (in the main text) of the status of treatment-effect modifiers of the variables,TRUE,NA,NA,NA
10.2217/cer-2019-0169,31948278,methodology,3,NA,"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)",NA,NA,Yes,TRUE,NA,NA,NA
10.2217/cer-2019-0169,31948278,methodology,3,NA,Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale),NA,NA,No,TRUE,NA,NA,NA
10.2217/cer-2019-0169,31948278,results,1,NA,Sample size of the population of interest in the non IPD treatment arm,NA,NA,1212,TRUE,NA,NA,NA
10.2217/cer-2019-0169,31948278,results,1,NA,Initial sample size of the population of interest in the IPD treatment arm,NA,NA,1773,TRUE,NA,NA,NA
10.2217/cer-2019-0169,31948278,results,1,NA,"Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC",NA,NA,597,TRUE,NA,NA,NA
10.2217/cer-2019-0169,31948278,results,1,NA,Reporting of a weights' distribution evaluation (MAIC),NA,NA,Not mentioned,TRUE,NA,NA,NA
10.2217/cer-2019-0169,31948278,results,1,NA,Reporting of the list of the covariates adjusted for/matched on,NA,NA,Yes,TRUE,NA,NA,NA
10.2217/cer-2019-0169,31948278,results,1,NA,Number of covariates adjusted for/matched on,NA,NA,11,TRUE,NA,NA,NA
10.2217/cer-2019-0169,31948278,results,1,NA,Covariates adjusted for/matched on in the indirect comparison,"Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Past treatments for the disease of interest, Comorbidities and medical history (beside pathology/disease of interest in the comparison), Other(s)","Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Past treatments for the disease of interest, Comorbidities and medical history (beside pathology/disease of interest in the comparison)","Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Past treatments for the disease of interest, Comorbidities and medical history (beside pathology/disease of interest in the comparison), Other(s)",FALSE,NA,NA,NA
10.2217/cer-2019-0169,31948278,results,1,NA,Primary outcome: treatment effect contrast,NA,NA,Risk difference,TRUE,NA,NA,NA
10.2217/cer-2019-0169,31948278,results,1,NA,Direction of the treatment effect contrast: IPD treatment is:,NA,NA,"Numerator if ratio, or left side if difference",TRUE,NA,NA,NA
10.2217/cer-2019-0169,31948278,results,1,NA,Primary outcome: adjusted treatment effect,NA,NA,-1.4,TRUE,NA,NA,NA
10.2217/cer-2019-0169,31948278,results,1,NA,"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])",NA,NA,<0.001,TRUE,NA,NA,NA
10.2217/cer-2019-0169,31948278,results,2,NA,Sample size of the population of interest in the non IPD treatment arm,NA,NA,429,TRUE,NA,NA,NA
10.2217/cer-2019-0169,31948278,results,2,NA,"If anchored comparison, sample size of the population of interest in the non IPD treatment anchor arm",NA,NA,431,TRUE,NA,NA,NA
10.2217/cer-2019-0169,31948278,results,2,NA,Initial sample size of the population of interest in the IPD treatment arm,NA,NA,882,TRUE,NA,NA,NA
10.2217/cer-2019-0169,31948278,results,2,NA,"Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC",317,276,276,FALSE,NA,NA,NA
10.2217/cer-2019-0169,31948278,results,2,NA,"If anchored comparison, initial sample size of the population of interest in the IPD anchor arm",NA,NA,885,TRUE,NA,NA,NA
10.2217/cer-2019-0169,31948278,results,2,NA,"If anchored comparison, effective sample size after reweighting for MAIC; or sample size used in the regression model for STC in the IPD anchor arm",NA,NA,317,TRUE,NA,NA,NA
10.2217/cer-2019-0169,31948278,results,2,NA,Reporting of a weights' distribution evaluation (MAIC),NA,NA,Not mentioned,TRUE,NA,NA,NA
10.2217/cer-2019-0169,31948278,results,2,NA,Reporting of the list of the covariates adjusted for/matched on,NA,NA,Yes,TRUE,NA,NA,NA
10.2217/cer-2019-0169,31948278,results,2,NA,Number of covariates adjusted for/matched on,NA,NA,9,TRUE,NA,NA,NA
10.2217/cer-2019-0169,31948278,results,2,NA,Covariates adjusted for/matched on in the indirect comparison,NA,NA,"Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Past treatments for the disease of interest, Other(s)",TRUE,NA,NA,NA
10.2217/cer-2019-0169,31948278,results,2,NA,Primary outcome: treatment effect contrast,NA,NA,Risk difference,TRUE,NA,NA,NA
10.2217/cer-2019-0169,31948278,results,2,NA,Direction of the treatment effect contrast: IPD treatment is:,NA,NA,"Numerator if ratio, or left side if difference",TRUE,NA,NA,NA
10.2217/cer-2019-0169,31948278,results,2,NA,Primary outcome: adjusted treatment effect,NA,NA,-9.9,TRUE,NA,NA,NA
10.2217/cer-2019-0169,31948278,results,2,NA,"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])",NA,NA,<0.05,TRUE,NA,NA,NA
10.2217/cer-2019-0169,31948278,results,3,NA,Sample size of the population of interest in the non IPD treatment arm,NA,NA,783,TRUE,NA,NA,NA
10.2217/cer-2019-0169,31948278,results,3,NA,Initial sample size of the population of interest in the IPD treatment arm,NA,NA,434,TRUE,NA,NA,NA
10.2217/cer-2019-0169,31948278,results,3,NA,"Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC",NA,NA,158,TRUE,NA,NA,NA
10.2217/cer-2019-0169,31948278,results,3,NA,Reporting of a weights' distribution evaluation (MAIC),NA,NA,Not mentioned,TRUE,NA,NA,NA
10.2217/cer-2019-0169,31948278,results,3,NA,Reporting of the list of the covariates adjusted for/matched on,NA,NA,Yes,TRUE,NA,NA,NA
10.2217/cer-2019-0169,31948278,results,3,NA,Number of covariates adjusted for/matched on,NA,NA,8,TRUE,NA,NA,NA
10.2217/cer-2019-0169,31948278,results,3,NA,Covariates adjusted for/matched on in the indirect comparison,NA,NA,"Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Past treatments for the disease of interest",TRUE,NA,NA,NA
10.2217/cer-2019-0169,31948278,results,3,NA,Primary outcome: treatment effect contrast,NA,NA,Risk difference,TRUE,NA,NA,NA
10.2217/cer-2019-0169,31948278,results,3,NA,Direction of the treatment effect contrast: IPD treatment is:,NA,NA,"Numerator if ratio, or left side if difference",TRUE,NA,NA,NA
10.2217/cer-2019-0169,31948278,results,3,NA,Primary outcome: adjusted treatment effect,NA,NA,-22.7,TRUE,NA,NA,NA
10.2217/cer-2019-0169,31948278,results,3,NA,"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])",NA,NA,<0.001,TRUE,NA,NA,NA
10.1080/03007995.2020.1747999,32220214,general_information,NA,NA,Medical Condition of Interest Name,NA,NA,secondary progressive multiple sclerosis,TRUE,NA,NA,NA
10.1080/03007995.2020.1747999,32220214,general_information,NA,NA,Countries of first author affiliations,NA,NA,canada,TRUE,NA,NA,NA
10.1080/03007995.2020.1747999,32220214,general_information,NA,NA,Countries of last author affiliations,NA,NA,switzerland,TRUE,NA,NA,NA
10.1080/03007995.2020.1747999,32220214,general_information,NA,NA,"Positions of study investigators (for any authors of the article, any that applies)",NA,NA,"Academic, Pharmaceutical Industry, Private Data Analysis Company",TRUE,NA,NA,NA
10.1080/03007995.2020.1747999,32220214,general_information,NA,NA,"At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company",NA,NA,Yes,TRUE,NA,NA,NA
10.1080/03007995.2020.1747999,32220214,general_information,NA,NA,Mentioned sources of funding,NA,NA,Pharmaceutical Industry,TRUE,NA,NA,NA
10.1080/03007995.2020.1747999,32220214,general_information,NA,NA,"Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article",NA,NA,Yes,TRUE,NA,NA,NA
10.1080/03007995.2020.1747999,32220214,general_information,NA,NA,Mention of a systematic review to find the studies to compare treatments of interest,NA,NA,Yes,TRUE,NA,NA,NA
10.1080/03007995.2020.1747999,32220214,study_information,NA,1,Patient-level data used,NA,NA,Yes,TRUE,NA,NA,NA
10.1080/03007995.2020.1747999,32220214,study_information,NA,1,Clinical Trial,NA,NA,Yes,TRUE,NA,NA,NA
10.1080/03007995.2020.1747999,32220214,study_information,NA,1,NCT (only for clinical trial registered on clinicaltrials.gov),NA,NA,NCT01665144,TRUE,NA,NA,NA
10.1080/03007995.2020.1747999,32220214,study_information,NA,1,Country where the clinical trial/observational study was conducted (international if more than one),NA,NA,international,TRUE,NA,NA,NA
10.1080/03007995.2020.1747999,32220214,study_information,NA,1,Phase of the clinical trial (clinical trial only),NA,NA,3,TRUE,NA,NA,NA
10.1080/03007995.2020.1747999,32220214,study_information,NA,1,Number of treatment arms (clinical trial only),NA,NA,2 or more,TRUE,NA,NA,NA
10.1080/03007995.2020.1747999,32220214,study_information,NA,2,Patient-level data used,NA,NA,No,TRUE,NA,NA,NA
10.1080/03007995.2020.1747999,32220214,study_information,NA,2,Clinical Trial,NA,NA,Yes,TRUE,NA,NA,NA
10.1080/03007995.2020.1747999,32220214,study_information,NA,2,NCT (only for clinical trial registered on clinicaltrials.gov),NA,NA,NCT01416181,TRUE,NA,NA,NA
10.1080/03007995.2020.1747999,32220214,study_information,NA,2,Country where the clinical trial/observational study was conducted (international if more than one),NA,NA,international,TRUE,NA,NA,NA
10.1080/03007995.2020.1747999,32220214,study_information,NA,2,Phase of the clinical trial (clinical trial only),NA,NA,3,TRUE,NA,NA,NA
10.1080/03007995.2020.1747999,32220214,study_information,NA,2,Number of treatment arms (clinical trial only),NA,NA,2 or more,TRUE,NA,NA,NA
10.1080/03007995.2020.1747999,32220214,study_information,NA,3,Patient-level data used,NA,NA,No,TRUE,NA,NA,NA
10.1080/03007995.2020.1747999,32220214,study_information,NA,3,Clinical Trial,NA,NA,Yes,TRUE,NA,NA,NA
10.1080/03007995.2020.1747999,32220214,study_information,NA,3,Data source name (only if observational study or clinical trial without NCT),NA,NA,nordic spms study,TRUE,NA,NA,NA
10.1080/03007995.2020.1747999,32220214,study_information,NA,3,Country where the clinical trial/observational study was conducted (international if more than one),NA,NA,international,TRUE,NA,NA,NA
10.1080/03007995.2020.1747999,32220214,study_information,NA,3,Number of treatment arms (clinical trial only),NA,NA,2 or more,TRUE,NA,NA,NA
10.1080/03007995.2020.1747999,32220214,study_information,NA,3,Phase of the clinical trial (clinical trial only),3,NA,XXXX,FALSE,NA,NA,NA
10.1080/03007995.2020.1747999,32220214,study_information,NA,4,Patient-level data used,NA,NA,No,TRUE,NA,NA,NA
10.1080/03007995.2020.1747999,32220214,study_information,NA,4,Clinical Trial,NA,NA,Yes,TRUE,NA,NA,NA
10.1080/03007995.2020.1747999,32220214,study_information,NA,4,Data source name (only if observational study or clinical trial without NCT),NA,NA,panitch et al. (2004) (north american study),TRUE,NA,NA,NA
10.1080/03007995.2020.1747999,32220214,study_information,NA,4,Country where the clinical trial/observational study was conducted (international if more than one),NA,NA,international,TRUE,NA,NA,NA
10.1080/03007995.2020.1747999,32220214,study_information,NA,4,Number of treatment arms (clinical trial only),NA,NA,2 or more,TRUE,NA,NA,NA
10.1080/03007995.2020.1747999,32220214,study_information,NA,5,Patient-level data used,NA,NA,No,TRUE,NA,NA,NA
10.1080/03007995.2020.1747999,32220214,study_information,NA,5,Clinical Trial,NA,NA,Yes,TRUE,NA,NA,NA
10.1080/03007995.2020.1747999,32220214,study_information,NA,5,Data source name (only if observational study or clinical trial without NCT),NA,NA,cohen et al. (2002) (impact),TRUE,NA,NA,NA
10.1080/03007995.2020.1747999,32220214,study_information,NA,5,Number of treatment arms (clinical trial only),NA,NA,2 or more,TRUE,NA,NA,NA
10.1080/03007995.2020.1747999,32220214,study_information,NA,5,Country where the clinical trial/observational study was conducted (international if more than one),international,NA,XXXX,FALSE,NA,NA,NA
10.1080/03007995.2020.1747999,32220214,study_information,NA,6,Patient-level data used,NA,NA,No,TRUE,NA,NA,NA
10.1080/03007995.2020.1747999,32220214,study_information,NA,6,Clinical Trial,NA,NA,Yes,TRUE,NA,NA,NA
10.1080/03007995.2020.1747999,32220214,study_information,NA,6,Data source name (only if observational study or clinical trial without NCT),NA,NA,spectrims study group (2001) li et al. (2001),TRUE,NA,NA,NA
10.1080/03007995.2020.1747999,32220214,study_information,NA,6,Number of treatment arms (clinical trial only),NA,NA,2 or more,TRUE,NA,NA,NA
10.1080/03007995.2020.1747999,32220214,study_information,NA,6,Country where the clinical trial/observational study was conducted (international if more than one),international,NA,XXXX,FALSE,NA,NA,NA
10.1080/03007995.2020.1747999,32220214,study_information,NA,7,Patient-level data used,NA,NA,No,TRUE,NA,NA,NA
10.1080/03007995.2020.1747999,32220214,study_information,NA,7,Clinical Trial,NA,NA,Yes,TRUE,NA,NA,NA
10.1080/03007995.2020.1747999,32220214,study_information,NA,7,Data source name (only if observational study or clinical trial without NCT),NA,NA,european study group (1998) kappos et al. (2001),TRUE,NA,NA,NA
10.1080/03007995.2020.1747999,32220214,study_information,NA,7,Country where the clinical trial/observational study was conducted (international if more than one),NA,NA,international,TRUE,NA,NA,NA
10.1080/03007995.2020.1747999,32220214,study_information,NA,7,Number of treatment arms (clinical trial only),NA,NA,2 or more,TRUE,NA,NA,NA
10.1080/03007995.2020.1747999,32220214,methodology,1,NA,Treatment name 1,NA,NA,siponimod,TRUE,"Also conduct a STC, but only report results in supplemental materials   Non IPD 939
	IPD 543   410","N non IPD (bras intervention + bras placebo) = 939
N IPD (bras intervention + bras placebo) = 543
ESS IPD (bras intervention + bras placebo) = 410",NA
10.1080/03007995.2020.1747999,32220214,methodology,1,NA,Study 'number(s)' for treatment 1,NA,NA,1,TRUE,NA,NA,NA
10.1080/03007995.2020.1747999,32220214,methodology,1,NA,Treatment name 2,NA,NA,ifnÎ²-1b 250 Î¼g once every other day (q2d),TRUE,NA,NA,NA
10.1080/03007995.2020.1747999,32220214,methodology,1,NA,Study 'number(s)' for treatment 2,NA,NA,4,TRUE,NA,NA,NA
10.1080/03007995.2020.1747999,32220214,methodology,1,NA,Type of population-adjusted indirect comparisons performed,NA,NA,MAIC,TRUE,NA,NA,NA
10.1080/03007995.2020.1747999,32220214,methodology,1,NA,Anchored comparison?,NA,NA,Yes,TRUE,NA,NA,NA
10.1080/03007995.2020.1747999,32220214,methodology,1,NA,Form of the indirect comparison,NA,NA,Simple (ie treatments effects extracted from two studies),TRUE,NA,NA,NA
10.1080/03007995.2020.1747999,32220214,methodology,1,NA,Definition of a single primary outcome for the indirect comparison,NA,NA,"No primary outcome defined, or multiple primary outcomes without any clear distinction between them",TRUE,NA,NA,NA
10.1080/03007995.2020.1747999,32220214,methodology,1,NA,Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined),risk of sustained disability at 6 month,time to confirmed disability progression at six months (cdp-6),time to confirmed disability progression at six months (cdp-6),FALSE,NA,NA,NA
10.1080/03007995.2020.1747999,32220214,methodology,1,NA,Primary outcome: variable type,NA,NA,Time-to-event,TRUE,NA,NA,NA
10.1080/03007995.2020.1747999,32220214,methodology,1,NA,Justification for selecting variables to be included in the adjustment model (in the main text),NA,NA,"Status of prognostic factor/treatment effect modified assessed in the IPD dataset, A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion)",TRUE,NA,NA,NA
10.1080/03007995.2020.1747999,32220214,methodology,1,NA,Inclusion of prognostic factors in the adjustment/matching model,NA,NA,No,TRUE,NA,NA,NA
10.1080/03007995.2020.1747999,32220214,methodology,1,NA,Inclusion of treatment-effect modifiers in the adjustment/matching model,NA,NA,Yes,TRUE,NA,NA,NA
10.1080/03007995.2020.1747999,32220214,methodology,1,NA,"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)",NA,NA,No,TRUE,NA,NA,NA
10.1080/03007995.2020.1747999,32220214,methodology,1,NA,Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale),NA,NA,No,TRUE,NA,NA,NA
10.1080/03007995.2020.1747999,32220214,methodology,2,NA,Treatment name 1,NA,NA,siponimod,TRUE,"NonIPD   364
IPD  578   Scenario A 157","N non IPD (bras intervention + bras placebo) = 364
N IPD (bras intervention + bras placebo) = 578
ESS IPD (bras intervention + bras placebo) = 157",NA
10.1080/03007995.2020.1747999,32220214,methodology,2,NA,Study 'number(s)' for treatment 1,NA,NA,1,TRUE,NA,NA,NA
10.1080/03007995.2020.1747999,32220214,methodology,2,NA,Treatment name 2,NA,NA,ifnÎ²-1a 22 Î¼g once weekly (qw),TRUE,NA,NA,NA
10.1080/03007995.2020.1747999,32220214,methodology,2,NA,Study 'number(s)' for treatment 2,NA,NA,3,TRUE,NA,NA,NA
10.1080/03007995.2020.1747999,32220214,methodology,2,NA,Type of population-adjusted indirect comparisons performed,NA,NA,MAIC,TRUE,NA,NA,NA
10.1080/03007995.2020.1747999,32220214,methodology,2,NA,Anchored comparison?,NA,NA,Yes,TRUE,NA,NA,NA
10.1080/03007995.2020.1747999,32220214,methodology,2,NA,Form of the indirect comparison,NA,NA,Simple (ie treatments effects extracted from two studies),TRUE,NA,NA,NA
10.1080/03007995.2020.1747999,32220214,methodology,2,NA,Definition of a single primary outcome for the indirect comparison,NA,NA,"No primary outcome defined, or multiple primary outcomes without any clear distinction between them",TRUE,NA,NA,NA
10.1080/03007995.2020.1747999,32220214,methodology,2,NA,Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined),risk of sustained disability at 6 month,time to confirmed disability progression at six months (cdp-6),time to confirmed disability progression at six months (cdp-6),FALSE,NA,NA,NA
10.1080/03007995.2020.1747999,32220214,methodology,2,NA,Primary outcome: variable type,NA,NA,Time-to-event,TRUE,NA,NA,NA
10.1080/03007995.2020.1747999,32220214,methodology,2,NA,Justification for selecting variables to be included in the adjustment model (in the main text),NA,NA,"Status of prognostic factor/treatment effect modified assessed in the IPD dataset, A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion)",TRUE,NA,NA,NA
10.1080/03007995.2020.1747999,32220214,methodology,2,NA,Inclusion of prognostic factors in the adjustment/matching model,NA,NA,No,TRUE,NA,NA,NA
10.1080/03007995.2020.1747999,32220214,methodology,2,NA,Inclusion of treatment-effect modifiers in the adjustment/matching model,NA,NA,Yes,TRUE,NA,NA,NA
10.1080/03007995.2020.1747999,32220214,methodology,2,NA,"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)",NA,NA,No,TRUE,NA,NA,NA
10.1080/03007995.2020.1747999,32220214,methodology,2,NA,Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale),NA,NA,No,TRUE,NA,NA,NA
10.1080/03007995.2020.1747999,32220214,methodology,3,NA,Treatment name 1,NA,NA,siponimod,TRUE,"NonIPD 887
IPD 608  Scenario A 516","N non IPD (bras intervention + bras placebo) = 887
N IPD (bras intervention + bras placebo) = 608
ESS IPD (bras intervention + bras placebo) = 516",NA
10.1080/03007995.2020.1747999,32220214,methodology,3,NA,Study 'number(s)' for treatment 1,NA,NA,1,TRUE,NA,NA,NA
10.1080/03007995.2020.1747999,32220214,methodology,3,NA,Treatment name 2,NA,NA,natalizumab,TRUE,NA,NA,NA
10.1080/03007995.2020.1747999,32220214,methodology,3,NA,Study 'number(s)' for treatment 2,NA,NA,2,TRUE,NA,NA,NA
10.1080/03007995.2020.1747999,32220214,methodology,3,NA,Type of population-adjusted indirect comparisons performed,NA,NA,MAIC,TRUE,NA,NA,NA
10.1080/03007995.2020.1747999,32220214,methodology,3,NA,Anchored comparison?,NA,NA,Yes,TRUE,NA,NA,NA
10.1080/03007995.2020.1747999,32220214,methodology,3,NA,Form of the indirect comparison,NA,NA,Simple (ie treatments effects extracted from two studies),TRUE,NA,NA,NA
10.1080/03007995.2020.1747999,32220214,methodology,3,NA,Definition of a single primary outcome for the indirect comparison,NA,NA,"No primary outcome defined, or multiple primary outcomes without any clear distinction between them",TRUE,NA,NA,NA
10.1080/03007995.2020.1747999,32220214,methodology,3,NA,Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined),risk of sustained disability at 6 month,the proportion of patients who experienced cdp-6 (confirmed disability progression at six months) by 96 weeks based on an increase in edss alone,the proportion of patients who experienced cdp-6 (confirmed disability progression at six months) by 96 weeks based on an increase in edss alone,FALSE,NA,NA,NA
10.1080/03007995.2020.1747999,32220214,methodology,3,NA,Primary outcome: variable type,Time-to-event,Binary (eg rates),Binary (eg rates),FALSE,NA,NA,NA
10.1080/03007995.2020.1747999,32220214,methodology,3,NA,Justification for selecting variables to be included in the adjustment model (in the main text),NA,NA,"Status of prognostic factor/treatment effect modified assessed in the IPD dataset, A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion)",TRUE,NA,NA,NA
10.1080/03007995.2020.1747999,32220214,methodology,3,NA,Inclusion of prognostic factors in the adjustment/matching model,NA,NA,No,TRUE,NA,NA,NA
10.1080/03007995.2020.1747999,32220214,methodology,3,NA,Inclusion of treatment-effect modifiers in the adjustment/matching model,NA,NA,Yes,TRUE,NA,NA,NA
10.1080/03007995.2020.1747999,32220214,methodology,3,NA,"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)",NA,NA,No,TRUE,NA,NA,NA
10.1080/03007995.2020.1747999,32220214,methodology,3,NA,Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale),NA,NA,No,TRUE,NA,NA,NA
10.1080/03007995.2020.1747999,32220214,methodology,4,NA,Treatment name 1,NA,NA,siponimod,TRUE,"NonIPD  618
	IPD 455   Scenario A 237","N non IPD (bras  IFNÎ²-1a 22ug + bras  IFNÎ²-1a 44ug + bras placebo) = 618
N IPD (bras intervention + bras placebo) = 455
ESS IPD (bras intervention + bras placebo) = 237",NA
10.1080/03007995.2020.1747999,32220214,methodology,4,NA,Study 'number(s)' for treatment 1,NA,NA,1,TRUE,NA,NA,NA
10.1080/03007995.2020.1747999,32220214,methodology,4,NA,Treatment name 2,NA,NA,sc ifnÎ²-1a 22 Î¼g three times weekly,TRUE,NA,NA,NA
10.1080/03007995.2020.1747999,32220214,methodology,4,NA,Study 'number(s)' for treatment 2,NA,NA,6,TRUE,NA,NA,NA
10.1080/03007995.2020.1747999,32220214,methodology,4,NA,Type of population-adjusted indirect comparisons performed,NA,NA,MAIC,TRUE,NA,NA,NA
10.1080/03007995.2020.1747999,32220214,methodology,4,NA,Anchored comparison?,NA,NA,Yes,TRUE,NA,NA,NA
10.1080/03007995.2020.1747999,32220214,methodology,4,NA,Form of the indirect comparison,NA,NA,Simple (ie treatments effects extracted from two studies),TRUE,NA,NA,NA
10.1080/03007995.2020.1747999,32220214,methodology,4,NA,Definition of a single primary outcome for the indirect comparison,NA,NA,"No primary outcome defined, or multiple primary outcomes without any clear distinction between them",TRUE,NA,NA,NA
10.1080/03007995.2020.1747999,32220214,methodology,4,NA,Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined),risk of sustained disability at 6 month,time to confirmed disability progression at three months (cdp-3),time to confirmed disability progression at three months (cdp-3),FALSE,NA,NA,NA
10.1080/03007995.2020.1747999,32220214,methodology,4,NA,Primary outcome: variable type,NA,NA,Time-to-event,TRUE,NA,NA,NA
10.1080/03007995.2020.1747999,32220214,methodology,4,NA,Justification for selecting variables to be included in the adjustment model (in the main text),NA,NA,"Status of prognostic factor/treatment effect modified assessed in the IPD dataset, A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion)",TRUE,NA,NA,NA
10.1080/03007995.2020.1747999,32220214,methodology,4,NA,Inclusion of prognostic factors in the adjustment/matching model,NA,NA,No,TRUE,NA,NA,NA
10.1080/03007995.2020.1747999,32220214,methodology,4,NA,Inclusion of treatment-effect modifiers in the adjustment/matching model,NA,NA,Yes,TRUE,NA,NA,NA
10.1080/03007995.2020.1747999,32220214,methodology,4,NA,"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)",NA,NA,No,TRUE,NA,NA,NA
10.1080/03007995.2020.1747999,32220214,methodology,4,NA,Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale),NA,NA,No,TRUE,NA,NA,NA
10.1080/03007995.2020.1747999,32220214,methodology,5,NA,Treatment name 1,NA,NA,siponimod,TRUE,"NonIPD  618
IPD 455   Scenario A 237","N non IPD (bras  IFNÎ²-1a 22ug + bras  IFNÎ²-1a 44ug + bras placebo) = 618
N IPD (bras intervention + bras placebo) = 455
ESS IPD (bras intervention + bras placebo) = 237",NA
10.1080/03007995.2020.1747999,32220214,methodology,5,NA,Study 'number(s)' for treatment 1,NA,NA,1,TRUE,NA,NA,NA
10.1080/03007995.2020.1747999,32220214,methodology,5,NA,Treatment name 2,NA,NA,sc ifnÎ²-1a 44 Î¼g three times weekly,TRUE,NA,NA,NA
10.1080/03007995.2020.1747999,32220214,methodology,5,NA,Study 'number(s)' for treatment 2,NA,NA,6,TRUE,NA,NA,NA
10.1080/03007995.2020.1747999,32220214,methodology,5,NA,Type of population-adjusted indirect comparisons performed,NA,NA,MAIC,TRUE,NA,NA,NA
10.1080/03007995.2020.1747999,32220214,methodology,5,NA,Anchored comparison?,Yes,No,Yes,FALSE,NA,NA,NA
10.1080/03007995.2020.1747999,32220214,methodology,5,NA,Form of the indirect comparison,NA,NA,Simple (ie treatments effects extracted from two studies),TRUE,NA,NA,NA
10.1080/03007995.2020.1747999,32220214,methodology,5,NA,Definition of a single primary outcome for the indirect comparison,NA,NA,"No primary outcome defined, or multiple primary outcomes without any clear distinction between them",TRUE,NA,NA,NA
10.1080/03007995.2020.1747999,32220214,methodology,5,NA,Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined),risk of sustained disability at 6 month,time to confirmed disability progression at three months (cdp-3),time to confirmed disability progression at three months (cdp-3),FALSE,NA,NA,NA
10.1080/03007995.2020.1747999,32220214,methodology,5,NA,Primary outcome: variable type,NA,NA,Time-to-event,TRUE,NA,NA,NA
10.1080/03007995.2020.1747999,32220214,methodology,5,NA,Justification for selecting variables to be included in the adjustment model (in the main text),NA,NA,"Status of prognostic factor/treatment effect modified assessed in the IPD dataset, A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion)",TRUE,NA,NA,NA
10.1080/03007995.2020.1747999,32220214,methodology,5,NA,Inclusion of prognostic factors in the adjustment/matching model,NA,NA,No,TRUE,NA,NA,NA
10.1080/03007995.2020.1747999,32220214,methodology,5,NA,Inclusion of treatment-effect modifiers in the adjustment/matching model,NA,NA,Yes,TRUE,NA,NA,NA
10.1080/03007995.2020.1747999,32220214,methodology,5,NA,"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)",NA,NA,No,TRUE,NA,NA,NA
10.1080/03007995.2020.1747999,32220214,methodology,5,NA,Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale),NA,NA,No,TRUE,NA,NA,NA
10.1080/03007995.2020.1747999,32220214,methodology,6,NA,Treatment name 1,NA,NA,siponimod,TRUE,"NonIPD 718
	IPD 455  Scenario A 140","N non IPD (bras intervention + bras placebo) = 718
N IPD (bras intervention + bras placebo) = 455
ESS IPD (bras intervention + bras placebo) = 140",NA
10.1080/03007995.2020.1747999,32220214,methodology,6,NA,Study 'number(s)' for treatment 1,NA,NA,1,TRUE,NA,NA,NA
10.1080/03007995.2020.1747999,32220214,methodology,6,NA,Treatment name 2,NA,NA,ifnÎ²-1b 8 miu once every other day,TRUE,NA,NA,NA
10.1080/03007995.2020.1747999,32220214,methodology,6,NA,Study 'number(s)' for treatment 2,NA,NA,7,TRUE,NA,NA,NA
10.1080/03007995.2020.1747999,32220214,methodology,6,NA,Type of population-adjusted indirect comparisons performed,NA,NA,MAIC,TRUE,NA,NA,NA
10.1080/03007995.2020.1747999,32220214,methodology,6,NA,Anchored comparison?,NA,NA,Yes,TRUE,NA,NA,NA
10.1080/03007995.2020.1747999,32220214,methodology,6,NA,Form of the indirect comparison,NA,NA,Simple (ie treatments effects extracted from two studies),TRUE,NA,NA,NA
10.1080/03007995.2020.1747999,32220214,methodology,6,NA,Definition of a single primary outcome for the indirect comparison,NA,NA,"No primary outcome defined, or multiple primary outcomes without any clear distinction between them",TRUE,NA,NA,NA
10.1080/03007995.2020.1747999,32220214,methodology,6,NA,Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined),risk of sustained disability at 6 month,time to confirmed disability progression at three months (cdp-3),time to confirmed disability progression at three months (cdp-3),FALSE,NA,NA,NA
10.1080/03007995.2020.1747999,32220214,methodology,6,NA,Primary outcome: variable type,NA,NA,Time-to-event,TRUE,NA,NA,NA
10.1080/03007995.2020.1747999,32220214,methodology,6,NA,Justification for selecting variables to be included in the adjustment model (in the main text),NA,NA,"Status of prognostic factor/treatment effect modified assessed in the IPD dataset, A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion)",TRUE,NA,NA,NA
10.1080/03007995.2020.1747999,32220214,methodology,6,NA,Inclusion of prognostic factors in the adjustment/matching model,NA,NA,No,TRUE,NA,NA,NA
10.1080/03007995.2020.1747999,32220214,methodology,6,NA,Inclusion of treatment-effect modifiers in the adjustment/matching model,NA,NA,Yes,TRUE,NA,NA,NA
10.1080/03007995.2020.1747999,32220214,methodology,6,NA,"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)",NA,NA,No,TRUE,NA,NA,NA
10.1080/03007995.2020.1747999,32220214,methodology,6,NA,Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale),NA,NA,No,TRUE,NA,NA,NA
10.1080/03007995.2020.1747999,32220214,methodology,7,NA,Treatment name 1,NA,NA,siponimod,TRUE,"NonIPD  436
	IPD   563  113","N non IPD (bras intervention + bras placebo) = 436
N IPD (bras intervention + bras placebo) = 563
ESS IPD (bras intervention + bras placebo) = 113

Pour chacune de ces 7 formulaire (MAIC), une autre MAIC a Ã©tÃ© rÃ©alisÃ©e pour un autre outcome (annualized relapse rate) avec d'autres covariables (5) et des effectifs diffÃ©rents.",NA
10.1080/03007995.2020.1747999,32220214,methodology,7,NA,Study 'number(s)' for treatment 1,NA,NA,1,TRUE,NA,NA,NA
10.1080/03007995.2020.1747999,32220214,methodology,7,NA,Treatment name 2,NA,NA,im ifnÎ²-1a 60 Î¼g once weekly,TRUE,NA,NA,NA
10.1080/03007995.2020.1747999,32220214,methodology,7,NA,Study 'number(s)' for treatment 2,NA,NA,5,TRUE,NA,NA,NA
10.1080/03007995.2020.1747999,32220214,methodology,7,NA,Type of population-adjusted indirect comparisons performed,NA,NA,MAIC,TRUE,NA,NA,NA
10.1080/03007995.2020.1747999,32220214,methodology,7,NA,Anchored comparison?,NA,NA,Yes,TRUE,NA,NA,NA
10.1080/03007995.2020.1747999,32220214,methodology,7,NA,Form of the indirect comparison,NA,NA,Simple (ie treatments effects extracted from two studies),TRUE,NA,NA,NA
10.1080/03007995.2020.1747999,32220214,methodology,7,NA,Definition of a single primary outcome for the indirect comparison,NA,NA,"No primary outcome defined, or multiple primary outcomes without any clear distinction between them",TRUE,NA,NA,NA
10.1080/03007995.2020.1747999,32220214,methodology,7,NA,Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined),risk of sustained disability at 6 month,time to confirmed disability progression at three months (cdp-3),time to confirmed disability progression at three months (cdp-3),FALSE,NA,NA,NA
10.1080/03007995.2020.1747999,32220214,methodology,7,NA,Primary outcome: variable type,NA,NA,Time-to-event,TRUE,NA,NA,NA
10.1080/03007995.2020.1747999,32220214,methodology,7,NA,Justification for selecting variables to be included in the adjustment model (in the main text),NA,NA,"Status of prognostic factor/treatment effect modified assessed in the IPD dataset, A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion)",TRUE,NA,NA,NA
10.1080/03007995.2020.1747999,32220214,methodology,7,NA,Inclusion of prognostic factors in the adjustment/matching model,NA,NA,No,TRUE,NA,NA,NA
10.1080/03007995.2020.1747999,32220214,methodology,7,NA,Inclusion of treatment-effect modifiers in the adjustment/matching model,NA,NA,Yes,TRUE,NA,NA,NA
10.1080/03007995.2020.1747999,32220214,methodology,7,NA,"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)",NA,NA,No,TRUE,NA,NA,NA
10.1080/03007995.2020.1747999,32220214,methodology,7,NA,Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale),NA,NA,No,TRUE,NA,NA,NA
10.1080/03007995.2020.1747999,32220214,results,1,NA,Reporting of a weights' distribution evaluation (MAIC),NA,NA,Not mentioned,TRUE,NA,NA,NA
10.1080/03007995.2020.1747999,32220214,results,1,NA,Reporting of the list of the covariates adjusted for/matched on,NA,NA,Yes,TRUE,NA,NA,NA
10.1080/03007995.2020.1747999,32220214,results,1,NA,Number of covariates adjusted for/matched on,6,10,10,FALSE,NA,NA,NA
10.1080/03007995.2020.1747999,32220214,results,1,NA,Covariates adjusted for/matched on in the indirect comparison,"Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease)","Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Past treatments for the disease of interest","Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Past treatments for the disease of interest",FALSE,NA,NA,NA
10.1080/03007995.2020.1747999,32220214,results,1,NA,Primary outcome: treatment effect contrast,NA,NA,HR,TRUE,NA,NA,NA
10.1080/03007995.2020.1747999,32220214,results,1,NA,Direction of the treatment effect contrast: IPD treatment is:,NA,NA,"Numerator if ratio, or left side if difference",TRUE,NA,NA,NA
10.1080/03007995.2020.1747999,32220214,results,1,NA,Primary outcome: adjusted treatment effect,NA,NA,0.55,TRUE,NA,NA,NA
10.1080/03007995.2020.1747999,32220214,results,1,NA,"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])",NA,NA,[0.33;0.91],TRUE,NA,NA,NA
10.1080/03007995.2020.1747999,32220214,results,2,NA,Reporting of a weights' distribution evaluation (MAIC),NA,NA,Not mentioned,TRUE,NA,NA,NA
10.1080/03007995.2020.1747999,32220214,results,2,NA,Reporting of the list of the covariates adjusted for/matched on,NA,NA,Yes,TRUE,NA,NA,NA
10.1080/03007995.2020.1747999,32220214,results,2,NA,Number of covariates adjusted for/matched on,5,10,10,FALSE,NA,NA,NA
10.1080/03007995.2020.1747999,32220214,results,2,NA,Covariates adjusted for/matched on in the indirect comparison,"Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease)","Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Past treatments for the disease of interest","Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Past treatments for the disease of interest",FALSE,NA,NA,NA
10.1080/03007995.2020.1747999,32220214,results,2,NA,Primary outcome: treatment effect contrast,NA,NA,HR,TRUE,NA,NA,NA
10.1080/03007995.2020.1747999,32220214,results,2,NA,Direction of the treatment effect contrast: IPD treatment is:,NA,NA,"Numerator if ratio, or left side if difference",TRUE,NA,NA,NA
10.1080/03007995.2020.1747999,32220214,results,2,NA,Primary outcome: adjusted treatment effect,NA,NA,0.43,TRUE,NA,NA,NA
10.1080/03007995.2020.1747999,32220214,results,2,NA,"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])",NA,NA,[0.20;0.93],TRUE,NA,NA,NA
10.1080/03007995.2020.1747999,32220214,results,3,NA,Reporting of a weights' distribution evaluation (MAIC),NA,NA,Not mentioned,TRUE,NA,NA,NA
10.1080/03007995.2020.1747999,32220214,results,3,NA,Reporting of the list of the covariates adjusted for/matched on,NA,NA,Yes,TRUE,NA,NA,NA
10.1080/03007995.2020.1747999,32220214,results,3,NA,Number of covariates adjusted for/matched on,NA,NA,10,TRUE,NA,NA,NA
10.1080/03007995.2020.1747999,32220214,results,3,NA,Covariates adjusted for/matched on in the indirect comparison,"Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Past treatments for the disease of interest, Other(s)","Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Past treatments for the disease of interest","Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Past treatments for the disease of interest",FALSE,NA,NA,NA
10.1080/03007995.2020.1747999,32220214,results,3,NA,Primary outcome: treatment effect contrast,HR,OR,OR,FALSE,NA,NA,NA
10.1080/03007995.2020.1747999,32220214,results,3,NA,Direction of the treatment effect contrast: IPD treatment is:,NA,NA,"Numerator if ratio, or left side if difference",TRUE,NA,NA,NA
10.1080/03007995.2020.1747999,32220214,results,3,NA,Primary outcome: adjusted treatment effect,NA,NA,0.76,TRUE,NA,NA,NA
10.1080/03007995.2020.1747999,32220214,results,3,NA,"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])",NA,NA,[0.44;1.30],TRUE,NA,NA,NA
10.1080/03007995.2020.1747999,32220214,results,4,NA,Reporting of a weights' distribution evaluation (MAIC),NA,NA,Not mentioned,TRUE,NA,NA,NA
10.1080/03007995.2020.1747999,32220214,results,4,NA,Reporting of the list of the covariates adjusted for/matched on,NA,NA,Yes,TRUE,NA,NA,NA
10.1080/03007995.2020.1747999,32220214,results,4,NA,Number of covariates adjusted for/matched on,6,10,10,FALSE,NA,NA,NA
10.1080/03007995.2020.1747999,32220214,results,4,NA,Covariates adjusted for/matched on in the indirect comparison,"Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease)","Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Past treatments for the disease of interest","Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Past treatments for the disease of interest",FALSE,NA,NA,NA
10.1080/03007995.2020.1747999,32220214,results,4,NA,Primary outcome: treatment effect contrast,NA,NA,HR,TRUE,NA,NA,NA
10.1080/03007995.2020.1747999,32220214,results,4,NA,Direction of the treatment effect contrast: IPD treatment is:,NA,NA,"Numerator if ratio, or left side if difference",TRUE,NA,NA,NA
10.1080/03007995.2020.1747999,32220214,results,4,NA,Primary outcome: adjusted treatment effect,NA,NA,0.8,TRUE,NA,NA,NA
10.1080/03007995.2020.1747999,32220214,results,4,NA,"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])",NA,NA,[0.46;1.38],TRUE,NA,NA,NA
10.1080/03007995.2020.1747999,32220214,results,5,NA,Reporting of a weights' distribution evaluation (MAIC),NA,NA,Not mentioned,TRUE,NA,NA,NA
10.1080/03007995.2020.1747999,32220214,results,5,NA,Reporting of the list of the covariates adjusted for/matched on,NA,NA,Yes,TRUE,NA,NA,NA
10.1080/03007995.2020.1747999,32220214,results,5,NA,Number of covariates adjusted for/matched on,6,10,10,FALSE,NA,NA,NA
10.1080/03007995.2020.1747999,32220214,results,5,NA,Covariates adjusted for/matched on in the indirect comparison,"Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease)","Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Past treatments for the disease of interest","Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Past treatments for the disease of interest",FALSE,NA,NA,NA
10.1080/03007995.2020.1747999,32220214,results,5,NA,Primary outcome: treatment effect contrast,NA,NA,HR,TRUE,NA,NA,NA
10.1080/03007995.2020.1747999,32220214,results,5,NA,Direction of the treatment effect contrast: IPD treatment is:,NA,NA,"Numerator if ratio, or left side if difference",TRUE,NA,NA,NA
10.1080/03007995.2020.1747999,32220214,results,5,NA,Primary outcome: adjusted treatment effect,NA,NA,0.84,TRUE,NA,NA,NA
10.1080/03007995.2020.1747999,32220214,results,5,NA,"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])",NA,NA,[0.49;1.47],TRUE,NA,NA,NA
10.1080/03007995.2020.1747999,32220214,results,6,NA,Reporting of a weights' distribution evaluation (MAIC),NA,NA,Not mentioned,TRUE,NA,NA,NA
10.1080/03007995.2020.1747999,32220214,results,6,NA,Reporting of the list of the covariates adjusted for/matched on,NA,NA,Yes,TRUE,NA,NA,NA
10.1080/03007995.2020.1747999,32220214,results,6,NA,Number of covariates adjusted for/matched on,6,10,10,FALSE,NA,NA,NA
10.1080/03007995.2020.1747999,32220214,results,6,NA,Covariates adjusted for/matched on in the indirect comparison,"Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease)","Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Past treatments for the disease of interest","Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Past treatments for the disease of interest",FALSE,NA,NA,NA
10.1080/03007995.2020.1747999,32220214,results,6,NA,Primary outcome: treatment effect contrast,NA,NA,HR,TRUE,NA,NA,NA
10.1080/03007995.2020.1747999,32220214,results,6,NA,Direction of the treatment effect contrast: IPD treatment is:,NA,NA,"Numerator if ratio, or left side if difference",TRUE,NA,NA,NA
10.1080/03007995.2020.1747999,32220214,results,6,NA,Primary outcome: adjusted treatment effect,NA,NA,0.82,TRUE,NA,NA,NA
10.1080/03007995.2020.1747999,32220214,results,6,NA,"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])",NA,NA,[0.42;1.63],TRUE,NA,NA,NA
10.1080/03007995.2020.1747999,32220214,results,7,NA,Reporting of a weights' distribution evaluation (MAIC),NA,NA,Not mentioned,TRUE,NA,NA,NA
10.1080/03007995.2020.1747999,32220214,results,7,NA,Reporting of the list of the covariates adjusted for/matched on,NA,NA,Yes,TRUE,NA,NA,NA
10.1080/03007995.2020.1747999,32220214,results,7,NA,Number of covariates adjusted for/matched on,6,10,10,FALSE,NA,NA,NA
10.1080/03007995.2020.1747999,32220214,results,7,NA,Covariates adjusted for/matched on in the indirect comparison,"Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease)","Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Past treatments for the disease of interest","Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Past treatments for the disease of interest",FALSE,NA,NA,NA
10.1080/03007995.2020.1747999,32220214,results,7,NA,Primary outcome: treatment effect contrast,NA,NA,HR,TRUE,NA,NA,NA
10.1080/03007995.2020.1747999,32220214,results,7,NA,Direction of the treatment effect contrast: IPD treatment is:,NA,NA,"Numerator if ratio, or left side if difference",TRUE,NA,NA,NA
10.1080/03007995.2020.1747999,32220214,results,7,NA,Primary outcome: adjusted treatment effect,NA,NA,0.42,TRUE,NA,NA,NA
10.1080/03007995.2020.1747999,32220214,results,7,NA,"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])",NA,NA,[0.20;0.88],TRUE,NA,NA,NA
10.1080/09546634.2020.1747592,32299269,general_information,NA,NA,Medical Condition of Interest Name,NA,NA,moderate-to-severe plaque psoriasis,TRUE,NA,NA,NA
10.1080/09546634.2020.1747592,32299269,general_information,NA,NA,Countries of first author affiliations,NA,NA,usa,TRUE,NA,NA,NA
10.1080/09546634.2020.1747592,32299269,general_information,NA,NA,Countries of last author affiliations,NA,NA,germany,TRUE,NA,NA,NA
10.1080/09546634.2020.1747592,32299269,general_information,NA,NA,"Positions of study investigators (for any authors of the article, any that applies)",NA,NA,"Academic, Pharmaceutical Industry",TRUE,NA,NA,NA
10.1080/09546634.2020.1747592,32299269,general_information,NA,NA,"At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company",Yes,Not mentioned,XXXX,FALSE,NA,NA,NA
10.1080/09546634.2020.1747592,32299269,general_information,NA,NA,Mentioned sources of funding,NA,NA,Pharmaceutical Industry,TRUE,NA,NA,NA
10.1080/09546634.2020.1747592,32299269,general_information,NA,NA,"Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article",NA,NA,Yes,TRUE,NA,NA,NA
10.1080/09546634.2020.1747592,32299269,general_information,NA,NA,Mention of a systematic review to find the studies to compare treatments of interest,NA,NA,No,TRUE,NA,NA,NA
10.1080/09546634.2020.1747592,32299269,study_information,NA,1,Patient-level data used,NA,NA,Yes,TRUE,NA,NA,NA
10.1080/09546634.2020.1747592,32299269,study_information,NA,1,Clinical Trial,NA,NA,Yes,TRUE,NA,NA,NA
10.1080/09546634.2020.1747592,32299269,study_information,NA,1,NCT (only for clinical trial registered on clinicaltrials.gov),NCT01474512,NCT01646177,NCT01646177,FALSE,NA,NA,NA
10.1080/09546634.2020.1747592,32299269,study_information,NA,1,Country where the clinical trial/observational study was conducted (international if more than one),NA,NA,international,TRUE,NA,NA,NA
10.1080/09546634.2020.1747592,32299269,study_information,NA,1,Phase of the clinical trial (clinical trial only),NA,NA,3,TRUE,NA,NA,NA
10.1080/09546634.2020.1747592,32299269,study_information,NA,1,Number of treatment arms (clinical trial only),NA,NA,2 or more,TRUE,NA,NA,NA
10.1080/09546634.2020.1747592,32299269,study_information,NA,2,Patient-level data used,NA,NA,Yes,TRUE,NA,NA,NA
10.1080/09546634.2020.1747592,32299269,study_information,NA,2,Clinical Trial,NA,NA,Yes,TRUE,NA,NA,NA
10.1080/09546634.2020.1747592,32299269,study_information,NA,2,NCT (only for clinical trial registered on clinicaltrials.gov),NA,NA,NCT01597245,TRUE,NA,NA,NA
10.1080/09546634.2020.1747592,32299269,study_information,NA,2,Country where the clinical trial/observational study was conducted (international if more than one),NA,NA,international,TRUE,NA,NA,NA
10.1080/09546634.2020.1747592,32299269,study_information,NA,2,Phase of the clinical trial (clinical trial only),NA,NA,3,TRUE,NA,NA,NA
10.1080/09546634.2020.1747592,32299269,study_information,NA,2,Number of treatment arms (clinical trial only),NA,NA,2 or more,TRUE,NA,NA,NA
10.1080/09546634.2020.1747592,32299269,study_information,NA,3,Patient-level data used,NA,NA,Yes,TRUE,NA,NA,NA
10.1080/09546634.2020.1747592,32299269,study_information,NA,3,Clinical Trial,NA,NA,Yes,TRUE,NA,NA,NA
10.1080/09546634.2020.1747592,32299269,study_information,NA,3,NCT (only for clinical trial registered on clinicaltrials.gov),NA,NA,NCT01646177,TRUE,NA,NA,NA
10.1080/09546634.2020.1747592,32299269,study_information,NA,3,Country where the clinical trial/observational study was conducted (international if more than one),NA,NA,international,TRUE,NA,NA,NA
10.1080/09546634.2020.1747592,32299269,study_information,NA,3,Phase of the clinical trial (clinical trial only),NA,NA,3,TRUE,NA,NA,NA
10.1080/09546634.2020.1747592,32299269,study_information,NA,3,Number of treatment arms (clinical trial only),NA,NA,2 or more,TRUE,NA,NA,NA
10.1080/09546634.2020.1747592,32299269,study_information,NA,4,Patient-level data used,NA,NA,Yes,TRUE,NA,NA,NA
10.1080/09546634.2020.1747592,32299269,study_information,NA,4,Clinical Trial,NA,NA,Yes,TRUE,NA,NA,NA
10.1080/09546634.2020.1747592,32299269,study_information,NA,4,NCT (only for clinical trial registered on clinicaltrials.gov),NA,NA,NCT02561806,TRUE,NA,NA,NA
10.1080/09546634.2020.1747592,32299269,study_information,NA,4,Country where the clinical trial/observational study was conducted (international if more than one),NA,NA,international,TRUE,NA,NA,NA
10.1080/09546634.2020.1747592,32299269,study_information,NA,4,Phase of the clinical trial (clinical trial only),NA,NA,3,TRUE,NA,NA,NA
10.1080/09546634.2020.1747592,32299269,study_information,NA,4,Number of treatment arms (clinical trial only),NA,NA,2 or more,TRUE,NA,NA,NA
10.1080/09546634.2020.1747592,32299269,study_information,NA,5,Patient-level data used,NA,NA,No,TRUE,NA,NA,NA
10.1080/09546634.2020.1747592,32299269,study_information,NA,5,Clinical Trial,NA,NA,Yes,TRUE,NA,NA,NA
10.1080/09546634.2020.1747592,32299269,study_information,NA,5,NCT (only for clinical trial registered on clinicaltrials.gov),NA,NA,NCT02207244,TRUE,NA,NA,NA
10.1080/09546634.2020.1747592,32299269,study_information,NA,5,Country where the clinical trial/observational study was conducted (international if more than one),NA,NA,international,TRUE,NA,NA,NA
10.1080/09546634.2020.1747592,32299269,study_information,NA,5,Phase of the clinical trial (clinical trial only),NA,NA,3,TRUE,NA,NA,NA
10.1080/09546634.2020.1747592,32299269,study_information,NA,5,Number of treatment arms (clinical trial only),NA,NA,2 or more,TRUE,NA,NA,NA
10.1080/09546634.2020.1747592,32299269,study_information,NA,6,Patient-level data used,NA,NA,No,TRUE,NA,NA,NA
10.1080/09546634.2020.1747592,32299269,study_information,NA,6,Clinical Trial,NA,NA,Yes,TRUE,NA,NA,NA
10.1080/09546634.2020.1747592,32299269,study_information,NA,6,NCT (only for clinical trial registered on clinicaltrials.gov),NA,NA,NCT01722331,TRUE,NA,NA,NA
10.1080/09546634.2020.1747592,32299269,study_information,NA,6,Phase of the clinical trial (clinical trial only),NA,NA,3,TRUE,NA,NA,NA
10.1080/09546634.2020.1747592,32299269,study_information,NA,6,Number of treatment arms (clinical trial only),NA,NA,2 or more,TRUE,NA,NA,NA
10.1080/09546634.2020.1747592,32299269,study_information,NA,7,Patient-level data used,NA,NA,No,TRUE,NA,NA,NA
10.1080/09546634.2020.1747592,32299269,study_information,NA,7,Clinical Trial,NA,NA,Yes,TRUE,NA,NA,NA
10.1080/09546634.2020.1747592,32299269,study_information,NA,7,NCT (only for clinical trial registered on clinicaltrials.gov),NA,NA,NCT01729754,TRUE,NA,NA,NA
10.1080/09546634.2020.1747592,32299269,study_information,NA,7,Phase of the clinical trial (clinical trial only),NA,NA,3,TRUE,NA,NA,NA
10.1080/09546634.2020.1747592,32299269,study_information,NA,7,Number of treatment arms (clinical trial only),NA,NA,2 or more,TRUE,NA,NA,NA
10.1080/09546634.2020.1747592,32299269,study_information,NA,8,Patient-level data used,NA,NA,No,TRUE,NA,NA,NA
10.1080/09546634.2020.1747592,32299269,study_information,NA,8,Clinical Trial,NA,NA,Yes,TRUE,NA,NA,NA
10.1080/09546634.2020.1747592,32299269,study_information,NA,8,NCT (only for clinical trial registered on clinicaltrials.gov),NA,NA,NCT02684370,TRUE,NA,NA,NA
10.1080/09546634.2020.1747592,32299269,study_information,NA,8,Phase of the clinical trial (clinical trial only),NA,NA,3,TRUE,NA,NA,NA
10.1080/09546634.2020.1747592,32299269,study_information,NA,8,Number of treatment arms (clinical trial only),NA,NA,2 or more,TRUE,NA,NA,NA
10.1080/09546634.2020.1747592,32299269,study_information,NA,9,Patient-level data used,NA,NA,No,TRUE,NA,NA,NA
10.1080/09546634.2020.1747592,32299269,study_information,NA,9,Clinical Trial,NA,NA,Yes,TRUE,NA,NA,NA
10.1080/09546634.2020.1747592,32299269,study_information,NA,9,NCT (only for clinical trial registered on clinicaltrials.gov),NA,NA,NCT02684357,TRUE,NA,NA,NA
10.1080/09546634.2020.1747592,32299269,study_information,NA,9,Phase of the clinical trial (clinical trial only),NA,NA,3,TRUE,NA,NA,NA
10.1080/09546634.2020.1747592,32299269,study_information,NA,9,Number of treatment arms (clinical trial only),NA,NA,2 or more,TRUE,NA,NA,NA
10.1080/09546634.2020.1747592,32299269,methodology,1,NA,Treatment name 1,NA,NA,ixekizumab,TRUE,"Using PASI 75 at week 12 
NCT provided in the article are not correct (seems like copy pasting error), the corrected ones are the one from the form
   N non IPD  927
	IPD 1952 
	ESS 1565","It seems the authors got the NCTs wrong for UNCOVER-1/2/3 :
UNCOVER-1 : NCT01597245 (NCT01474512 ???)
UNCOVER-2 : NCT01646177 (NCT01597245 ???)
UNCOVER-3 : NCT01646177 (NCT01646177 ???)   Overall matching.

Results for matching per treatment arm separately : 7.5 (1.4,
13.6)  p < 0.05

Weight = other covariates

Sample size non IPD (Guselkumab + placebo arms) = 503
Initial sample size IPD (ixekizumab + placebo arms) = 1952
ESS IPD (ixekizumab + placebo arms) = 1717
""Our analyses were not head-to-head comparisons between ixekizumab and the IL-23 p19 inhibitors, and the same limitations associated with all MAIC apply, including the assumptions that treatment effects are population dependent and that all treatment effect modifiers and prognostic factors were taken into account "" ==> Which means they used prognosis factors for weighting",NA
10.1080/09546634.2020.1747592,32299269,methodology,1,NA,Study 'number(s)' for treatment 1,NA,NA,1;2;3,TRUE,NA,NA,NA
10.1080/09546634.2020.1747592,32299269,methodology,1,NA,Treatment name 2,NA,NA,guselkumab,TRUE,NA,NA,NA
10.1080/09546634.2020.1747592,32299269,methodology,1,NA,Study 'number(s)' for treatment 2,NA,NA,5,TRUE,NA,NA,NA
10.1080/09546634.2020.1747592,32299269,methodology,1,NA,Type of population-adjusted indirect comparisons performed,NA,NA,MAIC,TRUE,NA,NA,NA
10.1080/09546634.2020.1747592,32299269,methodology,1,NA,Anchored comparison?,NA,NA,Yes,TRUE,NA,NA,NA
10.1080/09546634.2020.1747592,32299269,methodology,1,NA,Form of the indirect comparison,NA,NA,"Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate)",TRUE,NA,NA,NA
10.1080/09546634.2020.1747592,32299269,methodology,1,NA,Definition of a single primary outcome for the indirect comparison,NA,NA,"No primary outcome defined, or multiple primary outcomes without any clear distinction between them",TRUE,NA,NA,NA
10.1080/09546634.2020.1747592,32299269,methodology,1,NA,Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined),NA,NA,rate of psoriasis area severity index (pasi) 75% improvement responders,TRUE,NA,NA,NA
10.1080/09546634.2020.1747592,32299269,methodology,1,NA,Primary outcome: variable type,"Continuous (count, mean, ...)",Binary (eg rates),Binary (eg rates),FALSE,NA,NA,NA
10.1080/09546634.2020.1747592,32299269,methodology,1,NA,Justification for selecting variables to be included in the adjustment model (in the main text),NA,NA,"Nothing mentioned, not reported",TRUE,NA,NA,NA
10.1080/09546634.2020.1747592,32299269,methodology,1,NA,Inclusion of prognostic factors in the adjustment/matching model,NA,NA,Yes,TRUE,NA,NA,NA
10.1080/09546634.2020.1747592,32299269,methodology,1,NA,Inclusion of treatment-effect modifiers in the adjustment/matching model,NA,NA,Yes,TRUE,NA,NA,NA
10.1080/09546634.2020.1747592,32299269,methodology,1,NA,"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)",NA,NA,No,TRUE,NA,NA,NA
10.1080/09546634.2020.1747592,32299269,methodology,1,NA,Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale),NA,NA,No,TRUE,NA,NA,NA
10.1080/09546634.2020.1747592,32299269,methodology,2,NA,Treatment name 1,NA,NA,ixekizumab,TRUE,"Sample sizes and effect size found in supplementary materials
mean risk difference PASI 75 response at week 12 
N non IPD  927
	IPD 1952 
	ESS 1565
","Overall matching with placebo as a bridge and and 100mg as dosage for tildrakizumab

Results for matching per treatment arm separately : 26.8 (21.4,
32.8)  p < 0.001

Sample size non IPD (tildrakizumab + placebo arms) = 927
Initial sample size IPD (ixekizumab + placebo arms) = 1952
ESS IPD (ixekizumab + placebo arms) = 1565",NA
10.1080/09546634.2020.1747592,32299269,methodology,2,NA,Study 'number(s)' for treatment 1,NA,NA,1;2;3,TRUE,NA,NA,NA
10.1080/09546634.2020.1747592,32299269,methodology,2,NA,Treatment name 2,NA,NA,tildrakizumab 100mg,TRUE,NA,NA,NA
10.1080/09546634.2020.1747592,32299269,methodology,2,NA,Study 'number(s)' for treatment 2,NA,NA,6;7,TRUE,NA,NA,NA
10.1080/09546634.2020.1747592,32299269,methodology,2,NA,Type of population-adjusted indirect comparisons performed,NA,NA,MAIC,TRUE,NA,NA,NA
10.1080/09546634.2020.1747592,32299269,methodology,2,NA,Anchored comparison?,NA,NA,Yes,TRUE,NA,NA,NA
10.1080/09546634.2020.1747592,32299269,methodology,2,NA,Form of the indirect comparison,NA,NA,"Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate)",TRUE,NA,NA,NA
10.1080/09546634.2020.1747592,32299269,methodology,2,NA,Definition of a single primary outcome for the indirect comparison,NA,NA,"No primary outcome defined, or multiple primary outcomes without any clear distinction between them",TRUE,NA,NA,NA
10.1080/09546634.2020.1747592,32299269,methodology,2,NA,Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined),NA,NA,rate of psoriasis area severity index (pasi) 75% improvement responders,TRUE,NA,NA,NA
10.1080/09546634.2020.1747592,32299269,methodology,2,NA,Primary outcome: variable type,"Continuous (count, mean, ...)",Binary (eg rates),Binary (eg rates),FALSE,NA,NA,NA
10.1080/09546634.2020.1747592,32299269,methodology,2,NA,Justification for selecting variables to be included in the adjustment model (in the main text),NA,NA,"Nothing mentioned, not reported",TRUE,NA,NA,NA
10.1080/09546634.2020.1747592,32299269,methodology,2,NA,Inclusion of prognostic factors in the adjustment/matching model,NA,NA,Yes,TRUE,NA,NA,NA
10.1080/09546634.2020.1747592,32299269,methodology,2,NA,Inclusion of treatment-effect modifiers in the adjustment/matching model,NA,NA,Yes,TRUE,NA,NA,NA
10.1080/09546634.2020.1747592,32299269,methodology,2,NA,"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)",NA,NA,No,TRUE,NA,NA,NA
10.1080/09546634.2020.1747592,32299269,methodology,2,NA,Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale),NA,NA,No,TRUE,NA,NA,NA
10.1080/09546634.2020.1747592,32299269,methodology,3,NA,Treatment name 1,NA,NA,ixekizumab,TRUE,"ixekizumab vs tildrakizumab 200mg   (placebo as anchor)
N non IPD  927
	IPD 1952 
	ESS 1588","Overall matching with placebo as a bridge and and 200mg as dosage for tildrakizumab

Results for matching per treatment arm separately : 25.6 (20.2,
30.9)  p < 0.001

Sample size non IPD (tildrakizumab + placebo arms) = 927
Initial sample size IPD (ixekizumab + placebo arms) = 1952
ESS IPD (ixekizumab + placebo arms) = 1588",NA
10.1080/09546634.2020.1747592,32299269,methodology,3,NA,Study 'number(s)' for treatment 1,NA,NA,1;2;3,TRUE,NA,NA,NA
10.1080/09546634.2020.1747592,32299269,methodology,3,NA,Treatment name 2,NA,NA,tildrakizumab 200mg,TRUE,NA,NA,NA
10.1080/09546634.2020.1747592,32299269,methodology,3,NA,Study 'number(s)' for treatment 2,NA,NA,6;7,TRUE,NA,NA,NA
10.1080/09546634.2020.1747592,32299269,methodology,3,NA,Type of population-adjusted indirect comparisons performed,NA,NA,MAIC,TRUE,NA,NA,NA
10.1080/09546634.2020.1747592,32299269,methodology,3,NA,Anchored comparison?,NA,NA,Yes,TRUE,NA,NA,NA
10.1080/09546634.2020.1747592,32299269,methodology,3,NA,Form of the indirect comparison,NA,NA,"Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate)",TRUE,NA,NA,NA
10.1080/09546634.2020.1747592,32299269,methodology,3,NA,Definition of a single primary outcome for the indirect comparison,NA,NA,"No primary outcome defined, or multiple primary outcomes without any clear distinction between them",TRUE,NA,NA,NA
10.1080/09546634.2020.1747592,32299269,methodology,3,NA,Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined),NA,NA,rate of psoriasis area severity index (pasi) 75% improvement responders,TRUE,NA,NA,NA
10.1080/09546634.2020.1747592,32299269,methodology,3,NA,Primary outcome: variable type,"Continuous (count, mean, ...)",Binary (eg rates),Binary (eg rates),FALSE,NA,NA,NA
10.1080/09546634.2020.1747592,32299269,methodology,3,NA,Justification for selecting variables to be included in the adjustment model (in the main text),NA,NA,"Nothing mentioned, not reported",TRUE,NA,NA,NA
10.1080/09546634.2020.1747592,32299269,methodology,3,NA,Inclusion of prognostic factors in the adjustment/matching model,NA,NA,Yes,TRUE,NA,NA,NA
10.1080/09546634.2020.1747592,32299269,methodology,3,NA,Inclusion of treatment-effect modifiers in the adjustment/matching model,NA,NA,Yes,TRUE,NA,NA,NA
10.1080/09546634.2020.1747592,32299269,methodology,3,NA,"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)",NA,NA,No,TRUE,NA,NA,NA
10.1080/09546634.2020.1747592,32299269,methodology,3,NA,Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale),NA,NA,No,TRUE,NA,NA,NA
10.1080/09546634.2020.1747592,32299269,methodology,4,NA,Treatment name 1,NA,NA,ixekizumab,TRUE,"ixekizumab vs tildrakizumab 100mg   (etanercept as anchor)
	N non IPD  463
	IPD 1470
	ESS 1108","Overall matching with Etanercept as a bridge and and 100mg as dosage for tildrakizumab

Results for matching per treatment arm separately : 25.8 (16.6,
35.0)  p < 0.001

Sample size non IPD (tildrakizumab + placebo arms) = 463
Initial sample size IPD (ixekizumab + placebo arms) = 1470
ESS IPD (ixekizumab + placebo arms) = 1108",NA
10.1080/09546634.2020.1747592,32299269,methodology,4,NA,Study 'number(s)' for treatment 1,1;2;3,2;3,2;3,FALSE,NA,NA,NA
10.1080/09546634.2020.1747592,32299269,methodology,4,NA,Treatment name 2,NA,NA,tildrakizumab 100mg,TRUE,NA,NA,NA
10.1080/09546634.2020.1747592,32299269,methodology,4,NA,Study 'number(s)' for treatment 2,NA,NA,6;7,TRUE,NA,NA,NA
10.1080/09546634.2020.1747592,32299269,methodology,4,NA,Type of population-adjusted indirect comparisons performed,NA,NA,MAIC,TRUE,NA,NA,NA
10.1080/09546634.2020.1747592,32299269,methodology,4,NA,Anchored comparison?,NA,NA,Yes,TRUE,NA,NA,NA
10.1080/09546634.2020.1747592,32299269,methodology,4,NA,Form of the indirect comparison,NA,NA,"Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate)",TRUE,NA,NA,NA
10.1080/09546634.2020.1747592,32299269,methodology,4,NA,Definition of a single primary outcome for the indirect comparison,NA,NA,"No primary outcome defined, or multiple primary outcomes without any clear distinction between them",TRUE,NA,NA,NA
10.1080/09546634.2020.1747592,32299269,methodology,4,NA,Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined),NA,NA,rate of psoriasis area severity index (pasi) 75% improvement responders,TRUE,NA,NA,NA
10.1080/09546634.2020.1747592,32299269,methodology,4,NA,Primary outcome: variable type,"Continuous (count, mean, ...)",Binary (eg rates),Binary (eg rates),FALSE,NA,NA,NA
10.1080/09546634.2020.1747592,32299269,methodology,4,NA,Justification for selecting variables to be included in the adjustment model (in the main text),NA,NA,"Nothing mentioned, not reported",TRUE,NA,NA,NA
10.1080/09546634.2020.1747592,32299269,methodology,4,NA,Inclusion of prognostic factors in the adjustment/matching model,NA,NA,Yes,TRUE,NA,NA,NA
10.1080/09546634.2020.1747592,32299269,methodology,4,NA,Inclusion of treatment-effect modifiers in the adjustment/matching model,NA,NA,Yes,TRUE,NA,NA,NA
10.1080/09546634.2020.1747592,32299269,methodology,4,NA,"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)",NA,NA,No,TRUE,NA,NA,NA
10.1080/09546634.2020.1747592,32299269,methodology,4,NA,Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale),NA,NA,No,TRUE,NA,NA,NA
10.1080/09546634.2020.1747592,32299269,methodology,5,NA,Treatment name 1,NA,NA,ixekizumab,TRUE,"ixekizumab vs tildrakizumab 200mg   (etanercept as anchor)
	N non IPD  470
	IPD 1470
	ESS 1163","Overall matching with Etanercept as a bridge and and 200mg as dosage for tildrakizumab

Results for matching per treatment arm separately : 21.8 (12.8;
30.9)  p < 0.001

Sample size non IPD (tildrakizumab + placebo arms) = 470
Initial sample size IPD (ixekizumab + placebo arms) = 1470
ESS IPD (ixekizumab + placebo arms) = 1163",NA
10.1080/09546634.2020.1747592,32299269,methodology,5,NA,Study 'number(s)' for treatment 1,1;2;3,2;3,2;3,FALSE,NA,NA,NA
10.1080/09546634.2020.1747592,32299269,methodology,5,NA,Treatment name 2,NA,NA,tildrakizumab 200mg,TRUE,NA,NA,NA
10.1080/09546634.2020.1747592,32299269,methodology,5,NA,Study 'number(s)' for treatment 2,NA,NA,6;7,TRUE,NA,NA,NA
10.1080/09546634.2020.1747592,32299269,methodology,5,NA,Type of population-adjusted indirect comparisons performed,NA,NA,MAIC,TRUE,NA,NA,NA
10.1080/09546634.2020.1747592,32299269,methodology,5,NA,Anchored comparison?,NA,NA,Yes,TRUE,NA,NA,NA
10.1080/09546634.2020.1747592,32299269,methodology,5,NA,Form of the indirect comparison,NA,NA,"Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate)",TRUE,NA,NA,NA
10.1080/09546634.2020.1747592,32299269,methodology,5,NA,Definition of a single primary outcome for the indirect comparison,NA,NA,"No primary outcome defined, or multiple primary outcomes without any clear distinction between them",TRUE,NA,NA,NA
10.1080/09546634.2020.1747592,32299269,methodology,5,NA,Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined),NA,NA,rate of psoriasis area severity index (pasi) 75% improvement responders,TRUE,NA,NA,NA
10.1080/09546634.2020.1747592,32299269,methodology,5,NA,Primary outcome: variable type,"Continuous (count, mean, ...)",Binary (eg rates),Binary (eg rates),FALSE,NA,NA,NA
10.1080/09546634.2020.1747592,32299269,methodology,5,NA,Justification for selecting variables to be included in the adjustment model (in the main text),NA,NA,"Nothing mentioned, not reported",TRUE,NA,NA,NA
10.1080/09546634.2020.1747592,32299269,methodology,5,NA,Inclusion of prognostic factors in the adjustment/matching model,NA,NA,Yes,TRUE,NA,NA,NA
10.1080/09546634.2020.1747592,32299269,methodology,5,NA,Inclusion of treatment-effect modifiers in the adjustment/matching model,NA,NA,Yes,TRUE,NA,NA,NA
10.1080/09546634.2020.1747592,32299269,methodology,5,NA,"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)",NA,NA,No,TRUE,NA,NA,NA
10.1080/09546634.2020.1747592,32299269,methodology,5,NA,Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale),NA,NA,No,TRUE,NA,NA,NA
10.1080/09546634.2020.1747592,32299269,methodology,6,NA,Treatment name 1,NA,NA,ixekizumab,TRUE,"ixekizumab vs risankizumab (placebo as anchor)
weights and BMI counted as 2 variables
	N non IPD 798  
	IPD 1952
	ESS 1398
","Overall matching with Placebo as a bridge

Results for matching per treatment arm separately : 5.6 [0.1;11.2]   p<0.05

Sample size non IPD (risankizumab + placebo arms) = 798
Initial sample size IPD (ixekizumab + placebo arms) = 1952
ESS IPD (ixekizumab + placebo arms) = 1398

Weight = other covariate (Weight and BMI as the same covariate)",NA
10.1080/09546634.2020.1747592,32299269,methodology,6,NA,Study 'number(s)' for treatment 1,NA,NA,1;2;3,TRUE,NA,NA,NA
10.1080/09546634.2020.1747592,32299269,methodology,6,NA,Treatment name 2,NA,NA,risankizumab,TRUE,NA,NA,NA
10.1080/09546634.2020.1747592,32299269,methodology,6,NA,Study 'number(s)' for treatment 2,8;9,8,8,FALSE,NA,NA,NA
10.1080/09546634.2020.1747592,32299269,methodology,6,NA,Type of population-adjusted indirect comparisons performed,NA,NA,MAIC,TRUE,NA,NA,NA
10.1080/09546634.2020.1747592,32299269,methodology,6,NA,Anchored comparison?,NA,NA,Yes,TRUE,NA,NA,NA
10.1080/09546634.2020.1747592,32299269,methodology,6,NA,Form of the indirect comparison,NA,NA,"Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate)",TRUE,NA,NA,NA
10.1080/09546634.2020.1747592,32299269,methodology,6,NA,Definition of a single primary outcome for the indirect comparison,NA,NA,"No primary outcome defined, or multiple primary outcomes without any clear distinction between them",TRUE,NA,NA,NA
10.1080/09546634.2020.1747592,32299269,methodology,6,NA,Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined),NA,NA,rate of psoriasis area severity index (pasi) 75% improvement responders,TRUE,NA,NA,NA
10.1080/09546634.2020.1747592,32299269,methodology,6,NA,Primary outcome: variable type,"Continuous (count, mean, ...)",Binary (eg rates),Binary (eg rates),FALSE,NA,NA,NA
10.1080/09546634.2020.1747592,32299269,methodology,6,NA,Justification for selecting variables to be included in the adjustment model (in the main text),NA,NA,"Nothing mentioned, not reported",TRUE,NA,NA,NA
10.1080/09546634.2020.1747592,32299269,methodology,6,NA,Inclusion of prognostic factors in the adjustment/matching model,NA,NA,Yes,TRUE,NA,NA,NA
10.1080/09546634.2020.1747592,32299269,methodology,6,NA,Inclusion of treatment-effect modifiers in the adjustment/matching model,NA,NA,Yes,TRUE,NA,NA,NA
10.1080/09546634.2020.1747592,32299269,methodology,6,NA,"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)",NA,NA,No,TRUE,NA,NA,NA
10.1080/09546634.2020.1747592,32299269,methodology,6,NA,Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale),NA,NA,No,TRUE,NA,NA,NA
10.1080/09546634.2020.1747592,32299269,methodology,7,NA,Treatment name 1,NA,NA,ixekizumab,TRUE,"ixekizumab vs risankizumab (ustekinumab as anchor)
weights and BMI counted as 2 variables
N non IPD 797  
	IPD 252
	ESS 116","Overall matching with ustekinumab as a bridge

Results for matching per treatment arm separately : 5.7 [-9.6;20.9] 

Sample size non IPD (risankizumab + placebo arms) = 797
Initial sample size IPD (ixekizumab + placebo arms) = 256
ESS IPD (ixekizumab + placebo arms) = 116

Weight = other covariate (Weight and BMI as the same covariate)",NA
10.1080/09546634.2020.1747592,32299269,methodology,7,NA,Study 'number(s)' for treatment 1,NA,NA,4,TRUE,NA,NA,NA
10.1080/09546634.2020.1747592,32299269,methodology,7,NA,Treatment name 2,NA,NA,risankizumab,TRUE,NA,NA,NA
10.1080/09546634.2020.1747592,32299269,methodology,7,NA,Study 'number(s)' for treatment 2,NA,NA,8;9,TRUE,NA,NA,NA
10.1080/09546634.2020.1747592,32299269,methodology,7,NA,Type of population-adjusted indirect comparisons performed,NA,NA,MAIC,TRUE,NA,NA,NA
10.1080/09546634.2020.1747592,32299269,methodology,7,NA,Anchored comparison?,NA,NA,Yes,TRUE,NA,NA,NA
10.1080/09546634.2020.1747592,32299269,methodology,7,NA,Form of the indirect comparison,NA,NA,"Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate)",TRUE,NA,NA,NA
10.1080/09546634.2020.1747592,32299269,methodology,7,NA,Definition of a single primary outcome for the indirect comparison,NA,NA,"No primary outcome defined, or multiple primary outcomes without any clear distinction between them",TRUE,NA,NA,NA
10.1080/09546634.2020.1747592,32299269,methodology,7,NA,Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined),NA,NA,rate of psoriasis area severity index (pasi) 75% improvement responders,TRUE,NA,NA,NA
10.1080/09546634.2020.1747592,32299269,methodology,7,NA,Primary outcome: variable type,"Continuous (count, mean, ...)",Binary (eg rates),Binary (eg rates),FALSE,NA,NA,NA
10.1080/09546634.2020.1747592,32299269,methodology,7,NA,Justification for selecting variables to be included in the adjustment model (in the main text),Literature based (clinically or methodologically relevant to adjust on these variables based on the literature search conducted for this specific purpose),"Nothing mentioned, not reported","Nothing mentioned, not reported",FALSE,NA,NA,NA
10.1080/09546634.2020.1747592,32299269,methodology,7,NA,Inclusion of prognostic factors in the adjustment/matching model,NA,NA,Yes,TRUE,NA,NA,NA
10.1080/09546634.2020.1747592,32299269,methodology,7,NA,Inclusion of treatment-effect modifiers in the adjustment/matching model,NA,NA,Yes,TRUE,NA,NA,NA
10.1080/09546634.2020.1747592,32299269,methodology,7,NA,"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)",NA,NA,No,TRUE,NA,NA,NA
10.1080/09546634.2020.1747592,32299269,methodology,7,NA,Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale),NA,NA,No,TRUE,NA,NA,NA
10.1080/09546634.2020.1747592,32299269,results,1,NA,Reporting of a weights' distribution evaluation (MAIC),NA,NA,Not mentioned,TRUE,NA,NA,NA
10.1080/09546634.2020.1747592,32299269,results,1,NA,Reporting of the list of the covariates adjusted for/matched on,NA,NA,Yes,TRUE,NA,NA,NA
10.1080/09546634.2020.1747592,32299269,results,1,NA,Number of covariates adjusted for/matched on,NA,NA,8,TRUE,NA,NA,NA
10.1080/09546634.2020.1747592,32299269,results,1,NA,Covariates adjusted for/matched on in the indirect comparison,NA,NA,"Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Past treatments for the disease of interest, Other(s)",TRUE,NA,NA,NA
10.1080/09546634.2020.1747592,32299269,results,1,NA,Primary outcome: treatment effect contrast,Means difference,Risk difference,Risk difference,FALSE,NA,NA,NA
10.1080/09546634.2020.1747592,32299269,results,1,NA,Direction of the treatment effect contrast: IPD treatment is:,NA,NA,"Numerator if ratio, or left side if difference",TRUE,NA,NA,NA
10.1080/09546634.2020.1747592,32299269,results,1,NA,Primary outcome: unadjusted treatment effect,NA,NA,8.3,TRUE,NA,NA,NA
10.1080/09546634.2020.1747592,32299269,results,1,NA,"p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])",[2.4;14.2] <0.01,[2.4;14.2] p<0.01,[2.4;14.2] p<0.01,FALSE,NA,NA,NA
10.1080/09546634.2020.1747592,32299269,results,1,NA,Primary outcome: adjusted treatment effect,NA,NA,8,TRUE,NA,NA,NA
10.1080/09546634.2020.1747592,32299269,results,1,NA,"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])",[2.0;14.1] <0.01,[2.0;14.1] p<0.01,[2.0;14.1] p<0.01,FALSE,NA,NA,NA
10.1080/09546634.2020.1747592,32299269,results,2,NA,Reporting of a weights' distribution evaluation (MAIC),NA,NA,Not mentioned,TRUE,NA,NA,NA
10.1080/09546634.2020.1747592,32299269,results,2,NA,Reporting of the list of the covariates adjusted for/matched on,NA,NA,Yes,TRUE,NA,NA,NA
10.1080/09546634.2020.1747592,32299269,results,2,NA,Number of covariates adjusted for/matched on,NA,NA,5,TRUE,NA,NA,NA
10.1080/09546634.2020.1747592,32299269,results,2,NA,Covariates adjusted for/matched on in the indirect comparison,NA,NA,"Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Past treatments for the disease of interest",TRUE,NA,NA,NA
10.1080/09546634.2020.1747592,32299269,results,2,NA,Primary outcome: treatment effect contrast,Means difference,Risk difference,Risk difference,FALSE,NA,NA,NA
10.1080/09546634.2020.1747592,32299269,results,2,NA,Direction of the treatment effect contrast: IPD treatment is:,NA,NA,"Numerator if ratio, or left side if difference",TRUE,NA,NA,NA
10.1080/09546634.2020.1747592,32299269,results,2,NA,Primary outcome: unadjusted treatment effect,NA,NA,27.7,TRUE,NA,NA,NA
10.1080/09546634.2020.1747592,32299269,results,2,NA,"p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])",<0.001,[22.5;32.8] p<0.001,[22.5;32.8] p<0.001,FALSE,NA,NA,NA
10.1080/09546634.2020.1747592,32299269,results,2,NA,Primary outcome: adjusted treatment effect,NA,NA,27,TRUE,NA,NA,NA
10.1080/09546634.2020.1747592,32299269,results,2,NA,"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])",<0.001,[21.6;32.3] p<0.001,[21.6;32.3] p<0.001,FALSE,NA,NA,NA
10.1080/09546634.2020.1747592,32299269,results,3,NA,Reporting of a weights' distribution evaluation (MAIC),NA,NA,Not mentioned,TRUE,NA,NA,NA
10.1080/09546634.2020.1747592,32299269,results,3,NA,Reporting of the list of the covariates adjusted for/matched on,NA,NA,Yes,TRUE,NA,NA,NA
10.1080/09546634.2020.1747592,32299269,results,3,NA,Number of covariates adjusted for/matched on,NA,NA,5,TRUE,NA,NA,NA
10.1080/09546634.2020.1747592,32299269,results,3,NA,Covariates adjusted for/matched on in the indirect comparison,NA,NA,"Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Past treatments for the disease of interest",TRUE,NA,NA,NA
10.1080/09546634.2020.1747592,32299269,results,3,NA,Primary outcome: treatment effect contrast,Means difference,Risk difference,Risk difference,FALSE,NA,NA,NA
10.1080/09546634.2020.1747592,32299269,results,3,NA,Direction of the treatment effect contrast: IPD treatment is:,NA,NA,"Numerator if ratio, or left side if difference",TRUE,NA,NA,NA
10.1080/09546634.2020.1747592,32299269,results,3,NA,Primary outcome: unadjusted treatment effect,NA,NA,26.4,TRUE,NA,NA,NA
10.1080/09546634.2020.1747592,32299269,results,3,NA,"p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])",<0.001,[21.3;31.5] p<0.001,[21.3;31.5] p<0.001,FALSE,NA,NA,NA
10.1080/09546634.2020.1747592,32299269,results,3,NA,Primary outcome: adjusted treatment effect,NA,NA,25.7,TRUE,NA,NA,NA
10.1080/09546634.2020.1747592,32299269,results,3,NA,"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])",<0.001,[20.4;31.0] p<0.001,[20.4;31.0] p<0.001,FALSE,NA,NA,NA
10.1080/09546634.2020.1747592,32299269,results,4,NA,Reporting of a weights' distribution evaluation (MAIC),NA,NA,Not mentioned,TRUE,NA,NA,NA
10.1080/09546634.2020.1747592,32299269,results,4,NA,Reporting of the list of the covariates adjusted for/matched on,NA,NA,Yes,TRUE,NA,NA,NA
10.1080/09546634.2020.1747592,32299269,results,4,NA,Number of covariates adjusted for/matched on,NA,NA,5,TRUE,NA,NA,NA
10.1080/09546634.2020.1747592,32299269,results,4,NA,Covariates adjusted for/matched on in the indirect comparison,"Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Past treatments for the disease of interest","Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Past treatments for the disease of interest","Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Past treatments for the disease of interest",FALSE,NA,NA,NA
10.1080/09546634.2020.1747592,32299269,results,4,NA,Primary outcome: treatment effect contrast,Means difference,Risk difference,Risk difference,FALSE,NA,NA,NA
10.1080/09546634.2020.1747592,32299269,results,4,NA,Direction of the treatment effect contrast: IPD treatment is:,NA,NA,"Numerator if ratio, or left side if difference",TRUE,NA,NA,NA
10.1080/09546634.2020.1747592,32299269,results,4,NA,Primary outcome: unadjusted treatment effect,NA,NA,28.1,TRUE,NA,NA,NA
10.1080/09546634.2020.1747592,32299269,results,4,NA,"p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])",<0.001,[19.2;37.0] p<0.001,[19.2;37.0] p<0.001,FALSE,NA,NA,NA
10.1080/09546634.2020.1747592,32299269,results,4,NA,Primary outcome: adjusted treatment effect,NA,NA,25.7,TRUE,NA,NA,NA
10.1080/09546634.2020.1747592,32299269,results,4,NA,"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])",<0.001,[16.5;34.9] p<0.001,[16.5;34.9] p<0.001,FALSE,NA,NA,NA
10.1080/09546634.2020.1747592,32299269,results,5,NA,Reporting of a weights' distribution evaluation (MAIC),NA,NA,Not mentioned,TRUE,NA,NA,NA
10.1080/09546634.2020.1747592,32299269,results,5,NA,Reporting of the list of the covariates adjusted for/matched on,NA,NA,Yes,TRUE,NA,NA,NA
10.1080/09546634.2020.1747592,32299269,results,5,NA,Number of covariates adjusted for/matched on,NA,NA,5,TRUE,NA,NA,NA
10.1080/09546634.2020.1747592,32299269,results,5,NA,Covariates adjusted for/matched on in the indirect comparison,NA,NA,"Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Past treatments for the disease of interest",TRUE,NA,NA,NA
10.1080/09546634.2020.1747592,32299269,results,5,NA,Primary outcome: treatment effect contrast,Means difference,Risk difference,Risk difference,FALSE,NA,NA,NA
10.1080/09546634.2020.1747592,32299269,results,5,NA,Direction of the treatment effect contrast: IPD treatment is:,NA,NA,"Numerator if ratio, or left side if difference",TRUE,NA,NA,NA
10.1080/09546634.2020.1747592,32299269,results,5,NA,Primary outcome: unadjusted treatment effect,26.4,24.1,24.1,FALSE,NA,NA,NA
10.1080/09546634.2020.1747592,32299269,results,5,NA,"p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])",<0.001,[15.3;32.9] p<0.001,[15.3;32.9] p<0.001,FALSE,NA,NA,NA
10.1080/09546634.2020.1747592,32299269,results,5,NA,Primary outcome: adjusted treatment effect,25.7,21.7,21.7,FALSE,NA,NA,NA
10.1080/09546634.2020.1747592,32299269,results,5,NA,"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])",<0.001,[12.7;30.7] p<0.001,[12.7;30.7] p<0.001,FALSE,NA,NA,NA
10.1080/09546634.2020.1747592,32299269,results,6,NA,Reporting of a weights' distribution evaluation (MAIC),NA,NA,Not mentioned,TRUE,NA,NA,NA
10.1080/09546634.2020.1747592,32299269,results,6,NA,Reporting of the list of the covariates adjusted for/matched on,NA,NA,Yes,TRUE,NA,NA,NA
10.1080/09546634.2020.1747592,32299269,results,6,NA,Number of covariates adjusted for/matched on,8,7,8,FALSE,NA,NA,NA
10.1080/09546634.2020.1747592,32299269,results,6,NA,Covariates adjusted for/matched on in the indirect comparison,"Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Past treatments for the disease of interest, Other(s)","Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Race/ethnicity, Past treatments for the disease of interest, Other(s)","Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Race/ethnicity, Past treatments for the disease of interest, Other(s)",FALSE,NA,NA,NA
10.1080/09546634.2020.1747592,32299269,results,6,NA,Primary outcome: treatment effect contrast,Means difference,Risk difference,Risk difference,FALSE,NA,NA,NA
10.1080/09546634.2020.1747592,32299269,results,6,NA,Direction of the treatment effect contrast: IPD treatment is:,NA,NA,"Numerator if ratio, or left side if difference",TRUE,NA,NA,NA
10.1080/09546634.2020.1747592,32299269,results,6,NA,Primary outcome: unadjusted treatment effect,NA,NA,5.5,TRUE,NA,NA,NA
10.1080/09546634.2020.1747592,32299269,results,6,NA,"p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])",<0.5,[0.2;10.8] p<0.05,[0.2;10.8] p<0.05,FALSE,NA,NA,NA
10.1080/09546634.2020.1747592,32299269,results,6,NA,Primary outcome: adjusted treatment effect,NA,NA,5.5,TRUE,NA,NA,NA
10.1080/09546634.2020.1747592,32299269,results,6,NA,"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])",NA,NA,[-0.1;11.0],TRUE,NA,NA,NA
10.1080/09546634.2020.1747592,32299269,results,7,NA,Reporting of a weights' distribution evaluation (MAIC),NA,NA,Not mentioned,TRUE,NA,NA,NA
10.1080/09546634.2020.1747592,32299269,results,7,NA,Reporting of the list of the covariates adjusted for/matched on,NA,NA,Yes,TRUE,NA,NA,NA
10.1080/09546634.2020.1747592,32299269,results,7,NA,Number of covariates adjusted for/matched on,8,7,8,FALSE,NA,NA,NA
10.1080/09546634.2020.1747592,32299269,results,7,NA,Covariates adjusted for/matched on in the indirect comparison,"Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Past treatments for the disease of interest, Other(s)","Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Race/ethnicity, Past treatments for the disease of interest, Other(s)","Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Race/ethnicity, Past treatments for the disease of interest, Other(s)",FALSE,NA,NA,NA
10.1080/09546634.2020.1747592,32299269,results,7,NA,Primary outcome: treatment effect contrast,Means difference,Risk difference,Risk difference,FALSE,NA,NA,NA
10.1080/09546634.2020.1747592,32299269,results,7,NA,Direction of the treatment effect contrast: IPD treatment is:,NA,NA,"Numerator if ratio, or left side if difference",TRUE,NA,NA,NA
10.1080/09546634.2020.1747592,32299269,results,7,NA,Primary outcome: unadjusted treatment effect,NA,NA,0.8,TRUE,NA,NA,NA
10.1080/09546634.2020.1747592,32299269,results,7,NA,"p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])",NA,NA,[-10.9;12.6],TRUE,NA,NA,NA
10.1080/09546634.2020.1747592,32299269,results,7,NA,Primary outcome: adjusted treatment effect,NA,NA,7.8,TRUE,NA,NA,NA
10.1080/09546634.2020.1747592,32299269,results,7,NA,"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])",NA,NA,[-6.7;22.3],TRUE,NA,NA,NA
10.1007/s12325-020-01378-y,32424805,general_information,NA,NA,Medical Condition of Interest Name,NA,NA,advanced hepatocellular carcinoma,TRUE,NA,NA,NA
10.1007/s12325-020-01378-y,32424805,general_information,NA,NA,Countries of first author affiliations,NA,NA,usa,TRUE,NA,NA,NA
10.1007/s12325-020-01378-y,32424805,general_information,NA,NA,Countries of last author affiliations,NA,NA,usa,TRUE,NA,NA,NA
10.1007/s12325-020-01378-y,32424805,general_information,NA,NA,"Positions of study investigators (for any authors of the article, any that applies)",NA,NA,"Academic, Pharmaceutical Industry, Private Data Analysis Company",TRUE,NA,NA,NA
10.1007/s12325-020-01378-y,32424805,general_information,NA,NA,"At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company",NA,NA,Yes,TRUE,NA,NA,NA
10.1007/s12325-020-01378-y,32424805,general_information,NA,NA,Mentioned sources of funding,NA,NA,Pharmaceutical Industry,TRUE,NA,NA,NA
10.1007/s12325-020-01378-y,32424805,general_information,NA,NA,"Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article",NA,NA,Yes,TRUE,NA,NA,NA
10.1007/s12325-020-01378-y,32424805,general_information,NA,NA,Mention of a systematic review to find the studies to compare treatments of interest,Yes,No,No,FALSE,NA,NA,NA
10.1007/s12325-020-01378-y,32424805,study_information,NA,1,Patient-level data used,NA,NA,Yes,TRUE,NA,NA,NA
10.1007/s12325-020-01378-y,32424805,study_information,NA,1,Clinical Trial,NA,NA,Yes,TRUE,NA,NA,NA
10.1007/s12325-020-01378-y,32424805,study_information,NA,1,NCT (only for clinical trial registered on clinicaltrials.gov),NA,NA,NCT01908426,TRUE,NA,NA,NA
10.1007/s12325-020-01378-y,32424805,study_information,NA,1,Country where the clinical trial/observational study was conducted (international if more than one),NA,NA,international,TRUE,NA,NA,NA
10.1007/s12325-020-01378-y,32424805,study_information,NA,1,Phase of the clinical trial (clinical trial only),NA,NA,3,TRUE,NA,NA,NA
10.1007/s12325-020-01378-y,32424805,study_information,NA,1,Number of treatment arms (clinical trial only),NA,NA,2 or more,TRUE,NA,NA,NA
10.1007/s12325-020-01378-y,32424805,study_information,NA,2,Patient-level data used,NA,NA,No,TRUE,NA,NA,NA
10.1007/s12325-020-01378-y,32424805,study_information,NA,2,Clinical Trial,NA,NA,Yes,TRUE,NA,NA,NA
10.1007/s12325-020-01378-y,32424805,study_information,NA,2,NCT (only for clinical trial registered on clinicaltrials.gov),NA,NA,NCT01774344,TRUE,NA,NA,NA
10.1007/s12325-020-01378-y,32424805,study_information,NA,2,Country where the clinical trial/observational study was conducted (international if more than one),NA,NA,international,TRUE,NA,NA,NA
10.1007/s12325-020-01378-y,32424805,study_information,NA,2,Phase of the clinical trial (clinical trial only),NA,NA,3,TRUE,NA,NA,NA
10.1007/s12325-020-01378-y,32424805,study_information,NA,2,Number of treatment arms (clinical trial only),NA,NA,2 or more,TRUE,NA,NA,NA
10.1007/s12325-020-01378-y,32424805,methodology,1,NA,Treatment name 1,NA,NA,cabozantinib,TRUE,say can't do an anchored analysis because proportional risk hypothesis not respected,"Efficacity analysis /
Pas de calcul du HR.
OS median Cabozatinib (months) :
- Population initiale : 10.46 (IC95 = 9.46;11.58)
- MAIC : 11.40 (IC95 = 10.01;12.96)
OS median Regorafenib = 10.6 (ICç( = 9.1;12.1]
Median difference = 0.8 months",NA
10.1007/s12325-020-01378-y,32424805,methodology,1,NA,Study 'number(s)' for treatment 1,NA,NA,1,TRUE,NA,NA,NA
10.1007/s12325-020-01378-y,32424805,methodology,1,NA,Treatment name 2,NA,NA,regorafenib,TRUE,NA,NA,NA
10.1007/s12325-020-01378-y,32424805,methodology,1,NA,Study 'number(s)' for treatment 2,NA,NA,2,TRUE,NA,NA,NA
10.1007/s12325-020-01378-y,32424805,methodology,1,NA,Type of population-adjusted indirect comparisons performed,NA,NA,MAIC,TRUE,NA,NA,NA
10.1007/s12325-020-01378-y,32424805,methodology,1,NA,Anchored comparison?,NA,NA,No,TRUE,NA,NA,NA
10.1007/s12325-020-01378-y,32424805,methodology,1,NA,Form of the indirect comparison,NA,NA,Simple (ie treatments effects extracted from two studies),TRUE,NA,NA,NA
10.1007/s12325-020-01378-y,32424805,methodology,1,NA,Definition of a single primary outcome for the indirect comparison,NA,NA,"No primary outcome defined, or multiple primary outcomes without any clear distinction between them",TRUE,NA,NA,NA
10.1007/s12325-020-01378-y,32424805,methodology,1,NA,Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined),NA,NA,overall survival,TRUE,NA,NA,NA
10.1007/s12325-020-01378-y,32424805,methodology,1,NA,Primary outcome: variable type,"Continuous (count, mean, ...)",Time-to-event,Time-to-event,FALSE,NA,NA,NA
10.1007/s12325-020-01378-y,32424805,methodology,1,NA,Justification for selecting variables to be included in the adjustment model (in the main text),NA,NA,"Statistical imbalanced between treatment groups (independently of the status of prognostic/effect modifier), A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion)",TRUE,NA,NA,NA
10.1007/s12325-020-01378-y,32424805,methodology,1,NA,Inclusion of prognostic factors in the adjustment/matching model,NA,NA,No,TRUE,NA,NA,NA
10.1007/s12325-020-01378-y,32424805,methodology,1,NA,Inclusion of treatment-effect modifiers in the adjustment/matching model,NA,NA,Yes,TRUE,NA,NA,NA
10.1007/s12325-020-01378-y,32424805,methodology,1,NA,"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)",NA,NA,No,TRUE,NA,NA,NA
10.1007/s12325-020-01378-y,32424805,methodology,1,NA,Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale),NA,NA,No,TRUE,NA,NA,NA
10.1007/s12325-020-01378-y,32424805,methodology,xx,NA,Treatment name 1,NA,cabozantinib,XXXX,FALSE,NA,2nd MAIC is anchored.,NA
10.1007/s12325-020-01378-y,32424805,methodology,xx,NA,Study 'number(s)' for treatment 1,NA,1,XXXX,FALSE,NA,NA,NA
10.1007/s12325-020-01378-y,32424805,methodology,xx,NA,Treatment name 2,NA,regorafenib,XXXX,FALSE,NA,NA,NA
10.1007/s12325-020-01378-y,32424805,methodology,xx,NA,Study 'number(s)' for treatment 2,NA,2,XXXX,FALSE,NA,NA,NA
10.1007/s12325-020-01378-y,32424805,methodology,xx,NA,Type of population-adjusted indirect comparisons performed,NA,MAIC,XXXX,FALSE,NA,NA,NA
10.1007/s12325-020-01378-y,32424805,methodology,xx,NA,Anchored comparison?,NA,Yes,XXXX,FALSE,NA,NA,NA
10.1007/s12325-020-01378-y,32424805,methodology,xx,NA,Form of the indirect comparison,NA,Simple (ie treatments effects extracted from two studies),XXXX,FALSE,NA,NA,NA
10.1007/s12325-020-01378-y,32424805,methodology,xx,NA,Definition of a single primary outcome for the indirect comparison,NA,"No primary outcome defined, or multiple primary outcomes without any clear distinction between them",XXXX,FALSE,NA,NA,NA
10.1007/s12325-020-01378-y,32424805,methodology,xx,NA,Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined),NA,frequency of grade 3 or 4 teaes (treatment-emergent adverse events) : fatigue,XXXX,FALSE,NA,NA,NA
10.1007/s12325-020-01378-y,32424805,methodology,xx,NA,Primary outcome: variable type,NA,Binary (eg rates),XXXX,FALSE,NA,NA,NA
10.1007/s12325-020-01378-y,32424805,methodology,xx,NA,Justification for selecting variables to be included in the adjustment model (in the main text),NA,"Statistical imbalanced between treatment groups (independently of the status of prognostic/effect modifier), A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion)",XXXX,FALSE,NA,NA,NA
10.1007/s12325-020-01378-y,32424805,methodology,xx,NA,Inclusion of prognostic factors in the adjustment/matching model,NA,No,XXXX,FALSE,NA,NA,NA
10.1007/s12325-020-01378-y,32424805,methodology,xx,NA,Inclusion of treatment-effect modifiers in the adjustment/matching model,NA,Yes,XXXX,FALSE,NA,NA,NA
10.1007/s12325-020-01378-y,32424805,methodology,xx,NA,"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)",NA,No,XXXX,FALSE,NA,NA,NA
10.1007/s12325-020-01378-y,32424805,methodology,xx,NA,Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale),NA,No,XXXX,FALSE,NA,NA,NA
10.1007/s12325-020-01378-y,32424805,results,1,NA,Sample size of the population of interest in the non IPD treatment arm,NA,NA,379,TRUE,NA,NA,NA
10.1007/s12325-020-01378-y,32424805,results,1,NA,Initial sample size of the population of interest in the IPD treatment arm,326,470,326,FALSE,NA,NA,NA
10.1007/s12325-020-01378-y,32424805,results,1,NA,"Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC",NA,NA,187,TRUE,NA,NA,NA
10.1007/s12325-020-01378-y,32424805,results,1,NA,Reporting of a weights' distribution evaluation (MAIC),NA,NA,Not mentioned,TRUE,NA,NA,NA
10.1007/s12325-020-01378-y,32424805,results,1,NA,Reporting of the list of the covariates adjusted for/matched on,NA,NA,Yes,TRUE,NA,NA,NA
10.1007/s12325-020-01378-y,32424805,results,1,NA,Number of covariates adjusted for/matched on,11,10,11,FALSE,NA,NA,NA
10.1007/s12325-020-01378-y,32424805,results,1,NA,Covariates adjusted for/matched on in the indirect comparison,NA,NA,"Age, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Race/ethnicity, Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Past treatments for the disease of interest, Other(s)",TRUE,NA,NA,NA
10.1007/s12325-020-01378-y,32424805,results,1,NA,Primary outcome: treatment effect contrast,Median difference,"Pas de calcul du HR, seulement test du log-rank",Median difference,FALSE,NA,NA,NA
10.1007/s12325-020-01378-y,32424805,results,1,NA,Direction of the treatment effect contrast: IPD treatment is:,"Numerator if ratio, or left side if difference",NA,"Numerator if ratio, or left side if difference",FALSE,NA,NA,NA
10.1007/s12325-020-01378-y,32424805,results,1,NA,Primary outcome: adjusted treatment effect,0.8,NA,0.8,FALSE,NA,NA,NA
10.1007/s12325-020-01378-y,32424805,results,1,NA,"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])",NA,NA,0.3474,TRUE,NA,NA,NA
10.1007/s12325-020-01378-y,32424805,results,xx,NA,Sample size of the population of interest in the non IPD treatment arm,NA,379,XXXX,FALSE,NA,NA,NA
10.1007/s12325-020-01378-y,32424805,results,xx,NA,"If anchored comparison, sample size of the population of interest in the non IPD treatment anchor arm",NA,194,XXXX,FALSE,NA,NA,NA
10.1007/s12325-020-01378-y,32424805,results,xx,NA,Initial sample size of the population of interest in the IPD treatment arm,NA,470,XXXX,FALSE,NA,NA,NA
10.1007/s12325-020-01378-y,32424805,results,xx,NA,"Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC",NA,187,XXXX,FALSE,NA,NA,NA
10.1007/s12325-020-01378-y,32424805,results,xx,NA,"If anchored comparison, initial sample size of the population of interest in the IPD anchor arm",NA,237,XXXX,FALSE,NA,NA,NA
10.1007/s12325-020-01378-y,32424805,results,xx,NA,"If anchored comparison, effective sample size after reweighting for MAIC; or sample size used in the regression model for STC in the IPD anchor arm",NA,81,XXXX,FALSE,NA,NA,NA
10.1007/s12325-020-01378-y,32424805,results,xx,NA,Reporting of a weights' distribution evaluation (MAIC),NA,Not mentioned,XXXX,FALSE,NA,NA,NA
10.1007/s12325-020-01378-y,32424805,results,xx,NA,Reporting of the list of the covariates adjusted for/matched on,NA,Yes,XXXX,FALSE,NA,NA,NA
10.1007/s12325-020-01378-y,32424805,results,xx,NA,Number of covariates adjusted for/matched on,NA,10,XXXX,FALSE,NA,NA,NA
10.1007/s12325-020-01378-y,32424805,results,xx,NA,Covariates adjusted for/matched on in the indirect comparison,NA,"Age, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Race/ethnicity, Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Past treatments for the disease of interest, Other(s)",XXXX,FALSE,NA,NA,NA
10.1007/s12325-020-01378-y,32424805,results,xx,NA,Primary outcome: treatment effect contrast,NA,Log-OR,XXXX,FALSE,NA,NA,NA
10.1007/s12325-020-01378-y,32424805,results,xx,NA,Direction of the treatment effect contrast: IPD treatment is:,NA,"Numerator if ratio, or left side if difference",XXXX,FALSE,NA,NA,NA
10.1007/s12325-020-01378-y,32424805,results,xx,NA,Primary outcome: unadjusted treatment effect,NA,0.07,XXXX,FALSE,NA,NA,NA
10.1007/s12325-020-01378-y,32424805,results,xx,NA,"p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])",NA,0.9404,XXXX,FALSE,NA,NA,NA
10.1007/s12325-020-01378-y,32424805,results,xx,NA,Primary outcome: adjusted treatment effect,NA,0.09,XXXX,FALSE,NA,NA,NA
10.1007/s12325-020-01378-y,32424805,results,xx,NA,"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])",NA,0.9313,XXXX,FALSE,NA,NA,NA
10.2217/cer-2020-0069,32602756,general_information,NA,NA,Medical Condition of Interest Name,pediatric acute lymphoblastic leukemia,https://www.futuremedicine.com/doi/epub/10.2217/cer-2020-0069,pediatric acute lymphoblastic leukemia,FALSE,NA,NA,NA
10.2217/cer-2020-0069,32602756,general_information,NA,NA,Countries of first author affiliations,NA,NA,usa,TRUE,NA,NA,NA
10.2217/cer-2020-0069,32602756,general_information,NA,NA,Countries of last author affiliations,NA,NA,usa,TRUE,NA,NA,NA
10.2217/cer-2020-0069,32602756,general_information,NA,NA,"Positions of study investigators (for any authors of the article, any that applies)",NA,NA,"Pharmaceutical Industry, Private Data Analysis Company",TRUE,NA,NA,NA
10.2217/cer-2020-0069,32602756,general_information,NA,NA,"At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company",NA,NA,Yes,TRUE,NA,NA,NA
10.2217/cer-2020-0069,32602756,general_information,NA,NA,Mentioned sources of funding,NA,NA,Pharmaceutical Industry,TRUE,NA,NA,NA
10.2217/cer-2020-0069,32602756,general_information,NA,NA,"Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article",NA,NA,Yes,TRUE,NA,NA,NA
10.2217/cer-2020-0069,32602756,general_information,NA,NA,Mention of a systematic review to find the studies to compare treatments of interest,NA,NA,Yes,TRUE,NA,NA,NA
10.2217/cer-2020-0069,32602756,study_information,NA,1,Patient-level data used,NA,NA,Yes,TRUE,NA,NA,NA
10.2217/cer-2020-0069,32602756,study_information,NA,1,Clinical Trial,NA,NA,Yes,TRUE,NA,NA,NA
10.2217/cer-2020-0069,32602756,study_information,NA,1,NCT (only for clinical trial registered on clinicaltrials.gov),NA,NA,NCT02435849,TRUE,NA,NA,NA
10.2217/cer-2020-0069,32602756,study_information,NA,1,Country where the clinical trial/observational study was conducted (international if more than one),NA,NA,international,TRUE,NA,NA,NA
10.2217/cer-2020-0069,32602756,study_information,NA,1,Phase of the clinical trial (clinical trial only),NA,NA,2,TRUE,NA,NA,NA
10.2217/cer-2020-0069,32602756,study_information,NA,1,Number of treatment arms (clinical trial only),NA,NA,1,TRUE,NA,NA,NA
10.2217/cer-2020-0069,32602756,study_information,NA,2,Patient-level data used,NA,NA,No,TRUE,NA,NA,NA
10.2217/cer-2020-0069,32602756,study_information,NA,2,Clinical Trial,NA,NA,Yes,TRUE,NA,NA,NA
10.2217/cer-2020-0069,32602756,study_information,NA,2,NCT (only for clinical trial registered on clinicaltrials.gov),NA,NA,NCT01471782,TRUE,NA,NA,NA
10.2217/cer-2020-0069,32602756,study_information,NA,2,Country where the clinical trial/observational study was conducted (international if more than one),NA,NA,international,TRUE,NA,NA,NA
10.2217/cer-2020-0069,32602756,study_information,NA,2,Phase of the clinical trial (clinical trial only),NA,NA,"1, 2",TRUE,NA,NA,NA
10.2217/cer-2020-0069,32602756,study_information,NA,2,Number of treatment arms (clinical trial only),NA,NA,1,TRUE,NA,NA,NA
10.2217/cer-2020-0069,32602756,study_information,NA,3,Patient-level data used,NA,NA,No,TRUE,NA,NA,NA
10.2217/cer-2020-0069,32602756,study_information,NA,3,Clinical Trial,NA,NA,Yes,TRUE,NA,NA,NA
10.2217/cer-2020-0069,32602756,study_information,NA,3,Data source name (only if observational study or clinical trial without NCT),NA,NA,jeha et al. (2006),TRUE,NA,NA,NA
10.2217/cer-2020-0069,32602756,study_information,NA,3,Phase of the clinical trial (clinical trial only),NA,NA,2,TRUE,NA,NA,NA
10.2217/cer-2020-0069,32602756,study_information,NA,3,Number of treatment arms (clinical trial only),NA,NA,1,TRUE,NA,NA,NA
10.2217/cer-2020-0069,32602756,study_information,NA,3,Country where the clinical trial/observational study was conducted (international if more than one),usa,NA,XXXX,FALSE,NA,NA,NA
10.2217/cer-2020-0069,32602756,study_information,NA,4,Patient-level data used,NA,NA,No,TRUE,NA,NA,NA
10.2217/cer-2020-0069,32602756,study_information,NA,4,Clinical Trial,NA,NA,Yes,TRUE,NA,NA,NA
10.2217/cer-2020-0069,32602756,study_information,NA,4,NCT (only for clinical trial registered on clinicaltrials.gov),NA,NA,NCT00315705,TRUE,NA,NA,NA
10.2217/cer-2020-0069,32602756,study_information,NA,4,Country where the clinical trial/observational study was conducted (international if more than one),NA,NA,usa,TRUE,NA,NA,NA
10.2217/cer-2020-0069,32602756,study_information,NA,4,Phase of the clinical trial (clinical trial only),2,"1, 2",XXXX,FALSE,NA,NA,NA
10.2217/cer-2020-0069,32602756,study_information,NA,4,Number of treatment arms (clinical trial only),NA,NA,1,TRUE,NA,NA,NA
10.2217/cer-2020-0069,32602756,study_information,NA,5,Patient-level data used,NA,NA,No,TRUE,NA,NA,NA
10.2217/cer-2020-0069,32602756,study_information,NA,5,Clinical Trial,NA,NA,Yes,TRUE,NA,NA,NA
10.2217/cer-2020-0069,32602756,study_information,NA,5,Data source name (only if observational study or clinical trial without NCT),NA,NA,locatelli et al. (2017),TRUE,NA,NA,NA
10.2217/cer-2020-0069,32602756,study_information,NA,5,Phase of the clinical trial (clinical trial only),NA,NA,2,TRUE,NA,NA,NA
10.2217/cer-2020-0069,32602756,study_information,NA,5,Number of treatment arms (clinical trial only),NA,NA,1,TRUE,NA,NA,NA
10.2217/cer-2020-0069,32602756,study_information,NA,5,Country where the clinical trial/observational study was conducted (international if more than one),italy,NA,XXXX,FALSE,NA,NA,NA
10.2217/cer-2020-0069,32602756,study_information,NA,6,Patient-level data used,NA,NA,No,TRUE,NA,NA,NA
10.2217/cer-2020-0069,32602756,study_information,NA,6,Clinical Trial,Yes,No,XXXX,FALSE,NA,NA,NA
10.2217/cer-2020-0069,32602756,study_information,NA,6,Data source name (only if observational study or clinical trial without NCT),NA,NA,miano et al. (2012),TRUE,NA,NA,NA
10.2217/cer-2020-0069,32602756,study_information,NA,6,Country where the clinical trial/observational study was conducted (international if more than one),NA,NA,italy,TRUE,NA,NA,NA
10.2217/cer-2020-0069,32602756,study_information,NA,6,Number of treatment arms (clinical trial only),1,NA,XXXX,FALSE,NA,NA,NA
10.2217/cer-2020-0069,32602756,study_information,NA,7,Patient-level data used,NA,NA,No,TRUE,NA,NA,NA
10.2217/cer-2020-0069,32602756,study_information,NA,7,Clinical Trial,Yes,No,XXXX,FALSE,NA,NA,NA
10.2217/cer-2020-0069,32602756,study_information,NA,7,Data source name (only if observational study or clinical trial without NCT),NA,NA,von stackelbeg et al. (2010),TRUE,NA,NA,NA
10.2217/cer-2020-0069,32602756,study_information,NA,7,Country where the clinical trial/observational study was conducted (international if more than one),NA,germany,XXXX,FALSE,NA,NA,NA
10.2217/cer-2020-0069,32602756,study_information,NA,8,Patient-level data used,NA,NA,No,TRUE,NA,NA,NA
10.2217/cer-2020-0069,32602756,study_information,NA,8,Clinical Trial,Yes,No,XXXX,FALSE,NA,NA,NA
10.2217/cer-2020-0069,32602756,study_information,NA,8,Data source name (only if observational study or clinical trial without NCT),NA,NA,all-sct-bfm 2003 & all-sct-bfm,TRUE,NA,NA,NA
10.2217/cer-2020-0069,32602756,study_information,NA,8,Country where the clinical trial/observational study was conducted (international if more than one),NA,international,XXXX,FALSE,NA,NA,NA
10.2217/cer-2020-0069,32602756,methodology,1,NA,Treatment name 1,NA,NA,tisagenlecleucel,TRUE,NA,"Geographic region = other covariate
Les effectifs/ESS proviennent des courbes de survie.",NA
10.2217/cer-2020-0069,32602756,methodology,1,NA,Study 'number(s)' for treatment 1,NA,NA,1,TRUE,NA,NA,NA
10.2217/cer-2020-0069,32602756,methodology,1,NA,Treatment name 2,NA,NA,blinatumomab,TRUE,NA,NA,NA
10.2217/cer-2020-0069,32602756,methodology,1,NA,Study 'number(s)' for treatment 2,NA,NA,2,TRUE,NA,NA,NA
10.2217/cer-2020-0069,32602756,methodology,1,NA,Type of population-adjusted indirect comparisons performed,NA,NA,MAIC,TRUE,NA,NA,NA
10.2217/cer-2020-0069,32602756,methodology,1,NA,Anchored comparison?,NA,NA,No,TRUE,NA,NA,NA
10.2217/cer-2020-0069,32602756,methodology,1,NA,Form of the indirect comparison,NA,NA,Simple (ie treatments effects extracted from two studies),TRUE,NA,NA,NA
10.2217/cer-2020-0069,32602756,methodology,1,NA,Definition of a single primary outcome for the indirect comparison,NA,NA,"No primary outcome defined, or multiple primary outcomes without any clear distinction between them",TRUE,NA,NA,NA
10.2217/cer-2020-0069,32602756,methodology,1,NA,Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined),NA,NA,overall survival,TRUE,NA,NA,NA
10.2217/cer-2020-0069,32602756,methodology,1,NA,Primary outcome: variable type,NA,NA,Time-to-event,TRUE,NA,NA,NA
10.2217/cer-2020-0069,32602756,methodology,1,NA,Justification for selecting variables to be included in the adjustment model (in the main text),"Nothing mentioned, not reported","A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion), Literature based (clinically or methodologically relevant to adjust on these variables based on the literature search conducted for this specific purpose)","A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion), Literature based (clinically or methodologically relevant to adjust on these variables based on the literature search conducted for this specific purpose)",FALSE,NA,NA,NA
10.2217/cer-2020-0069,32602756,methodology,1,NA,Inclusion of prognostic factors in the adjustment/matching model,NA,NA,No discussion (in the main text) of the status of prognostic factors of the variables,TRUE,NA,NA,NA
10.2217/cer-2020-0069,32602756,methodology,1,NA,Inclusion of treatment-effect modifiers in the adjustment/matching model,NA,NA,No discussion (in the main text) of the status of treatment-effect modifiers of the variables,TRUE,NA,NA,NA
10.2217/cer-2020-0069,32602756,methodology,1,NA,"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)",NA,NA,No,TRUE,NA,NA,NA
10.2217/cer-2020-0069,32602756,methodology,1,NA,Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale),NA,NA,No,TRUE,NA,NA,NA
10.2217/cer-2020-0069,32602756,methodology,2,NA,Treatment name 1,NA,NA,tisagenlecleucel,TRUE,NA,"
Les effectifs/ESS proviennent des courbes de survie.",NA
10.2217/cer-2020-0069,32602756,methodology,2,NA,Study 'number(s)' for treatment 1,NA,NA,1,TRUE,NA,NA,NA
10.2217/cer-2020-0069,32602756,methodology,2,NA,Treatment name 2,clofarabine,clofarabine monotherapy,clofarabine,FALSE,NA,NA,NA
10.2217/cer-2020-0069,32602756,methodology,2,NA,Study 'number(s)' for treatment 2,NA,NA,3,TRUE,NA,NA,NA
10.2217/cer-2020-0069,32602756,methodology,2,NA,Type of population-adjusted indirect comparisons performed,NA,NA,MAIC,TRUE,NA,NA,NA
10.2217/cer-2020-0069,32602756,methodology,2,NA,Anchored comparison?,NA,NA,No,TRUE,NA,NA,NA
10.2217/cer-2020-0069,32602756,methodology,2,NA,Form of the indirect comparison,NA,NA,Simple (ie treatments effects extracted from two studies),TRUE,NA,NA,NA
10.2217/cer-2020-0069,32602756,methodology,2,NA,Definition of a single primary outcome for the indirect comparison,NA,NA,"No primary outcome defined, or multiple primary outcomes without any clear distinction between them",TRUE,NA,NA,NA
10.2217/cer-2020-0069,32602756,methodology,2,NA,Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined),NA,NA,overall survival,TRUE,NA,NA,NA
10.2217/cer-2020-0069,32602756,methodology,2,NA,Primary outcome: variable type,NA,NA,Time-to-event,TRUE,NA,NA,NA
10.2217/cer-2020-0069,32602756,methodology,2,NA,Justification for selecting variables to be included in the adjustment model (in the main text),"Nothing mentioned, not reported","A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion), Literature based (clinically or methodologically relevant to adjust on these variables based on the literature search conducted for this specific purpose)","A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion), Literature based (clinically or methodologically relevant to adjust on these variables based on the literature search conducted for this specific purpose)",FALSE,NA,NA,NA
10.2217/cer-2020-0069,32602756,methodology,2,NA,Inclusion of prognostic factors in the adjustment/matching model,NA,NA,No discussion (in the main text) of the status of prognostic factors of the variables,TRUE,NA,NA,NA
10.2217/cer-2020-0069,32602756,methodology,2,NA,Inclusion of treatment-effect modifiers in the adjustment/matching model,NA,NA,No discussion (in the main text) of the status of treatment-effect modifiers of the variables,TRUE,NA,NA,NA
10.2217/cer-2020-0069,32602756,methodology,2,NA,"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)",NA,NA,No,TRUE,NA,NA,NA
10.2217/cer-2020-0069,32602756,methodology,2,NA,Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale),NA,NA,No,TRUE,NA,NA,NA
10.2217/cer-2020-0069,32602756,methodology,3,NA,Treatment name 1,NA,NA,tisagenlecleucel,TRUE,NA,Les effectifs/ESS proviennent des courbes de survies.,NA
10.2217/cer-2020-0069,32602756,methodology,3,NA,Study 'number(s)' for treatment 1,NA,NA,1,TRUE,NA,NA,NA
10.2217/cer-2020-0069,32602756,methodology,3,NA,Treatment name 2,clofarabine + etoposide plus cyclophosphamide,clofarabine + etoposide plus cyclophosphamide combination therapy,clofarabine + etoposide plus cyclophosphamide,FALSE,NA,NA,NA
10.2217/cer-2020-0069,32602756,methodology,3,NA,Study 'number(s)' for treatment 2,NA,NA,4;5;6,TRUE,NA,NA,NA
10.2217/cer-2020-0069,32602756,methodology,3,NA,Type of population-adjusted indirect comparisons performed,NA,NA,MAIC,TRUE,NA,NA,NA
10.2217/cer-2020-0069,32602756,methodology,3,NA,Anchored comparison?,NA,NA,No,TRUE,NA,NA,NA
10.2217/cer-2020-0069,32602756,methodology,3,NA,Form of the indirect comparison,NA,NA,"Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate)",TRUE,NA,NA,NA
10.2217/cer-2020-0069,32602756,methodology,3,NA,Definition of a single primary outcome for the indirect comparison,NA,NA,"No primary outcome defined, or multiple primary outcomes without any clear distinction between them",TRUE,NA,NA,NA
10.2217/cer-2020-0069,32602756,methodology,3,NA,Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined),NA,NA,overall survival,TRUE,NA,NA,NA
10.2217/cer-2020-0069,32602756,methodology,3,NA,Primary outcome: variable type,NA,NA,Time-to-event,TRUE,NA,NA,NA
10.2217/cer-2020-0069,32602756,methodology,3,NA,Justification for selecting variables to be included in the adjustment model (in the main text),"Nothing mentioned, not reported","A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion), Literature based (clinically or methodologically relevant to adjust on these variables based on the literature search conducted for this specific purpose)","A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion), Literature based (clinically or methodologically relevant to adjust on these variables based on the literature search conducted for this specific purpose)",FALSE,NA,NA,NA
10.2217/cer-2020-0069,32602756,methodology,3,NA,Inclusion of prognostic factors in the adjustment/matching model,NA,NA,No discussion (in the main text) of the status of prognostic factors of the variables,TRUE,NA,NA,NA
10.2217/cer-2020-0069,32602756,methodology,3,NA,Inclusion of treatment-effect modifiers in the adjustment/matching model,NA,NA,No discussion (in the main text) of the status of treatment-effect modifiers of the variables,TRUE,NA,NA,NA
10.2217/cer-2020-0069,32602756,methodology,3,NA,"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)",NA,NA,No,TRUE,NA,NA,NA
10.2217/cer-2020-0069,32602756,methodology,3,NA,Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale),NA,NA,No,TRUE,NA,NA,NA
10.2217/cer-2020-0069,32602756,methodology,4,NA,Treatment name 1,NA,NA,tisagenlecleucel,TRUE,NA,Les effectifs/ESS proviennent des courbes de survies.,NA
10.2217/cer-2020-0069,32602756,methodology,4,NA,Study 'number(s)' for treatment 1,NA,NA,1,TRUE,NA,NA,NA
10.2217/cer-2020-0069,32602756,methodology,4,NA,Treatment name 2,salvage chemotherapy/treatment,polychemotherapy/high-dose single-agent regimens/stem-cell transplantation (salvage-1),polychemotherapy/high-dose single-agent regimens/stem-cell transplantation (salvage-1),FALSE,NA,NA,NA
10.2217/cer-2020-0069,32602756,methodology,4,NA,Study 'number(s)' for treatment 2,NA,NA,7,TRUE,NA,NA,NA
10.2217/cer-2020-0069,32602756,methodology,4,NA,Type of population-adjusted indirect comparisons performed,NA,NA,MAIC,TRUE,NA,NA,NA
10.2217/cer-2020-0069,32602756,methodology,4,NA,Anchored comparison?,NA,NA,No,TRUE,NA,NA,NA
10.2217/cer-2020-0069,32602756,methodology,4,NA,Form of the indirect comparison,NA,NA,Simple (ie treatments effects extracted from two studies),TRUE,NA,NA,NA
10.2217/cer-2020-0069,32602756,methodology,4,NA,Definition of a single primary outcome for the indirect comparison,NA,NA,"No primary outcome defined, or multiple primary outcomes without any clear distinction between them",TRUE,NA,NA,NA
10.2217/cer-2020-0069,32602756,methodology,4,NA,Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined),NA,NA,overall survival,TRUE,NA,NA,NA
10.2217/cer-2020-0069,32602756,methodology,4,NA,Primary outcome: variable type,NA,NA,Time-to-event,TRUE,NA,NA,NA
10.2217/cer-2020-0069,32602756,methodology,4,NA,Justification for selecting variables to be included in the adjustment model (in the main text),"Nothing mentioned, not reported","A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion), Literature based (clinically or methodologically relevant to adjust on these variables based on the literature search conducted for this specific purpose)","A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion), Literature based (clinically or methodologically relevant to adjust on these variables based on the literature search conducted for this specific purpose)",FALSE,NA,NA,NA
10.2217/cer-2020-0069,32602756,methodology,4,NA,Inclusion of prognostic factors in the adjustment/matching model,NA,NA,No discussion (in the main text) of the status of prognostic factors of the variables,TRUE,NA,NA,NA
10.2217/cer-2020-0069,32602756,methodology,4,NA,Inclusion of treatment-effect modifiers in the adjustment/matching model,NA,NA,No discussion (in the main text) of the status of treatment-effect modifiers of the variables,TRUE,NA,NA,NA
10.2217/cer-2020-0069,32602756,methodology,4,NA,"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)",NA,NA,No,TRUE,NA,NA,NA
10.2217/cer-2020-0069,32602756,methodology,4,NA,Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale),NA,NA,No,TRUE,NA,NA,NA
10.2217/cer-2020-0069,32602756,methodology,5,NA,Treatment name 1,NA,NA,tisagenlecleucel,TRUE,NA,Les effectifs/ESS proviennent des courbes de survies.,NA
10.2217/cer-2020-0069,32602756,methodology,5,NA,Study 'number(s)' for treatment 1,NA,NA,1,TRUE,NA,NA,NA
10.2217/cer-2020-0069,32602756,methodology,5,NA,Treatment name 2,paliative therapy/salvage therapy,palliative therapy/salvage therapy ± second stem-cell transplantation (salvage-2),palliative therapy/salvage therapy ± second stem-cell transplantation (salvage-2),FALSE,NA,NA,NA
10.2217/cer-2020-0069,32602756,methodology,5,NA,Study 'number(s)' for treatment 2,NA,NA,8,TRUE,NA,NA,NA
10.2217/cer-2020-0069,32602756,methodology,5,NA,Type of population-adjusted indirect comparisons performed,NA,NA,MAIC,TRUE,NA,NA,NA
10.2217/cer-2020-0069,32602756,methodology,5,NA,Anchored comparison?,NA,NA,No,TRUE,NA,NA,NA
10.2217/cer-2020-0069,32602756,methodology,5,NA,Form of the indirect comparison,NA,NA,Simple (ie treatments effects extracted from two studies),TRUE,NA,NA,NA
10.2217/cer-2020-0069,32602756,methodology,5,NA,Definition of a single primary outcome for the indirect comparison,NA,NA,"No primary outcome defined, or multiple primary outcomes without any clear distinction between them",TRUE,NA,NA,NA
10.2217/cer-2020-0069,32602756,methodology,5,NA,Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined),NA,NA,overall survival,TRUE,NA,NA,NA
10.2217/cer-2020-0069,32602756,methodology,5,NA,Primary outcome: variable type,NA,NA,Time-to-event,TRUE,NA,NA,NA
10.2217/cer-2020-0069,32602756,methodology,5,NA,Justification for selecting variables to be included in the adjustment model (in the main text),"Nothing mentioned, not reported","A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion), Literature based (clinically or methodologically relevant to adjust on these variables based on the literature search conducted for this specific purpose)","A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion), Literature based (clinically or methodologically relevant to adjust on these variables based on the literature search conducted for this specific purpose)",FALSE,NA,NA,NA
10.2217/cer-2020-0069,32602756,methodology,5,NA,Inclusion of prognostic factors in the adjustment/matching model,NA,NA,No discussion (in the main text) of the status of prognostic factors of the variables,TRUE,NA,NA,NA
10.2217/cer-2020-0069,32602756,methodology,5,NA,Inclusion of treatment-effect modifiers in the adjustment/matching model,NA,NA,No discussion (in the main text) of the status of treatment-effect modifiers of the variables,TRUE,NA,NA,NA
10.2217/cer-2020-0069,32602756,methodology,5,NA,"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)",NA,NA,No,TRUE,NA,NA,NA
10.2217/cer-2020-0069,32602756,methodology,5,NA,Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale),NA,NA,No,TRUE,NA,NA,NA
10.2217/cer-2020-0069,32602756,results,1,NA,Sample size of the population of interest in the non IPD treatment arm,NA,NA,70,TRUE,NA,NA,NA
10.2217/cer-2020-0069,32602756,results,1,NA,Initial sample size of the population of interest in the IPD treatment arm,NA,NA,79,TRUE,NA,NA,NA
10.2217/cer-2020-0069,32602756,results,1,NA,"Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC",NA,28.7,28.7,FALSE,NA,NA,NA
10.2217/cer-2020-0069,32602756,results,1,NA,Reporting of a weights' distribution evaluation (MAIC),NA,NA,Not mentioned,TRUE,NA,NA,NA
10.2217/cer-2020-0069,32602756,results,1,NA,Reporting of the list of the covariates adjusted for/matched on,NA,NA,Yes,TRUE,NA,NA,NA
10.2217/cer-2020-0069,32602756,results,1,NA,Number of covariates adjusted for/matched on,NA,NA,9,TRUE,NA,NA,NA
10.2217/cer-2020-0069,32602756,results,1,NA,Covariates adjusted for/matched on in the indirect comparison,NA,NA,"Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Past treatments for the disease of interest, Other(s)",TRUE,NA,NA,NA
10.2217/cer-2020-0069,32602756,results,1,NA,Primary outcome: treatment effect contrast,NA,NA,HR,TRUE,NA,NA,NA
10.2217/cer-2020-0069,32602756,results,1,NA,Direction of the treatment effect contrast: IPD treatment is:,NA,NA,"Numerator if ratio, or left side if difference",TRUE,NA,NA,NA
10.2217/cer-2020-0069,32602756,results,1,NA,Primary outcome: unadjusted treatment effect,NA,0.28,0.28,FALSE,NA,NA,NA
10.2217/cer-2020-0069,32602756,results,1,NA,"p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])",NA,<0.0001,<0.0001,FALSE,NA,NA,NA
10.2217/cer-2020-0069,32602756,results,1,NA,Primary outcome: adjusted treatment effect,NA,NA,0.32,TRUE,NA,NA,NA
10.2217/cer-2020-0069,32602756,results,1,NA,"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])",NA,NA,0.0015,TRUE,NA,NA,NA
10.2217/cer-2020-0069,32602756,results,2,NA,Sample size of the population of interest in the non IPD treatment arm,NA,NA,61,TRUE,NA,NA,NA
10.2217/cer-2020-0069,32602756,results,2,NA,Initial sample size of the population of interest in the IPD treatment arm,NA,NA,79,TRUE,NA,NA,NA
10.2217/cer-2020-0069,32602756,results,2,NA,"Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC",NA,43,43,FALSE,NA,NA,NA
10.2217/cer-2020-0069,32602756,results,2,NA,Reporting of a weights' distribution evaluation (MAIC),NA,NA,Not mentioned,TRUE,NA,NA,NA
10.2217/cer-2020-0069,32602756,results,2,NA,Reporting of the list of the covariates adjusted for/matched on,NA,NA,Yes,TRUE,NA,NA,NA
10.2217/cer-2020-0069,32602756,results,2,NA,Number of covariates adjusted for/matched on,NA,NA,5,TRUE,NA,NA,NA
10.2217/cer-2020-0069,32602756,results,2,NA,Covariates adjusted for/matched on in the indirect comparison,NA,NA,"Age, Sex, Race/ethnicity, Past treatments for the disease of interest",TRUE,NA,NA,NA
10.2217/cer-2020-0069,32602756,results,2,NA,Primary outcome: treatment effect contrast,NA,NA,HR,TRUE,NA,NA,NA
10.2217/cer-2020-0069,32602756,results,2,NA,Direction of the treatment effect contrast: IPD treatment is:,NA,NA,"Numerator if ratio, or left side if difference",TRUE,NA,NA,NA
10.2217/cer-2020-0069,32602756,results,2,NA,Primary outcome: unadjusted treatment effect,NA,0.17,0.17,FALSE,NA,NA,NA
10.2217/cer-2020-0069,32602756,results,2,NA,"p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])",NA,<0.0001,<0.0001,FALSE,NA,NA,NA
10.2217/cer-2020-0069,32602756,results,2,NA,Primary outcome: adjusted treatment effect,NA,NA,0.24,TRUE,NA,NA,NA
10.2217/cer-2020-0069,32602756,results,2,NA,"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])",NA,NA,<0.0001,TRUE,NA,NA,NA
10.2217/cer-2020-0069,32602756,results,3,NA,Sample size of the population of interest in the non IPD treatment arm,NA,NA,74,TRUE,NA,NA,NA
10.2217/cer-2020-0069,32602756,results,3,NA,Initial sample size of the population of interest in the IPD treatment arm,NA,NA,79,TRUE,NA,NA,NA
10.2217/cer-2020-0069,32602756,results,3,NA,"Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC",NA,53.5,53.5,FALSE,NA,NA,NA
10.2217/cer-2020-0069,32602756,results,3,NA,Reporting of a weights' distribution evaluation (MAIC),NA,NA,Not mentioned,TRUE,NA,NA,NA
10.2217/cer-2020-0069,32602756,results,3,NA,Reporting of the list of the covariates adjusted for/matched on,NA,NA,Yes,TRUE,NA,NA,NA
10.2217/cer-2020-0069,32602756,results,3,NA,Number of covariates adjusted for/matched on,NA,NA,2,TRUE,NA,NA,NA
10.2217/cer-2020-0069,32602756,results,3,NA,Covariates adjusted for/matched on in the indirect comparison,NA,NA,"Sex, Past treatments for the disease of interest",TRUE,NA,NA,NA
10.2217/cer-2020-0069,32602756,results,3,NA,Primary outcome: treatment effect contrast,NA,NA,HR,TRUE,NA,NA,NA
10.2217/cer-2020-0069,32602756,results,3,NA,Direction of the treatment effect contrast: IPD treatment is:,NA,NA,"Numerator if ratio, or left side if difference",TRUE,NA,NA,NA
10.2217/cer-2020-0069,32602756,results,3,NA,Primary outcome: unadjusted treatment effect,NA,0.22,0.22,FALSE,NA,NA,NA
10.2217/cer-2020-0069,32602756,results,3,NA,"p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])",NA,<0.0001,<0.0001,FALSE,NA,NA,NA
10.2217/cer-2020-0069,32602756,results,3,NA,Primary outcome: adjusted treatment effect,0.15,0.26,0.26,FALSE,NA,NA,NA
10.2217/cer-2020-0069,32602756,results,3,NA,"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])",NA,NA,<0.0001,TRUE,NA,NA,NA
10.2217/cer-2020-0069,32602756,results,4,NA,Sample size of the population of interest in the non IPD treatment arm,NA,NA,51,TRUE,NA,NA,NA
10.2217/cer-2020-0069,32602756,results,4,NA,Initial sample size of the population of interest in the IPD treatment arm,51,79,79,FALSE,NA,NA,NA
10.2217/cer-2020-0069,32602756,results,4,NA,"Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC",NA,75,75,FALSE,NA,NA,NA
10.2217/cer-2020-0069,32602756,results,4,NA,Reporting of a weights' distribution evaluation (MAIC),NA,NA,Not mentioned,TRUE,NA,NA,NA
10.2217/cer-2020-0069,32602756,results,4,NA,Reporting of the list of the covariates adjusted for/matched on,NA,NA,Yes,TRUE,NA,NA,NA
10.2217/cer-2020-0069,32602756,results,4,NA,Number of covariates adjusted for/matched on,NA,NA,3,TRUE,NA,NA,NA
10.2217/cer-2020-0069,32602756,results,4,NA,Covariates adjusted for/matched on in the indirect comparison,NA,NA,"Age, Sex, Past treatments for the disease of interest",TRUE,NA,NA,NA
10.2217/cer-2020-0069,32602756,results,4,NA,Primary outcome: treatment effect contrast,NA,NA,HR,TRUE,NA,NA,NA
10.2217/cer-2020-0069,32602756,results,4,NA,Direction of the treatment effect contrast: IPD treatment is:,NA,NA,"Numerator if ratio, or left side if difference",TRUE,NA,NA,NA
10.2217/cer-2020-0069,32602756,results,4,NA,Primary outcome: unadjusted treatment effect,NA,0.14,0.14,FALSE,NA,NA,NA
10.2217/cer-2020-0069,32602756,results,4,NA,"p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])",NA,<0.0001,<0.0001,FALSE,NA,NA,NA
10.2217/cer-2020-0069,32602756,results,4,NA,Primary outcome: adjusted treatment effect,NA,NA,0.15,TRUE,NA,NA,NA
10.2217/cer-2020-0069,32602756,results,4,NA,"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])",NA,NA,<0.0001,TRUE,NA,NA,NA
10.2217/cer-2020-0069,32602756,results,5,NA,Sample size of the population of interest in the non IPD treatment arm,NA,NA,242,TRUE,NA,NA,NA
10.2217/cer-2020-0069,32602756,results,5,NA,Initial sample size of the population of interest in the IPD treatment arm,NA,NA,79,TRUE,NA,NA,NA
10.2217/cer-2020-0069,32602756,results,5,NA,"Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC",NA,36.2,36.2,FALSE,NA,NA,NA
10.2217/cer-2020-0069,32602756,results,5,NA,Reporting of a weights' distribution evaluation (MAIC),NA,NA,Not mentioned,TRUE,NA,NA,NA
10.2217/cer-2020-0069,32602756,results,5,NA,Reporting of the list of the covariates adjusted for/matched on,NA,NA,Yes,TRUE,NA,NA,NA
10.2217/cer-2020-0069,32602756,results,5,NA,Number of covariates adjusted for/matched on,2,3,3,FALSE,NA,NA,NA
10.2217/cer-2020-0069,32602756,results,5,NA,Covariates adjusted for/matched on in the indirect comparison,NA,NA,"Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease)",TRUE,NA,NA,NA
10.2217/cer-2020-0069,32602756,results,5,NA,Primary outcome: treatment effect contrast,NA,NA,HR,TRUE,NA,NA,NA
10.2217/cer-2020-0069,32602756,results,5,NA,Direction of the treatment effect contrast: IPD treatment is:,NA,NA,"Numerator if ratio, or left side if difference",TRUE,NA,NA,NA
10.2217/cer-2020-0069,32602756,results,5,NA,Primary outcome: unadjusted treatment effect,NA,0.28,0.28,FALSE,NA,NA,NA
10.2217/cer-2020-0069,32602756,results,5,NA,"p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])",NA,<0.0001,<0.0001,FALSE,NA,NA,NA
10.2217/cer-2020-0069,32602756,results,5,NA,Primary outcome: adjusted treatment effect,NA,NA,0.27,TRUE,NA,NA,NA
10.2217/cer-2020-0069,32602756,results,5,NA,"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])",NA,NA,<0.0001,TRUE,NA,NA,NA
10.1016/j.clgc.2020.07.006,32826180,general_information,NA,NA,Medical Condition of Interest Name,locally advanced or metastatic urothelial cancer,pd-l1–positive locaadvanced or metastatic urothelial carcinoma,XXXX,FALSE,NA,NA,NA
10.1016/j.clgc.2020.07.006,32826180,general_information,NA,NA,Countries of first author affiliations,NA,NA,uk,TRUE,NA,NA,NA
10.1016/j.clgc.2020.07.006,32826180,general_information,NA,NA,Countries of last author affiliations,NA,NA,usa,TRUE,NA,NA,NA
10.1016/j.clgc.2020.07.006,32826180,general_information,NA,NA,"Positions of study investigators (for any authors of the article, any that applies)",NA,NA,"Academic, Pharmaceutical Industry, Private Data Analysis Company",TRUE,NA,NA,NA
10.1016/j.clgc.2020.07.006,32826180,general_information,NA,NA,"At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company",NA,NA,Yes,TRUE,NA,NA,NA
10.1016/j.clgc.2020.07.006,32826180,general_information,NA,NA,Mentioned sources of funding,NA,NA,Pharmaceutical Industry,TRUE,NA,NA,NA
10.1016/j.clgc.2020.07.006,32826180,general_information,NA,NA,"Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article",NA,NA,Yes,TRUE,NA,NA,NA
10.1016/j.clgc.2020.07.006,32826180,general_information,NA,NA,Mention of a systematic review to find the studies to compare treatments of interest,NA,NA,No,TRUE,NA,NA,NA
10.1016/j.clgc.2020.07.006,32826180,study_information,NA,1,Patient-level data used,NA,NA,Yes,TRUE,NA,NA,NA
10.1016/j.clgc.2020.07.006,32826180,study_information,NA,1,Clinical Trial,NA,NA,Yes,TRUE,NA,NA,NA
10.1016/j.clgc.2020.07.006,32826180,study_information,NA,1,NCT (only for clinical trial registered on clinicaltrials.gov),NA,NA,NCT02335424,TRUE,NA,NA,NA
10.1016/j.clgc.2020.07.006,32826180,study_information,NA,1,Country where the clinical trial/observational study was conducted (international if more than one),unknown,international,XXXX,FALSE,NA,NA,NA
10.1016/j.clgc.2020.07.006,32826180,study_information,NA,1,Phase of the clinical trial (clinical trial only),NA,NA,2,TRUE,NA,NA,NA
10.1016/j.clgc.2020.07.006,32826180,study_information,NA,1,Number of treatment arms (clinical trial only),NA,NA,1,TRUE,NA,NA,NA
10.1016/j.clgc.2020.07.006,32826180,study_information,NA,2,Patient-level data used,NA,NA,No,TRUE,NA,NA,NA
10.1016/j.clgc.2020.07.006,32826180,study_information,NA,2,Clinical Trial,NA,NA,Yes,TRUE,NA,NA,NA
10.1016/j.clgc.2020.07.006,32826180,study_information,NA,2,Data source name (only if observational study or clinical trial without NCT),NA,NA,bamias et al. (2007),TRUE,NA,NA,NA
10.1016/j.clgc.2020.07.006,32826180,study_information,NA,2,Country where the clinical trial/observational study was conducted (international if more than one),NA,greece,XXXX,FALSE,NA,NA,NA
10.1016/j.clgc.2020.07.006,32826180,study_information,NA,2,Number of treatment arms (clinical trial only),1,NA,XXXX,FALSE,NA,NA,NA
10.1016/j.clgc.2020.07.006,32826180,study_information,NA,3,Patient-level data used,NA,NA,No,TRUE,NA,NA,NA
10.1016/j.clgc.2020.07.006,32826180,study_information,NA,3,Clinical Trial,NA,NA,No,TRUE,NA,NA,NA
10.1016/j.clgc.2020.07.006,32826180,study_information,NA,3,Data source name (only if observational study or clinical trial without NCT),NA,NA,carles et al. (2000),TRUE,NA,NA,NA
10.1016/j.clgc.2020.07.006,32826180,study_information,NA,3,Country where the clinical trial/observational study was conducted (international if more than one),NA,NA,spain,TRUE,NA,NA,NA
10.1016/j.clgc.2020.07.006,32826180,study_information,NA,4,Patient-level data used,NA,NA,No,TRUE,NA,NA,NA
10.1016/j.clgc.2020.07.006,32826180,study_information,NA,4,Clinical Trial,NA,NA,Yes,TRUE,NA,NA,NA
10.1016/j.clgc.2020.07.006,32826180,study_information,NA,4,NCT (only for clinical trial registered on clinicaltrials.gov),NCT00111787,NCT00014274,NCT00014274,FALSE,NA,NA,NA
10.1016/j.clgc.2020.07.006,32826180,study_information,NA,4,Country where the clinical trial/observational study was conducted (international if more than one),NA,NA,international,TRUE,NA,NA,NA
10.1016/j.clgc.2020.07.006,32826180,study_information,NA,4,Phase of the clinical trial (clinical trial only),2,"2, 3",XXXX,FALSE,NA,NA,NA
10.1016/j.clgc.2020.07.006,32826180,study_information,NA,4,Number of treatment arms (clinical trial only),1,2 or more,XXXX,FALSE,NA,NA,NA
10.1016/j.clgc.2020.07.006,32826180,study_information,NA,5,Patient-level data used,NA,NA,No,TRUE,NA,NA,NA
10.1016/j.clgc.2020.07.006,32826180,study_information,NA,5,Clinical Trial,NA,NA,Yes,TRUE,NA,NA,NA
10.1016/j.clgc.2020.07.006,32826180,study_information,NA,5,Data source name (only if observational study or clinical trial without NCT),NA,NA,linardou et al. (2004),TRUE,NA,NA,NA
10.1016/j.clgc.2020.07.006,32826180,study_information,NA,5,Country where the clinical trial/observational study was conducted (international if more than one),NA,greece,XXXX,FALSE,NA,NA,NA
10.1016/j.clgc.2020.07.006,32826180,study_information,NA,5,Phase of the clinical trial (clinical trial only),2,NA,XXXX,FALSE,NA,NA,NA
10.1016/j.clgc.2020.07.006,32826180,study_information,NA,5,Number of treatment arms (clinical trial only),1,NA,XXXX,FALSE,NA,NA,NA
10.1016/j.clgc.2020.07.006,32826180,methodology,1,NA,Treatment name 1,NA,NA,pembrolizumab,TRUE,Associated with an economic analysis,"Cost-effectivness (economic) analysis

""This analysis uses a simulated treatment comparison to adjust for cross-study differences then applies a relative treatment effect based on a standard meta-analysis model. The approach was detailed in previous publications""",NA
10.1016/j.clgc.2020.07.006,32826180,methodology,1,NA,Study 'number(s)' for treatment 1,NA,NA,1,TRUE,NA,NA,NA
10.1016/j.clgc.2020.07.006,32826180,methodology,1,NA,Treatment name 2,NA,NA,carboplatin + gemcitabine,TRUE,NA,NA,NA
10.1016/j.clgc.2020.07.006,32826180,methodology,1,NA,Study 'number(s)' for treatment 2,2;3;4;5²,2;3;4;5,2;3;4;5,FALSE,NA,NA,NA
10.1016/j.clgc.2020.07.006,32826180,methodology,1,NA,Type of population-adjusted indirect comparisons performed,NA,NA,STC,TRUE,NA,NA,NA
10.1016/j.clgc.2020.07.006,32826180,methodology,1,NA,Anchored comparison?,NA,NA,No,TRUE,NA,NA,NA
10.1016/j.clgc.2020.07.006,32826180,methodology,1,NA,Form of the indirect comparison,NA,NA,"Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate)",TRUE,NA,NA,NA
10.1016/j.clgc.2020.07.006,32826180,methodology,1,NA,Definition of a single primary outcome for the indirect comparison,NA,NA,"No primary outcome defined, or multiple primary outcomes without any clear distinction between them",TRUE,NA,NA,NA
10.1016/j.clgc.2020.07.006,32826180,methodology,1,NA,Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined),NA,NA,overall survival,TRUE,NA,NA,NA
10.1016/j.clgc.2020.07.006,32826180,methodology,1,NA,Primary outcome: variable type,NA,NA,Time-to-event,TRUE,NA,NA,NA
10.1016/j.clgc.2020.07.006,32826180,methodology,1,NA,Justification for selecting variables to be included in the adjustment model (in the main text),NA,NA,"Nothing mentioned, not reported",TRUE,NA,NA,NA
10.1016/j.clgc.2020.07.006,32826180,methodology,1,NA,Inclusion of prognostic factors in the adjustment/matching model,NA,NA,No discussion (in the main text) of the status of prognostic factors of the variables,TRUE,NA,NA,NA
10.1016/j.clgc.2020.07.006,32826180,methodology,1,NA,Inclusion of treatment-effect modifiers in the adjustment/matching model,NA,NA,No discussion (in the main text) of the status of treatment-effect modifiers of the variables,TRUE,NA,NA,NA
10.1016/j.clgc.2020.07.006,32826180,methodology,1,NA,"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)",NA,NA,No,TRUE,NA,NA,NA
10.1016/j.clgc.2020.07.006,32826180,methodology,1,NA,Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale),NA,NA,No,TRUE,NA,NA,NA
10.1016/j.clgc.2020.07.006,32826180,results,1,NA,Reporting of a weights' distribution evaluation (MAIC),NA,Not mentioned,XXXX,FALSE,NA,NA,NA
10.1016/j.clgc.2020.07.006,32826180,results,1,NA,Reporting of the list of the covariates adjusted for/matched on,NA,NA,No,TRUE,NA,NA,NA
10.1016/j.clgc.2020.07.006,32826180,results,1,NA,Primary outcome: treatment effect contrast,NA,NA,HR,TRUE,NA,NA,NA
10.1016/j.clgc.2020.07.006,32826180,results,1,NA,Direction of the treatment effect contrast: IPD treatment is:,NA,NA,"Denominator if ratio, or rightside if difference",TRUE,NA,NA,NA
10.1016/j.clgc.2020.07.006,32826180,results,1,NA,Primary outcome: adjusted treatment effect,NA,NA,2.34,TRUE,NA,NA,NA
10.1016/j.clgc.2020.07.006,32826180,results,1,NA,"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])",NA,[1.92;2.85],[1.92;2.85],FALSE,NA,NA,NA
10.2217/fon-2020-0823,33052055,general_information,NA,NA,Medical Condition of Interest Name,NA,NA,advanced cutaneous squamous cell carcinoma,TRUE,NA,NA,NA
10.2217/fon-2020-0823,33052055,general_information,NA,NA,Countries of first author affiliations,NA,NA,canada,TRUE,NA,NA,NA
10.2217/fon-2020-0823,33052055,general_information,NA,NA,Countries of last author affiliations,NA,NA,usa,TRUE,NA,NA,NA
10.2217/fon-2020-0823,33052055,general_information,NA,NA,"Positions of study investigators (for any authors of the article, any that applies)",NA,NA,"Academic, Pharmaceutical Industry, Private Data Analysis Company",TRUE,NA,NA,NA
10.2217/fon-2020-0823,33052055,general_information,NA,NA,"At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company",NA,NA,Yes,TRUE,NA,NA,NA
10.2217/fon-2020-0823,33052055,general_information,NA,NA,Mentioned sources of funding,NA,NA,Pharmaceutical Industry,TRUE,NA,NA,NA
10.2217/fon-2020-0823,33052055,general_information,NA,NA,"Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article",NA,NA,Yes,TRUE,NA,NA,NA
10.2217/fon-2020-0823,33052055,general_information,NA,NA,Mention of a systematic review to find the studies to compare treatments of interest,NA,NA,Yes,TRUE,NA,NA,NA
10.2217/fon-2020-0823,33052055,study_information,NA,1,Patient-level data used,NA,NA,Yes,TRUE,NA,NA,NA
10.2217/fon-2020-0823,33052055,study_information,NA,1,Clinical Trial,NA,NA,Yes,TRUE,NA,NA,NA
10.2217/fon-2020-0823,33052055,study_information,NA,1,NCT (only for clinical trial registered on clinicaltrials.gov),NA,NA,NCT02760498,TRUE,NA,NA,NA
10.2217/fon-2020-0823,33052055,study_information,NA,1,Country where the clinical trial/observational study was conducted (international if more than one),NA,NA,international,TRUE,NA,NA,NA
10.2217/fon-2020-0823,33052055,study_information,NA,1,Phase of the clinical trial (clinical trial only),NA,NA,2,TRUE,NA,NA,NA
10.2217/fon-2020-0823,33052055,study_information,NA,1,Number of treatment arms (clinical trial only),NA,NA,1,TRUE,NA,NA,NA
10.2217/fon-2020-0823,33052055,study_information,NA,10,Patient-level data used,NA,NA,No,TRUE,NA,NA,NA
10.2217/fon-2020-0823,33052055,study_information,NA,10,Clinical Trial,NA,NA,Yes,TRUE,NA,NA,NA
10.2217/fon-2020-0823,33052055,study_information,NA,10,NCT (only for clinical trial registered on clinicaltrials.gov),NA,NA,NCT03284424,TRUE,NA,NA,NA
10.2217/fon-2020-0823,33052055,study_information,NA,10,Country where the clinical trial/observational study was conducted (international if more than one),NA,NA,international,TRUE,NA,NA,NA
10.2217/fon-2020-0823,33052055,study_information,NA,10,Phase of the clinical trial (clinical trial only),NA,NA,2,TRUE,NA,NA,NA
10.2217/fon-2020-0823,33052055,study_information,NA,10,Number of treatment arms (clinical trial only),NA,NA,1,TRUE,NA,NA,NA
10.2217/fon-2020-0823,33052055,study_information,NA,11,Patient-level data used,NA,NA,No,TRUE,NA,NA,NA
10.2217/fon-2020-0823,33052055,study_information,NA,11,Clinical Trial,NA,NA,No,TRUE,NA,NA,NA
10.2217/fon-2020-0823,33052055,study_information,NA,11,Data source name (only if observational study or clinical trial without NCT),NA,NA,peyrade et al. (2018),TRUE,NA,NA,NA
10.2217/fon-2020-0823,33052055,study_information,NA,2,Patient-level data used,NA,NA,No,TRUE,NA,NA,NA
10.2217/fon-2020-0823,33052055,study_information,NA,2,Clinical Trial,NA,NA,Yes,TRUE,NA,NA,NA
10.2217/fon-2020-0823,33052055,study_information,NA,2,NCT (only for clinical trial registered on clinicaltrials.gov),NA,NA,NCT01198028,TRUE,NA,NA,NA
10.2217/fon-2020-0823,33052055,study_information,NA,2,Country where the clinical trial/observational study was conducted (international if more than one),NA,NA,usa,TRUE,NA,NA,NA
10.2217/fon-2020-0823,33052055,study_information,NA,2,Phase of the clinical trial (clinical trial only),NA,NA,2,TRUE,NA,NA,NA
10.2217/fon-2020-0823,33052055,study_information,NA,2,Number of treatment arms (clinical trial only),NA,NA,1,TRUE,NA,NA,NA
10.2217/fon-2020-0823,33052055,study_information,NA,3,Patient-level data used,NA,NA,No,TRUE,NA,NA,NA
10.2217/fon-2020-0823,33052055,study_information,NA,3,Clinical Trial,NA,NA,No,TRUE,NA,NA,NA
10.2217/fon-2020-0823,33052055,study_information,NA,3,Data source name (only if observational study or clinical trial without NCT),NA,NA,jarkowski et al. (2016),TRUE,NA,NA,NA
10.2217/fon-2020-0823,33052055,study_information,NA,4,Patient-level data used,NA,NA,No,TRUE,NA,NA,NA
10.2217/fon-2020-0823,33052055,study_information,NA,4,Clinical Trial,NA,NA,Yes,TRUE,NA,NA,NA
10.2217/fon-2020-0823,33052055,study_information,NA,4,NCT (only for clinical trial registered on clinicaltrials.gov),NA,NA,NCT00240682,TRUE,NA,NA,NA
10.2217/fon-2020-0823,33052055,study_information,NA,4,Country where the clinical trial/observational study was conducted (international if more than one),NA,NA,france,TRUE,NA,NA,NA
10.2217/fon-2020-0823,33052055,study_information,NA,4,Phase of the clinical trial (clinical trial only),NA,NA,2,TRUE,NA,NA,NA
10.2217/fon-2020-0823,33052055,study_information,NA,4,Number of treatment arms (clinical trial only),NA,NA,1,TRUE,NA,NA,NA
10.2217/fon-2020-0823,33052055,study_information,NA,5,Patient-level data used,NA,NA,No,TRUE,NA,NA,NA
10.2217/fon-2020-0823,33052055,study_information,NA,5,Clinical Trial,NA,NA,No,TRUE,NA,NA,NA
10.2217/fon-2020-0823,33052055,study_information,NA,5,Data source name (only if observational study or clinical trial without NCT),NA,NA,picard et al. (2017),TRUE,NA,NA,NA
10.2217/fon-2020-0823,33052055,study_information,NA,5,Country where the clinical trial/observational study was conducted (international if more than one),NA,NA,france,TRUE,NA,NA,NA
10.2217/fon-2020-0823,33052055,study_information,NA,6,Patient-level data used,NA,NA,No,TRUE,NA,NA,NA
10.2217/fon-2020-0823,33052055,study_information,NA,6,Clinical Trial,NA,NA,Yes,TRUE,NA,NA,NA
10.2217/fon-2020-0823,33052055,study_information,NA,6,NCT (only for clinical trial registered on clinicaltrials.gov),NA,NA,NCT00054691,TRUE,NA,NA,NA
10.2217/fon-2020-0823,33052055,study_information,NA,6,Country where the clinical trial/observational study was conducted (international if more than one),NA,NA,usa,TRUE,NA,NA,NA
10.2217/fon-2020-0823,33052055,study_information,NA,6,Phase of the clinical trial (clinical trial only),NA,NA,2,TRUE,NA,NA,NA
10.2217/fon-2020-0823,33052055,study_information,NA,6,Number of treatment arms (clinical trial only),NA,NA,1,TRUE,NA,NA,NA
10.2217/fon-2020-0823,33052055,study_information,NA,7,Patient-level data used,NA,NA,No,TRUE,NA,NA,NA
10.2217/fon-2020-0823,33052055,study_information,NA,7,Clinical Trial,NA,NA,Yes,TRUE,NA,NA,NA
10.2217/fon-2020-0823,33052055,study_information,NA,7,NCT (only for clinical trial registered on clinicaltrials.gov),NA,NA,NCT02268747,TRUE,NA,NA,NA
10.2217/fon-2020-0823,33052055,study_information,NA,7,Country where the clinical trial/observational study was conducted (international if more than one),NA,NA,italy,TRUE,NA,NA,NA
10.2217/fon-2020-0823,33052055,study_information,NA,7,Phase of the clinical trial (clinical trial only),NA,NA,2,TRUE,NA,NA,NA
10.2217/fon-2020-0823,33052055,study_information,NA,7,Number of treatment arms (clinical trial only),NA,NA,1,TRUE,NA,NA,NA
10.2217/fon-2020-0823,33052055,study_information,NA,8,Patient-level data used,NA,NA,No,TRUE,NA,NA,NA
10.2217/fon-2020-0823,33052055,study_information,NA,8,Clinical Trial,NA,NA,Yes,TRUE,NA,NA,NA
10.2217/fon-2020-0823,33052055,study_information,NA,8,Data source name (only if observational study or clinical trial without NCT),NA,NA,foote et al. (2014),TRUE,NA,NA,NA
10.2217/fon-2020-0823,33052055,study_information,NA,8,Country where the clinical trial/observational study was conducted (international if more than one),NA,NA,australia,TRUE,NA,NA,NA
10.2217/fon-2020-0823,33052055,study_information,NA,8,Phase of the clinical trial (clinical trial only),NA,NA,2,TRUE,NA,NA,NA
10.2217/fon-2020-0823,33052055,study_information,NA,8,Number of treatment arms (clinical trial only),NA,NA,1,TRUE,NA,NA,NA
10.2217/fon-2020-0823,33052055,study_information,NA,9,Patient-level data used,NA,NA,No,TRUE,NA,NA,NA
10.2217/fon-2020-0823,33052055,study_information,NA,9,Clinical Trial,NA,NA,Yes,TRUE,NA,NA,NA
10.2217/fon-2020-0823,33052055,study_information,NA,9,NCT (only for clinical trial registered on clinicaltrials.gov),NA,NA,NCT02883556,TRUE,NA,NA,NA
10.2217/fon-2020-0823,33052055,study_information,NA,9,Country where the clinical trial/observational study was conducted (international if more than one),NA,NA,france,TRUE,NA,NA,NA
10.2217/fon-2020-0823,33052055,study_information,NA,9,Phase of the clinical trial (clinical trial only),NA,NA,2,TRUE,NA,NA,NA
10.2217/fon-2020-0823,33052055,study_information,NA,9,Number of treatment arms (clinical trial only),NA,NA,1,TRUE,NA,NA,NA
10.2217/fon-2020-0823,33052055,methodology,1,NA,Treatment name 1,NA,NA,cemiplimab,TRUE,NA,"""The distribution of the estimated weights and effective sample sizes are reported in the results section."" ==> Can't find them, either in the main-text or in the supplementary data.

Initial sample size IPD = 193 ??",NA
10.2217/fon-2020-0823,33052055,methodology,1,NA,Study 'number(s)' for treatment 1,NA,NA,1,TRUE,NA,NA,NA
10.2217/fon-2020-0823,33052055,methodology,1,NA,Treatment name 2,NA,NA,erlotinib,TRUE,NA,NA,NA
10.2217/fon-2020-0823,33052055,methodology,1,NA,Study 'number(s)' for treatment 2,NA,NA,2,TRUE,NA,NA,NA
10.2217/fon-2020-0823,33052055,methodology,1,NA,Type of population-adjusted indirect comparisons performed,NA,NA,MAIC,TRUE,NA,NA,NA
10.2217/fon-2020-0823,33052055,methodology,1,NA,Anchored comparison?,NA,NA,No,TRUE,NA,NA,NA
10.2217/fon-2020-0823,33052055,methodology,1,NA,Form of the indirect comparison,NA,NA,Simple (ie treatments effects extracted from two studies),TRUE,NA,NA,NA
10.2217/fon-2020-0823,33052055,methodology,1,NA,Definition of a single primary outcome for the indirect comparison,NA,NA,"No primary outcome defined, or multiple primary outcomes without any clear distinction between them",TRUE,NA,NA,NA
10.2217/fon-2020-0823,33052055,methodology,1,NA,Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined),NA,NA,overall survival,TRUE,NA,NA,NA
10.2217/fon-2020-0823,33052055,methodology,1,NA,Primary outcome: variable type,NA,NA,Time-to-event,TRUE,NA,NA,NA
10.2217/fon-2020-0823,33052055,methodology,1,NA,Justification for selecting variables to be included in the adjustment model (in the main text),NA,NA,Literature based (clinically or methodologically relevant to adjust on these variables based on the literature search conducted for this specific purpose),TRUE,NA,NA,NA
10.2217/fon-2020-0823,33052055,methodology,1,NA,Inclusion of prognostic factors in the adjustment/matching model,NA,NA,Yes,TRUE,NA,NA,NA
10.2217/fon-2020-0823,33052055,methodology,1,NA,Inclusion of treatment-effect modifiers in the adjustment/matching model,NA,NA,No discussion (in the main text) of the status of treatment-effect modifiers of the variables,TRUE,NA,NA,NA
10.2217/fon-2020-0823,33052055,methodology,1,NA,"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)",NA,NA,No,TRUE,NA,NA,NA
10.2217/fon-2020-0823,33052055,methodology,1,NA,Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale),NA,NA,No,TRUE,NA,NA,NA
10.2217/fon-2020-0823,33052055,methodology,10,NA,Treatment name 1,NA,NA,cemiplimab,TRUE,NA,"""The distribution of the estimated weights and effective sample sizes are reported in the results section."" ==> Can't find them, either in the main-text or in the supplementary data.",NA
10.2217/fon-2020-0823,33052055,methodology,10,NA,Study 'number(s)' for treatment 1,NA,NA,1,TRUE,NA,NA,NA
10.2217/fon-2020-0823,33052055,methodology,10,NA,Treatment name 2,NA,NA,gefitinib,TRUE,NA,NA,NA
10.2217/fon-2020-0823,33052055,methodology,10,NA,Study 'number(s)' for treatment 2,NA,NA,6,TRUE,NA,NA,NA
10.2217/fon-2020-0823,33052055,methodology,10,NA,Type of population-adjusted indirect comparisons performed,NA,NA,STC,TRUE,NA,NA,NA
10.2217/fon-2020-0823,33052055,methodology,10,NA,Anchored comparison?,NA,NA,No,TRUE,NA,NA,NA
10.2217/fon-2020-0823,33052055,methodology,10,NA,Form of the indirect comparison,NA,NA,Simple (ie treatments effects extracted from two studies),TRUE,NA,NA,NA
10.2217/fon-2020-0823,33052055,methodology,10,NA,Definition of a single primary outcome for the indirect comparison,NA,NA,"No primary outcome defined, or multiple primary outcomes without any clear distinction between them",TRUE,NA,NA,NA
10.2217/fon-2020-0823,33052055,methodology,10,NA,Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined),NA,NA,overall survival,TRUE,NA,NA,NA
10.2217/fon-2020-0823,33052055,methodology,10,NA,Primary outcome: variable type,NA,NA,Time-to-event,TRUE,NA,NA,NA
10.2217/fon-2020-0823,33052055,methodology,10,NA,Justification for selecting variables to be included in the adjustment model (in the main text),NA,NA,Literature based (clinically or methodologically relevant to adjust on these variables based on the literature search conducted for this specific purpose),TRUE,NA,NA,NA
10.2217/fon-2020-0823,33052055,methodology,10,NA,Inclusion of prognostic factors in the adjustment/matching model,NA,NA,Yes,TRUE,NA,NA,NA
10.2217/fon-2020-0823,33052055,methodology,10,NA,Inclusion of treatment-effect modifiers in the adjustment/matching model,NA,NA,No discussion (in the main text) of the status of treatment-effect modifiers of the variables,TRUE,NA,NA,NA
10.2217/fon-2020-0823,33052055,methodology,10,NA,"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)",NA,NA,No,TRUE,NA,NA,NA
10.2217/fon-2020-0823,33052055,methodology,10,NA,Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale),NA,NA,No,TRUE,NA,NA,NA
10.2217/fon-2020-0823,33052055,methodology,11,NA,Treatment name 1,NA,NA,cemiplimab,TRUE,NA,"""The distribution of the estimated weights and effective sample sizes are reported in the results section."" ==> Can't find them, either in the main-text or in the supplementary data.

Initial sample size IPD = 193 ??",NA
10.2217/fon-2020-0823,33052055,methodology,11,NA,Study 'number(s)' for treatment 1,NA,NA,1,TRUE,NA,NA,NA
10.2217/fon-2020-0823,33052055,methodology,11,NA,Treatment name 2,NA,NA,dacomitinib,TRUE,NA,NA,NA
10.2217/fon-2020-0823,33052055,methodology,11,NA,Study 'number(s)' for treatment 2,NA,NA,7,TRUE,NA,NA,NA
10.2217/fon-2020-0823,33052055,methodology,11,NA,Type of population-adjusted indirect comparisons performed,NA,NA,MAIC,TRUE,NA,NA,NA
10.2217/fon-2020-0823,33052055,methodology,11,NA,Anchored comparison?,NA,NA,No,TRUE,NA,NA,NA
10.2217/fon-2020-0823,33052055,methodology,11,NA,Form of the indirect comparison,NA,NA,Simple (ie treatments effects extracted from two studies),TRUE,NA,NA,NA
10.2217/fon-2020-0823,33052055,methodology,11,NA,Definition of a single primary outcome for the indirect comparison,NA,NA,"No primary outcome defined, or multiple primary outcomes without any clear distinction between them",TRUE,NA,NA,NA
10.2217/fon-2020-0823,33052055,methodology,11,NA,Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined),NA,NA,overall survival,TRUE,NA,NA,NA
10.2217/fon-2020-0823,33052055,methodology,11,NA,Primary outcome: variable type,NA,NA,Time-to-event,TRUE,NA,NA,NA
10.2217/fon-2020-0823,33052055,methodology,11,NA,Justification for selecting variables to be included in the adjustment model (in the main text),NA,NA,Literature based (clinically or methodologically relevant to adjust on these variables based on the literature search conducted for this specific purpose),TRUE,NA,NA,NA
10.2217/fon-2020-0823,33052055,methodology,11,NA,Inclusion of prognostic factors in the adjustment/matching model,NA,NA,Yes,TRUE,NA,NA,NA
10.2217/fon-2020-0823,33052055,methodology,11,NA,Inclusion of treatment-effect modifiers in the adjustment/matching model,NA,NA,No discussion (in the main text) of the status of treatment-effect modifiers of the variables,TRUE,NA,NA,NA
10.2217/fon-2020-0823,33052055,methodology,11,NA,"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)",NA,NA,No,TRUE,NA,NA,NA
10.2217/fon-2020-0823,33052055,methodology,11,NA,Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale),NA,NA,No,TRUE,NA,NA,NA
10.2217/fon-2020-0823,33052055,methodology,12,NA,Treatment name 1,NA,NA,cemiplimab,TRUE,NA,"""The distribution of the estimated weights and effective sample sizes are reported in the results section."" ==> Can't find them, either in the main-text or in the supplementary data.",NA
10.2217/fon-2020-0823,33052055,methodology,12,NA,Study 'number(s)' for treatment 1,NA,NA,1,TRUE,NA,NA,NA
10.2217/fon-2020-0823,33052055,methodology,12,NA,Treatment name 2,NA,NA,dacomitinib,TRUE,NA,NA,NA
10.2217/fon-2020-0823,33052055,methodology,12,NA,Study 'number(s)' for treatment 2,NA,NA,7,TRUE,NA,NA,NA
10.2217/fon-2020-0823,33052055,methodology,12,NA,Type of population-adjusted indirect comparisons performed,NA,NA,STC,TRUE,NA,NA,NA
10.2217/fon-2020-0823,33052055,methodology,12,NA,Anchored comparison?,NA,NA,No,TRUE,NA,NA,NA
10.2217/fon-2020-0823,33052055,methodology,12,NA,Form of the indirect comparison,NA,NA,Simple (ie treatments effects extracted from two studies),TRUE,NA,NA,NA
10.2217/fon-2020-0823,33052055,methodology,12,NA,Definition of a single primary outcome for the indirect comparison,NA,NA,"No primary outcome defined, or multiple primary outcomes without any clear distinction between them",TRUE,NA,NA,NA
10.2217/fon-2020-0823,33052055,methodology,12,NA,Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined),NA,NA,overall survival,TRUE,NA,NA,NA
10.2217/fon-2020-0823,33052055,methodology,12,NA,Primary outcome: variable type,NA,NA,Time-to-event,TRUE,NA,NA,NA
10.2217/fon-2020-0823,33052055,methodology,12,NA,Justification for selecting variables to be included in the adjustment model (in the main text),NA,NA,Literature based (clinically or methodologically relevant to adjust on these variables based on the literature search conducted for this specific purpose),TRUE,NA,NA,NA
10.2217/fon-2020-0823,33052055,methodology,12,NA,Inclusion of prognostic factors in the adjustment/matching model,NA,NA,Yes,TRUE,NA,NA,NA
10.2217/fon-2020-0823,33052055,methodology,12,NA,Inclusion of treatment-effect modifiers in the adjustment/matching model,NA,NA,No discussion (in the main text) of the status of treatment-effect modifiers of the variables,TRUE,NA,NA,NA
10.2217/fon-2020-0823,33052055,methodology,12,NA,"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)",NA,NA,No,TRUE,NA,NA,NA
10.2217/fon-2020-0823,33052055,methodology,12,NA,Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale),NA,NA,No,TRUE,NA,NA,NA
10.2217/fon-2020-0823,33052055,methodology,13,NA,Treatment name 1,NA,NA,cemiplimab,TRUE,NA,"""The distribution of the estimated weights and effective sample sizes are reported in the results section."" ==> Can't find them, either in the main-text or in the supplementary data.

Initial sample size IPD = 193 ??",NA
10.2217/fon-2020-0823,33052055,methodology,13,NA,Study 'number(s)' for treatment 1,NA,NA,1,TRUE,NA,NA,NA
10.2217/fon-2020-0823,33052055,methodology,13,NA,Treatment name 2,NA,NA,panitumumab,TRUE,NA,NA,NA
10.2217/fon-2020-0823,33052055,methodology,13,NA,Study 'number(s)' for treatment 2,NA,NA,8,TRUE,NA,NA,NA
10.2217/fon-2020-0823,33052055,methodology,13,NA,Type of population-adjusted indirect comparisons performed,NA,NA,MAIC,TRUE,NA,NA,NA
10.2217/fon-2020-0823,33052055,methodology,13,NA,Anchored comparison?,NA,NA,No,TRUE,NA,NA,NA
10.2217/fon-2020-0823,33052055,methodology,13,NA,Form of the indirect comparison,NA,NA,Simple (ie treatments effects extracted from two studies),TRUE,NA,NA,NA
10.2217/fon-2020-0823,33052055,methodology,13,NA,Definition of a single primary outcome for the indirect comparison,NA,NA,"No primary outcome defined, or multiple primary outcomes without any clear distinction between them",TRUE,NA,NA,NA
10.2217/fon-2020-0823,33052055,methodology,13,NA,Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined),NA,NA,overall survival,TRUE,NA,NA,NA
10.2217/fon-2020-0823,33052055,methodology,13,NA,Primary outcome: variable type,NA,NA,Time-to-event,TRUE,NA,NA,NA
10.2217/fon-2020-0823,33052055,methodology,13,NA,Justification for selecting variables to be included in the adjustment model (in the main text),NA,NA,Literature based (clinically or methodologically relevant to adjust on these variables based on the literature search conducted for this specific purpose),TRUE,NA,NA,NA
10.2217/fon-2020-0823,33052055,methodology,13,NA,Inclusion of prognostic factors in the adjustment/matching model,NA,NA,Yes,TRUE,NA,NA,NA
10.2217/fon-2020-0823,33052055,methodology,13,NA,Inclusion of treatment-effect modifiers in the adjustment/matching model,NA,NA,No discussion (in the main text) of the status of treatment-effect modifiers of the variables,TRUE,NA,NA,NA
10.2217/fon-2020-0823,33052055,methodology,13,NA,"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)",NA,NA,No,TRUE,NA,NA,NA
10.2217/fon-2020-0823,33052055,methodology,13,NA,Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale),NA,NA,No,TRUE,NA,NA,NA
10.2217/fon-2020-0823,33052055,methodology,14,NA,Treatment name 1,NA,NA,cemiplimab,TRUE,NA,"""The distribution of the estimated weights and effective sample sizes are reported in the results section."" ==> Can't find them, either in the main-text or in the supplementary data.",NA
10.2217/fon-2020-0823,33052055,methodology,14,NA,Study 'number(s)' for treatment 1,NA,NA,1,TRUE,NA,NA,NA
10.2217/fon-2020-0823,33052055,methodology,14,NA,Treatment name 2,NA,NA,panitumumab,TRUE,NA,NA,NA
10.2217/fon-2020-0823,33052055,methodology,14,NA,Study 'number(s)' for treatment 2,NA,NA,8,TRUE,NA,NA,NA
10.2217/fon-2020-0823,33052055,methodology,14,NA,Type of population-adjusted indirect comparisons performed,NA,NA,STC,TRUE,NA,NA,NA
10.2217/fon-2020-0823,33052055,methodology,14,NA,Anchored comparison?,NA,NA,No,TRUE,NA,NA,NA
10.2217/fon-2020-0823,33052055,methodology,14,NA,Form of the indirect comparison,NA,NA,Simple (ie treatments effects extracted from two studies),TRUE,NA,NA,NA
10.2217/fon-2020-0823,33052055,methodology,14,NA,Definition of a single primary outcome for the indirect comparison,NA,NA,"No primary outcome defined, or multiple primary outcomes without any clear distinction between them",TRUE,NA,NA,NA
10.2217/fon-2020-0823,33052055,methodology,14,NA,Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined),NA,NA,overall survival,TRUE,NA,NA,NA
10.2217/fon-2020-0823,33052055,methodology,14,NA,Primary outcome: variable type,NA,NA,Time-to-event,TRUE,NA,NA,NA
10.2217/fon-2020-0823,33052055,methodology,14,NA,Justification for selecting variables to be included in the adjustment model (in the main text),NA,NA,Literature based (clinically or methodologically relevant to adjust on these variables based on the literature search conducted for this specific purpose),TRUE,NA,NA,NA
10.2217/fon-2020-0823,33052055,methodology,14,NA,Inclusion of prognostic factors in the adjustment/matching model,NA,NA,Yes,TRUE,NA,NA,NA
10.2217/fon-2020-0823,33052055,methodology,14,NA,Inclusion of treatment-effect modifiers in the adjustment/matching model,NA,NA,No discussion (in the main text) of the status of treatment-effect modifiers of the variables,TRUE,NA,NA,NA
10.2217/fon-2020-0823,33052055,methodology,14,NA,"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)",NA,NA,No,TRUE,NA,NA,NA
10.2217/fon-2020-0823,33052055,methodology,14,NA,Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale),NA,NA,No,TRUE,NA,NA,NA
10.2217/fon-2020-0823,33052055,methodology,15,NA,Treatment name 1,NA,NA,cemiplimab,TRUE,NA,"""The distribution of the estimated weights and effective sample sizes are reported in the results section."" ==> Can't find them, either in the main-text or in the supplementary data.

Initial sample size IPD = 193 ??",NA
10.2217/fon-2020-0823,33052055,methodology,15,NA,Study 'number(s)' for treatment 1,NA,NA,1,TRUE,NA,NA,NA
10.2217/fon-2020-0823,33052055,methodology,15,NA,Treatment name 2,NA,NA,pembrolizumab,TRUE,NA,NA,NA
10.2217/fon-2020-0823,33052055,methodology,15,NA,Study 'number(s)' for treatment 2,NA,NA,9,TRUE,NA,NA,NA
10.2217/fon-2020-0823,33052055,methodology,15,NA,Type of population-adjusted indirect comparisons performed,NA,NA,MAIC,TRUE,NA,NA,NA
10.2217/fon-2020-0823,33052055,methodology,15,NA,Anchored comparison?,NA,NA,No,TRUE,NA,NA,NA
10.2217/fon-2020-0823,33052055,methodology,15,NA,Form of the indirect comparison,NA,NA,Simple (ie treatments effects extracted from two studies),TRUE,NA,NA,NA
10.2217/fon-2020-0823,33052055,methodology,15,NA,Definition of a single primary outcome for the indirect comparison,NA,NA,"No primary outcome defined, or multiple primary outcomes without any clear distinction between them",TRUE,NA,NA,NA
10.2217/fon-2020-0823,33052055,methodology,15,NA,Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined),NA,NA,overall survival,TRUE,NA,NA,NA
10.2217/fon-2020-0823,33052055,methodology,15,NA,Primary outcome: variable type,NA,NA,Time-to-event,TRUE,NA,NA,NA
10.2217/fon-2020-0823,33052055,methodology,15,NA,Justification for selecting variables to be included in the adjustment model (in the main text),NA,NA,Literature based (clinically or methodologically relevant to adjust on these variables based on the literature search conducted for this specific purpose),TRUE,NA,NA,NA
10.2217/fon-2020-0823,33052055,methodology,15,NA,Inclusion of prognostic factors in the adjustment/matching model,NA,NA,Yes,TRUE,NA,NA,NA
10.2217/fon-2020-0823,33052055,methodology,15,NA,Inclusion of treatment-effect modifiers in the adjustment/matching model,NA,NA,No discussion (in the main text) of the status of treatment-effect modifiers of the variables,TRUE,NA,NA,NA
10.2217/fon-2020-0823,33052055,methodology,15,NA,"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)",NA,NA,No,TRUE,NA,NA,NA
10.2217/fon-2020-0823,33052055,methodology,15,NA,Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale),NA,NA,No,TRUE,NA,NA,NA
10.2217/fon-2020-0823,33052055,methodology,16,NA,Treatment name 1,NA,NA,cemiplimab,TRUE,NA,"""The distribution of the estimated weights and effective sample sizes are reported in the results section."" ==> Can't find them, either in the main-text or in the supplementary data.",NA
10.2217/fon-2020-0823,33052055,methodology,16,NA,Study 'number(s)' for treatment 1,NA,NA,1,TRUE,NA,NA,NA
10.2217/fon-2020-0823,33052055,methodology,16,NA,Treatment name 2,NA,NA,pembrolizumab,TRUE,NA,NA,NA
10.2217/fon-2020-0823,33052055,methodology,16,NA,Study 'number(s)' for treatment 2,NA,NA,9,TRUE,NA,NA,NA
10.2217/fon-2020-0823,33052055,methodology,16,NA,Type of population-adjusted indirect comparisons performed,NA,NA,STC,TRUE,NA,NA,NA
10.2217/fon-2020-0823,33052055,methodology,16,NA,Anchored comparison?,NA,NA,No,TRUE,NA,NA,NA
10.2217/fon-2020-0823,33052055,methodology,16,NA,Form of the indirect comparison,NA,NA,Simple (ie treatments effects extracted from two studies),TRUE,NA,NA,NA
10.2217/fon-2020-0823,33052055,methodology,16,NA,Definition of a single primary outcome for the indirect comparison,NA,NA,"No primary outcome defined, or multiple primary outcomes without any clear distinction between them",TRUE,NA,NA,NA
10.2217/fon-2020-0823,33052055,methodology,16,NA,Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined),NA,NA,overall survival,TRUE,NA,NA,NA
10.2217/fon-2020-0823,33052055,methodology,16,NA,Primary outcome: variable type,NA,NA,Time-to-event,TRUE,NA,NA,NA
10.2217/fon-2020-0823,33052055,methodology,16,NA,Justification for selecting variables to be included in the adjustment model (in the main text),NA,NA,Literature based (clinically or methodologically relevant to adjust on these variables based on the literature search conducted for this specific purpose),TRUE,NA,NA,NA
10.2217/fon-2020-0823,33052055,methodology,16,NA,Inclusion of prognostic factors in the adjustment/matching model,NA,NA,Yes,TRUE,NA,NA,NA
10.2217/fon-2020-0823,33052055,methodology,16,NA,Inclusion of treatment-effect modifiers in the adjustment/matching model,NA,NA,No discussion (in the main text) of the status of treatment-effect modifiers of the variables,TRUE,NA,NA,NA
10.2217/fon-2020-0823,33052055,methodology,16,NA,"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)",NA,NA,No,TRUE,NA,NA,NA
10.2217/fon-2020-0823,33052055,methodology,16,NA,Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale),NA,NA,No,TRUE,NA,NA,NA
10.2217/fon-2020-0823,33052055,methodology,17,NA,Treatment name 1,NA,NA,cemiplimab,TRUE,NA,"""The distribution of the estimated weights and effective sample sizes are reported in the results section."" ==> Can't find them, either in the main-text or in the supplementary data.

Initial sample size IPD = 193 ??",NA
10.2217/fon-2020-0823,33052055,methodology,17,NA,Study 'number(s)' for treatment 1,NA,NA,1,TRUE,NA,NA,NA
10.2217/fon-2020-0823,33052055,methodology,17,NA,Treatment name 2,NA,NA,pembrolizumab,TRUE,NA,NA,NA
10.2217/fon-2020-0823,33052055,methodology,17,NA,Study 'number(s)' for treatment 2,NA,NA,10,TRUE,NA,NA,NA
10.2217/fon-2020-0823,33052055,methodology,17,NA,Type of population-adjusted indirect comparisons performed,NA,NA,MAIC,TRUE,NA,NA,NA
10.2217/fon-2020-0823,33052055,methodology,17,NA,Anchored comparison?,NA,NA,No,TRUE,NA,NA,NA
10.2217/fon-2020-0823,33052055,methodology,17,NA,Form of the indirect comparison,NA,NA,Simple (ie treatments effects extracted from two studies),TRUE,NA,NA,NA
10.2217/fon-2020-0823,33052055,methodology,17,NA,Definition of a single primary outcome for the indirect comparison,NA,NA,"No primary outcome defined, or multiple primary outcomes without any clear distinction between them",TRUE,NA,NA,NA
10.2217/fon-2020-0823,33052055,methodology,17,NA,Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined),NA,NA,overall survival,TRUE,NA,NA,NA
10.2217/fon-2020-0823,33052055,methodology,17,NA,Primary outcome: variable type,NA,NA,Time-to-event,TRUE,NA,NA,NA
10.2217/fon-2020-0823,33052055,methodology,17,NA,Justification for selecting variables to be included in the adjustment model (in the main text),NA,NA,Literature based (clinically or methodologically relevant to adjust on these variables based on the literature search conducted for this specific purpose),TRUE,NA,NA,NA
10.2217/fon-2020-0823,33052055,methodology,17,NA,Inclusion of prognostic factors in the adjustment/matching model,NA,NA,Yes,TRUE,NA,NA,NA
10.2217/fon-2020-0823,33052055,methodology,17,NA,Inclusion of treatment-effect modifiers in the adjustment/matching model,NA,NA,No discussion (in the main text) of the status of treatment-effect modifiers of the variables,TRUE,NA,NA,NA
10.2217/fon-2020-0823,33052055,methodology,17,NA,"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)",NA,NA,No,TRUE,NA,NA,NA
10.2217/fon-2020-0823,33052055,methodology,17,NA,Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale),NA,NA,No,TRUE,NA,NA,NA
10.2217/fon-2020-0823,33052055,methodology,18,NA,Treatment name 1,NA,NA,cemiplimab,TRUE,NA,"""The distribution of the estimated weights and effective sample sizes are reported in the results section."" ==> Can't find them, either in the main-text or in the supplementary data.",NA
10.2217/fon-2020-0823,33052055,methodology,18,NA,Study 'number(s)' for treatment 1,NA,NA,1,TRUE,NA,NA,NA
10.2217/fon-2020-0823,33052055,methodology,18,NA,Treatment name 2,NA,NA,pembrolizumab,TRUE,NA,NA,NA
10.2217/fon-2020-0823,33052055,methodology,18,NA,Study 'number(s)' for treatment 2,NA,NA,10,TRUE,NA,NA,NA
10.2217/fon-2020-0823,33052055,methodology,18,NA,Type of population-adjusted indirect comparisons performed,NA,NA,STC,TRUE,NA,NA,NA
10.2217/fon-2020-0823,33052055,methodology,18,NA,Anchored comparison?,NA,NA,No,TRUE,NA,NA,NA
10.2217/fon-2020-0823,33052055,methodology,18,NA,Form of the indirect comparison,NA,NA,Simple (ie treatments effects extracted from two studies),TRUE,NA,NA,NA
10.2217/fon-2020-0823,33052055,methodology,18,NA,Definition of a single primary outcome for the indirect comparison,NA,NA,"No primary outcome defined, or multiple primary outcomes without any clear distinction between them",TRUE,NA,NA,NA
10.2217/fon-2020-0823,33052055,methodology,18,NA,Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined),NA,NA,overall survival,TRUE,NA,NA,NA
10.2217/fon-2020-0823,33052055,methodology,18,NA,Primary outcome: variable type,NA,NA,Time-to-event,TRUE,NA,NA,NA
10.2217/fon-2020-0823,33052055,methodology,18,NA,Justification for selecting variables to be included in the adjustment model (in the main text),NA,NA,Literature based (clinically or methodologically relevant to adjust on these variables based on the literature search conducted for this specific purpose),TRUE,NA,NA,NA
10.2217/fon-2020-0823,33052055,methodology,18,NA,Inclusion of prognostic factors in the adjustment/matching model,NA,NA,Yes,TRUE,NA,NA,NA
10.2217/fon-2020-0823,33052055,methodology,18,NA,Inclusion of treatment-effect modifiers in the adjustment/matching model,NA,NA,No discussion (in the main text) of the status of treatment-effect modifiers of the variables,TRUE,NA,NA,NA
10.2217/fon-2020-0823,33052055,methodology,18,NA,"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)",NA,NA,No,TRUE,NA,NA,NA
10.2217/fon-2020-0823,33052055,methodology,18,NA,Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale),NA,NA,No,TRUE,NA,NA,NA
10.2217/fon-2020-0823,33052055,methodology,19,NA,Treatment name 1,NA,NA,cemiplimab,TRUE,NA,"""The distribution of the estimated weights and effective sample sizes are reported in the results section."" ==> Can't find them, either in the main-text or in the supplementary data.

Initial sample size IPD = 193 ??",NA
10.2217/fon-2020-0823,33052055,methodology,19,NA,Study 'number(s)' for treatment 1,NA,NA,1,TRUE,NA,NA,NA
10.2217/fon-2020-0823,33052055,methodology,19,NA,Treatment name 2,NA,NA,cetuximab,TRUE,NA,NA,NA
10.2217/fon-2020-0823,33052055,methodology,19,NA,Study 'number(s)' for treatment 2,NA,NA,11,TRUE,NA,NA,NA
10.2217/fon-2020-0823,33052055,methodology,19,NA,Type of population-adjusted indirect comparisons performed,NA,NA,MAIC,TRUE,NA,NA,NA
10.2217/fon-2020-0823,33052055,methodology,19,NA,Anchored comparison?,NA,NA,No,TRUE,NA,NA,NA
10.2217/fon-2020-0823,33052055,methodology,19,NA,Form of the indirect comparison,NA,NA,Simple (ie treatments effects extracted from two studies),TRUE,NA,NA,NA
10.2217/fon-2020-0823,33052055,methodology,19,NA,Definition of a single primary outcome for the indirect comparison,NA,NA,"No primary outcome defined, or multiple primary outcomes without any clear distinction between them",TRUE,NA,NA,NA
10.2217/fon-2020-0823,33052055,methodology,19,NA,Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined),NA,NA,overall survival,TRUE,NA,NA,NA
10.2217/fon-2020-0823,33052055,methodology,19,NA,Primary outcome: variable type,NA,NA,Time-to-event,TRUE,NA,NA,NA
10.2217/fon-2020-0823,33052055,methodology,19,NA,Justification for selecting variables to be included in the adjustment model (in the main text),NA,NA,Literature based (clinically or methodologically relevant to adjust on these variables based on the literature search conducted for this specific purpose),TRUE,NA,NA,NA
10.2217/fon-2020-0823,33052055,methodology,19,NA,Inclusion of prognostic factors in the adjustment/matching model,NA,NA,Yes,TRUE,NA,NA,NA
10.2217/fon-2020-0823,33052055,methodology,19,NA,Inclusion of treatment-effect modifiers in the adjustment/matching model,NA,NA,No discussion (in the main text) of the status of treatment-effect modifiers of the variables,TRUE,NA,NA,NA
10.2217/fon-2020-0823,33052055,methodology,19,NA,"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)",NA,NA,No,TRUE,NA,NA,NA
10.2217/fon-2020-0823,33052055,methodology,19,NA,Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale),NA,NA,No,TRUE,NA,NA,NA
10.2217/fon-2020-0823,33052055,methodology,2,NA,Treatment name 1,NA,NA,cemiplimab,TRUE,NA,"The distribution of the estimated weights and effective sample sizes are reported in the results section."""" ==> Can't find them, either in the main-text or in the supplementary data.",NA
10.2217/fon-2020-0823,33052055,methodology,2,NA,Study 'number(s)' for treatment 1,NA,NA,1,TRUE,NA,NA,NA
10.2217/fon-2020-0823,33052055,methodology,2,NA,Treatment name 2,NA,NA,erlotinib,TRUE,NA,NA,NA
10.2217/fon-2020-0823,33052055,methodology,2,NA,Study 'number(s)' for treatment 2,NA,NA,2,TRUE,NA,NA,NA
10.2217/fon-2020-0823,33052055,methodology,2,NA,Type of population-adjusted indirect comparisons performed,NA,NA,STC,TRUE,NA,NA,NA
10.2217/fon-2020-0823,33052055,methodology,2,NA,Anchored comparison?,NA,NA,No,TRUE,NA,NA,NA
10.2217/fon-2020-0823,33052055,methodology,2,NA,Form of the indirect comparison,NA,NA,Simple (ie treatments effects extracted from two studies),TRUE,NA,NA,NA
10.2217/fon-2020-0823,33052055,methodology,2,NA,Definition of a single primary outcome for the indirect comparison,NA,NA,"No primary outcome defined, or multiple primary outcomes without any clear distinction between them",TRUE,NA,NA,NA
10.2217/fon-2020-0823,33052055,methodology,2,NA,Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined),NA,NA,overall survival,TRUE,NA,NA,NA
10.2217/fon-2020-0823,33052055,methodology,2,NA,Primary outcome: variable type,NA,NA,Time-to-event,TRUE,NA,NA,NA
10.2217/fon-2020-0823,33052055,methodology,2,NA,Justification for selecting variables to be included in the adjustment model (in the main text),NA,NA,Literature based (clinically or methodologically relevant to adjust on these variables based on the literature search conducted for this specific purpose),TRUE,NA,NA,NA
10.2217/fon-2020-0823,33052055,methodology,2,NA,Inclusion of prognostic factors in the adjustment/matching model,NA,NA,Yes,TRUE,NA,NA,NA
10.2217/fon-2020-0823,33052055,methodology,2,NA,Inclusion of treatment-effect modifiers in the adjustment/matching model,NA,NA,No discussion (in the main text) of the status of treatment-effect modifiers of the variables,TRUE,NA,NA,NA
10.2217/fon-2020-0823,33052055,methodology,2,NA,"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)",NA,NA,No,TRUE,NA,NA,NA
10.2217/fon-2020-0823,33052055,methodology,2,NA,Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale),NA,NA,No,TRUE,NA,NA,NA
10.2217/fon-2020-0823,33052055,methodology,20,NA,Treatment name 1,NA,NA,cemiplimab,TRUE,NA,"""The distribution of the estimated weights and effective sample sizes are reported in the results section."" ==> Can't find them, either in the main-text or in the supplementary data.",NA
10.2217/fon-2020-0823,33052055,methodology,20,NA,Study 'number(s)' for treatment 1,NA,NA,1,TRUE,NA,NA,NA
10.2217/fon-2020-0823,33052055,methodology,20,NA,Treatment name 2,NA,NA,cetuximab,TRUE,NA,NA,NA
10.2217/fon-2020-0823,33052055,methodology,20,NA,Study 'number(s)' for treatment 2,NA,NA,11,TRUE,NA,NA,NA
10.2217/fon-2020-0823,33052055,methodology,20,NA,Type of population-adjusted indirect comparisons performed,NA,NA,STC,TRUE,NA,NA,NA
10.2217/fon-2020-0823,33052055,methodology,20,NA,Anchored comparison?,No,Yes,No,FALSE,NA,NA,NA
10.2217/fon-2020-0823,33052055,methodology,20,NA,Form of the indirect comparison,NA,NA,Simple (ie treatments effects extracted from two studies),TRUE,NA,NA,NA
10.2217/fon-2020-0823,33052055,methodology,20,NA,Definition of a single primary outcome for the indirect comparison,NA,NA,"No primary outcome defined, or multiple primary outcomes without any clear distinction between them",TRUE,NA,NA,NA
10.2217/fon-2020-0823,33052055,methodology,20,NA,Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined),NA,NA,overall survival,TRUE,NA,NA,NA
10.2217/fon-2020-0823,33052055,methodology,20,NA,Primary outcome: variable type,NA,NA,Time-to-event,TRUE,NA,NA,NA
10.2217/fon-2020-0823,33052055,methodology,20,NA,Justification for selecting variables to be included in the adjustment model (in the main text),NA,NA,Literature based (clinically or methodologically relevant to adjust on these variables based on the literature search conducted for this specific purpose),TRUE,NA,NA,NA
10.2217/fon-2020-0823,33052055,methodology,20,NA,Inclusion of prognostic factors in the adjustment/matching model,NA,NA,Yes,TRUE,NA,NA,NA
10.2217/fon-2020-0823,33052055,methodology,20,NA,Inclusion of treatment-effect modifiers in the adjustment/matching model,NA,NA,No discussion (in the main text) of the status of treatment-effect modifiers of the variables,TRUE,NA,NA,NA
10.2217/fon-2020-0823,33052055,methodology,20,NA,"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)",NA,NA,No,TRUE,NA,NA,NA
10.2217/fon-2020-0823,33052055,methodology,20,NA,Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale),NA,NA,No,TRUE,NA,NA,NA
10.2217/fon-2020-0823,33052055,methodology,3,NA,Treatment name 1,NA,NA,cemiplimab,TRUE,NA,"The distribution of the estimated weights and effective sample sizes are reported in the results section."""" ==> Can't find them, either in the main-text or in the supplementary data.

Initial sample size IPD = 193 ??",NA
10.2217/fon-2020-0823,33052055,methodology,3,NA,Study 'number(s)' for treatment 1,NA,NA,1,TRUE,NA,NA,NA
10.2217/fon-2020-0823,33052055,methodology,3,NA,Treatment name 2,NA,NA,platinum-based chemotherapy,TRUE,NA,NA,NA
10.2217/fon-2020-0823,33052055,methodology,3,NA,Study 'number(s)' for treatment 2,NA,NA,3,TRUE,NA,NA,NA
10.2217/fon-2020-0823,33052055,methodology,3,NA,Type of population-adjusted indirect comparisons performed,NA,NA,MAIC,TRUE,NA,NA,NA
10.2217/fon-2020-0823,33052055,methodology,3,NA,Anchored comparison?,NA,NA,No,TRUE,NA,NA,NA
10.2217/fon-2020-0823,33052055,methodology,3,NA,Form of the indirect comparison,NA,NA,Simple (ie treatments effects extracted from two studies),TRUE,NA,NA,NA
10.2217/fon-2020-0823,33052055,methodology,3,NA,Definition of a single primary outcome for the indirect comparison,NA,NA,"No primary outcome defined, or multiple primary outcomes without any clear distinction between them",TRUE,NA,NA,NA
10.2217/fon-2020-0823,33052055,methodology,3,NA,Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined),NA,NA,overall survival,TRUE,NA,NA,NA
10.2217/fon-2020-0823,33052055,methodology,3,NA,Primary outcome: variable type,NA,NA,Time-to-event,TRUE,NA,NA,NA
10.2217/fon-2020-0823,33052055,methodology,3,NA,Justification for selecting variables to be included in the adjustment model (in the main text),NA,NA,Literature based (clinically or methodologically relevant to adjust on these variables based on the literature search conducted for this specific purpose),TRUE,NA,NA,NA
10.2217/fon-2020-0823,33052055,methodology,3,NA,Inclusion of prognostic factors in the adjustment/matching model,NA,NA,Yes,TRUE,NA,NA,NA
10.2217/fon-2020-0823,33052055,methodology,3,NA,Inclusion of treatment-effect modifiers in the adjustment/matching model,NA,NA,No discussion (in the main text) of the status of treatment-effect modifiers of the variables,TRUE,NA,NA,NA
10.2217/fon-2020-0823,33052055,methodology,3,NA,"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)",NA,NA,No,TRUE,NA,NA,NA
10.2217/fon-2020-0823,33052055,methodology,3,NA,Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale),NA,NA,No,TRUE,NA,NA,NA
10.2217/fon-2020-0823,33052055,methodology,4,NA,Treatment name 1,NA,NA,cemiplimab,TRUE,NA,"""The distribution of the estimated weights and effective sample sizes are reported in the results section."" ==> Can't find them, either in the main-text or in the supplementary data.",NA
10.2217/fon-2020-0823,33052055,methodology,4,NA,Study 'number(s)' for treatment 1,NA,NA,1,TRUE,NA,NA,NA
10.2217/fon-2020-0823,33052055,methodology,4,NA,Treatment name 2,NA,NA,platinum-based chemotherapy,TRUE,NA,NA,NA
10.2217/fon-2020-0823,33052055,methodology,4,NA,Study 'number(s)' for treatment 2,NA,NA,3,TRUE,NA,NA,NA
10.2217/fon-2020-0823,33052055,methodology,4,NA,Type of population-adjusted indirect comparisons performed,NA,NA,STC,TRUE,NA,NA,NA
10.2217/fon-2020-0823,33052055,methodology,4,NA,Anchored comparison?,NA,NA,No,TRUE,NA,NA,NA
10.2217/fon-2020-0823,33052055,methodology,4,NA,Form of the indirect comparison,NA,NA,Simple (ie treatments effects extracted from two studies),TRUE,NA,NA,NA
10.2217/fon-2020-0823,33052055,methodology,4,NA,Definition of a single primary outcome for the indirect comparison,NA,NA,"No primary outcome defined, or multiple primary outcomes without any clear distinction between them",TRUE,NA,NA,NA
10.2217/fon-2020-0823,33052055,methodology,4,NA,Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined),NA,NA,overall survival,TRUE,NA,NA,NA
10.2217/fon-2020-0823,33052055,methodology,4,NA,Primary outcome: variable type,NA,NA,Time-to-event,TRUE,NA,NA,NA
10.2217/fon-2020-0823,33052055,methodology,4,NA,Justification for selecting variables to be included in the adjustment model (in the main text),NA,NA,Literature based (clinically or methodologically relevant to adjust on these variables based on the literature search conducted for this specific purpose),TRUE,NA,NA,NA
10.2217/fon-2020-0823,33052055,methodology,4,NA,Inclusion of prognostic factors in the adjustment/matching model,NA,NA,Yes,TRUE,NA,NA,NA
10.2217/fon-2020-0823,33052055,methodology,4,NA,Inclusion of treatment-effect modifiers in the adjustment/matching model,NA,NA,No discussion (in the main text) of the status of treatment-effect modifiers of the variables,TRUE,NA,NA,NA
10.2217/fon-2020-0823,33052055,methodology,4,NA,"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)",NA,NA,No,TRUE,NA,NA,NA
10.2217/fon-2020-0823,33052055,methodology,4,NA,Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale),NA,NA,No,TRUE,NA,NA,NA
10.2217/fon-2020-0823,33052055,methodology,5,NA,Treatment name 1,NA,NA,cemiplimab,TRUE,NA,"""The distribution of the estimated weights and effective sample sizes are reported in the results section."" ==> Can't find them, either in the main-text or in the supplementary data.

Initial sample size IPD = 193 ??",NA
10.2217/fon-2020-0823,33052055,methodology,5,NA,Study 'number(s)' for treatment 1,NA,NA,1,TRUE,NA,NA,NA
10.2217/fon-2020-0823,33052055,methodology,5,NA,Treatment name 2,NA,NA,cetuximab,TRUE,NA,NA,NA
10.2217/fon-2020-0823,33052055,methodology,5,NA,Study 'number(s)' for treatment 2,NA,NA,4,TRUE,NA,NA,NA
10.2217/fon-2020-0823,33052055,methodology,5,NA,Type of population-adjusted indirect comparisons performed,NA,NA,MAIC,TRUE,NA,NA,NA
10.2217/fon-2020-0823,33052055,methodology,5,NA,Anchored comparison?,NA,NA,No,TRUE,NA,NA,NA
10.2217/fon-2020-0823,33052055,methodology,5,NA,Form of the indirect comparison,NA,NA,Simple (ie treatments effects extracted from two studies),TRUE,NA,NA,NA
10.2217/fon-2020-0823,33052055,methodology,5,NA,Definition of a single primary outcome for the indirect comparison,NA,NA,"No primary outcome defined, or multiple primary outcomes without any clear distinction between them",TRUE,NA,NA,NA
10.2217/fon-2020-0823,33052055,methodology,5,NA,Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined),NA,NA,overall survival,TRUE,NA,NA,NA
10.2217/fon-2020-0823,33052055,methodology,5,NA,Primary outcome: variable type,NA,NA,Time-to-event,TRUE,NA,NA,NA
10.2217/fon-2020-0823,33052055,methodology,5,NA,Justification for selecting variables to be included in the adjustment model (in the main text),NA,NA,Literature based (clinically or methodologically relevant to adjust on these variables based on the literature search conducted for this specific purpose),TRUE,NA,NA,NA
10.2217/fon-2020-0823,33052055,methodology,5,NA,Inclusion of prognostic factors in the adjustment/matching model,NA,NA,Yes,TRUE,NA,NA,NA
10.2217/fon-2020-0823,33052055,methodology,5,NA,Inclusion of treatment-effect modifiers in the adjustment/matching model,NA,NA,No discussion (in the main text) of the status of treatment-effect modifiers of the variables,TRUE,NA,NA,NA
10.2217/fon-2020-0823,33052055,methodology,5,NA,"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)",NA,NA,No,TRUE,NA,NA,NA
10.2217/fon-2020-0823,33052055,methodology,5,NA,Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale),NA,NA,No,TRUE,NA,NA,NA
10.2217/fon-2020-0823,33052055,methodology,6,NA,Treatment name 1,NA,NA,cemiplimab,TRUE,NA,"""The distribution of the estimated weights and effective sample sizes are reported in the results section."" ==> Can't find them, either in the main-text or in the supplementary data.",NA
10.2217/fon-2020-0823,33052055,methodology,6,NA,Study 'number(s)' for treatment 1,NA,NA,1,TRUE,NA,NA,NA
10.2217/fon-2020-0823,33052055,methodology,6,NA,Treatment name 2,NA,NA,cetuximab,TRUE,NA,NA,NA
10.2217/fon-2020-0823,33052055,methodology,6,NA,Study 'number(s)' for treatment 2,NA,NA,4,TRUE,NA,NA,NA
10.2217/fon-2020-0823,33052055,methodology,6,NA,Type of population-adjusted indirect comparisons performed,NA,NA,STC,TRUE,NA,NA,NA
10.2217/fon-2020-0823,33052055,methodology,6,NA,Anchored comparison?,NA,NA,No,TRUE,NA,NA,NA
10.2217/fon-2020-0823,33052055,methodology,6,NA,Form of the indirect comparison,NA,NA,Simple (ie treatments effects extracted from two studies),TRUE,NA,NA,NA
10.2217/fon-2020-0823,33052055,methodology,6,NA,Definition of a single primary outcome for the indirect comparison,NA,NA,"No primary outcome defined, or multiple primary outcomes without any clear distinction between them",TRUE,NA,NA,NA
10.2217/fon-2020-0823,33052055,methodology,6,NA,Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined),NA,NA,overall survival,TRUE,NA,NA,NA
10.2217/fon-2020-0823,33052055,methodology,6,NA,Primary outcome: variable type,NA,NA,Time-to-event,TRUE,NA,NA,NA
10.2217/fon-2020-0823,33052055,methodology,6,NA,Justification for selecting variables to be included in the adjustment model (in the main text),NA,NA,Literature based (clinically or methodologically relevant to adjust on these variables based on the literature search conducted for this specific purpose),TRUE,NA,NA,NA
10.2217/fon-2020-0823,33052055,methodology,6,NA,Inclusion of prognostic factors in the adjustment/matching model,NA,NA,Yes,TRUE,NA,NA,NA
10.2217/fon-2020-0823,33052055,methodology,6,NA,Inclusion of treatment-effect modifiers in the adjustment/matching model,NA,NA,No discussion (in the main text) of the status of treatment-effect modifiers of the variables,TRUE,NA,NA,NA
10.2217/fon-2020-0823,33052055,methodology,6,NA,"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)",NA,NA,No,TRUE,NA,NA,NA
10.2217/fon-2020-0823,33052055,methodology,6,NA,Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale),NA,NA,No,TRUE,NA,NA,NA
10.2217/fon-2020-0823,33052055,methodology,7,NA,Treatment name 1,NA,NA,cemiplimab,TRUE,NA,"""The distribution of the estimated weights and effective sample sizes are reported in the results section."" ==> Can't find them, either in the main-text or in the supplementary data.

Initial sample size IPD = 193 ??",NA
10.2217/fon-2020-0823,33052055,methodology,7,NA,Study 'number(s)' for treatment 1,NA,NA,1,TRUE,NA,NA,NA
10.2217/fon-2020-0823,33052055,methodology,7,NA,Treatment name 2,NA,NA,cetuximab,TRUE,NA,NA,NA
10.2217/fon-2020-0823,33052055,methodology,7,NA,Study 'number(s)' for treatment 2,NA,NA,5,TRUE,NA,NA,NA
10.2217/fon-2020-0823,33052055,methodology,7,NA,Type of population-adjusted indirect comparisons performed,NA,NA,MAIC,TRUE,NA,NA,NA
10.2217/fon-2020-0823,33052055,methodology,7,NA,Anchored comparison?,NA,NA,No,TRUE,NA,NA,NA
10.2217/fon-2020-0823,33052055,methodology,7,NA,Form of the indirect comparison,NA,NA,Simple (ie treatments effects extracted from two studies),TRUE,NA,NA,NA
10.2217/fon-2020-0823,33052055,methodology,7,NA,Definition of a single primary outcome for the indirect comparison,"No primary outcome defined, or multiple primary outcomes without any clear distinction between them",Yes,"No primary outcome defined, or multiple primary outcomes without any clear distinction between them",FALSE,NA,NA,NA
10.2217/fon-2020-0823,33052055,methodology,7,NA,Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined),NA,NA,overall survival,TRUE,NA,NA,NA
10.2217/fon-2020-0823,33052055,methodology,7,NA,Primary outcome: variable type,NA,NA,Time-to-event,TRUE,NA,NA,NA
10.2217/fon-2020-0823,33052055,methodology,7,NA,Justification for selecting variables to be included in the adjustment model (in the main text),NA,NA,Literature based (clinically or methodologically relevant to adjust on these variables based on the literature search conducted for this specific purpose),TRUE,NA,NA,NA
10.2217/fon-2020-0823,33052055,methodology,7,NA,Inclusion of prognostic factors in the adjustment/matching model,NA,NA,Yes,TRUE,NA,NA,NA
10.2217/fon-2020-0823,33052055,methodology,7,NA,Inclusion of treatment-effect modifiers in the adjustment/matching model,NA,NA,No discussion (in the main text) of the status of treatment-effect modifiers of the variables,TRUE,NA,NA,NA
10.2217/fon-2020-0823,33052055,methodology,7,NA,"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)",NA,NA,No,TRUE,NA,NA,NA
10.2217/fon-2020-0823,33052055,methodology,7,NA,Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale),NA,NA,No,TRUE,NA,NA,NA
10.2217/fon-2020-0823,33052055,methodology,8,NA,Treatment name 1,NA,NA,cemiplimab,TRUE,NA,"""The distribution of the estimated weights and effective sample sizes are reported in the results section."" ==> Can't find them, either in the main-text or in the supplementary data.",NA
10.2217/fon-2020-0823,33052055,methodology,8,NA,Study 'number(s)' for treatment 1,NA,NA,1,TRUE,NA,NA,NA
10.2217/fon-2020-0823,33052055,methodology,8,NA,Treatment name 2,NA,NA,cetuximab,TRUE,NA,NA,NA
10.2217/fon-2020-0823,33052055,methodology,8,NA,Study 'number(s)' for treatment 2,NA,NA,5,TRUE,NA,NA,NA
10.2217/fon-2020-0823,33052055,methodology,8,NA,Type of population-adjusted indirect comparisons performed,NA,NA,STC,TRUE,NA,NA,NA
10.2217/fon-2020-0823,33052055,methodology,8,NA,Anchored comparison?,NA,NA,No,TRUE,NA,NA,NA
10.2217/fon-2020-0823,33052055,methodology,8,NA,Form of the indirect comparison,NA,NA,Simple (ie treatments effects extracted from two studies),TRUE,NA,NA,NA
10.2217/fon-2020-0823,33052055,methodology,8,NA,Definition of a single primary outcome for the indirect comparison,"No primary outcome defined, or multiple primary outcomes without any clear distinction between them",Yes,"No primary outcome defined, or multiple primary outcomes without any clear distinction between them",FALSE,NA,NA,NA
10.2217/fon-2020-0823,33052055,methodology,8,NA,Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined),NA,NA,overall survival,TRUE,NA,NA,NA
10.2217/fon-2020-0823,33052055,methodology,8,NA,Primary outcome: variable type,NA,NA,Time-to-event,TRUE,NA,NA,NA
10.2217/fon-2020-0823,33052055,methodology,8,NA,Justification for selecting variables to be included in the adjustment model (in the main text),NA,NA,Literature based (clinically or methodologically relevant to adjust on these variables based on the literature search conducted for this specific purpose),TRUE,NA,NA,NA
10.2217/fon-2020-0823,33052055,methodology,8,NA,Inclusion of prognostic factors in the adjustment/matching model,NA,NA,Yes,TRUE,NA,NA,NA
10.2217/fon-2020-0823,33052055,methodology,8,NA,Inclusion of treatment-effect modifiers in the adjustment/matching model,NA,NA,No discussion (in the main text) of the status of treatment-effect modifiers of the variables,TRUE,NA,NA,NA
10.2217/fon-2020-0823,33052055,methodology,8,NA,"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)",NA,NA,No,TRUE,NA,NA,NA
10.2217/fon-2020-0823,33052055,methodology,8,NA,Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale),NA,NA,No,TRUE,NA,NA,NA
10.2217/fon-2020-0823,33052055,methodology,9,NA,Treatment name 1,NA,NA,cemiplimab,TRUE,NA,"""The distribution of the estimated weights and effective sample sizes are reported in the results section."" ==> Can't find them, either in the main-text or in the supplementary data.

Initial sample size IPD = 193 ??",NA
10.2217/fon-2020-0823,33052055,methodology,9,NA,Study 'number(s)' for treatment 1,NA,NA,1,TRUE,NA,NA,NA
10.2217/fon-2020-0823,33052055,methodology,9,NA,Treatment name 2,NA,NA,gefitinib,TRUE,NA,NA,NA
10.2217/fon-2020-0823,33052055,methodology,9,NA,Study 'number(s)' for treatment 2,NA,NA,6,TRUE,NA,NA,NA
10.2217/fon-2020-0823,33052055,methodology,9,NA,Type of population-adjusted indirect comparisons performed,NA,NA,MAIC,TRUE,NA,NA,NA
10.2217/fon-2020-0823,33052055,methodology,9,NA,Anchored comparison?,NA,NA,No,TRUE,NA,NA,NA
10.2217/fon-2020-0823,33052055,methodology,9,NA,Form of the indirect comparison,NA,NA,Simple (ie treatments effects extracted from two studies),TRUE,NA,NA,NA
10.2217/fon-2020-0823,33052055,methodology,9,NA,Definition of a single primary outcome for the indirect comparison,NA,NA,"No primary outcome defined, or multiple primary outcomes without any clear distinction between them",TRUE,NA,NA,NA
10.2217/fon-2020-0823,33052055,methodology,9,NA,Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined),NA,NA,overall survival,TRUE,NA,NA,NA
10.2217/fon-2020-0823,33052055,methodology,9,NA,Primary outcome: variable type,NA,NA,Time-to-event,TRUE,NA,NA,NA
10.2217/fon-2020-0823,33052055,methodology,9,NA,Justification for selecting variables to be included in the adjustment model (in the main text),NA,NA,Literature based (clinically or methodologically relevant to adjust on these variables based on the literature search conducted for this specific purpose),TRUE,NA,NA,NA
10.2217/fon-2020-0823,33052055,methodology,9,NA,Inclusion of prognostic factors in the adjustment/matching model,NA,NA,Yes,TRUE,NA,NA,NA
10.2217/fon-2020-0823,33052055,methodology,9,NA,Inclusion of treatment-effect modifiers in the adjustment/matching model,NA,NA,No discussion (in the main text) of the status of treatment-effect modifiers of the variables,TRUE,NA,NA,NA
10.2217/fon-2020-0823,33052055,methodology,9,NA,"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)",NA,NA,No,TRUE,NA,NA,NA
10.2217/fon-2020-0823,33052055,methodology,9,NA,Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale),NA,NA,No,TRUE,NA,NA,NA
10.2217/fon-2020-0823,33052055,results,1,NA,Sample size of the population of interest in the non IPD treatment arm,NA,NA,39,TRUE,NA,NA,NA
10.2217/fon-2020-0823,33052055,results,1,NA,Reporting of a weights' distribution evaluation (MAIC),Not mentioned,"Yes, mentions that the weights distribution has been studied, but weights distribution not reported","Yes, mentions that the weights distribution has been studied, but weights distribution not reported",FALSE,NA,NA,NA
10.2217/fon-2020-0823,33052055,results,1,NA,Reporting of the list of the covariates adjusted for/matched on,NA,NA,Yes,TRUE,NA,NA,NA
10.2217/fon-2020-0823,33052055,results,1,NA,Number of covariates adjusted for/matched on,8,4,8,FALSE,NA,NA,NA
10.2217/fon-2020-0823,33052055,results,1,NA,Covariates adjusted for/matched on in the indirect comparison,"Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Past treatments for the disease of interest","Age, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease)","Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Past treatments for the disease of interest",FALSE,NA,NA,NA
10.2217/fon-2020-0823,33052055,results,1,NA,Primary outcome: treatment effect contrast,NA,NA,HR,TRUE,NA,NA,NA
10.2217/fon-2020-0823,33052055,results,1,NA,Direction of the treatment effect contrast: IPD treatment is:,NA,NA,"Numerator if ratio, or left side if difference",TRUE,NA,NA,NA
10.2217/fon-2020-0823,33052055,results,1,NA,Primary outcome: unadjusted treatment effect,NA,NA,0.28,TRUE,NA,NA,NA
10.2217/fon-2020-0823,33052055,results,1,NA,"p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])",NA,NA,[0.16;0.50],TRUE,NA,NA,NA
10.2217/fon-2020-0823,33052055,results,1,NA,Primary outcome: adjusted treatment effect,NA,NA,0.41,TRUE,NA,NA,NA
10.2217/fon-2020-0823,33052055,results,1,NA,"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])",NA,NA,[0.24;0.70],TRUE,NA,NA,NA
10.2217/fon-2020-0823,33052055,results,1,NA,Initial sample size of the population of interest in the IPD treatment arm,193,NA,193,FALSE,NA,NA,NA
10.2217/fon-2020-0823,33052055,results,10,NA,Sample size of the population of interest in the non IPD treatment arm,NA,NA,40,TRUE,NA,NA,NA
10.2217/fon-2020-0823,33052055,results,10,NA,Initial sample size of the population of interest in the IPD treatment arm,NA,NA,193,TRUE,NA,NA,NA
10.2217/fon-2020-0823,33052055,results,10,NA,"Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC",NA,NA,193,TRUE,NA,NA,NA
10.2217/fon-2020-0823,33052055,results,10,NA,Reporting of the list of the covariates adjusted for/matched on,NA,NA,Yes,TRUE,NA,NA,NA
10.2217/fon-2020-0823,33052055,results,10,NA,Number of covariates adjusted for/matched on,8,4,8,FALSE,NA,NA,NA
10.2217/fon-2020-0823,33052055,results,10,NA,Covariates adjusted for/matched on in the indirect comparison,"Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Past treatments for the disease of interest","Age, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease)","Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Past treatments for the disease of interest",FALSE,NA,NA,NA
10.2217/fon-2020-0823,33052055,results,10,NA,Primary outcome: treatment effect contrast,NA,NA,HR,TRUE,NA,NA,NA
10.2217/fon-2020-0823,33052055,results,10,NA,Direction of the treatment effect contrast: IPD treatment is:,NA,NA,"Numerator if ratio, or left side if difference",TRUE,NA,NA,NA
10.2217/fon-2020-0823,33052055,results,10,NA,Primary outcome: unadjusted treatment effect,NA,NA,0.27,TRUE,NA,NA,NA
10.2217/fon-2020-0823,33052055,results,10,NA,"p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])",NA,NA,[0.16;0.44],TRUE,NA,NA,NA
10.2217/fon-2020-0823,33052055,results,10,NA,Primary outcome: adjusted treatment effect,NA,NA,0.29,TRUE,NA,NA,NA
10.2217/fon-2020-0823,33052055,results,10,NA,"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])",NA,NA,[0.18;0.45],TRUE,NA,NA,NA
10.2217/fon-2020-0823,33052055,results,11,NA,Sample size of the population of interest in the non IPD treatment arm,NA,NA,42,TRUE,NA,NA,NA
10.2217/fon-2020-0823,33052055,results,11,NA,Reporting of a weights' distribution evaluation (MAIC),Not mentioned,"Yes, mentions that the weights distribution has been studied, but weights distribution not reported","Yes, mentions that the weights distribution has been studied, but weights distribution not reported",FALSE,NA,NA,NA
10.2217/fon-2020-0823,33052055,results,11,NA,Reporting of the list of the covariates adjusted for/matched on,NA,NA,Yes,TRUE,NA,NA,NA
10.2217/fon-2020-0823,33052055,results,11,NA,Number of covariates adjusted for/matched on,8,4,8,FALSE,NA,NA,NA
10.2217/fon-2020-0823,33052055,results,11,NA,Covariates adjusted for/matched on in the indirect comparison,"Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Past treatments for the disease of interest","Age, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease)","Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Past treatments for the disease of interest",FALSE,NA,NA,NA
10.2217/fon-2020-0823,33052055,results,11,NA,Primary outcome: treatment effect contrast,NA,NA,HR,TRUE,NA,NA,NA
10.2217/fon-2020-0823,33052055,results,11,NA,Direction of the treatment effect contrast: IPD treatment is:,NA,NA,"Numerator if ratio, or left side if difference",TRUE,NA,NA,NA
10.2217/fon-2020-0823,33052055,results,11,NA,Primary outcome: unadjusted treatment effect,NA,NA,0.2,TRUE,NA,NA,NA
10.2217/fon-2020-0823,33052055,results,11,NA,"p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])",NA,NA,[0.13;0.33],TRUE,NA,NA,NA
10.2217/fon-2020-0823,33052055,results,11,NA,Primary outcome: adjusted treatment effect,NA,NA,0.17,TRUE,NA,NA,NA
10.2217/fon-2020-0823,33052055,results,11,NA,"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])",[0.10;0.28],[0.1;0.28],[0.10;0.28],FALSE,NA,NA,NA
10.2217/fon-2020-0823,33052055,results,11,NA,Initial sample size of the population of interest in the IPD treatment arm,193,NA,193,FALSE,NA,NA,NA
10.2217/fon-2020-0823,33052055,results,12,NA,Sample size of the population of interest in the non IPD treatment arm,NA,NA,42,TRUE,NA,NA,NA
10.2217/fon-2020-0823,33052055,results,12,NA,Initial sample size of the population of interest in the IPD treatment arm,NA,NA,193,TRUE,NA,NA,NA
10.2217/fon-2020-0823,33052055,results,12,NA,"Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC",NA,NA,193,TRUE,NA,NA,NA
10.2217/fon-2020-0823,33052055,results,12,NA,Reporting of the list of the covariates adjusted for/matched on,NA,NA,Yes,TRUE,NA,NA,NA
10.2217/fon-2020-0823,33052055,results,12,NA,Number of covariates adjusted for/matched on,8,4,8,FALSE,NA,NA,NA
10.2217/fon-2020-0823,33052055,results,12,NA,Covariates adjusted for/matched on in the indirect comparison,"Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Past treatments for the disease of interest","Age, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease)","Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Past treatments for the disease of interest",FALSE,NA,NA,NA
10.2217/fon-2020-0823,33052055,results,12,NA,Primary outcome: treatment effect contrast,NA,NA,HR,TRUE,NA,NA,NA
10.2217/fon-2020-0823,33052055,results,12,NA,Direction of the treatment effect contrast: IPD treatment is:,NA,NA,"Numerator if ratio, or left side if difference",TRUE,NA,NA,NA
10.2217/fon-2020-0823,33052055,results,12,NA,Primary outcome: unadjusted treatment effect,NA,NA,0.2,TRUE,NA,NA,NA
10.2217/fon-2020-0823,33052055,results,12,NA,"p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])",NA,NA,[0.13;0.33],TRUE,NA,NA,NA
10.2217/fon-2020-0823,33052055,results,12,NA,Primary outcome: adjusted treatment effect,NA,NA,0.07,TRUE,NA,NA,NA
10.2217/fon-2020-0823,33052055,results,12,NA,"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])",NA,NA,[0.04;0.13],TRUE,NA,NA,NA
10.2217/fon-2020-0823,33052055,results,13,NA,Sample size of the population of interest in the non IPD treatment arm,NA,NA,16,TRUE,NA,NA,NA
10.2217/fon-2020-0823,33052055,results,13,NA,Reporting of a weights' distribution evaluation (MAIC),Not mentioned,"Yes, mentions that the weights distribution has been studied, but weights distribution not reported","Yes, mentions that the weights distribution has been studied, but weights distribution not reported",FALSE,NA,NA,NA
10.2217/fon-2020-0823,33052055,results,13,NA,Reporting of the list of the covariates adjusted for/matched on,NA,NA,Yes,TRUE,NA,NA,NA
10.2217/fon-2020-0823,33052055,results,13,NA,Number of covariates adjusted for/matched on,8,4,8,FALSE,NA,NA,NA
10.2217/fon-2020-0823,33052055,results,13,NA,Covariates adjusted for/matched on in the indirect comparison,"Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Past treatments for the disease of interest","Age, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease)","Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Past treatments for the disease of interest",FALSE,NA,NA,NA
10.2217/fon-2020-0823,33052055,results,13,NA,Primary outcome: treatment effect contrast,NA,NA,HR,TRUE,NA,NA,NA
10.2217/fon-2020-0823,33052055,results,13,NA,Direction of the treatment effect contrast: IPD treatment is:,NA,NA,"Numerator if ratio, or left side if difference",TRUE,NA,NA,NA
10.2217/fon-2020-0823,33052055,results,13,NA,Primary outcome: unadjusted treatment effect,NA,NA,0.27,TRUE,NA,NA,NA
10.2217/fon-2020-0823,33052055,results,13,NA,"p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])",NA,NA,[0.13;0.54],TRUE,NA,NA,NA
10.2217/fon-2020-0823,33052055,results,13,NA,Primary outcome: adjusted treatment effect,NA,NA,0.52,TRUE,NA,NA,NA
10.2217/fon-2020-0823,33052055,results,13,NA,"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])",NA,NA,[0.26;1.01],TRUE,NA,NA,NA
10.2217/fon-2020-0823,33052055,results,13,NA,Initial sample size of the population of interest in the IPD treatment arm,193,NA,193,FALSE,NA,NA,NA
10.2217/fon-2020-0823,33052055,results,14,NA,Sample size of the population of interest in the non IPD treatment arm,NA,NA,16,TRUE,NA,NA,NA
10.2217/fon-2020-0823,33052055,results,14,NA,Initial sample size of the population of interest in the IPD treatment arm,NA,NA,193,TRUE,NA,NA,NA
10.2217/fon-2020-0823,33052055,results,14,NA,"Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC",NA,NA,193,TRUE,NA,NA,NA
10.2217/fon-2020-0823,33052055,results,14,NA,Reporting of the list of the covariates adjusted for/matched on,NA,NA,Yes,TRUE,NA,NA,NA
10.2217/fon-2020-0823,33052055,results,14,NA,Number of covariates adjusted for/matched on,8,4,8,FALSE,NA,NA,NA
10.2217/fon-2020-0823,33052055,results,14,NA,Covariates adjusted for/matched on in the indirect comparison,"Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Past treatments for the disease of interest","Age, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease)","Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Past treatments for the disease of interest",FALSE,NA,NA,NA
10.2217/fon-2020-0823,33052055,results,14,NA,Primary outcome: treatment effect contrast,NA,NA,HR,TRUE,NA,NA,NA
10.2217/fon-2020-0823,33052055,results,14,NA,Direction of the treatment effect contrast: IPD treatment is:,NA,NA,"Numerator if ratio, or left side if difference",TRUE,NA,NA,NA
10.2217/fon-2020-0823,33052055,results,14,NA,Primary outcome: unadjusted treatment effect,NA,NA,0.27,TRUE,NA,NA,NA
10.2217/fon-2020-0823,33052055,results,14,NA,"p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])",NA,NA,[0.13;0.54],TRUE,NA,NA,NA
10.2217/fon-2020-0823,33052055,results,14,NA,Primary outcome: adjusted treatment effect,NA,NA,0.36,TRUE,NA,NA,NA
10.2217/fon-2020-0823,33052055,results,14,NA,"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])",NA,NA,[0.18;0.70],TRUE,NA,NA,NA
10.2217/fon-2020-0823,33052055,results,15,NA,Sample size of the population of interest in the non IPD treatment arm,NA,NA,39,TRUE,NA,NA,NA
10.2217/fon-2020-0823,33052055,results,15,NA,Reporting of a weights' distribution evaluation (MAIC),Not mentioned,"Yes, mentions that the weights distribution has been studied, but weights distribution not reported","Yes, mentions that the weights distribution has been studied, but weights distribution not reported",FALSE,NA,NA,NA
10.2217/fon-2020-0823,33052055,results,15,NA,Reporting of the list of the covariates adjusted for/matched on,NA,NA,Yes,TRUE,NA,NA,NA
10.2217/fon-2020-0823,33052055,results,15,NA,Number of covariates adjusted for/matched on,8,4,8,FALSE,NA,NA,NA
10.2217/fon-2020-0823,33052055,results,15,NA,Covariates adjusted for/matched on in the indirect comparison,"Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Past treatments for the disease of interest","Age, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease)","Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Past treatments for the disease of interest",FALSE,NA,NA,NA
10.2217/fon-2020-0823,33052055,results,15,NA,Primary outcome: treatment effect contrast,NA,NA,HR,TRUE,NA,NA,NA
10.2217/fon-2020-0823,33052055,results,15,NA,Direction of the treatment effect contrast: IPD treatment is:,NA,NA,"Numerator if ratio, or left side if difference",TRUE,NA,NA,NA
10.2217/fon-2020-0823,33052055,results,15,NA,Primary outcome: unadjusted treatment effect,NA,NA,0.41,TRUE,NA,NA,NA
10.2217/fon-2020-0823,33052055,results,15,NA,"p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])",NA,NA,[0.20;0.87],TRUE,NA,NA,NA
10.2217/fon-2020-0823,33052055,results,15,NA,Primary outcome: adjusted treatment effect,NA,NA,0.39,TRUE,NA,NA,NA
10.2217/fon-2020-0823,33052055,results,15,NA,"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])",NA,NA,[0.17;0.86],TRUE,NA,NA,NA
10.2217/fon-2020-0823,33052055,results,15,NA,Initial sample size of the population of interest in the IPD treatment arm,193,NA,193,FALSE,NA,NA,NA
10.2217/fon-2020-0823,33052055,results,16,NA,Sample size of the population of interest in the non IPD treatment arm,NA,NA,39,TRUE,NA,NA,NA
10.2217/fon-2020-0823,33052055,results,16,NA,Initial sample size of the population of interest in the IPD treatment arm,NA,NA,193,TRUE,NA,NA,NA
10.2217/fon-2020-0823,33052055,results,16,NA,"Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC",NA,NA,193,TRUE,NA,NA,NA
10.2217/fon-2020-0823,33052055,results,16,NA,Reporting of the list of the covariates adjusted for/matched on,NA,NA,Yes,TRUE,NA,NA,NA
10.2217/fon-2020-0823,33052055,results,16,NA,Number of covariates adjusted for/matched on,8,4,8,FALSE,NA,NA,NA
10.2217/fon-2020-0823,33052055,results,16,NA,Covariates adjusted for/matched on in the indirect comparison,"Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Past treatments for the disease of interest","Age, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease)","Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Past treatments for the disease of interest",FALSE,NA,NA,NA
10.2217/fon-2020-0823,33052055,results,16,NA,Primary outcome: treatment effect contrast,NA,NA,HR,TRUE,NA,NA,NA
10.2217/fon-2020-0823,33052055,results,16,NA,Direction of the treatment effect contrast: IPD treatment is:,NA,NA,"Numerator if ratio, or left side if difference",TRUE,NA,NA,NA
10.2217/fon-2020-0823,33052055,results,16,NA,Primary outcome: unadjusted treatment effect,NA,NA,0.41,TRUE,NA,NA,NA
10.2217/fon-2020-0823,33052055,results,16,NA,"p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])",NA,NA,[0.20;0.87],TRUE,NA,NA,NA
10.2217/fon-2020-0823,33052055,results,16,NA,Primary outcome: adjusted treatment effect,NA,NA,0.21,TRUE,NA,NA,NA
10.2217/fon-2020-0823,33052055,results,16,NA,"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])",NA,NA,[0.09;0.48],TRUE,NA,NA,NA
10.2217/fon-2020-0823,33052055,results,17,NA,Sample size of the population of interest in the non IPD treatment arm,NA,NA,105,TRUE,NA,NA,NA
10.2217/fon-2020-0823,33052055,results,17,NA,Reporting of a weights' distribution evaluation (MAIC),Not mentioned,"Yes, mentions that the weights distribution has been studied, but weights distribution not reported","Yes, mentions that the weights distribution has been studied, but weights distribution not reported",FALSE,NA,NA,NA
10.2217/fon-2020-0823,33052055,results,17,NA,Reporting of the list of the covariates adjusted for/matched on,NA,NA,Yes,TRUE,NA,NA,NA
10.2217/fon-2020-0823,33052055,results,17,NA,Number of covariates adjusted for/matched on,7,4,8,FALSE,NA,NA,NA
10.2217/fon-2020-0823,33052055,results,17,NA,Covariates adjusted for/matched on in the indirect comparison,"Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Past treatments for the disease of interest","Age, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease)","Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Past treatments for the disease of interest",FALSE,NA,NA,NA
10.2217/fon-2020-0823,33052055,results,17,NA,Primary outcome: treatment effect contrast,NA,NA,HR,TRUE,NA,NA,NA
10.2217/fon-2020-0823,33052055,results,17,NA,Direction of the treatment effect contrast: IPD treatment is:,NA,NA,"Numerator if ratio, or left side if difference",TRUE,NA,NA,NA
10.2217/fon-2020-0823,33052055,results,17,NA,Primary outcome: unadjusted treatment effect,NA,NA,0.4,TRUE,NA,NA,NA
10.2217/fon-2020-0823,33052055,results,17,NA,"p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])",NA,NA,[0.25;0.63],TRUE,NA,NA,NA
10.2217/fon-2020-0823,33052055,results,17,NA,Primary outcome: adjusted treatment effect,NA,NA,0.52,TRUE,NA,NA,NA
10.2217/fon-2020-0823,33052055,results,17,NA,"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])",NA,NA,[0.34;0.80],TRUE,NA,NA,NA
10.2217/fon-2020-0823,33052055,results,17,NA,Initial sample size of the population of interest in the IPD treatment arm,193,NA,193,FALSE,NA,NA,NA
10.2217/fon-2020-0823,33052055,results,18,NA,Sample size of the population of interest in the non IPD treatment arm,NA,NA,105,TRUE,NA,NA,NA
10.2217/fon-2020-0823,33052055,results,18,NA,Initial sample size of the population of interest in the IPD treatment arm,NA,NA,193,TRUE,NA,NA,NA
10.2217/fon-2020-0823,33052055,results,18,NA,"Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC",NA,NA,193,TRUE,NA,NA,NA
10.2217/fon-2020-0823,33052055,results,18,NA,Reporting of the list of the covariates adjusted for/matched on,NA,NA,Yes,TRUE,NA,NA,NA
10.2217/fon-2020-0823,33052055,results,18,NA,Number of covariates adjusted for/matched on,8,4,8,FALSE,NA,NA,NA
10.2217/fon-2020-0823,33052055,results,18,NA,Covariates adjusted for/matched on in the indirect comparison,"Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Past treatments for the disease of interest","Age, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease)","Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Past treatments for the disease of interest",FALSE,NA,NA,NA
10.2217/fon-2020-0823,33052055,results,18,NA,Primary outcome: treatment effect contrast,NA,NA,HR,TRUE,NA,NA,NA
10.2217/fon-2020-0823,33052055,results,18,NA,Direction of the treatment effect contrast: IPD treatment is:,NA,NA,"Numerator if ratio, or left side if difference",TRUE,NA,NA,NA
10.2217/fon-2020-0823,33052055,results,18,NA,Primary outcome: unadjusted treatment effect,NA,NA,0.4,TRUE,NA,NA,NA
10.2217/fon-2020-0823,33052055,results,18,NA,"p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])",NA,NA,[0.25;0.63],TRUE,NA,NA,NA
10.2217/fon-2020-0823,33052055,results,18,NA,Primary outcome: adjusted treatment effect,NA,NA,0.26,TRUE,NA,NA,NA
10.2217/fon-2020-0823,33052055,results,18,NA,"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])",NA,NA,[0.16;0.42],TRUE,NA,NA,NA
10.2217/fon-2020-0823,33052055,results,19,NA,Sample size of the population of interest in the non IPD treatment arm,NA,NA,58,TRUE,NA,NA,NA
10.2217/fon-2020-0823,33052055,results,19,NA,Reporting of a weights' distribution evaluation (MAIC),Not mentioned,"Yes, mentions that the weights distribution has been studied, but weights distribution not reported","Yes, mentions that the weights distribution has been studied, but weights distribution not reported",FALSE,NA,NA,NA
10.2217/fon-2020-0823,33052055,results,19,NA,Reporting of the list of the covariates adjusted for/matched on,NA,NA,Yes,TRUE,NA,NA,NA
10.2217/fon-2020-0823,33052055,results,19,NA,Number of covariates adjusted for/matched on,8,4,8,FALSE,NA,NA,NA
10.2217/fon-2020-0823,33052055,results,19,NA,Covariates adjusted for/matched on in the indirect comparison,"Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Past treatments for the disease of interest","Age, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease)","Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Past treatments for the disease of interest",FALSE,NA,NA,NA
10.2217/fon-2020-0823,33052055,results,19,NA,Primary outcome: treatment effect contrast,NA,NA,HR,TRUE,NA,NA,NA
10.2217/fon-2020-0823,33052055,results,19,NA,Direction of the treatment effect contrast: IPD treatment is:,NA,NA,"Numerator if ratio, or left side if difference",TRUE,NA,NA,NA
10.2217/fon-2020-0823,33052055,results,19,NA,Primary outcome: unadjusted treatment effect,NA,NA,0.34,TRUE,NA,NA,NA
10.2217/fon-2020-0823,33052055,results,19,NA,"p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])",[0.21;0.55],[0.21.0.55],[0.21;0.55],FALSE,NA,NA,NA
10.2217/fon-2020-0823,33052055,results,19,NA,Primary outcome: adjusted treatment effect,NA,NA,0.29,TRUE,NA,NA,NA
10.2217/fon-2020-0823,33052055,results,19,NA,"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])",NA,NA,[0.16;0.54],TRUE,NA,NA,NA
10.2217/fon-2020-0823,33052055,results,19,NA,Initial sample size of the population of interest in the IPD treatment arm,193,NA,193,FALSE,NA,NA,NA
10.2217/fon-2020-0823,33052055,results,2,NA,Sample size of the population of interest in the non IPD treatment arm,NA,NA,39,TRUE,NA,NA,NA
10.2217/fon-2020-0823,33052055,results,2,NA,Initial sample size of the population of interest in the IPD treatment arm,NA,NA,193,TRUE,NA,NA,NA
10.2217/fon-2020-0823,33052055,results,2,NA,"Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC",NA,NA,193,TRUE,NA,NA,NA
10.2217/fon-2020-0823,33052055,results,2,NA,Reporting of the list of the covariates adjusted for/matched on,NA,NA,Yes,TRUE,NA,NA,NA
10.2217/fon-2020-0823,33052055,results,2,NA,Number of covariates adjusted for/matched on,8,4,8,FALSE,NA,NA,NA
10.2217/fon-2020-0823,33052055,results,2,NA,Covariates adjusted for/matched on in the indirect comparison,"Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Past treatments for the disease of interest","Age, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease)","Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Past treatments for the disease of interest",FALSE,NA,NA,NA
10.2217/fon-2020-0823,33052055,results,2,NA,Primary outcome: treatment effect contrast,NA,NA,HR,TRUE,NA,NA,NA
10.2217/fon-2020-0823,33052055,results,2,NA,Direction of the treatment effect contrast: IPD treatment is:,NA,NA,"Numerator if ratio, or left side if difference",TRUE,NA,NA,NA
10.2217/fon-2020-0823,33052055,results,2,NA,Primary outcome: unadjusted treatment effect,NA,NA,0.28,TRUE,NA,NA,NA
10.2217/fon-2020-0823,33052055,results,2,NA,"p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])",NA,NA,[0.16;0.50],TRUE,NA,NA,NA
10.2217/fon-2020-0823,33052055,results,2,NA,Primary outcome: adjusted treatment effect,NA,NA,0.23,TRUE,NA,NA,NA
10.2217/fon-2020-0823,33052055,results,2,NA,"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])",NA,NA,[0.14;0.39],TRUE,NA,NA,NA
10.2217/fon-2020-0823,33052055,results,20,NA,Sample size of the population of interest in the non IPD treatment arm,NA,NA,58,TRUE,NA,NA,NA
10.2217/fon-2020-0823,33052055,results,20,NA,Initial sample size of the population of interest in the IPD treatment arm,NA,NA,193,TRUE,NA,NA,NA
10.2217/fon-2020-0823,33052055,results,20,NA,"Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC",NA,NA,193,TRUE,NA,NA,NA
10.2217/fon-2020-0823,33052055,results,20,NA,Reporting of the list of the covariates adjusted for/matched on,NA,NA,Yes,TRUE,NA,NA,NA
10.2217/fon-2020-0823,33052055,results,20,NA,Number of covariates adjusted for/matched on,8,4,8,FALSE,NA,NA,NA
10.2217/fon-2020-0823,33052055,results,20,NA,Covariates adjusted for/matched on in the indirect comparison,"Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Past treatments for the disease of interest","Age, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease)","Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Past treatments for the disease of interest",FALSE,NA,NA,NA
10.2217/fon-2020-0823,33052055,results,20,NA,Primary outcome: treatment effect contrast,NA,NA,HR,TRUE,NA,NA,NA
10.2217/fon-2020-0823,33052055,results,20,NA,Direction of the treatment effect contrast: IPD treatment is:,NA,NA,"Numerator if ratio, or left side if difference",TRUE,NA,NA,NA
10.2217/fon-2020-0823,33052055,results,20,NA,Primary outcome: unadjusted treatment effect,NA,NA,0.34,TRUE,NA,NA,NA
10.2217/fon-2020-0823,33052055,results,20,NA,"p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])",[0.21;0.55],[0.21.0.55],[0.21;0.55],FALSE,NA,NA,NA
10.2217/fon-2020-0823,33052055,results,20,NA,Primary outcome: adjusted treatment effect,NA,NA,0.19,TRUE,NA,NA,NA
10.2217/fon-2020-0823,33052055,results,20,NA,"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])",NA,NA,[0.11;0.31],TRUE,NA,NA,NA
10.2217/fon-2020-0823,33052055,results,3,NA,Sample size of the population of interest in the non IPD treatment arm,25,18,18,FALSE,NA,NA,NA
10.2217/fon-2020-0823,33052055,results,3,NA,Reporting of a weights' distribution evaluation (MAIC),Not mentioned,"Yes, mentions that the weights distribution has been studied, but weights distribution not reported","Yes, mentions that the weights distribution has been studied, but weights distribution not reported",FALSE,NA,NA,NA
10.2217/fon-2020-0823,33052055,results,3,NA,Reporting of the list of the covariates adjusted for/matched on,NA,NA,Yes,TRUE,NA,NA,NA
10.2217/fon-2020-0823,33052055,results,3,NA,Number of covariates adjusted for/matched on,NA,NA,4,TRUE,NA,NA,NA
10.2217/fon-2020-0823,33052055,results,3,NA,Covariates adjusted for/matched on in the indirect comparison,NA,NA,"Age, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease)",TRUE,NA,NA,NA
10.2217/fon-2020-0823,33052055,results,3,NA,Primary outcome: treatment effect contrast,NA,NA,HR,TRUE,NA,NA,NA
10.2217/fon-2020-0823,33052055,results,3,NA,Direction of the treatment effect contrast: IPD treatment is:,NA,NA,"Numerator if ratio, or left side if difference",TRUE,NA,NA,NA
10.2217/fon-2020-0823,33052055,results,3,NA,Primary outcome: unadjusted treatment effect,NA,NA,0.3,TRUE,NA,NA,NA
10.2217/fon-2020-0823,33052055,results,3,NA,"p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])",NA,NA,[0.16;0.58],TRUE,NA,NA,NA
10.2217/fon-2020-0823,33052055,results,3,NA,Primary outcome: adjusted treatment effect,NA,NA,0.19,TRUE,NA,NA,NA
10.2217/fon-2020-0823,33052055,results,3,NA,"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])",[0.10;0.39],[0.1;0.39],[0.10;0.39],FALSE,NA,NA,NA
10.2217/fon-2020-0823,33052055,results,3,NA,Initial sample size of the population of interest in the IPD treatment arm,193,NA,193,FALSE,NA,NA,NA
10.2217/fon-2020-0823,33052055,results,4,NA,Sample size of the population of interest in the non IPD treatment arm,25,18,18,FALSE,NA,NA,NA
10.2217/fon-2020-0823,33052055,results,4,NA,Initial sample size of the population of interest in the IPD treatment arm,193,139,193,FALSE,NA,NA,NA
10.2217/fon-2020-0823,33052055,results,4,NA,"Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC",193,139,193,FALSE,NA,NA,NA
10.2217/fon-2020-0823,33052055,results,4,NA,Reporting of the list of the covariates adjusted for/matched on,NA,NA,Yes,TRUE,NA,NA,NA
10.2217/fon-2020-0823,33052055,results,4,NA,Number of covariates adjusted for/matched on,NA,NA,4,TRUE,NA,NA,NA
10.2217/fon-2020-0823,33052055,results,4,NA,Covariates adjusted for/matched on in the indirect comparison,NA,NA,"Age, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease)",TRUE,NA,NA,NA
10.2217/fon-2020-0823,33052055,results,4,NA,Primary outcome: treatment effect contrast,NA,NA,HR,TRUE,NA,NA,NA
10.2217/fon-2020-0823,33052055,results,4,NA,Direction of the treatment effect contrast: IPD treatment is:,NA,NA,"Numerator if ratio, or left side if difference",TRUE,NA,NA,NA
10.2217/fon-2020-0823,33052055,results,4,NA,Primary outcome: unadjusted treatment effect,NA,NA,0.3,TRUE,NA,NA,NA
10.2217/fon-2020-0823,33052055,results,4,NA,"p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])",NA,NA,[0.16;0.58],TRUE,NA,NA,NA
10.2217/fon-2020-0823,33052055,results,4,NA,Primary outcome: adjusted treatment effect,NA,NA,0.17,TRUE,NA,NA,NA
10.2217/fon-2020-0823,33052055,results,4,NA,"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])",NA,NA,[0.09;0.33],TRUE,NA,NA,NA
10.2217/fon-2020-0823,33052055,results,5,NA,Sample size of the population of interest in the non IPD treatment arm,NA,NA,36,TRUE,NA,NA,NA
10.2217/fon-2020-0823,33052055,results,5,NA,Reporting of a weights' distribution evaluation (MAIC),Not mentioned,"Yes, mentions that the weights distribution has been studied, but weights distribution not reported","Yes, mentions that the weights distribution has been studied, but weights distribution not reported",FALSE,NA,NA,NA
10.2217/fon-2020-0823,33052055,results,5,NA,Reporting of the list of the covariates adjusted for/matched on,NA,NA,Yes,TRUE,NA,NA,NA
10.2217/fon-2020-0823,33052055,results,5,NA,Number of covariates adjusted for/matched on,8,4,8,FALSE,NA,NA,NA
10.2217/fon-2020-0823,33052055,results,5,NA,Covariates adjusted for/matched on in the indirect comparison,"Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Past treatments for the disease of interest","Age, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease)","Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Past treatments for the disease of interest",FALSE,NA,NA,NA
10.2217/fon-2020-0823,33052055,results,5,NA,Primary outcome: treatment effect contrast,NA,NA,HR,TRUE,NA,NA,NA
10.2217/fon-2020-0823,33052055,results,5,NA,Direction of the treatment effect contrast: IPD treatment is:,NA,NA,"Numerator if ratio, or left side if difference",TRUE,NA,NA,NA
10.2217/fon-2020-0823,33052055,results,5,NA,Primary outcome: unadjusted treatment effect,NA,NA,0.25,TRUE,NA,NA,NA
10.2217/fon-2020-0823,33052055,results,5,NA,"p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])",NA,NA,[0.13;0.46],TRUE,NA,NA,NA
10.2217/fon-2020-0823,33052055,results,5,NA,Primary outcome: adjusted treatment effect,0.11,0.25,0.25,FALSE,NA,NA,NA
10.2217/fon-2020-0823,33052055,results,5,NA,"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])",NA,NA,[0.13;0.49],TRUE,NA,NA,NA
10.2217/fon-2020-0823,33052055,results,5,NA,Initial sample size of the population of interest in the IPD treatment arm,193,NA,193,FALSE,NA,NA,NA
10.2217/fon-2020-0823,33052055,results,6,NA,Sample size of the population of interest in the non IPD treatment arm,25,36,36,FALSE,NA,NA,NA
10.2217/fon-2020-0823,33052055,results,6,NA,Initial sample size of the population of interest in the IPD treatment arm,NA,NA,193,TRUE,NA,NA,NA
10.2217/fon-2020-0823,33052055,results,6,NA,"Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC",NA,NA,193,TRUE,NA,NA,NA
10.2217/fon-2020-0823,33052055,results,6,NA,Reporting of the list of the covariates adjusted for/matched on,NA,NA,Yes,TRUE,NA,NA,NA
10.2217/fon-2020-0823,33052055,results,6,NA,Number of covariates adjusted for/matched on,8,4,8,FALSE,NA,NA,NA
10.2217/fon-2020-0823,33052055,results,6,NA,Covariates adjusted for/matched on in the indirect comparison,"Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Past treatments for the disease of interest","Age, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease)","Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Past treatments for the disease of interest",FALSE,NA,NA,NA
10.2217/fon-2020-0823,33052055,results,6,NA,Primary outcome: treatment effect contrast,NA,NA,HR,TRUE,NA,NA,NA
10.2217/fon-2020-0823,33052055,results,6,NA,Direction of the treatment effect contrast: IPD treatment is:,NA,NA,"Numerator if ratio, or left side if difference",TRUE,NA,NA,NA
10.2217/fon-2020-0823,33052055,results,6,NA,Primary outcome: unadjusted treatment effect,NA,NA,0.25,TRUE,NA,NA,NA
10.2217/fon-2020-0823,33052055,results,6,NA,"p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])",NA,NA,[0.13;0.46],TRUE,NA,NA,NA
10.2217/fon-2020-0823,33052055,results,6,NA,Primary outcome: adjusted treatment effect,NA,NA,0.11,TRUE,NA,NA,NA
10.2217/fon-2020-0823,33052055,results,6,NA,"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])",NA,NA,[0.05;0.22],TRUE,NA,NA,NA
10.2217/fon-2020-0823,33052055,results,7,NA,Sample size of the population of interest in the non IPD treatment arm,NA,NA,31,TRUE,NA,NA,NA
10.2217/fon-2020-0823,33052055,results,7,NA,Reporting of a weights' distribution evaluation (MAIC),Not mentioned,"Yes, mentions that the weights distribution has been studied, but weights distribution not reported","Yes, mentions that the weights distribution has been studied, but weights distribution not reported",FALSE,NA,NA,NA
10.2217/fon-2020-0823,33052055,results,7,NA,Reporting of the list of the covariates adjusted for/matched on,NA,NA,Yes,TRUE,NA,NA,NA
10.2217/fon-2020-0823,33052055,results,7,NA,Number of covariates adjusted for/matched on,8,4,8,FALSE,NA,NA,NA
10.2217/fon-2020-0823,33052055,results,7,NA,Covariates adjusted for/matched on in the indirect comparison,"Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Past treatments for the disease of interest","Age, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease)","Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Past treatments for the disease of interest",FALSE,NA,NA,NA
10.2217/fon-2020-0823,33052055,results,7,NA,Primary outcome: treatment effect contrast,NA,NA,HR,TRUE,NA,NA,NA
10.2217/fon-2020-0823,33052055,results,7,NA,Direction of the treatment effect contrast: IPD treatment is:,NA,NA,"Numerator if ratio, or left side if difference",TRUE,NA,NA,NA
10.2217/fon-2020-0823,33052055,results,7,NA,Primary outcome: unadjusted treatment effect,NA,NA,0.28,TRUE,NA,NA,NA
10.2217/fon-2020-0823,33052055,results,7,NA,"p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])",NA,NA,[0.16;0.50],TRUE,NA,NA,NA
10.2217/fon-2020-0823,33052055,results,7,NA,Primary outcome: adjusted treatment effect,NA,NA,0.37,TRUE,NA,NA,NA
10.2217/fon-2020-0823,33052055,results,7,NA,"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])",NA,NA,[0.20;0.69],TRUE,NA,NA,NA
10.2217/fon-2020-0823,33052055,results,7,NA,Initial sample size of the population of interest in the IPD treatment arm,193,NA,193,FALSE,NA,NA,NA
10.2217/fon-2020-0823,33052055,results,8,NA,Sample size of the population of interest in the non IPD treatment arm,NA,NA,31,TRUE,NA,NA,NA
10.2217/fon-2020-0823,33052055,results,8,NA,Initial sample size of the population of interest in the IPD treatment arm,NA,NA,193,TRUE,NA,NA,NA
10.2217/fon-2020-0823,33052055,results,8,NA,"Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC",NA,NA,193,TRUE,NA,NA,NA
10.2217/fon-2020-0823,33052055,results,8,NA,Reporting of the list of the covariates adjusted for/matched on,NA,NA,Yes,TRUE,NA,NA,NA
10.2217/fon-2020-0823,33052055,results,8,NA,Number of covariates adjusted for/matched on,8,4,8,FALSE,NA,NA,NA
10.2217/fon-2020-0823,33052055,results,8,NA,Covariates adjusted for/matched on in the indirect comparison,"Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Past treatments for the disease of interest","Age, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease)","Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Past treatments for the disease of interest",FALSE,NA,NA,NA
10.2217/fon-2020-0823,33052055,results,8,NA,Primary outcome: treatment effect contrast,NA,NA,HR,TRUE,NA,NA,NA
10.2217/fon-2020-0823,33052055,results,8,NA,Direction of the treatment effect contrast: IPD treatment is:,NA,NA,"Numerator if ratio, or left side if difference",TRUE,NA,NA,NA
10.2217/fon-2020-0823,33052055,results,8,NA,Primary outcome: unadjusted treatment effect,NA,NA,0.28,TRUE,NA,NA,NA
10.2217/fon-2020-0823,33052055,results,8,NA,"p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])",NA,NA,[0.16;0.50],TRUE,NA,NA,NA
10.2217/fon-2020-0823,33052055,results,8,NA,Primary outcome: adjusted treatment effect,NA,NA,0.25,TRUE,NA,NA,NA
10.2217/fon-2020-0823,33052055,results,8,NA,"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])",NA,NA,[0.14;0.44],TRUE,NA,NA,NA
10.2217/fon-2020-0823,33052055,results,9,NA,Sample size of the population of interest in the non IPD treatment arm,NA,NA,40,TRUE,NA,NA,NA
10.2217/fon-2020-0823,33052055,results,9,NA,Reporting of a weights' distribution evaluation (MAIC),Not mentioned,"Yes, mentions that the weights distribution has been studied, but weights distribution not reported","Yes, mentions that the weights distribution has been studied, but weights distribution not reported",FALSE,NA,NA,NA
10.2217/fon-2020-0823,33052055,results,9,NA,Reporting of the list of the covariates adjusted for/matched on,NA,NA,Yes,TRUE,NA,NA,NA
10.2217/fon-2020-0823,33052055,results,9,NA,Number of covariates adjusted for/matched on,8,4,8,FALSE,NA,NA,NA
10.2217/fon-2020-0823,33052055,results,9,NA,Covariates adjusted for/matched on in the indirect comparison,"Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Past treatments for the disease of interest","Age, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease)","Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Past treatments for the disease of interest",FALSE,NA,NA,NA
10.2217/fon-2020-0823,33052055,results,9,NA,Primary outcome: treatment effect contrast,NA,NA,HR,TRUE,NA,NA,NA
10.2217/fon-2020-0823,33052055,results,9,NA,Direction of the treatment effect contrast: IPD treatment is:,NA,NA,"Numerator if ratio, or left side if difference",TRUE,NA,NA,NA
10.2217/fon-2020-0823,33052055,results,9,NA,Primary outcome: unadjusted treatment effect,NA,NA,0.27,TRUE,NA,NA,NA
10.2217/fon-2020-0823,33052055,results,9,NA,"p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])",NA,NA,[0.16;0.44],TRUE,NA,NA,NA
10.2217/fon-2020-0823,33052055,results,9,NA,Primary outcome: adjusted treatment effect,NA,NA,0.47,TRUE,NA,NA,NA
10.2217/fon-2020-0823,33052055,results,9,NA,"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])",NA,NA,[0.29;0.75],TRUE,NA,NA,NA
10.2217/fon-2020-0823,33052055,results,9,NA,Initial sample size of the population of interest in the IPD treatment arm,193,NA,193,FALSE,NA,NA,NA
10.1007/s40744-020-00257-w,33244703,general_information,NA,NA,Medical Condition of Interest Name,NA,NA,moderate-to-severe rheumatoid arthritis,TRUE,NA,NA,NA
10.1007/s40744-020-00257-w,33244703,general_information,NA,NA,Countries of first author affiliations,NA,NA,uk,TRUE,NA,NA,NA
10.1007/s40744-020-00257-w,33244703,general_information,NA,NA,Countries of last author affiliations,NA,NA,usa,TRUE,NA,NA,NA
10.1007/s40744-020-00257-w,33244703,general_information,NA,NA,"Positions of study investigators (for any authors of the article, any that applies)",NA,NA,"Academic, Pharmaceutical Industry, Private Data Analysis Company",TRUE,NA,NA,NA
10.1007/s40744-020-00257-w,33244703,general_information,NA,NA,"At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company",NA,NA,Yes,TRUE,NA,NA,NA
10.1007/s40744-020-00257-w,33244703,general_information,NA,NA,Mentioned sources of funding,NA,NA,Pharmaceutical Industry,TRUE,NA,NA,NA
10.1007/s40744-020-00257-w,33244703,general_information,NA,NA,"Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article",NA,NA,Yes,TRUE,NA,NA,NA
10.1007/s40744-020-00257-w,33244703,general_information,NA,NA,Mention of a systematic review to find the studies to compare treatments of interest,NA,NA,Yes,TRUE,NA,NA,NA
10.1007/s40744-020-00257-w,33244703,study_information,NA,1,Patient-level data used,NA,NA,Yes,TRUE,NA,NA,NA
10.1007/s40744-020-00257-w,33244703,study_information,NA,1,Clinical Trial,NA,NA,Yes,TRUE,NA,NA,NA
10.1007/s40744-020-00257-w,33244703,study_information,NA,1,NCT (only for clinical trial registered on clinicaltrials.gov),NA,NA,NCT02706951,TRUE,NA,NA,NA
10.1007/s40744-020-00257-w,33244703,study_information,NA,1,Country where the clinical trial/observational study was conducted (international if more than one),NA,NA,international,TRUE,NA,NA,NA
10.1007/s40744-020-00257-w,33244703,study_information,NA,1,Phase of the clinical trial (clinical trial only),NA,NA,3,TRUE,NA,NA,NA
10.1007/s40744-020-00257-w,33244703,study_information,NA,1,Number of treatment arms (clinical trial only),NA,NA,2 or more,TRUE,NA,NA,NA
10.1007/s40744-020-00257-w,33244703,study_information,NA,2,Patient-level data used,NA,NA,Yes,TRUE,NA,NA,NA
10.1007/s40744-020-00257-w,33244703,study_information,NA,2,Clinical Trial,NA,NA,Yes,TRUE,NA,NA,NA
10.1007/s40744-020-00257-w,33244703,study_information,NA,2,NCT (only for clinical trial registered on clinicaltrials.gov),NA,NA,NCT02629159,TRUE,NA,NA,NA
10.1007/s40744-020-00257-w,33244703,study_information,NA,2,Country where the clinical trial/observational study was conducted (international if more than one),NA,NA,international,TRUE,NA,NA,NA
10.1007/s40744-020-00257-w,33244703,study_information,NA,2,Phase of the clinical trial (clinical trial only),NA,NA,3,TRUE,NA,NA,NA
10.1007/s40744-020-00257-w,33244703,study_information,NA,2,Number of treatment arms (clinical trial only),NA,NA,2 or more,TRUE,NA,NA,NA
10.1007/s40744-020-00257-w,33244703,study_information,NA,3,Patient-level data used,NA,NA,No,TRUE,NA,NA,NA
10.1007/s40744-020-00257-w,33244703,study_information,NA,3,Clinical Trial,NA,NA,Yes,TRUE,NA,NA,NA
10.1007/s40744-020-00257-w,33244703,study_information,NA,3,NCT (only for clinical trial registered on clinicaltrials.gov),NA,NA,NCT00853385,TRUE,NA,NA,NA
10.1007/s40744-020-00257-w,33244703,study_information,NA,3,Country where the clinical trial/observational study was conducted (international if more than one),NA,NA,international,TRUE,NA,NA,NA
10.1007/s40744-020-00257-w,33244703,study_information,NA,3,Phase of the clinical trial (clinical trial only),NA,NA,3,TRUE,NA,NA,NA
10.1007/s40744-020-00257-w,33244703,study_information,NA,3,Number of treatment arms (clinical trial only),NA,NA,2 or more,TRUE,NA,NA,NA
10.1007/s40744-020-00257-w,33244703,study_information,NA,4,Patient-level data used,NA,NA,No,TRUE,NA,NA,NA
10.1007/s40744-020-00257-w,33244703,study_information,NA,4,Clinical Trial,NA,NA,Yes,TRUE,NA,NA,NA
10.1007/s40744-020-00257-w,33244703,study_information,NA,4,NCT (only for clinical trial registered on clinicaltrials.gov),NA,NA,NCT02187055,TRUE,NA,NA,NA
10.1007/s40744-020-00257-w,33244703,study_information,NA,4,Country where the clinical trial/observational study was conducted (international if more than one),NA,NA,international,TRUE,NA,NA,NA
10.1007/s40744-020-00257-w,33244703,study_information,NA,4,Phase of the clinical trial (clinical trial only),"3, 4",4,XXXX,FALSE,NA,NA,NA
10.1007/s40744-020-00257-w,33244703,study_information,NA,4,Number of treatment arms (clinical trial only),NA,NA,2 or more,TRUE,NA,NA,NA
10.1007/s40744-020-00257-w,33244703,methodology,1,NA,Treatment name 1,upadacitinib,upadacitinib monotherapy,upadacitinib monotherapy,FALSE,Apply a Bonferroni correction for multiple testing,NA,NA
10.1007/s40744-020-00257-w,33244703,methodology,1,NA,Study 'number(s)' for treatment 1,NA,NA,1,TRUE,NA,NA,NA
10.1007/s40744-020-00257-w,33244703,methodology,1,NA,Treatment name 2,NA,NA,tofacitinib + methotrexate,TRUE,NA,NA,NA
10.1007/s40744-020-00257-w,33244703,methodology,1,NA,Study 'number(s)' for treatment 2,NA,NA,3,TRUE,NA,NA,NA
10.1007/s40744-020-00257-w,33244703,methodology,1,NA,Type of population-adjusted indirect comparisons performed,NA,NA,MAIC,TRUE,NA,NA,NA
10.1007/s40744-020-00257-w,33244703,methodology,1,NA,Anchored comparison?,NA,NA,Yes,TRUE,NA,NA,NA
10.1007/s40744-020-00257-w,33244703,methodology,1,NA,Form of the indirect comparison,NA,NA,Simple (ie treatments effects extracted from two studies),TRUE,NA,NA,NA
10.1007/s40744-020-00257-w,33244703,methodology,1,NA,Definition of a single primary outcome for the indirect comparison,NA,NA,"No primary outcome defined, or multiple primary outcomes without any clear distinction between them",TRUE,NA,NA,NA
10.1007/s40744-020-00257-w,33244703,methodology,1,NA,Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined),american college of rheumatology 70% criteria,proportions of patients achieving 70% improvement in the acr criteria (acr70) at month 3,proportions of patients achieving 70% improvement in the acr criteria (acr70) at month 3,FALSE,NA,NA,NA
10.1007/s40744-020-00257-w,33244703,methodology,1,NA,Primary outcome: variable type,"Continuous (count, mean, ...)",Binary (eg rates),Binary (eg rates),FALSE,NA,NA,NA
10.1007/s40744-020-00257-w,33244703,methodology,1,NA,Justification for selecting variables to be included in the adjustment model (in the main text),"Nothing mentioned, not reported",A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion),A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion),FALSE,NA,NA,NA
10.1007/s40744-020-00257-w,33244703,methodology,1,NA,Inclusion of prognostic factors in the adjustment/matching model,NA,NA,No discussion (in the main text) of the status of prognostic factors of the variables,TRUE,NA,NA,NA
10.1007/s40744-020-00257-w,33244703,methodology,1,NA,Inclusion of treatment-effect modifiers in the adjustment/matching model,NA,NA,No discussion (in the main text) of the status of treatment-effect modifiers of the variables,TRUE,NA,NA,NA
10.1007/s40744-020-00257-w,33244703,methodology,1,NA,"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)",NA,NA,No,TRUE,NA,NA,NA
10.1007/s40744-020-00257-w,33244703,methodology,1,NA,Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale),NA,NA,No,TRUE,NA,NA,NA
10.1007/s40744-020-00257-w,33244703,methodology,2,NA,Treatment name 1,NA,NA,upadacitinib + methotrexate,TRUE,NA,NA,NA
10.1007/s40744-020-00257-w,33244703,methodology,2,NA,Study 'number(s)' for treatment 1,NA,NA,2,TRUE,NA,NA,NA
10.1007/s40744-020-00257-w,33244703,methodology,2,NA,Treatment name 2,NA,NA,tofacitinib + methotrexate,TRUE,NA,NA,NA
10.1007/s40744-020-00257-w,33244703,methodology,2,NA,Study 'number(s)' for treatment 2,NA,NA,4,TRUE,NA,NA,NA
10.1007/s40744-020-00257-w,33244703,methodology,2,NA,Type of population-adjusted indirect comparisons performed,NA,NA,MAIC,TRUE,NA,NA,NA
10.1007/s40744-020-00257-w,33244703,methodology,2,NA,Anchored comparison?,NA,NA,Yes,TRUE,NA,NA,NA
10.1007/s40744-020-00257-w,33244703,methodology,2,NA,Form of the indirect comparison,NA,NA,Simple (ie treatments effects extracted from two studies),TRUE,NA,NA,NA
10.1007/s40744-020-00257-w,33244703,methodology,2,NA,Definition of a single primary outcome for the indirect comparison,NA,NA,"No primary outcome defined, or multiple primary outcomes without any clear distinction between them",TRUE,NA,NA,NA
10.1007/s40744-020-00257-w,33244703,methodology,2,NA,Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined),american college of rheumatology 50% criteria,"proportions of patients achieving 50% improvement in the acr criteria (acr50)at month 3,","proportions of patients achieving 50% improvement in the acr criteria (acr50)at month 3,",FALSE,NA,NA,NA
10.1007/s40744-020-00257-w,33244703,methodology,2,NA,Primary outcome: variable type,"Continuous (count, mean, ...)",Binary (eg rates),Binary (eg rates),FALSE,NA,NA,NA
10.1007/s40744-020-00257-w,33244703,methodology,2,NA,Justification for selecting variables to be included in the adjustment model (in the main text),"Nothing mentioned, not reported",A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion),A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion),FALSE,NA,NA,NA
10.1007/s40744-020-00257-w,33244703,methodology,2,NA,Inclusion of prognostic factors in the adjustment/matching model,NA,NA,No discussion (in the main text) of the status of prognostic factors of the variables,TRUE,NA,NA,NA
10.1007/s40744-020-00257-w,33244703,methodology,2,NA,Inclusion of treatment-effect modifiers in the adjustment/matching model,NA,NA,No discussion (in the main text) of the status of treatment-effect modifiers of the variables,TRUE,NA,NA,NA
10.1007/s40744-020-00257-w,33244703,methodology,2,NA,"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)",NA,NA,No,TRUE,NA,NA,NA
10.1007/s40744-020-00257-w,33244703,methodology,2,NA,Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale),NA,NA,No,TRUE,NA,NA,NA
10.1007/s40744-020-00257-w,33244703,results,1,NA,Sample size of the population of interest in the non IPD treatment arm,NA,NA,204,TRUE,NA,NA,NA
10.1007/s40744-020-00257-w,33244703,results,1,NA,"If anchored comparison, sample size of the population of interest in the non IPD treatment anchor arm",NA,NA,108,TRUE,NA,NA,NA
10.1007/s40744-020-00257-w,33244703,results,1,NA,Initial sample size of the population of interest in the IPD treatment arm,217,216,217,FALSE,NA,NA,NA
10.1007/s40744-020-00257-w,33244703,results,1,NA,"Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC",NA,NA,173,TRUE,NA,NA,NA
10.1007/s40744-020-00257-w,33244703,results,1,NA,"If anchored comparison, initial sample size of the population of interest in the IPD anchor arm",NA,NA,216,TRUE,NA,NA,NA
10.1007/s40744-020-00257-w,33244703,results,1,NA,"If anchored comparison, effective sample size after reweighting for MAIC; or sample size used in the regression model for STC in the IPD anchor arm",NA,NA,158,TRUE,NA,NA,NA
10.1007/s40744-020-00257-w,33244703,results,1,NA,Reporting of a weights' distribution evaluation (MAIC),NA,NA,Not mentioned,TRUE,NA,NA,NA
10.1007/s40744-020-00257-w,33244703,results,1,NA,Reporting of the list of the covariates adjusted for/matched on,NA,NA,Yes,TRUE,NA,NA,NA
10.1007/s40744-020-00257-w,33244703,results,1,NA,Number of covariates adjusted for/matched on,NA,NA,7,TRUE,NA,NA,NA
10.1007/s40744-020-00257-w,33244703,results,1,NA,Covariates adjusted for/matched on in the indirect comparison,NA,NA,"Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Race/ethnicity",TRUE,NA,NA,NA
10.1007/s40744-020-00257-w,33244703,results,1,NA,Primary outcome: treatment effect contrast,NA,NA,Means difference,TRUE,NA,NA,NA
10.1007/s40744-020-00257-w,33244703,results,1,NA,Direction of the treatment effect contrast: IPD treatment is:,NA,NA,"Numerator if ratio, or left side if difference",TRUE,NA,NA,NA
10.1007/s40744-020-00257-w,33244703,results,1,NA,Primary outcome: unadjusted treatment effect,9.6,9.60%,9.60%,FALSE,NA,NA,NA
10.1007/s40744-020-00257-w,33244703,results,1,NA,"p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])",NA,NA,0.018,TRUE,NA,NA,NA
10.1007/s40744-020-00257-w,33244703,results,1,NA,Primary outcome: adjusted treatment effect,9.9,9.90%,9.90%,FALSE,NA,NA,NA
10.1007/s40744-020-00257-w,33244703,results,1,NA,"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])",NA,NA,0.019,TRUE,NA,NA,NA
10.1007/s40744-020-00257-w,33244703,results,2,NA,Sample size of the population of interest in the non IPD treatment arm,NA,NA,376,TRUE,NA,NA,NA
10.1007/s40744-020-00257-w,33244703,results,2,NA,"If anchored comparison, sample size of the population of interest in the non IPD treatment anchor arm",NA,NA,386,TRUE,NA,NA,NA
10.1007/s40744-020-00257-w,33244703,results,2,NA,Initial sample size of the population of interest in the IPD treatment arm,NA,NA,647,TRUE,NA,NA,NA
10.1007/s40744-020-00257-w,33244703,results,2,NA,"Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC",NA,NA,480,TRUE,NA,NA,NA
10.1007/s40744-020-00257-w,33244703,results,2,NA,"If anchored comparison, initial sample size of the population of interest in the IPD anchor arm",NA,NA,324,TRUE,NA,NA,NA
10.1007/s40744-020-00257-w,33244703,results,2,NA,"If anchored comparison, effective sample size after reweighting for MAIC; or sample size used in the regression model for STC in the IPD anchor arm",NA,NA,228,TRUE,NA,NA,NA
10.1007/s40744-020-00257-w,33244703,results,2,NA,Reporting of a weights' distribution evaluation (MAIC),NA,NA,Not mentioned,TRUE,NA,NA,NA
10.1007/s40744-020-00257-w,33244703,results,2,NA,Reporting of the list of the covariates adjusted for/matched on,NA,NA,Yes,TRUE,NA,NA,NA
10.1007/s40744-020-00257-w,33244703,results,2,NA,Number of covariates adjusted for/matched on,NA,NA,7,TRUE,NA,NA,NA
10.1007/s40744-020-00257-w,33244703,results,2,NA,Covariates adjusted for/matched on in the indirect comparison,NA,NA,"Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Race/ethnicity",TRUE,NA,NA,NA
10.1007/s40744-020-00257-w,33244703,results,2,NA,Primary outcome: treatment effect contrast,NA,NA,Means difference,TRUE,NA,NA,NA
10.1007/s40744-020-00257-w,33244703,results,2,NA,Direction of the treatment effect contrast: IPD treatment is:,NA,NA,"Numerator if ratio, or left side if difference",TRUE,NA,NA,NA
10.1007/s40744-020-00257-w,33244703,results,2,NA,Primary outcome: unadjusted treatment effect,12.7,12.70%,12.70%,FALSE,NA,NA,NA
10.1007/s40744-020-00257-w,33244703,results,2,NA,"p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])",NA,NA,0.008,TRUE,NA,NA,NA
10.1007/s40744-020-00257-w,33244703,results,2,NA,Primary outcome: adjusted treatment effect,12.9,12.90%,12.90%,FALSE,NA,NA,NA
10.1007/s40744-020-00257-w,33244703,results,2,NA,"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])",NA,NA,0.011,TRUE,NA,NA,NA
10.1007/s12325-020-01599-1,33377987,general_information,NA,NA,Medical Condition of Interest Name,NA,NA,haemophilia a,TRUE,NA,NA,NA
10.1007/s12325-020-01599-1,33377987,general_information,NA,NA,Countries of first author affiliations,NA,NA,sweden,TRUE,NA,NA,NA
10.1007/s12325-020-01599-1,33377987,general_information,NA,NA,Countries of last author affiliations,NA,NA,sweden,TRUE,NA,NA,NA
10.1007/s12325-020-01599-1,33377987,general_information,NA,NA,"Positions of study investigators (for any authors of the article, any that applies)",NA,NA,"Academic, Pharmaceutical Industry",TRUE,NA,NA,NA
10.1007/s12325-020-01599-1,33377987,general_information,NA,NA,"At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company",NA,NA,Not mentioned,TRUE,NA,NA,NA
10.1007/s12325-020-01599-1,33377987,general_information,NA,NA,Mentioned sources of funding,NA,NA,Pharmaceutical Industry,TRUE,NA,NA,NA
10.1007/s12325-020-01599-1,33377987,general_information,NA,NA,"Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article",NA,NA,Yes,TRUE,NA,NA,NA
10.1007/s12325-020-01599-1,33377987,general_information,NA,NA,Mention of a systematic review to find the studies to compare treatments of interest,NA,NA,No,TRUE,NA,NA,NA
10.1007/s12325-020-01599-1,33377987,study_information,NA,1,Patient-level data used,NA,NA,Yes,TRUE,NA,NA,NA
10.1007/s12325-020-01599-1,33377987,study_information,NA,1,Clinical Trial,NA,NA,Yes,TRUE,NA,NA,NA
10.1007/s12325-020-01599-1,33377987,study_information,NA,1,NCT (only for clinical trial registered on clinicaltrials.gov),NA,NA,NCT01181128,TRUE,NA,NA,NA
10.1007/s12325-020-01599-1,33377987,study_information,NA,1,Country where the clinical trial/observational study was conducted (international if more than one),international,NA,XXXX,FALSE,NA,NA,NA
10.1007/s12325-020-01599-1,33377987,study_information,NA,1,Phase of the clinical trial (clinical trial only),NA,NA,3,TRUE,NA,NA,NA
10.1007/s12325-020-01599-1,33377987,study_information,NA,1,Number of treatment arms (clinical trial only),NA,NA,1,TRUE,NA,NA,NA
10.1007/s12325-020-01599-1,33377987,study_information,NA,2,Patient-level data used,NA,NA,No,TRUE,NA,NA,NA
10.1007/s12325-020-01599-1,33377987,study_information,NA,2,Clinical Trial,Yes,No,XXXX,FALSE,NA,NA,NA
10.1007/s12325-020-01599-1,33377987,study_information,NA,2,NCT (only for clinical trial registered on clinicaltrials.gov),NA,NA,NCT01580293,TRUE,NA,NA,NA
10.1007/s12325-020-01599-1,33377987,study_information,NA,2,Country where the clinical trial/observational study was conducted (international if more than one),NA,NA,international,TRUE,NA,NA,NA
10.1007/s12325-020-01599-1,33377987,study_information,NA,2,Phase of the clinical trial (clinical trial only),NA,NA,"2, 3",TRUE,NA,NA,NA
10.1007/s12325-020-01599-1,33377987,study_information,NA,2,Number of treatment arms (clinical trial only),1,2 or more,XXXX,FALSE,NA,NA,NA
10.1007/s12325-020-01599-1,33377987,methodology,1,NA,Treatment name 1,recombinant fviiifc,rfviiifc,recombinant fviiifc,FALSE,"Opposite analysis with 10.2147/JBM.S206806, with conflicting results (at least conflicting brought forward results, because they don't analyse the same patient subgroups, and argue that the patient subgroups analyzed in the other study is not the relevant one)","PROTECT VIII pooled prophylaxis regimens

BMI = other

""weighted negative binomial regression model"" is equavalent to method of moment ?",NA
10.1007/s12325-020-01599-1,33377987,methodology,1,NA,Study 'number(s)' for treatment 1,NA,NA,1,TRUE,NA,NA,NA
10.1007/s12325-020-01599-1,33377987,methodology,1,NA,Treatment name 2,damoctocog alfa pegol (pooled prophylaxis),bay 94-9027,damoctocog alfa pegol (pooled prophylaxis),FALSE,NA,NA,NA
10.1007/s12325-020-01599-1,33377987,methodology,1,NA,Study 'number(s)' for treatment 2,NA,NA,2,TRUE,NA,NA,NA
10.1007/s12325-020-01599-1,33377987,methodology,1,NA,Type of population-adjusted indirect comparisons performed,NA,NA,MAIC,TRUE,NA,NA,NA
10.1007/s12325-020-01599-1,33377987,methodology,1,NA,Anchored comparison?,NA,NA,No,TRUE,NA,NA,NA
10.1007/s12325-020-01599-1,33377987,methodology,1,NA,Form of the indirect comparison,NA,NA,Simple (ie treatments effects extracted from two studies),TRUE,NA,NA,NA
10.1007/s12325-020-01599-1,33377987,methodology,1,NA,Definition of a single primary outcome for the indirect comparison,NA,NA,"No primary outcome defined, or multiple primary outcomes without any clear distinction between them",TRUE,NA,NA,NA
10.1007/s12325-020-01599-1,33377987,methodology,1,NA,Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined),mean annualized bleeding rates,annualised bleeding rate (abr),mean annualized bleeding rates,FALSE,NA,NA,NA
10.1007/s12325-020-01599-1,33377987,methodology,1,NA,Primary outcome: variable type,NA,NA,"Continuous (count, mean, ...)",TRUE,NA,NA,NA
10.1007/s12325-020-01599-1,33377987,methodology,1,NA,Justification for selecting variables to be included in the adjustment model (in the main text),NA,NA,Literature based (clinically or methodologically relevant to adjust on these variables based on the literature search conducted for this specific purpose),TRUE,NA,NA,NA
10.1007/s12325-020-01599-1,33377987,methodology,1,NA,Inclusion of prognostic factors in the adjustment/matching model,NA,NA,No discussion (in the main text) of the status of prognostic factors of the variables,TRUE,NA,NA,NA
10.1007/s12325-020-01599-1,33377987,methodology,1,NA,Inclusion of treatment-effect modifiers in the adjustment/matching model,NA,NA,No discussion (in the main text) of the status of treatment-effect modifiers of the variables,TRUE,NA,NA,NA
10.1007/s12325-020-01599-1,33377987,methodology,1,NA,"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)",NA,NA,Yes,TRUE,NA,NA,NA
10.1007/s12325-020-01599-1,33377987,methodology,1,NA,Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale),NA,NA,No,TRUE,NA,NA,NA
10.1007/s12325-020-01599-1,33377987,methodology,2,NA,Treatment name 1,recombinant fviiifc,fviiifc,recombinant fviiifc,FALSE,NA,"PROTECT VIII ""Twice weekly"" regimen

BMI = others",NA
10.1007/s12325-020-01599-1,33377987,methodology,2,NA,Study 'number(s)' for treatment 1,NA,NA,1,TRUE,NA,NA,NA
10.1007/s12325-020-01599-1,33377987,methodology,2,NA,Treatment name 2,damoctocog alfa pegol twice weekly,bay 94-9027,damoctocog alfa pegol twice weekly,FALSE,NA,NA,NA
10.1007/s12325-020-01599-1,33377987,methodology,2,NA,Study 'number(s)' for treatment 2,NA,NA,2,TRUE,NA,NA,NA
10.1007/s12325-020-01599-1,33377987,methodology,2,NA,Type of population-adjusted indirect comparisons performed,NA,NA,MAIC,TRUE,NA,NA,NA
10.1007/s12325-020-01599-1,33377987,methodology,2,NA,Anchored comparison?,NA,NA,No,TRUE,NA,NA,NA
10.1007/s12325-020-01599-1,33377987,methodology,2,NA,Form of the indirect comparison,NA,NA,Simple (ie treatments effects extracted from two studies),TRUE,NA,NA,NA
10.1007/s12325-020-01599-1,33377987,methodology,2,NA,Definition of a single primary outcome for the indirect comparison,NA,NA,"No primary outcome defined, or multiple primary outcomes without any clear distinction between them",TRUE,NA,NA,NA
10.1007/s12325-020-01599-1,33377987,methodology,2,NA,Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined),mean annualised bleeding rate,annualised bleeding rate (abr),mean annualised bleeding rate,FALSE,NA,NA,NA
10.1007/s12325-020-01599-1,33377987,methodology,2,NA,Primary outcome: variable type,NA,NA,"Continuous (count, mean, ...)",TRUE,NA,NA,NA
10.1007/s12325-020-01599-1,33377987,methodology,2,NA,Justification for selecting variables to be included in the adjustment model (in the main text),Literature based (clinically or methodologically relevant to adjust on these variables based on the literature search conducted for this specific purpose),"Nothing mentioned, not reported",Literature based (clinically or methodologically relevant to adjust on these variables based on the literature search conducted for this specific purpose),FALSE,NA,NA,NA
10.1007/s12325-020-01599-1,33377987,methodology,2,NA,Inclusion of prognostic factors in the adjustment/matching model,NA,NA,No discussion (in the main text) of the status of prognostic factors of the variables,TRUE,NA,NA,NA
10.1007/s12325-020-01599-1,33377987,methodology,2,NA,Inclusion of treatment-effect modifiers in the adjustment/matching model,NA,NA,No discussion (in the main text) of the status of treatment-effect modifiers of the variables,TRUE,NA,NA,NA
10.1007/s12325-020-01599-1,33377987,methodology,2,NA,"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)",NA,NA,Yes,TRUE,NA,NA,NA
10.1007/s12325-020-01599-1,33377987,methodology,2,NA,Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale),NA,NA,No,TRUE,NA,NA,NA
10.1007/s12325-020-01599-1,33377987,methodology,3,NA,Treatment name 1,recombinant fviiifc,fviiifc,recombinant fviiifc,FALSE,NA,"PROTECT VIII ""Q5D"" regimen

BMI = other",NA
10.1007/s12325-020-01599-1,33377987,methodology,3,NA,Study 'number(s)' for treatment 1,NA,NA,1,TRUE,NA,NA,NA
10.1007/s12325-020-01599-1,33377987,methodology,3,NA,Treatment name 2,damoctocog alfa pegol q5d,bay 94-9027,damoctocog alfa pegol q5d,FALSE,NA,NA,NA
10.1007/s12325-020-01599-1,33377987,methodology,3,NA,Study 'number(s)' for treatment 2,NA,NA,2,TRUE,NA,NA,NA
10.1007/s12325-020-01599-1,33377987,methodology,3,NA,Type of population-adjusted indirect comparisons performed,NA,NA,MAIC,TRUE,NA,NA,NA
10.1007/s12325-020-01599-1,33377987,methodology,3,NA,Anchored comparison?,NA,NA,No,TRUE,NA,NA,NA
10.1007/s12325-020-01599-1,33377987,methodology,3,NA,Form of the indirect comparison,NA,NA,Simple (ie treatments effects extracted from two studies),TRUE,NA,NA,NA
10.1007/s12325-020-01599-1,33377987,methodology,3,NA,Definition of a single primary outcome for the indirect comparison,NA,NA,"No primary outcome defined, or multiple primary outcomes without any clear distinction between them",TRUE,NA,NA,NA
10.1007/s12325-020-01599-1,33377987,methodology,3,NA,Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined),mean annualised bleeding rate,annualised bleeding rate (abr),mean annualised bleeding rate,FALSE,NA,NA,NA
10.1007/s12325-020-01599-1,33377987,methodology,3,NA,Primary outcome: variable type,NA,NA,"Continuous (count, mean, ...)",TRUE,NA,NA,NA
10.1007/s12325-020-01599-1,33377987,methodology,3,NA,Justification for selecting variables to be included in the adjustment model (in the main text),Literature based (clinically or methodologically relevant to adjust on these variables based on the literature search conducted for this specific purpose),"Nothing mentioned, not reported",Literature based (clinically or methodologically relevant to adjust on these variables based on the literature search conducted for this specific purpose),FALSE,NA,NA,NA
10.1007/s12325-020-01599-1,33377987,methodology,3,NA,Inclusion of prognostic factors in the adjustment/matching model,NA,NA,No discussion (in the main text) of the status of prognostic factors of the variables,TRUE,NA,NA,NA
10.1007/s12325-020-01599-1,33377987,methodology,3,NA,Inclusion of treatment-effect modifiers in the adjustment/matching model,NA,NA,No discussion (in the main text) of the status of treatment-effect modifiers of the variables,TRUE,NA,NA,NA
10.1007/s12325-020-01599-1,33377987,methodology,3,NA,"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)",NA,NA,Yes,TRUE,NA,NA,NA
10.1007/s12325-020-01599-1,33377987,methodology,3,NA,Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale),NA,NA,No,TRUE,NA,NA,NA
10.1007/s12325-020-01599-1,33377987,methodology,4,NA,Treatment name 1,recombinant fviiifc,fviiifc,recombinant fviiifc,FALSE,NA,"PROTECT VIII ""Q7D"" regimen

BMI = other",NA
10.1007/s12325-020-01599-1,33377987,methodology,4,NA,Study 'number(s)' for treatment 1,NA,NA,1,TRUE,NA,NA,NA
10.1007/s12325-020-01599-1,33377987,methodology,4,NA,Treatment name 2,damoctocog alfa pegol q7d,bay 94-9027,damoctocog alfa pegol q7d,FALSE,NA,NA,NA
10.1007/s12325-020-01599-1,33377987,methodology,4,NA,Study 'number(s)' for treatment 2,NA,NA,2,TRUE,NA,NA,NA
10.1007/s12325-020-01599-1,33377987,methodology,4,NA,Type of population-adjusted indirect comparisons performed,NA,NA,MAIC,TRUE,NA,NA,NA
10.1007/s12325-020-01599-1,33377987,methodology,4,NA,Anchored comparison?,NA,NA,No,TRUE,NA,NA,NA
10.1007/s12325-020-01599-1,33377987,methodology,4,NA,Form of the indirect comparison,NA,NA,Simple (ie treatments effects extracted from two studies),TRUE,NA,NA,NA
10.1007/s12325-020-01599-1,33377987,methodology,4,NA,Definition of a single primary outcome for the indirect comparison,NA,NA,"No primary outcome defined, or multiple primary outcomes without any clear distinction between them",TRUE,NA,NA,NA
10.1007/s12325-020-01599-1,33377987,methodology,4,NA,Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined),mean annualised bleeding rate,annualised bleeding rate (abr),mean annualised bleeding rate,FALSE,NA,NA,NA
10.1007/s12325-020-01599-1,33377987,methodology,4,NA,Primary outcome: variable type,NA,NA,"Continuous (count, mean, ...)",TRUE,NA,NA,NA
10.1007/s12325-020-01599-1,33377987,methodology,4,NA,Justification for selecting variables to be included in the adjustment model (in the main text),Literature based (clinically or methodologically relevant to adjust on these variables based on the literature search conducted for this specific purpose),"Nothing mentioned, not reported",Literature based (clinically or methodologically relevant to adjust on these variables based on the literature search conducted for this specific purpose),FALSE,NA,NA,NA
10.1007/s12325-020-01599-1,33377987,methodology,4,NA,Inclusion of prognostic factors in the adjustment/matching model,NA,NA,No discussion (in the main text) of the status of prognostic factors of the variables,TRUE,NA,NA,NA
10.1007/s12325-020-01599-1,33377987,methodology,4,NA,Inclusion of treatment-effect modifiers in the adjustment/matching model,NA,NA,No discussion (in the main text) of the status of treatment-effect modifiers of the variables,TRUE,NA,NA,NA
10.1007/s12325-020-01599-1,33377987,methodology,4,NA,"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)",NA,NA,Yes,TRUE,NA,NA,NA
10.1007/s12325-020-01599-1,33377987,methodology,4,NA,Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale),NA,NA,No,TRUE,NA,NA,NA
10.1007/s12325-020-01599-1,33377987,results,1,NA,Sample size of the population of interest in the non IPD treatment arm,NA,NA,110,TRUE,NA,NA,NA
10.1007/s12325-020-01599-1,33377987,results,1,NA,Initial sample size of the population of interest in the IPD treatment arm,NA,NA,117,TRUE,NA,NA,NA
10.1007/s12325-020-01599-1,33377987,results,1,NA,"Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC",NA,NA,81,TRUE,NA,NA,NA
10.1007/s12325-020-01599-1,33377987,results,1,NA,Reporting of a weights' distribution evaluation (MAIC),NA,NA,Not mentioned,TRUE,NA,NA,NA
10.1007/s12325-020-01599-1,33377987,results,1,NA,Reporting of the list of the covariates adjusted for/matched on,NA,NA,Yes,TRUE,NA,NA,NA
10.1007/s12325-020-01599-1,33377987,results,1,NA,Number of covariates adjusted for/matched on,NA,NA,6,TRUE,NA,NA,NA
10.1007/s12325-020-01599-1,33377987,results,1,NA,Covariates adjusted for/matched on in the indirect comparison,NA,NA,"Age, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Race/ethnicity, Other(s)",TRUE,NA,NA,NA
10.1007/s12325-020-01599-1,33377987,results,1,NA,Primary outcome: treatment effect contrast,NA,NA,Means difference,TRUE,NA,NA,NA
10.1007/s12325-020-01599-1,33377987,results,1,NA,Direction of the treatment effect contrast: IPD treatment is:,NA,NA,"Numerator if ratio, or left side if difference",TRUE,NA,NA,NA
10.1007/s12325-020-01599-1,33377987,results,1,NA,Primary outcome: unadjusted treatment effect,NA,NA,-2,TRUE,NA,NA,NA
10.1007/s12325-020-01599-1,33377987,results,1,NA,"p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])",NA,NA,[-3.5;-0.4],TRUE,NA,NA,NA
10.1007/s12325-020-01599-1,33377987,results,1,NA,Primary outcome: adjusted treatment effect,NA,NA,-1.9,TRUE,NA,NA,NA
10.1007/s12325-020-01599-1,33377987,results,1,NA,"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])",NA,NA,[-3.5;-0.4],TRUE,NA,NA,NA
10.1007/s12325-020-01599-1,33377987,results,2,NA,Sample size of the population of interest in the non IPD treatment arm,NA,NA,24,TRUE,NA,NA,NA
10.1007/s12325-020-01599-1,33377987,results,2,NA,Initial sample size of the population of interest in the IPD treatment arm,NA,NA,117,TRUE,NA,NA,NA
10.1007/s12325-020-01599-1,33377987,results,2,NA,"Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC",NA,NA,62,TRUE,NA,NA,NA
10.1007/s12325-020-01599-1,33377987,results,2,NA,Reporting of a weights' distribution evaluation (MAIC),NA,NA,Not mentioned,TRUE,NA,NA,NA
10.1007/s12325-020-01599-1,33377987,results,2,NA,Reporting of the list of the covariates adjusted for/matched on,NA,NA,Yes,TRUE,NA,NA,NA
10.1007/s12325-020-01599-1,33377987,results,2,NA,Number of covariates adjusted for/matched on,NA,NA,6,TRUE,NA,NA,NA
10.1007/s12325-020-01599-1,33377987,results,2,NA,Covariates adjusted for/matched on in the indirect comparison,NA,NA,"Age, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Race/ethnicity, Other(s)",TRUE,NA,NA,NA
10.1007/s12325-020-01599-1,33377987,results,2,NA,Primary outcome: treatment effect contrast,NA,NA,Means difference,TRUE,NA,NA,NA
10.1007/s12325-020-01599-1,33377987,results,2,NA,Direction of the treatment effect contrast: IPD treatment is:,NA,NA,"Numerator if ratio, or left side if difference",TRUE,NA,NA,NA
10.1007/s12325-020-01599-1,33377987,results,2,NA,Primary outcome: unadjusted treatment effect,NA,NA,-2,TRUE,NA,NA,NA
10.1007/s12325-020-01599-1,33377987,results,2,NA,"p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])",[-4.6;-0.4],[-4.6;0.6],[-4.6;0.6],FALSE,NA,NA,NA
10.1007/s12325-020-01599-1,33377987,results,2,NA,Primary outcome: adjusted treatment effect,NA,NA,-1.6,TRUE,NA,NA,NA
10.1007/s12325-020-01599-1,33377987,results,2,NA,"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])",NA,NA,[-4.2;1.1],TRUE,NA,NA,NA
10.1007/s12325-020-01599-1,33377987,results,3,NA,Sample size of the population of interest in the non IPD treatment arm,NA,NA,43,TRUE,NA,NA,NA
10.1007/s12325-020-01599-1,33377987,results,3,NA,Initial sample size of the population of interest in the IPD treatment arm,NA,NA,117,TRUE,NA,NA,NA
10.1007/s12325-020-01599-1,33377987,results,3,NA,"Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC",43,79,79,FALSE,NA,NA,NA
10.1007/s12325-020-01599-1,33377987,results,3,NA,Reporting of a weights' distribution evaluation (MAIC),NA,NA,Not mentioned,TRUE,NA,NA,NA
10.1007/s12325-020-01599-1,33377987,results,3,NA,Reporting of the list of the covariates adjusted for/matched on,NA,NA,Yes,TRUE,NA,NA,NA
10.1007/s12325-020-01599-1,33377987,results,3,NA,Number of covariates adjusted for/matched on,NA,NA,6,TRUE,NA,NA,NA
10.1007/s12325-020-01599-1,33377987,results,3,NA,Covariates adjusted for/matched on in the indirect comparison,NA,NA,"Age, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Race/ethnicity, Other(s)",TRUE,NA,NA,NA
10.1007/s12325-020-01599-1,33377987,results,3,NA,Primary outcome: treatment effect contrast,NA,NA,Means difference,TRUE,NA,NA,NA
10.1007/s12325-020-01599-1,33377987,results,3,NA,Direction of the treatment effect contrast: IPD treatment is:,NA,NA,"Numerator if ratio, or left side if difference",TRUE,NA,NA,NA
10.1007/s12325-020-01599-1,33377987,results,3,NA,Primary outcome: unadjusted treatment effect,NA,NA,-0.4,TRUE,NA,NA,NA
10.1007/s12325-020-01599-1,33377987,results,3,NA,"p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])",NA,NA,[-1.9;1.1],TRUE,NA,NA,NA
10.1007/s12325-020-01599-1,33377987,results,3,NA,Primary outcome: adjusted treatment effect,NA,NA,-0.6,TRUE,NA,NA,NA
10.1007/s12325-020-01599-1,33377987,results,3,NA,"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])",NA,NA,[-2.0;0.8],TRUE,NA,NA,NA
10.1007/s12325-020-01599-1,33377987,results,4,NA,Sample size of the population of interest in the non IPD treatment arm,NA,NA,43,TRUE,NA,NA,NA
10.1007/s12325-020-01599-1,33377987,results,4,NA,Initial sample size of the population of interest in the IPD treatment arm,NA,NA,117,TRUE,NA,NA,NA
10.1007/s12325-020-01599-1,33377987,results,4,NA,"Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC",NA,NA,45,TRUE,NA,NA,NA
10.1007/s12325-020-01599-1,33377987,results,4,NA,Reporting of a weights' distribution evaluation (MAIC),NA,NA,Not mentioned,TRUE,NA,NA,NA
10.1007/s12325-020-01599-1,33377987,results,4,NA,Reporting of the list of the covariates adjusted for/matched on,NA,NA,Yes,TRUE,NA,NA,NA
10.1007/s12325-020-01599-1,33377987,results,4,NA,Number of covariates adjusted for/matched on,NA,NA,6,TRUE,NA,NA,NA
10.1007/s12325-020-01599-1,33377987,results,4,NA,Covariates adjusted for/matched on in the indirect comparison,NA,NA,"Age, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Race/ethnicity, Other(s)",TRUE,NA,NA,NA
10.1007/s12325-020-01599-1,33377987,results,4,NA,Primary outcome: treatment effect contrast,NA,NA,Means difference,TRUE,NA,NA,NA
10.1007/s12325-020-01599-1,33377987,results,4,NA,Direction of the treatment effect contrast: IPD treatment is:,NA,NA,"Numerator if ratio, or left side if difference",TRUE,NA,NA,NA
10.1007/s12325-020-01599-1,33377987,results,4,NA,Primary outcome: unadjusted treatment effect,NA,NA,-3.5,TRUE,NA,NA,NA
10.1007/s12325-020-01599-1,33377987,results,4,NA,"p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])",NA,NA,[-6.6;-0.4],TRUE,NA,NA,NA
10.1007/s12325-020-01599-1,33377987,results,4,NA,Primary outcome: adjusted treatment effect,NA,NA,-3.3,TRUE,NA,NA,NA
10.1007/s12325-020-01599-1,33377987,results,4,NA,"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])",[-6.4;-0.2],0.04,[-6.4;-0.2],FALSE,NA,NA,NA
10.1177/1756286420975916,33488773,general_information,NA,NA,Medical Condition of Interest Name,relapsing multiple sclerosis,"relapsing forms of multiple sclerosis,",XXXX,FALSE,NA,NA,NA
10.1177/1756286420975916,33488773,general_information,NA,NA,Countries of first author affiliations,NA,NA,usa,TRUE,NA,NA,NA
10.1177/1756286420975916,33488773,general_information,NA,NA,Countries of last author affiliations,NA,NA,usa,TRUE,NA,NA,NA
10.1177/1756286420975916,33488773,general_information,NA,NA,"Positions of study investigators (for any authors of the article, any that applies)",NA,NA,"Academic, Pharmaceutical Industry",TRUE,NA,NA,NA
10.1177/1756286420975916,33488773,general_information,NA,NA,"At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company",NA,NA,Not mentioned,TRUE,NA,NA,NA
10.1177/1756286420975916,33488773,general_information,NA,NA,Mentioned sources of funding,NA,NA,Pharmaceutical Industry,TRUE,NA,NA,NA
10.1177/1756286420975916,33488773,general_information,NA,NA,"Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article",NA,NA,Yes,TRUE,NA,NA,NA
10.1177/1756286420975916,33488773,general_information,NA,NA,Mention of a systematic review to find the studies to compare treatments of interest,NA,NA,No,TRUE,NA,NA,NA
10.1177/1756286420975916,33488773,study_information,NA,1,Patient-level data used,NA,NA,Yes,TRUE,NA,NA,NA
10.1177/1756286420975916,33488773,study_information,NA,1,Clinical Trial,NA,NA,Yes,TRUE,NA,NA,NA
10.1177/1756286420975916,33488773,study_information,NA,1,NCT (only for clinical trial registered on clinicaltrials.gov),NA,NA,NCT00906399,TRUE,NA,NA,NA
10.1177/1756286420975916,33488773,study_information,NA,1,Country where the clinical trial/observational study was conducted (international if more than one),NA,NA,international,TRUE,NA,NA,NA
10.1177/1756286420975916,33488773,study_information,NA,1,Phase of the clinical trial (clinical trial only),NA,NA,3,TRUE,NA,NA,NA
10.1177/1756286420975916,33488773,study_information,NA,1,Number of treatment arms (clinical trial only),NA,NA,2 or more,TRUE,NA,NA,NA
10.1177/1756286420975916,33488773,study_information,NA,2,Patient-level data used,NA,NA,No,TRUE,NA,NA,NA
10.1177/1756286420975916,33488773,study_information,NA,2,Clinical Trial,NA,NA,Yes,TRUE,NA,NA,NA
10.1177/1756286420975916,33488773,study_information,NA,2,NCT (only for clinical trial registered on clinicaltrials.gov),NA,NA,NCT01067521,TRUE,NA,NA,NA
10.1177/1756286420975916,33488773,study_information,NA,2,Country where the clinical trial/observational study was conducted (international if more than one),NA,NA,international,TRUE,NA,NA,NA
10.1177/1756286420975916,33488773,study_information,NA,2,Phase of the clinical trial (clinical trial only),NA,NA,3,TRUE,NA,NA,NA
10.1177/1756286420975916,33488773,study_information,NA,2,Number of treatment arms (clinical trial only),NA,NA,2 or more,TRUE,NA,NA,NA
10.1177/1756286420975916,33488773,methodology,1,NA,Treatment name 1,NA,NA,peginterferon beta-1a,TRUE,NA,"ARR difference = -0.04 (Have not been calculated by the authors)

ARR = rate OR continuous ???",NA
10.1177/1756286420975916,33488773,methodology,1,NA,Study 'number(s)' for treatment 1,NA,NA,1,TRUE,NA,NA,NA
10.1177/1756286420975916,33488773,methodology,1,NA,Treatment name 2,NA,NA,glatiramer acetate,TRUE,NA,NA,NA
10.1177/1756286420975916,33488773,methodology,1,NA,Study 'number(s)' for treatment 2,NA,NA,2,TRUE,NA,NA,NA
10.1177/1756286420975916,33488773,methodology,1,NA,Type of population-adjusted indirect comparisons performed,NA,NA,MAIC,TRUE,NA,NA,NA
10.1177/1756286420975916,33488773,methodology,1,NA,Anchored comparison?,NA,NA,No,TRUE,NA,NA,NA
10.1177/1756286420975916,33488773,methodology,1,NA,Form of the indirect comparison,NA,NA,Simple (ie treatments effects extracted from two studies),TRUE,NA,NA,NA
10.1177/1756286420975916,33488773,methodology,1,NA,Definition of a single primary outcome for the indirect comparison,NA,NA,"No primary outcome defined, or multiple primary outcomes without any clear distinction between them",TRUE,NA,NA,NA
10.1177/1756286420975916,33488773,methodology,1,NA,Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined),annualized relapse rate,annualized relapse rate (arr) at 1 year,annualized relapse rate (arr) at 1 year,FALSE,NA,NA,NA
10.1177/1756286420975916,33488773,methodology,1,NA,Primary outcome: variable type,Binary (eg rates),"Continuous (count, mean, ...)",Binary (eg rates),FALSE,NA,NA,NA
10.1177/1756286420975916,33488773,methodology,1,NA,Justification for selecting variables to be included in the adjustment model (in the main text),NA,NA,"Nothing mentioned, not reported",TRUE,NA,NA,NA
10.1177/1756286420975916,33488773,methodology,1,NA,Inclusion of prognostic factors in the adjustment/matching model,NA,NA,No discussion (in the main text) of the status of prognostic factors of the variables,TRUE,NA,NA,NA
10.1177/1756286420975916,33488773,methodology,1,NA,Inclusion of treatment-effect modifiers in the adjustment/matching model,NA,NA,No discussion (in the main text) of the status of treatment-effect modifiers of the variables,TRUE,NA,NA,NA
10.1177/1756286420975916,33488773,methodology,1,NA,"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)",NA,NA,No,TRUE,NA,NA,NA
10.1177/1756286420975916,33488773,methodology,1,NA,Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale),NA,NA,No,TRUE,NA,NA,NA
10.1177/1756286420975916,33488773,results,1,NA,Sample size of the population of interest in the non IPD treatment arm,NA,NA,834,TRUE,NA,NA,NA
10.1177/1756286420975916,33488773,results,1,NA,Initial sample size of the population of interest in the IPD treatment arm,NA,NA,407,TRUE,NA,NA,NA
10.1177/1756286420975916,33488773,results,1,NA,"Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC",NA,NA,276,TRUE,NA,NA,NA
10.1177/1756286420975916,33488773,results,1,NA,Reporting of a weights' distribution evaluation (MAIC),NA,NA,Not mentioned,TRUE,NA,NA,NA
10.1177/1756286420975916,33488773,results,1,NA,Reporting of the list of the covariates adjusted for/matched on,NA,NA,Yes,TRUE,NA,NA,NA
10.1177/1756286420975916,33488773,results,1,NA,Number of covariates adjusted for/matched on,NA,NA,5,TRUE,NA,NA,NA
10.1177/1756286420975916,33488773,results,1,NA,Covariates adjusted for/matched on in the indirect comparison,"Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease)","Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Other(s)","Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Other(s)",FALSE,NA,NA,NA
10.1177/1756286420975916,33488773,results,1,NA,Primary outcome: treatment effect contrast,Rate difference,"Aucune ""mesure"" n'est calculÃ©e : test de diffÃ©rence",Rate difference,FALSE,NA,NA,NA
10.1177/1756286420975916,33488773,results,1,NA,Direction of the treatment effect contrast: IPD treatment is:,"Numerator if ratio, or left side if difference",NA,"Numerator if ratio, or left side if difference",FALSE,NA,NA,NA
10.1177/1756286420975916,33488773,results,1,NA,Primary outcome: adjusted treatment effect,-0.04,NA,-0.04,FALSE,NA,NA,NA
10.1177/1756286420975916,33488773,results,1,NA,"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])",0.278,0.375,0.375,FALSE,NA,NA,NA
10.2217/cer-2020-0272,33626934,general_information,NA,NA,Medical Condition of Interest Name,hr+/her2- advanced breast cancer,hormone receptor-positive/her2-negative advanced breast cancer,XXXX,FALSE,NA,NA,NA
10.2217/cer-2020-0272,33626934,general_information,NA,NA,Countries of first author affiliations,NA,NA,usa,TRUE,NA,NA,NA
10.2217/cer-2020-0272,33626934,general_information,NA,NA,Countries of last author affiliations,canada,usa,XXXX,FALSE,NA,NA,NA
10.2217/cer-2020-0272,33626934,general_information,NA,NA,"Positions of study investigators (for any authors of the article, any that applies)",NA,NA,"Academic, Pharmaceutical Industry, Private Data Analysis Company",TRUE,NA,NA,NA
10.2217/cer-2020-0272,33626934,general_information,NA,NA,"At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company",NA,NA,Yes,TRUE,NA,NA,NA
10.2217/cer-2020-0272,33626934,general_information,NA,NA,Mentioned sources of funding,NA,NA,Pharmaceutical Industry,TRUE,NA,NA,NA
10.2217/cer-2020-0272,33626934,general_information,NA,NA,"Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article",NA,NA,Yes,TRUE,NA,NA,NA
10.2217/cer-2020-0272,33626934,general_information,NA,NA,Mention of a systematic review to find the studies to compare treatments of interest,NA,NA,No,TRUE,NA,NA,NA
10.2217/cer-2020-0272,33626934,study_information,NA,1,Patient-level data used,NA,NA,Yes,TRUE,NA,NA,NA
10.2217/cer-2020-0272,33626934,study_information,NA,1,Clinical Trial,NA,NA,Yes,TRUE,NA,NA,NA
10.2217/cer-2020-0272,33626934,study_information,NA,1,NCT (only for clinical trial registered on clinicaltrials.gov),NA,NA,NCT01942135,TRUE,NA,NA,NA
10.2217/cer-2020-0272,33626934,study_information,NA,1,Country where the clinical trial/observational study was conducted (international if more than one),NA,NA,international,TRUE,NA,NA,NA
10.2217/cer-2020-0272,33626934,study_information,NA,1,Phase of the clinical trial (clinical trial only),NA,NA,3,TRUE,NA,NA,NA
10.2217/cer-2020-0272,33626934,study_information,NA,1,Number of treatment arms (clinical trial only),NA,NA,2 or more,TRUE,NA,NA,NA
10.2217/cer-2020-0272,33626934,study_information,NA,2,Patient-level data used,NA,NA,No,TRUE,NA,NA,NA
10.2217/cer-2020-0272,33626934,study_information,NA,2,Clinical Trial,NA,NA,Yes,TRUE,NA,NA,NA
10.2217/cer-2020-0272,33626934,study_information,NA,2,NCT (only for clinical trial registered on clinicaltrials.gov),NA,NA,NCT02107703,TRUE,NA,NA,NA
10.2217/cer-2020-0272,33626934,study_information,NA,2,Country where the clinical trial/observational study was conducted (international if more than one),NA,NA,international,TRUE,NA,NA,NA
10.2217/cer-2020-0272,33626934,study_information,NA,2,Phase of the clinical trial (clinical trial only),NA,NA,3,TRUE,NA,NA,NA
10.2217/cer-2020-0272,33626934,study_information,NA,2,Number of treatment arms (clinical trial only),NA,NA,2 or more,TRUE,NA,NA,NA
10.2217/cer-2020-0272,33626934,study_information,NA,3,Patient-level data used,NA,NA,No,TRUE,NA,NA,NA
10.2217/cer-2020-0272,33626934,study_information,NA,3,Clinical Trial,NA,NA,Yes,TRUE,NA,NA,NA
10.2217/cer-2020-0272,33626934,study_information,NA,3,NCT (only for clinical trial registered on clinicaltrials.gov),NA,NA,NCT02422615,TRUE,NA,NA,NA
10.2217/cer-2020-0272,33626934,study_information,NA,3,Country where the clinical trial/observational study was conducted (international if more than one),NA,NA,international,TRUE,NA,NA,NA
10.2217/cer-2020-0272,33626934,study_information,NA,3,Phase of the clinical trial (clinical trial only),NA,NA,3,TRUE,NA,NA,NA
10.2217/cer-2020-0272,33626934,study_information,NA,3,Number of treatment arms (clinical trial only),NA,NA,2 or more,TRUE,NA,NA,NA
10.2217/cer-2020-0272,33626934,methodology,1,NA,Treatment name 1,palbociclib + fulvestran,palbociclib + fulvestrant,palbociclib + fulvestrant,FALSE,"Don't give the ESS per treatment arms, but only global = ESS = 135 (52% sample size reduction)
Comprises good example of illustrations for the MAIC step-by-step procedure (for future MAIC articles)","Region = other

N (2 arms) :
*N non-IPD = 669
*N IPD = 280
*ESS PALOMA-3 = 135",NA
10.2217/cer-2020-0272,33626934,methodology,1,NA,Study 'number(s)' for treatment 1,NA,NA,1,TRUE,NA,NA,NA
10.2217/cer-2020-0272,33626934,methodology,1,NA,Treatment name 2,NA,NA,abemaciclib + fulvestrant,TRUE,NA,NA,NA
10.2217/cer-2020-0272,33626934,methodology,1,NA,Study 'number(s)' for treatment 2,NA,NA,2,TRUE,NA,NA,NA
10.2217/cer-2020-0272,33626934,methodology,1,NA,Type of population-adjusted indirect comparisons performed,NA,NA,MAIC,TRUE,NA,NA,NA
10.2217/cer-2020-0272,33626934,methodology,1,NA,Anchored comparison?,NA,NA,Yes,TRUE,NA,NA,NA
10.2217/cer-2020-0272,33626934,methodology,1,NA,Form of the indirect comparison,NA,NA,Simple (ie treatments effects extracted from two studies),TRUE,NA,NA,NA
10.2217/cer-2020-0272,33626934,methodology,1,NA,Definition of a single primary outcome for the indirect comparison,NA,NA,Yes,TRUE,NA,NA,NA
10.2217/cer-2020-0272,33626934,methodology,1,NA,Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined),overall survival,overall survival (os),overall survival,FALSE,NA,NA,NA
10.2217/cer-2020-0272,33626934,methodology,1,NA,Primary outcome: variable type,NA,NA,Time-to-event,TRUE,NA,NA,NA
10.2217/cer-2020-0272,33626934,methodology,1,NA,Justification for selecting variables to be included in the adjustment model (in the main text),NA,NA,"Statistical imbalanced between treatment groups (independently of the status of prognostic/effect modifier), Status of prognostic factor/treatment effect modified assessed in the IPD dataset, A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion), Literature based (clinically or methodologically relevant to adjust on these variables based on the literature search conducted for this specific purpose)",TRUE,NA,NA,NA
10.2217/cer-2020-0272,33626934,methodology,1,NA,Inclusion of prognostic factors in the adjustment/matching model,NA,NA,No,TRUE,NA,NA,NA
10.2217/cer-2020-0272,33626934,methodology,1,NA,Inclusion of treatment-effect modifiers in the adjustment/matching model,NA,NA,Yes,TRUE,NA,NA,NA
10.2217/cer-2020-0272,33626934,methodology,1,NA,"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)",NA,NA,No,TRUE,NA,NA,NA
10.2217/cer-2020-0272,33626934,methodology,1,NA,Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale),NA,NA,No,TRUE,NA,NA,NA
10.2217/cer-2020-0272,33626934,methodology,2,NA,Treatment name 1,NA,NA,palbociclib + fulvestrant,TRUE,"Don't give the ESS per treatment arms, but only global = ESS = 64 (71% sample size reduction)","Region = other

N (2 arms) : 
*N non-IPD = 726 
*N IPD = 217 
*ESS PALOMA-3 = 64",NA
10.2217/cer-2020-0272,33626934,methodology,2,NA,Study 'number(s)' for treatment 1,NA,NA,1,TRUE,NA,NA,NA
10.2217/cer-2020-0272,33626934,methodology,2,NA,Treatment name 2,NA,NA,ribociclib + fulvestrant,TRUE,NA,NA,NA
10.2217/cer-2020-0272,33626934,methodology,2,NA,Study 'number(s)' for treatment 2,NA,NA,3,TRUE,NA,NA,NA
10.2217/cer-2020-0272,33626934,methodology,2,NA,Type of population-adjusted indirect comparisons performed,NA,NA,MAIC,TRUE,NA,NA,NA
10.2217/cer-2020-0272,33626934,methodology,2,NA,Anchored comparison?,NA,NA,Yes,TRUE,NA,NA,NA
10.2217/cer-2020-0272,33626934,methodology,2,NA,Form of the indirect comparison,NA,NA,Simple (ie treatments effects extracted from two studies),TRUE,NA,NA,NA
10.2217/cer-2020-0272,33626934,methodology,2,NA,Definition of a single primary outcome for the indirect comparison,NA,NA,Yes,TRUE,NA,NA,NA
10.2217/cer-2020-0272,33626934,methodology,2,NA,Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined),NA,NA,overall survival,TRUE,NA,NA,NA
10.2217/cer-2020-0272,33626934,methodology,2,NA,Primary outcome: variable type,NA,NA,Time-to-event,TRUE,NA,NA,NA
10.2217/cer-2020-0272,33626934,methodology,2,NA,Justification for selecting variables to be included in the adjustment model (in the main text),NA,NA,"Statistical imbalanced between treatment groups (independently of the status of prognostic/effect modifier), Status of prognostic factor/treatment effect modified assessed in the IPD dataset, A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion), Literature based (clinically or methodologically relevant to adjust on these variables based on the literature search conducted for this specific purpose)",TRUE,NA,NA,NA
10.2217/cer-2020-0272,33626934,methodology,2,NA,Inclusion of prognostic factors in the adjustment/matching model,NA,NA,No,TRUE,NA,NA,NA
10.2217/cer-2020-0272,33626934,methodology,2,NA,Inclusion of treatment-effect modifiers in the adjustment/matching model,NA,NA,Yes,TRUE,NA,NA,NA
10.2217/cer-2020-0272,33626934,methodology,2,NA,"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)",NA,NA,No,TRUE,NA,NA,NA
10.2217/cer-2020-0272,33626934,methodology,2,NA,Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale),NA,NA,No,TRUE,NA,NA,NA
10.2217/cer-2020-0272,33626934,results,1,NA,Initial sample size of the population of interest in the IPD treatment arm,NA,NA,183,TRUE,NA,NA,NA
10.2217/cer-2020-0272,33626934,results,1,NA,"If anchored comparison, initial sample size of the population of interest in the IPD anchor arm",NA,NA,97,TRUE,NA,NA,NA
10.2217/cer-2020-0272,33626934,results,1,NA,Reporting of a weights' distribution evaluation (MAIC),NA,NA,Not mentioned,TRUE,NA,NA,NA
10.2217/cer-2020-0272,33626934,results,1,NA,Reporting of the list of the covariates adjusted for/matched on,NA,NA,Yes,TRUE,NA,NA,NA
10.2217/cer-2020-0272,33626934,results,1,NA,Number of covariates adjusted for/matched on,NA,NA,12,TRUE,NA,NA,NA
10.2217/cer-2020-0272,33626934,results,1,NA,Covariates adjusted for/matched on in the indirect comparison,"Age, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Race/ethnicity, Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Past treatments for the disease of interest, Comorbidities and medical history (beside pathology/disease of interest in the comparison), Other(s)","Age, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Race/ethnicity, Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Past treatments for the disease of interest, Other(s)","Age, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Race/ethnicity, Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Past treatments for the disease of interest, Other(s)",FALSE,NA,NA,NA
10.2217/cer-2020-0272,33626934,results,1,NA,Primary outcome: treatment effect contrast,NA,NA,HR,TRUE,NA,NA,NA
10.2217/cer-2020-0272,33626934,results,1,NA,Direction of the treatment effect contrast: IPD treatment is:,NA,NA,"Numerator if ratio, or left side if difference",TRUE,NA,NA,NA
10.2217/cer-2020-0272,33626934,results,1,NA,Primary outcome: unadjusted treatment effect,1.09,1.02,1.02,FALSE,NA,NA,NA
10.2217/cer-2020-0272,33626934,results,1,NA,"p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])",[0.70;1.69],[0.69;1.52],[0.69;1.52],FALSE,NA,NA,NA
10.2217/cer-2020-0272,33626934,results,1,NA,Primary outcome: adjusted treatment effect,0.89,0.87,0.87,FALSE,NA,NA,NA
10.2217/cer-2020-0272,33626934,results,1,NA,"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])",[0.48;1.63],[0.54;1.40],[0.54;1.40],FALSE,NA,NA,NA
10.2217/cer-2020-0272,33626934,results,2,NA,Initial sample size of the population of interest in the IPD treatment arm,NA,NA,142,TRUE,NA,NA,NA
10.2217/cer-2020-0272,33626934,results,2,NA,"If anchored comparison, initial sample size of the population of interest in the IPD anchor arm",NA,NA,75,TRUE,NA,NA,NA
10.2217/cer-2020-0272,33626934,results,2,NA,Reporting of a weights' distribution evaluation (MAIC),NA,NA,Not mentioned,TRUE,NA,NA,NA
10.2217/cer-2020-0272,33626934,results,2,NA,Reporting of the list of the covariates adjusted for/matched on,NA,NA,Yes,TRUE,NA,NA,NA
10.2217/cer-2020-0272,33626934,results,2,NA,Number of covariates adjusted for/matched on,16,8,8,FALSE,NA,NA,NA
10.2217/cer-2020-0272,33626934,results,2,NA,Covariates adjusted for/matched on in the indirect comparison,"Age, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Race/ethnicity, Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Past treatments for the disease of interest, Comorbidities and medical history (beside pathology/disease of interest in the comparison), Other(s)","Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Race/ethnicity, Past treatments for the disease of interest, Other(s)","Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Race/ethnicity, Past treatments for the disease of interest, Other(s)",FALSE,NA,NA,NA
10.2217/cer-2020-0272,33626934,results,2,NA,Primary outcome: treatment effect contrast,NA,NA,HR,TRUE,NA,NA,NA
10.2217/cer-2020-0272,33626934,results,2,NA,Direction of the treatment effect contrast: IPD treatment is:,NA,NA,"Numerator if ratio, or left side if difference",TRUE,NA,NA,NA
10.2217/cer-2020-0272,33626934,results,2,NA,Primary outcome: unadjusted treatment effect,NA,NA,1.09,TRUE,NA,NA,NA
10.2217/cer-2020-0272,33626934,results,2,NA,"p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])",NA,NA,[0.70;1.69],TRUE,NA,NA,NA
10.2217/cer-2020-0272,33626934,results,2,NA,Primary outcome: adjusted treatment effect,NA,NA,0.89,TRUE,NA,NA,NA
10.2217/cer-2020-0272,33626934,results,2,NA,"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])",NA,NA,[0.48;1.63],TRUE,NA,NA,NA
10.2147/jbm.s288283,33664606,general_information,NA,NA,Medical Condition of Interest Name,hemophilia a without inhibitors,hemophilia a,XXXX,FALSE,NA,NA,NA
10.2147/jbm.s288283,33664606,general_information,NA,NA,Countries of first author affiliations,NA,NA,germany,TRUE,NA,NA,NA
10.2147/jbm.s288283,33664606,general_information,NA,NA,Countries of last author affiliations,NA,NA,usa,TRUE,NA,NA,NA
10.2147/jbm.s288283,33664606,general_information,NA,NA,"Positions of study investigators (for any authors of the article, any that applies)",NA,NA,"Academic, Pharmaceutical Industry, Private Data Analysis Company",TRUE,NA,NA,NA
10.2147/jbm.s288283,33664606,general_information,NA,NA,"At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company",NA,NA,Yes,TRUE,NA,NA,NA
10.2147/jbm.s288283,33664606,general_information,NA,NA,Mentioned sources of funding,NA,NA,Pharmaceutical Industry,TRUE,NA,NA,NA
10.2147/jbm.s288283,33664606,general_information,NA,NA,"Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article",NA,NA,Yes,TRUE,NA,NA,NA
10.2147/jbm.s288283,33664606,general_information,NA,NA,Mention of a systematic review to find the studies to compare treatments of interest,NA,NA,No,TRUE,NA,NA,NA
10.2147/jbm.s288283,33664606,study_information,NA,1,Patient-level data used,NA,NA,Yes,TRUE,NA,NA,NA
10.2147/jbm.s288283,33664606,study_information,NA,1,Clinical Trial,NA,NA,Yes,TRUE,NA,NA,NA
10.2147/jbm.s288283,33664606,study_information,NA,1,NCT (only for clinical trial registered on clinicaltrials.gov),NA,NA,NCT01181128,TRUE,NA,NA,NA
10.2147/jbm.s288283,33664606,study_information,NA,1,Country where the clinical trial/observational study was conducted (international if more than one),NA,NA,international,TRUE,NA,NA,NA
10.2147/jbm.s288283,33664606,study_information,NA,1,Phase of the clinical trial (clinical trial only),NA,NA,3,TRUE,NA,NA,NA
10.2147/jbm.s288283,33664606,study_information,NA,1,Number of treatment arms (clinical trial only),1,2 or more,XXXX,FALSE,NA,NA,NA
10.2147/jbm.s288283,33664606,study_information,NA,2,Patient-level data used,NA,NA,No,TRUE,NA,NA,NA
10.2147/jbm.s288283,33664606,study_information,NA,2,Clinical Trial,NA,NA,Yes,TRUE,NA,NA,NA
10.2147/jbm.s288283,33664606,study_information,NA,2,NCT (only for clinical trial registered on clinicaltrials.gov),NCT02622321,NCT02847637,NCT02847637,FALSE,NA,NA,NA
10.2147/jbm.s288283,33664606,study_information,NA,2,Country where the clinical trial/observational study was conducted (international if more than one),NA,NA,international,TRUE,NA,NA,NA
10.2147/jbm.s288283,33664606,study_information,NA,2,Phase of the clinical trial (clinical trial only),NA,NA,3,TRUE,NA,NA,NA
10.2147/jbm.s288283,33664606,study_information,NA,2,Number of treatment arms (clinical trial only),1,2 or more,XXXX,FALSE,NA,NA,NA
10.2147/jbm.s288283,33664606,study_information,NA,3,Patient-level data used,NA,No,XXXX,FALSE,NA,NA,NA
10.2147/jbm.s288283,33664606,study_information,NA,3,Clinical Trial,NA,Yes,XXXX,FALSE,NA,NA,NA
10.2147/jbm.s288283,33664606,study_information,NA,3,NCT (only for clinical trial registered on clinicaltrials.gov),NA,NCT03020160,NCT03020160,FALSE,NA,NA,NA
10.2147/jbm.s288283,33664606,study_information,NA,3,Country where the clinical trial/observational study was conducted (international if more than one),NA,international,XXXX,FALSE,NA,NA,NA
10.2147/jbm.s288283,33664606,study_information,NA,3,Phase of the clinical trial (clinical trial only),NA,3,XXXX,FALSE,NA,NA,NA
10.2147/jbm.s288283,33664606,study_information,NA,3,Number of treatment arms (clinical trial only),NA,1,XXXX,FALSE,NA,NA,NA
10.2147/jbm.s288283,33664606,methodology,1,NA,Treatment name 1,NA,NA,rfviiifc,TRUE,"Unduly say that NMA is unfeasible that's why they do a MAIC, missing the point that anchored MAIC is unfeasible and that's why they do an unanchored MAIC",Q1W regimen,NA
10.2147/jbm.s288283,33664606,methodology,1,NA,Study 'number(s)' for treatment 1,NA,NA,1,TRUE,NA,NA,NA
10.2147/jbm.s288283,33664606,methodology,1,NA,Treatment name 2,emicizumab every week,emicizumab q1w,emicizumab every week,FALSE,NA,NA,NA
10.2147/jbm.s288283,33664606,methodology,1,NA,Study 'number(s)' for treatment 2,NA,NA,2,TRUE,NA,NA,NA
10.2147/jbm.s288283,33664606,methodology,1,NA,Type of population-adjusted indirect comparisons performed,NA,NA,MAIC,TRUE,NA,NA,NA
10.2147/jbm.s288283,33664606,methodology,1,NA,Anchored comparison?,NA,NA,No,TRUE,NA,NA,NA
10.2147/jbm.s288283,33664606,methodology,1,NA,Form of the indirect comparison,Simple (ie treatments effects extracted from two studies),"Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate)",Simple (ie treatments effects extracted from two studies),FALSE,NA,NA,NA
10.2147/jbm.s288283,33664606,methodology,1,NA,Definition of a single primary outcome for the indirect comparison,NA,NA,"No primary outcome defined, or multiple primary outcomes without any clear distinction between them",TRUE,NA,NA,NA
10.2147/jbm.s288283,33664606,methodology,1,NA,Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined),mean annualized bleeding rate,annualized bleeding rate (abr),mean annualized bleeding rate,FALSE,NA,NA,NA
10.2147/jbm.s288283,33664606,methodology,1,NA,Primary outcome: variable type,NA,NA,Binary (eg rates),TRUE,NA,NA,NA
10.2147/jbm.s288283,33664606,methodology,1,NA,Justification for selecting variables to be included in the adjustment model (in the main text),NA,NA,"Nothing mentioned, not reported",TRUE,NA,NA,NA
10.2147/jbm.s288283,33664606,methodology,1,NA,Inclusion of prognostic factors in the adjustment/matching model,NA,NA,No discussion (in the main text) of the status of prognostic factors of the variables,TRUE,NA,NA,NA
10.2147/jbm.s288283,33664606,methodology,1,NA,Inclusion of treatment-effect modifiers in the adjustment/matching model,NA,NA,No discussion (in the main text) of the status of treatment-effect modifiers of the variables,TRUE,NA,NA,NA
10.2147/jbm.s288283,33664606,methodology,1,NA,"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)",Yes,No,Yes,FALSE,NA,NA,NA
10.2147/jbm.s288283,33664606,methodology,1,NA,Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale),NA,NA,No,TRUE,NA,NA,NA
10.2147/jbm.s288283,33664606,methodology,2,NA,Treatment name 1,NA,NA,rfviiifc,TRUE,NA,Emicizumab Q2W regimen,NA
10.2147/jbm.s288283,33664606,methodology,2,NA,Study 'number(s)' for treatment 1,NA,NA,1,TRUE,NA,NA,NA
10.2147/jbm.s288283,33664606,methodology,2,NA,Treatment name 2,emicizumab every 2 weeks,emicizumab q2w regimen,emicizumab every 2 weeks,FALSE,NA,NA,NA
10.2147/jbm.s288283,33664606,methodology,2,NA,Study 'number(s)' for treatment 2,NA,NA,2,TRUE,NA,NA,NA
10.2147/jbm.s288283,33664606,methodology,2,NA,Type of population-adjusted indirect comparisons performed,NA,NA,MAIC,TRUE,NA,NA,NA
10.2147/jbm.s288283,33664606,methodology,2,NA,Anchored comparison?,NA,NA,No,TRUE,NA,NA,NA
10.2147/jbm.s288283,33664606,methodology,2,NA,Form of the indirect comparison,NA,NA,Simple (ie treatments effects extracted from two studies),TRUE,NA,NA,NA
10.2147/jbm.s288283,33664606,methodology,2,NA,Definition of a single primary outcome for the indirect comparison,NA,NA,"No primary outcome defined, or multiple primary outcomes without any clear distinction between them",TRUE,NA,NA,NA
10.2147/jbm.s288283,33664606,methodology,2,NA,Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined),mean annualized bleeding rate,annualized bleeding rate (abr),mean annualized bleeding rate,FALSE,NA,NA,NA
10.2147/jbm.s288283,33664606,methodology,2,NA,Primary outcome: variable type,NA,NA,Binary (eg rates),TRUE,NA,NA,NA
10.2147/jbm.s288283,33664606,methodology,2,NA,Justification for selecting variables to be included in the adjustment model (in the main text),NA,NA,"Nothing mentioned, not reported",TRUE,NA,NA,NA
10.2147/jbm.s288283,33664606,methodology,2,NA,Inclusion of prognostic factors in the adjustment/matching model,NA,NA,No discussion (in the main text) of the status of prognostic factors of the variables,TRUE,NA,NA,NA
10.2147/jbm.s288283,33664606,methodology,2,NA,Inclusion of treatment-effect modifiers in the adjustment/matching model,NA,NA,No discussion (in the main text) of the status of treatment-effect modifiers of the variables,TRUE,NA,NA,NA
10.2147/jbm.s288283,33664606,methodology,2,NA,"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)",Yes,No,Yes,FALSE,NA,NA,NA
10.2147/jbm.s288283,33664606,methodology,2,NA,Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale),NA,NA,No,TRUE,NA,NA,NA
10.2147/jbm.s288283,33664606,methodology,3,NA,Treatment name 1,NA,NA,rfviiifc,TRUE,NA,Emicizumab Q4W regimen,NA
10.2147/jbm.s288283,33664606,methodology,3,NA,Study 'number(s)' for treatment 1,NA,NA,1,TRUE,NA,NA,NA
10.2147/jbm.s288283,33664606,methodology,3,NA,Treatment name 2,emicizumab every 4 weeks,emicizumab q4w regimen,emicizumab every 4 weeks,FALSE,NA,NA,NA
10.2147/jbm.s288283,33664606,methodology,3,NA,Study 'number(s)' for treatment 2,2,3,3,FALSE,NA,NA,NA
10.2147/jbm.s288283,33664606,methodology,3,NA,Type of population-adjusted indirect comparisons performed,NA,NA,MAIC,TRUE,NA,NA,NA
10.2147/jbm.s288283,33664606,methodology,3,NA,Anchored comparison?,NA,NA,No,TRUE,NA,NA,NA
10.2147/jbm.s288283,33664606,methodology,3,NA,Form of the indirect comparison,NA,NA,Simple (ie treatments effects extracted from two studies),TRUE,NA,NA,NA
10.2147/jbm.s288283,33664606,methodology,3,NA,Definition of a single primary outcome for the indirect comparison,NA,NA,"No primary outcome defined, or multiple primary outcomes without any clear distinction between them",TRUE,NA,NA,NA
10.2147/jbm.s288283,33664606,methodology,3,NA,Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined),mean annualized bleeding rate,annualized bleeding rate (abr),mean annualized bleeding rate,FALSE,NA,NA,NA
10.2147/jbm.s288283,33664606,methodology,3,NA,Primary outcome: variable type,NA,NA,Binary (eg rates),TRUE,NA,NA,NA
10.2147/jbm.s288283,33664606,methodology,3,NA,Justification for selecting variables to be included in the adjustment model (in the main text),NA,NA,"Nothing mentioned, not reported",TRUE,NA,NA,NA
10.2147/jbm.s288283,33664606,methodology,3,NA,Inclusion of prognostic factors in the adjustment/matching model,NA,NA,No discussion (in the main text) of the status of prognostic factors of the variables,TRUE,NA,NA,NA
10.2147/jbm.s288283,33664606,methodology,3,NA,Inclusion of treatment-effect modifiers in the adjustment/matching model,NA,NA,No discussion (in the main text) of the status of treatment-effect modifiers of the variables,TRUE,NA,NA,NA
10.2147/jbm.s288283,33664606,methodology,3,NA,"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)",Yes,No,Yes,FALSE,NA,NA,NA
10.2147/jbm.s288283,33664606,methodology,3,NA,Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale),NA,NA,No,TRUE,NA,NA,NA
10.2147/jbm.s288283,33664606,results,1,NA,Sample size of the population of interest in the non IPD treatment arm,NA,NA,99,TRUE,NA,NA,NA
10.2147/jbm.s288283,33664606,results,1,NA,Initial sample size of the population of interest in the IPD treatment arm,NA,NA,117,TRUE,NA,NA,NA
10.2147/jbm.s288283,33664606,results,1,NA,"Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC",NA,NA,94,TRUE,NA,NA,NA
10.2147/jbm.s288283,33664606,results,1,NA,Reporting of a weights' distribution evaluation (MAIC),NA,NA,Not mentioned,TRUE,NA,NA,NA
10.2147/jbm.s288283,33664606,results,1,NA,Reporting of the list of the covariates adjusted for/matched on,NA,NA,Yes,TRUE,NA,NA,NA
10.2147/jbm.s288283,33664606,results,1,NA,Number of covariates adjusted for/matched on,NA,NA,5,TRUE,NA,NA,NA
10.2147/jbm.s288283,33664606,results,1,NA,Covariates adjusted for/matched on in the indirect comparison,"Age, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Race/ethnicity, Past treatments for the disease of interest","Age, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Race/ethnicity, Past treatments for the disease of interest, Other(s)","Age, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Race/ethnicity, Past treatments for the disease of interest",FALSE,NA,NA,NA
10.2147/jbm.s288283,33664606,results,1,NA,Primary outcome: treatment effect contrast,NA,NA,Incidence Rate Ratio,TRUE,NA,NA,NA
10.2147/jbm.s288283,33664606,results,1,NA,Direction of the treatment effect contrast: IPD treatment is:,NA,NA,"Numerator if ratio, or left side if difference",TRUE,NA,NA,NA
10.2147/jbm.s288283,33664606,results,1,NA,Primary outcome: adjusted treatment effect,NA,NA,0.93,TRUE,NA,NA,NA
10.2147/jbm.s288283,33664606,results,1,NA,"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])",NA,NA,[0.63;1.39],TRUE,NA,NA,NA
10.2147/jbm.s288283,33664606,results,2,NA,Sample size of the population of interest in the non IPD treatment arm,NA,NA,35,TRUE,NA,NA,NA
10.2147/jbm.s288283,33664606,results,2,NA,Initial sample size of the population of interest in the IPD treatment arm,NA,NA,117,TRUE,NA,NA,NA
10.2147/jbm.s288283,33664606,results,2,NA,"Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC",NA,NA,19,TRUE,NA,NA,NA
10.2147/jbm.s288283,33664606,results,2,NA,Reporting of a weights' distribution evaluation (MAIC),NA,NA,Not mentioned,TRUE,NA,NA,NA
10.2147/jbm.s288283,33664606,results,2,NA,Reporting of the list of the covariates adjusted for/matched on,NA,NA,Yes,TRUE,NA,NA,NA
10.2147/jbm.s288283,33664606,results,2,NA,Number of covariates adjusted for/matched on,NA,NA,5,TRUE,NA,NA,NA
10.2147/jbm.s288283,33664606,results,2,NA,Covariates adjusted for/matched on in the indirect comparison,"Age, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Race/ethnicity, Past treatments for the disease of interest","Age, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Race/ethnicity, Past treatments for the disease of interest, Other(s)","Age, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Race/ethnicity, Past treatments for the disease of interest",FALSE,NA,NA,NA
10.2147/jbm.s288283,33664606,results,2,NA,Primary outcome: treatment effect contrast,NA,NA,Incidence Rate Ratio,TRUE,NA,NA,NA
10.2147/jbm.s288283,33664606,results,2,NA,Direction of the treatment effect contrast: IPD treatment is:,NA,NA,"Numerator if ratio, or left side if difference",TRUE,NA,NA,NA
10.2147/jbm.s288283,33664606,results,2,NA,Primary outcome: adjusted treatment effect,NA,NA,0.57,TRUE,NA,NA,NA
10.2147/jbm.s288283,33664606,results,2,NA,"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])",NA,NA,[0.28;1.17],TRUE,NA,NA,NA
10.2147/jbm.s288283,33664606,results,3,NA,Sample size of the population of interest in the non IPD treatment arm,NA,NA,41,TRUE,NA,NA,NA
10.2147/jbm.s288283,33664606,results,3,NA,Initial sample size of the population of interest in the IPD treatment arm,NA,NA,117,TRUE,NA,NA,NA
10.2147/jbm.s288283,33664606,results,3,NA,"Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC",NA,NA,36,TRUE,NA,NA,NA
10.2147/jbm.s288283,33664606,results,3,NA,Reporting of a weights' distribution evaluation (MAIC),NA,NA,Not mentioned,TRUE,NA,NA,NA
10.2147/jbm.s288283,33664606,results,3,NA,Reporting of the list of the covariates adjusted for/matched on,NA,NA,Yes,TRUE,NA,NA,NA
10.2147/jbm.s288283,33664606,results,3,NA,Number of covariates adjusted for/matched on,NA,NA,5,TRUE,NA,NA,NA
10.2147/jbm.s288283,33664606,results,3,NA,Covariates adjusted for/matched on in the indirect comparison,"Age, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Race/ethnicity, Past treatments for the disease of interest","Age, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Race/ethnicity, Past treatments for the disease of interest, Other(s)","Age, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Race/ethnicity, Past treatments for the disease of interest",FALSE,NA,NA,NA
10.2147/jbm.s288283,33664606,results,3,NA,Primary outcome: treatment effect contrast,NA,NA,Incidence Rate Ratio,TRUE,NA,NA,NA
10.2147/jbm.s288283,33664606,results,3,NA,Direction of the treatment effect contrast: IPD treatment is:,NA,NA,"Numerator if ratio, or left side if difference",TRUE,NA,NA,NA
10.2147/jbm.s288283,33664606,results,3,NA,Primary outcome: adjusted treatment effect,NA,NA,0.61,TRUE,NA,NA,NA
10.2147/jbm.s288283,33664606,results,3,NA,"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])",NA,NA,[0.37;1.02],TRUE,NA,NA,NA
10.2217/cer-2020-0280,33733815,general_information,NA,NA,Medical Condition of Interest Name,NA,NA,acute myeloid leukemia,TRUE,NA,NA,NA
10.2217/cer-2020-0280,33733815,general_information,NA,NA,Countries of first author affiliations,NA,NA,canada,TRUE,NA,NA,NA
10.2217/cer-2020-0280,33733815,general_information,NA,NA,Countries of last author affiliations,NA,NA,usa,TRUE,NA,NA,NA
10.2217/cer-2020-0280,33733815,general_information,NA,NA,"Positions of study investigators (for any authors of the article, any that applies)",NA,NA,"Pharmaceutical Industry, Private Data Analysis Company",TRUE,NA,NA,NA
10.2217/cer-2020-0280,33733815,general_information,NA,NA,"At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company",NA,NA,Yes,TRUE,NA,NA,NA
10.2217/cer-2020-0280,33733815,general_information,NA,NA,Mentioned sources of funding,NA,NA,Pharmaceutical Industry,TRUE,NA,NA,NA
10.2217/cer-2020-0280,33733815,general_information,NA,NA,"Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article",NA,NA,Yes,TRUE,NA,NA,NA
10.2217/cer-2020-0280,33733815,general_information,NA,NA,Mention of a systematic review to find the studies to compare treatments of interest,NA,NA,No,TRUE,NA,NA,NA
10.2217/cer-2020-0280,33733815,study_information,NA,1,Patient-level data used,NA,NA,Yes,TRUE,NA,NA,NA
10.2217/cer-2020-0280,33733815,study_information,NA,1,Clinical Trial,NA,NA,Yes,TRUE,NA,NA,NA
10.2217/cer-2020-0280,33733815,study_information,NA,1,NCT (only for clinical trial registered on clinicaltrials.gov),NA,NA,NCT01546038,TRUE,NA,NA,NA
10.2217/cer-2020-0280,33733815,study_information,NA,1,Country where the clinical trial/observational study was conducted (international if more than one),NA,NA,international,TRUE,NA,NA,NA
10.2217/cer-2020-0280,33733815,study_information,NA,1,Phase of the clinical trial (clinical trial only),NA,NA,2,TRUE,NA,NA,NA
10.2217/cer-2020-0280,33733815,study_information,NA,1,Number of treatment arms (clinical trial only),NA,NA,2 or more,TRUE,NA,NA,NA
10.2217/cer-2020-0280,33733815,study_information,NA,2,Patient-level data used,NA,NA,No,TRUE,NA,NA,NA
10.2217/cer-2020-0280,33733815,study_information,NA,2,Clinical Trial,NA,NA,Yes,TRUE,NA,NA,NA
10.2217/cer-2020-0280,33733815,study_information,NA,2,NCT (only for clinical trial registered on clinicaltrials.gov),NA,NA,NCT03069352,TRUE,NA,NA,NA
10.2217/cer-2020-0280,33733815,study_information,NA,2,Country where the clinical trial/observational study was conducted (international if more than one),NA,NA,international,TRUE,NA,NA,NA
10.2217/cer-2020-0280,33733815,study_information,NA,2,Phase of the clinical trial (clinical trial only),NA,NA,3,TRUE,NA,NA,NA
10.2217/cer-2020-0280,33733815,study_information,NA,2,Number of treatment arms (clinical trial only),NA,NA,2 or more,TRUE,NA,NA,NA
10.2217/cer-2020-0280,33733815,methodology,1,NA,Treatment name 1,glasdegib + low-dose cytarabine,glasdegib + low-dos ecytarabine,glasdegib + low-dose cytarabine,FALSE,NA,Full exponential model,NA
10.2217/cer-2020-0280,33733815,methodology,1,NA,Study 'number(s)' for treatment 1,NA,NA,1,TRUE,NA,NA,NA
10.2217/cer-2020-0280,33733815,methodology,1,NA,Treatment name 2,NA,NA,venetoclax + low-dose cytarabine,TRUE,NA,NA,NA
10.2217/cer-2020-0280,33733815,methodology,1,NA,Study 'number(s)' for treatment 2,NA,NA,2,TRUE,NA,NA,NA
10.2217/cer-2020-0280,33733815,methodology,1,NA,Type of population-adjusted indirect comparisons performed,NA,NA,STC,TRUE,NA,NA,NA
10.2217/cer-2020-0280,33733815,methodology,1,NA,Anchored comparison?,NA,NA,Yes,TRUE,NA,NA,NA
10.2217/cer-2020-0280,33733815,methodology,1,NA,Form of the indirect comparison,NA,NA,Simple (ie treatments effects extracted from two studies),TRUE,NA,NA,NA
10.2217/cer-2020-0280,33733815,methodology,1,NA,Definition of a single primary outcome for the indirect comparison,NA,NA,"No primary outcome defined, or multiple primary outcomes without any clear distinction between them",TRUE,NA,NA,NA
10.2217/cer-2020-0280,33733815,methodology,1,NA,Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined),NA,NA,overall survival,TRUE,NA,NA,NA
10.2217/cer-2020-0280,33733815,methodology,1,NA,Primary outcome: variable type,NA,NA,Time-to-event,TRUE,NA,NA,NA
10.2217/cer-2020-0280,33733815,methodology,1,NA,Justification for selecting variables to be included in the adjustment model (in the main text),"Statistical imbalanced between treatment groups (independently of the status of prognostic/effect modifier), Literature based (clinically or methodologically relevant to adjust on these variables based on the literature search conducted for this specific purpose)",Literature based (clinically or methodologically relevant to adjust on these variables based on the literature search conducted for this specific purpose),"Statistical imbalanced between treatment groups (independently of the status of prognostic/effect modifier), Literature based (clinically or methodologically relevant to adjust on these variables based on the literature search conducted for this specific purpose)",FALSE,NA,NA,NA
10.2217/cer-2020-0280,33733815,methodology,1,NA,Inclusion of prognostic factors in the adjustment/matching model,NA,NA,Yes,TRUE,NA,NA,NA
10.2217/cer-2020-0280,33733815,methodology,1,NA,Inclusion of treatment-effect modifiers in the adjustment/matching model,NA,NA,Yes,TRUE,NA,NA,NA
10.2217/cer-2020-0280,33733815,methodology,1,NA,Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale),Yes,No,Yes,FALSE,NA,NA,NA
10.2217/cer-2020-0280,33733815,methodology,1,NA,"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)",NA,Yes,Yes,FALSE,NA,NA,NA
10.2217/cer-2020-0280,33733815,results,1,NA,Sample size of the population of interest in the non IPD treatment arm,NA,NA,143,TRUE,NA,NA,NA
10.2217/cer-2020-0280,33733815,results,1,NA,"If anchored comparison, sample size of the population of interest in the non IPD treatment anchor arm",NA,NA,68,TRUE,NA,NA,NA
10.2217/cer-2020-0280,33733815,results,1,NA,Initial sample size of the population of interest in the IPD treatment arm,NA,NA,78,TRUE,NA,NA,NA
10.2217/cer-2020-0280,33733815,results,1,NA,"Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC",NA,NA,78,TRUE,NA,NA,NA
10.2217/cer-2020-0280,33733815,results,1,NA,"If anchored comparison, initial sample size of the population of interest in the IPD anchor arm",NA,NA,38,TRUE,NA,NA,NA
10.2217/cer-2020-0280,33733815,results,1,NA,"If anchored comparison, effective sample size after reweighting for MAIC; or sample size used in the regression model for STC in the IPD anchor arm",NA,NA,38,TRUE,NA,NA,NA
10.2217/cer-2020-0280,33733815,results,1,NA,Reporting of the list of the covariates adjusted for/matched on,NA,NA,Yes,TRUE,NA,NA,NA
10.2217/cer-2020-0280,33733815,results,1,NA,Number of covariates adjusted for/matched on,NA,NA,6,TRUE,NA,NA,NA
10.2217/cer-2020-0280,33733815,results,1,NA,Covariates adjusted for/matched on in the indirect comparison,NA,NA,"Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...)",TRUE,NA,NA,NA
10.2217/cer-2020-0280,33733815,results,1,NA,Primary outcome: treatment effect contrast,NA,NA,HR,TRUE,NA,NA,NA
10.2217/cer-2020-0280,33733815,results,1,NA,Direction of the treatment effect contrast: IPD treatment is:,NA,NA,"Numerator if ratio, or left side if difference",TRUE,NA,NA,NA
10.2217/cer-2020-0280,33733815,results,1,NA,Primary outcome: unadjusted treatment effect,NA,NA,0.66,TRUE,NA,NA,NA
10.2217/cer-2020-0280,33733815,results,1,NA,"p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])",NA,NA,[0.38;1.15],TRUE,NA,NA,NA
10.2217/cer-2020-0280,33733815,results,1,NA,Primary outcome: adjusted treatment effect,NA,NA,0.56,TRUE,NA,NA,NA
10.2217/cer-2020-0280,33733815,results,1,NA,"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])",NA,NA,[0.24;1.32],TRUE,NA,NA,NA
10.36469/jheor.2021.19008,33768123,general_information,NA,NA,Medical Condition of Interest Name,steroid-refractory acute graft-versus-host disease,steroid-refractory acute graft-versus-host,XXXX,FALSE,NA,NA,NA
10.36469/jheor.2021.19008,33768123,general_information,NA,NA,Countries of first author affiliations,NA,NA,usa,TRUE,NA,NA,NA
10.36469/jheor.2021.19008,33768123,general_information,NA,NA,Countries of last author affiliations,NA,NA,usa,TRUE,NA,NA,NA
10.36469/jheor.2021.19008,33768123,general_information,NA,NA,"Positions of study investigators (for any authors of the article, any that applies)",NA,NA,"Pharmaceutical Industry, Private Data Analysis Company",TRUE,NA,NA,NA
10.36469/jheor.2021.19008,33768123,general_information,NA,NA,"At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company",NA,NA,Yes,TRUE,NA,NA,NA
10.36469/jheor.2021.19008,33768123,general_information,NA,NA,Mentioned sources of funding,NA,NA,None mentioned,TRUE,NA,NA,NA
10.36469/jheor.2021.19008,33768123,general_information,NA,NA,"Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article",NA,NA,No such section presenting competing interest/conflict of interest,TRUE,NA,NA,NA
10.36469/jheor.2021.19008,33768123,general_information,NA,NA,Mention of a systematic review to find the studies to compare treatments of interest,NA,NA,No,TRUE,NA,NA,NA
10.36469/jheor.2021.19008,33768123,study_information,NA,1,Patient-level data used,NA,NA,Yes,TRUE,NA,NA,NA
10.36469/jheor.2021.19008,33768123,study_information,NA,1,Clinical Trial,NA,NA,Yes,TRUE,NA,NA,NA
10.36469/jheor.2021.19008,33768123,study_information,NA,1,NCT (only for clinical trial registered on clinicaltrials.gov),NA,NA,NCT02336230,TRUE,NA,NA,NA
10.36469/jheor.2021.19008,33768123,study_information,NA,1,Country where the clinical trial/observational study was conducted (international if more than one),NA,NA,usa,TRUE,NA,NA,NA
10.36469/jheor.2021.19008,33768123,study_information,NA,1,Phase of the clinical trial (clinical trial only),NA,NA,3,TRUE,NA,NA,NA
10.36469/jheor.2021.19008,33768123,study_information,NA,1,Number of treatment arms (clinical trial only),NA,NA,1,TRUE,NA,NA,NA
10.36469/jheor.2021.19008,33768123,study_information,NA,2,Patient-level data used,NA,NA,No,TRUE,NA,NA,NA
10.36469/jheor.2021.19008,33768123,study_information,NA,2,Clinical Trial,NA,NA,Yes,TRUE,NA,NA,NA
10.36469/jheor.2021.19008,33768123,study_information,NA,2,NCT (only for clinical trial registered on clinicaltrials.gov),NA,NA,NCT02953678,TRUE,NA,NA,NA
10.36469/jheor.2021.19008,33768123,study_information,NA,2,Country where the clinical trial/observational study was conducted (international if more than one),NA,NA,usa,TRUE,NA,NA,NA
10.36469/jheor.2021.19008,33768123,study_information,NA,2,Phase of the clinical trial (clinical trial only),NA,NA,2,TRUE,NA,NA,NA
10.36469/jheor.2021.19008,33768123,study_information,NA,2,Number of treatment arms (clinical trial only),NA,NA,1,TRUE,NA,NA,NA
10.36469/jheor.2021.19008,33768123,methodology,1,NA,Treatment name 1,NA,NA,remestemcel-l-rknd,TRUE,"Say they do an STC to avoid sample size shrinkage, but comes down to just giving an overimportant weights to patients irrelevant for the target population, and rely much more on the assumption of linearity of effects

MAIC would have been unfeasible, since it would have proven impossible to adjust for age: infringement to the positivity assumption. Acknowledge this limitation and say that it is still better to try any adjustment on something rather than conducting unadjusted ITC.",NA,NA
10.36469/jheor.2021.19008,33768123,methodology,1,NA,Study 'number(s)' for treatment 1,NA,NA,1,TRUE,NA,NA,NA
10.36469/jheor.2021.19008,33768123,methodology,1,NA,Treatment name 2,NA,NA,ruxolitinib,TRUE,NA,NA,NA
10.36469/jheor.2021.19008,33768123,methodology,1,NA,Study 'number(s)' for treatment 2,NA,NA,2,TRUE,NA,NA,NA
10.36469/jheor.2021.19008,33768123,methodology,1,NA,Type of population-adjusted indirect comparisons performed,NA,NA,STC,TRUE,NA,NA,NA
10.36469/jheor.2021.19008,33768123,methodology,1,NA,Anchored comparison?,NA,NA,No,TRUE,NA,NA,NA
10.36469/jheor.2021.19008,33768123,methodology,1,NA,Form of the indirect comparison,NA,NA,Simple (ie treatments effects extracted from two studies),TRUE,NA,NA,NA
10.36469/jheor.2021.19008,33768123,methodology,1,NA,Definition of a single primary outcome for the indirect comparison,NA,NA,Yes,TRUE,NA,NA,NA
10.36469/jheor.2021.19008,33768123,methodology,1,NA,Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined),overall response rate,day 28 overall response rate (orr),day 28 overall response rate (orr),FALSE,NA,NA,NA
10.36469/jheor.2021.19008,33768123,methodology,1,NA,Primary outcome: variable type,NA,NA,Binary (eg rates),TRUE,NA,NA,NA
10.36469/jheor.2021.19008,33768123,methodology,1,NA,Justification for selecting variables to be included in the adjustment model (in the main text),NA,NA,"Status of prognostic factor/treatment effect modified assessed in the IPD dataset, A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion), Literature based (clinically or methodologically relevant to adjust on these variables based on the literature search conducted for this specific purpose)",TRUE,NA,NA,NA
10.36469/jheor.2021.19008,33768123,methodology,1,NA,Inclusion of prognostic factors in the adjustment/matching model,NA,NA,Yes,TRUE,NA,NA,NA
10.36469/jheor.2021.19008,33768123,methodology,1,NA,Inclusion of treatment-effect modifiers in the adjustment/matching model,NA,NA,Yes,TRUE,NA,NA,NA
10.36469/jheor.2021.19008,33768123,methodology,1,NA,"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)",NA,NA,No,TRUE,NA,NA,NA
10.36469/jheor.2021.19008,33768123,methodology,1,NA,Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale),NA,NA,No,TRUE,NA,NA,NA
10.36469/jheor.2021.19008,33768123,results,1,NA,Sample size of the population of interest in the non IPD treatment arm,NA,NA,49,TRUE,NA,NA,NA
10.36469/jheor.2021.19008,33768123,results,1,NA,Initial sample size of the population of interest in the IPD treatment arm,NA,NA,55,TRUE,NA,NA,NA
10.36469/jheor.2021.19008,33768123,results,1,NA,"Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC",NA,NA,55,TRUE,NA,NA,NA
10.36469/jheor.2021.19008,33768123,results,1,NA,Reporting of the list of the covariates adjusted for/matched on,NA,NA,Yes,TRUE,NA,NA,NA
10.36469/jheor.2021.19008,33768123,results,1,NA,Number of covariates adjusted for/matched on,NA,NA,3,TRUE,NA,NA,NA
10.36469/jheor.2021.19008,33768123,results,1,NA,Covariates adjusted for/matched on in the indirect comparison,NA,NA,"Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Race/ethnicity",TRUE,NA,NA,NA
10.36469/jheor.2021.19008,33768123,results,1,NA,Primary outcome: treatment effect contrast,NA,NA,RR,TRUE,NA,NA,NA
10.36469/jheor.2021.19008,33768123,results,1,NA,Direction of the treatment effect contrast: IPD treatment is:,NA,NA,"Numerator if ratio, or left side if difference",TRUE,NA,NA,NA
10.36469/jheor.2021.19008,33768123,results,1,NA,Primary outcome: unadjusted treatment effect,NA,NA,1.21,TRUE,NA,NA,NA
10.36469/jheor.2021.19008,33768123,results,1,NA,"p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])",NA,NA,0.21,TRUE,NA,NA,NA
10.36469/jheor.2021.19008,33768123,results,1,NA,Primary outcome: adjusted treatment effect,NA,NA,1.13,TRUE,NA,NA,NA
10.36469/jheor.2021.19008,33768123,results,1,NA,"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])",NA,NA,0.45,TRUE,NA,NA,NA
10.1007/s12325-021-01700-2,33822328,general_information,NA,NA,Medical Condition of Interest Name,NA,NA,hepatocellular carcinoma,TRUE,NA,NA,NA
10.1007/s12325-021-01700-2,33822328,general_information,NA,NA,Countries of first author affiliations,NA,NA,germany,TRUE,NA,NA,NA
10.1007/s12325-021-01700-2,33822328,general_information,NA,NA,Countries of last author affiliations,NA,NA,germany,TRUE,NA,NA,NA
10.1007/s12325-021-01700-2,33822328,general_information,NA,NA,"Positions of study investigators (for any authors of the article, any that applies)",NA,NA,"Academic, Pharmaceutical Industry, Private Data Analysis Company",TRUE,NA,NA,NA
10.1007/s12325-021-01700-2,33822328,general_information,NA,NA,"At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company",NA,NA,Yes,TRUE,NA,NA,NA
10.1007/s12325-021-01700-2,33822328,general_information,NA,NA,Mentioned sources of funding,NA,NA,Pharmaceutical Industry,TRUE,NA,NA,NA
10.1007/s12325-021-01700-2,33822328,general_information,NA,NA,"Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article",NA,NA,Yes,TRUE,NA,NA,NA
10.1007/s12325-021-01700-2,33822328,general_information,NA,NA,Mention of a systematic review to find the studies to compare treatments of interest,NA,NA,No,TRUE,NA,NA,NA
10.1007/s12325-021-01700-2,33822328,study_information,NA,1,Patient-level data used,NA,NA,Yes,TRUE,NA,NA,NA
10.1007/s12325-021-01700-2,33822328,study_information,NA,1,Clinical Trial,NA,NA,Yes,TRUE,NA,NA,NA
10.1007/s12325-021-01700-2,33822328,study_information,NA,1,NCT (only for clinical trial registered on clinicaltrials.gov),NA,NA,NCT01908426,TRUE,NA,NA,NA
10.1007/s12325-021-01700-2,33822328,study_information,NA,1,Country where the clinical trial/observational study was conducted (international if more than one),NA,NA,international,TRUE,NA,NA,NA
10.1007/s12325-021-01700-2,33822328,study_information,NA,1,Phase of the clinical trial (clinical trial only),NA,NA,3,TRUE,NA,NA,NA
10.1007/s12325-021-01700-2,33822328,study_information,NA,1,Number of treatment arms (clinical trial only),NA,NA,2 or more,TRUE,NA,NA,NA
10.1007/s12325-021-01700-2,33822328,study_information,NA,2,Patient-level data used,NA,NA,No,TRUE,NA,NA,NA
10.1007/s12325-021-01700-2,33822328,study_information,NA,2,Clinical Trial,NA,NA,Yes,TRUE,NA,NA,NA
10.1007/s12325-021-01700-2,33822328,study_information,NA,2,NCT (only for clinical trial registered on clinicaltrials.gov),NA,NA,NCT02435433,TRUE,NA,NA,NA
10.1007/s12325-021-01700-2,33822328,study_information,NA,2,Country where the clinical trial/observational study was conducted (international if more than one),NA,NA,international,TRUE,NA,NA,NA
10.1007/s12325-021-01700-2,33822328,study_information,NA,2,Phase of the clinical trial (clinical trial only),NA,NA,3,TRUE,NA,NA,NA
10.1007/s12325-021-01700-2,33822328,study_information,NA,2,Number of treatment arms (clinical trial only),NA,NA,2 or more,TRUE,NA,NA,NA
10.1007/s12325-021-01700-2,33822328,methodology,1,NA,Treatment name 1,NA,NA,cabozantinib,TRUE,NA,"Mediane OS Carbozantinib = 10.6 (IC : 9.5; 17.3)
Mediane OS Ramicurimab = 8.7 (IC : 7.3; 10.8)
Median difference = 1.9
P-value Log-rank = 0.104",NA
10.1007/s12325-021-01700-2,33822328,methodology,1,NA,Study 'number(s)' for treatment 1,NA,NA,1,TRUE,NA,NA,NA
10.1007/s12325-021-01700-2,33822328,methodology,1,NA,Treatment name 2,NA,NA,ramucirumab,TRUE,NA,NA,NA
10.1007/s12325-021-01700-2,33822328,methodology,1,NA,Study 'number(s)' for treatment 2,NA,NA,2,TRUE,NA,NA,NA
10.1007/s12325-021-01700-2,33822328,methodology,1,NA,Type of population-adjusted indirect comparisons performed,NA,NA,MAIC,TRUE,NA,NA,NA
10.1007/s12325-021-01700-2,33822328,methodology,1,NA,Anchored comparison?,NA,NA,No,TRUE,NA,NA,NA
10.1007/s12325-021-01700-2,33822328,methodology,1,NA,Form of the indirect comparison,NA,NA,Simple (ie treatments effects extracted from two studies),TRUE,NA,NA,NA
10.1007/s12325-021-01700-2,33822328,methodology,1,NA,Definition of a single primary outcome for the indirect comparison,NA,NA,"No primary outcome defined, or multiple primary outcomes without any clear distinction between them",TRUE,NA,NA,NA
10.1007/s12325-021-01700-2,33822328,methodology,1,NA,Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined),median overall survival,overall survival,overall survival,FALSE,NA,NA,NA
10.1007/s12325-021-01700-2,33822328,methodology,1,NA,Primary outcome: variable type,"Continuous (count, mean, ...)",Time-to-event,Time-to-event,FALSE,NA,NA,NA
10.1007/s12325-021-01700-2,33822328,methodology,1,NA,Justification for selecting variables to be included in the adjustment model (in the main text),NA,NA,A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion),TRUE,NA,NA,NA
10.1007/s12325-021-01700-2,33822328,methodology,1,NA,Inclusion of prognostic factors in the adjustment/matching model,NA,NA,No,TRUE,NA,NA,NA
10.1007/s12325-021-01700-2,33822328,methodology,1,NA,Inclusion of treatment-effect modifiers in the adjustment/matching model,NA,NA,Yes,TRUE,NA,NA,NA
10.1007/s12325-021-01700-2,33822328,methodology,1,NA,"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)",NA,NA,No,TRUE,NA,NA,NA
10.1007/s12325-021-01700-2,33822328,methodology,1,NA,Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale),Yes,No,Yes,FALSE,NA,NA,NA
10.1007/s12325-021-01700-2,33822328,results,1,NA,Sample size of the population of interest in the non IPD treatment arm,NA,NA,197,TRUE,NA,NA,NA
10.1007/s12325-021-01700-2,33822328,results,1,NA,Initial sample size of the population of interest in the IPD treatment arm,NA,NA,114,TRUE,NA,NA,NA
10.1007/s12325-021-01700-2,33822328,results,1,NA,"Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC",NA,NA,63,TRUE,NA,NA,NA
10.1007/s12325-021-01700-2,33822328,results,1,NA,Reporting of a weights' distribution evaluation (MAIC),NA,NA,"Yes, mentions that the weights distribution has been studied, and weights distribution reported in main article or supplemental materials",TRUE,NA,NA,NA
10.1007/s12325-021-01700-2,33822328,results,1,NA,Reporting of the list of the covariates adjusted for/matched on,NA,NA,Yes,TRUE,NA,NA,NA
10.1007/s12325-021-01700-2,33822328,results,1,NA,Number of covariates adjusted for/matched on,NA,NA,9,TRUE,NA,NA,NA
10.1007/s12325-021-01700-2,33822328,results,1,NA,Covariates adjusted for/matched on in the indirect comparison,NA,NA,"Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Past treatments for the disease of interest",TRUE,NA,NA,NA
10.1007/s12325-021-01700-2,33822328,results,1,NA,Primary outcome: treatment effect contrast,Median difference,"Pas de Hazard Ratio calculÃ©, uniquement test du log-rank",Median difference,FALSE,NA,NA,NA
10.1007/s12325-021-01700-2,33822328,results,1,NA,Direction of the treatment effect contrast: IPD treatment is:,"Numerator if ratio, or left side if difference",NA,"Numerator if ratio, or left side if difference",FALSE,NA,NA,NA
10.1007/s12325-021-01700-2,33822328,results,1,NA,Primary outcome: adjusted treatment effect,1.9,NA,1.9,FALSE,NA,NA,NA
10.1007/s12325-021-01700-2,33822328,results,1,NA,"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])",NA,NA,0.104,TRUE,NA,NA,NA
10.1016/j.lungcan.2021.03.020,33839603,general_information,NA,NA,Medical Condition of Interest Name,non-squamous non-small cell lung cancer,non-squamous non-small cell lung cancer (nsclc),XXXX,FALSE,NA,NA,NA
10.1016/j.lungcan.2021.03.020,33839603,general_information,NA,NA,Countries of first author affiliations,NA,NA,usa,TRUE,NA,NA,NA
10.1016/j.lungcan.2021.03.020,33839603,general_information,NA,NA,Countries of last author affiliations,NA,NA,usa,TRUE,NA,NA,NA
10.1016/j.lungcan.2021.03.020,33839603,general_information,NA,NA,"Positions of study investigators (for any authors of the article, any that applies)",NA,NA,"Academic, Pharmaceutical Industry, Private Data Analysis Company",TRUE,NA,NA,NA
10.1016/j.lungcan.2021.03.020,33839603,general_information,NA,NA,"At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company",NA,NA,Yes,TRUE,NA,NA,NA
10.1016/j.lungcan.2021.03.020,33839603,general_information,NA,NA,Mentioned sources of funding,NA,NA,Pharmaceutical Industry,TRUE,NA,NA,NA
10.1016/j.lungcan.2021.03.020,33839603,general_information,NA,NA,"Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article",NA,NA,Yes,TRUE,NA,NA,NA
10.1016/j.lungcan.2021.03.020,33839603,general_information,NA,NA,Mention of a systematic review to find the studies to compare treatments of interest,NA,NA,Yes,TRUE,NA,NA,NA
10.1016/j.lungcan.2021.03.020,33839603,study_information,NA,1,Patient-level data used,NA,NA,Yes,TRUE,NA,NA,NA
10.1016/j.lungcan.2021.03.020,33839603,study_information,NA,1,Clinical Trial,NA,NA,Yes,TRUE,NA,NA,NA
10.1016/j.lungcan.2021.03.020,33839603,study_information,NA,1,NCT (only for clinical trial registered on clinicaltrials.gov),NA,NA,NCT02039674,TRUE,NA,NA,NA
10.1016/j.lungcan.2021.03.020,33839603,study_information,NA,1,Phase of the clinical trial (clinical trial only),2,"1, 2",XXXX,FALSE,NA,NA,NA
10.1016/j.lungcan.2021.03.020,33839603,study_information,NA,1,Number of treatment arms (clinical trial only),NA,NA,2 or more,TRUE,NA,NA,NA
10.1016/j.lungcan.2021.03.020,33839603,study_information,NA,1,Country where the clinical trial/observational study was conducted (international if more than one),unknown,NA,XXXX,FALSE,NA,NA,NA
10.1016/j.lungcan.2021.03.020,33839603,study_information,NA,2,Patient-level data used,NA,NA,Yes,TRUE,NA,NA,NA
10.1016/j.lungcan.2021.03.020,33839603,study_information,NA,2,Clinical Trial,NA,NA,Yes,TRUE,NA,NA,NA
10.1016/j.lungcan.2021.03.020,33839603,study_information,NA,2,NCT (only for clinical trial registered on clinicaltrials.gov),NA,NA,NCT02578680,TRUE,NA,NA,NA
10.1016/j.lungcan.2021.03.020,33839603,study_information,NA,2,Phase of the clinical trial (clinical trial only),NA,NA,3,TRUE,NA,NA,NA
10.1016/j.lungcan.2021.03.020,33839603,study_information,NA,2,Number of treatment arms (clinical trial only),NA,NA,2 or more,TRUE,NA,NA,NA
10.1016/j.lungcan.2021.03.020,33839603,study_information,NA,2,Country where the clinical trial/observational study was conducted (international if more than one),unknown,NA,XXXX,FALSE,NA,NA,NA
10.1016/j.lungcan.2021.03.020,33839603,study_information,NA,3,Patient-level data used,NA,NA,No,TRUE,NA,NA,NA
10.1016/j.lungcan.2021.03.020,33839603,study_information,NA,3,Clinical Trial,NA,NA,Yes,TRUE,NA,NA,NA
10.1016/j.lungcan.2021.03.020,33839603,study_information,NA,3,NCT (only for clinical trial registered on clinicaltrials.gov),NA,NA,NCT02367781,TRUE,NA,NA,NA
10.1016/j.lungcan.2021.03.020,33839603,study_information,NA,3,Country where the clinical trial/observational study was conducted (international if more than one),NA,NA,international,TRUE,NA,NA,NA
10.1016/j.lungcan.2021.03.020,33839603,study_information,NA,3,Phase of the clinical trial (clinical trial only),NA,NA,3,TRUE,NA,NA,NA
10.1016/j.lungcan.2021.03.020,33839603,study_information,NA,3,Number of treatment arms (clinical trial only),NA,NA,2 or more,TRUE,NA,NA,NA
10.1016/j.lungcan.2021.03.020,33839603,study_information,NA,4,Patient-level data used,NA,NA,No,TRUE,NA,NA,NA
10.1016/j.lungcan.2021.03.020,33839603,study_information,NA,4,Clinical Trial,NA,NA,Yes,TRUE,NA,NA,NA
10.1016/j.lungcan.2021.03.020,33839603,study_information,NA,4,NCT (only for clinical trial registered on clinicaltrials.gov),NA,NA,NCT02366143,TRUE,NA,NA,NA
10.1016/j.lungcan.2021.03.020,33839603,study_information,NA,4,Country where the clinical trial/observational study was conducted (international if more than one),NA,NA,international,TRUE,NA,NA,NA
10.1016/j.lungcan.2021.03.020,33839603,study_information,NA,4,Phase of the clinical trial (clinical trial only),NA,NA,3,TRUE,NA,NA,NA
10.1016/j.lungcan.2021.03.020,33839603,study_information,NA,4,Number of treatment arms (clinical trial only),NA,NA,2 or more,TRUE,NA,NA,NA
10.1016/j.lungcan.2021.03.020,33839603,methodology,1,NA,Treatment name 1,NA,NA,pembrolizumab + chemotherapy,TRUE,NA,"""The selection of potential effect modifiers and prognostic factors was based on a statistical assessment of the baseline characteristics reported in trials, clinical expertise and review of the clinical literature""  ==> But no details on the statistical asseseement of the se baseline characterestics

Smoking status = other",NA
10.1016/j.lungcan.2021.03.020,33839603,methodology,1,NA,Study 'number(s)' for treatment 1,NA,NA,1;2,TRUE,NA,NA,NA
10.1016/j.lungcan.2021.03.020,33839603,methodology,1,NA,Treatment name 2,NA,NA,atezolizumab + chemotherapy,TRUE,NA,NA,NA
10.1016/j.lungcan.2021.03.020,33839603,methodology,1,NA,Study 'number(s)' for treatment 2,3;4,3,3;4,FALSE,NA,NA,NA
10.1016/j.lungcan.2021.03.020,33839603,methodology,1,NA,Type of population-adjusted indirect comparisons performed,NA,NA,MAIC,TRUE,NA,NA,NA
10.1016/j.lungcan.2021.03.020,33839603,methodology,1,NA,Anchored comparison?,NA,NA,No,TRUE,NA,NA,NA
10.1016/j.lungcan.2021.03.020,33839603,methodology,1,NA,Form of the indirect comparison,NA,NA,"Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate)",TRUE,NA,NA,NA
10.1016/j.lungcan.2021.03.020,33839603,methodology,1,NA,Definition of a single primary outcome for the indirect comparison,NA,NA,"No primary outcome defined, or multiple primary outcomes without any clear distinction between them",TRUE,NA,NA,NA
10.1016/j.lungcan.2021.03.020,33839603,methodology,1,NA,Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined),NA,NA,overall survival,TRUE,NA,NA,NA
10.1016/j.lungcan.2021.03.020,33839603,methodology,1,NA,Primary outcome: variable type,NA,NA,Time-to-event,TRUE,NA,NA,NA
10.1016/j.lungcan.2021.03.020,33839603,methodology,1,NA,Justification for selecting variables to be included in the adjustment model (in the main text),"Status of prognostic factor/treatment effect modified assessed in the IPD dataset, A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion), Literature based (clinically or methodologically relevant to adjust on these variables based on the literature search conducted for this specific purpose)","Statistical imbalanced between treatment groups (independently of the status of prognostic/effect modifier), A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion), Literature based (clinically or methodologically relevant to adjust on these variables based on the literature search conducted for this specific purpose)","Statistical imbalanced between treatment groups (independently of the status of prognostic/effect modifier), A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion), Literature based (clinically or methodologically relevant to adjust on these variables based on the literature search conducted for this specific purpose)",FALSE,NA,NA,NA
10.1016/j.lungcan.2021.03.020,33839603,methodology,1,NA,Inclusion of prognostic factors in the adjustment/matching model,NA,NA,Yes,TRUE,NA,NA,NA
10.1016/j.lungcan.2021.03.020,33839603,methodology,1,NA,Inclusion of treatment-effect modifiers in the adjustment/matching model,NA,NA,Yes,TRUE,NA,NA,NA
10.1016/j.lungcan.2021.03.020,33839603,methodology,1,NA,"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)",NA,NA,No,TRUE,NA,NA,NA
10.1016/j.lungcan.2021.03.020,33839603,methodology,1,NA,Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale),NA,NA,No,TRUE,NA,NA,NA
10.1016/j.lungcan.2021.03.020,33839603,methodology,2,NA,Treatment name 1,NA,NA,pembrolizumab + chemotherapy,TRUE,other (smoking status),Smoking status = other,NA
10.1016/j.lungcan.2021.03.020,33839603,methodology,2,NA,Study 'number(s)' for treatment 1,NA,NA,1;2,TRUE,NA,NA,NA
10.1016/j.lungcan.2021.03.020,33839603,methodology,2,NA,Treatment name 2,atezolizumab + bevacizumab + chemotherapy,atezolizumab + chemotherapy+bevacizumab,atezolizumab + bevacizumab + chemotherapy,FALSE,NA,NA,NA
10.1016/j.lungcan.2021.03.020,33839603,methodology,2,NA,Study 'number(s)' for treatment 2,3;4,4,4,FALSE,NA,NA,NA
10.1016/j.lungcan.2021.03.020,33839603,methodology,2,NA,Type of population-adjusted indirect comparisons performed,NA,NA,MAIC,TRUE,NA,NA,NA
10.1016/j.lungcan.2021.03.020,33839603,methodology,2,NA,Anchored comparison?,NA,NA,No,TRUE,NA,NA,NA
10.1016/j.lungcan.2021.03.020,33839603,methodology,2,NA,Form of the indirect comparison,NA,NA,"Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate)",TRUE,NA,NA,NA
10.1016/j.lungcan.2021.03.020,33839603,methodology,2,NA,Definition of a single primary outcome for the indirect comparison,NA,NA,"No primary outcome defined, or multiple primary outcomes without any clear distinction between them",TRUE,NA,NA,NA
10.1016/j.lungcan.2021.03.020,33839603,methodology,2,NA,Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined),NA,NA,overall survival,TRUE,NA,NA,NA
10.1016/j.lungcan.2021.03.020,33839603,methodology,2,NA,Primary outcome: variable type,NA,NA,Time-to-event,TRUE,NA,NA,NA
10.1016/j.lungcan.2021.03.020,33839603,methodology,2,NA,Justification for selecting variables to be included in the adjustment model (in the main text),"Status of prognostic factor/treatment effect modified assessed in the IPD dataset, A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion), Literature based (clinically or methodologically relevant to adjust on these variables based on the literature search conducted for this specific purpose)","Statistical imbalanced between treatment groups (independently of the status of prognostic/effect modifier), A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion), Literature based (clinically or methodologically relevant to adjust on these variables based on the literature search conducted for this specific purpose)","Statistical imbalanced between treatment groups (independently of the status of prognostic/effect modifier), A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion), Literature based (clinically or methodologically relevant to adjust on these variables based on the literature search conducted for this specific purpose)",FALSE,NA,NA,NA
10.1016/j.lungcan.2021.03.020,33839603,methodology,2,NA,Inclusion of prognostic factors in the adjustment/matching model,NA,NA,Yes,TRUE,NA,NA,NA
10.1016/j.lungcan.2021.03.020,33839603,methodology,2,NA,Inclusion of treatment-effect modifiers in the adjustment/matching model,NA,NA,Yes,TRUE,NA,NA,NA
10.1016/j.lungcan.2021.03.020,33839603,methodology,2,NA,"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)",NA,NA,No,TRUE,NA,NA,NA
10.1016/j.lungcan.2021.03.020,33839603,methodology,2,NA,Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale),NA,NA,No,TRUE,NA,NA,NA
10.1016/j.lungcan.2021.03.020,33839603,results,1,NA,Sample size of the population of interest in the non IPD treatment arm,NA,NA,451,TRUE,NA,NA,NA
10.1016/j.lungcan.2021.03.020,33839603,results,1,NA,Initial sample size of the population of interest in the IPD treatment arm,NA,NA,469,TRUE,NA,NA,NA
10.1016/j.lungcan.2021.03.020,33839603,results,1,NA,"Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC",NA,NA,428,TRUE,NA,NA,NA
10.1016/j.lungcan.2021.03.020,33839603,results,1,NA,Reporting of a weights' distribution evaluation (MAIC),NA,NA,Not mentioned,TRUE,NA,NA,NA
10.1016/j.lungcan.2021.03.020,33839603,results,1,NA,Reporting of the list of the covariates adjusted for/matched on,NA,NA,Yes,TRUE,NA,NA,NA
10.1016/j.lungcan.2021.03.020,33839603,results,1,NA,Number of covariates adjusted for/matched on,NA,NA,6,TRUE,NA,NA,NA
10.1016/j.lungcan.2021.03.020,33839603,results,1,NA,Covariates adjusted for/matched on in the indirect comparison,NA,NA,"Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Race/ethnicity, Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Other(s)",TRUE,NA,NA,NA
10.1016/j.lungcan.2021.03.020,33839603,results,1,NA,Primary outcome: treatment effect contrast,NA,NA,HR,TRUE,NA,NA,NA
10.1016/j.lungcan.2021.03.020,33839603,results,1,NA,Direction of the treatment effect contrast: IPD treatment is:,NA,NA,"Numerator if ratio, or left side if difference",TRUE,NA,NA,NA
10.1016/j.lungcan.2021.03.020,33839603,results,1,NA,Primary outcome: unadjusted treatment effect,NA,NA,0.8,TRUE,NA,NA,NA
10.1016/j.lungcan.2021.03.020,33839603,results,1,NA,"p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])",NA,NA,0.009,TRUE,NA,NA,NA
10.1016/j.lungcan.2021.03.020,33839603,results,1,NA,Primary outcome: adjusted treatment effect,NA,NA,0.8,TRUE,NA,NA,NA
10.1016/j.lungcan.2021.03.020,33839603,results,1,NA,"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])",NA,NA,0.012,TRUE,NA,NA,NA
10.1016/j.lungcan.2021.03.020,33839603,results,2,NA,Sample size of the population of interest in the non IPD treatment arm,NA,NA,356,TRUE,NA,NA,NA
10.1016/j.lungcan.2021.03.020,33839603,results,2,NA,Initial sample size of the population of interest in the IPD treatment arm,NA,NA,469,TRUE,NA,NA,NA
10.1016/j.lungcan.2021.03.020,33839603,results,2,NA,"Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC",NA,NA,389,TRUE,NA,NA,NA
10.1016/j.lungcan.2021.03.020,33839603,results,2,NA,Reporting of a weights' distribution evaluation (MAIC),NA,NA,Not mentioned,TRUE,NA,NA,NA
10.1016/j.lungcan.2021.03.020,33839603,results,2,NA,Reporting of the list of the covariates adjusted for/matched on,NA,NA,Yes,TRUE,NA,NA,NA
10.1016/j.lungcan.2021.03.020,33839603,results,2,NA,Number of covariates adjusted for/matched on,NA,NA,6,TRUE,NA,NA,NA
10.1016/j.lungcan.2021.03.020,33839603,results,2,NA,Covariates adjusted for/matched on in the indirect comparison,NA,NA,"Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Race/ethnicity, Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Other(s)",TRUE,NA,NA,NA
10.1016/j.lungcan.2021.03.020,33839603,results,2,NA,Primary outcome: treatment effect contrast,NA,NA,HR,TRUE,NA,NA,NA
10.1016/j.lungcan.2021.03.020,33839603,results,2,NA,Direction of the treatment effect contrast: IPD treatment is:,NA,NA,"Numerator if ratio, or left side if difference",TRUE,NA,NA,NA
10.1016/j.lungcan.2021.03.020,33839603,results,2,NA,Primary outcome: unadjusted treatment effect,NA,NA,0.84,TRUE,NA,NA,NA
10.1016/j.lungcan.2021.03.020,33839603,results,2,NA,"p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])",NA,NA,0.04,TRUE,NA,NA,NA
10.1016/j.lungcan.2021.03.020,33839603,results,2,NA,Primary outcome: adjusted treatment effect,NA,NA,0.86,TRUE,NA,NA,NA
10.1016/j.lungcan.2021.03.020,33839603,results,2,NA,"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])",NA,NA,0.099,TRUE,NA,NA,NA
10.1080/10428194.2021.1913143,33896344,general_information,NA,NA,Medical Condition of Interest Name,NA,NA,relapsed and refractory multiple myeloma,TRUE,NA,NA,NA
10.1080/10428194.2021.1913143,33896344,general_information,NA,NA,Countries of first author affiliations,NA,NA,spain,TRUE,NA,NA,NA
10.1080/10428194.2021.1913143,33896344,general_information,NA,NA,Countries of last author affiliations,NA,NA,switzerland,TRUE,NA,NA,NA
10.1080/10428194.2021.1913143,33896344,general_information,NA,NA,"Positions of study investigators (for any authors of the article, any that applies)",NA,NA,"Academic, Pharmaceutical Industry, Private Data Analysis Company",TRUE,NA,NA,NA
10.1080/10428194.2021.1913143,33896344,general_information,NA,NA,"At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company",NA,NA,Yes,TRUE,NA,NA,NA
10.1080/10428194.2021.1913143,33896344,general_information,NA,NA,Mentioned sources of funding,NA,NA,Pharmaceutical Industry,TRUE,NA,NA,NA
10.1080/10428194.2021.1913143,33896344,general_information,NA,NA,"Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article",NA,NA,Yes,TRUE,NA,NA,NA
10.1080/10428194.2021.1913143,33896344,general_information,NA,NA,Mention of a systematic review to find the studies to compare treatments of interest,NA,NA,Yes,TRUE,NA,NA,NA
10.1080/10428194.2021.1913143,33896344,study_information,NA,1,Patient-level data used,NA,NA,Yes,TRUE,NA,NA,NA
10.1080/10428194.2021.1913143,33896344,study_information,NA,1,Clinical Trial,NA,NA,Yes,TRUE,NA,NA,NA
10.1080/10428194.2021.1913143,33896344,study_information,NA,1,NCT (only for clinical trial registered on clinicaltrials.gov),NA,NA,NCT03361748,TRUE,NA,NA,NA
10.1080/10428194.2021.1913143,33896344,study_information,NA,1,Country where the clinical trial/observational study was conducted (international if more than one),NA,NA,international,TRUE,NA,NA,NA
10.1080/10428194.2021.1913143,33896344,study_information,NA,1,Phase of the clinical trial (clinical trial only),NA,NA,2,TRUE,NA,NA,NA
10.1080/10428194.2021.1913143,33896344,study_information,NA,1,Number of treatment arms (clinical trial only),NA,NA,1,TRUE,NA,NA,NA
10.1080/10428194.2021.1913143,33896344,study_information,NA,2,Patient-level data used,NA,NA,No,TRUE,NA,NA,NA
10.1080/10428194.2021.1913143,33896344,study_information,NA,2,Clinical Trial,NA,NA,Yes,TRUE,NA,NA,NA
10.1080/10428194.2021.1913143,33896344,study_information,NA,2,NCT (only for clinical trial registered on clinicaltrials.gov),NA,NA,NCT02336815,TRUE,NA,NA,NA
10.1080/10428194.2021.1913143,33896344,study_information,NA,2,Country where the clinical trial/observational study was conducted (international if more than one),NA,NA,international,TRUE,NA,NA,NA
10.1080/10428194.2021.1913143,33896344,study_information,NA,2,Phase of the clinical trial (clinical trial only),NA,NA,2,TRUE,NA,NA,NA
10.1080/10428194.2021.1913143,33896344,study_information,NA,2,Number of treatment arms (clinical trial only),NA,NA,1,TRUE,NA,NA,NA
10.1080/10428194.2021.1913143,33896344,study_information,NA,3,Patient-level data used,NA,NA,No,TRUE,NA,NA,NA
10.1080/10428194.2021.1913143,33896344,study_information,NA,3,Clinical Trial,NA,NA,Yes,TRUE,NA,NA,NA
10.1080/10428194.2021.1913143,33896344,study_information,NA,3,NCT (only for clinical trial registered on clinicaltrials.gov),NA,NA,NCT03525678,TRUE,NA,NA,NA
10.1080/10428194.2021.1913143,33896344,study_information,NA,3,Country where the clinical trial/observational study was conducted (international if more than one),NA,NA,international,TRUE,NA,NA,NA
10.1080/10428194.2021.1913143,33896344,study_information,NA,3,Phase of the clinical trial (clinical trial only),NA,NA,2,TRUE,NA,NA,NA
10.1080/10428194.2021.1913143,33896344,study_information,NA,3,Number of treatment arms (clinical trial only),NA,NA,1,TRUE,NA,NA,NA
10.1080/10428194.2021.1913143,33896344,methodology,1,NA,Treatment name 1,NA,NA,idecabtagene vicleucel,TRUE,NA,NA,NA
10.1080/10428194.2021.1913143,33896344,methodology,1,NA,Study 'number(s)' for treatment 1,NA,NA,1,TRUE,NA,NA,NA
10.1080/10428194.2021.1913143,33896344,methodology,1,NA,Treatment name 2,NA,NA,selinexor + dexamethasone,TRUE,NA,NA,NA
10.1080/10428194.2021.1913143,33896344,methodology,1,NA,Study 'number(s)' for treatment 2,NA,NA,2,TRUE,NA,NA,NA
10.1080/10428194.2021.1913143,33896344,methodology,1,NA,Type of population-adjusted indirect comparisons performed,NA,NA,MAIC,TRUE,NA,NA,NA
10.1080/10428194.2021.1913143,33896344,methodology,1,NA,Anchored comparison?,NA,NA,No,TRUE,NA,NA,NA
10.1080/10428194.2021.1913143,33896344,methodology,1,NA,Form of the indirect comparison,NA,NA,Simple (ie treatments effects extracted from two studies),TRUE,NA,NA,NA
10.1080/10428194.2021.1913143,33896344,methodology,1,NA,Definition of a single primary outcome for the indirect comparison,NA,NA,"No primary outcome defined, or multiple primary outcomes without any clear distinction between them",TRUE,NA,NA,NA
10.1080/10428194.2021.1913143,33896344,methodology,1,NA,Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined),NA,NA,overall response rate,TRUE,NA,NA,NA
10.1080/10428194.2021.1913143,33896344,methodology,1,NA,Primary outcome: variable type,NA,NA,Binary (eg rates),TRUE,NA,NA,NA
10.1080/10428194.2021.1913143,33896344,methodology,1,NA,Justification for selecting variables to be included in the adjustment model (in the main text),"Nothing mentioned, not reported","Statistical imbalanced between treatment groups (independently of the status of prognostic/effect modifier), A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion), Literature based (clinically or methodologically relevant to adjust on these variables based on the literature search conducted for this specific purpose)","Statistical imbalanced between treatment groups (independently of the status of prognostic/effect modifier), A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion), Literature based (clinically or methodologically relevant to adjust on these variables based on the literature search conducted for this specific purpose)",FALSE,NA,NA,NA
10.1080/10428194.2021.1913143,33896344,methodology,1,NA,Inclusion of prognostic factors in the adjustment/matching model,NA,NA,Yes,TRUE,NA,NA,NA
10.1080/10428194.2021.1913143,33896344,methodology,1,NA,Inclusion of treatment-effect modifiers in the adjustment/matching model,NA,NA,No discussion (in the main text) of the status of treatment-effect modifiers of the variables,TRUE,NA,NA,NA
10.1080/10428194.2021.1913143,33896344,methodology,1,NA,"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)",NA,NA,No,TRUE,NA,NA,NA
10.1080/10428194.2021.1913143,33896344,methodology,1,NA,Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale),NA,NA,No,TRUE,NA,NA,NA
10.1080/10428194.2021.1913143,33896344,methodology,2,NA,Treatment name 1,idecabtagene vicleucel,idecabtagene + vicleucel,idecabtagene + vicleucel,FALSE,NA,NA,NA
10.1080/10428194.2021.1913143,33896344,methodology,2,NA,Study 'number(s)' for treatment 1,NA,NA,1,TRUE,NA,NA,NA
10.1080/10428194.2021.1913143,33896344,methodology,2,NA,Treatment name 2,NA,NA,belantamab mafodotin,TRUE,NA,NA,NA
10.1080/10428194.2021.1913143,33896344,methodology,2,NA,Study 'number(s)' for treatment 2,NA,NA,3,TRUE,NA,NA,NA
10.1080/10428194.2021.1913143,33896344,methodology,2,NA,Type of population-adjusted indirect comparisons performed,NA,NA,MAIC,TRUE,NA,NA,NA
10.1080/10428194.2021.1913143,33896344,methodology,2,NA,Anchored comparison?,NA,NA,No,TRUE,NA,NA,NA
10.1080/10428194.2021.1913143,33896344,methodology,2,NA,Form of the indirect comparison,NA,NA,Simple (ie treatments effects extracted from two studies),TRUE,NA,NA,NA
10.1080/10428194.2021.1913143,33896344,methodology,2,NA,Definition of a single primary outcome for the indirect comparison,NA,NA,"No primary outcome defined, or multiple primary outcomes without any clear distinction between them",TRUE,NA,NA,NA
10.1080/10428194.2021.1913143,33896344,methodology,2,NA,Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined),NA,NA,overall response rate,TRUE,NA,NA,NA
10.1080/10428194.2021.1913143,33896344,methodology,2,NA,Primary outcome: variable type,NA,NA,Binary (eg rates),TRUE,NA,NA,NA
10.1080/10428194.2021.1913143,33896344,methodology,2,NA,Justification for selecting variables to be included in the adjustment model (in the main text),"Nothing mentioned, not reported","Statistical imbalanced between treatment groups (independently of the status of prognostic/effect modifier), A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion), Literature based (clinically or methodologically relevant to adjust on these variables based on the literature search conducted for this specific purpose)","Statistical imbalanced between treatment groups (independently of the status of prognostic/effect modifier), A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion), Literature based (clinically or methodologically relevant to adjust on these variables based on the literature search conducted for this specific purpose)",FALSE,NA,NA,NA
10.1080/10428194.2021.1913143,33896344,methodology,2,NA,Inclusion of prognostic factors in the adjustment/matching model,NA,NA,Yes,TRUE,NA,NA,NA
10.1080/10428194.2021.1913143,33896344,methodology,2,NA,Inclusion of treatment-effect modifiers in the adjustment/matching model,NA,NA,No discussion (in the main text) of the status of treatment-effect modifiers of the variables,TRUE,NA,NA,NA
10.1080/10428194.2021.1913143,33896344,methodology,2,NA,"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)",NA,NA,No,TRUE,NA,NA,NA
10.1080/10428194.2021.1913143,33896344,methodology,2,NA,Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale),NA,NA,No,TRUE,NA,NA,NA
10.1080/10428194.2021.1913143,33896344,results,1,NA,Sample size of the population of interest in the non IPD treatment arm,NA,NA,122,TRUE,NA,NA,NA
10.1080/10428194.2021.1913143,33896344,results,1,NA,Initial sample size of the population of interest in the IPD treatment arm,NA,NA,128,TRUE,NA,NA,NA
10.1080/10428194.2021.1913143,33896344,results,1,NA,"Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC",NA,NA,56,TRUE,NA,NA,NA
10.1080/10428194.2021.1913143,33896344,results,1,NA,Reporting of a weights' distribution evaluation (MAIC),NA,NA,Not mentioned,TRUE,NA,NA,NA
10.1080/10428194.2021.1913143,33896344,results,1,NA,Reporting of the list of the covariates adjusted for/matched on,NA,NA,Yes,TRUE,NA,NA,NA
10.1080/10428194.2021.1913143,33896344,results,1,NA,Number of covariates adjusted for/matched on,5,6,6,FALSE,NA,NA,NA
10.1080/10428194.2021.1913143,33896344,results,1,NA,Covariates adjusted for/matched on in the indirect comparison,NA,NA,"Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Past treatments for the disease of interest",TRUE,NA,NA,NA
10.1080/10428194.2021.1913143,33896344,results,1,NA,Primary outcome: treatment effect contrast,NA,NA,OR,TRUE,NA,NA,NA
10.1080/10428194.2021.1913143,33896344,results,1,NA,Direction of the treatment effect contrast: IPD treatment is:,NA,NA,"Numerator if ratio, or left side if difference",TRUE,NA,NA,NA
10.1080/10428194.2021.1913143,33896344,results,1,NA,Primary outcome: unadjusted treatment effect,NA,NA,7.78,TRUE,NA,NA,NA
10.1080/10428194.2021.1913143,33896344,results,1,NA,"p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])",NA,NA,[4.43;13.65],TRUE,NA,NA,NA
10.1080/10428194.2021.1913143,33896344,results,1,NA,Primary outcome: adjusted treatment effect,NA,NA,7.74,TRUE,NA,NA,NA
10.1080/10428194.2021.1913143,33896344,results,1,NA,"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX",NA,NA,[3.83;15.62],TRUE,NA,NA,NA
10.1080/10428194.2021.1913143,33896344,results,2,NA,Sample size of the population of interest in the non IPD treatment arm,NA,NA,97,TRUE,NA,NA,NA
10.1080/10428194.2021.1913143,33896344,results,2,NA,Initial sample size of the population of interest in the IPD treatment arm,NA,NA,128,TRUE,NA,NA,NA
10.1080/10428194.2021.1913143,33896344,results,2,NA,"Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC",NA,NA,45,TRUE,NA,NA,NA
10.1080/10428194.2021.1913143,33896344,results,2,NA,Reporting of a weights' distribution evaluation (MAIC),NA,NA,Not mentioned,TRUE,NA,NA,NA
10.1080/10428194.2021.1913143,33896344,results,2,NA,Reporting of the list of the covariates adjusted for/matched on,NA,NA,Yes,TRUE,NA,NA,NA
10.1080/10428194.2021.1913143,33896344,results,2,NA,Number of covariates adjusted for/matched on,NA,NA,6,TRUE,NA,NA,NA
10.1080/10428194.2021.1913143,33896344,results,2,NA,Covariates adjusted for/matched on in the indirect comparison,NA,NA,"Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Past treatments for the disease of interest",TRUE,NA,NA,NA
10.1080/10428194.2021.1913143,33896344,results,2,NA,Primary outcome: treatment effect contrast,NA,NA,OR,TRUE,NA,NA,NA
10.1080/10428194.2021.1913143,33896344,results,2,NA,Direction of the treatment effect contrast: IPD treatment is:,NA,NA,"Numerator if ratio, or left side if difference",TRUE,NA,NA,NA
10.1080/10428194.2021.1913143,33896344,results,2,NA,Primary outcome: unadjusted treatment effect,NA,NA,6.17,TRUE,NA,NA,NA
10.1080/10428194.2021.1913143,33896344,results,2,NA,"p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])",[3.15,NA,[3.45;11.05],FALSE,NA,NA,NA
10.1080/10428194.2021.1913143,33896344,results,2,NA,Primary outcome: adjusted treatment effect,NA,NA,5.12,TRUE,NA,NA,NA
10.1080/10428194.2021.1913143,33896344,results,2,NA,"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX",NA,NA,[2.35;11.13],TRUE,NA,NA,NA
10.1007/s12325-021-01756-0,33970454,general_information,NA,NA,Medical Condition of Interest Name,NA,NA,relapsed/refractory diffuse large b-cell lymphoma,TRUE,NA,NA,NA
10.1007/s12325-021-01756-0,33970454,general_information,NA,NA,Countries of first author affiliations,NA,NA,usa,TRUE,NA,NA,NA
10.1007/s12325-021-01756-0,33970454,general_information,NA,NA,Countries of last author affiliations,NA,NA,switzerland,TRUE,NA,NA,NA
10.1007/s12325-021-01756-0,33970454,general_information,NA,NA,"Positions of study investigators (for any authors of the article, any that applies)",NA,NA,"Academic, Pharmaceutical Industry, Private Data Analysis Company",TRUE,NA,NA,NA
10.1007/s12325-021-01756-0,33970454,general_information,NA,NA,"At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company",NA,NA,Yes,TRUE,NA,NA,NA
10.1007/s12325-021-01756-0,33970454,general_information,NA,NA,Mentioned sources of funding,NA,NA,Pharmaceutical Industry,TRUE,NA,NA,NA
10.1007/s12325-021-01756-0,33970454,general_information,NA,NA,"Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article",NA,NA,Yes,TRUE,NA,NA,NA
10.1007/s12325-021-01756-0,33970454,general_information,NA,NA,Mention of a systematic review to find the studies to compare treatments of interest,NA,NA,Yes,TRUE,NA,NA,NA
10.1007/s12325-021-01756-0,33970454,study_information,NA,1,Patient-level data used,NA,NA,Yes,TRUE,NA,NA,NA
10.1007/s12325-021-01756-0,33970454,study_information,NA,1,Clinical Trial,NA,NA,Yes,TRUE,NA,NA,NA
10.1007/s12325-021-01756-0,33970454,study_information,NA,1,NCT (only for clinical trial registered on clinicaltrials.gov),NA,NA,NCT02631044,TRUE,NA,NA,NA
10.1007/s12325-021-01756-0,33970454,study_information,NA,1,Country where the clinical trial/observational study was conducted (international if more than one),NA,NA,usa,TRUE,NA,NA,NA
10.1007/s12325-021-01756-0,33970454,study_information,NA,1,Phase of the clinical trial (clinical trial only),NA,NA,1,TRUE,NA,NA,NA
10.1007/s12325-021-01756-0,33970454,study_information,NA,1,Number of treatment arms (clinical trial only),NA,NA,1,TRUE,NA,NA,NA
10.1007/s12325-021-01756-0,33970454,study_information,NA,2,Patient-level data used,NA,NA,No,TRUE,NA,NA,NA
10.1007/s12325-021-01756-0,33970454,study_information,NA,2,Clinical Trial,NA,NA,No,TRUE,NA,NA,NA
10.1007/s12325-021-01756-0,33970454,study_information,NA,2,Data source name (only if observational study or clinical trial without NCT),NA,NA,scholar-1,TRUE,NA,NA,NA
10.1007/s12325-021-01756-0,33970454,study_information,NA,2,Country where the clinical trial/observational study was conducted (international if more than one),NA,NA,international,TRUE,NA,NA,NA
10.1007/s12325-021-01756-0,33970454,methodology,1,NA,Treatment name 1,NA,NA,lisocabtagene maraleucel,TRUE,NA,Did not use A performance Score as a matching variable,NA
10.1007/s12325-021-01756-0,33970454,methodology,1,NA,Study 'number(s)' for treatment 1,NA,NA,1,TRUE,NA,NA,NA
10.1007/s12325-021-01756-0,33970454,methodology,1,NA,Treatment name 2,NA,NA,salvage chemotherapy,TRUE,NA,NA,NA
10.1007/s12325-021-01756-0,33970454,methodology,1,NA,Study 'number(s)' for treatment 2,NA,NA,2,TRUE,NA,NA,NA
10.1007/s12325-021-01756-0,33970454,methodology,1,NA,Type of population-adjusted indirect comparisons performed,NA,NA,MAIC,TRUE,NA,NA,NA
10.1007/s12325-021-01756-0,33970454,methodology,1,NA,Anchored comparison?,NA,NA,No,TRUE,NA,NA,NA
10.1007/s12325-021-01756-0,33970454,methodology,1,NA,Form of the indirect comparison,NA,NA,Simple (ie treatments effects extracted from two studies),TRUE,NA,NA,NA
10.1007/s12325-021-01756-0,33970454,methodology,1,NA,Definition of a single primary outcome for the indirect comparison,NA,NA,"No primary outcome defined, or multiple primary outcomes without any clear distinction between them",TRUE,NA,NA,NA
10.1007/s12325-021-01756-0,33970454,methodology,1,NA,Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined),overall response rate,objective response rate (orr),objective response rate (orr),FALSE,NA,NA,NA
10.1007/s12325-021-01756-0,33970454,methodology,1,NA,Primary outcome: variable type,NA,NA,Binary (eg rates),TRUE,NA,NA,NA
10.1007/s12325-021-01756-0,33970454,methodology,1,NA,Justification for selecting variables to be included in the adjustment model (in the main text),NA,NA,"Nothing mentioned, not reported",TRUE,NA,NA,NA
10.1007/s12325-021-01756-0,33970454,methodology,1,NA,Inclusion of prognostic factors in the adjustment/matching model,NA,NA,No discussion (in the main text) of the status of prognostic factors of the variables,TRUE,NA,NA,NA
10.1007/s12325-021-01756-0,33970454,methodology,1,NA,Inclusion of treatment-effect modifiers in the adjustment/matching model,NA,NA,No discussion (in the main text) of the status of treatment-effect modifiers of the variables,TRUE,NA,NA,NA
10.1007/s12325-021-01756-0,33970454,methodology,1,NA,"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)",NA,NA,No,TRUE,NA,NA,NA
10.1007/s12325-021-01756-0,33970454,methodology,1,NA,Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale),NA,NA,No,TRUE,NA,NA,NA
10.1007/s12325-021-01756-0,33970454,results,1,NA,Sample size of the population of interest in the non IPD treatment arm,NA,NA,523,TRUE,NA,NA,NA
10.1007/s12325-021-01756-0,33970454,results,1,NA,Initial sample size of the population of interest in the IPD treatment arm,NA,NA,248,TRUE,NA,NA,NA
10.1007/s12325-021-01756-0,33970454,results,1,NA,"Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC",143,142,142,FALSE,NA,NA,NA
10.1007/s12325-021-01756-0,33970454,results,1,NA,Reporting of a weights' distribution evaluation (MAIC),NA,NA,Not mentioned,TRUE,NA,NA,NA
10.1007/s12325-021-01756-0,33970454,results,1,NA,Reporting of the list of the covariates adjusted for/matched on,NA,NA,Yes,TRUE,NA,NA,NA
10.1007/s12325-021-01756-0,33970454,results,1,NA,Number of covariates adjusted for/matched on,NA,NA,7,TRUE,NA,NA,NA
10.1007/s12325-021-01756-0,33970454,results,1,NA,Covariates adjusted for/matched on in the indirect comparison,NA,NA,"Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Past treatments for the disease of interest",TRUE,NA,NA,NA
10.1007/s12325-021-01756-0,33970454,results,1,NA,Primary outcome: treatment effect contrast,NA,NA,OR,TRUE,NA,NA,NA
10.1007/s12325-021-01756-0,33970454,results,1,NA,Direction of the treatment effect contrast: IPD treatment is:,NA,NA,"Numerator if ratio, or left side if difference",TRUE,NA,NA,NA
10.1007/s12325-021-01756-0,33970454,results,1,NA,Primary outcome: unadjusted treatment effect,NA,NA,7.7,TRUE,NA,NA,NA
10.1007/s12325-021-01756-0,33970454,results,1,NA,"p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])",<0.001,< 0.001,<0.001,FALSE,NA,NA,NA
10.1007/s12325-021-01756-0,33970454,results,1,NA,Primary outcome: adjusted treatment effect,NA,NA,7,TRUE,NA,NA,NA
10.1007/s12325-021-01756-0,33970454,results,1,NA,"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])",<0.001,< 0.001,<0.001,FALSE,NA,NA,NA
10.1111/head.14128,34021585,general_information,NA,NA,Medical Condition of Interest Name,NA,NA,migraine,TRUE,NA,NA,NA
10.1111/head.14128,34021585,general_information,NA,NA,Countries of first author affiliations,NA,NA,canada,TRUE,NA,NA,NA
10.1111/head.14128,34021585,general_information,NA,NA,Countries of last author affiliations,NA,NA,usa,TRUE,NA,NA,NA
10.1111/head.14128,34021585,general_information,NA,NA,"Positions of study investigators (for any authors of the article, any that applies)",NA,NA,"Academic, Pharmaceutical Industry, Private Data Analysis Company",TRUE,NA,NA,NA
10.1111/head.14128,34021585,general_information,NA,NA,"At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company",NA,NA,Yes,TRUE,NA,NA,NA
10.1111/head.14128,34021585,general_information,NA,NA,Mentioned sources of funding,NA,NA,Pharmaceutical Industry,TRUE,NA,NA,NA
10.1111/head.14128,34021585,general_information,NA,NA,"Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article",NA,NA,Yes,TRUE,NA,NA,NA
10.1111/head.14128,34021585,general_information,NA,NA,Mention of a systematic review to find the studies to compare treatments of interest,NA,NA,No,TRUE,NA,NA,NA
10.1111/head.14128,34021585,study_information,NA,1,Patient-level data used,NA,NA,Yes,TRUE,NA,NA,NA
10.1111/head.14128,34021585,study_information,NA,1,Clinical Trial,NA,NA,Yes,TRUE,NA,NA,NA
10.1111/head.14128,34021585,study_information,NA,1,NCT (only for clinical trial registered on clinicaltrials.gov),NA,NA,NCT03266588,TRUE,NA,NA,NA
10.1111/head.14128,34021585,study_information,NA,1,Country where the clinical trial/observational study was conducted (international if more than one),NA,NA,usa,TRUE,NA,NA,NA
10.1111/head.14128,34021585,study_information,NA,1,Phase of the clinical trial (clinical trial only),NA,NA,"2, 3",TRUE,NA,NA,NA
10.1111/head.14128,34021585,study_information,NA,1,Number of treatment arms (clinical trial only),NA,NA,1,TRUE,NA,NA,NA
10.1111/head.14128,34021585,study_information,NA,2,Patient-level data used,NA,NA,No,TRUE,NA,NA,NA
10.1111/head.14128,34021585,study_information,NA,2,Clinical Trial,NA,NA,Yes,TRUE,NA,NA,NA
10.1111/head.14128,34021585,study_information,NA,2,NCT (only for clinical trial registered on clinicaltrials.gov),NA,NA,NCT02614183,TRUE,NA,NA,NA
10.1111/head.14128,34021585,study_information,NA,2,Country where the clinical trial/observational study was conducted (international if more than one),NA,NA,international,TRUE,NA,NA,NA
10.1111/head.14128,34021585,study_information,NA,2,Phase of the clinical trial (clinical trial only),NA,NA,3,TRUE,NA,NA,NA
10.1111/head.14128,34021585,study_information,NA,2,Number of treatment arms (clinical trial only),NA,NA,2 or more,TRUE,NA,NA,NA
10.1111/head.14128,34021585,study_information,NA,3,Patient-level data used,NA,NA,No,TRUE,NA,NA,NA
10.1111/head.14128,34021585,study_information,NA,3,Clinical Trial,NA,NA,Yes,TRUE,NA,NA,NA
10.1111/head.14128,34021585,study_information,NA,3,NCT (only for clinical trial registered on clinicaltrials.gov),NA,NA,NCT02614196,TRUE,NA,NA,NA
10.1111/head.14128,34021585,study_information,NA,3,Country where the clinical trial/observational study was conducted (international if more than one),NA,NA,international,TRUE,NA,NA,NA
10.1111/head.14128,34021585,study_information,NA,3,Phase of the clinical trial (clinical trial only),NA,NA,3,TRUE,NA,NA,NA
10.1111/head.14128,34021585,study_information,NA,3,Number of treatment arms (clinical trial only),NA,NA,2 or more,TRUE,NA,NA,NA
10.1111/head.14128,34021585,study_information,NA,4,Patient-level data used,NA,NA,No,TRUE,NA,NA,NA
10.1111/head.14128,34021585,study_information,NA,4,Clinical Trial,NA,NA,Yes,TRUE,NA,NA,NA
10.1111/head.14128,34021585,study_information,NA,4,NCT (only for clinical trial registered on clinicaltrials.gov),NA,NA,NCT02456740,TRUE,NA,NA,NA
10.1111/head.14128,34021585,study_information,NA,4,Country where the clinical trial/observational study was conducted (international if more than one),NA,NA,international,TRUE,NA,NA,NA
10.1111/head.14128,34021585,study_information,NA,4,Phase of the clinical trial (clinical trial only),NA,NA,3,TRUE,NA,NA,NA
10.1111/head.14128,34021585,study_information,NA,4,Number of treatment arms (clinical trial only),NA,NA,2 or more,TRUE,NA,NA,NA
10.1111/head.14128,34021585,methodology,1,NA,Treatment name 1,NA,NA,rimegepant,TRUE,"MIDAS: lower score better
State that there hypothesis is equivalence, but only tested for efficacy; so seems like a results based hypothesis
",NA,NA
10.1111/head.14128,34021585,methodology,1,NA,Study 'number(s)' for treatment 1,NA,NA,1,TRUE,NA,NA,NA
10.1111/head.14128,34021585,methodology,1,NA,Treatment name 2,NA,NA,placebo,TRUE,NA,NA,NA
10.1111/head.14128,34021585,methodology,1,NA,Study 'number(s)' for treatment 2,NA,NA,2;3,TRUE,NA,NA,NA
10.1111/head.14128,34021585,methodology,1,NA,Type of population-adjusted indirect comparisons performed,NA,NA,MAIC,TRUE,NA,NA,NA
10.1111/head.14128,34021585,methodology,1,NA,Anchored comparison?,NA,NA,No,TRUE,NA,NA,NA
10.1111/head.14128,34021585,methodology,1,NA,Form of the indirect comparison,NA,NA,"Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate)",TRUE,NA,NA,NA
10.1111/head.14128,34021585,methodology,1,NA,Definition of a single primary outcome for the indirect comparison,NA,NA,"No primary outcome defined, or multiple primary outcomes without any clear distinction between them",TRUE,NA,NA,NA
10.1111/head.14128,34021585,methodology,1,NA,Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined),migraine disability assessment test,change in midas (migraine disability assessment) from baseline to 12 weeks,change in midas (migraine disability assessment) from baseline to 12 weeks,FALSE,NA,NA,NA
10.1111/head.14128,34021585,methodology,1,NA,Primary outcome: variable type,NA,NA,"Continuous (count, mean, ...)",TRUE,NA,NA,NA
10.1111/head.14128,34021585,methodology,1,NA,Justification for selecting variables to be included in the adjustment model (in the main text),Statistical imbalanced between treatment groups (independently of the status of prognostic/effect modifier),"Nothing mentioned, not reported","Nothing mentioned, not reported",FALSE,NA,NA,NA
10.1111/head.14128,34021585,methodology,1,NA,Inclusion of prognostic factors in the adjustment/matching model,NA,NA,No discussion (in the main text) of the status of prognostic factors of the variables,TRUE,NA,NA,NA
10.1111/head.14128,34021585,methodology,1,NA,Inclusion of treatment-effect modifiers in the adjustment/matching model,NA,NA,No discussion (in the main text) of the status of treatment-effect modifiers of the variables,TRUE,NA,NA,NA
10.1111/head.14128,34021585,methodology,1,NA,"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)",NA,NA,Yes,TRUE,NA,NA,NA
10.1111/head.14128,34021585,methodology,1,NA,Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale),NA,NA,No,TRUE,NA,NA,NA
10.1111/head.14128,34021585,methodology,2,NA,Treatment name 1,NA,NA,rimegepant,TRUE,Sample size for individual treatment arms from the non IPD studies not reported,NA,NA
10.1111/head.14128,34021585,methodology,2,NA,Study 'number(s)' for treatment 1,NA,NA,1,TRUE,NA,NA,NA
10.1111/head.14128,34021585,methodology,2,NA,Treatment name 2,NA,NA,galcanezumab,TRUE,NA,NA,NA
10.1111/head.14128,34021585,methodology,2,NA,Study 'number(s)' for treatment 2,2.3,2;3,2;3,FALSE,NA,NA,NA
10.1111/head.14128,34021585,methodology,2,NA,Type of population-adjusted indirect comparisons performed,NA,NA,MAIC,TRUE,NA,NA,NA
10.1111/head.14128,34021585,methodology,2,NA,Anchored comparison?,NA,NA,No,TRUE,NA,NA,NA
10.1111/head.14128,34021585,methodology,2,NA,Form of the indirect comparison,NA,NA,"Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate)",TRUE,NA,NA,NA
10.1111/head.14128,34021585,methodology,2,NA,Definition of a single primary outcome for the indirect comparison,NA,NA,"No primary outcome defined, or multiple primary outcomes without any clear distinction between them",TRUE,NA,NA,NA
10.1111/head.14128,34021585,methodology,2,NA,Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined),migraine disability assessment test,change in midas (migraine disability assessment) from baseline to 12 weeks,change in midas (migraine disability assessment) from baseline to 12 weeks,FALSE,NA,NA,NA
10.1111/head.14128,34021585,methodology,2,NA,Primary outcome: variable type,NA,NA,"Continuous (count, mean, ...)",TRUE,NA,NA,NA
10.1111/head.14128,34021585,methodology,2,NA,Justification for selecting variables to be included in the adjustment model (in the main text),Statistical imbalanced between treatment groups (independently of the status of prognostic/effect modifier),"Nothing mentioned, not reported","Nothing mentioned, not reported",FALSE,NA,NA,NA
10.1111/head.14128,34021585,methodology,2,NA,Inclusion of prognostic factors in the adjustment/matching model,NA,NA,No discussion (in the main text) of the status of prognostic factors of the variables,TRUE,NA,NA,NA
10.1111/head.14128,34021585,methodology,2,NA,Inclusion of treatment-effect modifiers in the adjustment/matching model,NA,NA,No discussion (in the main text) of the status of treatment-effect modifiers of the variables,TRUE,NA,NA,NA
10.1111/head.14128,34021585,methodology,2,NA,"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)",NA,NA,Yes,TRUE,NA,NA,NA
10.1111/head.14128,34021585,methodology,2,NA,Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale),NA,NA,No,TRUE,NA,NA,NA
10.1111/head.14128,34021585,methodology,3,NA,Treatment name 1,NA,NA,rimegepant,TRUE,NA,NA,NA
10.1111/head.14128,34021585,methodology,3,NA,Study 'number(s)' for treatment 1,NA,NA,1,TRUE,NA,NA,NA
10.1111/head.14128,34021585,methodology,3,NA,Treatment name 2,NA,NA,placebo,TRUE,NA,NA,NA
10.1111/head.14128,34021585,methodology,3,NA,Study 'number(s)' for treatment 2,NA,NA,4,TRUE,NA,NA,NA
10.1111/head.14128,34021585,methodology,3,NA,Type of population-adjusted indirect comparisons performed,NA,NA,MAIC,TRUE,NA,NA,NA
10.1111/head.14128,34021585,methodology,3,NA,Anchored comparison?,NA,NA,No,TRUE,NA,NA,NA
10.1111/head.14128,34021585,methodology,3,NA,Form of the indirect comparison,NA,NA,Simple (ie treatments effects extracted from two studies),TRUE,NA,NA,NA
10.1111/head.14128,34021585,methodology,3,NA,Definition of a single primary outcome for the indirect comparison,NA,NA,"No primary outcome defined, or multiple primary outcomes without any clear distinction between them",TRUE,NA,NA,NA
10.1111/head.14128,34021585,methodology,3,NA,Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined),migraine disability assessment test,change in midas (migraine disability assessment) from baseline to 12 weeks,change in midas (migraine disability assessment) from baseline to 12 weeks,FALSE,NA,NA,NA
10.1111/head.14128,34021585,methodology,3,NA,Primary outcome: variable type,NA,NA,"Continuous (count, mean, ...)",TRUE,NA,NA,NA
10.1111/head.14128,34021585,methodology,3,NA,Justification for selecting variables to be included in the adjustment model (in the main text),Statistical imbalanced between treatment groups (independently of the status of prognostic/effect modifier),"Nothing mentioned, not reported","Nothing mentioned, not reported",FALSE,NA,NA,NA
10.1111/head.14128,34021585,methodology,3,NA,Inclusion of prognostic factors in the adjustment/matching model,NA,NA,No discussion (in the main text) of the status of prognostic factors of the variables,TRUE,NA,NA,NA
10.1111/head.14128,34021585,methodology,3,NA,Inclusion of treatment-effect modifiers in the adjustment/matching model,NA,NA,No discussion (in the main text) of the status of treatment-effect modifiers of the variables,TRUE,NA,NA,NA
10.1111/head.14128,34021585,methodology,3,NA,"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)",NA,NA,Yes,TRUE,NA,NA,NA
10.1111/head.14128,34021585,methodology,3,NA,Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale),NA,NA,No,TRUE,NA,NA,NA
10.1111/head.14128,34021585,methodology,4,NA,Treatment name 1,NA,NA,rimegepant,TRUE,NA,NA,NA
10.1111/head.14128,34021585,methodology,4,NA,Study 'number(s)' for treatment 1,NA,NA,1,TRUE,NA,NA,NA
10.1111/head.14128,34021585,methodology,4,NA,Treatment name 2,NA,NA,erenumab,TRUE,NA,NA,NA
10.1111/head.14128,34021585,methodology,4,NA,Study 'number(s)' for treatment 2,NA,NA,4,TRUE,NA,NA,NA
10.1111/head.14128,34021585,methodology,4,NA,Type of population-adjusted indirect comparisons performed,NA,NA,MAIC,TRUE,NA,NA,NA
10.1111/head.14128,34021585,methodology,4,NA,Anchored comparison?,NA,NA,No,TRUE,NA,NA,NA
10.1111/head.14128,34021585,methodology,4,NA,Form of the indirect comparison,NA,NA,Simple (ie treatments effects extracted from two studies),TRUE,NA,NA,NA
10.1111/head.14128,34021585,methodology,4,NA,Definition of a single primary outcome for the indirect comparison,NA,NA,"No primary outcome defined, or multiple primary outcomes without any clear distinction between them",TRUE,NA,NA,NA
10.1111/head.14128,34021585,methodology,4,NA,Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined),migraine disability assessment testmigraine disability assessment test,change in midas (migraine disability assessment) from baseline to 12 weeks,change in midas (migraine disability assessment) from baseline to 12 weeks,FALSE,NA,NA,NA
10.1111/head.14128,34021585,methodology,4,NA,Primary outcome: variable type,NA,NA,"Continuous (count, mean, ...)",TRUE,NA,NA,NA
10.1111/head.14128,34021585,methodology,4,NA,Justification for selecting variables to be included in the adjustment model (in the main text),Statistical imbalanced between treatment groups (independently of the status of prognostic/effect modifier),"Nothing mentioned, not reported","Nothing mentioned, not reported",FALSE,NA,NA,NA
10.1111/head.14128,34021585,methodology,4,NA,Inclusion of prognostic factors in the adjustment/matching model,NA,NA,No discussion (in the main text) of the status of prognostic factors of the variables,TRUE,NA,NA,NA
10.1111/head.14128,34021585,methodology,4,NA,Inclusion of treatment-effect modifiers in the adjustment/matching model,NA,NA,No discussion (in the main text) of the status of treatment-effect modifiers of the variables,TRUE,NA,NA,NA
10.1111/head.14128,34021585,methodology,4,NA,"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)",NA,NA,Yes,TRUE,NA,NA,NA
10.1111/head.14128,34021585,methodology,4,NA,Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale),NA,NA,No,TRUE,NA,NA,NA
10.1111/head.14128,34021585,results,1,NA,Sample size of the population of interest in the non IPD treatment arm,NA,NA,1773,TRUE,NA,NA,NA
10.1111/head.14128,34021585,results,1,NA,Initial sample size of the population of interest in the IPD treatment arm,NA,NA,257,TRUE,NA,NA,NA
10.1111/head.14128,34021585,results,1,NA,"Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC",NA,NA,169,TRUE,NA,NA,NA
10.1111/head.14128,34021585,results,1,NA,Reporting of a weights' distribution evaluation (MAIC),NA,NA,"Yes, mentions that the weights distribution has been studied, and weights distribution reported in main article or supplemental materials",TRUE,NA,NA,NA
10.1111/head.14128,34021585,results,1,NA,Reporting of the list of the covariates adjusted for/matched on,NA,NA,Yes,TRUE,NA,NA,NA
10.1111/head.14128,34021585,results,1,NA,Number of covariates adjusted for/matched on,NA,NA,6,TRUE,NA,NA,NA
10.1111/head.14128,34021585,results,1,NA,Covariates adjusted for/matched on in the indirect comparison,NA,NA,"Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Race/ethnicity",TRUE,NA,NA,NA
10.1111/head.14128,34021585,results,1,NA,Primary outcome: treatment effect contrast,NA,NA,Means difference,TRUE,NA,NA,NA
10.1111/head.14128,34021585,results,1,NA,Direction of the treatment effect contrast: IPD treatment is:,NA,NA,"Numerator if ratio, or left side if difference",TRUE,NA,NA,NA
10.1111/head.14128,34021585,results,1,NA,Primary outcome: unadjusted treatment effect,-3.97,-5.54,-5.54,FALSE,NA,NA,NA
10.1111/head.14128,34021585,results,1,NA,"p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])",0.12,0.026,0.026,FALSE,NA,NA,NA
10.1111/head.14128,34021585,results,1,NA,Primary outcome: adjusted treatment effect,-5.54,-7.37,-7.37,FALSE,NA,NA,NA
10.1111/head.14128,34021585,results,1,NA,"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])",0.026,0.009,0.009,FALSE,NA,NA,NA
10.1111/head.14128,34021585,results,2,NA,Initial sample size of the population of interest in the IPD treatment arm,NA,NA,257,TRUE,NA,NA,NA
10.1111/head.14128,34021585,results,2,NA,"Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC",NA,NA,169,TRUE,NA,NA,NA
10.1111/head.14128,34021585,results,2,NA,Reporting of a weights' distribution evaluation (MAIC),NA,NA,"Yes, mentions that the weights distribution has been studied, and weights distribution reported in main article or supplemental materials",TRUE,NA,NA,NA
10.1111/head.14128,34021585,results,2,NA,Reporting of the list of the covariates adjusted for/matched on,NA,NA,Yes,TRUE,NA,NA,NA
10.1111/head.14128,34021585,results,2,NA,Number of covariates adjusted for/matched on,NA,NA,6,TRUE,NA,NA,NA
10.1111/head.14128,34021585,results,2,NA,Covariates adjusted for/matched on in the indirect comparison,NA,NA,"Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Race/ethnicity",TRUE,NA,NA,NA
10.1111/head.14128,34021585,results,2,NA,Primary outcome: treatment effect contrast,NA,NA,Means difference,TRUE,NA,NA,NA
10.1111/head.14128,34021585,results,2,NA,Direction of the treatment effect contrast: IPD treatment is:,NA,NA,"Numerator if ratio, or left side if difference",TRUE,NA,NA,NA
10.1111/head.14128,34021585,results,2,NA,Primary outcome: unadjusted treatment effect,3.48,1.75,1.75,FALSE,NA,NA,NA
10.1111/head.14128,34021585,results,2,NA,"p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])",0.172,0.528,0.528,FALSE,NA,NA,NA
10.1111/head.14128,34021585,results,2,NA,Primary outcome: adjusted treatment effect,-5.54,-0.09,-0.09,FALSE,NA,NA,NA
10.1111/head.14128,34021585,results,2,NA,"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])",0.026,0.979,0.979,FALSE,NA,NA,NA
10.1111/head.14128,34021585,results,2,NA,Sample size of the population of interest in the non IPD treatment arm,NA,1773,XXXX,FALSE,NA,NA,NA
10.1111/head.14128,34021585,results,3,NA,Initial sample size of the population of interest in the IPD treatment arm,NA,NA,257,TRUE,NA,NA,NA
10.1111/head.14128,34021585,results,3,NA,"Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC",NA,NA,214,TRUE,NA,NA,NA
10.1111/head.14128,34021585,results,3,NA,Reporting of a weights' distribution evaluation (MAIC),NA,NA,"Yes, mentions that the weights distribution has been studied, and weights distribution reported in main article or supplemental materials",TRUE,NA,NA,NA
10.1111/head.14128,34021585,results,3,NA,Reporting of the list of the covariates adjusted for/matched on,NA,NA,Yes,TRUE,NA,NA,NA
10.1111/head.14128,34021585,results,3,NA,Number of covariates adjusted for/matched on,4,6,4,FALSE,NA,NA,NA
10.1111/head.14128,34021585,results,3,NA,Covariates adjusted for/matched on in the indirect comparison,NA,NA,"Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Race/ethnicity",TRUE,NA,NA,NA
10.1111/head.14128,34021585,results,3,NA,Primary outcome: treatment effect contrast,NA,NA,Means difference,TRUE,NA,NA,NA
10.1111/head.14128,34021585,results,3,NA,Direction of the treatment effect contrast: IPD treatment is:,NA,NA,"Numerator if ratio, or left side if difference",TRUE,NA,NA,NA
10.1111/head.14128,34021585,results,3,NA,Primary outcome: unadjusted treatment effect,-5.57,-3.94,-3.94,FALSE,NA,NA,NA
10.1111/head.14128,34021585,results,3,NA,"p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])",0.026,0.121,0.121,FALSE,NA,NA,NA
10.1111/head.14128,34021585,results,3,NA,Primary outcome: adjusted treatment effect,-7.37,-5.67,-5.67,FALSE,NA,NA,NA
10.1111/head.14128,34021585,results,3,NA,"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])",0.009,0.025,0.025,FALSE,NA,NA,NA
10.1111/head.14128,34021585,results,3,NA,Sample size of the population of interest in the non IPD treatment arm,NA,955,XXXX,FALSE,NA,NA,NA
10.1111/head.14128,34021585,results,4,NA,Initial sample size of the population of interest in the IPD treatment arm,NA,NA,257,TRUE,NA,NA,NA
10.1111/head.14128,34021585,results,4,NA,"Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC",NA,NA,214,TRUE,NA,NA,NA
10.1111/head.14128,34021585,results,4,NA,Reporting of a weights' distribution evaluation (MAIC),NA,NA,"Yes, mentions that the weights distribution has been studied, and weights distribution reported in main article or supplemental materials",TRUE,NA,NA,NA
10.1111/head.14128,34021585,results,4,NA,Reporting of the list of the covariates adjusted for/matched on,NA,NA,Yes,TRUE,NA,NA,NA
10.1111/head.14128,34021585,results,4,NA,Number of covariates adjusted for/matched on,4,6,4,FALSE,NA,NA,NA
10.1111/head.14128,34021585,results,4,NA,Covariates adjusted for/matched on in the indirect comparison,NA,NA,"Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Race/ethnicity",TRUE,NA,NA,NA
10.1111/head.14128,34021585,results,4,NA,Primary outcome: treatment effect contrast,NA,NA,Means difference,TRUE,NA,NA,NA
10.1111/head.14128,34021585,results,4,NA,Direction of the treatment effect contrast: IPD treatment is:,NA,NA,"Numerator if ratio, or left side if difference",TRUE,NA,NA,NA
10.1111/head.14128,34021585,results,4,NA,Primary outcome: unadjusted treatment effect,1.75,3.48,3.48,FALSE,NA,NA,NA
10.1111/head.14128,34021585,results,4,NA,"p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])",0.528,0.172,0.172,FALSE,NA,NA,NA
10.1111/head.14128,34021585,results,4,NA,Primary outcome: adjusted treatment effect,-0.09,1.75,1.75,FALSE,NA,NA,NA
10.1111/head.14128,34021585,results,4,NA,"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])",0.979,0.501,0.501,FALSE,NA,NA,NA
10.1111/head.14128,34021585,results,4,NA,Sample size of the population of interest in the non IPD treatment arm,NA,955,XXXX,FALSE,NA,NA,NA
10.3390/biom11060780,34067288,general_information,NA,NA,Medical Condition of Interest Name,NA,NA,metastatic pancreatic cancer,TRUE,NA,NA,NA
10.3390/biom11060780,34067288,general_information,NA,NA,Countries of first author affiliations,italy,itally,XXXX,FALSE,NA,NA,NA
10.3390/biom11060780,34067288,general_information,NA,NA,Countries of last author affiliations,NA,NA,italy,TRUE,NA,NA,NA
10.3390/biom11060780,34067288,general_information,NA,NA,"Positions of study investigators (for any authors of the article, any that applies)",NA,NA,Academic,TRUE,NA,NA,NA
10.3390/biom11060780,34067288,general_information,NA,NA,"At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company",NA,NA,Not mentioned,TRUE,NA,NA,NA
10.3390/biom11060780,34067288,general_information,NA,NA,Mentioned sources of funding,None mentioned,This research received no external funding.,XXXX,FALSE,NA,NA,NA
10.3390/biom11060780,34067288,general_information,NA,NA,"Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article",NA,NA,None,TRUE,NA,NA,NA
10.3390/biom11060780,34067288,general_information,NA,NA,Mention of a systematic review to find the studies to compare treatments of interest,NA,NA,No,TRUE,NA,NA,NA
10.3390/biom11060780,34067288,study_information,NA,1,Patient-level data used,NA,NA,Yes,TRUE,NA,NA,NA
10.3390/biom11060780,34067288,study_information,NA,1,Clinical Trial,NA,NA,No,TRUE,NA,NA,NA
10.3390/biom11060780,34067288,study_information,NA,1,Data source name (only if observational study or clinical trial without NCT),NA,NA,local retrospective cohort from ehr,TRUE,NA,NA,NA
10.3390/biom11060780,34067288,study_information,NA,1,Country where the clinical trial/observational study was conducted (international if more than one),NA,NA,italy,TRUE,NA,NA,NA
10.3390/biom11060780,34067288,study_information,NA,2,Patient-level data used,NA,NA,No,TRUE,NA,NA,NA
10.3390/biom11060780,34067288,study_information,NA,2,Clinical Trial,NA,NA,Yes,TRUE,NA,NA,NA
10.3390/biom11060780,34067288,study_information,NA,2,NCT (only for clinical trial registered on clinicaltrials.gov),NCT01804790,NCT00112658,NCT00112658,FALSE,NA,NA,NA
10.3390/biom11060780,34067288,study_information,NA,2,Country where the clinical trial/observational study was conducted (international if more than one),NA,NA,france,TRUE,NA,NA,NA
10.3390/biom11060780,34067288,study_information,NA,2,Phase of the clinical trial (clinical trial only),3,"2, 3",XXXX,FALSE,NA,NA,NA
10.3390/biom11060780,34067288,study_information,NA,2,Number of treatment arms (clinical trial only),NA,NA,2 or more,TRUE,NA,NA,NA
10.3390/biom11060780,34067288,methodology,1,NA,Treatment name 1,folfirinox,gemcitabine + nab-paclitaxel,gemcitabine + nab-paclitaxel,FALSE,"Similar efficacy but different safety profiles
Mention of the target population 
Almost no description of the PRODIGE clinical trial
Almost no discussion of the assumptions of MAIC, especially of the unanchored ones. Complete overlook of the covariate inclusion criteria. 
We can guess that the variables presented in the table 1 are the ones that have been matched on,  but not completely obvious, and one of the modality of the metastatic sites is not balanced between populations (despite the fact that the d value is very low)
Poor quality article, submitted and accepted within 30 days",NA,NA
10.3390/biom11060780,34067288,methodology,1,NA,Study 'number(s)' for treatment 1,NA,NA,1,TRUE,NA,NA,NA
10.3390/biom11060780,34067288,methodology,1,NA,Treatment name 2,gemcitabine + nab-paclitaxel,folfirinox,folfirinox,FALSE,NA,NA,NA
10.3390/biom11060780,34067288,methodology,1,NA,Study 'number(s)' for treatment 2,NA,NA,2,TRUE,NA,NA,NA
10.3390/biom11060780,34067288,methodology,1,NA,Type of population-adjusted indirect comparisons performed,NA,NA,MAIC,TRUE,NA,NA,NA
10.3390/biom11060780,34067288,methodology,1,NA,Anchored comparison?,NA,NA,No,TRUE,NA,NA,NA
10.3390/biom11060780,34067288,methodology,1,NA,Form of the indirect comparison,NA,NA,Simple (ie treatments effects extracted from two studies),TRUE,NA,NA,NA
10.3390/biom11060780,34067288,methodology,1,NA,Definition of a single primary outcome for the indirect comparison,NA,NA,"No primary outcome defined, or multiple primary outcomes without any clear distinction between them",TRUE,NA,NA,NA
10.3390/biom11060780,34067288,methodology,1,NA,Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined),overall survival,overall survival (os),overall survival (os),FALSE,NA,NA,NA
10.3390/biom11060780,34067288,methodology,1,NA,Primary outcome: variable type,NA,NA,Time-to-event,TRUE,NA,NA,NA
10.3390/biom11060780,34067288,methodology,1,NA,Justification for selecting variables to be included in the adjustment model (in the main text),"Nothing mentioned, not reported
","Nothing mentioned, not reported","Nothing mentioned, not reported",FALSE,NA,NA,NA
10.3390/biom11060780,34067288,methodology,1,NA,Inclusion of prognostic factors in the adjustment/matching model,NA,NA,No discussion (in the main text) of the status of prognostic factors of the variables,TRUE,NA,NA,NA
10.3390/biom11060780,34067288,methodology,1,NA,Inclusion of treatment-effect modifiers in the adjustment/matching model,NA,NA,No discussion (in the main text) of the status of treatment-effect modifiers of the variables,TRUE,NA,NA,NA
10.3390/biom11060780,34067288,methodology,1,NA,"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)",NA,NA,No,TRUE,NA,NA,NA
10.3390/biom11060780,34067288,methodology,1,NA,Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale),NA,NA,No,TRUE,NA,NA,NA
10.3390/biom11060780,34067288,results,1,NA,Sample size of the population of interest in the non IPD treatment arm,268,171,171,FALSE,NA,NA,NA
10.3390/biom11060780,34067288,results,1,NA,Initial sample size of the population of interest in the IPD treatment arm,171,268,268,FALSE,NA,NA,NA
10.3390/biom11060780,34067288,results,1,NA,Reporting of a weights' distribution evaluation (MAIC),NA,NA,Not mentioned,TRUE,NA,NA,NA
10.3390/biom11060780,34067288,results,1,NA,Reporting of the list of the covariates adjusted for/matched on,Yes,No,Yes,FALSE,NA,NA,NA
10.3390/biom11060780,34067288,results,1,NA,Covariates adjusted for/matched on in the indirect comparison,"Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Past treatments for the disease of interest, Comorbidities and medical history (beside pathology/disease of interest in the comparison)",NA,"Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Past treatments for the disease of interest, Comorbidities and medical history (beside pathology/disease of interest in the comparison)",FALSE,NA,NA,NA
10.3390/biom11060780,34067288,results,1,NA,Primary outcome: treatment effect contrast,NA,NA,HR,TRUE,NA,NA,NA
10.3390/biom11060780,34067288,results,1,NA,Direction of the treatment effect contrast: IPD treatment is:,NA,NA,"Denominator if ratio, or rightside if difference",TRUE,NA,NA,NA
10.3390/biom11060780,34067288,results,1,NA,Primary outcome: adjusted treatment effect,NA,NA,1.1,TRUE,NA,NA,NA
10.3390/biom11060780,34067288,results,1,NA,"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])",NA,NA,0.527,TRUE,NA,NA,NA
10.1080/03007995.2021.1947216,34236007,general_information,NA,NA,Medical Condition of Interest Name,NA,NA,spinal muscular atrophy type 1,TRUE,NA,NA,NA
10.1080/03007995.2021.1947216,34236007,general_information,NA,NA,Countries of first author affiliations,switzerland,switzeland,XXXX,FALSE,NA,NA,NA
10.1080/03007995.2021.1947216,34236007,general_information,NA,NA,Countries of last author affiliations,NA,NA,usa,TRUE,NA,NA,NA
10.1080/03007995.2021.1947216,34236007,general_information,NA,NA,"Positions of study investigators (for any authors of the article, any that applies)",NA,NA,"Pharmaceutical Industry, Private Data Analysis Company",TRUE,NA,NA,NA
10.1080/03007995.2021.1947216,34236007,general_information,NA,NA,"At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company",NA,NA,Yes,TRUE,NA,NA,NA
10.1080/03007995.2021.1947216,34236007,general_information,NA,NA,Mentioned sources of funding,NA,NA,Pharmaceutical Industry,TRUE,NA,NA,NA
10.1080/03007995.2021.1947216,34236007,general_information,NA,NA,"Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article",NA,NA,Yes,TRUE,NA,NA,NA
10.1080/03007995.2021.1947216,34236007,general_information,NA,NA,Mention of a systematic review to find the studies to compare treatments of interest,NA,NA,Yes,TRUE,NA,NA,NA
10.1080/03007995.2021.1947216,34236007,study_information,NA,1,Patient-level data used,NA,NA,Yes,TRUE,NA,NA,NA
10.1080/03007995.2021.1947216,34236007,study_information,NA,1,Clinical Trial,NA,NA,Yes,TRUE,NA,NA,NA
10.1080/03007995.2021.1947216,34236007,study_information,NA,1,NCT (only for clinical trial registered on clinicaltrials.gov),NA,NA,NCT02122952,TRUE,NA,NA,NA
10.1080/03007995.2021.1947216,34236007,study_information,NA,1,Country where the clinical trial/observational study was conducted (international if more than one),NA,NA,usa,TRUE,NA,NA,NA
10.1080/03007995.2021.1947216,34236007,study_information,NA,1,Phase of the clinical trial (clinical trial only),NA,NA,1,TRUE,NA,NA,NA
10.1080/03007995.2021.1947216,34236007,study_information,NA,1,Number of treatment arms (clinical trial only),1,2 or more,XXXX,FALSE,NA,NA,NA
10.1080/03007995.2021.1947216,34236007,study_information,NA,2,Patient-level data used,NA,NA,Yes,TRUE,NA,NA,NA
10.1080/03007995.2021.1947216,34236007,study_information,NA,2,Clinical Trial,NA,NA,Yes,TRUE,NA,NA,NA
10.1080/03007995.2021.1947216,34236007,study_information,NA,2,NCT (only for clinical trial registered on clinicaltrials.gov),NA,NA,NCT03306277,TRUE,NA,NA,NA
10.1080/03007995.2021.1947216,34236007,study_information,NA,2,Country where the clinical trial/observational study was conducted (international if more than one),NA,NA,usa,TRUE,NA,NA,NA
10.1080/03007995.2021.1947216,34236007,study_information,NA,2,Phase of the clinical trial (clinical trial only),NA,NA,3,TRUE,NA,NA,NA
10.1080/03007995.2021.1947216,34236007,study_information,NA,2,Number of treatment arms (clinical trial only),NA,NA,1,TRUE,NA,NA,NA
10.1080/03007995.2021.1947216,34236007,study_information,NA,3,Patient-level data used,NA,NA,No,TRUE,NA,NA,NA
10.1080/03007995.2021.1947216,34236007,study_information,NA,3,Clinical Trial,NA,NA,Yes,TRUE,NA,NA,NA
10.1080/03007995.2021.1947216,34236007,study_information,NA,3,NCT (only for clinical trial registered on clinicaltrials.gov),NCT02594124,NA,NCT02594124,FALSE,NA,NA,NA
10.1080/03007995.2021.1947216,34236007,study_information,NA,3,Country where the clinical trial/observational study was conducted (international if more than one),usa,international,XXXX,FALSE,NA,NA,NA
10.1080/03007995.2021.1947216,34236007,study_information,NA,3,Phase of the clinical trial (clinical trial only),NA,NA,3,TRUE,NA,NA,NA
10.1080/03007995.2021.1947216,34236007,study_information,NA,3,Number of treatment arms (clinical trial only),NA,NA,1,TRUE,NA,NA,NA
10.1080/03007995.2021.1947216,34236007,methodology,1,NA,Treatment name 1,NA,NA,onasemnogene abeparvovec,TRUE,"Discard nonIPD data for one of the trial identified by the literature, without any explanation about it (ENDEAR NCT02193074 ): only uses it to conduct ITC, but not the MAIC
Seems like there are only 2 events in the IPD trial, but still significant",NA,NA
10.1080/03007995.2021.1947216,34236007,methodology,1,NA,Study 'number(s)' for treatment 1,NA,NA,1;2,TRUE,NA,NA,NA
10.1080/03007995.2021.1947216,34236007,methodology,1,NA,Treatment name 2,NA,NA,nusinersen,TRUE,NA,NA,NA
10.1080/03007995.2021.1947216,34236007,methodology,1,NA,Study 'number(s)' for treatment 2,NA,NA,3,TRUE,NA,NA,NA
10.1080/03007995.2021.1947216,34236007,methodology,1,NA,Type of population-adjusted indirect comparisons performed,NA,NA,MAIC,TRUE,NA,NA,NA
10.1080/03007995.2021.1947216,34236007,methodology,1,NA,Anchored comparison?,NA,NA,No,TRUE,NA,NA,NA
10.1080/03007995.2021.1947216,34236007,methodology,1,NA,Form of the indirect comparison,NA,NA,"Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate)",TRUE,NA,NA,NA
10.1080/03007995.2021.1947216,34236007,methodology,1,NA,Definition of a single primary outcome for the indirect comparison,NA,NA,"No primary outcome defined, or multiple primary outcomes without any clear distinction between them",TRUE,NA,NA,NA
10.1080/03007995.2021.1947216,34236007,methodology,1,NA,Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined),NA,NA,event-free survival,TRUE,NA,NA,NA
10.1080/03007995.2021.1947216,34236007,methodology,1,NA,Primary outcome: variable type,NA,NA,Time-to-event,TRUE,NA,NA,NA
10.1080/03007995.2021.1947216,34236007,methodology,1,NA,Justification for selecting variables to be included in the adjustment model (in the main text),"Status of prognostic factor/treatment effect modified assessed in the IPD dataset, A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion)",A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion),A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion),FALSE,NA,NA,NA
10.1080/03007995.2021.1947216,34236007,methodology,1,NA,Inclusion of prognostic factors in the adjustment/matching model,NA,NA,Yes,TRUE,NA,NA,NA
10.1080/03007995.2021.1947216,34236007,methodology,1,NA,Inclusion of treatment-effect modifiers in the adjustment/matching model,NA,NA,Yes,TRUE,NA,NA,NA
10.1080/03007995.2021.1947216,34236007,methodology,1,NA,"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)",No,Yes,Yes,FALSE,NA,NA,NA
10.1080/03007995.2021.1947216,34236007,methodology,1,NA,Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale),NA,NA,No,TRUE,NA,NA,NA
10.1080/03007995.2021.1947216,34236007,results,1,NA,Sample size of the population of interest in the non IPD treatment arm,NA,NA,81,TRUE,NA,NA,NA
10.1080/03007995.2021.1947216,34236007,results,1,NA,Initial sample size of the population of interest in the IPD treatment arm,NA,NA,34,TRUE,NA,NA,NA
10.1080/03007995.2021.1947216,34236007,results,1,NA,"Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC",24.6,"24,6",24.6,FALSE,NA,NA,NA
10.1080/03007995.2021.1947216,34236007,results,1,NA,Reporting of a weights' distribution evaluation (MAIC),NA,NA,Not mentioned,TRUE,NA,NA,NA
10.1080/03007995.2021.1947216,34236007,results,1,NA,Reporting of the list of the covariates adjusted for/matched on,NA,NA,Yes,TRUE,NA,NA,NA
10.1080/03007995.2021.1947216,34236007,results,1,NA,Number of covariates adjusted for/matched on,NA,NA,2,TRUE,NA,NA,NA
10.1080/03007995.2021.1947216,34236007,results,1,NA,Covariates adjusted for/matched on in the indirect comparison,NA,NA,"Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease)",TRUE,NA,NA,NA
10.1080/03007995.2021.1947216,34236007,results,1,NA,Primary outcome: treatment effect contrast,NA,NA,HR,TRUE,NA,NA,NA
10.1080/03007995.2021.1947216,34236007,results,1,NA,Direction of the treatment effect contrast: IPD treatment is:,NA,NA,"Numerator if ratio, or left side if difference",TRUE,NA,NA,NA
10.1080/03007995.2021.1947216,34236007,results,1,NA,Primary outcome: adjusted treatment effect,0.19,"0,19",0.19,FALSE,NA,NA,NA
10.1080/03007995.2021.1947216,34236007,results,1,NA,"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])",NA,NA,[0.07;0.54],TRUE,NA,NA,NA
10.1080/03007995.2021.1953456,34256668,general_information,NA,NA,Medical Condition of Interest Name,NA,NA,relapsed or refractory multiple myeloma,TRUE,NA,NA,NA
10.1080/03007995.2021.1953456,34256668,general_information,NA,NA,Countries of first author affiliations,NA,NA,usa,TRUE,NA,NA,NA
10.1080/03007995.2021.1953456,34256668,general_information,NA,NA,Countries of last author affiliations,NA,NA,canada,TRUE,NA,NA,NA
10.1080/03007995.2021.1953456,34256668,general_information,NA,NA,"Positions of study investigators (for any authors of the article, any that applies)",NA,NA,"Academic, Pharmaceutical Industry, Private Data Analysis Company",TRUE,NA,NA,NA
10.1080/03007995.2021.1953456,34256668,general_information,NA,NA,"At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company",NA,NA,Yes,TRUE,NA,NA,NA
10.1080/03007995.2021.1953456,34256668,general_information,NA,NA,Mentioned sources of funding,NA,NA,Pharmaceutical Industry,TRUE,NA,NA,NA
10.1080/03007995.2021.1953456,34256668,general_information,NA,NA,"Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article",NA,NA,Yes,TRUE,NA,NA,NA
10.1080/03007995.2021.1953456,34256668,general_information,NA,NA,Mention of a systematic review to find the studies to compare treatments of interest,NA,NA,No,TRUE,NA,NA,NA
10.1080/03007995.2021.1953456,34256668,study_information,NA,1,Patient-level data used,NA,NA,Yes,TRUE,NA,NA,NA
10.1080/03007995.2021.1953456,34256668,study_information,NA,1,Clinical Trial,NA,NA,Yes,TRUE,NA,NA,NA
10.1080/03007995.2021.1953456,34256668,study_information,NA,1,NCT (only for clinical trial registered on clinicaltrials.gov),NA,NA,NCT03548207,TRUE,NA,NA,NA
10.1080/03007995.2021.1953456,34256668,study_information,NA,1,Country where the clinical trial/observational study was conducted (international if more than one),NA,NA,international,TRUE,NA,NA,NA
10.1080/03007995.2021.1953456,34256668,study_information,NA,1,Phase of the clinical trial (clinical trial only),NA,NA,"1, 2",TRUE,NA,NA,NA
10.1080/03007995.2021.1953456,34256668,study_information,NA,1,Number of treatment arms (clinical trial only),NA,NA,1,TRUE,NA,NA,NA
10.1080/03007995.2021.1953456,34256668,study_information,NA,2,Patient-level data used,NA,NA,No,TRUE,NA,NA,NA
10.1080/03007995.2021.1953456,34256668,study_information,NA,2,Clinical Trial,NA,NA,Yes,TRUE,NA,NA,NA
10.1080/03007995.2021.1953456,34256668,study_information,NA,2,NCT (only for clinical trial registered on clinicaltrials.gov),NA,NA,NCT03361748,TRUE,NA,NA,NA
10.1080/03007995.2021.1953456,34256668,study_information,NA,2,Country where the clinical trial/observational study was conducted (international if more than one),NA,NA,international,TRUE,NA,NA,NA
10.1080/03007995.2021.1953456,34256668,study_information,NA,2,Phase of the clinical trial (clinical trial only),NA,NA,2,TRUE,NA,NA,NA
10.1080/03007995.2021.1953456,34256668,study_information,NA,2,Number of treatment arms (clinical trial only),NA,NA,1,TRUE,NA,NA,NA
10.1080/03007995.2021.1953456,34256668,methodology,1,NA,Treatment name 1,NA,NA,ciltacabtagene autoleucel,TRUE,NA,NA,NA
10.1080/03007995.2021.1953456,34256668,methodology,1,NA,Study 'number(s)' for treatment 1,NA,NA,1,TRUE,NA,NA,NA
10.1080/03007995.2021.1953456,34256668,methodology,1,NA,Treatment name 2,NA,NA,idecabtagene vicleucel,TRUE,NA,NA,NA
10.1080/03007995.2021.1953456,34256668,methodology,1,NA,Study 'number(s)' for treatment 2,NA,NA,2,TRUE,NA,NA,NA
10.1080/03007995.2021.1953456,34256668,methodology,1,NA,Type of population-adjusted indirect comparisons performed,NA,NA,MAIC,TRUE,NA,NA,NA
10.1080/03007995.2021.1953456,34256668,methodology,1,NA,Anchored comparison?,NA,NA,No,TRUE,NA,NA,NA
10.1080/03007995.2021.1953456,34256668,methodology,1,NA,Form of the indirect comparison,NA,NA,Simple (ie treatments effects extracted from two studies),TRUE,NA,NA,NA
10.1080/03007995.2021.1953456,34256668,methodology,1,NA,Definition of a single primary outcome for the indirect comparison,NA,NA,"No primary outcome defined, or multiple primary outcomes without any clear distinction between them",TRUE,NA,NA,NA
10.1080/03007995.2021.1953456,34256668,methodology,1,NA,Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined),NA,NA,overall response rate,TRUE,NA,NA,NA
10.1080/03007995.2021.1953456,34256668,methodology,1,NA,Primary outcome: variable type,NA,NA,Binary (eg rates),TRUE,NA,NA,NA
10.1080/03007995.2021.1953456,34256668,methodology,1,NA,Justification for selecting variables to be included in the adjustment model (in the main text),NA,NA,"A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion), Literature based (clinically or methodologically relevant to adjust on these variables based on the literature search conducted for this specific purpose)",TRUE,NA,NA,NA
10.1080/03007995.2021.1953456,34256668,methodology,1,NA,Inclusion of prognostic factors in the adjustment/matching model,NA,NA,Yes,TRUE,NA,NA,NA
10.1080/03007995.2021.1953456,34256668,methodology,1,NA,Inclusion of treatment-effect modifiers in the adjustment/matching model,NA,NA,No discussion (in the main text) of the status of treatment-effect modifiers of the variables,TRUE,NA,NA,NA
10.1080/03007995.2021.1953456,34256668,methodology,1,NA,"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)",NA,NA,No,TRUE,NA,NA,NA
10.1080/03007995.2021.1953456,34256668,methodology,1,NA,Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale),NA,NA,No,TRUE,NA,NA,NA
10.1080/03007995.2021.1953456,34256668,results,1,NA,Sample size of the population of interest in the non IPD treatment arm,NA,NA,124,TRUE,NA,NA,NA
10.1080/03007995.2021.1953456,34256668,results,1,NA,Initial sample size of the population of interest in the IPD treatment arm,97,96,97,FALSE,NA,NA,NA
10.1080/03007995.2021.1953456,34256668,results,1,NA,"Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC",NA,NA,52,TRUE,NA,NA,NA
10.1080/03007995.2021.1953456,34256668,results,1,NA,Reporting of a weights' distribution evaluation (MAIC),NA,NA,"Yes, mentions that the weights distribution has been studied, and weights distribution reported in main article or supplemental materials",TRUE,NA,NA,NA
10.1080/03007995.2021.1953456,34256668,results,1,NA,Reporting of the list of the covariates adjusted for/matched on,NA,NA,Yes,TRUE,NA,NA,NA
10.1080/03007995.2021.1953456,34256668,results,1,NA,Number of covariates adjusted for/matched on,NA,NA,4,TRUE,NA,NA,NA
10.1080/03007995.2021.1953456,34256668,results,1,NA,Covariates adjusted for/matched on in the indirect comparison,NA,NA,"Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease)",TRUE,NA,NA,NA
10.1080/03007995.2021.1953456,34256668,results,1,NA,Primary outcome: treatment effect contrast,NA,NA,OR,TRUE,NA,NA,NA
10.1080/03007995.2021.1953456,34256668,results,1,NA,Direction of the treatment effect contrast: IPD treatment is:,NA,NA,"Numerator if ratio, or left side if difference",TRUE,NA,NA,NA
10.1080/03007995.2021.1953456,34256668,results,1,NA,Primary outcome: unadjusted treatment effect,NA,NA,16.52,TRUE,NA,NA,NA
10.1080/03007995.2021.1953456,34256668,results,1,NA,"p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])",NA,NA,0.0002,TRUE,NA,NA,NA
10.1080/03007995.2021.1953456,34256668,results,1,NA,Primary outcome: adjusted treatment effect,NA,NA,94.93,TRUE,NA,NA,NA
10.1080/03007995.2021.1953456,34256668,results,1,NA,"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])",NA,NA,<0.0001,TRUE,NA,NA,NA
10.1111/dom.14497,34286894,general_information,NA,NA,Medical Condition of Interest Name,NA,NA,type 2 diabetes,TRUE,NA,NA,NA
10.1111/dom.14497,34286894,general_information,NA,NA,Countries of first author affiliations,NA,NA,usa,TRUE,NA,NA,NA
10.1111/dom.14497,34286894,general_information,NA,NA,Countries of last author affiliations,denmark,danemark,XXXX,FALSE,NA,NA,NA
10.1111/dom.14497,34286894,general_information,NA,NA,"Positions of study investigators (for any authors of the article, any that applies)",NA,NA,"Academic, Pharmaceutical Industry, Private Data Analysis Company",TRUE,NA,NA,NA
10.1111/dom.14497,34286894,general_information,NA,NA,"At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company",NA,NA,Yes,TRUE,NA,NA,NA
10.1111/dom.14497,34286894,general_information,NA,NA,Mentioned sources of funding,NA,NA,Pharmaceutical Industry,TRUE,NA,NA,NA
10.1111/dom.14497,34286894,general_information,NA,NA,"Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article",NA,NA,Yes,TRUE,NA,NA,NA
10.1111/dom.14497,34286894,general_information,NA,NA,Mention of a systematic review to find the studies to compare treatments of interest,NA,NA,No,TRUE,NA,NA,NA
10.1111/dom.14497,34286894,study_information,NA,1,Patient-level data used,NA,NA,Yes,TRUE,NA,NA,NA
10.1111/dom.14497,34286894,study_information,NA,1,Clinical Trial,NA,NA,Yes,TRUE,NA,NA,NA
10.1111/dom.14497,34286894,study_information,NA,1,NCT (only for clinical trial registered on clinicaltrials.gov),NA,NA,NCT02648204,TRUE,NA,NA,NA
10.1111/dom.14497,34286894,study_information,NA,1,Country where the clinical trial/observational study was conducted (international if more than one),NA,NA,international,TRUE,NA,NA,NA
10.1111/dom.14497,34286894,study_information,NA,1,Phase of the clinical trial (clinical trial only),NA,NA,3,TRUE,NA,NA,NA
10.1111/dom.14497,34286894,study_information,NA,1,Number of treatment arms (clinical trial only),NA,NA,2 or more,TRUE,NA,NA,NA
10.1111/dom.14497,34286894,study_information,NA,2,Patient-level data used,NA,NA,No,TRUE,NA,NA,NA
10.1111/dom.14497,34286894,study_information,NA,2,Clinical Trial,NA,NA,Yes,TRUE,NA,NA,NA
10.1111/dom.14497,34286894,study_information,NA,2,NCT (only for clinical trial registered on clinicaltrials.gov),NA,NA,NCT03495102,TRUE,NA,NA,NA
10.1111/dom.14497,34286894,study_information,NA,2,Country where the clinical trial/observational study was conducted (international if more than one),NA,NA,international,TRUE,NA,NA,NA
10.1111/dom.14497,34286894,study_information,NA,2,Phase of the clinical trial (clinical trial only),NA,NA,3,TRUE,NA,NA,NA
10.1111/dom.14497,34286894,study_information,NA,2,Number of treatment arms (clinical trial only),1,2 or more,XXXX,FALSE,NA,NA,NA
10.1111/dom.14497,34286894,study_information,NA,3,Patient-level data used,NA,No,XXXX,FALSE,NA,NA,NA
10.1111/dom.14497,34286894,study_information,NA,3,Clinical Trial,NA,Yes,XXXX,FALSE,NA,NA,NA
10.1111/dom.14497,34286894,study_information,NA,3,NCT (only for clinical trial registered on clinicaltrials.gov),NA,NCT03495102,NA,FALSE,NA,NA,NA
10.1111/dom.14497,34286894,study_information,NA,3,Country where the clinical trial/observational study was conducted (international if more than one),NA,international,XXXX,FALSE,NA,NA,NA
10.1111/dom.14497,34286894,study_information,NA,3,Phase of the clinical trial (clinical trial only),NA,3,XXXX,FALSE,NA,NA,NA
10.1111/dom.14497,34286894,study_information,NA,3,Number of treatment arms (clinical trial only),NA,2 or more,XXXX,FALSE,NA,NA,NA
10.1111/dom.14497,34286894,methodology,1,NA,Treatment name 1,semaglutide 1.0mg,semaglutide 1.0 mg,semaglutide 1.0mg,FALSE,"MAIC as a sensitivity analysis, Bucher is the primary one because 'no evidence of treatment effect modifiers based on a post hoc analysis', referring to an article of the investigators of the original trial, who determined that based on their data there was no observed heterogeneity of treatment effect based on these charactersitics. Therefore, choice of the covariates  = 'Status of prognostic factor/treatment effect modified assessed in the IPD dataset""""
Methodology and purpose of the research very close to than 10.1210/clinem/dgab905
Incidentally, they say that safety endpoints are more difficult to assess in indirect comparisons because usually they are assessed differently between trials, could be an interesting reference in the article
","Sensitivity analysis 2
BMI = others",NA
10.1111/dom.14497,34286894,methodology,1,NA,Study 'number(s)' for treatment 1,NA,NA,1,TRUE,NA,NA,NA
10.1111/dom.14497,34286894,methodology,1,NA,Treatment name 2,dulaglutide 3.0mg,dulaglutide 3.0 mg,dulaglutide 3.0mg,FALSE,NA,NA,NA
10.1111/dom.14497,34286894,methodology,1,NA,Study 'number(s)' for treatment 2,NA,NA,2,TRUE,NA,NA,NA
10.1111/dom.14497,34286894,methodology,1,NA,Type of population-adjusted indirect comparisons performed,NA,NA,MAIC,TRUE,NA,NA,NA
10.1111/dom.14497,34286894,methodology,1,NA,Anchored comparison?,NA,NA,Yes,TRUE,NA,NA,NA
10.1111/dom.14497,34286894,methodology,1,NA,Form of the indirect comparison,NA,NA,Simple (ie treatments effects extracted from two studies),TRUE,NA,NA,NA
10.1111/dom.14497,34286894,methodology,1,NA,Definition of a single primary outcome for the indirect comparison,NA,NA,"No primary outcome defined, or multiple primary outcomes without any clear distinction between them",TRUE,NA,NA,NA
10.1111/dom.14497,34286894,methodology,1,NA,Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined),change from baseline hba1c,change from baseline in hba1c,change from baseline in hba1c,FALSE,NA,NA,NA
10.1111/dom.14497,34286894,methodology,1,NA,Primary outcome: variable type,NA,NA,"Continuous (count, mean, ...)",TRUE,NA,NA,NA
10.1111/dom.14497,34286894,methodology,1,NA,Justification for selecting variables to be included in the adjustment model (in the main text),Status of prognostic factor/treatment effect modified assessed in the IPD dataset,"Nothing mentioned, not reported","Nothing mentioned, not reported",FALSE,NA,NA,NA
10.1111/dom.14497,34286894,methodology,1,NA,Inclusion of prognostic factors in the adjustment/matching model,NA,NA,No,TRUE,NA,NA,NA
10.1111/dom.14497,34286894,methodology,1,NA,Inclusion of treatment-effect modifiers in the adjustment/matching model,NA,NA,Yes,TRUE,NA,NA,NA
10.1111/dom.14497,34286894,methodology,1,NA,"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)",No,Yes,Yes,FALSE,NA,NA,NA
10.1111/dom.14497,34286894,methodology,1,NA,Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale),NA,NA,No,TRUE,NA,NA,NA
10.1111/dom.14497,34286894,methodology,2,NA,Treatment name 1,semaglutide 1.0mg,semaglutide 1.0 mg,semaglutide 1.0mg,FALSE,NA,"Sensitivity analysis 2
BMI = others",NA
10.1111/dom.14497,34286894,methodology,2,NA,Study 'number(s)' for treatment 1,NA,NA,1,TRUE,NA,NA,NA
10.1111/dom.14497,34286894,methodology,2,NA,Treatment name 2,dulaglutide 4.5mg,dulaglutide 4.5 mg,dulaglutide 4.5mg,FALSE,NA,NA,NA
10.1111/dom.14497,34286894,methodology,2,NA,Study 'number(s)' for treatment 2,2,3,2,FALSE,NA,NA,NA
10.1111/dom.14497,34286894,methodology,2,NA,Type of population-adjusted indirect comparisons performed,NA,NA,MAIC,TRUE,NA,NA,NA
10.1111/dom.14497,34286894,methodology,2,NA,Anchored comparison?,NA,NA,Yes,TRUE,NA,NA,NA
10.1111/dom.14497,34286894,methodology,2,NA,Form of the indirect comparison,NA,NA,Simple (ie treatments effects extracted from two studies),TRUE,NA,NA,NA
10.1111/dom.14497,34286894,methodology,2,NA,Definition of a single primary outcome for the indirect comparison,NA,NA,"No primary outcome defined, or multiple primary outcomes without any clear distinction between them",TRUE,NA,NA,NA
10.1111/dom.14497,34286894,methodology,2,NA,Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined),change from baseline hba1c,change from baseline in hba1c,change from baseline in hba1c,FALSE,NA,NA,NA
10.1111/dom.14497,34286894,methodology,2,NA,Primary outcome: variable type,NA,NA,"Continuous (count, mean, ...)",TRUE,NA,NA,NA
10.1111/dom.14497,34286894,methodology,2,NA,Justification for selecting variables to be included in the adjustment model (in the main text),Status of prognostic factor/treatment effect modified assessed in the IPD dataset,"Nothing mentioned, not reported","Nothing mentioned, not reported",FALSE,NA,NA,NA
10.1111/dom.14497,34286894,methodology,2,NA,Inclusion of prognostic factors in the adjustment/matching model,No,No discussion (in the main text) of the status of prognostic factors of the variables,No,FALSE,NA,NA,NA
10.1111/dom.14497,34286894,methodology,2,NA,Inclusion of treatment-effect modifiers in the adjustment/matching model,NA,NA,Yes,TRUE,NA,NA,NA
10.1111/dom.14497,34286894,methodology,2,NA,"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)",No,Yes,Yes,FALSE,NA,NA,NA
10.1111/dom.14497,34286894,methodology,2,NA,Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale),NA,NA,No,TRUE,NA,NA,NA
10.1111/dom.14497,34286894,results,1,NA,Sample size of the population of interest in the non IPD treatment arm,NA,NA,616,TRUE,NA,NA,NA
10.1111/dom.14497,34286894,results,1,NA,"If anchored comparison, sample size of the population of interest in the non IPD treatment anchor arm",NA,NA,612,TRUE,NA,NA,NA
10.1111/dom.14497,34286894,results,1,NA,Initial sample size of the population of interest in the IPD treatment arm,NA,NA,300,TRUE,NA,NA,NA
10.1111/dom.14497,34286894,results,1,NA,"If anchored comparison, initial sample size of the population of interest in the IPD anchor arm",NA,NA,299,TRUE,NA,NA,NA
10.1111/dom.14497,34286894,results,1,NA,Reporting of a weights' distribution evaluation (MAIC),NA,NA,Not mentioned,TRUE,NA,NA,NA
10.1111/dom.14497,34286894,results,1,NA,Reporting of the list of the covariates adjusted for/matched on,NA,NA,Yes,TRUE,NA,NA,NA
10.1111/dom.14497,34286894,results,1,NA,Number of covariates adjusted for/matched on,NA,NA,3,TRUE,NA,NA,NA
10.1111/dom.14497,34286894,results,1,NA,Covariates adjusted for/matched on in the indirect comparison,"Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Other(s)","Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Comorbidities and medical history (beside pathology/disease of interest in the comparison), Other(s)","Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Comorbidities and medical history (beside pathology/disease of interest in the comparison), Other(s)",FALSE,NA,NA,NA
10.1111/dom.14497,34286894,results,1,NA,Primary outcome: treatment effect contrast,NA,NA,Means difference,TRUE,NA,NA,NA
10.1111/dom.14497,34286894,results,1,NA,Direction of the treatment effect contrast: IPD treatment is:,NA,NA,"Numerator if ratio, or left side if difference",TRUE,NA,NA,NA
10.1111/dom.14497,34286894,results,1,NA,Primary outcome: unadjusted treatment effect,NA,NA,-0.24,TRUE,NA,NA,NA
10.1111/dom.14497,34286894,results,1,NA,"p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])",NA,NA,0.016,TRUE,NA,NA,NA
10.1111/dom.14497,34286894,results,1,NA,Primary outcome: adjusted treatment effect,-0.26,-0.25,-0.25,FALSE,NA,NA,NA
10.1111/dom.14497,34286894,results,1,NA,"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])",0.047,0.037,0.037,FALSE,NA,NA,NA
10.1111/dom.14497,34286894,results,2,NA,Sample size of the population of interest in the non IPD treatment arm,NA,NA,614,TRUE,NA,NA,NA
10.1111/dom.14497,34286894,results,2,NA,"If anchored comparison, sample size of the population of interest in the non IPD treatment anchor arm",NA,NA,612,TRUE,NA,NA,NA
10.1111/dom.14497,34286894,results,2,NA,Initial sample size of the population of interest in the IPD treatment arm,NA,NA,300,TRUE,NA,NA,NA
10.1111/dom.14497,34286894,results,2,NA,"If anchored comparison, initial sample size of the population of interest in the IPD anchor arm",NA,NA,299,TRUE,NA,NA,NA
10.1111/dom.14497,34286894,results,2,NA,Reporting of a weights' distribution evaluation (MAIC),NA,NA,Not mentioned,TRUE,NA,NA,NA
10.1111/dom.14497,34286894,results,2,NA,Reporting of the list of the covariates adjusted for/matched on,NA,NA,Yes,TRUE,NA,NA,NA
10.1111/dom.14497,34286894,results,2,NA,Number of covariates adjusted for/matched on,NA,NA,3,TRUE,NA,NA,NA
10.1111/dom.14497,34286894,results,2,NA,Covariates adjusted for/matched on in the indirect comparison,NA,NA,"Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Other(s)",TRUE,NA,NA,NA
10.1111/dom.14497,34286894,results,2,NA,Primary outcome: treatment effect contrast,NA,NA,Means difference,TRUE,NA,NA,NA
10.1111/dom.14497,34286894,results,2,NA,Direction of the treatment effect contrast: IPD treatment is:,NA,NA,"Numerator if ratio, or left side if difference",TRUE,NA,NA,NA
10.1111/dom.14497,34286894,results,2,NA,Primary outcome: unadjusted treatment effect,NA,NA,-0.07,TRUE,NA,NA,NA
10.1111/dom.14497,34286894,results,2,NA,"p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])",NA,NA,0.484,TRUE,NA,NA,NA
10.1111/dom.14497,34286894,results,2,NA,Primary outcome: adjusted treatment effect,NA,NA,-0.08,TRUE,NA,NA,NA
10.1111/dom.14497,34286894,results,2,NA,"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])",NA,NA,0.523,TRUE,NA,NA,NA
10.1007/s12325-021-01853-0,34368918,general_information,NA,NA,Medical Condition of Interest Name,NA,NA,severe haemophilia a,TRUE,NA,NA,NA
10.1007/s12325-021-01853-0,34368918,general_information,NA,NA,Countries of first author affiliations,NA,NA,spain,TRUE,NA,NA,NA
10.1007/s12325-021-01853-0,34368918,general_information,NA,NA,Countries of last author affiliations,NA,NA,portugal,TRUE,NA,NA,NA
10.1007/s12325-021-01853-0,34368918,general_information,NA,NA,"Positions of study investigators (for any authors of the article, any that applies)",NA,NA,"Academic, Pharmaceutical Industry, Private Data Analysis Company",TRUE,NA,NA,NA
10.1007/s12325-021-01853-0,34368918,general_information,NA,NA,"At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company",NA,NA,Yes,TRUE,NA,NA,NA
10.1007/s12325-021-01853-0,34368918,general_information,NA,NA,Mentioned sources of funding,NA,NA,Pharmaceutical Industry,TRUE,NA,NA,NA
10.1007/s12325-021-01853-0,34368918,general_information,NA,NA,"Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article",NA,NA,Yes,TRUE,NA,NA,NA
10.1007/s12325-021-01853-0,34368918,general_information,NA,NA,Mention of a systematic review to find the studies to compare treatments of interest,NA,NA,Yes,TRUE,NA,NA,NA
10.1007/s12325-021-01853-0,34368918,study_information,NA,1,Patient-level data used,NA,NA,Yes,TRUE,NA,NA,NA
10.1007/s12325-021-01853-0,34368918,study_information,NA,1,Clinical Trial,NA,NA,Yes,TRUE,NA,NA,NA
10.1007/s12325-021-01853-0,34368918,study_information,NA,1,NCT (only for clinical trial registered on clinicaltrials.gov),NA,NA,NCT01486927,TRUE,NA,NA,NA
10.1007/s12325-021-01853-0,34368918,study_information,NA,1,Country where the clinical trial/observational study was conducted (international if more than one),NA,NA,international,TRUE,NA,NA,NA
10.1007/s12325-021-01853-0,34368918,study_information,NA,1,Phase of the clinical trial (clinical trial only),"2, 3","1, 3",XXXX,FALSE,NA,NA,NA
10.1007/s12325-021-01853-0,34368918,study_information,NA,1,Number of treatment arms (clinical trial only),2 or more,1,XXXX,FALSE,NA,NA,NA
10.1007/s12325-021-01853-0,34368918,study_information,NA,2,Patient-level data used,NA,NA,No,TRUE,NA,NA,NA
10.1007/s12325-021-01853-0,34368918,study_information,NA,2,Clinical Trial,NA,NA,Yes,TRUE,NA,NA,NA
10.1007/s12325-021-01853-0,34368918,study_information,NA,2,Data source name (only if observational study or clinical trial without NCT),NA,NA,rahf-pfm-2004 - part 2 10.1111/j.1365-2516.2004.00932.x,TRUE,NA,NA,NA
10.1007/s12325-021-01853-0,34368918,study_information,NA,2,Country where the clinical trial/observational study was conducted (international if more than one),NA,NA,international,TRUE,NA,NA,NA
10.1007/s12325-021-01853-0,34368918,study_information,NA,2,Number of treatment arms (clinical trial only),2 or more,1,XXXX,FALSE,NA,NA,NA
10.1007/s12325-021-01853-0,34368918,study_information,NA,3,Patient-level data used,NA,NA,No,TRUE,NA,NA,NA
10.1007/s12325-021-01853-0,34368918,study_information,NA,3,Clinical Trial,NA,NA,Yes,TRUE,NA,NA,NA
10.1007/s12325-021-01853-0,34368918,study_information,NA,3,NCT (only for clinical trial registered on clinicaltrials.gov),NA,NA,NCT00243386,TRUE,NA,NA,NA
10.1007/s12325-021-01853-0,34368918,study_information,NA,3,Country where the clinical trial/observational study was conducted (international if more than one),NA,NA,international,TRUE,NA,NA,NA
10.1007/s12325-021-01853-0,34368918,study_information,NA,3,Phase of the clinical trial (clinical trial only),4,NA,XXXX,FALSE,NA,NA,NA
10.1007/s12325-021-01853-0,34368918,study_information,NA,3,Number of treatment arms (clinical trial only),1,2 or more,XXXX,FALSE,NA,NA,NA
10.1007/s12325-021-01853-0,34368918,study_information,NA,4,Patient-level data used,NA,NA,No,TRUE,NA,NA,NA
10.1007/s12325-021-01853-0,34368918,study_information,NA,4,Clinical Trial,NA,NA,Yes,TRUE,NA,NA,NA
10.1007/s12325-021-01853-0,34368918,study_information,NA,4,NCT (only for clinical trial registered on clinicaltrials.gov),NCT02172950,NCT01181128,NCT01181128,FALSE,NA,NA,NA
10.1007/s12325-021-01853-0,34368918,study_information,NA,4,Country where the clinical trial/observational study was conducted (international if more than one),NA,NA,international,TRUE,NA,NA,NA
10.1007/s12325-021-01853-0,34368918,study_information,NA,4,Phase of the clinical trial (clinical trial only),NA,NA,3,TRUE,NA,NA,NA
10.1007/s12325-021-01853-0,34368918,study_information,NA,4,Number of treatment arms (clinical trial only),1,2 or more,XXXX,FALSE,NA,NA,NA
10.1007/s12325-021-01853-0,34368918,methodology,1,NA,Treatment name 1,rviii-singlechain lonoctocog alfa,rviii-singlechain,rviii-singlechain,FALSE,"test hypothesis appears to be for equivalence, but test for superiority and don't find any difference, and then conclude to equivalence
don't even mention the fact that the MAIC is unanchored, and that there are very different assumptions. Don't talk about prognostic factors and ttt effect modifiers. just baseline characteristics
Characteristics adjusted for not very obvious, but seems to be all baseline characteristics available in both studies for each ITC. Seem like they also included characteristics that were already balanced initially.","L'essai rAHF-PFM-2012 : Phase 4
Covariates from table 1",NA
10.1007/s12325-021-01853-0,34368918,methodology,1,NA,Study 'number(s)' for treatment 1,NA,NA,1,TRUE,NA,NA,NA
10.1007/s12325-021-01853-0,34368918,methodology,1,NA,Treatment name 2,rahf-pfm octocog alfa,rahf-pfm,rahf-pfm,FALSE,NA,NA,NA
10.1007/s12325-021-01853-0,34368918,methodology,1,NA,Study 'number(s)' for treatment 2,NA,NA,2,TRUE,NA,NA,NA
10.1007/s12325-021-01853-0,34368918,methodology,1,NA,Type of population-adjusted indirect comparisons performed,NA,NA,MAIC,TRUE,NA,NA,NA
10.1007/s12325-021-01853-0,34368918,methodology,1,NA,Anchored comparison?,NA,NA,No,TRUE,NA,NA,NA
10.1007/s12325-021-01853-0,34368918,methodology,1,NA,Form of the indirect comparison,NA,NA,Simple (ie treatments effects extracted from two studies),TRUE,NA,NA,NA
10.1007/s12325-021-01853-0,34368918,methodology,1,NA,Definition of a single primary outcome for the indirect comparison,NA,NA,"No primary outcome defined, or multiple primary outcomes without any clear distinction between them",TRUE,NA,NA,NA
10.1007/s12325-021-01853-0,34368918,methodology,1,NA,Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined),mean annualized bleeding rates,"annualized bleeding rate (abr),","annualized bleeding rate (abr),",FALSE,NA,NA,NA
10.1007/s12325-021-01853-0,34368918,methodology,1,NA,Primary outcome: variable type,NA,NA,Binary (eg rates),TRUE,NA,NA,NA
10.1007/s12325-021-01853-0,34368918,methodology,1,NA,Justification for selecting variables to be included in the adjustment model (in the main text),NA,NA,"Nothing mentioned, not reported",TRUE,NA,NA,NA
10.1007/s12325-021-01853-0,34368918,methodology,1,NA,Inclusion of prognostic factors in the adjustment/matching model,NA,NA,No discussion (in the main text) of the status of prognostic factors of the variables,TRUE,NA,NA,NA
10.1007/s12325-021-01853-0,34368918,methodology,1,NA,Inclusion of treatment-effect modifiers in the adjustment/matching model,NA,NA,No discussion (in the main text) of the status of treatment-effect modifiers of the variables,TRUE,NA,NA,NA
10.1007/s12325-021-01853-0,34368918,methodology,1,NA,"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)",NA,NA,No,TRUE,NA,NA,NA
10.1007/s12325-021-01853-0,34368918,methodology,1,NA,Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale),NA,NA,No,TRUE,NA,NA,NA
10.1007/s12325-021-01853-0,34368918,methodology,2,NA,Treatment name 1,rviii-singlechain lonoctocog alfa,rviii-singlechain,rviii-singlechain,FALSE,NA,"Outcome : mean square root transformed ABR
Covariates from table 2",NA
10.1007/s12325-021-01853-0,34368918,methodology,2,NA,Study 'number(s)' for treatment 1,NA,NA,1,TRUE,NA,NA,NA
10.1007/s12325-021-01853-0,34368918,methodology,2,NA,Treatment name 2,rahf-pfm octocog alf,rahf-pfm,rahf-pfm,FALSE,NA,NA,NA
10.1007/s12325-021-01853-0,34368918,methodology,2,NA,Study 'number(s)' for treatment 2,NA,NA,3,TRUE,NA,NA,NA
10.1007/s12325-021-01853-0,34368918,methodology,2,NA,Type of population-adjusted indirect comparisons performed,NA,NA,MAIC,TRUE,NA,NA,NA
10.1007/s12325-021-01853-0,34368918,methodology,2,NA,Anchored comparison?,NA,NA,No,TRUE,NA,NA,NA
10.1007/s12325-021-01853-0,34368918,methodology,2,NA,Form of the indirect comparison,NA,NA,Simple (ie treatments effects extracted from two studies),TRUE,NA,NA,NA
10.1007/s12325-021-01853-0,34368918,methodology,2,NA,Definition of a single primary outcome for the indirect comparison,NA,NA,"No primary outcome defined, or multiple primary outcomes without any clear distinction between them",TRUE,NA,NA,NA
10.1007/s12325-021-01853-0,34368918,methodology,2,NA,Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined),mean annualized bleeding rates,annualized bleeding rate (abr),annualized bleeding rate (abr),FALSE,NA,NA,NA
10.1007/s12325-021-01853-0,34368918,methodology,2,NA,Primary outcome: variable type,NA,NA,Binary (eg rates),TRUE,NA,NA,NA
10.1007/s12325-021-01853-0,34368918,methodology,2,NA,Justification for selecting variables to be included in the adjustment model (in the main text),NA,NA,"Nothing mentioned, not reported",TRUE,NA,NA,NA
10.1007/s12325-021-01853-0,34368918,methodology,2,NA,Inclusion of prognostic factors in the adjustment/matching model,NA,NA,No discussion (in the main text) of the status of prognostic factors of the variables,TRUE,NA,NA,NA
10.1007/s12325-021-01853-0,34368918,methodology,2,NA,Inclusion of treatment-effect modifiers in the adjustment/matching model,NA,NA,No discussion (in the main text) of the status of treatment-effect modifiers of the variables,TRUE,NA,NA,NA
10.1007/s12325-021-01853-0,34368918,methodology,2,NA,"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)",NA,NA,No,TRUE,NA,NA,NA
10.1007/s12325-021-01853-0,34368918,methodology,2,NA,Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale),NA,NA,No,TRUE,NA,NA,NA
10.1007/s12325-021-01853-0,34368918,methodology,3,NA,Treatment name 1,rviii-singlechain lonoctocog alfa,rviii-singlechain,rviii-singlechain,FALSE,NA,"Covariates from table 3
Region and weight = others",NA
10.1007/s12325-021-01853-0,34368918,methodology,3,NA,Study 'number(s)' for treatment 1,NA,NA,1,TRUE,NA,NA,NA
10.1007/s12325-021-01853-0,34368918,methodology,3,NA,Treatment name 2,rfviiifc (efmoroctocog alfa),rfviiifc,rfviiifc,FALSE,NA,NA,NA
10.1007/s12325-021-01853-0,34368918,methodology,3,NA,Study 'number(s)' for treatment 2,NA,NA,4,TRUE,NA,NA,NA
10.1007/s12325-021-01853-0,34368918,methodology,3,NA,Type of population-adjusted indirect comparisons performed,NA,NA,MAIC,TRUE,NA,NA,NA
10.1007/s12325-021-01853-0,34368918,methodology,3,NA,Anchored comparison?,NA,NA,No,TRUE,NA,NA,NA
10.1007/s12325-021-01853-0,34368918,methodology,3,NA,Form of the indirect comparison,NA,NA,Simple (ie treatments effects extracted from two studies),TRUE,NA,NA,NA
10.1007/s12325-021-01853-0,34368918,methodology,3,NA,Definition of a single primary outcome for the indirect comparison,NA,NA,"No primary outcome defined, or multiple primary outcomes without any clear distinction between them",TRUE,NA,NA,NA
10.1007/s12325-021-01853-0,34368918,methodology,3,NA,Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined),mean annualized bleeding rates,annualized bleeding rate (abr),annualized bleeding rate (abr),FALSE,NA,NA,NA
10.1007/s12325-021-01853-0,34368918,methodology,3,NA,Primary outcome: variable type,NA,NA,Binary (eg rates),TRUE,NA,NA,NA
10.1007/s12325-021-01853-0,34368918,methodology,3,NA,Justification for selecting variables to be included in the adjustment model (in the main text),NA,NA,"Nothing mentioned, not reported",TRUE,NA,NA,NA
10.1007/s12325-021-01853-0,34368918,methodology,3,NA,Inclusion of prognostic factors in the adjustment/matching model,NA,NA,No discussion (in the main text) of the status of prognostic factors of the variables,TRUE,NA,NA,NA
10.1007/s12325-021-01853-0,34368918,methodology,3,NA,Inclusion of treatment-effect modifiers in the adjustment/matching model,NA,NA,No discussion (in the main text) of the status of treatment-effect modifiers of the variables,TRUE,NA,NA,NA
10.1007/s12325-021-01853-0,34368918,methodology,3,NA,"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)",NA,NA,No,TRUE,NA,NA,NA
10.1007/s12325-021-01853-0,34368918,methodology,3,NA,Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale),NA,NA,No,TRUE,NA,NA,NA
10.1007/s12325-021-01853-0,34368918,results,1,NA,Sample size of the population of interest in the non IPD treatment arm,NA,NA,111,TRUE,NA,NA,NA
10.1007/s12325-021-01853-0,34368918,results,1,NA,Initial sample size of the population of interest in the IPD treatment arm,NA,NA,146,TRUE,NA,NA,NA
10.1007/s12325-021-01853-0,34368918,results,1,NA,"Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC",25.01,25.1,25.1,FALSE,NA,NA,NA
10.1007/s12325-021-01853-0,34368918,results,1,NA,Reporting of a weights' distribution evaluation (MAIC),NA,NA,Not mentioned,TRUE,NA,NA,NA
10.1007/s12325-021-01853-0,34368918,results,1,NA,Reporting of the list of the covariates adjusted for/matched on,NA,NA,Yes,TRUE,NA,NA,NA
10.1007/s12325-021-01853-0,34368918,results,1,NA,Number of covariates adjusted for/matched on,NA,NA,4,TRUE,NA,NA,NA
10.1007/s12325-021-01853-0,34368918,results,1,NA,Covariates adjusted for/matched on in the indirect comparison,NA,NA,"Age, Race/ethnicity, Other(s)",TRUE,NA,NA,NA
10.1007/s12325-021-01853-0,34368918,results,1,NA,Primary outcome: treatment effect contrast,NA,NA,RR,TRUE,NA,NA,NA
10.1007/s12325-021-01853-0,34368918,results,1,NA,Direction of the treatment effect contrast: IPD treatment is:,NA,NA,"Numerator if ratio, or left side if difference",TRUE,NA,NA,NA
10.1007/s12325-021-01853-0,34368918,results,1,NA,Primary outcome: unadjusted treatment effect,NA,NA,0.55,TRUE,NA,NA,NA
10.1007/s12325-021-01853-0,34368918,results,1,NA,"p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])",NA,NA,[0.17;3.12],TRUE,NA,NA,NA
10.1007/s12325-021-01853-0,34368918,results,1,NA,Primary outcome: adjusted treatment effect,NA,NA,0.74,TRUE,NA,NA,NA
10.1007/s12325-021-01853-0,34368918,results,1,NA,"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])",[0.16;3.48],0.7,[0.16;3.48],FALSE,NA,NA,NA
10.1007/s12325-021-01853-0,34368918,results,2,NA,Sample size of the population of interest in the non IPD treatment arm,NA,NA,32,TRUE,NA,NA,NA
10.1007/s12325-021-01853-0,34368918,results,2,NA,Initial sample size of the population of interest in the IPD treatment arm,NA,NA,146,TRUE,NA,NA,NA
10.1007/s12325-021-01853-0,34368918,results,2,NA,"Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC",NA,NA,79,TRUE,NA,NA,NA
10.1007/s12325-021-01853-0,34368918,results,2,NA,Reporting of a weights' distribution evaluation (MAIC),NA,NA,Not mentioned,TRUE,NA,NA,NA
10.1007/s12325-021-01853-0,34368918,results,2,NA,Reporting of the list of the covariates adjusted for/matched on,Yes,No,Yes,FALSE,NA,NA,NA
10.1007/s12325-021-01853-0,34368918,results,2,NA,Number of covariates adjusted for/matched on,NA,NA,2,TRUE,NA,NA,NA
10.1007/s12325-021-01853-0,34368918,results,2,NA,Covariates adjusted for/matched on in the indirect comparison,NA,NA,"Age, Race/ethnicity",TRUE,NA,NA,NA
10.1007/s12325-021-01853-0,34368918,results,2,NA,Primary outcome: treatment effect contrast,NA,NA,RR,TRUE,NA,NA,NA
10.1007/s12325-021-01853-0,34368918,results,2,NA,Direction of the treatment effect contrast: IPD treatment is:,NA,NA,"Numerator if ratio, or left side if difference",TRUE,NA,NA,NA
10.1007/s12325-021-01853-0,34368918,results,2,NA,Primary outcome: unadjusted treatment effect,NA,NA,0.07,TRUE,NA,NA,NA
10.1007/s12325-021-01853-0,34368918,results,2,NA,"p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])",NA,NA,[-3.09;3.23],TRUE,NA,NA,NA
10.1007/s12325-021-01853-0,34368918,results,2,NA,Primary outcome: adjusted treatment effect,NA,NA,0.01,TRUE,NA,NA,NA
10.1007/s12325-021-01853-0,34368918,results,2,NA,"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])",[-2.36;2.37],0.99,[-2.36;2.37],FALSE,NA,NA,NA
10.1007/s12325-021-01853-0,34368918,results,3,NA,Sample size of the population of interest in the non IPD treatment arm,NA,NA,118,TRUE,NA,NA,NA
10.1007/s12325-021-01853-0,34368918,results,3,NA,Initial sample size of the population of interest in the IPD treatment arm,NA,NA,146,TRUE,NA,NA,NA
10.1007/s12325-021-01853-0,34368918,results,3,NA,"Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC",NA,NA,123.6,TRUE,NA,NA,NA
10.1007/s12325-021-01853-0,34368918,results,3,NA,Reporting of a weights' distribution evaluation (MAIC),NA,NA,Not mentioned,TRUE,NA,NA,NA
10.1007/s12325-021-01853-0,34368918,results,3,NA,Reporting of the list of the covariates adjusted for/matched on,NA,NA,Yes,TRUE,NA,NA,NA
10.1007/s12325-021-01853-0,34368918,results,3,NA,Number of covariates adjusted for/matched on,NA,NA,4,TRUE,NA,NA,NA
10.1007/s12325-021-01853-0,34368918,results,3,NA,Covariates adjusted for/matched on in the indirect comparison,NA,NA,"Age, Race/ethnicity, Other(s)",TRUE,NA,NA,NA
10.1007/s12325-021-01853-0,34368918,results,3,NA,Primary outcome: treatment effect contrast,NA,NA,RR,TRUE,NA,NA,NA
10.1007/s12325-021-01853-0,34368918,results,3,NA,Direction of the treatment effect contrast: IPD treatment is:,NA,NA,"Numerator if ratio, or left side if difference",TRUE,NA,NA,NA
10.1007/s12325-021-01853-0,34368918,results,3,NA,Primary outcome: unadjusted treatment effect,NA,NA,1.14,TRUE,NA,NA,NA
10.1007/s12325-021-01853-0,34368918,results,3,NA,"p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])",NA,NA,[0.82;1.57],TRUE,NA,NA,NA
10.1007/s12325-021-01853-0,34368918,results,3,NA,Primary outcome: adjusted treatment effect,NA,NA,1.18,TRUE,NA,NA,NA
10.1007/s12325-021-01853-0,34368918,results,3,NA,"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])",[0.85;1.65],0.32,[0.85;1.65],FALSE,NA,NA,NA
10.1186/s13045-021-01144-9,34493319,general_information,NA,NA,Medical Condition of Interest Name,NA,NA,relapsed or refractory large b cell lymphoma,TRUE,NA,NA,NA
10.1186/s13045-021-01144-9,34493319,general_information,NA,NA,Countries of first author affiliations,NA,NA,usa,TRUE,NA,NA,NA
10.1186/s13045-021-01144-9,34493319,general_information,NA,NA,Countries of last author affiliations,NA,NA,france,TRUE,NA,NA,NA
10.1186/s13045-021-01144-9,34493319,general_information,NA,NA,"Positions of study investigators (for any authors of the article, any that applies)",NA,NA,"Academic, Pharmaceutical Industry, Private Data Analysis Company",TRUE,NA,NA,NA
10.1186/s13045-021-01144-9,34493319,general_information,NA,NA,"At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company",NA,NA,Yes,TRUE,NA,NA,NA
10.1186/s13045-021-01144-9,34493319,general_information,NA,NA,Mentioned sources of funding,NA,NA,Pharmaceutical Industry,TRUE,NA,NA,NA
10.1186/s13045-021-01144-9,34493319,general_information,NA,NA,"Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article",NA,NA,Yes,TRUE,NA,NA,NA
10.1186/s13045-021-01144-9,34493319,general_information,NA,NA,Mention of a systematic review to find the studies to compare treatments of interest,NA,NA,Yes,TRUE,NA,NA,NA
10.1186/s13045-021-01144-9,34493319,study_information,NA,1,Patient-level data used,NA,NA,Yes,TRUE,NA,NA,NA
10.1186/s13045-021-01144-9,34493319,study_information,NA,1,Clinical Trial,NA,NA,Yes,TRUE,NA,NA,NA
10.1186/s13045-021-01144-9,34493319,study_information,NA,1,NCT (only for clinical trial registered on clinicaltrials.gov),NA,NA,NCT02631044,TRUE,NA,NA,NA
10.1186/s13045-021-01144-9,34493319,study_information,NA,1,Country where the clinical trial/observational study was conducted (international if more than one),NA,NA,usa,TRUE,NA,NA,NA
10.1186/s13045-021-01144-9,34493319,study_information,NA,1,Phase of the clinical trial (clinical trial only),NA,NA,1,TRUE,NA,NA,NA
10.1186/s13045-021-01144-9,34493319,study_information,NA,1,Number of treatment arms (clinical trial only),NA,NA,1,TRUE,NA,NA,NA
10.1186/s13045-021-01144-9,34493319,study_information,NA,2,Patient-level data used,NA,NA,No,TRUE,NA,NA,NA
10.1186/s13045-021-01144-9,34493319,study_information,NA,2,Clinical Trial,NA,NA,Yes,TRUE,NA,NA,NA
10.1186/s13045-021-01144-9,34493319,study_information,NA,2,NCT (only for clinical trial registered on clinicaltrials.gov),NA,NA,NCT02348216,TRUE,NA,NA,NA
10.1186/s13045-021-01144-9,34493319,study_information,NA,2,Country where the clinical trial/observational study was conducted (international if more than one),NA,NA,international,TRUE,NA,NA,NA
10.1186/s13045-021-01144-9,34493319,study_information,NA,2,Phase of the clinical trial (clinical trial only),NA,NA,"1, 2",TRUE,NA,NA,NA
10.1186/s13045-021-01144-9,34493319,study_information,NA,2,Number of treatment arms (clinical trial only),NA,NA,1,TRUE,NA,NA,NA
10.1186/s13045-021-01144-9,34493319,methodology,1,NA,Treatment name 1,NA,NA,lisocabtagene maraleucel,TRUE,"
No real discussion in the main text of the status of treatment effect modifiers of the variables. 
Report no efficacy differences of the test treatments, but still better safety profile for the IPD treatment
adjust for 10 variables (reported exhaustively only in supplemental materials): 
",N IPD = 110 after removing patients who received Bridging therapy (Initialy = 256),NA
10.1186/s13045-021-01144-9,34493319,methodology,1,NA,Study 'number(s)' for treatment 1,NA,NA,1,TRUE,NA,NA,NA
10.1186/s13045-021-01144-9,34493319,methodology,1,NA,Treatment name 2,NA,NA,axicabtagene ciloleucel,TRUE,NA,NA,NA
10.1186/s13045-021-01144-9,34493319,methodology,1,NA,Study 'number(s)' for treatment 2,NA,NA,2,TRUE,NA,NA,NA
10.1186/s13045-021-01144-9,34493319,methodology,1,NA,Type of population-adjusted indirect comparisons performed,NA,NA,MAIC,TRUE,NA,NA,NA
10.1186/s13045-021-01144-9,34493319,methodology,1,NA,Anchored comparison?,NA,NA,No,TRUE,NA,NA,NA
10.1186/s13045-021-01144-9,34493319,methodology,1,NA,Form of the indirect comparison,NA,NA,Simple (ie treatments effects extracted from two studies),TRUE,NA,NA,NA
10.1186/s13045-021-01144-9,34493319,methodology,1,NA,Definition of a single primary outcome for the indirect comparison,NA,NA,"No primary outcome defined, or multiple primary outcomes without any clear distinction between them",TRUE,NA,NA,NA
10.1186/s13045-021-01144-9,34493319,methodology,1,NA,Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined),overall response rate,objective response rate (orr),objective response rate (orr),FALSE,NA,NA,NA
10.1186/s13045-021-01144-9,34493319,methodology,1,NA,Primary outcome: variable type,NA,NA,Binary (eg rates),TRUE,NA,NA,NA
10.1186/s13045-021-01144-9,34493319,methodology,1,NA,Justification for selecting variables to be included in the adjustment model (in the main text),"Status of prognostic factor/treatment effect modified assessed in the IPD dataset, A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion), Literature based (clinically or methodologically relevant to adjust on these variables based on the literature search conducted for this specific purpose)
","Status of prognostic factor/treatment effect modified assessed in the IPD dataset, A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion), Literature based (clinically or methodologically relevant to adjust on these variables based on the literature search conducted for this specific purpose)","Status of prognostic factor/treatment effect modified assessed in the IPD dataset, A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion), Literature based (clinically or methodologically relevant to adjust on these variables based on the literature search conducted for this specific purpose)",FALSE,NA,NA,NA
10.1186/s13045-021-01144-9,34493319,methodology,1,NA,Inclusion of prognostic factors in the adjustment/matching model,NA,NA,Yes,TRUE,NA,NA,NA
10.1186/s13045-021-01144-9,34493319,methodology,1,NA,Inclusion of treatment-effect modifiers in the adjustment/matching model,No discussion (in the main text) of the status of treatment-effect modifiers of the variables,Yes,Yes,FALSE,NA,NA,NA
10.1186/s13045-021-01144-9,34493319,methodology,1,NA,"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)",NA,NA,No,TRUE,NA,NA,NA
10.1186/s13045-021-01144-9,34493319,methodology,1,NA,Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale),NA,NA,No,TRUE,NA,NA,NA
10.1186/s13045-021-01144-9,34493319,results,1,NA,Sample size of the population of interest in the non IPD treatment arm,NA,NA,101,TRUE,NA,NA,NA
10.1186/s13045-021-01144-9,34493319,results,1,NA,Initial sample size of the population of interest in the IPD treatment arm,256,110,110,FALSE,NA,NA,NA
10.1186/s13045-021-01144-9,34493319,results,1,NA,"Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC",NA,NA,42.1,TRUE,NA,NA,NA
10.1186/s13045-021-01144-9,34493319,results,1,NA,Reporting of a weights' distribution evaluation (MAIC),Not mentioned,"Yes, mentions that the weights distribution has been studied, but weights distribution not reported","Yes, mentions that the weights distribution has been studied, but weights distribution not reported",FALSE,NA,NA,NA
10.1186/s13045-021-01144-9,34493319,results,1,NA,Reporting of the list of the covariates adjusted for/matched on,NA,NA,Yes,TRUE,NA,NA,NA
10.1186/s13045-021-01144-9,34493319,results,1,NA,Number of covariates adjusted for/matched on,NA,NA,10,TRUE,NA,NA,NA
10.1186/s13045-021-01144-9,34493319,results,1,NA,Covariates adjusted for/matched on in the indirect comparison,"Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Past treatments for the disease of interest, Other(s)","Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Past treatments for the disease of interest, Comorbidities and medical history (beside pathology/disease of interest in the comparison)","Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Past treatments for the disease of interest, Comorbidities and medical history (beside pathology/disease of interest in the comparison)",FALSE,NA,NA,NA
10.1186/s13045-021-01144-9,34493319,results,1,NA,Primary outcome: treatment effect contrast,NA,NA,OR,TRUE,NA,NA,NA
10.1186/s13045-021-01144-9,34493319,results,1,NA,Direction of the treatment effect contrast: IPD treatment is:,NA,NA,"Numerator if ratio, or left side if difference",TRUE,NA,NA,NA
10.1186/s13045-021-01144-9,34493319,results,1,NA,Primary outcome: unadjusted treatment effect,NA,NA,0.92,TRUE,NA,NA,NA
10.1186/s13045-021-01144-9,34493319,results,1,NA,"p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])",NA,NA,0.753,TRUE,NA,NA,NA
10.1186/s13045-021-01144-9,34493319,results,1,NA,Primary outcome: adjusted treatment effect,NA,NA,1.4,TRUE,NA,NA,NA
10.1186/s13045-021-01144-9,34493319,results,1,NA,"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])",NA,NA,0.476,TRUE,NA,NA,NA
10.1177/17588359211049639,34616492,general_information,NA,NA,Medical Condition of Interest Name,advanced ovarian cancer,newly diagnosed advanced ovarian cancer,XXXX,FALSE,NA,NA,NA
10.1177/17588359211049639,34616492,general_information,NA,NA,Countries of first author affiliations,NA,NA,uk,TRUE,NA,NA,NA
10.1177/17588359211049639,34616492,general_information,NA,NA,Countries of last author affiliations,NA,NA,uk,TRUE,NA,NA,NA
10.1177/17588359211049639,34616492,general_information,NA,NA,"Positions of study investigators (for any authors of the article, any that applies)",NA,NA,"Academic, Pharmaceutical Industry",TRUE,NA,NA,NA
10.1177/17588359211049639,34616492,general_information,NA,NA,"At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company",Yes,Not mentioned,XXXX,FALSE,NA,NA,NA
10.1177/17588359211049639,34616492,general_information,NA,NA,Mentioned sources of funding,NA,NA,Pharmaceutical Industry,TRUE,NA,NA,NA
10.1177/17588359211049639,34616492,general_information,NA,NA,"Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article",NA,NA,Yes,TRUE,NA,NA,NA
10.1177/17588359211049639,34616492,general_information,NA,NA,Mention of a systematic review to find the studies to compare treatments of interest,NA,NA,No,TRUE,NA,NA,NA
10.1177/17588359211049639,34616492,study_information,NA,1,Patient-level data used,NA,NA,Yes,TRUE,NA,NA,NA
10.1177/17588359211049639,34616492,study_information,NA,1,Clinical Trial,NA,NA,Yes,TRUE,NA,NA,NA
10.1177/17588359211049639,34616492,study_information,NA,1,NCT (only for clinical trial registered on clinicaltrials.gov),NA,NA,NCT02477644,TRUE,NA,NA,NA
10.1177/17588359211049639,34616492,study_information,NA,1,Country where the clinical trial/observational study was conducted (international if more than one),NA,NA,international,TRUE,NA,NA,NA
10.1177/17588359211049639,34616492,study_information,NA,1,Phase of the clinical trial (clinical trial only),NA,NA,3,TRUE,NA,NA,NA
10.1177/17588359211049639,34616492,study_information,NA,1,Number of treatment arms (clinical trial only),NA,NA,2 or more,TRUE,NA,NA,NA
10.1177/17588359211049639,34616492,study_information,NA,2,Patient-level data used,NA,NA,No,TRUE,NA,NA,NA
10.1177/17588359211049639,34616492,study_information,NA,2,Clinical Trial,NA,NA,Yes,TRUE,NA,NA,NA
10.1177/17588359211049639,34616492,study_information,NA,2,NCT (only for clinical trial registered on clinicaltrials.gov),NA,NA,NCT02655016,TRUE,NA,NA,NA
10.1177/17588359211049639,34616492,study_information,NA,2,Country where the clinical trial/observational study was conducted (international if more than one),NA,NA,international,TRUE,NA,NA,NA
10.1177/17588359211049639,34616492,study_information,NA,2,Phase of the clinical trial (clinical trial only),NA,NA,3,TRUE,NA,NA,NA
10.1177/17588359211049639,34616492,study_information,NA,2,Number of treatment arms (clinical trial only),NA,NA,2 or more,TRUE,NA,NA,NA
10.1177/17588359211049639,34616492,methodology,1,NA,Treatment name 1,bevacizumab + olaparib,olaparib + bevacizumab,olaparib + bevacizumab,FALSE,NA,biomarker-unselected population (ITT population),NA
10.1177/17588359211049639,34616492,methodology,1,NA,Study 'number(s)' for treatment 1,NA,NA,1,TRUE,NA,NA,NA
10.1177/17588359211049639,34616492,methodology,1,NA,Treatment name 2,NA,NA,niraparib,TRUE,NA,NA,NA
10.1177/17588359211049639,34616492,methodology,1,NA,Study 'number(s)' for treatment 2,NA,NA,2,TRUE,NA,NA,NA
10.1177/17588359211049639,34616492,methodology,1,NA,Type of population-adjusted indirect comparisons performed,NA,NA,MAIC,TRUE,NA,NA,NA
10.1177/17588359211049639,34616492,methodology,1,NA,Anchored comparison?,NA,NA,No,TRUE,NA,NA,NA
10.1177/17588359211049639,34616492,methodology,1,NA,Form of the indirect comparison,NA,NA,Simple (ie treatments effects extracted from two studies),TRUE,NA,NA,NA
10.1177/17588359211049639,34616492,methodology,1,NA,Definition of a single primary outcome for the indirect comparison,NA,NA,Yes,TRUE,NA,NA,NA
10.1177/17588359211049639,34616492,methodology,1,NA,Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined),NA,NA,progression-free survival,TRUE,NA,NA,NA
10.1177/17588359211049639,34616492,methodology,1,NA,Primary outcome: variable type,NA,NA,Time-to-event,TRUE,NA,NA,NA
10.1177/17588359211049639,34616492,methodology,1,NA,Justification for selecting variables to be included in the adjustment model (in the main text),NA,NA,Status of prognostic factor/treatment effect modified assessed in the IPD dataset,TRUE,NA,NA,NA
10.1177/17588359211049639,34616492,methodology,1,NA,Inclusion of prognostic factors in the adjustment/matching model,NA,NA,Yes,TRUE,NA,NA,NA
10.1177/17588359211049639,34616492,methodology,1,NA,Inclusion of treatment-effect modifiers in the adjustment/matching model,NA,NA,Yes,TRUE,NA,NA,NA
10.1177/17588359211049639,34616492,methodology,1,NA,"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)",NA,NA,No,TRUE,NA,NA,NA
10.1177/17588359211049639,34616492,methodology,1,NA,Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale),NA,NA,No,TRUE,NA,NA,NA
10.1177/17588359211049639,34616492,methodology,2,NA,Treatment name 1,niraparib,bevacizumab + placebo,bevacizumab + placebo,FALSE,NA,biomarker-unselected population (ITT population),NA
10.1177/17588359211049639,34616492,methodology,2,NA,Study 'number(s)' for treatment 1,2,1,1,FALSE,NA,NA,NA
10.1177/17588359211049639,34616492,methodology,2,NA,Treatment name 2,placebo + bevacizumab,niraparib,niraparib,FALSE,NA,NA,NA
10.1177/17588359211049639,34616492,methodology,2,NA,Study 'number(s)' for treatment 2,1,2,2,FALSE,NA,NA,NA
10.1177/17588359211049639,34616492,methodology,2,NA,Type of population-adjusted indirect comparisons performed,NA,NA,MAIC,TRUE,NA,NA,NA
10.1177/17588359211049639,34616492,methodology,2,NA,Anchored comparison?,NA,NA,No,TRUE,NA,NA,NA
10.1177/17588359211049639,34616492,methodology,2,NA,Form of the indirect comparison,NA,NA,Simple (ie treatments effects extracted from two studies),TRUE,NA,NA,NA
10.1177/17588359211049639,34616492,methodology,2,NA,Definition of a single primary outcome for the indirect comparison,NA,NA,Yes,TRUE,NA,NA,NA
10.1177/17588359211049639,34616492,methodology,2,NA,Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined),NA,NA,progression-free survival,TRUE,NA,NA,NA
10.1177/17588359211049639,34616492,methodology,2,NA,Primary outcome: variable type,NA,NA,Time-to-event,TRUE,NA,NA,NA
10.1177/17588359211049639,34616492,methodology,2,NA,Justification for selecting variables to be included in the adjustment model (in the main text),NA,NA,Status of prognostic factor/treatment effect modified assessed in the IPD dataset,TRUE,NA,NA,NA
10.1177/17588359211049639,34616492,methodology,2,NA,Inclusion of prognostic factors in the adjustment/matching model,NA,NA,Yes,TRUE,NA,NA,NA
10.1177/17588359211049639,34616492,methodology,2,NA,Inclusion of treatment-effect modifiers in the adjustment/matching model,NA,NA,Yes,TRUE,NA,NA,NA
10.1177/17588359211049639,34616492,methodology,2,NA,"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)",NA,NA,No,TRUE,NA,NA,NA
10.1177/17588359211049639,34616492,methodology,2,NA,Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale),NA,NA,No,TRUE,NA,NA,NA
10.1177/17588359211049639,34616492,methodology,3,NA,Treatment name 1,bevacizumab + olaparib,olaparib + bevacizumab,olaparib + bevacizumab,FALSE,NA,"HRD-positive population

Say seven variables were matched on but give 8 variables in table 1",NA
10.1177/17588359211049639,34616492,methodology,3,NA,Study 'number(s)' for treatment 1,NA,NA,1,TRUE,NA,NA,NA
10.1177/17588359211049639,34616492,methodology,3,NA,Treatment name 2,placebo,niraparib,placebo,FALSE,NA,NA,NA
10.1177/17588359211049639,34616492,methodology,3,NA,Study 'number(s)' for treatment 2,NA,NA,2,TRUE,NA,NA,NA
10.1177/17588359211049639,34616492,methodology,3,NA,Type of population-adjusted indirect comparisons performed,NA,NA,MAIC,TRUE,NA,NA,NA
10.1177/17588359211049639,34616492,methodology,3,NA,Anchored comparison?,NA,NA,No,TRUE,NA,NA,NA
10.1177/17588359211049639,34616492,methodology,3,NA,Form of the indirect comparison,NA,NA,Simple (ie treatments effects extracted from two studies),TRUE,NA,NA,NA
10.1177/17588359211049639,34616492,methodology,3,NA,Definition of a single primary outcome for the indirect comparison,NA,NA,Yes,TRUE,NA,NA,NA
10.1177/17588359211049639,34616492,methodology,3,NA,Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined),NA,NA,progression-free survival,TRUE,NA,NA,NA
10.1177/17588359211049639,34616492,methodology,3,NA,Primary outcome: variable type,NA,NA,Time-to-event,TRUE,NA,NA,NA
10.1177/17588359211049639,34616492,methodology,3,NA,Justification for selecting variables to be included in the adjustment model (in the main text),NA,NA,Status of prognostic factor/treatment effect modified assessed in the IPD dataset,TRUE,NA,NA,NA
10.1177/17588359211049639,34616492,methodology,3,NA,Inclusion of prognostic factors in the adjustment/matching model,NA,NA,Yes,TRUE,NA,NA,NA
10.1177/17588359211049639,34616492,methodology,3,NA,Inclusion of treatment-effect modifiers in the adjustment/matching model,NA,NA,Yes,TRUE,NA,NA,NA
10.1177/17588359211049639,34616492,methodology,3,NA,"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)",NA,NA,No,TRUE,NA,NA,NA
10.1177/17588359211049639,34616492,methodology,3,NA,Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale),NA,NA,No,TRUE,NA,NA,NA
10.1177/17588359211049639,34616492,methodology,4,NA,Treatment name 1,placebo + bevacizumab,bevacizumab + placebo,placebo + bevacizumab,FALSE,NA,"HRD-positive population

Say seven variable were matched on but give 8 variables in table 1",NA
10.1177/17588359211049639,34616492,methodology,4,NA,Study 'number(s)' for treatment 1,NA,NA,1,TRUE,NA,NA,NA
10.1177/17588359211049639,34616492,methodology,4,NA,Treatment name 2,placebo,niraparib,placebo,FALSE,NA,NA,NA
10.1177/17588359211049639,34616492,methodology,4,NA,Study 'number(s)' for treatment 2,NA,NA,2,TRUE,NA,NA,NA
10.1177/17588359211049639,34616492,methodology,4,NA,Type of population-adjusted indirect comparisons performed,NA,NA,MAIC,TRUE,NA,NA,NA
10.1177/17588359211049639,34616492,methodology,4,NA,Anchored comparison?,NA,NA,No,TRUE,NA,NA,NA
10.1177/17588359211049639,34616492,methodology,4,NA,Form of the indirect comparison,NA,NA,Simple (ie treatments effects extracted from two studies),TRUE,NA,NA,NA
10.1177/17588359211049639,34616492,methodology,4,NA,Definition of a single primary outcome for the indirect comparison,NA,NA,Yes,TRUE,NA,NA,NA
10.1177/17588359211049639,34616492,methodology,4,NA,Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined),NA,NA,progression-free survival,TRUE,NA,NA,NA
10.1177/17588359211049639,34616492,methodology,4,NA,Primary outcome: variable type,NA,NA,Time-to-event,TRUE,NA,NA,NA
10.1177/17588359211049639,34616492,methodology,4,NA,Justification for selecting variables to be included in the adjustment model (in the main text),NA,NA,Status of prognostic factor/treatment effect modified assessed in the IPD dataset,TRUE,NA,NA,NA
10.1177/17588359211049639,34616492,methodology,4,NA,Inclusion of prognostic factors in the adjustment/matching model,NA,NA,Yes,TRUE,NA,NA,NA
10.1177/17588359211049639,34616492,methodology,4,NA,Inclusion of treatment-effect modifiers in the adjustment/matching model,NA,NA,Yes,TRUE,NA,NA,NA
10.1177/17588359211049639,34616492,methodology,4,NA,"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)",NA,NA,No,TRUE,NA,NA,NA
10.1177/17588359211049639,34616492,methodology,4,NA,Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale),NA,NA,No,TRUE,NA,NA,NA
10.1177/17588359211049639,34616492,results,1,NA,Sample size of the population of interest in the non IPD treatment arm,NA,NA,487,TRUE,NA,NA,NA
10.1177/17588359211049639,34616492,results,1,NA,Initial sample size of the population of interest in the IPD treatment arm,NA,NA,399,TRUE,NA,NA,NA
10.1177/17588359211049639,34616492,results,1,NA,"Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC",NA,NA,358,TRUE,NA,NA,NA
10.1177/17588359211049639,34616492,results,1,NA,Reporting of a weights' distribution evaluation (MAIC),NA,NA,"Yes, mentions that the weights distribution has been studied, and weights distribution reported in main article or supplemental materials",TRUE,NA,NA,NA
10.1177/17588359211049639,34616492,results,1,NA,Reporting of the list of the covariates adjusted for/matched on,NA,NA,Yes,TRUE,NA,NA,NA
10.1177/17588359211049639,34616492,results,1,NA,Number of covariates adjusted for/matched on,NA,NA,8,TRUE,NA,NA,NA
10.1177/17588359211049639,34616492,results,1,NA,Covariates adjusted for/matched on in the indirect comparison,NA,NA,"Age, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Past treatments for the disease of interest",TRUE,NA,NA,NA
10.1177/17588359211049639,34616492,results,1,NA,Primary outcome: treatment effect contrast,NA,NA,HR,TRUE,NA,NA,NA
10.1177/17588359211049639,34616492,results,1,NA,Direction of the treatment effect contrast: IPD treatment is:,NA,NA,"Numerator if ratio, or left side if difference",TRUE,NA,NA,NA
10.1177/17588359211049639,34616492,results,1,NA,Primary outcome: adjusted treatment effect,NA,NA,0.57,TRUE,NA,NA,NA
10.1177/17588359211049639,34616492,results,1,NA,"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])",NA,NA,[0.47;0.69],TRUE,NA,NA,NA
10.1177/17588359211049639,34616492,results,2,NA,Sample size of the population of interest in the non IPD treatment arm,NA,NA,487,TRUE,NA,NA,NA
10.1177/17588359211049639,34616492,results,2,NA,Initial sample size of the population of interest in the IPD treatment arm,NA,NA,196,TRUE,NA,NA,NA
10.1177/17588359211049639,34616492,results,2,NA,"Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC",NA,NA,174,TRUE,NA,NA,NA
10.1177/17588359211049639,34616492,results,2,NA,Reporting of a weights' distribution evaluation (MAIC),NA,NA,"Yes, mentions that the weights distribution has been studied, and weights distribution reported in main article or supplemental materials",TRUE,NA,NA,NA
10.1177/17588359211049639,34616492,results,2,NA,Reporting of the list of the covariates adjusted for/matched on,NA,NA,Yes,TRUE,NA,NA,NA
10.1177/17588359211049639,34616492,results,2,NA,Number of covariates adjusted for/matched on,NA,NA,8,TRUE,NA,NA,NA
10.1177/17588359211049639,34616492,results,2,NA,Covariates adjusted for/matched on in the indirect comparison,NA,NA,"Age, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Past treatments for the disease of interest",TRUE,NA,NA,NA
10.1177/17588359211049639,34616492,results,2,NA,Primary outcome: treatment effect contrast,NA,NA,HR,TRUE,NA,NA,NA
10.1177/17588359211049639,34616492,results,2,NA,Direction of the treatment effect contrast: IPD treatment is:,NA,NA,"Denominator if ratio, or rightside if difference",TRUE,NA,NA,NA
10.1177/17588359211049639,34616492,results,2,NA,Primary outcome: adjusted treatment effect,NA,NA,1.07,TRUE,NA,NA,NA
10.1177/17588359211049639,34616492,results,2,NA,"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])",NA,NA,[0.87;1.32],TRUE,NA,NA,NA
10.1177/17588359211049639,34616492,results,3,NA,Sample size of the population of interest in the non IPD treatment arm,246,247,246,FALSE,NA,NA,NA
10.1177/17588359211049639,34616492,results,3,NA,Initial sample size of the population of interest in the IPD treatment arm,399,177,399,FALSE,NA,NA,NA
10.1177/17588359211049639,34616492,results,3,NA,"Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC",358,164,358,FALSE,NA,NA,NA
10.1177/17588359211049639,34616492,results,3,NA,Reporting of a weights' distribution evaluation (MAIC),NA,NA,"Yes, mentions that the weights distribution has been studied, and weights distribution reported in main article or supplemental materials",TRUE,NA,NA,NA
10.1177/17588359211049639,34616492,results,3,NA,Reporting of the list of the covariates adjusted for/matched on,NA,NA,Yes,TRUE,NA,NA,NA
10.1177/17588359211049639,34616492,results,3,NA,Number of covariates adjusted for/matched on,8,7,8,FALSE,NA,NA,NA
10.1177/17588359211049639,34616492,results,3,NA,Covariates adjusted for/matched on in the indirect comparison,NA,NA,"Age, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Past treatments for the disease of interest",TRUE,NA,NA,NA
10.1177/17588359211049639,34616492,results,3,NA,Primary outcome: treatment effect contrast,NA,NA,HR,TRUE,NA,NA,NA
10.1177/17588359211049639,34616492,results,3,NA,Direction of the treatment effect contrast: IPD treatment is:,NA,NA,"Numerator if ratio, or left side if difference",TRUE,NA,NA,NA
10.1177/17588359211049639,34616492,results,3,NA,Primary outcome: adjusted treatment effect,0.33,0.57,0.33,FALSE,NA,NA,NA
10.1177/17588359211049639,34616492,results,3,NA,"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])",[0.26;0.42],[0.41;0.79],[0.26;0.42],FALSE,NA,NA,NA
10.1177/17588359211049639,34616492,results,4,NA,Sample size of the population of interest in the non IPD treatment arm,246,247,246,FALSE,NA,NA,NA
10.1177/17588359211049639,34616492,results,4,NA,Initial sample size of the population of interest in the IPD treatment arm,196,89,196,FALSE,NA,NA,NA
10.1177/17588359211049639,34616492,results,4,NA,"Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC",174,79,174,FALSE,NA,NA,NA
10.1177/17588359211049639,34616492,results,4,NA,Reporting of a weights' distribution evaluation (MAIC),NA,NA,"Yes, mentions that the weights distribution has been studied, and weights distribution reported in main article or supplemental materials",TRUE,NA,NA,NA
10.1177/17588359211049639,34616492,results,4,NA,Reporting of the list of the covariates adjusted for/matched on,NA,NA,Yes,TRUE,NA,NA,NA
10.1177/17588359211049639,34616492,results,4,NA,Number of covariates adjusted for/matched on,8,7,8,FALSE,NA,NA,NA
10.1177/17588359211049639,34616492,results,4,NA,Covariates adjusted for/matched on in the indirect comparison,NA,NA,"Age, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Past treatments for the disease of interest",TRUE,NA,NA,NA
10.1177/17588359211049639,34616492,results,4,NA,Primary outcome: treatment effect contrast,NA,NA,HR,TRUE,NA,NA,NA
10.1177/17588359211049639,34616492,results,4,NA,Direction of the treatment effect contrast: IPD treatment is:,"Numerator if ratio, or left side if difference","Denominator if ratio, or rightside if difference","Numerator if ratio, or left side if difference",FALSE,NA,NA,NA
10.1177/17588359211049639,34616492,results,4,NA,Primary outcome: adjusted treatment effect,0.55,0.7,0.55,FALSE,NA,NA,NA
10.1177/17588359211049639,34616492,results,4,NA,"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])",[0.43;0.70],[0.51;0.97],[0.43;0.70],FALSE,NA,NA,NA
10.2217/cer-2021-0221,34751591,general_information,NA,NA,Medical Condition of Interest Name,NA,NA,hr+/her2- advanced breast cancer,TRUE,NA,NA,NA
10.2217/cer-2021-0221,34751591,general_information,NA,NA,Countries of first author affiliations,NA,NA,usa,TRUE,NA,NA,NA
10.2217/cer-2021-0221,34751591,general_information,NA,NA,Countries of last author affiliations,NA,NA,canada,TRUE,NA,NA,NA
10.2217/cer-2021-0221,34751591,general_information,NA,NA,"Positions of study investigators (for any authors of the article, any that applies)",NA,NA,"Pharmaceutical Industry, Private Data Analysis Company",TRUE,NA,NA,NA
10.2217/cer-2021-0221,34751591,general_information,NA,NA,"At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company",NA,NA,Yes,TRUE,NA,NA,NA
10.2217/cer-2021-0221,34751591,general_information,NA,NA,Mentioned sources of funding,NA,NA,Pharmaceutical Industry,TRUE,NA,NA,NA
10.2217/cer-2021-0221,34751591,general_information,NA,NA,"Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article",NA,NA,Yes,TRUE,NA,NA,NA
10.2217/cer-2021-0221,34751591,general_information,NA,NA,Mention of a systematic review to find the studies to compare treatments of interest,NA,NA,No,TRUE,NA,NA,NA
10.2217/cer-2021-0221,34751591,study_information,NA,1,Patient-level data used,Yes,No,XXXX,FALSE,NA,NA,NA
10.2217/cer-2021-0221,34751591,study_information,NA,1,Clinical Trial,NA,NA,Yes,TRUE,NA,NA,NA
10.2217/cer-2021-0221,34751591,study_information,NA,1,NCT (only for clinical trial registered on clinicaltrials.gov),NA,NA,NCT01942135,TRUE,NA,NA,NA
10.2217/cer-2021-0221,34751591,study_information,NA,1,Country where the clinical trial/observational study was conducted (international if more than one),NA,NA,international,TRUE,NA,NA,NA
10.2217/cer-2021-0221,34751591,study_information,NA,1,Phase of the clinical trial (clinical trial only),NA,NA,3,TRUE,NA,NA,NA
10.2217/cer-2021-0221,34751591,study_information,NA,1,Number of treatment arms (clinical trial only),NA,NA,2 or more,TRUE,NA,NA,NA
10.2217/cer-2021-0221,34751591,study_information,NA,2,Patient-level data used,NA,NA,No,TRUE,NA,NA,NA
10.2217/cer-2021-0221,34751591,study_information,NA,2,Clinical Trial,Yes,No,XXXX,FALSE,NA,NA,NA
10.2217/cer-2021-0221,34751591,study_information,NA,2,NCT (only for clinical trial registered on clinicaltrials.gov),NA,NA,NCT02107703,TRUE,NA,NA,NA
10.2217/cer-2021-0221,34751591,study_information,NA,2,Country where the clinical trial/observational study was conducted (international if more than one),NA,NA,international,TRUE,NA,NA,NA
10.2217/cer-2021-0221,34751591,study_information,NA,2,Phase of the clinical trial (clinical trial only),NA,NA,3,TRUE,NA,NA,NA
10.2217/cer-2021-0221,34751591,study_information,NA,2,Number of treatment arms (clinical trial only),NA,NA,2 or more,TRUE,NA,NA,NA
10.2217/cer-2021-0221,34751591,methodology,1,NA,Treatment name 1,palbociclib,palbociclib + fulvestrant,palbociclib + fulvestrant,FALSE,NA,"N non IPD (2 arms) = 669
N IPD (2 arms) = 501

Use effect-modifiers selected for another MAIC (Literature) which is based on ""assessment of the literature and clinical opinion, extent of treatment modifications, differences incharacteristics between trials and impact on effective sample size (ESS)""

",NA
10.2217/cer-2021-0221,34751591,methodology,1,NA,Study 'number(s)' for treatment 1,NA,NA,1,TRUE,NA,NA,NA
10.2217/cer-2021-0221,34751591,methodology,1,NA,Treatment name 2,abemaciclib,abemaciclib + fulvestrant,abemaciclib + fulvestrant,FALSE,NA,NA,NA
10.2217/cer-2021-0221,34751591,methodology,1,NA,Study 'number(s)' for treatment 2,NA,NA,2,TRUE,NA,NA,NA
10.2217/cer-2021-0221,34751591,methodology,1,NA,Type of population-adjusted indirect comparisons performed,NA,NA,MAIC,TRUE,NA,NA,NA
10.2217/cer-2021-0221,34751591,methodology,1,NA,Anchored comparison?,NA,NA,Yes,TRUE,NA,NA,NA
10.2217/cer-2021-0221,34751591,methodology,1,NA,Form of the indirect comparison,NA,NA,Simple (ie treatments effects extracted from two studies),TRUE,NA,NA,NA
10.2217/cer-2021-0221,34751591,methodology,1,NA,Definition of a single primary outcome for the indirect comparison,NA,NA,"No primary outcome defined, or multiple primary outcomes without any clear distinction between them",TRUE,NA,NA,NA
10.2217/cer-2021-0221,34751591,methodology,1,NA,Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined),eortc qlq-c30 global quality of life,global quality of life (european organisation for research and treatment of cancerquality of life questionnaire core 30 items) change from baseline,global quality of life (european organisation for research and treatment of cancerquality of life questionnaire core 30 items) change from baseline,FALSE,NA,NA,NA
10.2217/cer-2021-0221,34751591,methodology,1,NA,Primary outcome: variable type,"Continuous (count, mean, ...)","Categorical (more than 2 categories, ordered or not; eg scales)","Continuous (count, mean, ...)",FALSE,NA,NA,NA
10.2217/cer-2021-0221,34751591,methodology,1,NA,Justification for selecting variables to be included in the adjustment model (in the main text),"Statistical imbalanced between treatment groups (independently of the status of prognostic/effect modifier), Status of prognostic factor/treatment effect modified assessed in the IPD dataset, A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion), Literature based (clinically or methodologically relevant to adjust on these variables based on the literature search conducted for this specific purpose)",Literature based (clinically or methodologically relevant to adjust on these variables based on the literature search conducted for this specific purpose),"Statistical imbalanced between treatment groups (independently of the status of prognostic/effect modifier), Status of prognostic factor/treatment effect modified assessed in the IPD dataset, A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion), Literature based (clinically or methodologically relevant to adjust on these variables based on the literature search conducted for this specific purpose)",FALSE,NA,NA,NA
10.2217/cer-2021-0221,34751591,methodology,1,NA,Inclusion of prognostic factors in the adjustment/matching model,NA,NA,No,TRUE,NA,NA,NA
10.2217/cer-2021-0221,34751591,methodology,1,NA,Inclusion of treatment-effect modifiers in the adjustment/matching model,NA,NA,Yes,TRUE,NA,NA,NA
10.2217/cer-2021-0221,34751591,methodology,1,NA,"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)",NA,NA,No,TRUE,NA,NA,NA
10.2217/cer-2021-0221,34751591,methodology,1,NA,Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale),NA,NA,No,TRUE,NA,NA,NA
10.2217/cer-2021-0221,34751591,results,1,NA,Initial sample size of the population of interest in the IPD treatment arm,180,NA,180,FALSE,NA,NA,NA
10.2217/cer-2021-0221,34751591,results,1,NA,"If anchored comparison, initial sample size of the population of interest in the IPD anchor arm",90,NA,90,FALSE,NA,NA,NA
10.2217/cer-2021-0221,34751591,results,1,NA,Reporting of a weights' distribution evaluation (MAIC),NA,NA,"Yes, mentions that the weights distribution has been studied, and weights distribution reported in main article or supplemental materials",TRUE,NA,NA,NA
10.2217/cer-2021-0221,34751591,results,1,NA,Reporting of the list of the covariates adjusted for/matched on,NA,NA,Yes,TRUE,NA,NA,NA
10.2217/cer-2021-0221,34751591,results,1,NA,Number of covariates adjusted for/matched on,NA,NA,11,TRUE,NA,NA,NA
10.2217/cer-2021-0221,34751591,results,1,NA,Covariates adjusted for/matched on in the indirect comparison,NA,NA,"Age, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Race/ethnicity, Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Past treatments for the disease of interest, Other(s)",TRUE,NA,NA,NA
10.2217/cer-2021-0221,34751591,results,1,NA,Primary outcome: treatment effect contrast,NA,NA,Means difference,TRUE,NA,NA,NA
10.2217/cer-2021-0221,34751591,results,1,NA,Direction of the treatment effect contrast: IPD treatment is:,NA,NA,"Numerator if ratio, or left side if difference",TRUE,NA,NA,NA
10.2217/cer-2021-0221,34751591,results,1,NA,Primary outcome: unadjusted treatment effect,NA,NA,4.6,TRUE,NA,NA,NA
10.2217/cer-2021-0221,34751591,results,1,NA,"p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])",NA,NA,0.016,TRUE,NA,NA,NA
10.2217/cer-2021-0221,34751591,results,1,NA,Primary outcome: adjusted treatment effect,NA,NA,6.95,TRUE,NA,NA,NA
10.2217/cer-2021-0221,34751591,results,1,NA,"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])",NA,NA,0.004,TRUE,NA,NA,NA
10.2217/cer-2021-0221,34751591,results,1,NA,"Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC",NA,180,XXXX,FALSE,NA,NA,NA
10.2217/cer-2021-0221,34751591,results,1,NA,"If anchored comparison, effective sample size after reweighting for MAIC; or sample size used in the regression model for STC in the IPD anchor arm",NA,90,XXXX,FALSE,NA,NA,NA
10.2147/cmar.s325043,34754238,general_information,NA,NA,Medical Condition of Interest Name,NA,NA,hr+/her2âˆ’ advanced breast cancer,TRUE,NA,NA,NA
10.2147/cmar.s325043,34754238,general_information,NA,NA,Countries of first author affiliations,NA,NA,germany,TRUE,NA,NA,NA
10.2147/cmar.s325043,34754238,general_information,NA,NA,Countries of last author affiliations,NA,NA,usa,TRUE,NA,NA,NA
10.2147/cmar.s325043,34754238,general_information,NA,NA,"Positions of study investigators (for any authors of the article, any that applies)",NA,NA,"Academic, Pharmaceutical Industry, Private Data Analysis Company",TRUE,NA,NA,NA
10.2147/cmar.s325043,34754238,general_information,NA,NA,"At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company",NA,NA,Yes,TRUE,NA,NA,NA
10.2147/cmar.s325043,34754238,general_information,NA,NA,Mentioned sources of funding,NA,NA,Pharmaceutical Industry,TRUE,NA,NA,NA
10.2147/cmar.s325043,34754238,general_information,NA,NA,"Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article",NA,NA,Yes,TRUE,NA,NA,NA
10.2147/cmar.s325043,34754238,general_information,NA,NA,Mention of a systematic review to find the studies to compare treatments of interest,NA,NA,No,TRUE,NA,NA,NA
10.2147/cmar.s325043,34754238,study_information,NA,1,Patient-level data used,NA,NA,Yes,TRUE,NA,NA,NA
10.2147/cmar.s325043,34754238,study_information,NA,1,Clinical Trial,NA,NA,Yes,TRUE,NA,NA,NA
10.2147/cmar.s325043,34754238,study_information,NA,1,NCT (only for clinical trial registered on clinicaltrials.gov),NA,NA,NCT02422615,TRUE,NA,NA,NA
10.2147/cmar.s325043,34754238,study_information,NA,1,Country where the clinical trial/observational study was conducted (international if more than one),NA,NA,international,TRUE,NA,NA,NA
10.2147/cmar.s325043,34754238,study_information,NA,1,Phase of the clinical trial (clinical trial only),NA,NA,3,TRUE,NA,NA,NA
10.2147/cmar.s325043,34754238,study_information,NA,1,Number of treatment arms (clinical trial only),NA,NA,2 or more,TRUE,NA,NA,NA
10.2147/cmar.s325043,34754238,study_information,NA,2,Patient-level data used,NA,NA,No,TRUE,NA,NA,NA
10.2147/cmar.s325043,34754238,study_information,NA,2,Clinical Trial,NA,NA,Yes,TRUE,NA,NA,NA
10.2147/cmar.s325043,34754238,study_information,NA,2,NCT (only for clinical trial registered on clinicaltrials.gov),NA,NA,NCT00721409,TRUE,NA,NA,NA
10.2147/cmar.s325043,34754238,study_information,NA,2,Country where the clinical trial/observational study was conducted (international if more than one),NA,NA,international,TRUE,NA,NA,NA
10.2147/cmar.s325043,34754238,study_information,NA,2,Phase of the clinical trial (clinical trial only),NA,NA,2,TRUE,NA,NA,NA
10.2147/cmar.s325043,34754238,study_information,NA,2,Number of treatment arms (clinical trial only),NA,NA,2 or more,TRUE,NA,NA,NA
10.2147/cmar.s325043,34754238,methodology,1,NA,Treatment name 1,NA,NA,ribociclib + fulvestrant,TRUE,NA,NA,NA
10.2147/cmar.s325043,34754238,methodology,1,NA,Study 'number(s)' for treatment 1,NA,NA,1,TRUE,NA,NA,NA
10.2147/cmar.s325043,34754238,methodology,1,NA,Treatment name 2,NA,NA,palbociclib + letrozole,TRUE,NA,NA,NA
10.2147/cmar.s325043,34754238,methodology,1,NA,Study 'number(s)' for treatment 2,NA,NA,2,TRUE,NA,NA,NA
10.2147/cmar.s325043,34754238,methodology,1,NA,Type of population-adjusted indirect comparisons performed,NA,NA,MAIC,TRUE,NA,NA,NA
10.2147/cmar.s325043,34754238,methodology,1,NA,Anchored comparison?,NA,NA,No,TRUE,NA,NA,NA
10.2147/cmar.s325043,34754238,methodology,1,NA,Form of the indirect comparison,NA,NA,Simple (ie treatments effects extracted from two studies),TRUE,NA,NA,NA
10.2147/cmar.s325043,34754238,methodology,1,NA,Definition of a single primary outcome for the indirect comparison,NA,NA,"No primary outcome defined, or multiple primary outcomes without any clear distinction between them",TRUE,NA,NA,NA
10.2147/cmar.s325043,34754238,methodology,1,NA,Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined),NA,NA,progression-free survival,TRUE,NA,NA,NA
10.2147/cmar.s325043,34754238,methodology,1,NA,Primary outcome: variable type,NA,NA,Time-to-event,TRUE,NA,NA,NA
10.2147/cmar.s325043,34754238,methodology,1,NA,Justification for selecting variables to be included in the adjustment model (in the main text),NA,NA,"Nothing mentioned, not reported",TRUE,NA,NA,NA
10.2147/cmar.s325043,34754238,methodology,1,NA,Inclusion of prognostic factors in the adjustment/matching model,NA,NA,No discussion (in the main text) of the status of prognostic factors of the variables,TRUE,NA,NA,NA
10.2147/cmar.s325043,34754238,methodology,1,NA,Inclusion of treatment-effect modifiers in the adjustment/matching model,NA,NA,No discussion (in the main text) of the status of treatment-effect modifiers of the variables,TRUE,NA,NA,NA
10.2147/cmar.s325043,34754238,methodology,1,NA,"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)",NA,NA,No,TRUE,NA,NA,NA
10.2147/cmar.s325043,34754238,methodology,1,NA,Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale),NA,NA,No,TRUE,NA,NA,NA
10.2147/cmar.s325043,34754238,methodology,2,NA,Treatment name 1,NA,NA,placebo + fulvestrant,TRUE,NA,NA,NA
10.2147/cmar.s325043,34754238,methodology,2,NA,Study 'number(s)' for treatment 1,NA,NA,1,TRUE,NA,NA,NA
10.2147/cmar.s325043,34754238,methodology,2,NA,Treatment name 2,NA,NA,letrozole,TRUE,NA,NA,NA
10.2147/cmar.s325043,34754238,methodology,2,NA,Study 'number(s)' for treatment 2,NA,NA,2,TRUE,NA,NA,NA
10.2147/cmar.s325043,34754238,methodology,2,NA,Type of population-adjusted indirect comparisons performed,NA,NA,MAIC,TRUE,NA,NA,NA
10.2147/cmar.s325043,34754238,methodology,2,NA,Anchored comparison?,NA,NA,No,TRUE,NA,NA,NA
10.2147/cmar.s325043,34754238,methodology,2,NA,Form of the indirect comparison,NA,NA,Simple (ie treatments effects extracted from two studies),TRUE,NA,NA,NA
10.2147/cmar.s325043,34754238,methodology,2,NA,Definition of a single primary outcome for the indirect comparison,NA,NA,"No primary outcome defined, or multiple primary outcomes without any clear distinction between them",TRUE,NA,NA,NA
10.2147/cmar.s325043,34754238,methodology,2,NA,Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined),NA,NA,progression-free survival,TRUE,NA,NA,NA
10.2147/cmar.s325043,34754238,methodology,2,NA,Primary outcome: variable type,NA,NA,Time-to-event,TRUE,NA,NA,NA
10.2147/cmar.s325043,34754238,methodology,2,NA,Justification for selecting variables to be included in the adjustment model (in the main text),NA,NA,"Nothing mentioned, not reported",TRUE,NA,NA,NA
10.2147/cmar.s325043,34754238,methodology,2,NA,Inclusion of prognostic factors in the adjustment/matching model,NA,NA,No discussion (in the main text) of the status of prognostic factors of the variables,TRUE,NA,NA,NA
10.2147/cmar.s325043,34754238,methodology,2,NA,Inclusion of treatment-effect modifiers in the adjustment/matching model,NA,NA,No discussion (in the main text) of the status of treatment-effect modifiers of the variables,TRUE,NA,NA,NA
10.2147/cmar.s325043,34754238,methodology,2,NA,"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)",NA,NA,No,TRUE,NA,NA,NA
10.2147/cmar.s325043,34754238,methodology,2,NA,Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale),NA,NA,No,TRUE,NA,NA,NA
10.2147/cmar.s325043,34754238,results,1,NA,Sample size of the population of interest in the non IPD treatment arm,NA,NA,84,TRUE,NA,NA,NA
10.2147/cmar.s325043,34754238,results,1,NA,Initial sample size of the population of interest in the IPD treatment arm,NA,NA,329,TRUE,NA,NA,NA
10.2147/cmar.s325043,34754238,results,1,NA,"Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC",NA,NA,221,TRUE,NA,NA,NA
10.2147/cmar.s325043,34754238,results,1,NA,Reporting of a weights' distribution evaluation (MAIC),NA,NA,"Yes, mentions that the weights distribution has been studied, and weights distribution reported in main article or supplemental materials",TRUE,NA,NA,NA
10.2147/cmar.s325043,34754238,results,1,NA,Reporting of the list of the covariates adjusted for/matched on,NA,NA,Yes,TRUE,NA,NA,NA
10.2147/cmar.s325043,34754238,results,1,NA,Number of covariates adjusted for/matched on,NA,NA,7,TRUE,NA,NA,NA
10.2147/cmar.s325043,34754238,results,1,NA,Covariates adjusted for/matched on in the indirect comparison,NA,NA,"Age, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Past treatments for the disease of interest",TRUE,NA,NA,NA
10.2147/cmar.s325043,34754238,results,1,NA,Primary outcome: treatment effect contrast,NA,NA,HR,TRUE,NA,NA,NA
10.2147/cmar.s325043,34754238,results,1,NA,Direction of the treatment effect contrast: IPD treatment is:,NA,NA,"Numerator if ratio, or left side if difference",TRUE,NA,NA,NA
10.2147/cmar.s325043,34754238,results,1,NA,Primary outcome: unadjusted treatment effect,NA,NA,0.83,TRUE,NA,NA,NA
10.2147/cmar.s325043,34754238,results,1,NA,"p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])",NA,NA,0.2838,TRUE,NA,NA,NA
10.2147/cmar.s325043,34754238,results,1,NA,Primary outcome: adjusted treatment effect,NA,NA,0.77,TRUE,NA,NA,NA
10.2147/cmar.s325043,34754238,results,1,NA,"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])",NA,NA,0.1553,TRUE,NA,NA,NA
10.2147/cmar.s325043,34754238,results,2,NA,Sample size of the population of interest in the non IPD treatment arm,NA,NA,81,TRUE,NA,NA,NA
10.2147/cmar.s325043,34754238,results,2,NA,Initial sample size of the population of interest in the IPD treatment arm,NA,NA,178,TRUE,NA,NA,NA
10.2147/cmar.s325043,34754238,results,2,NA,"Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC",NA,NA,117,TRUE,NA,NA,NA
10.2147/cmar.s325043,34754238,results,2,NA,Reporting of a weights' distribution evaluation (MAIC),NA,NA,"Yes, mentions that the weights distribution has been studied, and weights distribution reported in main article or supplemental materials",TRUE,NA,NA,NA
10.2147/cmar.s325043,34754238,results,2,NA,Reporting of the list of the covariates adjusted for/matched on,NA,NA,Yes,TRUE,NA,NA,NA
10.2147/cmar.s325043,34754238,results,2,NA,Number of covariates adjusted for/matched on,NA,NA,7,TRUE,NA,NA,NA
10.2147/cmar.s325043,34754238,results,2,NA,Covariates adjusted for/matched on in the indirect comparison,NA,NA,"Age, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Past treatments for the disease of interest",TRUE,NA,NA,NA
10.2147/cmar.s325043,34754238,results,2,NA,Primary outcome: treatment effect contrast,NA,NA,HR,TRUE,NA,NA,NA
10.2147/cmar.s325043,34754238,results,2,NA,Direction of the treatment effect contrast: IPD treatment is:,NA,NA,"Numerator if ratio, or left side if difference",TRUE,NA,NA,NA
10.2147/cmar.s325043,34754238,results,2,NA,Primary outcome: unadjusted treatment effect,NA,NA,0.66,TRUE,NA,NA,NA
10.2147/cmar.s325043,34754238,results,2,NA,"p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])",NA,NA,0.0094,TRUE,NA,NA,NA
10.2147/cmar.s325043,34754238,results,2,NA,Primary outcome: adjusted treatment effect,NA,NA,0.58,TRUE,NA,NA,NA
10.2147/cmar.s325043,34754238,results,2,NA,"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])",NA,NA,0.0019,TRUE,NA,NA,NA
10.1007/s12325-021-01885-6,34797506,general_information,NA,NA,Medical Condition of Interest Name,non-metastatic castration-resistant prostate cancer receiving androgen deprivation therapy,non-metastatic castration-resistant prostate cancer,XXXX,FALSE,NA,NA,NA
10.1007/s12325-021-01885-6,34797506,general_information,NA,NA,Countries of first author affiliations,NA,NA,uk,TRUE,NA,NA,NA
10.1007/s12325-021-01885-6,34797506,general_information,NA,NA,Countries of last author affiliations,NA,NA,germany,TRUE,NA,NA,NA
10.1007/s12325-021-01885-6,34797506,general_information,NA,NA,"Positions of study investigators (for any authors of the article, any that applies)",NA,NA,"Academic, Pharmaceutical Industry",TRUE,NA,NA,NA
10.1007/s12325-021-01885-6,34797506,general_information,NA,NA,"At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company",NA,NA,Not mentioned,TRUE,NA,NA,NA
10.1007/s12325-021-01885-6,34797506,general_information,NA,NA,Mentioned sources of funding,NA,NA,Pharmaceutical Industry,TRUE,NA,NA,NA
10.1007/s12325-021-01885-6,34797506,general_information,NA,NA,"Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article",NA,NA,Yes,TRUE,NA,NA,NA
10.1007/s12325-021-01885-6,34797506,general_information,NA,NA,Mention of a systematic review to find the studies to compare treatments of interest,NA,NA,No,TRUE,NA,NA,NA
10.1007/s12325-021-01885-6,34797506,study_information,NA,1,Patient-level data used,NA,NA,Yes,TRUE,NA,NA,NA
10.1007/s12325-021-01885-6,34797506,study_information,NA,1,Clinical Trial,NA,NA,Yes,TRUE,NA,NA,NA
10.1007/s12325-021-01885-6,34797506,study_information,NA,1,NCT (only for clinical trial registered on clinicaltrials.gov),NA,NA,NCT01946204,TRUE,NA,NA,NA
10.1007/s12325-021-01885-6,34797506,study_information,NA,1,Country where the clinical trial/observational study was conducted (international if more than one),NA,NA,international,TRUE,NA,NA,NA
10.1007/s12325-021-01885-6,34797506,study_information,NA,1,Phase of the clinical trial (clinical trial only),NA,NA,3,TRUE,NA,NA,NA
10.1007/s12325-021-01885-6,34797506,study_information,NA,1,Number of treatment arms (clinical trial only),NA,NA,2 or more,TRUE,NA,NA,NA
10.1007/s12325-021-01885-6,34797506,study_information,NA,2,Patient-level data used,NA,NA,No,TRUE,NA,NA,NA
10.1007/s12325-021-01885-6,34797506,study_information,NA,2,Clinical Trial,NA,NA,Yes,TRUE,NA,NA,NA
10.1007/s12325-021-01885-6,34797506,study_information,NA,2,NCT (only for clinical trial registered on clinicaltrials.gov),NA,NA,NCT02200614,TRUE,NA,NA,NA
10.1007/s12325-021-01885-6,34797506,study_information,NA,2,Country where the clinical trial/observational study was conducted (international if more than one),NA,NA,international,TRUE,NA,NA,NA
10.1007/s12325-021-01885-6,34797506,study_information,NA,2,Phase of the clinical trial (clinical trial only),NA,NA,3,TRUE,NA,NA,NA
10.1007/s12325-021-01885-6,34797506,study_information,NA,2,Number of treatment arms (clinical trial only),NA,NA,2 or more,TRUE,NA,NA,NA
10.1007/s12325-021-01885-6,34797506,methodology,1,NA,Treatment name 1,apalutamide,apalutamide + adt,apalutamide + adt,FALSE,"MAIC within Bayesian framework 
A primary end point reported 
No real discussion of the status of the covariates adjusted for : that could potentially affect the relative treatment effect. So if we are to be nice we would still assume that they included both treatment effect modifiers and prognostic factors
","N IPD pour les 2 bras = 1150
ESS pour les 2 bras IPD = 455

Region = other",NA
10.1007/s12325-021-01885-6,34797506,methodology,1,NA,Study 'number(s)' for treatment 1,NA,NA,1,TRUE,NA,NA,NA
10.1007/s12325-021-01885-6,34797506,methodology,1,NA,Treatment name 2,darolutamide,darolutamide + adt,darolutamide + adt,FALSE,NA,NA,NA
10.1007/s12325-021-01885-6,34797506,methodology,1,NA,Study 'number(s)' for treatment 2,NA,NA,2,TRUE,NA,NA,NA
10.1007/s12325-021-01885-6,34797506,methodology,1,NA,Type of population-adjusted indirect comparisons performed,NA,NA,MAIC,TRUE,NA,NA,NA
10.1007/s12325-021-01885-6,34797506,methodology,1,NA,Anchored comparison?,NA,NA,Yes,TRUE,NA,NA,NA
10.1007/s12325-021-01885-6,34797506,methodology,1,NA,Form of the indirect comparison,NA,NA,Simple (ie treatments effects extracted from two studies),TRUE,NA,NA,NA
10.1007/s12325-021-01885-6,34797506,methodology,1,NA,Definition of a single primary outcome for the indirect comparison,NA,NA,Yes,TRUE,NA,NA,NA
10.1007/s12325-021-01885-6,34797506,methodology,1,NA,Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined),NA,NA,metastasis-free survival,TRUE,NA,NA,NA
10.1007/s12325-021-01885-6,34797506,methodology,1,NA,Primary outcome: variable type,NA,NA,Time-to-event,TRUE,NA,NA,NA
10.1007/s12325-021-01885-6,34797506,methodology,1,NA,Justification for selecting variables to be included in the adjustment model (in the main text),NA,NA,"Nothing mentioned, not reported",TRUE,NA,NA,NA
10.1007/s12325-021-01885-6,34797506,methodology,1,NA,Inclusion of prognostic factors in the adjustment/matching model,Yes,No discussion (in the main text) of the status of prognostic factors of the variables,No,FALSE,NA,NA,NA
10.1007/s12325-021-01885-6,34797506,methodology,1,NA,Inclusion of treatment-effect modifiers in the adjustment/matching model,Yes,No discussion (in the main text) of the status of treatment-effect modifiers of the variables,Yes,FALSE,NA,NA,NA
10.1007/s12325-021-01885-6,34797506,methodology,1,NA,"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)",NA,NA,No,TRUE,NA,NA,NA
10.1007/s12325-021-01885-6,34797506,methodology,1,NA,Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale),NA,NA,No,TRUE,NA,NA,NA
10.1007/s12325-021-01885-6,34797506,results,1,NA,Reporting of a weights' distribution evaluation (MAIC),NA,NA,Not mentioned,TRUE,NA,NA,NA
10.1007/s12325-021-01885-6,34797506,results,1,NA,Reporting of the list of the covariates adjusted for/matched on,NA,NA,Yes,TRUE,NA,NA,NA
10.1007/s12325-021-01885-6,34797506,results,1,NA,Number of covariates adjusted for/matched on,NA,NA,9,TRUE,NA,NA,NA
10.1007/s12325-021-01885-6,34797506,results,1,NA,Covariates adjusted for/matched on in the indirect comparison,NA,NA,"Age, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Past treatments for the disease of interest, Other(s)",TRUE,NA,NA,NA
10.1007/s12325-021-01885-6,34797506,results,1,NA,Primary outcome: treatment effect contrast,NA,NA,HR,TRUE,NA,NA,NA
10.1007/s12325-021-01885-6,34797506,results,1,NA,Direction of the treatment effect contrast: IPD treatment is:,NA,NA,"Numerator if ratio, or left side if difference",TRUE,NA,NA,NA
10.1007/s12325-021-01885-6,34797506,results,1,NA,Primary outcome: adjusted treatment effect,NA,NA,0.7,TRUE,NA,NA,NA
10.1007/s12325-021-01885-6,34797506,results,1,NA,"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])",[0.51.0.98],[0.51;0.98],[0.51;0.98],FALSE,NA,NA,NA
10.1007/s12325-021-01885-6,34797506,results,1,NA,Sample size of the population of interest in the non IPD treatment arm,NA,955,955,FALSE,NA,NA,NA
10.1007/s12325-021-01885-6,34797506,results,1,NA,"If anchored comparison, sample size of the population of interest in the non IPD treatment anchor arm",NA,554,554,FALSE,NA,NA,NA
10.1016/j.ejcsup.2021.06.002,34912478,general_information,NA,NA,Medical Condition of Interest Name,advanced unresctable gastroenteropancreatic neuroendocrine tumor,"advanced, unresectable gastrointestinal neuroendocrine tumours",XXXX,FALSE,NA,NA,NA
10.1016/j.ejcsup.2021.06.002,34912478,general_information,NA,NA,Countries of first author affiliations,NA,NA,uk,TRUE,NA,NA,NA
10.1016/j.ejcsup.2021.06.002,34912478,general_information,NA,NA,Countries of last author affiliations,NA,NA,germany,TRUE,NA,NA,NA
10.1016/j.ejcsup.2021.06.002,34912478,general_information,NA,NA,"Positions of study investigators (for any authors of the article, any that applies)",NA,NA,"Academic, Private Data Analysis Company",TRUE,NA,NA,NA
10.1016/j.ejcsup.2021.06.002,34912478,general_information,NA,NA,"At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company",NA,NA,Yes,TRUE,NA,NA,NA
10.1016/j.ejcsup.2021.06.002,34912478,general_information,NA,NA,Mentioned sources of funding,NA,NA,Pharmaceutical Industry,TRUE,NA,NA,NA
10.1016/j.ejcsup.2021.06.002,34912478,general_information,NA,NA,"Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article",NA,NA,Yes,TRUE,NA,NA,NA
10.1016/j.ejcsup.2021.06.002,34912478,general_information,NA,NA,Mention of a systematic review to find the studies to compare treatments of interest,NA,NA,No,TRUE,NA,NA,NA
10.1016/j.ejcsup.2021.06.002,34912478,study_information,NA,1,Patient-level data used,NA,NA,Yes,TRUE,NA,NA,NA
10.1016/j.ejcsup.2021.06.002,34912478,study_information,NA,1,Clinical Trial,NA,NA,Yes,TRUE,NA,NA,NA
10.1016/j.ejcsup.2021.06.002,34912478,study_information,NA,1,Data source name (only if observational study or clinical trial without NCT),NA,NA,erasmus study,TRUE,NA,NA,NA
10.1016/j.ejcsup.2021.06.002,34912478,study_information,NA,1,Country where the clinical trial/observational study was conducted (international if more than one),netherlands,NA,XXXX,FALSE,NA,NA,NA
10.1016/j.ejcsup.2021.06.002,34912478,study_information,NA,1,Number of treatment arms (clinical trial only),NA,NA,1,TRUE,NA,NA,NA
10.1016/j.ejcsup.2021.06.002,34912478,study_information,NA,2,Patient-level data used,NA,NA,No,TRUE,NA,NA,NA
10.1016/j.ejcsup.2021.06.002,34912478,study_information,NA,2,Clinical Trial,NA,NA,Yes,TRUE,NA,NA,NA
10.1016/j.ejcsup.2021.06.002,34912478,study_information,NA,2,NCT (only for clinical trial registered on clinicaltrials.gov),NA,NA,NCT01524783,TRUE,NA,NA,NA
10.1016/j.ejcsup.2021.06.002,34912478,study_information,NA,2,Country where the clinical trial/observational study was conducted (international if more than one),NA,NA,international,TRUE,NA,NA,NA
10.1016/j.ejcsup.2021.06.002,34912478,study_information,NA,2,Phase of the clinical trial (clinical trial only),NA,NA,3,TRUE,NA,NA,NA
10.1016/j.ejcsup.2021.06.002,34912478,study_information,NA,2,Number of treatment arms (clinical trial only),NA,NA,2 or more,TRUE,NA,NA,NA
10.1016/j.ejcsup.2021.06.002,34912478,study_information,NA,3,Patient-level data used,NA,NA,No,TRUE,NA,NA,NA
10.1016/j.ejcsup.2021.06.002,34912478,study_information,NA,3,Clinical Trial,NA,NA,Yes,TRUE,NA,NA,NA
10.1016/j.ejcsup.2021.06.002,34912478,study_information,NA,3,NCT (only for clinical trial registered on clinicaltrials.gov),NA,NA,NCT00510068,TRUE,NA,NA,NA
10.1016/j.ejcsup.2021.06.002,34912478,study_information,NA,3,Country where the clinical trial/observational study was conducted (international if more than one),NA,NA,international,TRUE,NA,NA,NA
10.1016/j.ejcsup.2021.06.002,34912478,study_information,NA,3,Phase of the clinical trial (clinical trial only),NA,NA,3,TRUE,NA,NA,NA
10.1016/j.ejcsup.2021.06.002,34912478,study_information,NA,3,Number of treatment arms (clinical trial only),NA,NA,2 or more,TRUE,NA,NA,NA
10.1016/j.ejcsup.2021.06.002,34912478,study_information,NA,4,Patient-level data used,NA,NA,No,TRUE,NA,NA,NA
10.1016/j.ejcsup.2021.06.002,34912478,study_information,NA,4,Clinical Trial,NA,NA,Yes,TRUE,NA,NA,NA
10.1016/j.ejcsup.2021.06.002,34912478,study_information,NA,4,NCT (only for clinical trial registered on clinicaltrials.gov),NA,NA,NCT00428597,TRUE,NA,NA,NA
10.1016/j.ejcsup.2021.06.002,34912478,study_information,NA,4,Country where the clinical trial/observational study was conducted (international if more than one),NA,NA,international,TRUE,NA,NA,NA
10.1016/j.ejcsup.2021.06.002,34912478,study_information,NA,4,Phase of the clinical trial (clinical trial only),NA,NA,3,TRUE,NA,NA,NA
10.1016/j.ejcsup.2021.06.002,34912478,study_information,NA,4,Number of treatment arms (clinical trial only),NA,NA,2 or more,TRUE,NA,NA,NA
10.1016/j.ejcsup.2021.06.002,34912478,methodology,1,NA,Treatment name 1,NA,NA,[177lu]lu-dota-tate,TRUE,"Inclusion almost only based on statistical significance, even though at some point they mention that they were chosen based on the clinical expert opinion also
acknowledge residual confounding
test safety endpoints too","G-NET

say ""A histogram describing the full distribution of weights is provided in the data supplement."" but couldn't be found.",NA
10.1016/j.ejcsup.2021.06.002,34912478,methodology,1,NA,Study 'number(s)' for treatment 1,NA,NA,1,TRUE,NA,NA,NA
10.1016/j.ejcsup.2021.06.002,34912478,methodology,1,NA,Treatment name 2,NA,NA,everolimus,TRUE,NA,NA,NA
10.1016/j.ejcsup.2021.06.002,34912478,methodology,1,NA,Study 'number(s)' for treatment 2,NA,NA,2,TRUE,NA,NA,NA
10.1016/j.ejcsup.2021.06.002,34912478,methodology,1,NA,Type of population-adjusted indirect comparisons performed,NA,NA,MAIC,TRUE,NA,NA,NA
10.1016/j.ejcsup.2021.06.002,34912478,methodology,1,NA,Anchored comparison?,NA,NA,No,TRUE,NA,NA,NA
10.1016/j.ejcsup.2021.06.002,34912478,methodology,1,NA,Form of the indirect comparison,NA,NA,Simple (ie treatments effects extracted from two studies),TRUE,NA,NA,NA
10.1016/j.ejcsup.2021.06.002,34912478,methodology,1,NA,Definition of a single primary outcome for the indirect comparison,"No primary outcome defined, or multiple primary outcomes without any clear distinction between them",Yes,"No primary outcome defined, or multiple primary outcomes without any clear distinction between them",FALSE,NA,NA,NA
10.1016/j.ejcsup.2021.06.002,34912478,methodology,1,NA,Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined),NA,NA,progression-free survival,TRUE,NA,NA,NA
10.1016/j.ejcsup.2021.06.002,34912478,methodology,1,NA,Primary outcome: variable type,NA,NA,Time-to-event,TRUE,NA,NA,NA
10.1016/j.ejcsup.2021.06.002,34912478,methodology,1,NA,Justification for selecting variables to be included in the adjustment model (in the main text),NA,NA,Status of prognostic factor/treatment effect modified assessed in the IPD dataset,TRUE,NA,NA,NA
10.1016/j.ejcsup.2021.06.002,34912478,methodology,1,NA,Inclusion of prognostic factors in the adjustment/matching model,NA,NA,Yes,TRUE,NA,NA,NA
10.1016/j.ejcsup.2021.06.002,34912478,methodology,1,NA,Inclusion of treatment-effect modifiers in the adjustment/matching model,NA,NA,No discussion (in the main text) of the status of treatment-effect modifiers of the variables,TRUE,NA,NA,NA
10.1016/j.ejcsup.2021.06.002,34912478,methodology,1,NA,"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)",NA,NA,No,TRUE,NA,NA,NA
10.1016/j.ejcsup.2021.06.002,34912478,methodology,1,NA,Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale),NA,NA,No,TRUE,NA,NA,NA
10.1016/j.ejcsup.2021.06.002,34912478,methodology,2,NA,Treatment name 1,[177lu]lu-dota-tate,[177lu]lu-dota-tat,[177lu]lu-dota-tate,FALSE,NA,"GI-NET

say ""A histogram describing the full distribution of weights is provided in the data supplement."" but couldn't be found.",NA
10.1016/j.ejcsup.2021.06.002,34912478,methodology,2,NA,Study 'number(s)' for treatment 1,NA,NA,1,TRUE,NA,NA,NA
10.1016/j.ejcsup.2021.06.002,34912478,methodology,2,NA,Treatment name 2,everolimus,best supportive care (bsc),best supportive care (bsc),FALSE,NA,NA,NA
10.1016/j.ejcsup.2021.06.002,34912478,methodology,2,NA,Study 'number(s)' for treatment 2,3,2,2,FALSE,NA,NA,NA
10.1016/j.ejcsup.2021.06.002,34912478,methodology,2,NA,Type of population-adjusted indirect comparisons performed,NA,NA,MAIC,TRUE,NA,NA,NA
10.1016/j.ejcsup.2021.06.002,34912478,methodology,2,NA,Anchored comparison?,NA,NA,No,TRUE,NA,NA,NA
10.1016/j.ejcsup.2021.06.002,34912478,methodology,2,NA,Form of the indirect comparison,NA,NA,Simple (ie treatments effects extracted from two studies),TRUE,NA,NA,NA
10.1016/j.ejcsup.2021.06.002,34912478,methodology,2,NA,Definition of a single primary outcome for the indirect comparison,"No primary outcome defined, or multiple primary outcomes without any clear distinction between them",Yes,"No primary outcome defined, or multiple primary outcomes without any clear distinction between them",FALSE,NA,NA,NA
10.1016/j.ejcsup.2021.06.002,34912478,methodology,2,NA,Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined),NA,NA,progression-free survival,TRUE,NA,NA,NA
10.1016/j.ejcsup.2021.06.002,34912478,methodology,2,NA,Primary outcome: variable type,NA,NA,Time-to-event,TRUE,NA,NA,NA
10.1016/j.ejcsup.2021.06.002,34912478,methodology,2,NA,Justification for selecting variables to be included in the adjustment model (in the main text),NA,NA,Status of prognostic factor/treatment effect modified assessed in the IPD dataset,TRUE,NA,NA,NA
10.1016/j.ejcsup.2021.06.002,34912478,methodology,2,NA,Inclusion of prognostic factors in the adjustment/matching model,NA,NA,Yes,TRUE,NA,NA,NA
10.1016/j.ejcsup.2021.06.002,34912478,methodology,2,NA,Inclusion of treatment-effect modifiers in the adjustment/matching model,NA,NA,No discussion (in the main text) of the status of treatment-effect modifiers of the variables,TRUE,NA,NA,NA
10.1016/j.ejcsup.2021.06.002,34912478,methodology,2,NA,"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)",NA,NA,No,TRUE,NA,NA,NA
10.1016/j.ejcsup.2021.06.002,34912478,methodology,2,NA,Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale),NA,NA,No,TRUE,NA,NA,NA
10.1016/j.ejcsup.2021.06.002,34912478,methodology,3,NA,Treatment name 1,NA,NA,[177lu]lu-dota-tate,TRUE,NA,"PI-NET

say ""A histogram describing the full distribution of weights is provided in the data supplement."" but couldn't be found.",NA
10.1016/j.ejcsup.2021.06.002,34912478,methodology,3,NA,Study 'number(s)' for treatment 1,NA,NA,1,TRUE,NA,NA,NA
10.1016/j.ejcsup.2021.06.002,34912478,methodology,3,NA,Treatment name 2,NA,NA,sunitinib,TRUE,NA,NA,NA
10.1016/j.ejcsup.2021.06.002,34912478,methodology,3,NA,Study 'number(s)' for treatment 2,NA,NA,4,TRUE,NA,NA,NA
10.1016/j.ejcsup.2021.06.002,34912478,methodology,3,NA,Type of population-adjusted indirect comparisons performed,NA,NA,MAIC,TRUE,NA,NA,NA
10.1016/j.ejcsup.2021.06.002,34912478,methodology,3,NA,Anchored comparison?,NA,NA,No,TRUE,NA,NA,NA
10.1016/j.ejcsup.2021.06.002,34912478,methodology,3,NA,Form of the indirect comparison,NA,NA,Simple (ie treatments effects extracted from two studies),TRUE,NA,NA,NA
10.1016/j.ejcsup.2021.06.002,34912478,methodology,3,NA,Definition of a single primary outcome for the indirect comparison,NA,NA,"No primary outcome defined, or multiple primary outcomes without any clear distinction between them",TRUE,NA,NA,NA
10.1016/j.ejcsup.2021.06.002,34912478,methodology,3,NA,Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined),NA,NA,progression-free survival,TRUE,NA,NA,NA
10.1016/j.ejcsup.2021.06.002,34912478,methodology,3,NA,Primary outcome: variable type,NA,NA,Time-to-event,TRUE,NA,NA,NA
10.1016/j.ejcsup.2021.06.002,34912478,methodology,3,NA,Justification for selecting variables to be included in the adjustment model (in the main text),NA,NA,Status of prognostic factor/treatment effect modified assessed in the IPD dataset,TRUE,NA,NA,NA
10.1016/j.ejcsup.2021.06.002,34912478,methodology,3,NA,Inclusion of prognostic factors in the adjustment/matching model,NA,NA,Yes,TRUE,NA,NA,NA
10.1016/j.ejcsup.2021.06.002,34912478,methodology,3,NA,Inclusion of treatment-effect modifiers in the adjustment/matching model,NA,NA,No discussion (in the main text) of the status of treatment-effect modifiers of the variables,TRUE,NA,NA,NA
10.1016/j.ejcsup.2021.06.002,34912478,methodology,3,NA,"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)",NA,NA,No,TRUE,NA,NA,NA
10.1016/j.ejcsup.2021.06.002,34912478,methodology,3,NA,Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale),NA,NA,No,TRUE,NA,NA,NA
10.1016/j.ejcsup.2021.06.002,34912478,methodology,4,NA,Treatment name 1,NA,NA,[177lu]lu-dota-tate,TRUE,NA,"PI-NET

say ""A histogram describing the full distribution of weights is provided in the data supplement."" but couldn't be found.",NA
10.1016/j.ejcsup.2021.06.002,34912478,methodology,4,NA,Study 'number(s)' for treatment 1,NA,NA,1,TRUE,NA,NA,NA
10.1016/j.ejcsup.2021.06.002,34912478,methodology,4,NA,Treatment name 2,best supportive care,best supportive care (bsc),best supportive care,FALSE,NA,NA,NA
10.1016/j.ejcsup.2021.06.002,34912478,methodology,4,NA,Study 'number(s)' for treatment 2,NA,NA,4,TRUE,NA,NA,NA
10.1016/j.ejcsup.2021.06.002,34912478,methodology,4,NA,Type of population-adjusted indirect comparisons performed,NA,NA,MAIC,TRUE,NA,NA,NA
10.1016/j.ejcsup.2021.06.002,34912478,methodology,4,NA,Anchored comparison?,NA,NA,No,TRUE,NA,NA,NA
10.1016/j.ejcsup.2021.06.002,34912478,methodology,4,NA,Form of the indirect comparison,NA,NA,Simple (ie treatments effects extracted from two studies),TRUE,NA,NA,NA
10.1016/j.ejcsup.2021.06.002,34912478,methodology,4,NA,Definition of a single primary outcome for the indirect comparison,NA,NA,"No primary outcome defined, or multiple primary outcomes without any clear distinction between them",TRUE,NA,NA,NA
10.1016/j.ejcsup.2021.06.002,34912478,methodology,4,NA,Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined),NA,NA,progression-free survival,TRUE,NA,NA,NA
10.1016/j.ejcsup.2021.06.002,34912478,methodology,4,NA,Primary outcome: variable type,NA,NA,Time-to-event,TRUE,NA,NA,NA
10.1016/j.ejcsup.2021.06.002,34912478,methodology,4,NA,Justification for selecting variables to be included in the adjustment model (in the main text),NA,NA,Status of prognostic factor/treatment effect modified assessed in the IPD dataset,TRUE,NA,NA,NA
10.1016/j.ejcsup.2021.06.002,34912478,methodology,4,NA,Inclusion of prognostic factors in the adjustment/matching model,NA,NA,Yes,TRUE,NA,NA,NA
10.1016/j.ejcsup.2021.06.002,34912478,methodology,4,NA,Inclusion of treatment-effect modifiers in the adjustment/matching model,NA,NA,No discussion (in the main text) of the status of treatment-effect modifiers of the variables,TRUE,NA,NA,NA
10.1016/j.ejcsup.2021.06.002,34912478,methodology,4,NA,"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)",NA,NA,No,TRUE,NA,NA,NA
10.1016/j.ejcsup.2021.06.002,34912478,methodology,4,NA,Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale),NA,NA,No,TRUE,NA,NA,NA
10.1016/j.ejcsup.2021.06.002,34912478,methodology,5,NA,Treatment name 1,NA,NA,[177lu]lu-dota-tate,TRUE,NA,GI-NET,NA
10.1016/j.ejcsup.2021.06.002,34912478,methodology,5,NA,Study 'number(s)' for treatment 1,NA,NA,1,TRUE,NA,NA,NA
10.1016/j.ejcsup.2021.06.002,34912478,methodology,5,NA,Treatment name 2,NA,NA,everolimus,TRUE,NA,NA,NA
10.1016/j.ejcsup.2021.06.002,34912478,methodology,5,NA,Study 'number(s)' for treatment 2,NA,NA,3,TRUE,NA,NA,NA
10.1016/j.ejcsup.2021.06.002,34912478,methodology,5,NA,Type of population-adjusted indirect comparisons performed,NA,NA,MAIC,TRUE,NA,NA,NA
10.1016/j.ejcsup.2021.06.002,34912478,methodology,5,NA,Anchored comparison?,NA,NA,No,TRUE,NA,NA,NA
10.1016/j.ejcsup.2021.06.002,34912478,methodology,5,NA,Form of the indirect comparison,NA,NA,Simple (ie treatments effects extracted from two studies),TRUE,NA,NA,NA
10.1016/j.ejcsup.2021.06.002,34912478,methodology,5,NA,Definition of a single primary outcome for the indirect comparison,NA,NA,"No primary outcome defined, or multiple primary outcomes without any clear distinction between them",TRUE,NA,NA,NA
10.1016/j.ejcsup.2021.06.002,34912478,methodology,5,NA,Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined),NA,NA,progression-free survival,TRUE,NA,NA,NA
10.1016/j.ejcsup.2021.06.002,34912478,methodology,5,NA,Primary outcome: variable type,NA,NA,Time-to-event,TRUE,NA,NA,NA
10.1016/j.ejcsup.2021.06.002,34912478,methodology,5,NA,Justification for selecting variables to be included in the adjustment model (in the main text),NA,NA,Status of prognostic factor/treatment effect modified assessed in the IPD dataset,TRUE,NA,NA,NA
10.1016/j.ejcsup.2021.06.002,34912478,methodology,5,NA,Inclusion of prognostic factors in the adjustment/matching model,NA,NA,Yes,TRUE,NA,NA,NA
10.1016/j.ejcsup.2021.06.002,34912478,methodology,5,NA,Inclusion of treatment-effect modifiers in the adjustment/matching model,NA,NA,No discussion (in the main text) of the status of treatment-effect modifiers of the variables,TRUE,NA,NA,NA
10.1016/j.ejcsup.2021.06.002,34912478,methodology,5,NA,"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)",NA,NA,No,TRUE,NA,NA,NA
10.1016/j.ejcsup.2021.06.002,34912478,methodology,5,NA,Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale),NA,NA,No,TRUE,NA,NA,NA
10.1016/j.ejcsup.2021.06.002,34912478,methodology,6,NA,Treatment name 1,NA,NA,[177lu]lu-dota-tate,TRUE,NA,"GI-NET

say ""A histogram describing the full distribution of weights is provided in the data supplement."" but couldn't be found.",NA
10.1016/j.ejcsup.2021.06.002,34912478,methodology,6,NA,Study 'number(s)' for treatment 1,NA,NA,1,TRUE,NA,NA,NA
10.1016/j.ejcsup.2021.06.002,34912478,methodology,6,NA,Treatment name 2,best supportive care,best supportive care (bsc),best supportive care,FALSE,NA,NA,NA
10.1016/j.ejcsup.2021.06.002,34912478,methodology,6,NA,Study 'number(s)' for treatment 2,NA,NA,3,TRUE,NA,NA,NA
10.1016/j.ejcsup.2021.06.002,34912478,methodology,6,NA,Type of population-adjusted indirect comparisons performed,NA,NA,MAIC,TRUE,NA,NA,NA
10.1016/j.ejcsup.2021.06.002,34912478,methodology,6,NA,Anchored comparison?,NA,NA,No,TRUE,NA,NA,NA
10.1016/j.ejcsup.2021.06.002,34912478,methodology,6,NA,Form of the indirect comparison,NA,NA,Simple (ie treatments effects extracted from two studies),TRUE,NA,NA,NA
10.1016/j.ejcsup.2021.06.002,34912478,methodology,6,NA,Definition of a single primary outcome for the indirect comparison,NA,NA,"No primary outcome defined, or multiple primary outcomes without any clear distinction between them",TRUE,NA,NA,NA
10.1016/j.ejcsup.2021.06.002,34912478,methodology,6,NA,Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined),NA,NA,progression-free survival,TRUE,NA,NA,NA
10.1016/j.ejcsup.2021.06.002,34912478,methodology,6,NA,Primary outcome: variable type,NA,NA,Time-to-event,TRUE,NA,NA,NA
10.1016/j.ejcsup.2021.06.002,34912478,methodology,6,NA,Justification for selecting variables to be included in the adjustment model (in the main text),NA,NA,Status of prognostic factor/treatment effect modified assessed in the IPD dataset,TRUE,NA,NA,NA
10.1016/j.ejcsup.2021.06.002,34912478,methodology,6,NA,Inclusion of prognostic factors in the adjustment/matching model,NA,NA,Yes,TRUE,NA,NA,NA
10.1016/j.ejcsup.2021.06.002,34912478,methodology,6,NA,Inclusion of treatment-effect modifiers in the adjustment/matching model,NA,NA,No discussion (in the main text) of the status of treatment-effect modifiers of the variables,TRUE,NA,NA,NA
10.1016/j.ejcsup.2021.06.002,34912478,methodology,6,NA,"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)",NA,NA,No,TRUE,NA,NA,NA
10.1016/j.ejcsup.2021.06.002,34912478,methodology,6,NA,Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale),NA,NA,No,TRUE,NA,NA,NA
10.1016/j.ejcsup.2021.06.002,34912478,results,1,NA,Sample size of the population of interest in the non IPD treatment arm,NA,NA,118,TRUE,NA,NA,NA
10.1016/j.ejcsup.2021.06.002,34912478,results,1,NA,Initial sample size of the population of interest in the IPD treatment arm,NA,NA,111,TRUE,NA,NA,NA
10.1016/j.ejcsup.2021.06.002,34912478,results,1,NA,"Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC",NA,NA,105,TRUE,NA,NA,NA
10.1016/j.ejcsup.2021.06.002,34912478,results,1,NA,Reporting of a weights' distribution evaluation (MAIC),"Yes, mentions that the weights distribution has been studied, and weights distribution reported in main article or supplemental materials","Yes, mentions that the weights distribution has been studied, but weights distribution not reported","Yes, mentions that the weights distribution has been studied, and weights distribution reported in main article or supplemental materials",FALSE,NA,NA,NA
10.1016/j.ejcsup.2021.06.002,34912478,results,1,NA,Reporting of the list of the covariates adjusted for/matched on,NA,NA,Yes,TRUE,NA,NA,NA
10.1016/j.ejcsup.2021.06.002,34912478,results,1,NA,Number of covariates adjusted for/matched on,NA,NA,1,TRUE,NA,NA,NA
10.1016/j.ejcsup.2021.06.002,34912478,results,1,NA,Covariates adjusted for/matched on in the indirect comparison,NA,NA,"Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...)",TRUE,NA,NA,NA
10.1016/j.ejcsup.2021.06.002,34912478,results,1,NA,Primary outcome: treatment effect contrast,NA,NA,HR,TRUE,NA,NA,NA
10.1016/j.ejcsup.2021.06.002,34912478,results,1,NA,Direction of the treatment effect contrast: IPD treatment is:,NA,NA,"Numerator if ratio, or left side if difference",TRUE,NA,NA,NA
10.1016/j.ejcsup.2021.06.002,34912478,results,1,NA,Primary outcome: adjusted treatment effect,NA,NA,0.38,TRUE,NA,NA,NA
10.1016/j.ejcsup.2021.06.002,34912478,results,1,NA,"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])",NA,NA,[0.25;0.58],TRUE,NA,NA,NA
10.1016/j.ejcsup.2021.06.002,34912478,results,2,NA,Sample size of the population of interest in the non IPD treatment arm,NA,NA,57,TRUE,NA,NA,NA
10.1016/j.ejcsup.2021.06.002,34912478,results,2,NA,Initial sample size of the population of interest in the IPD treatment arm,NA,NA,111,TRUE,NA,NA,NA
10.1016/j.ejcsup.2021.06.002,34912478,results,2,NA,"Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC",NA,NA,95,TRUE,NA,NA,NA
10.1016/j.ejcsup.2021.06.002,34912478,results,2,NA,Reporting of a weights' distribution evaluation (MAIC),"Yes, mentions that the weights distribution has been studied, and weights distribution reported in main article or supplemental materials","Yes, mentions that the weights distribution has been studied, but weights distribution not reported","Yes, mentions that the weights distribution has been studied, and weights distribution reported in main article or supplemental materials",FALSE,NA,NA,NA
10.1016/j.ejcsup.2021.06.002,34912478,results,2,NA,Reporting of the list of the covariates adjusted for/matched on,NA,NA,Yes,TRUE,NA,NA,NA
10.1016/j.ejcsup.2021.06.002,34912478,results,2,NA,Number of covariates adjusted for/matched on,NA,NA,1,TRUE,NA,NA,NA
10.1016/j.ejcsup.2021.06.002,34912478,results,2,NA,Covariates adjusted for/matched on in the indirect comparison,NA,NA,"Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...)",TRUE,NA,NA,NA
10.1016/j.ejcsup.2021.06.002,34912478,results,2,NA,Primary outcome: treatment effect contrast,NA,NA,HR,TRUE,NA,NA,NA
10.1016/j.ejcsup.2021.06.002,34912478,results,2,NA,Direction of the treatment effect contrast: IPD treatment is:,NA,NA,"Numerator if ratio, or left side if difference",TRUE,NA,NA,NA
10.1016/j.ejcsup.2021.06.002,34912478,results,2,NA,Primary outcome: adjusted treatment effect,NA,NA,0.35,TRUE,NA,NA,NA
10.1016/j.ejcsup.2021.06.002,34912478,results,2,NA,"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])",[0.24;0.59],[0.21;0.59],[0.21;0.59],FALSE,NA,NA,NA
10.1016/j.ejcsup.2021.06.002,34912478,results,3,NA,Sample size of the population of interest in the non IPD treatment arm,NA,NA,86,TRUE,NA,NA,NA
10.1016/j.ejcsup.2021.06.002,34912478,results,3,NA,Initial sample size of the population of interest in the IPD treatment arm,NA,NA,62,TRUE,NA,NA,NA
10.1016/j.ejcsup.2021.06.002,34912478,results,3,NA,"Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC",NA,NA,48,TRUE,NA,NA,NA
10.1016/j.ejcsup.2021.06.002,34912478,results,3,NA,Reporting of a weights' distribution evaluation (MAIC),"Yes, mentions that the weights distribution has been studied, and weights distribution reported in main article or supplemental materials","Yes, mentions that the weights distribution has been studied, but weights distribution not reported","Yes, mentions that the weights distribution has been studied, and weights distribution reported in main article or supplemental materials",FALSE,NA,NA,NA
10.1016/j.ejcsup.2021.06.002,34912478,results,3,NA,Reporting of the list of the covariates adjusted for/matched on,NA,NA,Yes,TRUE,NA,NA,NA
10.1016/j.ejcsup.2021.06.002,34912478,results,3,NA,Number of covariates adjusted for/matched on,NA,NA,4,TRUE,NA,NA,NA
10.1016/j.ejcsup.2021.06.002,34912478,results,3,NA,Covariates adjusted for/matched on in the indirect comparison,"Age, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...)","Age, Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Past treatments for the disease of interest","Age, Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Past treatments for the disease of interest",FALSE,NA,NA,NA
10.1016/j.ejcsup.2021.06.002,34912478,results,3,NA,Primary outcome: treatment effect contrast,NA,NA,HR,TRUE,NA,NA,NA
10.1016/j.ejcsup.2021.06.002,34912478,results,3,NA,Direction of the treatment effect contrast: IPD treatment is:,NA,NA,"Numerator if ratio, or left side if difference",TRUE,NA,NA,NA
10.1016/j.ejcsup.2021.06.002,34912478,results,3,NA,Primary outcome: adjusted treatment effect,NA,NA,0.36,TRUE,NA,NA,NA
10.1016/j.ejcsup.2021.06.002,34912478,results,3,NA,"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])",NA,NA,[0.18;0.70],TRUE,NA,NA,NA
10.1016/j.ejcsup.2021.06.002,34912478,results,4,NA,Sample size of the population of interest in the non IPD treatment arm,NA,NA,85,TRUE,NA,NA,NA
10.1016/j.ejcsup.2021.06.002,34912478,results,4,NA,Initial sample size of the population of interest in the IPD treatment arm,NA,NA,62,TRUE,NA,NA,NA
10.1016/j.ejcsup.2021.06.002,34912478,results,4,NA,"Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC",NA,NA,35,TRUE,NA,NA,NA
10.1016/j.ejcsup.2021.06.002,34912478,results,4,NA,Reporting of a weights' distribution evaluation (MAIC),"Yes, mentions that the weights distribution has been studied, and weights distribution reported in main article or supplemental materials","Yes, mentions that the weights distribution has been studied, but weights distribution not reported","Yes, mentions that the weights distribution has been studied, and weights distribution reported in main article or supplemental materials",FALSE,NA,NA,NA
10.1016/j.ejcsup.2021.06.002,34912478,results,4,NA,Reporting of the list of the covariates adjusted for/matched on,NA,NA,Yes,TRUE,NA,NA,NA
10.1016/j.ejcsup.2021.06.002,34912478,results,4,NA,Number of covariates adjusted for/matched on,NA,NA,4,TRUE,NA,NA,NA
10.1016/j.ejcsup.2021.06.002,34912478,results,4,NA,Covariates adjusted for/matched on in the indirect comparison,"Age, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease)","Age, Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Past treatments for the disease of interest","Age, Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Past treatments for the disease of interest",FALSE,NA,NA,NA
10.1016/j.ejcsup.2021.06.002,34912478,results,4,NA,Primary outcome: treatment effect contrast,NA,NA,HR,TRUE,NA,NA,NA
10.1016/j.ejcsup.2021.06.002,34912478,results,4,NA,Direction of the treatment effect contrast: IPD treatment is:,NA,NA,"Numerator if ratio, or left side if difference",TRUE,NA,NA,NA
10.1016/j.ejcsup.2021.06.002,34912478,results,4,NA,Primary outcome: adjusted treatment effect,NA,NA,0.13,TRUE,NA,NA,NA
10.1016/j.ejcsup.2021.06.002,34912478,results,4,NA,"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])",NA,NA,[0.08;0.22],TRUE,NA,NA,NA
10.1016/j.ejcsup.2021.06.002,34912478,results,5,NA,Sample size of the population of interest in the non IPD treatment arm,NA,NA,207,TRUE,NA,NA,NA
10.1016/j.ejcsup.2021.06.002,34912478,results,5,NA,Initial sample size of the population of interest in the IPD treatment arm,NA,NA,62,TRUE,NA,NA,NA
10.1016/j.ejcsup.2021.06.002,34912478,results,5,NA,"Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC",NA,NA,22,TRUE,NA,NA,NA
10.1016/j.ejcsup.2021.06.002,34912478,results,5,NA,Reporting of a weights' distribution evaluation (MAIC),"Yes, mentions that the weights distribution has been studied, and weights distribution reported in main article or supplemental materials","Yes, mentions that the weights distribution has been studied, but weights distribution not reported","Yes, mentions that the weights distribution has been studied, and weights distribution reported in main article or supplemental materials",FALSE,NA,NA,NA
10.1016/j.ejcsup.2021.06.002,34912478,results,5,NA,Reporting of the list of the covariates adjusted for/matched on,NA,NA,Yes,TRUE,NA,NA,NA
10.1016/j.ejcsup.2021.06.002,34912478,results,5,NA,Number of covariates adjusted for/matched on,NA,NA,4,TRUE,NA,NA,NA
10.1016/j.ejcsup.2021.06.002,34912478,results,5,NA,Covariates adjusted for/matched on in the indirect comparison,"Age, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Past treatments for the disease of interest, , Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...)","Age, Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Past treatments for the disease of interest","Age, Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Past treatments for the disease of interest",FALSE,NA,NA,NA
10.1016/j.ejcsup.2021.06.002,34912478,results,5,NA,Primary outcome: treatment effect contrast,NA,NA,HR,TRUE,NA,NA,NA
10.1016/j.ejcsup.2021.06.002,34912478,results,5,NA,Direction of the treatment effect contrast: IPD treatment is:,NA,NA,"Numerator if ratio, or left side if difference",TRUE,NA,NA,NA
10.1016/j.ejcsup.2021.06.002,34912478,results,5,NA,Primary outcome: adjusted treatment effect,NA,NA,0.46,TRUE,NA,NA,NA
10.1016/j.ejcsup.2021.06.002,34912478,results,5,NA,"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])",NA,NA,[0.30;0.71],TRUE,NA,NA,NA
10.1016/j.ejcsup.2021.06.002,34912478,results,6,NA,Sample size of the population of interest in the non IPD treatment arm,NA,NA,203,TRUE,NA,NA,NA
10.1016/j.ejcsup.2021.06.002,34912478,results,6,NA,Initial sample size of the population of interest in the IPD treatment arm,NA,NA,62,TRUE,NA,NA,NA
10.1016/j.ejcsup.2021.06.002,34912478,results,6,NA,"Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC",NA,NA,18,TRUE,NA,NA,NA
10.1016/j.ejcsup.2021.06.002,34912478,results,6,NA,Reporting of a weights' distribution evaluation (MAIC),"Yes, mentions that the weights distribution has been studied, and weights distribution reported in main article or supplemental materials","Yes, mentions that the weights distribution has been studied, but weights distribution not reported","Yes, mentions that the weights distribution has been studied, and weights distribution reported in main article or supplemental materials",FALSE,NA,NA,NA
10.1016/j.ejcsup.2021.06.002,34912478,results,6,NA,Reporting of the list of the covariates adjusted for/matched on,NA,NA,Yes,TRUE,NA,NA,NA
10.1016/j.ejcsup.2021.06.002,34912478,results,6,NA,Number of covariates adjusted for/matched on,NA,NA,4,TRUE,NA,NA,NA
10.1016/j.ejcsup.2021.06.002,34912478,results,6,NA,Covariates adjusted for/matched on in the indirect comparison,"Age, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease)","Age, Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Past treatments for the disease of interest","Age, Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Past treatments for the disease of interest",FALSE,NA,NA,NA
10.1016/j.ejcsup.2021.06.002,34912478,results,6,NA,Primary outcome: treatment effect contrast,NA,NA,HR,TRUE,NA,NA,NA
10.1016/j.ejcsup.2021.06.002,34912478,results,6,NA,Direction of the treatment effect contrast: IPD treatment is:,NA,NA,"Numerator if ratio, or left side if difference",TRUE,NA,NA,NA
10.1016/j.ejcsup.2021.06.002,34912478,results,6,NA,Primary outcome: adjusted treatment effect,NA,NA,0.21,TRUE,NA,NA,NA
10.1016/j.ejcsup.2021.06.002,34912478,results,6,NA,"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])",NA,NA,[0.13;0.32],TRUE,NA,NA,NA
10.1080/10428194.2021.2010069,34978255,general_information,NA,NA,Medical Condition of Interest Name,relapsed or refractory large b-cell lymphomas,relapsed/refractory large b-cell lymphomas,XXXX,FALSE,NA,NA,NA
10.1080/10428194.2021.2010069,34978255,general_information,NA,NA,Countries of first author affiliations,NA,NA,usa,TRUE,NA,NA,NA
10.1080/10428194.2021.2010069,34978255,general_information,NA,NA,Countries of last author affiliations,NA,NA,netherlands,TRUE,NA,NA,NA
10.1080/10428194.2021.2010069,34978255,general_information,NA,NA,"Positions of study investigators (for any authors of the article, any that applies)",NA,NA,"Academic, Pharmaceutical Industry, Private Data Analysis Company",TRUE,NA,NA,NA
10.1080/10428194.2021.2010069,34978255,general_information,NA,NA,"At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company",NA,NA,Yes,TRUE,NA,NA,NA
10.1080/10428194.2021.2010069,34978255,general_information,NA,NA,Mentioned sources of funding,NA,NA,Pharmaceutical Industry,TRUE,NA,NA,NA
10.1080/10428194.2021.2010069,34978255,general_information,NA,NA,"Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article",NA,NA,Yes,TRUE,NA,NA,NA
10.1080/10428194.2021.2010069,34978255,general_information,NA,NA,Mention of a systematic review to find the studies to compare treatments of interest,NA,NA,No,TRUE,NA,NA,NA
10.1080/10428194.2021.2010069,34978255,study_information,NA,1,Patient-level data used,NA,NA,Yes,TRUE,NA,NA,NA
10.1080/10428194.2021.2010069,34978255,study_information,NA,1,Clinical Trial,NA,NA,Yes,TRUE,NA,NA,NA
10.1080/10428194.2021.2010069,34978255,study_information,NA,1,NCT (only for clinical trial registered on clinicaltrials.gov),NA,NA,NCT02445248,TRUE,NA,NA,NA
10.1080/10428194.2021.2010069,34978255,study_information,NA,1,Country where the clinical trial/observational study was conducted (international if more than one),NA,NA,international,TRUE,NA,NA,NA
10.1080/10428194.2021.2010069,34978255,study_information,NA,1,Phase of the clinical trial (clinical trial only),NA,NA,2,TRUE,NA,NA,NA
10.1080/10428194.2021.2010069,34978255,study_information,NA,1,Number of treatment arms (clinical trial only),NA,NA,1,TRUE,NA,NA,NA
10.1080/10428194.2021.2010069,34978255,study_information,NA,2,Patient-level data used,NA,NA,No,TRUE,NA,NA,NA
10.1080/10428194.2021.2010069,34978255,study_information,NA,2,Clinical Trial,NA,NA,Yes,TRUE,NA,NA,NA
10.1080/10428194.2021.2010069,34978255,study_information,NA,2,NCT (only for clinical trial registered on clinicaltrials.gov),NA,NA,NCT02631044,TRUE,NA,NA,NA
10.1080/10428194.2021.2010069,34978255,study_information,NA,2,Country where the clinical trial/observational study was conducted (international if more than one),NA,NA,usa,TRUE,NA,NA,NA
10.1080/10428194.2021.2010069,34978255,study_information,NA,2,Phase of the clinical trial (clinical trial only),NA,NA,1,TRUE,NA,NA,NA
10.1080/10428194.2021.2010069,34978255,study_information,NA,2,Number of treatment arms (clinical trial only),NA,NA,1,TRUE,NA,NA,NA
10.1080/10428194.2021.2010069,34978255,methodology,1,NA,Treatment name 1,NA,NA,tisagenlecleucel,TRUE,"Another MAIC has been conducted on similar studies and outcomes, would be very intersting to compare results : 
but not original article 
https://ashpublications.org/blood/article/136/Supplement%201/18/471898/Matching-Adjusted-Indirect-Comparison-MAIC-of
","In Table 1 : Refractory status to prior therapies and ""Nver achieved CR with prior therapy"" are two different covariates.",NA
10.1080/10428194.2021.2010069,34978255,methodology,1,NA,Study 'number(s)' for treatment 1,NA,NA,1,TRUE,NA,NA,NA
10.1080/10428194.2021.2010069,34978255,methodology,1,NA,Treatment name 2,NA,NA,lisocabtagene,TRUE,NA,NA,NA
10.1080/10428194.2021.2010069,34978255,methodology,1,NA,Study 'number(s)' for treatment 2,NA,NA,2,TRUE,NA,NA,NA
10.1080/10428194.2021.2010069,34978255,methodology,1,NA,Type of population-adjusted indirect comparisons performed,NA,NA,MAIC,TRUE,NA,NA,NA
10.1080/10428194.2021.2010069,34978255,methodology,1,NA,Anchored comparison?,NA,NA,No,TRUE,NA,NA,NA
10.1080/10428194.2021.2010069,34978255,methodology,1,NA,Form of the indirect comparison,NA,NA,Simple (ie treatments effects extracted from two studies),TRUE,NA,NA,NA
10.1080/10428194.2021.2010069,34978255,methodology,1,NA,Definition of a single primary outcome for the indirect comparison,NA,NA,"No primary outcome defined, or multiple primary outcomes without any clear distinction between them",TRUE,NA,NA,NA
10.1080/10428194.2021.2010069,34978255,methodology,1,NA,Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined),NA,NA,overall response rate,TRUE,NA,NA,NA
10.1080/10428194.2021.2010069,34978255,methodology,1,NA,Primary outcome: variable type,NA,NA,Binary (eg rates),TRUE,NA,NA,NA
10.1080/10428194.2021.2010069,34978255,methodology,1,NA,Justification for selecting variables to be included in the adjustment model (in the main text),NA,NA,"A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion), Literature based (clinically or methodologically relevant to adjust on these variables based on the literature search conducted for this specific purpose)",TRUE,NA,NA,NA
10.1080/10428194.2021.2010069,34978255,methodology,1,NA,Inclusion of prognostic factors in the adjustment/matching model,NA,NA,Yes,TRUE,NA,NA,NA
10.1080/10428194.2021.2010069,34978255,methodology,1,NA,Inclusion of treatment-effect modifiers in the adjustment/matching model,Yes,No discussion (in the main text) of the status of treatment-effect modifiers of the variables,No discussion (in the main text) of the status of treatment-effect modifiers of the variables,FALSE,NA,NA,NA
10.1080/10428194.2021.2010069,34978255,methodology,1,NA,"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)",NA,NA,No,TRUE,NA,NA,NA
10.1080/10428194.2021.2010069,34978255,methodology,1,NA,Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale),NA,NA,No,TRUE,NA,NA,NA
10.1080/10428194.2021.2010069,34978255,results,1,NA,Sample size of the population of interest in the non IPD treatment arm,NA,NA,256,TRUE,NA,NA,NA
10.1080/10428194.2021.2010069,34978255,results,1,NA,Initial sample size of the population of interest in the IPD treatment arm,NA,NA,106,TRUE,NA,NA,NA
10.1080/10428194.2021.2010069,34978255,results,1,NA,"Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC",NA,NA,29,TRUE,NA,NA,NA
10.1080/10428194.2021.2010069,34978255,results,1,NA,Reporting of a weights' distribution evaluation (MAIC),NA,NA,Not mentioned,TRUE,NA,NA,NA
10.1080/10428194.2021.2010069,34978255,results,1,NA,Reporting of the list of the covariates adjusted for/matched on,NA,NA,Yes,TRUE,NA,NA,NA
10.1080/10428194.2021.2010069,34978255,results,1,NA,Number of covariates adjusted for/matched on,11,12,12,FALSE,NA,NA,NA
10.1080/10428194.2021.2010069,34978255,results,1,NA,Covariates adjusted for/matched on in the indirect comparison,NA,NA,"Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Past treatments for the disease of interest, Comorbidities and medical history (beside pathology/disease of interest in the comparison)",TRUE,NA,NA,NA
10.1080/10428194.2021.2010069,34978255,results,1,NA,Primary outcome: treatment effect contrast,NA,NA,Rate difference,TRUE,NA,NA,NA
10.1080/10428194.2021.2010069,34978255,results,1,NA,Direction of the treatment effect contrast: IPD treatment is:,NA,NA,"Numerator if ratio, or left side if difference",TRUE,NA,NA,NA
10.1080/10428194.2021.2010069,34978255,results,1,NA,Primary outcome: unadjusted treatment effect,-15.5,-15.50%,-15.50%,FALSE,NA,NA,NA
10.1080/10428194.2021.2010069,34978255,results,1,NA,"p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])",NA,NA,<0.01,TRUE,NA,NA,NA
10.1080/10428194.2021.2010069,34978255,results,1,NA,Primary outcome: adjusted treatment effect,-9.7,-9.70%,-9.70%,FALSE,NA,NA,NA
10.1080/10428194.2021.2010069,34978255,results,1,NA,"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])",NA,NA,0.07,TRUE,NA,NA,NA
10.1080/03007995.2022.2030112,35042448,general_information,NA,NA,Medical Condition of Interest Name,uncontrolled hypertension,hypertension suboptimally controlled by amlodipine 5 mg monotherapy,XXXX,FALSE,NA,NA,NA
10.1080/03007995.2022.2030112,35042448,general_information,NA,NA,Countries of first author affiliations,NA,NA,germany,TRUE,NA,NA,NA
10.1080/03007995.2022.2030112,35042448,general_information,NA,NA,Countries of last author affiliations,NA,NA,germany,TRUE,NA,NA,NA
10.1080/03007995.2022.2030112,35042448,general_information,NA,NA,"Positions of study investigators (for any authors of the article, any that applies)",NA,NA,Pharmaceutical Industry,TRUE,NA,NA,NA
10.1080/03007995.2022.2030112,35042448,general_information,NA,NA,"At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company",NA,NA,Yes,TRUE,NA,NA,NA
10.1080/03007995.2022.2030112,35042448,general_information,NA,NA,Mentioned sources of funding,NA,NA,Pharmaceutical Industry,TRUE,NA,NA,NA
10.1080/03007995.2022.2030112,35042448,general_information,NA,NA,"Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article",NA,NA,Yes,TRUE,NA,NA,NA
10.1080/03007995.2022.2030112,35042448,general_information,NA,NA,Mention of a systematic review to find the studies to compare treatments of interest,NA,NA,Yes,TRUE,NA,NA,NA
10.1080/03007995.2022.2030112,35042448,study_information,NA,1,Patient-level data used,NA,NA,Yes,TRUE,NA,NA,NA
10.1080/03007995.2022.2030112,35042448,study_information,NA,1,Clinical Trial,NA,NA,Yes,TRUE,NA,NA,NA
10.1080/03007995.2022.2030112,35042448,study_information,NA,1,EudraCT (only for clinical trials registered on clinicaltrialsregister.eu,NA,NA,2019-000751-13,TRUE,NA,NA,NA
10.1080/03007995.2022.2030112,35042448,study_information,NA,1,Country where the clinical trial/observational study was conducted (international if more than one),NA,NA,poland,TRUE,NA,NA,NA
10.1080/03007995.2022.2030112,35042448,study_information,NA,1,Phase of the clinical trial (clinical trial only),NA,NA,3,TRUE,NA,NA,NA
10.1080/03007995.2022.2030112,35042448,study_information,NA,1,Number of treatment arms (clinical trial only),NA,NA,2 or more,TRUE,NA,NA,NA
10.1080/03007995.2022.2030112,35042448,study_information,NA,2,Patient-level data used,NA,NA,No,TRUE,NA,NA,NA
10.1080/03007995.2022.2030112,35042448,study_information,NA,2,Clinical Trial,NA,NA,Yes,TRUE,NA,NA,NA
10.1080/03007995.2022.2030112,35042448,study_information,NA,2,NCT (only for clinical trial registered on clinicaltrials.gov),NA,NA,NCT00558428,TRUE,NA,NA,NA
10.1080/03007995.2022.2030112,35042448,study_information,NA,2,Country where the clinical trial/observational study was conducted (international if more than one),NA,NA,international,TRUE,NA,NA,NA
10.1080/03007995.2022.2030112,35042448,study_information,NA,2,Phase of the clinical trial (clinical trial only),NA,NA,3,TRUE,NA,NA,NA
10.1080/03007995.2022.2030112,35042448,study_information,NA,2,Number of treatment arms (clinical trial only),NA,NA,2 or more,TRUE,NA,NA,NA
10.1080/03007995.2022.2030112,35042448,methodology,1,NA,Treatment name 1,amlodipine + bisoprolol,amlodipine 5 mg + bisoprolol 5 mg,amlodipine 5 mg + bisoprolol 5 mg,FALSE,"Results of the RCT with individual data not published yet: 2019-000751-13
Explicitely mention that the target population analysis is the one from the other study
Explicitely mention that only effect modifiers and prognostic variables have been integrated 
Explicitely distinguish between effect modifiers and prognostic variables
Doesn't describe CI for unadjusted estimate, although it is calculable from the data","Smoking history = Others
Concomitant diabetes = comordbidity",NA
10.1080/03007995.2022.2030112,35042448,methodology,1,NA,Study 'number(s)' for treatment 1,NA,NA,1,TRUE,NA,NA,NA
10.1080/03007995.2022.2030112,35042448,methodology,1,NA,Treatment name 2,amlodipine,"amlodipine 10mg,","amlodipine 10mg,",FALSE,NA,NA,NA
10.1080/03007995.2022.2030112,35042448,methodology,1,NA,Study 'number(s)' for treatment 2,NA,NA,2,TRUE,NA,NA,NA
10.1080/03007995.2022.2030112,35042448,methodology,1,NA,Type of population-adjusted indirect comparisons performed,NA,NA,STC,TRUE,NA,NA,NA
10.1080/03007995.2022.2030112,35042448,methodology,1,NA,Anchored comparison?,NA,NA,Yes,TRUE,NA,NA,NA
10.1080/03007995.2022.2030112,35042448,methodology,1,NA,Form of the indirect comparison,NA,NA,Simple (ie treatments effects extracted from two studies),TRUE,NA,NA,NA
10.1080/03007995.2022.2030112,35042448,methodology,1,NA,Definition of a single primary outcome for the indirect comparison,NA,NA,"No primary outcome defined, or multiple primary outcomes without any clear distinction between them",TRUE,NA,NA,NA
10.1080/03007995.2022.2030112,35042448,methodology,1,NA,Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined),change in systolic blood pressure at 8 week,change in systolic blood pressures from baseline to following 8 weeks of treatment,change in systolic blood pressures from baseline to following 8 weeks of treatment,FALSE,NA,NA,NA
10.1080/03007995.2022.2030112,35042448,methodology,1,NA,Primary outcome: variable type,NA,NA,"Continuous (count, mean, ...)",TRUE,NA,NA,NA
10.1080/03007995.2022.2030112,35042448,methodology,1,NA,Justification for selecting variables to be included in the adjustment model (in the main text),NA,NA,Literature based (clinically or methodologically relevant to adjust on these variables based on the literature search conducted for this specific purpose),TRUE,NA,NA,NA
10.1080/03007995.2022.2030112,35042448,methodology,1,NA,Inclusion of prognostic factors in the adjustment/matching model,NA,NA,Yes,TRUE,NA,NA,NA
10.1080/03007995.2022.2030112,35042448,methodology,1,NA,Inclusion of treatment-effect modifiers in the adjustment/matching model,NA,NA,Yes,TRUE,NA,NA,NA
10.1080/03007995.2022.2030112,35042448,methodology,1,NA,"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)",NA,NA,No,TRUE,NA,NA,NA
10.1080/03007995.2022.2030112,35042448,methodology,1,NA,Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale),NA,NA,No,TRUE,NA,NA,NA
10.1080/03007995.2022.2030112,35042448,results,1,NA,Sample size of the population of interest in the non IPD treatment arm,NA,NA,261,TRUE,NA,NA,NA
10.1080/03007995.2022.2030112,35042448,results,1,NA,"If anchored comparison, sample size of the population of interest in the non IPD treatment anchor arm",NA,NA,255,TRUE,NA,NA,NA
10.1080/03007995.2022.2030112,35042448,results,1,NA,Initial sample size of the population of interest in the IPD treatment arm,NA,NA,178,TRUE,NA,NA,NA
10.1080/03007995.2022.2030112,35042448,results,1,NA,"Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC",NA,NA,178,TRUE,NA,NA,NA
10.1080/03007995.2022.2030112,35042448,results,1,NA,"If anchored comparison, initial sample size of the population of interest in the IPD anchor arm",NA,NA,179,TRUE,NA,NA,NA
10.1080/03007995.2022.2030112,35042448,results,1,NA,"If anchored comparison, effective sample size after reweighting for MAIC; or sample size used in the regression model for STC in the IPD anchor arm",NA,NA,179,TRUE,NA,NA,NA
10.1080/03007995.2022.2030112,35042448,results,1,NA,Reporting of the list of the covariates adjusted for/matched on,NA,NA,Yes,TRUE,NA,NA,NA
10.1080/03007995.2022.2030112,35042448,results,1,NA,Number of covariates adjusted for/matched on,NA,NA,7,TRUE,NA,NA,NA
10.1080/03007995.2022.2030112,35042448,results,1,NA,Covariates adjusted for/matched on in the indirect comparison,NA,NA,"Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Comorbidities and medical history (beside pathology/disease of interest in the comparison), Other(s)",TRUE,NA,NA,NA
10.1080/03007995.2022.2030112,35042448,results,1,NA,Primary outcome: treatment effect contrast,NA,NA,Means difference,TRUE,NA,NA,NA
10.1080/03007995.2022.2030112,35042448,results,1,NA,Direction of the treatment effect contrast: IPD treatment is:,NA,NA,"Numerator if ratio, or left side if difference",TRUE,NA,NA,NA
10.1080/03007995.2022.2030112,35042448,results,1,NA,Primary outcome: unadjusted treatment effect,NA,NA,-0.3,TRUE,NA,NA,NA
10.1080/03007995.2022.2030112,35042448,results,1,NA,Primary outcome: adjusted treatment effect,NA,NA,-1.6,TRUE,NA,NA,NA
10.1080/03007995.2022.2030112,35042448,results,1,NA,"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])",[-5.3;2.2],[-5.3-2.2],[-5.3;2.2],FALSE,NA,NA,NA
10.1080/03007995.2022.2030112,35042448,results,1,NA,Reporting of a weights' distribution evaluation (MAIC),NA,Not mentioned,Not mentioned,FALSE,NA,NA,NA
10.2217/imt-2021-0273,35073727,general_information,NA,NA,Medical Condition of Interest Name,metastatic non-small-cell lung cancer,metastatic non-small-cell lung cancer with pd-l1,XXXX,FALSE,NA,NA,NA
10.2217/imt-2021-0273,35073727,general_information,NA,NA,Countries of first author affiliations,NA,NA,usa,TRUE,NA,NA,NA
10.2217/imt-2021-0273,35073727,general_information,NA,NA,Countries of last author affiliations,NA,NA,usa,TRUE,NA,NA,NA
10.2217/imt-2021-0273,35073727,general_information,NA,NA,"Positions of study investigators (for any authors of the article, any that applies)",NA,NA,"Academic, Pharmaceutical Industry, Private Data Analysis Company",TRUE,NA,NA,NA
10.2217/imt-2021-0273,35073727,general_information,NA,NA,"At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company",NA,NA,Yes,TRUE,NA,NA,NA
10.2217/imt-2021-0273,35073727,general_information,NA,NA,Mentioned sources of funding,NA,NA,Pharmaceutical Industry,TRUE,NA,NA,NA
10.2217/imt-2021-0273,35073727,general_information,NA,NA,"Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article",NA,NA,Yes,TRUE,NA,NA,NA
10.2217/imt-2021-0273,35073727,general_information,NA,NA,Mention of a systematic review to find the studies to compare treatments of interest,NA,NA,Yes,TRUE,NA,NA,NA
10.2217/imt-2021-0273,35073727,study_information,NA,1,Patient-level data used,NA,NA,Yes,TRUE,NA,NA,NA
10.2217/imt-2021-0273,35073727,study_information,NA,1,Clinical Trial,NA,NA,Yes,TRUE,NA,NA,NA
10.2217/imt-2021-0273,35073727,study_information,NA,1,NCT (only for clinical trial registered on clinicaltrials.gov),NA,NA,NCT02142738,TRUE,NA,NA,NA
10.2217/imt-2021-0273,35073727,study_information,NA,1,Country where the clinical trial/observational study was conducted (international if more than one),international,NA,XXXX,FALSE,NA,NA,NA
10.2217/imt-2021-0273,35073727,study_information,NA,1,Phase of the clinical trial (clinical trial only),NA,NA,3,TRUE,NA,NA,NA
10.2217/imt-2021-0273,35073727,study_information,NA,1,Number of treatment arms (clinical trial only),NA,NA,2 or more,TRUE,NA,NA,NA
10.2217/imt-2021-0273,35073727,study_information,NA,2,Patient-level data used,NA,NA,Yes,TRUE,NA,NA,NA
10.2217/imt-2021-0273,35073727,study_information,NA,2,Clinical Trial,NA,NA,Yes,TRUE,NA,NA,NA
10.2217/imt-2021-0273,35073727,study_information,NA,2,NCT (only for clinical trial registered on clinicaltrials.gov),NA,NA,NCT02220894,TRUE,NA,NA,NA
10.2217/imt-2021-0273,35073727,study_information,NA,2,Country where the clinical trial/observational study was conducted (international if more than one),international,NA,XXXX,FALSE,NA,NA,NA
10.2217/imt-2021-0273,35073727,study_information,NA,2,Phase of the clinical trial (clinical trial only),NA,NA,3,TRUE,NA,NA,NA
10.2217/imt-2021-0273,35073727,study_information,NA,2,Number of treatment arms (clinical trial only),NA,NA,2 or more,TRUE,NA,NA,NA
10.2217/imt-2021-0273,35073727,study_information,NA,3,Patient-level data used,NA,NA,No,TRUE,NA,NA,NA
10.2217/imt-2021-0273,35073727,study_information,NA,3,Clinical Trial,NA,NA,Yes,TRUE,NA,NA,NA
10.2217/imt-2021-0273,35073727,study_information,NA,3,NCT (only for clinical trial registered on clinicaltrials.gov),NA,NA,NCT02477826,TRUE,NA,NA,NA
10.2217/imt-2021-0273,35073727,study_information,NA,3,Country where the clinical trial/observational study was conducted (international if more than one),NA,NA,international,TRUE,NA,NA,NA
10.2217/imt-2021-0273,35073727,study_information,NA,3,Phase of the clinical trial (clinical trial only),NA,NA,3,TRUE,NA,NA,NA
10.2217/imt-2021-0273,35073727,study_information,NA,3,Number of treatment arms (clinical trial only),NA,NA,2 or more,TRUE,NA,NA,NA
10.2217/imt-2021-0273,35073727,methodology,1,NA,Treatment name 1,NA,NA,pembrolizumab,TRUE,"Statistical assessment of the variables available in the trials, interpreted as ""status of prognostic fctors/treatment effect modifier assessed in the IPD dataset""","Effectifs donné par les auteurs = effectif du bras traitement d'interet + effectif du comparateur
Smoking status + region = others",NA
10.2217/imt-2021-0273,35073727,methodology,1,NA,Study 'number(s)' for treatment 1,1;2,1; 2,1;2,FALSE,NA,NA,NA
10.2217/imt-2021-0273,35073727,methodology,1,NA,Treatment name 2,NA,NA,nivolumab + ipilimumab,TRUE,NA,NA,NA
10.2217/imt-2021-0273,35073727,methodology,1,NA,Study 'number(s)' for treatment 2,NA,NA,3,TRUE,NA,NA,NA
10.2217/imt-2021-0273,35073727,methodology,1,NA,Type of population-adjusted indirect comparisons performed,NA,NA,MAIC,TRUE,NA,NA,NA
10.2217/imt-2021-0273,35073727,methodology,1,NA,Anchored comparison?,NA,NA,Yes,TRUE,NA,NA,NA
10.2217/imt-2021-0273,35073727,methodology,1,NA,Form of the indirect comparison,NA,NA,"Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate)",TRUE,NA,NA,NA
10.2217/imt-2021-0273,35073727,methodology,1,NA,Definition of a single primary outcome for the indirect comparison,NA,NA,"No primary outcome defined, or multiple primary outcomes without any clear distinction between them",TRUE,NA,NA,NA
10.2217/imt-2021-0273,35073727,methodology,1,NA,Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined),NA,NA,overall survival,TRUE,NA,NA,NA
10.2217/imt-2021-0273,35073727,methodology,1,NA,Primary outcome: variable type,NA,NA,Time-to-event,TRUE,NA,NA,NA
10.2217/imt-2021-0273,35073727,methodology,1,NA,Justification for selecting variables to be included in the adjustment model (in the main text),"Status of prognostic factor/treatment effect modified assessed in the IPD dataset, A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion), Literature based (clinically or methodologically relevant to adjust on these variables based on the literature search conducted for this specific purpose)","Statistical imbalanced between treatment groups (independently of the status of prognostic/effect modifier), A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion), Literature based (clinically or methodologically relevant to adjust on these variables based on the literature search conducted for this specific purpose)","Statistical imbalanced between treatment groups (independently of the status of prognostic/effect modifier), A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion), Literature based (clinically or methodologically relevant to adjust on these variables based on the literature search conducted for this specific purpose)",FALSE,NA,NA,NA
10.2217/imt-2021-0273,35073727,methodology,1,NA,Inclusion of prognostic factors in the adjustment/matching model,NA,NA,No,TRUE,NA,NA,NA
10.2217/imt-2021-0273,35073727,methodology,1,NA,Inclusion of treatment-effect modifiers in the adjustment/matching model,NA,NA,Yes,TRUE,NA,NA,NA
10.2217/imt-2021-0273,35073727,methodology,1,NA,"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)",NA,NA,No,TRUE,NA,NA,NA
10.2217/imt-2021-0273,35073727,methodology,1,NA,Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale),NA,NA,No,TRUE,NA,NA,NA
10.2217/imt-2021-0273,35073727,results,1,NA,Sample size of the population of interest in the non IPD treatment arm,NA,NA,793,TRUE,NA,NA,NA
10.2217/imt-2021-0273,35073727,results,1,NA,Initial sample size of the population of interest in the IPD treatment arm,NA,NA,1428,TRUE,NA,NA,NA
10.2217/imt-2021-0273,35073727,results,1,NA,"Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC",NA,NA,993,TRUE,NA,NA,NA
10.2217/imt-2021-0273,35073727,results,1,NA,Reporting of a weights' distribution evaluation (MAIC),NA,NA,Not mentioned,TRUE,NA,NA,NA
10.2217/imt-2021-0273,35073727,results,1,NA,Reporting of the list of the covariates adjusted for/matched on,NA,NA,Yes,TRUE,NA,NA,NA
10.2217/imt-2021-0273,35073727,results,1,NA,Number of covariates adjusted for/matched on,NA,NA,8,TRUE,NA,NA,NA
10.2217/imt-2021-0273,35073727,results,1,NA,Covariates adjusted for/matched on in the indirect comparison,"Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Other(s), Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...)","Age, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Race/ethnicity, Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Other(s)","Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Other(s), Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...)",FALSE,NA,NA,NA
10.2217/imt-2021-0273,35073727,results,1,NA,Primary outcome: treatment effect contrast,NA,NA,HR,TRUE,NA,NA,NA
10.2217/imt-2021-0273,35073727,results,1,NA,Direction of the treatment effect contrast: IPD treatment is:,NA,NA,"Numerator if ratio, or left side if difference",TRUE,NA,NA,NA
10.2217/imt-2021-0273,35073727,results,1,NA,Primary outcome: unadjusted treatment effect,NA,NA,0.98,TRUE,NA,NA,NA
10.2217/imt-2021-0273,35073727,results,1,NA,Primary outcome: adjusted treatment effect,NA,NA,1.07,TRUE,NA,NA,NA
10.2217/imt-2021-0273,35073727,results,1,NA,"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])",[0.82;1.39],0.617,[0.82;1.39],FALSE,NA,NA,NA
10.1007/s12325-022-02054-z,35157216,general_information,NA,NA,Medical Condition of Interest Name,NA,NA,relapsed or refractory follicular lymphoma,TRUE,NA,NA,NA
10.1007/s12325-022-02054-z,35157216,general_information,NA,NA,Countries of first author affiliations,NA,NA,usa,TRUE,NA,NA,NA
10.1007/s12325-022-02054-z,35157216,general_information,NA,NA,Countries of last author affiliations,NA,NA,usa,TRUE,NA,NA,NA
10.1007/s12325-022-02054-z,35157216,general_information,NA,NA,"Positions of study investigators (for any authors of the article, any that applies)",NA,NA,"Pharmaceutical Industry, Private Data Analysis Company",TRUE,NA,NA,NA
10.1007/s12325-022-02054-z,35157216,general_information,NA,NA,"At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company",NA,NA,Yes,TRUE,NA,NA,NA
10.1007/s12325-022-02054-z,35157216,general_information,NA,NA,Mentioned sources of funding,NA,NA,Pharmaceutical Industry,TRUE,NA,NA,NA
10.1007/s12325-022-02054-z,35157216,general_information,NA,NA,"Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article",NA,NA,Yes,TRUE,NA,NA,NA
10.1007/s12325-022-02054-z,35157216,general_information,NA,NA,Mention of a systematic review to find the studies to compare treatments of interest,NA,NA,Yes,TRUE,NA,NA,NA
10.1007/s12325-022-02054-z,35157216,study_information,NA,1,Patient-level data used,NA,NA,Yes,TRUE,NA,NA,NA
10.1007/s12325-022-02054-z,35157216,study_information,NA,1,Clinical Trial,NA,NA,Yes,TRUE,NA,NA,NA
10.1007/s12325-022-02054-z,35157216,study_information,NA,1,NCT (only for clinical trial registered on clinicaltrials.gov),NA,NA,NCT01897571,TRUE,NA,NA,NA
10.1007/s12325-022-02054-z,35157216,study_information,NA,1,Country where the clinical trial/observational study was conducted (international if more than one),NA,NA,international,TRUE,NA,NA,NA
10.1007/s12325-022-02054-z,35157216,study_information,NA,1,Phase of the clinical trial (clinical trial only),NA,NA,"1, 2",TRUE,NA,NA,NA
10.1007/s12325-022-02054-z,35157216,study_information,NA,1,Number of treatment arms (clinical trial only),NA,NA,1,TRUE,NA,NA,NA
10.1007/s12325-022-02054-z,35157216,study_information,NA,2,Patient-level data used,NA,NA,No,TRUE,NA,NA,NA
10.1007/s12325-022-02054-z,35157216,study_information,NA,2,Clinical Trial,NA,NA,Yes,TRUE,NA,NA,NA
10.1007/s12325-022-02054-z,35157216,study_information,NA,2,NCT (only for clinical trial registered on clinicaltrials.gov),NA,NA,NCT01282424,TRUE,NA,NA,NA
10.1007/s12325-022-02054-z,35157216,study_information,NA,2,Country where the clinical trial/observational study was conducted (international if more than one),NA,NA,international,TRUE,NA,NA,NA
10.1007/s12325-022-02054-z,35157216,study_information,NA,2,Phase of the clinical trial (clinical trial only),NA,NA,2,TRUE,NA,NA,NA
10.1007/s12325-022-02054-z,35157216,study_information,NA,2,Number of treatment arms (clinical trial only),NA,NA,1,TRUE,NA,NA,NA
10.1007/s12325-022-02054-z,35157216,study_information,NA,3,Patient-level data used,NA,NA,No,TRUE,NA,NA,NA
10.1007/s12325-022-02054-z,35157216,study_information,NA,3,Clinical Trial,NA,NA,Yes,TRUE,NA,NA,NA
10.1007/s12325-022-02054-z,35157216,study_information,NA,3,Country where the clinical trial/observational study was conducted (international if more than one),NA,NA,international,TRUE,NA,NA,NA
10.1007/s12325-022-02054-z,35157216,study_information,NA,3,Phase of the clinical trial (clinical trial only),NA,NA,2,TRUE,NA,NA,NA
10.1007/s12325-022-02054-z,35157216,study_information,NA,3,Number of treatment arms (clinical trial only),NA,NA,1,TRUE,NA,NA,NA
10.1007/s12325-022-02054-z,35157216,study_information,NA,3,NCT (only for clinical trial registered on clinicaltrials.gov),NA,NCT01882803,NCT01882803,FALSE,NA,NA,NA
10.1007/s12325-022-02054-z,35157216,study_information,NA,4,Patient-level data used,NA,NA,No,TRUE,NA,NA,NA
10.1007/s12325-022-02054-z,35157216,study_information,NA,4,Clinical Trial,NA,NA,Yes,TRUE,NA,NA,NA
10.1007/s12325-022-02054-z,35157216,study_information,NA,4,NCT (only for clinical trial registered on clinicaltrials.gov),NA,NA,NCT01660451,TRUE,NA,NA,NA
10.1007/s12325-022-02054-z,35157216,study_information,NA,4,Country where the clinical trial/observational study was conducted (international if more than one),NA,NA,international,TRUE,NA,NA,NA
10.1007/s12325-022-02054-z,35157216,study_information,NA,4,Phase of the clinical trial (clinical trial only),NA,NA,2,TRUE,NA,NA,NA
10.1007/s12325-022-02054-z,35157216,study_information,NA,4,Number of treatment arms (clinical trial only),NA,NA,1,TRUE,NA,NA,NA
10.1007/s12325-022-02054-z,35157216,study_information,NA,5,Patient-level data used,NA,NA,No,TRUE,NA,NA,NA
10.1007/s12325-022-02054-z,35157216,study_information,NA,5,Clinical Trial,NA,NA,Yes,TRUE,NA,NA,NA
10.1007/s12325-022-02054-z,35157216,study_information,NA,5,NCT (only for clinical trial registered on clinicaltrials.gov),NA,NA,NCT02793583,TRUE,NA,NA,NA
10.1007/s12325-022-02054-z,35157216,study_information,NA,5,Country where the clinical trial/observational study was conducted (international if more than one),NA,NA,international,TRUE,NA,NA,NA
10.1007/s12325-022-02054-z,35157216,study_information,NA,5,Phase of the clinical trial (clinical trial only),NA,NA,2,TRUE,NA,NA,NA
10.1007/s12325-022-02054-z,35157216,study_information,NA,5,Number of treatment arms (clinical trial only),1,2 or more,XXXX,FALSE,NA,NA,NA
10.1007/s12325-022-02054-z,35157216,methodology,1,NA,Treatment name 1,NA,NA,tazemetostat,TRUE,"Safety outcomes reported first in the article, so safety outcomes reported in the form

Mention using robust sandwich estimator, could be interesting to report whether MAIC usually uses it, but must often research must often miss this work

","""Sex was assumed not to be prognostic for the ORR in FL [30]."" => selection of sex as a covariate is literature based",NA
10.1007/s12325-022-02054-z,35157216,methodology,1,NA,Study 'number(s)' for treatment 1,NA,NA,1,TRUE,NA,NA,NA
10.1007/s12325-022-02054-z,35157216,methodology,1,NA,Treatment name 2,NA,NA,idelalisib,TRUE,NA,NA,NA
10.1007/s12325-022-02054-z,35157216,methodology,1,NA,Study 'number(s)' for treatment 2,NA,NA,2,TRUE,NA,NA,NA
10.1007/s12325-022-02054-z,35157216,methodology,1,NA,Type of population-adjusted indirect comparisons performed,NA,NA,MAIC,TRUE,NA,NA,NA
10.1007/s12325-022-02054-z,35157216,methodology,1,NA,Anchored comparison?,NA,NA,No,TRUE,NA,NA,NA
10.1007/s12325-022-02054-z,35157216,methodology,1,NA,Form of the indirect comparison,NA,NA,Simple (ie treatments effects extracted from two studies),TRUE,NA,NA,NA
10.1007/s12325-022-02054-z,35157216,methodology,1,NA,Definition of a single primary outcome for the indirect comparison,NA,NA,"No primary outcome defined, or multiple primary outcomes without any clear distinction between them",TRUE,NA,NA,NA
10.1007/s12325-022-02054-z,35157216,methodology,1,NA,Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined),grade >= 3 treatment emergent adverse event,incidence of any grade ? 3 treatment-emergent adverse event,grade >= 3 treatment emergent adverse event,FALSE,NA,NA,NA
10.1007/s12325-022-02054-z,35157216,methodology,1,NA,Primary outcome: variable type,NA,NA,Binary (eg rates),TRUE,NA,NA,NA
10.1007/s12325-022-02054-z,35157216,methodology,1,NA,Justification for selecting variables to be included in the adjustment model (in the main text),A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion),"A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion), Literature based (clinically or methodologically relevant to adjust on these variables based on the literature search conducted for this specific purpose)",A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion),FALSE,NA,NA,NA
10.1007/s12325-022-02054-z,35157216,methodology,1,NA,Inclusion of prognostic factors in the adjustment/matching model,NA,NA,Yes,TRUE,NA,NA,NA
10.1007/s12325-022-02054-z,35157216,methodology,1,NA,Inclusion of treatment-effect modifiers in the adjustment/matching model,NA,NA,Yes,TRUE,NA,NA,NA
10.1007/s12325-022-02054-z,35157216,methodology,1,NA,"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)",NA,NA,No,TRUE,NA,NA,NA
10.1007/s12325-022-02054-z,35157216,methodology,1,NA,Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale),NA,NA,No,TRUE,NA,NA,NA
10.1007/s12325-022-02054-z,35157216,methodology,2,NA,Treatment name 1,NA,NA,tazemetostat,TRUE,NA,NA,NA
10.1007/s12325-022-02054-z,35157216,methodology,2,NA,Study 'number(s)' for treatment 1,NA,NA,1,TRUE,NA,NA,NA
10.1007/s12325-022-02054-z,35157216,methodology,2,NA,Treatment name 2,NA,NA,duvelisib,TRUE,NA,NA,NA
10.1007/s12325-022-02054-z,35157216,methodology,2,NA,Study 'number(s)' for treatment 2,NA,NA,3,TRUE,NA,NA,NA
10.1007/s12325-022-02054-z,35157216,methodology,2,NA,Type of population-adjusted indirect comparisons performed,NA,NA,MAIC,TRUE,NA,NA,NA
10.1007/s12325-022-02054-z,35157216,methodology,2,NA,Anchored comparison?,NA,NA,No,TRUE,NA,NA,NA
10.1007/s12325-022-02054-z,35157216,methodology,2,NA,Form of the indirect comparison,NA,NA,Simple (ie treatments effects extracted from two studies),TRUE,NA,NA,NA
10.1007/s12325-022-02054-z,35157216,methodology,2,NA,Definition of a single primary outcome for the indirect comparison,NA,NA,"No primary outcome defined, or multiple primary outcomes without any clear distinction between them",TRUE,NA,NA,NA
10.1007/s12325-022-02054-z,35157216,methodology,2,NA,Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined),grade >= 3 treatment emergent adverse event,incidence of any grade ? 3 treatment-emergent adverse event,grade >= 3 treatment emergent adverse event,FALSE,NA,NA,NA
10.1007/s12325-022-02054-z,35157216,methodology,2,NA,Primary outcome: variable type,NA,NA,Binary (eg rates),TRUE,NA,NA,NA
10.1007/s12325-022-02054-z,35157216,methodology,2,NA,Justification for selecting variables to be included in the adjustment model (in the main text),A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion),"A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion), Literature based (clinically or methodologically relevant to adjust on these variables based on the literature search conducted for this specific purpose)",A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion),FALSE,NA,NA,NA
10.1007/s12325-022-02054-z,35157216,methodology,2,NA,Inclusion of prognostic factors in the adjustment/matching model,NA,NA,Yes,TRUE,NA,NA,NA
10.1007/s12325-022-02054-z,35157216,methodology,2,NA,Inclusion of treatment-effect modifiers in the adjustment/matching model,NA,NA,Yes,TRUE,NA,NA,NA
10.1007/s12325-022-02054-z,35157216,methodology,2,NA,"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)",NA,NA,No,TRUE,NA,NA,NA
10.1007/s12325-022-02054-z,35157216,methodology,2,NA,Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale),NA,NA,No,TRUE,NA,NA,NA
10.1007/s12325-022-02054-z,35157216,methodology,3,NA,Treatment name 1,NA,NA,tazemetostat,TRUE,NA,NA,NA
10.1007/s12325-022-02054-z,35157216,methodology,3,NA,Study 'number(s)' for treatment 1,NA,NA,1,TRUE,NA,NA,NA
10.1007/s12325-022-02054-z,35157216,methodology,3,NA,Treatment name 2,NA,NA,copanlisib,TRUE,NA,NA,NA
10.1007/s12325-022-02054-z,35157216,methodology,3,NA,Study 'number(s)' for treatment 2,NA,NA,4,TRUE,NA,NA,NA
10.1007/s12325-022-02054-z,35157216,methodology,3,NA,Type of population-adjusted indirect comparisons performed,NA,NA,MAIC,TRUE,NA,NA,NA
10.1007/s12325-022-02054-z,35157216,methodology,3,NA,Anchored comparison?,NA,NA,No,TRUE,NA,NA,NA
10.1007/s12325-022-02054-z,35157216,methodology,3,NA,Form of the indirect comparison,NA,NA,Simple (ie treatments effects extracted from two studies),TRUE,NA,NA,NA
10.1007/s12325-022-02054-z,35157216,methodology,3,NA,Definition of a single primary outcome for the indirect comparison,NA,NA,"No primary outcome defined, or multiple primary outcomes without any clear distinction between them",TRUE,NA,NA,NA
10.1007/s12325-022-02054-z,35157216,methodology,3,NA,Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined),grade >= 3 treatment emergent adverse event,incidence of any grade ? 3 treatment-emergent adverse event,grade >= 3 treatment emergent adverse event,FALSE,NA,NA,NA
10.1007/s12325-022-02054-z,35157216,methodology,3,NA,Primary outcome: variable type,NA,NA,Binary (eg rates),TRUE,NA,NA,NA
10.1007/s12325-022-02054-z,35157216,methodology,3,NA,Justification for selecting variables to be included in the adjustment model (in the main text),A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion),"A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion), Literature based (clinically or methodologically relevant to adjust on these variables based on the literature search conducted for this specific purpose)",A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion),FALSE,NA,NA,NA
10.1007/s12325-022-02054-z,35157216,methodology,3,NA,Inclusion of prognostic factors in the adjustment/matching model,NA,NA,Yes,TRUE,NA,NA,NA
10.1007/s12325-022-02054-z,35157216,methodology,3,NA,Inclusion of treatment-effect modifiers in the adjustment/matching model,NA,NA,Yes,TRUE,NA,NA,NA
10.1007/s12325-022-02054-z,35157216,methodology,3,NA,"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)",NA,NA,No,TRUE,NA,NA,NA
10.1007/s12325-022-02054-z,35157216,methodology,3,NA,Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale),NA,NA,No,TRUE,NA,NA,NA
10.1007/s12325-022-02054-z,35157216,methodology,4,NA,Treatment name 1,NA,NA,tazemetostat,TRUE,NA,NA,NA
10.1007/s12325-022-02054-z,35157216,methodology,4,NA,Study 'number(s)' for treatment 1,NA,NA,1,TRUE,NA,NA,NA
10.1007/s12325-022-02054-z,35157216,methodology,4,NA,Treatment name 2,NA,NA,umbralisib,TRUE,NA,NA,NA
10.1007/s12325-022-02054-z,35157216,methodology,4,NA,Study 'number(s)' for treatment 2,NA,NA,5,TRUE,NA,NA,NA
10.1007/s12325-022-02054-z,35157216,methodology,4,NA,Type of population-adjusted indirect comparisons performed,NA,NA,MAIC,TRUE,NA,NA,NA
10.1007/s12325-022-02054-z,35157216,methodology,4,NA,Anchored comparison?,NA,NA,No,TRUE,NA,NA,NA
10.1007/s12325-022-02054-z,35157216,methodology,4,NA,Form of the indirect comparison,NA,NA,Simple (ie treatments effects extracted from two studies),TRUE,NA,NA,NA
10.1007/s12325-022-02054-z,35157216,methodology,4,NA,Definition of a single primary outcome for the indirect comparison,NA,NA,"No primary outcome defined, or multiple primary outcomes without any clear distinction between them",TRUE,NA,NA,NA
10.1007/s12325-022-02054-z,35157216,methodology,4,NA,Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined),grade >= 3 treatment emergent adverse event,incidence of any grade ? 3 treatment-emergent adverse event,grade >= 3 treatment emergent adverse event,FALSE,NA,NA,NA
10.1007/s12325-022-02054-z,35157216,methodology,4,NA,Primary outcome: variable type,NA,NA,Binary (eg rates),TRUE,NA,NA,NA
10.1007/s12325-022-02054-z,35157216,methodology,4,NA,Justification for selecting variables to be included in the adjustment model (in the main text),A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion),"A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion), Literature based (clinically or methodologically relevant to adjust on these variables based on the literature search conducted for this specific purpose)",A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion),FALSE,NA,NA,NA
10.1007/s12325-022-02054-z,35157216,methodology,4,NA,Inclusion of prognostic factors in the adjustment/matching model,NA,NA,Yes,TRUE,NA,NA,NA
10.1007/s12325-022-02054-z,35157216,methodology,4,NA,Inclusion of treatment-effect modifiers in the adjustment/matching model,NA,NA,Yes,TRUE,NA,NA,NA
10.1007/s12325-022-02054-z,35157216,methodology,4,NA,"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)",NA,NA,No,TRUE,NA,NA,NA
10.1007/s12325-022-02054-z,35157216,methodology,4,NA,Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale),NA,NA,No,TRUE,NA,NA,NA
10.1007/s12325-022-02054-z,35157216,results,1,NA,Sample size of the population of interest in the non IPD treatment arm,NA,NA,72,TRUE,NA,NA,NA
10.1007/s12325-022-02054-z,35157216,results,1,NA,Initial sample size of the population of interest in the IPD treatment arm,NA,NA,99,TRUE,NA,NA,NA
10.1007/s12325-022-02054-z,35157216,results,1,NA,"Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC",NA,NA,36,TRUE,NA,NA,NA
10.1007/s12325-022-02054-z,35157216,results,1,NA,Reporting of a weights' distribution evaluation (MAIC),NA,NA,Not mentioned,TRUE,NA,NA,NA
10.1007/s12325-022-02054-z,35157216,results,1,NA,Reporting of the list of the covariates adjusted for/matched on,NA,NA,Yes,TRUE,NA,NA,NA
10.1007/s12325-022-02054-z,35157216,results,1,NA,Covariates adjusted for/matched on in the indirect comparison,"Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Past treatments for the disease of interest, Other(s), Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...)","Age, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Past treatments for the disease of interest","Age, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Past treatments for the disease of interest",FALSE,NA,NA,NA
10.1007/s12325-022-02054-z,35157216,results,1,NA,Primary outcome: treatment effect contrast,NA,NA,RR,TRUE,NA,NA,NA
10.1007/s12325-022-02054-z,35157216,results,1,NA,Direction of the treatment effect contrast: IPD treatment is:,NA,NA,"Numerator if ratio, or left side if difference",TRUE,NA,NA,NA
10.1007/s12325-022-02054-z,35157216,results,1,NA,Primary outcome: unadjusted treatment effect,0.59,"0,59",0.59,FALSE,NA,NA,NA
10.1007/s12325-022-02054-z,35157216,results,1,NA,"p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])",<0.001,< 0.001,<0.001,FALSE,NA,NA,NA
10.1007/s12325-022-02054-z,35157216,results,1,NA,Primary outcome: adjusted treatment effect,NA,NA,0.45,TRUE,NA,NA,NA
10.1007/s12325-022-02054-z,35157216,results,1,NA,"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])",<0.001,< 0.001,<0.001,FALSE,NA,NA,NA
10.1007/s12325-022-02054-z,35157216,results,1,NA,Number of covariates adjusted for/matched on,NA,8,8,FALSE,NA,NA,NA
10.1007/s12325-022-02054-z,35157216,results,2,NA,Sample size of the population of interest in the non IPD treatment arm,NA,NA,129,TRUE,NA,NA,NA
10.1007/s12325-022-02054-z,35157216,results,2,NA,Initial sample size of the population of interest in the IPD treatment arm,NA,NA,99,TRUE,NA,NA,NA
10.1007/s12325-022-02054-z,35157216,results,2,NA,"Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC",NA,NA,24,TRUE,NA,NA,NA
10.1007/s12325-022-02054-z,35157216,results,2,NA,Reporting of a weights' distribution evaluation (MAIC),NA,NA,Not mentioned,TRUE,NA,NA,NA
10.1007/s12325-022-02054-z,35157216,results,2,NA,Reporting of the list of the covariates adjusted for/matched on,NA,NA,Yes,TRUE,NA,NA,NA
10.1007/s12325-022-02054-z,35157216,results,2,NA,Number of covariates adjusted for/matched on,7,8,8,FALSE,NA,NA,NA
10.1007/s12325-022-02054-z,35157216,results,2,NA,Covariates adjusted for/matched on in the indirect comparison,"Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Past treatments for the disease of interest, Other(s), Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...)","Age, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Past treatments for the disease of interest","Age, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Past treatments for the disease of interest",FALSE,NA,NA,NA
10.1007/s12325-022-02054-z,35157216,results,2,NA,Primary outcome: treatment effect contrast,NA,NA,RR,TRUE,NA,NA,NA
10.1007/s12325-022-02054-z,35157216,results,2,NA,Direction of the treatment effect contrast: IPD treatment is:,NA,NA,"Numerator if ratio, or left side if difference",TRUE,NA,NA,NA
10.1007/s12325-022-02054-z,35157216,results,2,NA,Primary outcome: unadjusted treatment effect,0.45,"0,45",0.45,FALSE,NA,NA,NA
10.1007/s12325-022-02054-z,35157216,results,2,NA,"p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])",<0.001,< 0.001,<0.001,FALSE,NA,NA,NA
10.1007/s12325-022-02054-z,35157216,results,2,NA,Primary outcome: adjusted treatment effect,NA,NA,0.35,TRUE,NA,NA,NA
10.1007/s12325-022-02054-z,35157216,results,2,NA,"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])",<0.001,< 0.001,<0.001,FALSE,NA,NA,NA
10.1007/s12325-022-02054-z,35157216,results,3,NA,Sample size of the population of interest in the non IPD treatment arm,NA,NA,142,TRUE,NA,NA,NA
10.1007/s12325-022-02054-z,35157216,results,3,NA,"If anchored comparison, sample size of the population of interest in the non IPD treatment anchor arm",na,NA,XXXX,FALSE,NA,NA,NA
10.1007/s12325-022-02054-z,35157216,results,3,NA,Initial sample size of the population of interest in the IPD treatment arm,NA,NA,99,TRUE,NA,NA,NA
10.1007/s12325-022-02054-z,35157216,results,3,NA,"Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC",NA,NA,66,TRUE,NA,NA,NA
10.1007/s12325-022-02054-z,35157216,results,3,NA,"If anchored comparison, initial sample size of the population of interest in the IPD anchor arm",na,NA,XXXX,FALSE,NA,NA,NA
10.1007/s12325-022-02054-z,35157216,results,3,NA,"If anchored comparison, effective sample size after reweighting for MAIC; or sample size used in the regression model for STC in the IPD anchor arm",na,NA,XXXX,FALSE,NA,NA,NA
10.1007/s12325-022-02054-z,35157216,results,3,NA,Reporting of a weights' distribution evaluation (MAIC),NA,NA,Not mentioned,TRUE,NA,NA,NA
10.1007/s12325-022-02054-z,35157216,results,3,NA,Reporting of the list of the covariates adjusted for/matched on,NA,NA,Yes,TRUE,NA,NA,NA
10.1007/s12325-022-02054-z,35157216,results,3,NA,Number of covariates adjusted for/matched on,7,8,7,FALSE,NA,NA,NA
10.1007/s12325-022-02054-z,35157216,results,3,NA,Covariates adjusted for/matched on in the indirect comparison,"Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Past treatments for the disease of interest, Other(s), Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...)","Age, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Past treatments for the disease of interest","Age, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Past treatments for the disease of interest",FALSE,NA,NA,NA
10.1007/s12325-022-02054-z,35157216,results,3,NA,Primary outcome: treatment effect contrast,NA,NA,RR,TRUE,NA,NA,NA
10.1007/s12325-022-02054-z,35157216,results,3,NA,Direction of the treatment effect contrast: IPD treatment is:,NA,NA,"Numerator if ratio, or left side if difference",TRUE,NA,NA,NA
10.1007/s12325-022-02054-z,35157216,results,3,NA,Primary outcome: unadjusted treatment effect,0.47,"0,47",0.47,FALSE,NA,NA,NA
10.1007/s12325-022-02054-z,35157216,results,3,NA,"p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])",<0.001,< 0.001,<0.001,FALSE,NA,NA,NA
10.1007/s12325-022-02054-z,35157216,results,3,NA,Primary outcome: adjusted treatment effect,0.37,"0,37",0.37,FALSE,NA,NA,NA
10.1007/s12325-022-02054-z,35157216,results,3,NA,"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])",<0.001,< 0.001,<0.001,FALSE,NA,NA,NA
10.1007/s12325-022-02054-z,35157216,results,4,NA,Sample size of the population of interest in the non IPD treatment arm,NA,NA,208,TRUE,NA,NA,NA
10.1007/s12325-022-02054-z,35157216,results,4,NA,Initial sample size of the population of interest in the IPD treatment arm,NA,NA,99,TRUE,NA,NA,NA
10.1007/s12325-022-02054-z,35157216,results,4,NA,"Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC",NA,NA,60,TRUE,NA,NA,NA
10.1007/s12325-022-02054-z,35157216,results,4,NA,Reporting of a weights' distribution evaluation (MAIC),NA,NA,Not mentioned,TRUE,NA,NA,NA
10.1007/s12325-022-02054-z,35157216,results,4,NA,Reporting of the list of the covariates adjusted for/matched on,NA,NA,Yes,TRUE,NA,NA,NA
10.1007/s12325-022-02054-z,35157216,results,4,NA,Number of covariates adjusted for/matched on,7,8,6,FALSE,NA,NA,NA
10.1007/s12325-022-02054-z,35157216,results,4,NA,Covariates adjusted for/matched on in the indirect comparison,"Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Past treatments for the disease of interest, Other(s), Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...)","Age, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Past treatments for the disease of interest","Age, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Past treatments for the disease of interest",FALSE,NA,NA,NA
10.1007/s12325-022-02054-z,35157216,results,4,NA,Primary outcome: treatment effect contrast,NA,NA,RR,TRUE,NA,NA,NA
10.1007/s12325-022-02054-z,35157216,results,4,NA,Direction of the treatment effect contrast: IPD treatment is:,NA,NA,"Numerator if ratio, or left side if difference",TRUE,NA,NA,NA
10.1007/s12325-022-02054-z,35157216,results,4,NA,Primary outcome: unadjusted treatment effect,0.74,"0,47",0.74,FALSE,NA,NA,NA
10.1007/s12325-022-02054-z,35157216,results,4,NA,"p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])",<0.05,< 0.05,<0.05,FALSE,NA,NA,NA
10.1007/s12325-022-02054-z,35157216,results,4,NA,Primary outcome: adjusted treatment effect,0.65,"0,65",0.65,FALSE,NA,NA,NA
10.1007/s12325-022-02054-z,35157216,results,4,NA,"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])",<0.01,< 0.01,<0.01,FALSE,NA,NA,NA
10.2217/fon-2021-1102,35232230,general_information,NA,NA,Medical Condition of Interest Name,NA,NA,ros1-positive non-small-cell lung cancer,TRUE,NA,NA,NA
10.2217/fon-2021-1102,35232230,general_information,NA,NA,Countries of first author affiliations,NA,NA,usa,TRUE,NA,NA,NA
10.2217/fon-2021-1102,35232230,general_information,NA,NA,Countries of last author affiliations,NA,NA,usa,TRUE,NA,NA,NA
10.2217/fon-2021-1102,35232230,general_information,NA,NA,"Positions of study investigators (for any authors of the article, any that applies)","Academic, Private Data Analysis Company, Pharmaceutical Industry","Academic, Pharmaceutical Industry, Private Data Analysis Company",XXXX,FALSE,NA,NA,NA
10.2217/fon-2021-1102,35232230,general_information,NA,NA,"At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company",NA,NA,Yes,TRUE,NA,NA,NA
10.2217/fon-2021-1102,35232230,general_information,NA,NA,Mentioned sources of funding,NA,NA,Pharmaceutical Industry,TRUE,NA,NA,NA
10.2217/fon-2021-1102,35232230,general_information,NA,NA,"Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article",NA,NA,Yes,TRUE,NA,NA,NA
10.2217/fon-2021-1102,35232230,general_information,NA,NA,Mention of a systematic review to find the studies to compare treatments of interest,NA,NA,No,TRUE,NA,NA,NA
10.2217/fon-2021-1102,35232230,study_information,NA,1,Patient-level data used,NA,NA,Yes,TRUE,NA,NA,NA
10.2217/fon-2021-1102,35232230,study_information,NA,1,Clinical Trial,NA,NA,Yes,TRUE,NA,NA,NA
10.2217/fon-2021-1102,35232230,study_information,NA,1,NCT (only for clinical trial registered on clinicaltrials.gov),NA,NA,NCT00585195,TRUE,NA,NA,NA
10.2217/fon-2021-1102,35232230,study_information,NA,1,Country where the clinical trial/observational study was conducted (international if more than one),NA,NA,international,TRUE,NA,NA,NA
10.2217/fon-2021-1102,35232230,study_information,NA,1,Phase of the clinical trial (clinical trial only),NA,NA,1,TRUE,NA,NA,NA
10.2217/fon-2021-1102,35232230,study_information,NA,1,Number of treatment arms (clinical trial only),NA,NA,1,TRUE,NA,NA,NA
10.2217/fon-2021-1102,35232230,study_information,NA,2,Patient-level data used,NA,NA,No,TRUE,NA,NA,NA
10.2217/fon-2021-1102,35232230,study_information,NA,2,Clinical Trial,NA,NA,Yes,TRUE,NA,NA,NA
10.2217/fon-2021-1102,35232230,study_information,NA,2,EudraCT (only for clinical trials registered on clinicaltrialsregister.eu,NA,NA,2012-000148-88,TRUE,NA,NA,NA
10.2217/fon-2021-1102,35232230,study_information,NA,2,Country where the clinical trial/observational study was conducted (international if more than one),international,italy,XXXX,FALSE,NA,NA,NA
10.2217/fon-2021-1102,35232230,study_information,NA,2,Phase of the clinical trial (clinical trial only),NA,NA,1,TRUE,NA,NA,NA
10.2217/fon-2021-1102,35232230,study_information,NA,2,Number of treatment arms (clinical trial only),NA,NA,1,TRUE,NA,NA,NA
10.2217/fon-2021-1102,35232230,study_information,NA,3,Patient-level data used,No,Yes,XXXX,FALSE,NA,NA,NA
10.2217/fon-2021-1102,35232230,study_information,NA,3,Clinical Trial,NA,NA,Yes,TRUE,NA,NA,NA
10.2217/fon-2021-1102,35232230,study_information,NA,3,NCT (only for clinical trial registered on clinicaltrials.gov),NA,NA,NCT02097810,TRUE,NA,NA,NA
10.2217/fon-2021-1102,35232230,study_information,NA,3,Country where the clinical trial/observational study was conducted (international if more than one),NA,NA,international,TRUE,NA,NA,NA
10.2217/fon-2021-1102,35232230,study_information,NA,3,Phase of the clinical trial (clinical trial only),"1, 2",1,XXXX,FALSE,NA,NA,NA
10.2217/fon-2021-1102,35232230,study_information,NA,3,Number of treatment arms (clinical trial only),NA,NA,1,TRUE,NA,NA,NA
10.2217/fon-2021-1102,35232230,study_information,NA,4,Patient-level data used,NA,NA,No,TRUE,NA,NA,NA
10.2217/fon-2021-1102,35232230,study_information,NA,4,Clinical Trial,NA,NA,Yes,TRUE,NA,NA,NA
10.2217/fon-2021-1102,35232230,study_information,NA,4,NCT (only for clinical trial registered on clinicaltrials.gov),NCT02568267,NA,NCT02568267,FALSE,NA,NA,NA
10.2217/fon-2021-1102,35232230,study_information,NA,4,Country where the clinical trial/observational study was conducted (international if more than one),NA,NA,international,TRUE,NA,NA,NA
10.2217/fon-2021-1102,35232230,study_information,NA,4,Phase of the clinical trial (clinical trial only),NA,NA,2,TRUE,NA,NA,NA
10.2217/fon-2021-1102,35232230,study_information,NA,4,Number of treatment arms (clinical trial only),NA,NA,1,TRUE,NA,NA,NA
10.2217/fon-2021-1102,35232230,study_information,NA,5,Patient-level data used,NA,No,XXXX,FALSE,NA,NA,NA
10.2217/fon-2021-1102,35232230,study_information,NA,5,Clinical Trial,NA,No,XXXX,FALSE,NA,NA,NA
10.2217/fon-2021-1102,35232230,study_information,NA,5,Data source name (only if observational study or clinical trial without NCT),NA,flatiron health,flatiron health,FALSE,NA,NA,NA
10.2217/fon-2021-1102,35232230,study_information,NA,5,Country where the clinical trial/observational study was conducted (international if more than one),NA,usa,XXXX,FALSE,NA,NA,NA
10.2217/fon-2021-1102,35232230,study_information,NA,6,Patient-level data used,NA,NA,No,TRUE,NA,NA,NA
10.2217/fon-2021-1102,35232230,study_information,NA,6,Clinical Trial,NA,NA,No,TRUE,NA,NA,NA
10.2217/fon-2021-1102,35232230,study_information,NA,6,Data source name (only if observational study or clinical trial without NCT),NA,NA,ontada (oncology insights & technology),TRUE,NA,NA,NA
10.2217/fon-2021-1102,35232230,study_information,NA,6,Country where the clinical trial/observational study was conducted (international if more than one),NA,NA,usa,TRUE,NA,NA,NA
10.2217/fon-2021-1102,35232230,methodology,1,NA,Treatment name 1,NA,NA,crizotinib,TRUE,"Do an intersting secondary STC of clinical trials versus real world data

Ongoing clinical trial not published yet doing the same comparison as they do, so could be interesting to look at the actual result of this trial

Adding questions about EudraCT

Evaluates the imbalance in known prognostic factors and effect modifiers

Question about the distinction of prognostic factors and effect modifiers

Maybe reformulate in: 
        - Status of prognostic factors/effect modifiers
        - 

Reformulate 'study number' to 'study numbers'?

New questions to add: 
**
Justification for the need of a population adjusted indirect comparison: 
        - Presence of imbalance in effect modifiers between studies?
**

        - Mention imbalance in effect modifiers to justify population adjusted comparison
        - List the effect modifiers used to adjust the analysis
        - List the prognostic factors used to adjust the analysis


",Smoking status = other,NA
10.2217/fon-2021-1102,35232230,methodology,1,NA,Study 'number(s)' for treatment 1,NA,NA,1,TRUE,NA,NA,NA
10.2217/fon-2021-1102,35232230,methodology,1,NA,Treatment name 2,NA,NA,entrectinib,TRUE,NA,NA,NA
10.2217/fon-2021-1102,35232230,methodology,1,NA,Study 'number(s)' for treatment 2,NA,NA,2;3;4,TRUE,NA,NA,NA
10.2217/fon-2021-1102,35232230,methodology,1,NA,Type of population-adjusted indirect comparisons performed,NA,NA,STC,TRUE,NA,NA,NA
10.2217/fon-2021-1102,35232230,methodology,1,NA,Anchored comparison?,NA,NA,No,TRUE,NA,NA,NA
10.2217/fon-2021-1102,35232230,methodology,1,NA,Form of the indirect comparison,NA,NA,"Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate)",TRUE,NA,NA,NA
10.2217/fon-2021-1102,35232230,methodology,1,NA,Definition of a single primary outcome for the indirect comparison,NA,NA,"No primary outcome defined, or multiple primary outcomes without any clear distinction between them",TRUE,NA,NA,NA
10.2217/fon-2021-1102,35232230,methodology,1,NA,Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined),overall response rate,objective response rate (orr),objective response rate (orr),FALSE,NA,NA,NA
10.2217/fon-2021-1102,35232230,methodology,1,NA,Primary outcome: variable type,NA,NA,Binary (eg rates),TRUE,NA,NA,NA
10.2217/fon-2021-1102,35232230,methodology,1,NA,Justification for selecting variables to be included in the adjustment model (in the main text),A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion),"Statistical imbalanced between treatment groups (independently of the status of prognostic/effect modifier), A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion)","Statistical imbalanced between treatment groups (independently of the status of prognostic/effect modifier), A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion)",FALSE,NA,NA,NA
10.2217/fon-2021-1102,35232230,methodology,1,NA,Inclusion of prognostic factors in the adjustment/matching model,No discussion (in the main text) of the status of prognostic factors of the variables,Yes,Yes,FALSE,NA,NA,NA
10.2217/fon-2021-1102,35232230,methodology,1,NA,Inclusion of treatment-effect modifiers in the adjustment/matching model,No discussion (in the main text) of the status of treatment-effect modifiers of the variables,Yes,Yes,FALSE,NA,NA,NA
10.2217/fon-2021-1102,35232230,methodology,1,NA,"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)",NA,NA,No,TRUE,NA,NA,NA
10.2217/fon-2021-1102,35232230,methodology,1,NA,Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale),NA,NA,No,TRUE,NA,NA,NA
10.2217/fon-2021-1102,35232230,methodology,2,NA,Treatment name 1,NA,NA,crizotinib,TRUE,NA,Smoking status = other,NA
10.2217/fon-2021-1102,35232230,methodology,2,NA,Study 'number(s)' for treatment 1,NA,NA,1,TRUE,NA,NA,NA
10.2217/fon-2021-1102,35232230,methodology,2,NA,Treatment name 2,NA,NA,crizotinib,TRUE,NA,NA,NA
10.2217/fon-2021-1102,35232230,methodology,2,NA,Study 'number(s)' for treatment 2,NA,NA,5,TRUE,NA,NA,NA
10.2217/fon-2021-1102,35232230,methodology,2,NA,Type of population-adjusted indirect comparisons performed,NA,NA,STC,TRUE,NA,NA,NA
10.2217/fon-2021-1102,35232230,methodology,2,NA,Anchored comparison?,NA,NA,No,TRUE,NA,NA,NA
10.2217/fon-2021-1102,35232230,methodology,2,NA,Form of the indirect comparison,NA,NA,Simple (ie treatments effects extracted from two studies),TRUE,NA,NA,NA
10.2217/fon-2021-1102,35232230,methodology,2,NA,Definition of a single primary outcome for the indirect comparison,NA,NA,"No primary outcome defined, or multiple primary outcomes without any clear distinction between them",TRUE,NA,NA,NA
10.2217/fon-2021-1102,35232230,methodology,2,NA,Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined),progression free survival,progression-free survival,progression-free survival,FALSE,NA,NA,NA
10.2217/fon-2021-1102,35232230,methodology,2,NA,Primary outcome: variable type,NA,NA,Time-to-event,TRUE,NA,NA,NA
10.2217/fon-2021-1102,35232230,methodology,2,NA,Justification for selecting variables to be included in the adjustment model (in the main text),Literature based (clinically or methodologically relevant to adjust on these variables based on the literature search conducted for this specific purpose),"Statistical imbalanced between treatment groups (independently of the status of prognostic/effect modifier), A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion)","Statistical imbalanced between treatment groups (independently of the status of prognostic/effect modifier), A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion)",FALSE,NA,NA,NA
10.2217/fon-2021-1102,35232230,methodology,2,NA,Inclusion of prognostic factors in the adjustment/matching model,NA,NA,Yes,TRUE,NA,NA,NA
10.2217/fon-2021-1102,35232230,methodology,2,NA,Inclusion of treatment-effect modifiers in the adjustment/matching model,NA,NA,Yes,TRUE,NA,NA,NA
10.2217/fon-2021-1102,35232230,methodology,2,NA,"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)",NA,NA,No,TRUE,NA,NA,NA
10.2217/fon-2021-1102,35232230,methodology,2,NA,Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale),NA,NA,No,TRUE,NA,NA,NA
10.2217/fon-2021-1102,35232230,methodology,3,NA,Treatment name 1,NA,NA,crizotinib,TRUE,NA,Smoking status = other,NA
10.2217/fon-2021-1102,35232230,methodology,3,NA,Study 'number(s)' for treatment 1,NA,NA,1,TRUE,NA,NA,NA
10.2217/fon-2021-1102,35232230,methodology,3,NA,Treatment name 2,NA,NA,crizotinib,TRUE,NA,NA,NA
10.2217/fon-2021-1102,35232230,methodology,3,NA,Study 'number(s)' for treatment 2,NA,NA,6,TRUE,NA,NA,NA
10.2217/fon-2021-1102,35232230,methodology,3,NA,Type of population-adjusted indirect comparisons performed,NA,NA,STC,TRUE,NA,NA,NA
10.2217/fon-2021-1102,35232230,methodology,3,NA,Anchored comparison?,NA,NA,No,TRUE,NA,NA,NA
10.2217/fon-2021-1102,35232230,methodology,3,NA,Form of the indirect comparison,NA,NA,Simple (ie treatments effects extracted from two studies),TRUE,NA,NA,NA
10.2217/fon-2021-1102,35232230,methodology,3,NA,Definition of a single primary outcome for the indirect comparison,NA,NA,Yes,TRUE,NA,NA,NA
10.2217/fon-2021-1102,35232230,methodology,3,NA,Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined),NA,NA,overall survival,TRUE,NA,NA,NA
10.2217/fon-2021-1102,35232230,methodology,3,NA,Primary outcome: variable type,NA,NA,Time-to-event,TRUE,NA,NA,NA
10.2217/fon-2021-1102,35232230,methodology,3,NA,Justification for selecting variables to be included in the adjustment model (in the main text),Literature based (clinically or methodologically relevant to adjust on these variables based on the literature search conducted for this specific purpose),"Statistical imbalanced between treatment groups (independently of the status of prognostic/effect modifier), A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion)","Statistical imbalanced between treatment groups (independently of the status of prognostic/effect modifier), A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion)",FALSE,NA,NA,NA
10.2217/fon-2021-1102,35232230,methodology,3,NA,Inclusion of prognostic factors in the adjustment/matching model,NA,NA,Yes,TRUE,NA,NA,NA
10.2217/fon-2021-1102,35232230,methodology,3,NA,Inclusion of treatment-effect modifiers in the adjustment/matching model,NA,NA,Yes,TRUE,NA,NA,NA
10.2217/fon-2021-1102,35232230,methodology,3,NA,Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale),NA,NA,No,TRUE,NA,NA,NA
10.2217/fon-2021-1102,35232230,methodology,3,NA,"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)",NA,No,No,FALSE,NA,NA,NA
10.2217/fon-2021-1102,35232230,results,1,NA,Sample size of the population of interest in the non IPD treatment arm,NA,NA,161,TRUE,NA,NA,NA
10.2217/fon-2021-1102,35232230,results,1,NA,Initial sample size of the population of interest in the IPD treatment arm,NA,NA,53,TRUE,NA,NA,NA
10.2217/fon-2021-1102,35232230,results,1,NA,"Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC",NA,NA,53,TRUE,NA,NA,NA
10.2217/fon-2021-1102,35232230,results,1,NA,Reporting of the list of the covariates adjusted for/matched on,NA,NA,Yes,TRUE,NA,NA,NA
10.2217/fon-2021-1102,35232230,results,1,NA,Number of covariates adjusted for/matched on,NA,NA,4,TRUE,NA,NA,NA
10.2217/fon-2021-1102,35232230,results,1,NA,Covariates adjusted for/matched on in the indirect comparison,"Age, Sex, Comorbidities and medical history (beside pathology/disease of interest in the comparison), Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...)","Age, Sex, Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Other(s)","Age, Sex, Comorbidities and medical history (beside pathology/disease of interest in the comparison), Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...)",FALSE,NA,NA,NA
10.2217/fon-2021-1102,35232230,results,1,NA,Primary outcome: treatment effect contrast,NA,NA,RR,TRUE,NA,NA,NA
10.2217/fon-2021-1102,35232230,results,1,NA,Direction of the treatment effect contrast: IPD treatment is:,NA,NA,"Numerator if ratio, or left side if difference",TRUE,NA,NA,NA
10.2217/fon-2021-1102,35232230,results,1,NA,Primary outcome: unadjusted treatment effect,NA,NA,1.07,TRUE,NA,NA,NA
10.2217/fon-2021-1102,35232230,results,1,NA,"p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])",[0.88;1.31],[0.88–1.31],[0.88;1.31],FALSE,NA,NA,NA
10.2217/fon-2021-1102,35232230,results,1,NA,Primary outcome: adjusted treatment effect,NA,NA,1.04,TRUE,NA,NA,NA
10.2217/fon-2021-1102,35232230,results,1,NA,"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])",[0.85;1.28],[0.85–1.28],[0.85;1.28],FALSE,NA,NA,NA
10.2217/fon-2021-1102,35232230,results,2,NA,Sample size of the population of interest in the non IPD treatment arm,NA,NA,69,TRUE,NA,NA,NA
10.2217/fon-2021-1102,35232230,results,2,NA,Initial sample size of the population of interest in the IPD treatment arm,NA,NA,53,TRUE,NA,NA,NA
10.2217/fon-2021-1102,35232230,results,2,NA,"Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC",NA,NA,53,TRUE,NA,NA,NA
10.2217/fon-2021-1102,35232230,results,2,NA,Reporting of the list of the covariates adjusted for/matched on,NA,NA,Yes,TRUE,NA,NA,NA
10.2217/fon-2021-1102,35232230,results,2,NA,Number of covariates adjusted for/matched on,NA,NA,2,TRUE,NA,NA,NA
10.2217/fon-2021-1102,35232230,results,2,NA,Covariates adjusted for/matched on in the indirect comparison,"Other(s), Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...)","Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Other(s)","Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Other(s)",FALSE,NA,NA,NA
10.2217/fon-2021-1102,35232230,results,2,NA,Primary outcome: treatment effect contrast,Median difference,Means difference,Median difference,FALSE,NA,NA,NA
10.2217/fon-2021-1102,35232230,results,2,NA,Direction of the treatment effect contrast: IPD treatment is:,NA,NA,"Numerator if ratio, or left side if difference",TRUE,NA,NA,NA
10.2217/fon-2021-1102,35232230,results,2,NA,Primary outcome: unadjusted treatment effect,NA,NA,10.8,TRUE,NA,NA,NA
10.2217/fon-2021-1102,35232230,results,2,NA,Primary outcome: adjusted treatment effect,NA,NA,8.3,TRUE,NA,NA,NA
10.2217/fon-2021-1102,35232230,results,2,NA,"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])",0.26;16.94,[0.26;16.94],[0.26;16.94],FALSE,NA,NA,NA
10.2217/fon-2021-1102,35232230,results,3,NA,Sample size of the population of interest in the non IPD treatment arm,NA,NA,38,TRUE,NA,NA,NA
10.2217/fon-2021-1102,35232230,results,3,NA,Initial sample size of the population of interest in the IPD treatment arm,NA,NA,53,TRUE,NA,NA,NA
10.2217/fon-2021-1102,35232230,results,3,NA,"Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC",NA,NA,53,TRUE,NA,NA,NA
10.2217/fon-2021-1102,35232230,results,3,NA,Reporting of the list of the covariates adjusted for/matched on,NA,NA,Yes,TRUE,NA,NA,NA
10.2217/fon-2021-1102,35232230,results,3,NA,Number of covariates adjusted for/matched on,NA,NA,4,TRUE,NA,NA,NA
10.2217/fon-2021-1102,35232230,results,3,NA,Covariates adjusted for/matched on in the indirect comparison,"Age, Sex, Past treatments for the disease of interest, Other(s)","Age, Sex, Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Other(s)","Age, Sex, Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Comorbidities and medical history (beside pathology/disease of interest in the comparison)",FALSE,NA,NA,NA
10.2217/fon-2021-1102,35232230,results,3,NA,Primary outcome: treatment effect contrast,Median difference,Means difference,Median difference,FALSE,NA,NA,NA
10.2217/fon-2021-1102,35232230,results,3,NA,Direction of the treatment effect contrast: IPD treatment is:,NA,NA,"Numerator if ratio, or left side if difference",TRUE,NA,NA,NA
10.2217/fon-2021-1102,35232230,results,3,NA,Primary outcome: unadjusted treatment effect,NA,NA,15.2,TRUE,NA,NA,NA
10.2217/fon-2021-1102,35232230,results,3,NA,Primary outcome: adjusted treatment effect,NA,NA,-10.5,TRUE,NA,NA,NA
10.2217/fon-2021-1102,35232230,results,3,NA,Reporting of a weights' distribution evaluation (MAIC),NA,Not mentioned,Not mentioned,FALSE,NA,NA,NA
10.1080/10428194.2022.2047962,35289710,general_information,NA,NA,Medical Condition of Interest Name,10.1080/10428194.2022.2047962,multiple myeloma,XXXX,FALSE,NA,NA,NA
10.1080/10428194.2022.2047962,35289710,general_information,NA,NA,Countries of first author affiliations,NA,NA,germany,TRUE,NA,NA,NA
10.1080/10428194.2022.2047962,35289710,general_information,NA,NA,Countries of last author affiliations,NA,NA,usa,TRUE,NA,NA,NA
10.1080/10428194.2022.2047962,35289710,general_information,NA,NA,"Positions of study investigators (for any authors of the article, any that applies)",NA,NA,"Academic, Pharmaceutical Industry",TRUE,NA,NA,NA
10.1080/10428194.2022.2047962,35289710,general_information,NA,NA,"At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company",NA,NA,Yes,TRUE,NA,NA,NA
10.1080/10428194.2022.2047962,35289710,general_information,NA,NA,Mentioned sources of funding,NA,NA,Pharmaceutical Industry,TRUE,NA,NA,NA
10.1080/10428194.2022.2047962,35289710,general_information,NA,NA,"Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article",NA,NA,Yes,TRUE,NA,NA,NA
10.1080/10428194.2022.2047962,35289710,general_information,NA,NA,Mention of a systematic review to find the studies to compare treatments of interest,NA,NA,Yes,TRUE,NA,NA,NA
10.1080/10428194.2022.2047962,35289710,study_information,NA,1,Patient-level data used,NA,NA,Yes,TRUE,NA,NA,NA
10.1080/10428194.2022.2047962,35289710,study_information,NA,1,Clinical Trial,NA,NA,Yes,TRUE,NA,NA,NA
10.1080/10428194.2022.2047962,35289710,study_information,NA,1,NCT (only for clinical trial registered on clinicaltrials.gov),NA,NA,NCT03158688,TRUE,NA,NA,NA
10.1080/10428194.2022.2047962,35289710,study_information,NA,1,Country where the clinical trial/observational study was conducted (international if more than one),NA,NA,international,TRUE,NA,NA,NA
10.1080/10428194.2022.2047962,35289710,study_information,NA,1,Phase of the clinical trial (clinical trial only),NA,NA,3,TRUE,NA,NA,NA
10.1080/10428194.2022.2047962,35289710,study_information,NA,1,Number of treatment arms (clinical trial only),NA,NA,2 or more,TRUE,NA,NA,NA
10.1080/10428194.2022.2047962,35289710,study_information,NA,2,Patient-level data used,NA,NA,No,TRUE,NA,NA,NA
10.1080/10428194.2022.2047962,35289710,study_information,NA,2,Clinical Trial,NA,NA,Yes,TRUE,NA,NA,NA
10.1080/10428194.2022.2047962,35289710,study_information,NA,2,NCT (only for clinical trial registered on clinicaltrials.gov),NA,NA,NCT02136134,TRUE,NA,NA,NA
10.1080/10428194.2022.2047962,35289710,study_information,NA,2,Country where the clinical trial/observational study was conducted (international if more than one),NA,NA,international,TRUE,NA,NA,NA
10.1080/10428194.2022.2047962,35289710,study_information,NA,2,Phase of the clinical trial (clinical trial only),NA,NA,3,TRUE,NA,NA,NA
10.1080/10428194.2022.2047962,35289710,study_information,NA,2,Number of treatment arms (clinical trial only),NA,NA,2 or more,TRUE,NA,NA,NA
10.1080/10428194.2022.2047962,35289710,methodology,1,NA,Treatment name 1,carfizomib + dexamethasone+daratumumab,carfilzomib + dexamethasone + daratumumab (kdd),carfizomib + dexamethasone+daratumumab,FALSE,"No mention of treatment effect modifiers
One primary outcome, evaluated at different times (6,12,18 months), but so only one HR reported for the whole duration of the followup","""Details of the variable selection process have been described previously""",NA
10.1080/10428194.2022.2047962,35289710,methodology,1,NA,Study 'number(s)' for treatment 1,NA,NA,1,TRUE,NA,NA,NA
10.1080/10428194.2022.2047962,35289710,methodology,1,NA,Treatment name 2,daratumumab + velcade+dexamethasone,daratumumab + bortezomib + dexamethasone (dvd):,daratumumab + velcade+dexamethasone,FALSE,NA,NA,NA
10.1080/10428194.2022.2047962,35289710,methodology,1,NA,Study 'number(s)' for treatment 2,NA,NA,2,TRUE,NA,NA,NA
10.1080/10428194.2022.2047962,35289710,methodology,1,NA,Type of population-adjusted indirect comparisons performed,NA,NA,MAIC,TRUE,NA,NA,NA
10.1080/10428194.2022.2047962,35289710,methodology,1,NA,Anchored comparison?,NA,NA,No,TRUE,NA,NA,NA
10.1080/10428194.2022.2047962,35289710,methodology,1,NA,Form of the indirect comparison,NA,NA,Simple (ie treatments effects extracted from two studies),TRUE,NA,NA,NA
10.1080/10428194.2022.2047962,35289710,methodology,1,NA,Definition of a single primary outcome for the indirect comparison,NA,NA,Yes,TRUE,NA,NA,NA
10.1080/10428194.2022.2047962,35289710,methodology,1,NA,Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined),progression free survival,progression-free survival,progression-free survival,FALSE,NA,NA,NA
10.1080/10428194.2022.2047962,35289710,methodology,1,NA,Primary outcome: variable type,NA,NA,Time-to-event,TRUE,NA,NA,NA
10.1080/10428194.2022.2047962,35289710,methodology,1,NA,Justification for selecting variables to be included in the adjustment model (in the main text),NA,NA,A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion),TRUE,NA,NA,NA
10.1080/10428194.2022.2047962,35289710,methodology,1,NA,Inclusion of prognostic factors in the adjustment/matching model,NA,NA,Yes,TRUE,NA,NA,NA
10.1080/10428194.2022.2047962,35289710,methodology,1,NA,Inclusion of treatment-effect modifiers in the adjustment/matching model,NA,NA,No discussion (in the main text) of the status of treatment-effect modifiers of the variables,TRUE,NA,NA,NA
10.1080/10428194.2022.2047962,35289710,methodology,1,NA,"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)",NA,NA,No,TRUE,NA,NA,NA
10.1080/10428194.2022.2047962,35289710,methodology,1,NA,Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale),NA,NA,No,TRUE,NA,NA,NA
10.1080/10428194.2022.2047962,35289710,results,1,NA,Sample size of the population of interest in the non IPD treatment arm,NA,NA,251,TRUE,NA,NA,NA
10.1080/10428194.2022.2047962,35289710,results,1,NA,Initial sample size of the population of interest in the IPD treatment arm,NA,NA,198,TRUE,NA,NA,NA
10.1080/10428194.2022.2047962,35289710,results,1,NA,"Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC",NA,NA,82,TRUE,NA,NA,NA
10.1080/10428194.2022.2047962,35289710,results,1,NA,Reporting of a weights' distribution evaluation (MAIC),"Yes, mentions that the weights distribution has been studied, and weights distribution reported in main article or supplemental materials",Not mentioned,Not mentioned,FALSE,NA,NA,NA
10.1080/10428194.2022.2047962,35289710,results,1,NA,Reporting of the list of the covariates adjusted for/matched on,NA,NA,Yes,TRUE,NA,NA,NA
10.1080/10428194.2022.2047962,35289710,results,1,NA,Number of covariates adjusted for/matched on,NA,NA,10,TRUE,NA,NA,NA
10.1080/10428194.2022.2047962,35289710,results,1,NA,Covariates adjusted for/matched on in the indirect comparison,"Age, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Past treatments for the disease of interest, Comorbidities and medical history (beside pathology/disease of interest in the comparison), Other(s)","Age, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Past treatments for the disease of interest, Comorbidities and medical history (beside pathology/disease of interest in the comparison)","Age, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Past treatments for the disease of interest, Comorbidities and medical history (beside pathology/disease of interest in the comparison), Other(s)",FALSE,NA,NA,NA
10.1080/10428194.2022.2047962,35289710,results,1,NA,Primary outcome: treatment effect contrast,NA,NA,HR,TRUE,NA,NA,NA
10.1080/10428194.2022.2047962,35289710,results,1,NA,Direction of the treatment effect contrast: IPD treatment is:,"Numerator if ratio, or left side if difference",NA,"Numerator if ratio, or left side if difference",FALSE,NA,NA,NA
10.1080/10428194.2022.2047962,35289710,results,1,NA,Primary outcome: unadjusted treatment effect,NA,NA,0.54,TRUE,NA,NA,NA
10.1080/10428194.2022.2047962,35289710,results,1,NA,"p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])",[.41;0.70],[0.41;0.70],[0.41;0.70],FALSE,NA,NA,NA
10.1080/10428194.2022.2047962,35289710,results,1,NA,Primary outcome: adjusted treatment effect,NA,NA,0.64,TRUE,NA,NA,NA
10.1080/10428194.2022.2047962,35289710,results,1,NA,"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])",NA,NA,[0.46;0.90],TRUE,NA,NA,NA
10.1111/bjd.16140,29171861,general_information,NA,NA,Medical Condition of Interest Name,NA,NA,moderate-to-severe plaque psoriasis,TRUE,NA,NA,NA
10.1111/bjd.16140,29171861,general_information,NA,NA,Countries of first author affiliations,NA,NA,uk,TRUE,NA,NA,NA
10.1111/bjd.16140,29171861,general_information,NA,NA,Countries of last author affiliations,NA,NA,germany,TRUE,NA,NA,NA
10.1111/bjd.16140,29171861,general_information,NA,NA,"Positions of study investigators (for any authors of the article, any that applies)",NA,NA,"Academic, Pharmaceutical Industry",TRUE,NA,NA,NA
10.1111/bjd.16140,29171861,general_information,NA,NA,"At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company",Yes,Not mentioned,Not mentioned,FALSE,NA,NA,NA
10.1111/bjd.16140,29171861,general_information,NA,NA,Mentioned sources of funding,NA,NA,Pharmaceutical Industry,TRUE,NA,NA,NA
10.1111/bjd.16140,29171861,general_information,NA,NA,"Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article",NA,NA,Yes,TRUE,NA,NA,NA
10.1111/bjd.16140,29171861,general_information,NA,NA,Mention of a systematic review to find the studies to compare treatments of interest,NA,NA,Yes,TRUE,NA,NA,NA
10.1111/bjd.16140,29171861,study_information,NA,xx,Patient-level data used,NA,NA,Yes,TRUE,NA,NA,NA
10.1111/bjd.16140,29171861,study_information,NA,xx,Clinical Trial,NA,NA,Yes,TRUE,NA,NA,NA
10.1111/bjd.16140,29171861,study_information,NA,xx,NCT (only for clinical trial registered on clinicaltrials.gov),NA,NA,NCT01474512,TRUE,NA,NA,NA
10.1111/bjd.16140,29171861,study_information,NA,xx,Country where the clinical trial/observational study was conducted (international if more than one),NA,NA,international,TRUE,NA,NA,NA
10.1111/bjd.16140,29171861,study_information,NA,xx,Phase of the clinical trial (clinical trial only),NA,NA,3,TRUE,NA,NA,NA
10.1111/bjd.16140,29171861,study_information,NA,xx,Number of treatment arms (clinical trial only),NA,NA,2 or more,TRUE,NA,NA,NA
10.1111/bjd.16140,29171861,study_information,NA,2,Patient-level data used,NA,NA,Yes,TRUE,NA,NA,NA
10.1111/bjd.16140,29171861,study_information,NA,2,Clinical Trial,NA,NA,Yes,TRUE,NA,NA,NA
10.1111/bjd.16140,29171861,study_information,NA,2,NCT (only for clinical trial registered on clinicaltrials.gov),NA,NA,NCT01597245,TRUE,NA,NA,NA
10.1111/bjd.16140,29171861,study_information,NA,2,Country where the clinical trial/observational study was conducted (international if more than one),NA,NA,international,TRUE,NA,NA,NA
10.1111/bjd.16140,29171861,study_information,NA,2,Phase of the clinical trial (clinical trial only),NA,NA,3,TRUE,NA,NA,NA
10.1111/bjd.16140,29171861,study_information,NA,2,Number of treatment arms (clinical trial only),NA,NA,2 or more,TRUE,NA,NA,NA
10.1111/bjd.16140,29171861,study_information,NA,3,Patient-level data used,NA,NA,Yes,TRUE,NA,NA,NA
10.1111/bjd.16140,29171861,study_information,NA,3,Clinical Trial,NA,NA,Yes,TRUE,NA,NA,NA
10.1111/bjd.16140,29171861,study_information,NA,3,NCT (only for clinical trial registered on clinicaltrials.gov),NA,NA,NCT01646177,TRUE,NA,NA,NA
10.1111/bjd.16140,29171861,study_information,NA,3,Country where the clinical trial/observational study was conducted (international if more than one),NA,international,international,FALSE,NA,NA,NA
10.1111/bjd.16140,29171861,study_information,NA,3,Phase of the clinical trial (clinical trial only),NA,NA,3,TRUE,NA,NA,NA
10.1111/bjd.16140,29171861,study_information,NA,3,Number of treatment arms (clinical trial only),NA,NA,2 or more,TRUE,NA,NA,NA
10.1111/bjd.16140,29171861,study_information,NA,4,Patient-level data used,NA,NA,Yes,TRUE,NA,NA,NA
10.1111/bjd.16140,29171861,study_information,NA,4,Clinical Trial,NA,NA,Yes,TRUE,NA,NA,NA
10.1111/bjd.16140,29171861,study_information,NA,4,NCT (only for clinical trial registered on clinicaltrials.gov),NA,NA,NCT02561806,TRUE,NA,NA,NA
10.1111/bjd.16140,29171861,study_information,NA,4,Country where the clinical trial/observational study was conducted (international if more than one),NA,NA,international,TRUE,NA,NA,NA
10.1111/bjd.16140,29171861,study_information,NA,4,Phase of the clinical trial (clinical trial only),NA,NA,3,TRUE,NA,NA,NA
10.1111/bjd.16140,29171861,study_information,NA,4,Number of treatment arms (clinical trial only),NA,NA,2 or more,TRUE,NA,NA,NA
10.1111/bjd.16140,29171861,study_information,NA,5,Patient-level data used,NA,NA,No,TRUE,NA,NA,NA
10.1111/bjd.16140,29171861,study_information,NA,5,Clinical Trial,NA,NA,Yes,TRUE,NA,NA,NA
10.1111/bjd.16140,29171861,study_information,NA,5,NCT (only for clinical trial registered on clinicaltrials.gov),NA,NA,NCT01358578,TRUE,NA,NA,NA
10.1111/bjd.16140,29171861,study_information,NA,5,Country where the clinical trial/observational study was conducted (international if more than one),NA,NA,international,TRUE,NA,NA,NA
10.1111/bjd.16140,29171861,study_information,NA,5,Phase of the clinical trial (clinical trial only),NA,NA,3,TRUE,NA,NA,NA
10.1111/bjd.16140,29171861,study_information,NA,5,Number of treatment arms (clinical trial only),NA,NA,2 or more,TRUE,NA,NA,NA
10.1111/bjd.16140,29171861,study_information,NA,xx,Patient-level data used,NA,NA,No,TRUE,NA,NA,NA
10.1111/bjd.16140,29171861,study_information,NA,xx,Clinical Trial,NA,NA,Yes,TRUE,NA,NA,NA
10.1111/bjd.16140,29171861,study_information,NA,xx,NCT (only for clinical trial registered on clinicaltrials.gov),NA,NA,NCT01365455,TRUE,NA,NA,NA
10.1111/bjd.16140,29171861,study_information,NA,xx,Country where the clinical trial/observational study was conducted (international if more than one),NA,NA,international,TRUE,NA,NA,NA
10.1111/bjd.16140,29171861,study_information,NA,xx,Phase of the clinical trial (clinical trial only),NA,NA,3,TRUE,NA,NA,NA
10.1111/bjd.16140,29171861,study_information,NA,xx,Number of treatment arms (clinical trial only),NA,NA,2 or more,TRUE,NA,NA,NA
10.1111/bjd.16140,29171861,study_information,NA,xx,Patient-level data used,NA,NA,No,TRUE,NA,NA,NA
10.1111/bjd.16140,29171861,study_information,NA,xx,Clinical Trial,NA,NA,Yes,TRUE,NA,NA,NA
10.1111/bjd.16140,29171861,study_information,NA,xx,NCT (only for clinical trial registered on clinicaltrials.gov),NA,NA,NCT01555125,TRUE,NA,NA,NA
10.1111/bjd.16140,29171861,study_information,NA,xx,Country where the clinical trial/observational study was conducted (international if more than one),NA,NA,international,TRUE,NA,NA,NA
10.1111/bjd.16140,29171861,study_information,NA,xx,Phase of the clinical trial (clinical trial only),NA,NA,3,TRUE,NA,NA,NA
10.1111/bjd.16140,29171861,study_information,NA,xx,Number of treatment arms (clinical trial only),NA,NA,2 or more,TRUE,NA,NA,NA
10.1111/bjd.16140,29171861,study_information,NA,xx,Patient-level data used,NA,NA,No,TRUE,NA,NA,NA
10.1111/bjd.16140,29171861,study_information,NA,xx,Clinical Trial,NA,NA,Yes,TRUE,NA,NA,NA
10.1111/bjd.16140,29171861,study_information,NA,xx,NCT (only for clinical trial registered on clinicaltrials.gov),NA,NA,NCT01636687,TRUE,NA,NA,NA
10.1111/bjd.16140,29171861,study_information,NA,xx,Country where the clinical trial/observational study was conducted (international if more than one),NA,NA,international,TRUE,NA,NA,NA
10.1111/bjd.16140,29171861,study_information,NA,xx,Phase of the clinical trial (clinical trial only),NA,NA,3,TRUE,NA,NA,NA
10.1111/bjd.16140,29171861,study_information,NA,xx,Number of treatment arms (clinical trial only),NA,NA,2 or more,TRUE,NA,NA,NA
10.1111/bjd.16140,29171861,study_information,NA,9,Patient-level data used,NA,NA,No,TRUE,NA,NA,NA
10.1111/bjd.16140,29171861,study_information,NA,9,Clinical Trial,NA,NA,Yes,TRUE,NA,NA,NA
10.1111/bjd.16140,29171861,study_information,NA,9,NCT (only for clinical trial registered on clinicaltrials.gov),NA,NA,NCT02074982,TRUE,NA,NA,NA
10.1111/bjd.16140,29171861,study_information,NA,9,Country where the clinical trial/observational study was conducted (international if more than one),NA,NA,international,TRUE,NA,NA,NA
10.1111/bjd.16140,29171861,study_information,NA,9,Phase of the clinical trial (clinical trial only),NA,NA,3,TRUE,NA,NA,NA
10.1111/bjd.16140,29171861,study_information,NA,9,Number of treatment arms (clinical trial only),NA,NA,2 or more,TRUE,NA,NA,NA
10.1111/bjd.16140,29171861,methodology,xx,NA,Treatment name 1,NA,NA,ixekizumab,TRUE,"SG total placeboanchored
Sample sizes reported for both treatment and anchored arm together","weights calculation for the IPD is based on mean values of covariates for total population (SG total).
Commun comparator = Placebo
covariates : weight = other",NA
10.1111/bjd.16140,29171861,methodology,xx,NA,Study 'number(s)' for treatment 1,NA,NA,1;2;3,TRUE,NA,NA,NA
10.1111/bjd.16140,29171861,methodology,xx,NA,Treatment name 2,NA,NA,secukinumab,TRUE,NA,NA,NA
10.1111/bjd.16140,29171861,methodology,xx,NA,Study 'number(s)' for treatment 2,NA,NA,5;6;7;8,TRUE,NA,NA,NA
10.1111/bjd.16140,29171861,methodology,xx,NA,Type of population-adjusted indirect comparisons performed,NA,NA,MAIC,TRUE,NA,NA,NA
10.1111/bjd.16140,29171861,methodology,xx,NA,Anchored comparison?,NA,NA,Yes,TRUE,NA,NA,NA
10.1111/bjd.16140,29171861,methodology,xx,NA,Form of the indirect comparison,NA,NA,"Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate)",TRUE,NA,NA,NA
10.1111/bjd.16140,29171861,methodology,xx,NA,Definition of a single primary outcome for the indirect comparison,NA,NA,"No primary outcome defined, or multiple primary outcomes without any clear distinction between them",TRUE,NA,NA,NA
10.1111/bjd.16140,29171861,methodology,xx,NA,Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined),pasi 75 at week 12,psoriasis area severity index 75 response rate at week 12,psoriasis area severity index 75 response rate at week 12,FALSE,NA,NA,NA
10.1111/bjd.16140,29171861,methodology,xx,NA,Primary outcome: variable type,NA,NA,Binary (eg rates),TRUE,NA,NA,NA
10.1111/bjd.16140,29171861,methodology,xx,NA,Justification for selecting variables to be included in the adjustment model (in the main text),NA,NA,"Nothing mentioned, not reported",TRUE,NA,NA,NA
10.1111/bjd.16140,29171861,methodology,xx,NA,Inclusion of prognostic factors in the adjustment/matching model,No discussion (in the main text) of the status of prognostic factors of the variables,No,No,FALSE,NA,NA,NA
10.1111/bjd.16140,29171861,methodology,xx,NA,Inclusion of treatment-effect modifiers in the adjustment/matching model,NA,NA,Yes,TRUE,NA,NA,NA
10.1111/bjd.16140,29171861,methodology,xx,NA,"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)",No,Yes,No,FALSE,NA,NA,NA
10.1111/bjd.16140,29171861,methodology,xx,NA,Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale),NA,NA,No,TRUE,NA,NA,NA
10.1111/bjd.16140,29171861,methodology,xx,NA,Treatment name 1,NA,NA,ixekizumab,TRUE,"SG separate placebo anchored
Sample sizes reported for both treatment and anchored arm together","weights calculation for the IPD is based on mean values of covariates for each treatment arm separately (SG separate).
Commun comparator = Placebo
covariates : weight = other",NA
10.1111/bjd.16140,29171861,methodology,xx,NA,Study 'number(s)' for treatment 1,NA,NA,1;2;3,TRUE,NA,NA,NA
10.1111/bjd.16140,29171861,methodology,xx,NA,Treatment name 2,NA,NA,secukinumab,TRUE,NA,NA,NA
10.1111/bjd.16140,29171861,methodology,xx,NA,Study 'number(s)' for treatment 2,NA,NA,5;6;7;8,TRUE,NA,NA,NA
10.1111/bjd.16140,29171861,methodology,xx,NA,Type of population-adjusted indirect comparisons performed,NA,NA,MAIC,TRUE,NA,NA,NA
10.1111/bjd.16140,29171861,methodology,xx,NA,Anchored comparison?,NA,NA,Yes,TRUE,NA,NA,NA
10.1111/bjd.16140,29171861,methodology,xx,NA,Form of the indirect comparison,NA,NA,"Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate)",TRUE,NA,NA,NA
10.1111/bjd.16140,29171861,methodology,xx,NA,Definition of a single primary outcome for the indirect comparison,NA,NA,"No primary outcome defined, or multiple primary outcomes without any clear distinction between them",TRUE,NA,NA,NA
10.1111/bjd.16140,29171861,methodology,xx,NA,Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined),pasi 75 at week 12,psoriasis area severity index 75 response rate at week 12,psoriasis area severity index 75 response rate at week 12,FALSE,NA,NA,NA
10.1111/bjd.16140,29171861,methodology,xx,NA,Primary outcome: variable type,NA,NA,Binary (eg rates),TRUE,NA,NA,NA
10.1111/bjd.16140,29171861,methodology,xx,NA,Justification for selecting variables to be included in the adjustment model (in the main text),NA,NA,"Nothing mentioned, not reported",TRUE,NA,NA,NA
10.1111/bjd.16140,29171861,methodology,xx,NA,Inclusion of prognostic factors in the adjustment/matching model,No discussion (in the main text) of the status of prognostic factors of the variables,No,No discussion (in the main text) of the status of prognostic factors of the variables,FALSE,NA,NA,NA
10.1111/bjd.16140,29171861,methodology,xx,NA,Inclusion of treatment-effect modifiers in the adjustment/matching model,NA,NA,Yes,TRUE,NA,NA,NA
10.1111/bjd.16140,29171861,methodology,xx,NA,"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)",NA,NA,No,TRUE,NA,NA,NA
10.1111/bjd.16140,29171861,methodology,xx,NA,Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale),NA,NA,No,TRUE,NA,NA,NA
10.1111/bjd.16140,29171861,methodology,3,NA,Treatment name 1,NA,NA,ixekizumab,TRUE,"SG total etanercept anchored
Sample sizes reported for both treatment and anchored arm together","weights calculation for the IPD is based on mean values of covariates for total population (SG total).
Commun comparator = Etanercept
covariates : weight = other",NA
10.1111/bjd.16140,29171861,methodology,3,NA,Study 'number(s)' for treatment 1,NA,NA,2;3,TRUE,NA,NA,NA
10.1111/bjd.16140,29171861,methodology,3,NA,Treatment name 2,NA,NA,secukinumab,TRUE,NA,NA,NA
10.1111/bjd.16140,29171861,methodology,3,NA,Study 'number(s)' for treatment 2,NA,NA,5,TRUE,NA,NA,NA
10.1111/bjd.16140,29171861,methodology,3,NA,Type of population-adjusted indirect comparisons performed,NA,NA,MAIC,TRUE,NA,NA,NA
10.1111/bjd.16140,29171861,methodology,3,NA,Anchored comparison?,NA,NA,Yes,TRUE,NA,NA,NA
10.1111/bjd.16140,29171861,methodology,3,NA,Form of the indirect comparison,NA,NA,"Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate)",TRUE,NA,NA,NA
10.1111/bjd.16140,29171861,methodology,3,NA,Definition of a single primary outcome for the indirect comparison,NA,NA,"No primary outcome defined, or multiple primary outcomes without any clear distinction between them",TRUE,NA,NA,NA
10.1111/bjd.16140,29171861,methodology,3,NA,Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined),pasi 75 at week 12,psoriasis area severity index 75 response rate at week 12,psoriasis area severity index 75 response rate at week 12,FALSE,NA,NA,NA
10.1111/bjd.16140,29171861,methodology,3,NA,Primary outcome: variable type,NA,NA,Binary (eg rates),TRUE,NA,NA,NA
10.1111/bjd.16140,29171861,methodology,3,NA,Justification for selecting variables to be included in the adjustment model (in the main text),NA,NA,"Nothing mentioned, not reported",TRUE,NA,NA,NA
10.1111/bjd.16140,29171861,methodology,3,NA,Inclusion of prognostic factors in the adjustment/matching model,No discussion (in the main text) of the status of prognostic factors of the variables,No,No discussion (in the main text) of the status of prognostic factors of the variables,FALSE,NA,NA,NA
10.1111/bjd.16140,29171861,methodology,3,NA,Inclusion of treatment-effect modifiers in the adjustment/matching model,NA,NA,No discussion (in the main text) of the status of treatment-effect modifiers of the variables,TRUE,NA,NA,NA
10.1111/bjd.16140,29171861,methodology,3,NA,"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)",NA,NA,No,TRUE,NA,NA,NA
10.1111/bjd.16140,29171861,methodology,3,NA,Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale),NA,NA,No,TRUE,NA,NA,NA
10.1111/bjd.16140,29171861,methodology,xx,NA,Treatment name 1,NA,NA,ixekizumab,TRUE,"SG separate etanercept anchored
Sample sizes reported for both treatment and anchored arm together","weights calculation for the IPD is based on mean values of covariates for each treatment arm separately (SG separate).
Commun comparator = Etanercept
covariates : weight = other",NA
10.1111/bjd.16140,29171861,methodology,xx,NA,Study 'number(s)' for treatment 1,NA,NA,2;3,TRUE,NA,NA,NA
10.1111/bjd.16140,29171861,methodology,xx,NA,Treatment name 2,NA,NA,secukinumab,TRUE,NA,NA,NA
10.1111/bjd.16140,29171861,methodology,xx,NA,Study 'number(s)' for treatment 2,NA,NA,5,TRUE,NA,NA,NA
10.1111/bjd.16140,29171861,methodology,xx,NA,Type of population-adjusted indirect comparisons performed,NA,NA,MAIC,TRUE,NA,NA,NA
10.1111/bjd.16140,29171861,methodology,xx,NA,Anchored comparison?,NA,NA,Yes,TRUE,NA,NA,NA
10.1111/bjd.16140,29171861,methodology,xx,NA,Form of the indirect comparison,NA,NA,"Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate)",TRUE,NA,NA,NA
10.1111/bjd.16140,29171861,methodology,xx,NA,Definition of a single primary outcome for the indirect comparison,NA,NA,"No primary outcome defined, or multiple primary outcomes without any clear distinction between them",TRUE,NA,NA,NA
10.1111/bjd.16140,29171861,methodology,xx,NA,Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined),pasi 75 at week 12,psoriasis area severity index 75 response rate at week 12,psoriasis area severity index 75 response rate at week 12,FALSE,NA,NA,NA
10.1111/bjd.16140,29171861,methodology,xx,NA,Primary outcome: variable type,NA,NA,Binary (eg rates),TRUE,NA,NA,NA
10.1111/bjd.16140,29171861,methodology,xx,NA,Justification for selecting variables to be included in the adjustment model (in the main text),NA,NA,"Nothing mentioned, not reported",TRUE,NA,NA,NA
10.1111/bjd.16140,29171861,methodology,xx,NA,Inclusion of prognostic factors in the adjustment/matching model,No discussion (in the main text) of the status of prognostic factors of the variables,No,No discussion (in the main text) of the status of prognostic factors of the variables,FALSE,NA,NA,NA
10.1111/bjd.16140,29171861,methodology,xx,NA,Inclusion of treatment-effect modifiers in the adjustment/matching model,NA,NA,Yes,TRUE,NA,NA,NA
10.1111/bjd.16140,29171861,methodology,xx,NA,"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)",NA,NA,No,TRUE,NA,NA,NA
10.1111/bjd.16140,29171861,methodology,xx,NA,Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale),NA,NA,No,TRUE,NA,NA,NA
10.1111/bjd.16140,29171861,methodology,5,NA,Treatment name 1,NA,NA,ixekizumab,TRUE,"SG total ustekinumab anchored
Sample sizes reported for both treatment and anchored arm together","weights calculation for the IPD is based on mean values of covariates for total population (SG total).
Commun comparator = Ustekinumab
covariates : weight = other",NA
10.1111/bjd.16140,29171861,methodology,5,NA,Study 'number(s)' for treatment 1,NA,NA,4,TRUE,NA,NA,NA
10.1111/bjd.16140,29171861,methodology,5,NA,Treatment name 2,NA,NA,secukinumab,TRUE,NA,NA,NA
10.1111/bjd.16140,29171861,methodology,5,NA,Study 'number(s)' for treatment 2,NA,NA,9,TRUE,NA,NA,NA
10.1111/bjd.16140,29171861,methodology,5,NA,Type of population-adjusted indirect comparisons performed,NA,NA,MAIC,TRUE,NA,NA,NA
10.1111/bjd.16140,29171861,methodology,5,NA,Anchored comparison?,NA,NA,Yes,TRUE,NA,NA,NA
10.1111/bjd.16140,29171861,methodology,5,NA,Form of the indirect comparison,NA,NA,Simple (ie treatments effects extracted from two studies),TRUE,NA,NA,NA
10.1111/bjd.16140,29171861,methodology,5,NA,Definition of a single primary outcome for the indirect comparison,NA,NA,"No primary outcome defined, or multiple primary outcomes without any clear distinction between them",TRUE,NA,NA,NA
10.1111/bjd.16140,29171861,methodology,5,NA,Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined),pasi 75 at week 12,psoriasis area severity index 75 response rate at week 12,psoriasis area severity index 75 response rate at week 12,FALSE,NA,NA,NA
10.1111/bjd.16140,29171861,methodology,5,NA,Primary outcome: variable type,NA,NA,Binary (eg rates),TRUE,NA,NA,NA
10.1111/bjd.16140,29171861,methodology,5,NA,Justification for selecting variables to be included in the adjustment model (in the main text),NA,NA,"Nothing mentioned, not reported",TRUE,NA,NA,NA
10.1111/bjd.16140,29171861,methodology,5,NA,Inclusion of prognostic factors in the adjustment/matching model,No discussion (in the main text) of the status of prognostic factors of the variables,No,No discussion (in the main text) of the status of prognostic factors of the variables,FALSE,NA,NA,NA
10.1111/bjd.16140,29171861,methodology,5,NA,Inclusion of treatment-effect modifiers in the adjustment/matching model,NA,NA,No discussion (in the main text) of the status of treatment-effect modifiers of the variables,TRUE,NA,NA,NA
10.1111/bjd.16140,29171861,methodology,5,NA,"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)",NA,NA,No,TRUE,NA,NA,NA
10.1111/bjd.16140,29171861,methodology,5,NA,Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale),NA,NA,No,TRUE,NA,NA,NA
10.1111/bjd.16140,29171861,methodology,xx,NA,Treatment name 1,NA,NA,ixekizumab,TRUE,"SG separate ustekinumab anchored
Sample sizes reported for both treatment and anchored arm together","weights calculation for the IPD is based on mean values of covariates for each treatment arm separately (SG separate).
Commun comparator = Ustekinumab
covariates : weight = other",NA
10.1111/bjd.16140,29171861,methodology,xx,NA,Study 'number(s)' for treatment 1,NA,NA,4,TRUE,NA,NA,NA
10.1111/bjd.16140,29171861,methodology,xx,NA,Treatment name 2,NA,NA,secukinumab,TRUE,NA,NA,NA
10.1111/bjd.16140,29171861,methodology,xx,NA,Study 'number(s)' for treatment 2,9,6,9,FALSE,NA,NA,NA
10.1111/bjd.16140,29171861,methodology,xx,NA,Type of population-adjusted indirect comparisons performed,NA,NA,MAIC,TRUE,NA,NA,NA
10.1111/bjd.16140,29171861,methodology,xx,NA,Anchored comparison?,NA,NA,Yes,TRUE,NA,NA,NA
10.1111/bjd.16140,29171861,methodology,xx,NA,Form of the indirect comparison,NA,NA,Simple (ie treatments effects extracted from two studies),TRUE,NA,NA,NA
10.1111/bjd.16140,29171861,methodology,xx,NA,Definition of a single primary outcome for the indirect comparison,NA,NA,"No primary outcome defined, or multiple primary outcomes without any clear distinction between them",TRUE,NA,NA,NA
10.1111/bjd.16140,29171861,methodology,xx,NA,Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined),pasi 75 at week 12,psoriasis area severity index 75 response rate at week 12,psoriasis area severity index 75 response rate at week 12,FALSE,NA,NA,NA
10.1111/bjd.16140,29171861,methodology,xx,NA,Primary outcome: variable type,NA,NA,Binary (eg rates),TRUE,NA,NA,NA
10.1111/bjd.16140,29171861,methodology,xx,NA,Justification for selecting variables to be included in the adjustment model (in the main text),NA,NA,"Nothing mentioned, not reported",TRUE,NA,NA,NA
10.1111/bjd.16140,29171861,methodology,xx,NA,Inclusion of prognostic factors in the adjustment/matching model,No discussion (in the main text) of the status of prognostic factors of the variables,No,No discussion (in the main text) of the status of prognostic factors of the variables,FALSE,NA,NA,NA
10.1111/bjd.16140,29171861,methodology,xx,NA,Inclusion of treatment-effect modifiers in the adjustment/matching model,NA,NA,Yes,TRUE,NA,NA,NA
10.1111/bjd.16140,29171861,methodology,xx,NA,"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)",NA,NA,No,TRUE,NA,NA,NA
10.1111/bjd.16140,29171861,methodology,xx,NA,Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale),NA,NA,No,TRUE,NA,NA,NA
10.1111/bjd.16140,29171861,results,xx,NA,Initial sample size of the population of interest in the IPD treatment arm,NA,NA,1956,TRUE,NA,NA,NA
10.1111/bjd.16140,29171861,results,xx,NA,"Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC",NA,NA,1666,TRUE,NA,NA,NA
10.1111/bjd.16140,29171861,results,xx,NA,Reporting of a weights' distribution evaluation (MAIC),NA,NA,Not mentioned,TRUE,NA,NA,NA
10.1111/bjd.16140,29171861,results,xx,NA,Reporting of the list of the covariates adjusted for/matched on,NA,NA,Yes,TRUE,NA,NA,NA
10.1111/bjd.16140,29171861,results,xx,NA,Number of covariates adjusted for/matched on,NA,NA,6,TRUE,NA,NA,NA
10.1111/bjd.16140,29171861,results,xx,NA,Covariates adjusted for/matched on in the indirect comparison,NA,NA,"Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Past treatments for the disease of interest, Other(s)",TRUE,NA,NA,NA
10.1111/bjd.16140,29171861,results,xx,NA,Primary outcome: treatment effect contrast,NA,NA,Risk difference,TRUE,NA,NA,NA
10.1111/bjd.16140,29171861,results,xx,NA,Direction of the treatment effect contrast: IPD treatment is:,NA,NA,"Numerator if ratio, or left side if difference",TRUE,NA,NA,NA
10.1111/bjd.16140,29171861,results,xx,NA,Sample size of the population of interest in the non IPD treatment arm,653,NA,653,FALSE,NA,NA,NA
10.1111/bjd.16140,29171861,results,xx,NA,"p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])",0.00007,NA,NA,FALSE,NA,NA,NA
10.1111/bjd.16140,29171861,results,xx,NA,"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])",0.0002,NA,NA,FALSE,NA,NA,NA
10.1111/bjd.16140,29171861,results,xx,NA,Reporting of a weights' distribution evaluation (MAIC),NA,NA,Not mentioned,TRUE,NA,NA,NA
10.1111/bjd.16140,29171861,results,xx,NA,Reporting of the list of the covariates adjusted for/matched on,NA,NA,Yes,TRUE,NA,NA,NA
10.1111/bjd.16140,29171861,results,xx,NA,Number of covariates adjusted for/matched on,NA,NA,6,TRUE,NA,NA,NA
10.1111/bjd.16140,29171861,results,xx,NA,Covariates adjusted for/matched on in the indirect comparison,NA,NA,"Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Past treatments for the disease of interest, Other(s)",TRUE,NA,NA,NA
10.1111/bjd.16140,29171861,results,xx,NA,Primary outcome: treatment effect contrast,NA,NA,Risk difference,TRUE,NA,NA,NA
10.1111/bjd.16140,29171861,results,xx,NA,Direction of the treatment effect contrast: IPD treatment is:,NA,NA,"Numerator if ratio, or left side if difference",TRUE,NA,NA,NA
10.1111/bjd.16140,29171861,results,xx,NA,Sample size of the population of interest in the non IPD treatment arm,653,NA,NA,FALSE,NA,NA,NA
10.1111/bjd.16140,29171861,results,xx,NA,Initial sample size of the population of interest in the IPD treatment arm,1956,NA,NA,FALSE,NA,NA,NA
10.1111/bjd.16140,29171861,results,xx,NA,"Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC",1666,NA,NA,FALSE,NA,NA,NA
10.1111/bjd.16140,29171861,results,xx,NA,"p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])",0.00007,NA,NA,FALSE,NA,NA,NA
10.1111/bjd.16140,29171861,results,xx,NA,"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])",0.0003,NA,NA,FALSE,NA,NA,NA
10.1111/bjd.16140,29171861,results,3,NA,Initial sample size of the population of interest in the IPD treatment arm,NA,NA,1465,TRUE,NA,NA,NA
10.1111/bjd.16140,29171861,results,3,NA,"Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC",NA,NA,989,TRUE,NA,NA,NA
10.1111/bjd.16140,29171861,results,3,NA,Reporting of a weights' distribution evaluation (MAIC),NA,NA,Not mentioned,TRUE,NA,NA,NA
10.1111/bjd.16140,29171861,results,3,NA,Reporting of the list of the covariates adjusted for/matched on,NA,NA,Yes,TRUE,NA,NA,NA
10.1111/bjd.16140,29171861,results,3,NA,Number of covariates adjusted for/matched on,NA,NA,7,TRUE,NA,NA,NA
10.1111/bjd.16140,29171861,results,3,NA,Covariates adjusted for/matched on in the indirect comparison,NA,NA,"Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Past treatments for the disease of interest, Other(s)",TRUE,NA,NA,NA
10.1111/bjd.16140,29171861,results,3,NA,Primary outcome: treatment effect contrast,NA,NA,Risk difference,TRUE,NA,NA,NA
10.1111/bjd.16140,29171861,results,3,NA,Direction of the treatment effect contrast: IPD treatment is:,NA,NA,"Numerator if ratio, or left side if difference",TRUE,NA,NA,NA
10.1111/bjd.16140,29171861,results,3,NA,"p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])",0.1,0.7,0.1,FALSE,NA,NA,NA
10.1111/bjd.16140,29171861,results,3,NA,"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])",0.7,0.1,0.7,FALSE,NA,NA,NA
10.1111/bjd.16140,29171861,results,3,NA,Sample size of the population of interest in the non IPD treatment arm,653,NA,653,FALSE,NA,NA,NA
10.1111/bjd.16140,29171861,results,xx,NA,Reporting of a weights' distribution evaluation (MAIC),NA,NA,Not mentioned,TRUE,NA,NA,NA
10.1111/bjd.16140,29171861,results,xx,NA,Reporting of the list of the covariates adjusted for/matched on,NA,NA,Yes,TRUE,NA,NA,NA
10.1111/bjd.16140,29171861,results,xx,NA,Number of covariates adjusted for/matched on,NA,NA,7,TRUE,NA,NA,NA
10.1111/bjd.16140,29171861,results,xx,NA,Covariates adjusted for/matched on in the indirect comparison,NA,NA,"Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Past treatments for the disease of interest, Other(s)",TRUE,NA,NA,NA
10.1111/bjd.16140,29171861,results,xx,NA,Primary outcome: treatment effect contrast,NA,NA,Risk difference,TRUE,NA,NA,NA
10.1111/bjd.16140,29171861,results,xx,NA,Direction of the treatment effect contrast: IPD treatment is:,NA,NA,"Numerator if ratio, or left side if difference",TRUE,NA,NA,NA
10.1111/bjd.16140,29171861,results,xx,NA,"p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])",0.1,0.69,0.1,FALSE,NA,NA,NA
10.1111/bjd.16140,29171861,results,xx,NA,"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])",0.69,0.1,0.69,FALSE,NA,NA,NA
10.1111/bjd.16140,29171861,results,xx,NA,Sample size of the population of interest in the non IPD treatment arm,653,NA,653,FALSE,NA,NA,NA
10.1111/bjd.16140,29171861,results,xx,NA,Initial sample size of the population of interest in the IPD treatment arm,1465,NA,1465,FALSE,NA,NA,NA
10.1111/bjd.16140,29171861,results,xx,NA,"Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC",989,NA,989,FALSE,NA,NA,NA
10.1111/bjd.16140,29171861,results,5,NA,Initial sample size of the population of interest in the IPD treatment arm,NA,NA,259,TRUE,NA,NA,NA
10.1111/bjd.16140,29171861,results,5,NA,"Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC",NA,NA,122,TRUE,NA,NA,NA
10.1111/bjd.16140,29171861,results,5,NA,Reporting of a weights' distribution evaluation (MAIC),NA,NA,Not mentioned,TRUE,NA,NA,NA
10.1111/bjd.16140,29171861,results,5,NA,Reporting of the list of the covariates adjusted for/matched on,NA,NA,Yes,TRUE,NA,NA,NA
10.1111/bjd.16140,29171861,results,5,NA,Number of covariates adjusted for/matched on,NA,NA,8,TRUE,NA,NA,NA
10.1111/bjd.16140,29171861,results,5,NA,Covariates adjusted for/matched on in the indirect comparison,NA,NA,"Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Past treatments for the disease of interest, Other(s)",TRUE,NA,NA,NA
10.1111/bjd.16140,29171861,results,5,NA,Primary outcome: treatment effect contrast,Risk difference,Rate difference,Risk difference,FALSE,NA,NA,NA
10.1111/bjd.16140,29171861,results,5,NA,Direction of the treatment effect contrast: IPD treatment is:,NA,NA,"Numerator if ratio, or left side if difference",TRUE,NA,NA,NA
10.1111/bjd.16140,29171861,results,5,NA,"p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])",0.21,0.26,0.21,FALSE,NA,NA,NA
10.1111/bjd.16140,29171861,results,5,NA,"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])",0.33,0.21,0.26,FALSE,NA,NA,NA
10.1111/bjd.16140,29171861,results,5,NA,Sample size of the population of interest in the non IPD treatment arm,676,NA,676,FALSE,NA,NA,NA
10.1111/bjd.16140,29171861,results,xx,NA,Reporting of a weights' distribution evaluation (MAIC),NA,NA,Not mentioned,TRUE,NA,NA,NA
10.1111/bjd.16140,29171861,results,xx,NA,Reporting of the list of the covariates adjusted for/matched on,NA,NA,Yes,TRUE,NA,NA,NA
10.1111/bjd.16140,29171861,results,xx,NA,Number of covariates adjusted for/matched on,NA,NA,8,TRUE,NA,NA,NA
10.1111/bjd.16140,29171861,results,xx,NA,Covariates adjusted for/matched on in the indirect comparison,NA,NA,"Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Past treatments for the disease of interest, Other(s)",TRUE,NA,NA,NA
10.1111/bjd.16140,29171861,results,xx,NA,Primary outcome: treatment effect contrast,NA,NA,Risk difference,TRUE,NA,NA,NA
10.1111/bjd.16140,29171861,results,xx,NA,Direction of the treatment effect contrast: IPD treatment is:,NA,NA,"Numerator if ratio, or left side if difference",TRUE,NA,NA,NA
10.1111/bjd.16140,29171861,results,xx,NA,"p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])",0.21,0.16,NA,FALSE,NA,NA,NA
10.1111/bjd.16140,29171861,results,xx,NA,"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])",0.24,0.21,NA,FALSE,NA,NA,NA
10.1111/bjd.16140,29171861,results,xx,NA,Sample size of the population of interest in the non IPD treatment arm,676,NA,NA,FALSE,NA,NA,NA
10.1111/bjd.16140,29171861,results,xx,NA,Initial sample size of the population of interest in the IPD treatment arm,259,NA,NA,FALSE,NA,NA,NA
10.1111/bjd.16140,29171861,results,xx,NA,"Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC",122,NA,NA,FALSE,NA,NA,NA
10.2217/cer.15.49,26390233,general_information,NA,NA,Medical Condition of Interest Name,NA,NA,hepatitis c genotype 3,TRUE,NA,NA,JL
10.2217/cer.15.49,26390233,general_information,NA,NA,Countries of first author affiliations,NA,NA,usa,TRUE,NA,NA,JL
10.2217/cer.15.49,26390233,general_information,NA,NA,Countries of last author affiliations,NA,NA,usa,TRUE,NA,NA,JL
10.2217/cer.15.49,26390233,general_information,NA,NA,"Positions of study investigators (for any authors of the article, any that applies)",NA,NA,"Pharmaceutical Industry, Private Data Analysis Company",TRUE,NA,NA,JL
10.2217/cer.15.49,26390233,general_information,NA,NA,"At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company",NA,NA,Yes,TRUE,NA,NA,JL
10.2217/cer.15.49,26390233,general_information,NA,NA,Mentioned sources of funding,NA,NA,Pharmaceutical Industry,TRUE,NA,NA,JL
10.2217/cer.15.49,26390233,general_information,NA,NA,"Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article",NA,NA,Yes,TRUE,NA,NA,JL
10.2217/cer.15.49,26390233,general_information,NA,NA,Mention of a systematic review to find the studies to compare treatments of interest,NA,NA,Yes,TRUE,NA,NA,JL
10.2217/cer.15.49,26390233,study_information,NA,1,Patient-level data used,NA,NA,Yes,TRUE,NA,NA,JL
10.2217/cer.15.49,26390233,study_information,NA,1,Clinical Trial,NA,NA,Yes,TRUE,NA,NA,JL
10.2217/cer.15.49,26390233,study_information,NA,1,NCT (only for clinical trial registered on clinicaltrials.gov),NA,NA,NCT02032901,TRUE,NA,NA,JL
10.2217/cer.15.49,26390233,study_information,NA,1,Country where the clinical trial/observational study was conducted (international if more than one),international,usa,XXXX,FALSE,NA,NA,JL
10.2217/cer.15.49,26390233,study_information,NA,1,Phase of the clinical trial (clinical trial only),NA,NA,3,TRUE,NA,NA,JL
10.2217/cer.15.49,26390233,study_information,NA,1,Number of treatment arms (clinical trial only),NA,NA,1,TRUE,NA,NA,JL
10.2217/cer.15.49,26390233,study_information,NA,2,Patient-level data used,NA,NA,No,TRUE,NA,NA,JL
10.2217/cer.15.49,26390233,study_information,NA,2,Clinical Trial,NA,NA,Yes,TRUE,NA,NA,JL
10.2217/cer.15.49,26390233,study_information,NA,2,NCT (only for clinical trial registered on clinicaltrials.gov),NA,NA,NCT01682720,TRUE,NA,NA,JL
10.2217/cer.15.49,26390233,study_information,NA,2,Country where the clinical trial/observational study was conducted (international if more than one),NA,NA,international,TRUE,NA,NA,JL
10.2217/cer.15.49,26390233,study_information,NA,2,Phase of the clinical trial (clinical trial only),NA,NA,3,TRUE,NA,NA,JL
10.2217/cer.15.49,26390233,study_information,NA,2,Number of treatment arms (clinical trial only),NA,NA,2 or more,TRUE,NA,NA,JL
10.2217/cer.15.49,26390233,study_information,NA,3,Patient-level data used,NA,NA,No,TRUE,NA,NA,JL
10.2217/cer.15.49,26390233,study_information,NA,3,Clinical Trial,NA,NA,Yes,TRUE,NA,NA,JL
10.2217/cer.15.49,26390233,study_information,NA,3,Data source name (only if observational study or clinical trial without NCT),NA,NA,ferenci et al. (2008),TRUE,NA,NA,JL
10.2217/cer.15.49,26390233,study_information,NA,3,Country where the clinical trial/observational study was conducted (international if more than one),NA,austria,XXXX,FALSE,NA,NA,JL
10.2217/cer.15.49,26390233,study_information,NA,3,Number of treatment arms (clinical trial only),1,2 or more,XXXX,FALSE,NA,NA,JL
10.2217/cer.15.49,26390233,study_information,NA,4,Patient-level data used,NA,NA,No,TRUE,NA,NA,JL
10.2217/cer.15.49,26390233,study_information,NA,4,Clinical Trial,NA,NA,Yes,TRUE,NA,NA,JL
10.2217/cer.15.49,26390233,study_information,NA,4,NCT (only for clinical trial registered on clinicaltrials.gov),NA,NA,NCT00077636,TRUE,NA,NA,JL
10.2217/cer.15.49,26390233,study_information,NA,4,Country where the clinical trial/observational study was conducted (international if more than one),NA,NA,international,TRUE,NA,NA,JL
10.2217/cer.15.49,26390233,study_information,NA,4,Phase of the clinical trial (clinical trial only),NA,NA,4,TRUE,NA,NA,JL
10.2217/cer.15.49,26390233,study_information,NA,4,Number of treatment arms (clinical trial only),1,2 or more,XXXX,FALSE,NA,NA,JL
10.2217/cer.15.49,26390233,methodology,1,NA,Treatment name 1,NA,NA,daclatasvir + sofosbuvir,TRUE,"SVR rate difference not reported in the paper, but statistical test reported for it and the rate difference can be calculated
bmi = other
Prior interferon based treatment = 2 variables
Race = 2 variables (race and ethnicity, Hispanic/non hispanic = 2 variables)","No statistics were calculated in this study :
SVR12 non IPD = 85.2%
SVR12 IPD before adjustment = 89.6%  (p = 0.216)
SVR12 IPD after adjustment = 88.8%  (p = 0.537)

The list of the covariates adjusted for/matched on = from Table 1",JL
10.2217/cer.15.49,26390233,methodology,1,NA,Study 'number(s)' for treatment 1,NA,NA,1,TRUE,NA,NA,JL
10.2217/cer.15.49,26390233,methodology,1,NA,Treatment name 2,NA,NA,sofosbuvir + ribavirin,TRUE,NA,NA,JL
10.2217/cer.15.49,26390233,methodology,1,NA,Study 'number(s)' for treatment 2,NA,NA,2,TRUE,NA,NA,JL
10.2217/cer.15.49,26390233,methodology,1,NA,Type of population-adjusted indirect comparisons performed,NA,NA,MAIC,TRUE,NA,NA,JL
10.2217/cer.15.49,26390233,methodology,1,NA,Anchored comparison?,NA,NA,No,TRUE,NA,NA,JL
10.2217/cer.15.49,26390233,methodology,1,NA,Form of the indirect comparison,NA,NA,Simple (ie treatments effects extracted from two studies),TRUE,NA,NA,JL
10.2217/cer.15.49,26390233,methodology,1,NA,Definition of a single primary outcome for the indirect comparison,NA,NA,Yes,TRUE,NA,NA,JL
10.2217/cer.15.49,26390233,methodology,1,NA,Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined),sustained virologic response,sustained virologic response at week 12 post-treatment (svr12),sustained virologic response at week 12 post-treatment (svr12),FALSE,NA,NA,JL
10.2217/cer.15.49,26390233,methodology,1,NA,Primary outcome: variable type,NA,NA,Binary (eg rates),TRUE,NA,NA,JL
10.2217/cer.15.49,26390233,methodology,1,NA,Justification for selecting variables to be included in the adjustment model (in the main text),NA,NA,"Nothing mentioned, not reported",TRUE,NA,NA,JL
10.2217/cer.15.49,26390233,methodology,1,NA,Inclusion of prognostic factors in the adjustment/matching model,NA,NA,No discussion (in the main text) of the status of prognostic factors of the variables,TRUE,NA,NA,JL
10.2217/cer.15.49,26390233,methodology,1,NA,Inclusion of treatment-effect modifiers in the adjustment/matching model,NA,NA,No discussion (in the main text) of the status of treatment-effect modifiers of the variables,TRUE,NA,NA,JL
10.2217/cer.15.49,26390233,methodology,1,NA,"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)",Yes,No,No,FALSE,NA,NA,JL
10.2217/cer.15.49,26390233,methodology,1,NA,Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale),NA,NA,No,TRUE,NA,NA,JL
10.2217/cer.15.49,26390233,methodology,2,NA,Treatment name 1,NA,NA,daclatasvir + sofosbuvir,TRUE,"SVR rate difference not reported in the paper, but statistical test reported for it and the rate difference can be calculated
bmi = other","No statistics were calculated in this study :
SVR24 non IPD = 66.5%
SVR12 IPD before adjustment = 87.8%  (p<0.001)
SVR12 IPD after adjustment = 95.6%  (p<0.001)

The list of the covariates adjusted for/matched on = from Table 2

BMI = others covariates",JL
10.2217/cer.15.49,26390233,methodology,2,NA,Study 'number(s)' for treatment 1,NA,NA,1,TRUE,NA,NA,JL
10.2217/cer.15.49,26390233,methodology,2,NA,Treatment name 2,peginterferon-alfa + ribavirin,peginterferon-alfa + ribavirine,peginterferon-alfa + ribavirin,FALSE,NA,NA,JL
10.2217/cer.15.49,26390233,methodology,2,NA,Study 'number(s)' for treatment 2,NA,NA,3;4,TRUE,NA,NA,JL
10.2217/cer.15.49,26390233,methodology,2,NA,Type of population-adjusted indirect comparisons performed,NA,NA,MAIC,TRUE,NA,NA,JL
10.2217/cer.15.49,26390233,methodology,2,NA,Anchored comparison?,NA,NA,No,TRUE,NA,NA,JL
10.2217/cer.15.49,26390233,methodology,2,NA,Form of the indirect comparison,NA,NA,"Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate)",TRUE,NA,NA,JL
10.2217/cer.15.49,26390233,methodology,2,NA,Definition of a single primary outcome for the indirect comparison,NA,NA,Yes,TRUE,NA,NA,JL
10.2217/cer.15.49,26390233,methodology,2,NA,Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined),sustained virologic response,rate of svr12 in patients treated with dcv + sof (study 1). the rate of svr24 in patients treated with a/r (studies 3 and 4),rate of svr12 in patients treated with dcv + sof (study 1). the rate of svr24 in patients treated with a/r (studies 3 and 4),FALSE,NA,NA,JL
10.2217/cer.15.49,26390233,methodology,2,NA,Primary outcome: variable type,NA,NA,Binary (eg rates),TRUE,NA,NA,JL
10.2217/cer.15.49,26390233,methodology,2,NA,Justification for selecting variables to be included in the adjustment model (in the main text),NA,NA,"Nothing mentioned, not reported",TRUE,NA,NA,JL
10.2217/cer.15.49,26390233,methodology,2,NA,Inclusion of prognostic factors in the adjustment/matching model,NA,NA,No discussion (in the main text) of the status of prognostic factors of the variables,TRUE,NA,NA,JL
10.2217/cer.15.49,26390233,methodology,2,NA,Inclusion of treatment-effect modifiers in the adjustment/matching model,NA,NA,No discussion (in the main text) of the status of treatment-effect modifiers of the variables,TRUE,NA,NA,JL
10.2217/cer.15.49,26390233,methodology,2,NA,"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)",Yes,No,No,FALSE,NA,NA,JL
10.2217/cer.15.49,26390233,methodology,2,NA,Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale),NA,NA,No,TRUE,NA,NA,JL
10.2217/cer.15.49,26390233,results,1,NA,Sample size of the population of interest in the non IPD treatment arm,NA,NA,250,TRUE,NA,NA,JL
10.2217/cer.15.49,26390233,results,1,NA,Initial sample size of the population of interest in the IPD treatment arm,NA,NA,144,TRUE,NA,NA,JL
10.2217/cer.15.49,26390233,results,1,NA,Reporting of a weights' distribution evaluation (MAIC),NA,NA,Not mentioned,TRUE,NA,NA,JL
10.2217/cer.15.49,26390233,results,1,NA,Reporting of the list of the covariates adjusted for/matched on,NA,NA,Yes,TRUE,NA,NA,JL
10.2217/cer.15.49,26390233,results,1,NA,Number of covariates adjusted for/matched on,12,11,11,FALSE,NA,NA,JL
10.2217/cer.15.49,26390233,results,1,NA,Covariates adjusted for/matched on in the indirect comparison,NA,NA,"Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Race/ethnicity, Past treatments for the disease of interest, Other(s)",TRUE,NA,NA,JL
10.2217/cer.15.49,26390233,results,1,NA,Primary outcome: treatment effect contrast,Rate difference,NA,Rate difference,FALSE,NA,NA,JL
10.2217/cer.15.49,26390233,results,1,NA,Direction of the treatment effect contrast: IPD treatment is:,"Numerator if ratio, or left side if difference",NA,"Numerator if ratio, or left side if difference",FALSE,NA,NA,JL
10.2217/cer.15.49,26390233,results,1,NA,Primary outcome: unadjusted treatment effect,4.4,NA,4.40%,FALSE,NA,NA,JL
10.2217/cer.15.49,26390233,results,1,NA,"p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])",0.216,NA,0.216,FALSE,NA,NA,JL
10.2217/cer.15.49,26390233,results,1,NA,Primary outcome: adjusted treatment effect,3.6,NA,3.60%,FALSE,NA,NA,JL
10.2217/cer.15.49,26390233,results,1,NA,"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])",0.537,NA,0.537,FALSE,NA,NA,JL
10.2217/cer.15.49,26390233,results,2,NA,Sample size of the population of interest in the non IPD treatment arm,NA,NA,492,TRUE,NA,NA,JL
10.2217/cer.15.49,26390233,results,2,NA,Initial sample size of the population of interest in the IPD treatment arm,NA,NA,74,TRUE,NA,NA,JL
10.2217/cer.15.49,26390233,results,2,NA,Reporting of a weights' distribution evaluation (MAIC),NA,NA,Not mentioned,TRUE,NA,NA,JL
10.2217/cer.15.49,26390233,results,2,NA,Reporting of the list of the covariates adjusted for/matched on,NA,NA,Yes,TRUE,NA,NA,JL
10.2217/cer.15.49,26390233,results,2,NA,Number of covariates adjusted for/matched on,NA,NA,4,TRUE,NA,NA,JL
10.2217/cer.15.49,26390233,results,2,NA,Covariates adjusted for/matched on in the indirect comparison,NA,NA,"Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Other(s)",TRUE,NA,NA,JL
10.2217/cer.15.49,26390233,results,2,NA,Primary outcome: treatment effect contrast,Rate difference,NA,Rate difference,FALSE,NA,NA,JL
10.2217/cer.15.49,26390233,results,2,NA,Direction of the treatment effect contrast: IPD treatment is:,"Numerator if ratio, or left side if difference",NA,"Numerator if ratio, or left side if difference",FALSE,NA,NA,JL
10.2217/cer.15.49,26390233,results,2,NA,Primary outcome: unadjusted treatment effect,21.3,NA,21.30%,FALSE,NA,NA,JL
10.2217/cer.15.49,26390233,results,2,NA,"p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])",<0.001,NA,<0.001,FALSE,NA,NA,JL
10.2217/cer.15.49,26390233,results,2,NA,Primary outcome: adjusted treatment effect,18.9,NA,18.90%,FALSE,NA,NA,JL
10.2217/cer.15.49,26390233,results,2,NA,"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])",<0.001,NA,<0.001,FALSE,NA,NA,JL
10.5152/eurjrheum.2018.18162,30388073,general_information,NA,NA,Medical Condition of Interest Name,NA,NA,ankylosing spondylitis,TRUE,NA,NA,JL
10.5152/eurjrheum.2018.18162,30388073,general_information,NA,NA,Countries of first author affiliations,NA,NA,canada,TRUE,NA,NA,JL
10.5152/eurjrheum.2018.18162,30388073,general_information,NA,NA,Countries of last author affiliations,NA,NA,switzerland,TRUE,NA,NA,JL
10.5152/eurjrheum.2018.18162,30388073,general_information,NA,NA,"Positions of study investigators (for any authors of the article, any that applies)",NA,NA,"Academic, Pharmaceutical Industry, Private Data Analysis Company",TRUE,NA,NA,JL
10.5152/eurjrheum.2018.18162,30388073,general_information,NA,NA,"At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company",NA,NA,Yes,TRUE,NA,NA,JL
10.5152/eurjrheum.2018.18162,30388073,general_information,NA,NA,Mentioned sources of funding,NA,NA,Pharmaceutical Industry,TRUE,NA,NA,JL
10.5152/eurjrheum.2018.18162,30388073,general_information,NA,NA,"Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article",NA,NA,Yes,TRUE,NA,NA,JL
10.5152/eurjrheum.2018.18162,30388073,general_information,NA,NA,Mention of a systematic review to find the studies to compare treatments of interest,NA,NA,Yes,TRUE,NA,NA,JL
10.5152/eurjrheum.2018.18162,30388073,study_information,NA,1,Patient-level data used,NA,NA,Yes,TRUE,NA,NA,JL
10.5152/eurjrheum.2018.18162,30388073,study_information,NA,1,Clinical Trial,NA,NA,Yes,TRUE,NA,NA,JL
10.5152/eurjrheum.2018.18162,30388073,study_information,NA,1,NCT (only for clinical trial registered on clinicaltrials.gov),NA,NA,NCT01358175,TRUE,NA,NA,JL
10.5152/eurjrheum.2018.18162,30388073,study_information,NA,1,Country where the clinical trial/observational study was conducted (international if more than one),NA,NA,international,TRUE,NA,NA,JL
10.5152/eurjrheum.2018.18162,30388073,study_information,NA,1,Phase of the clinical trial (clinical trial only),NA,NA,3,TRUE,NA,NA,JL
10.5152/eurjrheum.2018.18162,30388073,study_information,NA,1,Number of treatment arms (clinical trial only),NA,NA,2 or more,TRUE,NA,NA,JL
10.5152/eurjrheum.2018.18162,30388073,study_information,NA,2,Patient-level data used,NA,NA,Yes,TRUE,NA,NA,JL
10.5152/eurjrheum.2018.18162,30388073,study_information,NA,2,Clinical Trial,NA,NA,Yes,TRUE,NA,NA,JL
10.5152/eurjrheum.2018.18162,30388073,study_information,NA,2,NCT (only for clinical trial registered on clinicaltrials.gov),NA,NA,NCT01649375,TRUE,NA,NA,JL
10.5152/eurjrheum.2018.18162,30388073,study_information,NA,2,Country where the clinical trial/observational study was conducted (international if more than one),NA,NA,international,TRUE,NA,NA,JL
10.5152/eurjrheum.2018.18162,30388073,study_information,NA,2,Phase of the clinical trial (clinical trial only),NA,NA,3,TRUE,NA,NA,JL
10.5152/eurjrheum.2018.18162,30388073,study_information,NA,2,Number of treatment arms (clinical trial only),NA,NA,2 or more,TRUE,NA,NA,JL
10.5152/eurjrheum.2018.18162,30388073,study_information,NA,3,Patient-level data used,NA,NA,No,TRUE,NA,NA,JL
10.5152/eurjrheum.2018.18162,30388073,study_information,NA,3,Clinical Trial,NA,NA,Yes,TRUE,NA,NA,JL
10.5152/eurjrheum.2018.18162,30388073,study_information,NA,3,NCT (only for clinical trial registered on clinicaltrials.gov),NA,NA,NCT00085644,TRUE,NA,NA,JL
10.5152/eurjrheum.2018.18162,30388073,study_information,NA,3,Country where the clinical trial/observational study was conducted (international if more than one),international,usa,XXXX,FALSE,NA,NA,JL
10.5152/eurjrheum.2018.18162,30388073,study_information,NA,3,Phase of the clinical trial (clinical trial only),2,3,XXXX,FALSE,NA,NA,JL
10.5152/eurjrheum.2018.18162,30388073,study_information,NA,3,Number of treatment arms (clinical trial only),NA,NA,2 or more,TRUE,NA,NA,JL
10.5152/eurjrheum.2018.18162,30388073,methodology,1,NA,Treatment name 1,secukinumab 150mg,secukinumab,secukinumab,FALSE,Similar comparison but opposite results to this MAIC  10.3899/jrheum.081048,placebo-adjusted at week 8,JL
10.5152/eurjrheum.2018.18162,30388073,methodology,1,NA,Study 'number(s)' for treatment 1,NA,NA,1;2,TRUE,NA,NA,JL
10.5152/eurjrheum.2018.18162,30388073,methodology,1,NA,Treatment name 2,adalimumab 150mg,adalimumab,adalimumab,FALSE,NA,NA,JL
10.5152/eurjrheum.2018.18162,30388073,methodology,1,NA,Study 'number(s)' for treatment 2,NA,NA,3,TRUE,NA,NA,JL
10.5152/eurjrheum.2018.18162,30388073,methodology,1,NA,Type of population-adjusted indirect comparisons performed,NA,NA,MAIC,TRUE,NA,NA,JL
10.5152/eurjrheum.2018.18162,30388073,methodology,1,NA,Anchored comparison?,NA,NA,Yes,TRUE,NA,NA,JL
10.5152/eurjrheum.2018.18162,30388073,methodology,1,NA,Form of the indirect comparison,NA,NA,"Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate)",TRUE,NA,NA,JL
10.5152/eurjrheum.2018.18162,30388073,methodology,1,NA,Definition of a single primary outcome for the indirect comparison,NA,NA,"No primary outcome defined, or multiple primary outcomes without any clear distinction between them",TRUE,NA,NA,JL
10.5152/eurjrheum.2018.18162,30388073,methodology,1,NA,Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined),assessment of spondyloarthritis international society at week 8,assessment of spondylarthritis international society (asas) 20 response rate at week 8,assessment of spondylarthritis international society (asas) 20 response rate at week 8,FALSE,NA,NA,JL
10.5152/eurjrheum.2018.18162,30388073,methodology,1,NA,Primary outcome: variable type,NA,NA,Binary (eg rates),TRUE,NA,NA,JL
10.5152/eurjrheum.2018.18162,30388073,methodology,1,NA,Justification for selecting variables to be included in the adjustment model (in the main text),NA,NA,"Status of prognostic factor/treatment effect modified assessed in the IPD dataset, A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion), Literature based (clinically or methodologically relevant to adjust on these variables based on the literature search conducted for this specific purpose)",TRUE,NA,NA,JL
10.5152/eurjrheum.2018.18162,30388073,methodology,1,NA,Inclusion of prognostic factors in the adjustment/matching model,NA,NA,Yes,TRUE,NA,NA,JL
10.5152/eurjrheum.2018.18162,30388073,methodology,1,NA,Inclusion of treatment-effect modifiers in the adjustment/matching model,NA,NA,Yes,TRUE,NA,NA,JL
10.5152/eurjrheum.2018.18162,30388073,methodology,1,NA,"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)",NA,NA,No,TRUE,NA,NA,JL
10.5152/eurjrheum.2018.18162,30388073,methodology,1,NA,Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale),NA,NA,No,TRUE,NA,NA,JL
10.5152/eurjrheum.2018.18162,30388073,methodology,2,NA,Treatment name 1,secukinumab 150mg,secukinumab,secukinumab,FALSE,NA,non-placebo-adjusted at week 16,JL
10.5152/eurjrheum.2018.18162,30388073,methodology,2,NA,Study 'number(s)' for treatment 1,NA,NA,1;2,TRUE,NA,NA,JL
10.5152/eurjrheum.2018.18162,30388073,methodology,2,NA,Treatment name 2,adalimumab 150mg,adalimumab,adalimumab,FALSE,NA,NA,JL
10.5152/eurjrheum.2018.18162,30388073,methodology,2,NA,Study 'number(s)' for treatment 2,NA,NA,3,TRUE,NA,NA,JL
10.5152/eurjrheum.2018.18162,30388073,methodology,2,NA,Type of population-adjusted indirect comparisons performed,NA,NA,MAIC,TRUE,NA,NA,JL
10.5152/eurjrheum.2018.18162,30388073,methodology,2,NA,Anchored comparison?,NA,NA,No,TRUE,NA,NA,JL
10.5152/eurjrheum.2018.18162,30388073,methodology,2,NA,Form of the indirect comparison,NA,NA,"Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate)",TRUE,NA,NA,JL
10.5152/eurjrheum.2018.18162,30388073,methodology,2,NA,Definition of a single primary outcome for the indirect comparison,NA,NA,"No primary outcome defined, or multiple primary outcomes without any clear distinction between them",TRUE,NA,NA,JL
10.5152/eurjrheum.2018.18162,30388073,methodology,2,NA,Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined),assessment of spondyloarthritis international society at week 16,assessment of spondylarthritis international society (asas) 20 response rate at week 16,assessment of spondylarthritis international society (asas) 20 response rate at week 16,FALSE,NA,NA,JL
10.5152/eurjrheum.2018.18162,30388073,methodology,2,NA,Primary outcome: variable type,NA,NA,Binary (eg rates),TRUE,NA,NA,JL
10.5152/eurjrheum.2018.18162,30388073,methodology,2,NA,Justification for selecting variables to be included in the adjustment model (in the main text),NA,NA,"Status of prognostic factor/treatment effect modified assessed in the IPD dataset, A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion), Literature based (clinically or methodologically relevant to adjust on these variables based on the literature search conducted for this specific purpose)",TRUE,NA,NA,JL
10.5152/eurjrheum.2018.18162,30388073,methodology,2,NA,Inclusion of prognostic factors in the adjustment/matching model,NA,NA,Yes,TRUE,NA,NA,JL
10.5152/eurjrheum.2018.18162,30388073,methodology,2,NA,Inclusion of treatment-effect modifiers in the adjustment/matching model,NA,NA,Yes,TRUE,NA,NA,JL
10.5152/eurjrheum.2018.18162,30388073,methodology,2,NA,"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)",NA,NA,No,TRUE,NA,NA,JL
10.5152/eurjrheum.2018.18162,30388073,methodology,2,NA,Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale),NA,NA,No,TRUE,NA,NA,JL
10.5152/eurjrheum.2018.18162,30388073,results,1,NA,Sample size of the population of interest in the non IPD treatment arm,NA,NA,208,TRUE,NA,NA,JL
10.5152/eurjrheum.2018.18162,30388073,results,1,NA,"If anchored comparison, sample size of the population of interest in the non IPD treatment anchor arm",NA,NA,107,TRUE,NA,NA,JL
10.5152/eurjrheum.2018.18162,30388073,results,1,NA,Initial sample size of the population of interest in the IPD treatment arm,NA,NA,197,TRUE,NA,NA,JL
10.5152/eurjrheum.2018.18162,30388073,results,1,NA,"Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC",NA,NA,120,TRUE,NA,NA,JL
10.5152/eurjrheum.2018.18162,30388073,results,1,NA,"If anchored comparison, initial sample size of the population of interest in the IPD anchor arm",NA,NA,196,TRUE,NA,NA,JL
10.5152/eurjrheum.2018.18162,30388073,results,1,NA,"If anchored comparison, effective sample size after reweighting for MAIC; or sample size used in the regression model for STC in the IPD anchor arm",NA,NA,120,TRUE,NA,NA,JL
10.5152/eurjrheum.2018.18162,30388073,results,1,NA,Reporting of a weights' distribution evaluation (MAIC),NA,NA,Not mentioned,TRUE,NA,NA,JL
10.5152/eurjrheum.2018.18162,30388073,results,1,NA,Reporting of the list of the covariates adjusted for/matched on,NA,NA,Yes,TRUE,NA,NA,JL
10.5152/eurjrheum.2018.18162,30388073,results,1,NA,Number of covariates adjusted for/matched on,NA,NA,5,TRUE,NA,NA,JL
10.5152/eurjrheum.2018.18162,30388073,results,1,NA,Covariates adjusted for/matched on in the indirect comparison,NA,NA,"Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Past treatments for the disease of interest",TRUE,NA,NA,JL
10.5152/eurjrheum.2018.18162,30388073,results,1,NA,Primary outcome: treatment effect contrast,NA,NA,OR,TRUE,NA,NA,JL
10.5152/eurjrheum.2018.18162,30388073,results,1,NA,Direction of the treatment effect contrast: IPD treatment is:,NA,NA,"Numerator if ratio, or left side if difference",TRUE,NA,NA,JL
10.5152/eurjrheum.2018.18162,30388073,results,1,NA,Primary outcome: adjusted treatment effect,NA,NA,0.91,TRUE,NA,NA,JL
10.5152/eurjrheum.2018.18162,30388073,results,1,NA,"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])",NA,NA,0.795,TRUE,NA,NA,JL
10.5152/eurjrheum.2018.18162,30388073,results,2,NA,Sample size of the population of interest in the non IPD treatment arm,NA,NA,208,TRUE,NA,NA,JL
10.5152/eurjrheum.2018.18162,30388073,results,2,NA,Initial sample size of the population of interest in the IPD treatment arm,NA,NA,197,TRUE,NA,NA,JL
10.5152/eurjrheum.2018.18162,30388073,results,2,NA,"Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC",NA,NA,120,TRUE,NA,NA,JL
10.5152/eurjrheum.2018.18162,30388073,results,2,NA,Reporting of a weights' distribution evaluation (MAIC),NA,NA,Not mentioned,TRUE,NA,NA,JL
10.5152/eurjrheum.2018.18162,30388073,results,2,NA,Reporting of the list of the covariates adjusted for/matched on,NA,NA,Yes,TRUE,NA,NA,JL
10.5152/eurjrheum.2018.18162,30388073,results,2,NA,Number of covariates adjusted for/matched on,NA,NA,5,TRUE,NA,NA,JL
10.5152/eurjrheum.2018.18162,30388073,results,2,NA,Covariates adjusted for/matched on in the indirect comparison,NA,NA,"Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Past treatments for the disease of interest",TRUE,NA,NA,JL
10.5152/eurjrheum.2018.18162,30388073,results,2,NA,Primary outcome: treatment effect contrast,NA,NA,OR,TRUE,NA,NA,JL
10.5152/eurjrheum.2018.18162,30388073,results,2,NA,Direction of the treatment effect contrast: IPD treatment is:,NA,NA,"Numerator if ratio, or left side if difference",TRUE,NA,NA,JL
10.5152/eurjrheum.2018.18162,30388073,results,2,NA,Primary outcome: adjusted treatment effect,NA,NA,1.6,TRUE,NA,NA,JL
10.5152/eurjrheum.2018.18162,30388073,results,2,NA,"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])",NA,NA,0.047,TRUE,NA,NA,JL
10.2217/imt-2018-0208,30852924,general_information,NA,NA,Medical Condition of Interest Name,braf-mutant advanced melanoma,braf-mutant advancedmelanoma,XXXX,FALSE,NA,NA,JL
10.2217/imt-2018-0208,30852924,general_information,NA,NA,Countries of first author affiliations,NA,NA,usa,TRUE,NA,NA,JL
10.2217/imt-2018-0208,30852924,general_information,NA,NA,Countries of last author affiliations,NA,NA,usa,TRUE,NA,NA,JL
10.2217/imt-2018-0208,30852924,general_information,NA,NA,"Positions of study investigators (for any authors of the article, any that applies)",NA,NA,"Academic, Pharmaceutical Industry, Private Data Analysis Company",TRUE,NA,NA,JL
10.2217/imt-2018-0208,30852924,general_information,NA,NA,"At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company",NA,NA,Yes,TRUE,NA,NA,JL
10.2217/imt-2018-0208,30852924,general_information,NA,NA,Mentioned sources of funding,NA,NA,Pharmaceutical Industry,TRUE,NA,NA,JL
10.2217/imt-2018-0208,30852924,general_information,NA,NA,"Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article",NA,NA,Yes,TRUE,NA,NA,JL
10.2217/imt-2018-0208,30852924,general_information,NA,NA,Mention of a systematic review to find the studies to compare treatments of interest,NA,NA,No,TRUE,NA,NA,JL
10.2217/imt-2018-0208,30852924,study_information,NA,1,Patient-level data used,NA,NA,Yes,TRUE,NA,NA,JL
10.2217/imt-2018-0208,30852924,study_information,NA,1,Clinical Trial,NA,NA,Yes,TRUE,NA,NA,JL
10.2217/imt-2018-0208,30852924,study_information,NA,1,NCT (only for clinical trial registered on clinicaltrials.gov),NA,NA,NCT01844505,TRUE,NA,NA,JL
10.2217/imt-2018-0208,30852924,study_information,NA,1,Country where the clinical trial/observational study was conducted (international if more than one),NA,NA,international,TRUE,NA,NA,JL
10.2217/imt-2018-0208,30852924,study_information,NA,1,Phase of the clinical trial (clinical trial only),NA,NA,3,TRUE,NA,NA,JL
10.2217/imt-2018-0208,30852924,study_information,NA,1,Number of treatment arms (clinical trial only),NA,NA,2 or more,TRUE,NA,NA,JL
10.2217/imt-2018-0208,30852924,study_information,NA,2,Patient-level data used,NA,NA,Yes,TRUE,NA,NA,JL
10.2217/imt-2018-0208,30852924,study_information,NA,2,Clinical Trial,NA,NA,Yes,TRUE,NA,NA,JL
10.2217/imt-2018-0208,30852924,study_information,NA,2,NCT (only for clinical trial registered on clinicaltrials.gov),NA,NA,NCT01927419,TRUE,NA,NA,JL
10.2217/imt-2018-0208,30852924,study_information,NA,2,Country where the clinical trial/observational study was conducted (international if more than one),NA,NA,international,TRUE,NA,NA,JL
10.2217/imt-2018-0208,30852924,study_information,NA,2,Phase of the clinical trial (clinical trial only),NA,NA,2,TRUE,NA,NA,JL
10.2217/imt-2018-0208,30852924,study_information,NA,2,Number of treatment arms (clinical trial only),NA,NA,2 or more,TRUE,NA,NA,JL
10.2217/imt-2018-0208,30852924,study_information,NA,3,Patient-level data used,NA,NA,No,TRUE,NA,NA,JL
10.2217/imt-2018-0208,30852924,study_information,NA,3,Clinical Trial,NA,NA,Yes,TRUE,NA,NA,JL
10.2217/imt-2018-0208,30852924,study_information,NA,3,NCT (only for clinical trial registered on clinicaltrials.gov),NA,NA,NCT01584648,TRUE,NA,NA,JL
10.2217/imt-2018-0208,30852924,study_information,NA,3,Country where the clinical trial/observational study was conducted (international if more than one),NA,NA,international,TRUE,NA,NA,JL
10.2217/imt-2018-0208,30852924,study_information,NA,3,Phase of the clinical trial (clinical trial only),NA,NA,3,TRUE,NA,NA,JL
10.2217/imt-2018-0208,30852924,study_information,NA,3,Number of treatment arms (clinical trial only),2 or more,NA,XXXX,FALSE,NA,NA,JL
10.2217/imt-2018-0208,30852924,study_information,NA,4,Patient-level data used,NA,NA,No,TRUE,NA,NA,JL
10.2217/imt-2018-0208,30852924,study_information,NA,4,Clinical Trial,NA,NA,Yes,TRUE,NA,NA,JL
10.2217/imt-2018-0208,30852924,study_information,NA,4,NCT (only for clinical trial registered on clinicaltrials.gov),NA,NA,NCT01597908,TRUE,NA,NA,JL
10.2217/imt-2018-0208,30852924,study_information,NA,4,Country where the clinical trial/observational study was conducted (international if more than one),NA,NA,international,TRUE,NA,NA,JL
10.2217/imt-2018-0208,30852924,study_information,NA,4,Phase of the clinical trial (clinical trial only),NA,NA,3,TRUE,NA,NA,JL
10.2217/imt-2018-0208,30852924,study_information,NA,4,Number of treatment arms (clinical trial only),NA,NA,2 or more,TRUE,NA,NA,JL
10.2217/imt-2018-0208,30852924,study_information,NA,5,Patient-level data used,NA,NA,No,TRUE,NA,NA,JL
10.2217/imt-2018-0208,30852924,study_information,NA,5,Clinical Trial,NA,NA,Yes,TRUE,NA,NA,JL
10.2217/imt-2018-0208,30852924,study_information,NA,5,NCT (only for clinical trial registered on clinicaltrials.gov),NA,NA,NCT01689519,TRUE,NA,NA,JL
10.2217/imt-2018-0208,30852924,study_information,NA,5,Country where the clinical trial/observational study was conducted (international if more than one),NA,NA,international,TRUE,NA,NA,JL
10.2217/imt-2018-0208,30852924,study_information,NA,5,Phase of the clinical trial (clinical trial only),NA,NA,3,TRUE,NA,NA,JL
10.2217/imt-2018-0208,30852924,study_information,NA,5,Number of treatment arms (clinical trial only),NA,NA,2 or more,TRUE,NA,NA,JL
10.2217/imt-2018-0208,30852924,methodology,1,NA,Treatment name 1,NA,NA,nivolumab + ipilimumab,TRUE,"“To ensure that the increase in uncertainty is reflected in the final relative effectiveness estimates, the index cohort weights were renormalized so they sum to the effective sample size.” (Atkins et al., 2019, p. 619): But no citation provided as to why this allows to carry uncertainty in final estimates.","Accordingly, in this analysis, matching was done on all reported patient characteristics that were determined to beof clinical relevance and predictive of outcomes (statistically assessed ?)",JL
10.2217/imt-2018-0208,30852924,methodology,1,NA,Study 'number(s)' for treatment 1,NA,NA,1;2,TRUE,NA,NA,JL
10.2217/imt-2018-0208,30852924,methodology,1,NA,Treatment name 2,NA,NA,dabrafenib + trametinib,TRUE,NA,NA,JL
10.2217/imt-2018-0208,30852924,methodology,1,NA,Study 'number(s)' for treatment 2,NA,NA,3;4,TRUE,NA,NA,JL
10.2217/imt-2018-0208,30852924,methodology,1,NA,Type of population-adjusted indirect comparisons performed,NA,NA,MAIC,TRUE,NA,NA,JL
10.2217/imt-2018-0208,30852924,methodology,1,NA,Anchored comparison?,NA,NA,No,TRUE,NA,NA,JL
10.2217/imt-2018-0208,30852924,methodology,1,NA,Form of the indirect comparison,NA,NA,"Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate)",TRUE,NA,NA,JL
10.2217/imt-2018-0208,30852924,methodology,1,NA,Definition of a single primary outcome for the indirect comparison,NA,NA,"No primary outcome defined, or multiple primary outcomes without any clear distinction between them",TRUE,NA,NA,JL
10.2217/imt-2018-0208,30852924,methodology,1,NA,Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined),NA,NA,overall survival,TRUE,NA,NA,JL
10.2217/imt-2018-0208,30852924,methodology,1,NA,Primary outcome: variable type,NA,NA,Time-to-event,TRUE,NA,NA,JL
10.2217/imt-2018-0208,30852924,methodology,1,NA,Justification for selecting variables to be included in the adjustment model (in the main text),"Status of prognostic factor/treatment effect modified assessed in the IPD dataset, A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion)",A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion),A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion),FALSE,NA,NA,JL
10.2217/imt-2018-0208,30852924,methodology,1,NA,Inclusion of prognostic factors in the adjustment/matching model,NA,NA,Yes,TRUE,NA,NA,JL
10.2217/imt-2018-0208,30852924,methodology,1,NA,Inclusion of treatment-effect modifiers in the adjustment/matching model,NA,NA,Yes,TRUE,NA,NA,JL
10.2217/imt-2018-0208,30852924,methodology,1,NA,"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)",NA,NA,No,TRUE,NA,NA,JL
10.2217/imt-2018-0208,30852924,methodology,1,NA,Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale),NA,NA,No,TRUE,NA,NA,JL
10.2217/imt-2018-0208,30852924,methodology,2,NA,Treatment name 1,NA,NA,nivolumab + ipilimumab,TRUE,NA,"geographic region (North America vsEurope vs rest of world)  = other

""Accordingly, in this analysis, matching was done on all reported patient characteristics that were determined to beof clinical relevance and predictive of outcomes"" (statistically assessed ?)",JL
10.2217/imt-2018-0208,30852924,methodology,2,NA,Study 'number(s)' for treatment 1,NA,NA,1;2,TRUE,NA,NA,JL
10.2217/imt-2018-0208,30852924,methodology,2,NA,Treatment name 2,NA,NA,vemurafenib + cobimetinib,TRUE,NA,NA,JL
10.2217/imt-2018-0208,30852924,methodology,2,NA,Study 'number(s)' for treatment 2,NA,NA,5,TRUE,NA,NA,JL
10.2217/imt-2018-0208,30852924,methodology,2,NA,Type of population-adjusted indirect comparisons performed,NA,NA,MAIC,TRUE,NA,NA,JL
10.2217/imt-2018-0208,30852924,methodology,2,NA,Anchored comparison?,NA,NA,No,TRUE,NA,NA,JL
10.2217/imt-2018-0208,30852924,methodology,2,NA,Form of the indirect comparison,NA,NA,"Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate)",TRUE,NA,NA,JL
10.2217/imt-2018-0208,30852924,methodology,2,NA,Definition of a single primary outcome for the indirect comparison,NA,NA,"No primary outcome defined, or multiple primary outcomes without any clear distinction between them",TRUE,NA,NA,JL
10.2217/imt-2018-0208,30852924,methodology,2,NA,Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined),NA,NA,overall survival,TRUE,NA,NA,JL
10.2217/imt-2018-0208,30852924,methodology,2,NA,Primary outcome: variable type,NA,NA,Time-to-event,TRUE,NA,NA,JL
10.2217/imt-2018-0208,30852924,methodology,2,NA,Justification for selecting variables to be included in the adjustment model (in the main text),"Status of prognostic factor/treatment effect modified assessed in the IPD dataset, A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion)",A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion),A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion),FALSE,NA,NA,JL
10.2217/imt-2018-0208,30852924,methodology,2,NA,Inclusion of prognostic factors in the adjustment/matching model,NA,NA,Yes,TRUE,NA,NA,JL
10.2217/imt-2018-0208,30852924,methodology,2,NA,Inclusion of treatment-effect modifiers in the adjustment/matching model,NA,NA,Yes,TRUE,NA,NA,JL
10.2217/imt-2018-0208,30852924,methodology,2,NA,"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)",NA,NA,No,TRUE,NA,NA,JL
10.2217/imt-2018-0208,30852924,methodology,2,NA,Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale),NA,NA,No,TRUE,NA,NA,JL
10.2217/imt-2018-0208,30852924,results,1,NA,Sample size of the population of interest in the non IPD treatment arm,NA,NA,563,TRUE,NA,NA,JL
10.2217/imt-2018-0208,30852924,results,1,NA,Initial sample size of the population of interest in the IPD treatment arm,NA,NA,124,TRUE,NA,NA,JL
10.2217/imt-2018-0208,30852924,results,1,NA,"Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC",NA,NA,106.3,TRUE,NA,NA,JL
10.2217/imt-2018-0208,30852924,results,1,NA,Reporting of a weights' distribution evaluation (MAIC),NA,NA,Not mentioned,TRUE,NA,NA,JL
10.2217/imt-2018-0208,30852924,results,1,NA,Reporting of the list of the covariates adjusted for/matched on,NA,NA,Yes,TRUE,NA,NA,JL
10.2217/imt-2018-0208,30852924,results,1,NA,Number of covariates adjusted for/matched on,NA,NA,7,TRUE,NA,NA,JL
10.2217/imt-2018-0208,30852924,results,1,NA,Covariates adjusted for/matched on in the indirect comparison,NA,NA,"Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Past treatments for the disease of interest",TRUE,NA,NA,JL
10.2217/imt-2018-0208,30852924,results,1,NA,Primary outcome: treatment effect contrast,NA,NA,HR,TRUE,NA,NA,JL
10.2217/imt-2018-0208,30852924,results,1,NA,Direction of the treatment effect contrast: IPD treatment is:,NA,NA,"Numerator if ratio, or left side if difference",TRUE,NA,NA,JL
10.2217/imt-2018-0208,30852924,results,1,NA,Primary outcome: unadjusted treatment effect,NA,NA,0.58,TRUE,NA,NA,JL
10.2217/imt-2018-0208,30852924,results,1,NA,"p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])",NA,NA,0.001,TRUE,NA,NA,JL
10.2217/imt-2018-0208,30852924,results,1,NA,Primary outcome: adjusted treatment effect,NA,NA,0.64,TRUE,NA,NA,JL
10.2217/imt-2018-0208,30852924,results,1,NA,"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])",NA,NA,0.009,TRUE,NA,NA,JL
10.2217/imt-2018-0208,30852924,results,2,NA,Sample size of the population of interest in the non IPD treatment arm,NA,NA,247,TRUE,NA,NA,JL
10.2217/imt-2018-0208,30852924,results,2,NA,Initial sample size of the population of interest in the IPD treatment arm,NA,NA,124,TRUE,NA,NA,JL
10.2217/imt-2018-0208,30852924,results,2,NA,"Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC",NA,NA,59.2,TRUE,NA,NA,JL
10.2217/imt-2018-0208,30852924,results,2,NA,Reporting of a weights' distribution evaluation (MAIC),NA,NA,Not mentioned,TRUE,NA,NA,JL
10.2217/imt-2018-0208,30852924,results,2,NA,Reporting of the list of the covariates adjusted for/matched on,NA,NA,Yes,TRUE,NA,NA,JL
10.2217/imt-2018-0208,30852924,results,2,NA,Number of covariates adjusted for/matched on,NA,NA,8,TRUE,NA,NA,JL
10.2217/imt-2018-0208,30852924,results,2,NA,Covariates adjusted for/matched on in the indirect comparison,NA,NA,"Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Race/ethnicity, Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Other(s)",TRUE,NA,NA,JL
10.2217/imt-2018-0208,30852924,results,2,NA,Primary outcome: treatment effect contrast,NA,NA,HR,TRUE,NA,NA,JL
10.2217/imt-2018-0208,30852924,results,2,NA,Direction of the treatment effect contrast: IPD treatment is:,NA,NA,"Numerator if ratio, or left side if difference",TRUE,NA,NA,JL
10.2217/imt-2018-0208,30852924,results,2,NA,Primary outcome: unadjusted treatment effect,NA,NA,0.53,TRUE,NA,NA,JL
10.2217/imt-2018-0208,30852924,results,2,NA,"p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])",NA,NA,<0.001,TRUE,NA,NA,JL
10.2217/imt-2018-0208,30852924,results,2,NA,Primary outcome: adjusted treatment effect,NA,NA,0.56,TRUE,NA,NA,JL
10.2217/imt-2018-0208,30852924,results,2,NA,"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])",NA,NA,0.014,TRUE,NA,NA,JL
10.2217/imt-2020-0266,33228440,general_information,NA,NA,Medical Condition of Interest Name,transplant-eligible newly diagnosed multiple myeloma,multiple myeloma,XXXX,FALSE,NA,NA,JL
10.2217/imt-2020-0266,33228440,general_information,NA,NA,Countries of first author affiliations,NA,NA,france,TRUE,NA,NA,JL
10.2217/imt-2020-0266,33228440,general_information,NA,NA,Countries of last author affiliations,NA,NA,the netherlands,TRUE,NA,NA,JL
10.2217/imt-2020-0266,33228440,general_information,NA,NA,"Positions of study investigators (for any authors of the article, any that applies)",NA,NA,"Academic, Pharmaceutical Industry, Private Data Analysis Company",TRUE,NA,NA,JL
10.2217/imt-2020-0266,33228440,general_information,NA,NA,"At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company",NA,NA,Yes,TRUE,NA,NA,JL
10.2217/imt-2020-0266,33228440,general_information,NA,NA,Mentioned sources of funding,Pharmaceutical Industry,"Pharmaceutical Industry, In collaboration with the Intergroupe Francophone du My  ?elome (IFM) and Dutch-Belgian Cooperative Trial Group for Hematology Oncology (HOVON).",XXXX,FALSE,NA,NA,JL
10.2217/imt-2020-0266,33228440,general_information,NA,NA,"Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article",NA,NA,Yes,TRUE,NA,NA,JL
10.2217/imt-2020-0266,33228440,general_information,NA,NA,Mention of a systematic review to find the studies to compare treatments of interest,NA,NA,Yes,TRUE,NA,NA,JL
10.2217/imt-2020-0266,33228440,study_information,NA,1,Patient-level data used,NA,NA,Yes,TRUE,NA,NA,JL
10.2217/imt-2020-0266,33228440,study_information,NA,1,Clinical Trial,NA,NA,Yes,TRUE,NA,NA,JL
10.2217/imt-2020-0266,33228440,study_information,NA,1,NCT (only for clinical trial registered on clinicaltrials.gov),NA,NA,NCT02541383,TRUE,NA,NA,JL
10.2217/imt-2020-0266,33228440,study_information,NA,1,Country where the clinical trial/observational study was conducted (international if more than one),france,international,XXXX,FALSE,NA,NA,JL
10.2217/imt-2020-0266,33228440,study_information,NA,1,Phase of the clinical trial (clinical trial only),NA,NA,3,TRUE,NA,NA,JL
10.2217/imt-2020-0266,33228440,study_information,NA,1,Number of treatment arms (clinical trial only),NA,NA,2 or more,TRUE,NA,NA,JL
10.2217/imt-2020-0266,33228440,study_information,NA,2,Patient-level data used,NA,NA,No,TRUE,NA,NA,JL
10.2217/imt-2020-0266,33228440,study_information,NA,2,Clinical Trial,NA,NA,Yes,TRUE,NA,NA,JL
10.2217/imt-2020-0266,33228440,study_information,NA,2,NCT (only for clinical trial registered on clinicaltrials.gov),NA,NA,NCT01191060,TRUE,NA,NA,JL
10.2217/imt-2020-0266,33228440,study_information,NA,2,Country where the clinical trial/observational study was conducted (international if more than one),NA,NA,france,TRUE,NA,NA,JL
10.2217/imt-2020-0266,33228440,study_information,NA,2,Phase of the clinical trial (clinical trial only),NA,NA,3,TRUE,NA,NA,JL
10.2217/imt-2020-0266,33228440,study_information,NA,2,Number of treatment arms (clinical trial only),NA,NA,2 or more,TRUE,NA,NA,JL
10.2217/imt-2020-0266,33228440,study_information,NA,3,Patient-level data used,NA,NA,No,TRUE,NA,NA,JL
10.2217/imt-2020-0266,33228440,study_information,NA,3,Clinical Trial,NA,NA,Yes,TRUE,NA,NA,JL
10.2217/imt-2020-0266,33228440,study_information,NA,3,EudraCT (only for clinical trials registered on clinicaltrialsregister.eu,NA,NA,2010-019173-16,TRUE,NA,NA,JL
10.2217/imt-2020-0266,33228440,study_information,NA,3,Country where the clinical trial/observational study was conducted (international if more than one),NA,NA,germany,TRUE,NA,NA,JL
10.2217/imt-2020-0266,33228440,study_information,NA,3,Phase of the clinical trial (clinical trial only),NA,NA,3,TRUE,NA,NA,JL
10.2217/imt-2020-0266,33228440,study_information,NA,3,Number of treatment arms (clinical trial only),NA,NA,2 or more,TRUE,NA,NA,JL
10.2217/imt-2020-0266,33228440,study_information,NA,4,Patient-level data used,NA,NA,No,TRUE,NA,NA,JL
10.2217/imt-2020-0266,33228440,study_information,NA,4,Clinical Trial,NA,NA,Yes,TRUE,NA,NA,JL
10.2217/imt-2020-0266,33228440,study_information,NA,4,NCT (only for clinical trial registered on clinicaltrials.gov),NA,NA,NCT00200681,TRUE,NA,NA,JL
10.2217/imt-2020-0266,33228440,study_information,NA,4,Country where the clinical trial/observational study was conducted (international if more than one),NA,NA,france,TRUE,NA,NA,JL
10.2217/imt-2020-0266,33228440,study_information,NA,4,Phase of the clinical trial (clinical trial only),NA,NA,3,TRUE,NA,NA,JL
10.2217/imt-2020-0266,33228440,study_information,NA,4,Number of treatment arms (clinical trial only),NA,NA,2 or more,TRUE,NA,NA,JL
10.2217/imt-2020-0266,33228440,methodology,1,NA,Treatment name 1,"daratumumab, bortezomib, thalidomide  +  dexamethasone",daratumumab + bortezomib + thalidomide + dexamethasone,daratumumab + bortezomib + thalidomide + dexamethasone,FALSE,Supplemental materials inaccessible (paywall),N non IPD = from Survival curves,JL
10.2217/imt-2020-0266,33228440,methodology,1,NA,Study 'number(s)' for treatment 1,NA,NA,1,TRUE,NA,NA,JL
10.2217/imt-2020-0266,33228440,methodology,1,NA,Treatment name 2,"bortezomib, lenalidomide  +  dexamethasone",bortezomib + lenalidomide + dexamethasone,bortezomib + lenalidomide + dexamethasone,FALSE,NA,NA,JL
10.2217/imt-2020-0266,33228440,methodology,1,NA,Study 'number(s)' for treatment 2,NA,NA,2,TRUE,NA,NA,JL
10.2217/imt-2020-0266,33228440,methodology,1,NA,Type of population-adjusted indirect comparisons performed,NA,NA,MAIC,TRUE,NA,NA,JL
10.2217/imt-2020-0266,33228440,methodology,1,NA,Anchored comparison?,NA,NA,No,TRUE,NA,NA,JL
10.2217/imt-2020-0266,33228440,methodology,1,NA,Form of the indirect comparison,NA,NA,Simple (ie treatments effects extracted from two studies),TRUE,NA,NA,JL
10.2217/imt-2020-0266,33228440,methodology,1,NA,Definition of a single primary outcome for the indirect comparison,NA,NA,"No primary outcome defined, or multiple primary outcomes without any clear distinction between them",TRUE,NA,NA,JL
10.2217/imt-2020-0266,33228440,methodology,1,NA,Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined),NA,NA,progression-free survival,TRUE,NA,NA,JL
10.2217/imt-2020-0266,33228440,methodology,1,NA,Primary outcome: variable type,NA,NA,Time-to-event,TRUE,NA,NA,JL
10.2217/imt-2020-0266,33228440,methodology,1,NA,Justification for selecting variables to be included in the adjustment model (in the main text),NA,NA,A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion),TRUE,NA,NA,JL
10.2217/imt-2020-0266,33228440,methodology,1,NA,Inclusion of prognostic factors in the adjustment/matching model,NA,NA,Yes,TRUE,NA,NA,JL
10.2217/imt-2020-0266,33228440,methodology,1,NA,Inclusion of treatment-effect modifiers in the adjustment/matching model,NA,NA,Yes,TRUE,NA,NA,JL
10.2217/imt-2020-0266,33228440,methodology,1,NA,"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)",NA,NA,No,TRUE,NA,NA,JL
10.2217/imt-2020-0266,33228440,methodology,1,NA,Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale),NA,NA,No,TRUE,NA,NA,JL
10.2217/imt-2020-0266,33228440,methodology,2,NA,Treatment name 1,"bortezomib, thalidomide  +  dexamethasone",bortezomib + thalidomide + dexamethasone,bortezomib + thalidomide + dexamethasone,FALSE,NA,N non IPD = from Survival curves,JL
10.2217/imt-2020-0266,33228440,methodology,2,NA,Study 'number(s)' for treatment 1,NA,NA,1,TRUE,NA,NA,JL
10.2217/imt-2020-0266,33228440,methodology,2,NA,Treatment name 2,"bortezomib, lenalidomide  +  dexamethasone",bortezomib + lenalidomide + dexamethasone,bortezomib + lenalidomide + dexamethasone,FALSE,NA,NA,JL
10.2217/imt-2020-0266,33228440,methodology,2,NA,Study 'number(s)' for treatment 2,NA,NA,2,TRUE,NA,NA,JL
10.2217/imt-2020-0266,33228440,methodology,2,NA,Type of population-adjusted indirect comparisons performed,NA,NA,MAIC,TRUE,NA,NA,JL
10.2217/imt-2020-0266,33228440,methodology,2,NA,Anchored comparison?,NA,NA,No,TRUE,NA,NA,JL
10.2217/imt-2020-0266,33228440,methodology,2,NA,Form of the indirect comparison,NA,NA,Simple (ie treatments effects extracted from two studies),TRUE,NA,NA,JL
10.2217/imt-2020-0266,33228440,methodology,2,NA,Definition of a single primary outcome for the indirect comparison,NA,NA,"No primary outcome defined, or multiple primary outcomes without any clear distinction between them",TRUE,NA,NA,JL
10.2217/imt-2020-0266,33228440,methodology,2,NA,Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined),NA,NA,progression-free survival,TRUE,NA,NA,JL
10.2217/imt-2020-0266,33228440,methodology,2,NA,Primary outcome: variable type,NA,NA,Time-to-event,TRUE,NA,NA,JL
10.2217/imt-2020-0266,33228440,methodology,2,NA,Justification for selecting variables to be included in the adjustment model (in the main text),NA,NA,A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion),TRUE,NA,NA,JL
10.2217/imt-2020-0266,33228440,methodology,2,NA,Inclusion of prognostic factors in the adjustment/matching model,NA,NA,Yes,TRUE,NA,NA,JL
10.2217/imt-2020-0266,33228440,methodology,2,NA,Inclusion of treatment-effect modifiers in the adjustment/matching model,NA,NA,Yes,TRUE,NA,NA,JL
10.2217/imt-2020-0266,33228440,methodology,2,NA,"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)",NA,NA,No,TRUE,NA,NA,JL
10.2217/imt-2020-0266,33228440,methodology,2,NA,Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale),NA,NA,No,TRUE,NA,NA,JL
10.2217/imt-2020-0266,33228440,methodology,3,NA,Treatment name 1,"daratumumab, bortezomib, thalidomide  +  dexamethasone",daratumumab + bortezomib + thalidomide + dexamethasone,daratumumab + bortezomib + thalidomide + dexamethasone,FALSE,NA,"N non IPD = from Survival curves
Baseline covariates based on clinical opinion as with D-VTd & VTd versus VRd analysis ??
Creatinine = comorbidities",JL
10.2217/imt-2020-0266,33228440,methodology,3,NA,Study 'number(s)' for treatment 1,NA,NA,1,TRUE,NA,NA,JL
10.2217/imt-2020-0266,33228440,methodology,3,NA,Treatment name 2,"bortezomib, cyclophosphamide  +  dexamethasone",bortezomib + cyclophosphamide + dexamethasone,bortezomib + cyclophosphamide + dexamethasone,FALSE,NA,NA,JL
10.2217/imt-2020-0266,33228440,methodology,3,NA,Study 'number(s)' for treatment 2,NA,NA,3,TRUE,NA,NA,JL
10.2217/imt-2020-0266,33228440,methodology,3,NA,Type of population-adjusted indirect comparisons performed,NA,NA,MAIC,TRUE,NA,NA,JL
10.2217/imt-2020-0266,33228440,methodology,3,NA,Anchored comparison?,NA,NA,No,TRUE,NA,NA,JL
10.2217/imt-2020-0266,33228440,methodology,3,NA,Form of the indirect comparison,NA,NA,Simple (ie treatments effects extracted from two studies),TRUE,NA,NA,JL
10.2217/imt-2020-0266,33228440,methodology,3,NA,Definition of a single primary outcome for the indirect comparison,NA,NA,"No primary outcome defined, or multiple primary outcomes without any clear distinction between them",TRUE,NA,NA,JL
10.2217/imt-2020-0266,33228440,methodology,3,NA,Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined),NA,NA,progression-free survival,TRUE,NA,NA,JL
10.2217/imt-2020-0266,33228440,methodology,3,NA,Primary outcome: variable type,NA,NA,Time-to-event,TRUE,NA,NA,JL
10.2217/imt-2020-0266,33228440,methodology,3,NA,Justification for selecting variables to be included in the adjustment model (in the main text),A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion),"Nothing mentioned, not reported",A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion),FALSE,NA,NA,JL
10.2217/imt-2020-0266,33228440,methodology,3,NA,Inclusion of prognostic factors in the adjustment/matching model,NA,NA,Yes,TRUE,NA,NA,JL
10.2217/imt-2020-0266,33228440,methodology,3,NA,Inclusion of treatment-effect modifiers in the adjustment/matching model,NA,NA,Yes,TRUE,NA,NA,JL
10.2217/imt-2020-0266,33228440,methodology,3,NA,"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)",NA,NA,No,TRUE,NA,NA,JL
10.2217/imt-2020-0266,33228440,methodology,3,NA,Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale),NA,NA,No,TRUE,NA,NA,JL
10.2217/imt-2020-0266,33228440,methodology,4,NA,Treatment name 1,"bortezomib, thalidomide  +  dexamethasone",bortezomib + thalidomide + dexamethasone,bortezomib + thalidomide + dexamethasone,FALSE,NA,"N non IPD = from Survival curves
Baseline covariates based on clinical opinion as with D-VTd & VTd versus VRd analysis ??
Creatinine = comorbidities",JL
10.2217/imt-2020-0266,33228440,methodology,4,NA,Study 'number(s)' for treatment 1,NA,NA,1,TRUE,NA,NA,JL
10.2217/imt-2020-0266,33228440,methodology,4,NA,Treatment name 2,"bortezomib, cyclophosphamide  +  dexamethasone",bortezomib + cyclophosphamide + dexamethasone,bortezomib + cyclophosphamide + dexamethasone,FALSE,NA,NA,JL
10.2217/imt-2020-0266,33228440,methodology,4,NA,Study 'number(s)' for treatment 2,NA,NA,3,TRUE,NA,NA,JL
10.2217/imt-2020-0266,33228440,methodology,4,NA,Type of population-adjusted indirect comparisons performed,NA,NA,MAIC,TRUE,NA,NA,JL
10.2217/imt-2020-0266,33228440,methodology,4,NA,Anchored comparison?,NA,NA,No,TRUE,NA,NA,JL
10.2217/imt-2020-0266,33228440,methodology,4,NA,Form of the indirect comparison,NA,NA,Simple (ie treatments effects extracted from two studies),TRUE,NA,NA,JL
10.2217/imt-2020-0266,33228440,methodology,4,NA,Definition of a single primary outcome for the indirect comparison,NA,NA,"No primary outcome defined, or multiple primary outcomes without any clear distinction between them",TRUE,NA,NA,JL
10.2217/imt-2020-0266,33228440,methodology,4,NA,Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined),NA,NA,progression-free survival,TRUE,NA,NA,JL
10.2217/imt-2020-0266,33228440,methodology,4,NA,Primary outcome: variable type,NA,NA,Time-to-event,TRUE,NA,NA,JL
10.2217/imt-2020-0266,33228440,methodology,4,NA,Justification for selecting variables to be included in the adjustment model (in the main text),A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion),"Nothing mentioned, not reported",A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion),FALSE,NA,NA,JL
10.2217/imt-2020-0266,33228440,methodology,4,NA,Inclusion of prognostic factors in the adjustment/matching model,NA,NA,Yes,TRUE,NA,NA,JL
10.2217/imt-2020-0266,33228440,methodology,4,NA,Inclusion of treatment-effect modifiers in the adjustment/matching model,NA,NA,Yes,TRUE,NA,NA,JL
10.2217/imt-2020-0266,33228440,methodology,4,NA,"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)",NA,NA,No,TRUE,NA,NA,JL
10.2217/imt-2020-0266,33228440,methodology,4,NA,Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale),NA,NA,No,TRUE,NA,NA,JL
10.2217/imt-2020-0266,33228440,methodology,5,NA,Treatment name 1,"daratumumab, bortezomib, thalidomide  +  dexamethasone",daratumumab + bortezomib + thalidomide + dexamethasone,daratumumab + bortezomib + thalidomide + dexamethasone,FALSE,NA,"N non IPD = from Survival curves
Baseline covariates based on clinical opinion as with D-VTd & VTd versus VRd analysis ??",JL
10.2217/imt-2020-0266,33228440,methodology,5,NA,Study 'number(s)' for treatment 1,NA,NA,1,TRUE,NA,NA,JL
10.2217/imt-2020-0266,33228440,methodology,5,NA,Treatment name 2,bortezomib  +  dexamethasone,bortezomib + dexamethasone,bortezomib + dexamethasone,FALSE,NA,NA,JL
10.2217/imt-2020-0266,33228440,methodology,5,NA,Study 'number(s)' for treatment 2,NA,NA,4,TRUE,NA,NA,JL
10.2217/imt-2020-0266,33228440,methodology,5,NA,Type of population-adjusted indirect comparisons performed,NA,NA,MAIC,TRUE,NA,NA,JL
10.2217/imt-2020-0266,33228440,methodology,5,NA,Anchored comparison?,NA,NA,No,TRUE,NA,NA,JL
10.2217/imt-2020-0266,33228440,methodology,5,NA,Form of the indirect comparison,NA,NA,Simple (ie treatments effects extracted from two studies),TRUE,NA,NA,JL
10.2217/imt-2020-0266,33228440,methodology,5,NA,Definition of a single primary outcome for the indirect comparison,NA,NA,"No primary outcome defined, or multiple primary outcomes without any clear distinction between them",TRUE,NA,NA,JL
10.2217/imt-2020-0266,33228440,methodology,5,NA,Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined),NA,NA,progression-free survival,TRUE,NA,NA,JL
10.2217/imt-2020-0266,33228440,methodology,5,NA,Primary outcome: variable type,NA,NA,Time-to-event,TRUE,NA,NA,JL
10.2217/imt-2020-0266,33228440,methodology,5,NA,Justification for selecting variables to be included in the adjustment model (in the main text),A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion),"Nothing mentioned, not reported",A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion),FALSE,NA,NA,JL
10.2217/imt-2020-0266,33228440,methodology,5,NA,Inclusion of prognostic factors in the adjustment/matching model,NA,NA,Yes,TRUE,NA,NA,JL
10.2217/imt-2020-0266,33228440,methodology,5,NA,Inclusion of treatment-effect modifiers in the adjustment/matching model,NA,NA,Yes,TRUE,NA,NA,JL
10.2217/imt-2020-0266,33228440,methodology,5,NA,"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)",NA,NA,No,TRUE,NA,NA,JL
10.2217/imt-2020-0266,33228440,methodology,5,NA,Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale),NA,NA,No,TRUE,NA,NA,JL
10.2217/imt-2020-0266,33228440,methodology,6,NA,Treatment name 1,"bortezomib, thalidomide  +  dexamethasone",bortezomib + thalidomide + dexamethasone,bortezomib + thalidomide + dexamethasone,FALSE,NA,"N non IPD = from Survival curves
Baseline covariates based on clinical opinion as with D-VTd & VTd versus VRd analysis ??",JL
10.2217/imt-2020-0266,33228440,methodology,6,NA,Study 'number(s)' for treatment 1,NA,NA,1,TRUE,NA,NA,JL
10.2217/imt-2020-0266,33228440,methodology,6,NA,Treatment name 2,bortezomib  +  dexamethasone,bortezomib + dexamethasone,bortezomib + dexamethasone,FALSE,NA,NA,JL
10.2217/imt-2020-0266,33228440,methodology,6,NA,Study 'number(s)' for treatment 2,4,5,4,FALSE,NA,NA,JL
10.2217/imt-2020-0266,33228440,methodology,6,NA,Type of population-adjusted indirect comparisons performed,NA,NA,MAIC,TRUE,NA,NA,JL
10.2217/imt-2020-0266,33228440,methodology,6,NA,Anchored comparison?,NA,NA,No,TRUE,NA,NA,JL
10.2217/imt-2020-0266,33228440,methodology,6,NA,Form of the indirect comparison,NA,NA,Simple (ie treatments effects extracted from two studies),TRUE,NA,NA,JL
10.2217/imt-2020-0266,33228440,methodology,6,NA,Definition of a single primary outcome for the indirect comparison,NA,NA,"No primary outcome defined, or multiple primary outcomes without any clear distinction between them",TRUE,NA,NA,JL
10.2217/imt-2020-0266,33228440,methodology,6,NA,Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined),NA,NA,progression-free survival,TRUE,NA,NA,JL
10.2217/imt-2020-0266,33228440,methodology,6,NA,Primary outcome: variable type,NA,NA,Time-to-event,TRUE,NA,NA,JL
10.2217/imt-2020-0266,33228440,methodology,6,NA,Justification for selecting variables to be included in the adjustment model (in the main text),A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion),"Nothing mentioned, not reported",A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion),FALSE,NA,NA,JL
10.2217/imt-2020-0266,33228440,methodology,6,NA,Inclusion of prognostic factors in the adjustment/matching model,NA,NA,Yes,TRUE,NA,NA,JL
10.2217/imt-2020-0266,33228440,methodology,6,NA,Inclusion of treatment-effect modifiers in the adjustment/matching model,NA,NA,Yes,TRUE,NA,NA,JL
10.2217/imt-2020-0266,33228440,methodology,6,NA,"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)",NA,NA,No,TRUE,NA,NA,JL
10.2217/imt-2020-0266,33228440,methodology,6,NA,Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale),NA,NA,No,TRUE,NA,NA,JL
10.2217/imt-2020-0266,33228440,results,1,NA,Initial sample size of the population of interest in the IPD treatment arm,NA,NA,543,TRUE,NA,NA,JL
10.2217/imt-2020-0266,33228440,results,1,NA,"Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC",525,529,529,FALSE,NA,NA,JL
10.2217/imt-2020-0266,33228440,results,1,NA,Reporting of a weights' distribution evaluation (MAIC),NA,NA,Not mentioned,TRUE,NA,NA,JL
10.2217/imt-2020-0266,33228440,results,1,NA,Reporting of the list of the covariates adjusted for/matched on,NA,NA,Yes,TRUE,NA,NA,JL
10.2217/imt-2020-0266,33228440,results,1,NA,Number of covariates adjusted for/matched on,NA,NA,4,TRUE,NA,NA,JL
10.2217/imt-2020-0266,33228440,results,1,NA,Covariates adjusted for/matched on in the indirect comparison,NA,NA,"Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease)",TRUE,NA,NA,JL
10.2217/imt-2020-0266,33228440,results,1,NA,Primary outcome: treatment effect contrast,NA,NA,HR,TRUE,NA,NA,JL
10.2217/imt-2020-0266,33228440,results,1,NA,Direction of the treatment effect contrast: IPD treatment is:,NA,NA,"Numerator if ratio, or left side if difference",TRUE,NA,NA,JL
10.2217/imt-2020-0266,33228440,results,1,NA,Primary outcome: unadjusted treatment effect,NA,NA,0.48,TRUE,NA,NA,JL
10.2217/imt-2020-0266,33228440,results,1,NA,"p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])",NA,NA,<0.001,TRUE,NA,NA,JL
10.2217/imt-2020-0266,33228440,results,1,NA,Primary outcome: adjusted treatment effect,NA,NA,0.47,TRUE,NA,NA,JL
10.2217/imt-2020-0266,33228440,results,1,NA,"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])",NA,NA,<0.001,TRUE,NA,NA,JL
10.2217/imt-2020-0266,33228440,results,1,NA,Sample size of the population of interest in the non IPD treatment arm,NA,350,350,FALSE,NA,NA,JL
10.2217/imt-2020-0266,33228440,results,2,NA,Initial sample size of the population of interest in the IPD treatment arm,NA,NA,542,TRUE,NA,NA,JL
10.2217/imt-2020-0266,33228440,results,2,NA,"Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC",NA,NA,515,TRUE,NA,NA,JL
10.2217/imt-2020-0266,33228440,results,2,NA,Reporting of a weights' distribution evaluation (MAIC),NA,NA,Not mentioned,TRUE,NA,NA,JL
10.2217/imt-2020-0266,33228440,results,2,NA,Reporting of the list of the covariates adjusted for/matched on,NA,NA,Yes,TRUE,NA,NA,JL
10.2217/imt-2020-0266,33228440,results,2,NA,Number of covariates adjusted for/matched on,NA,NA,4,TRUE,NA,NA,JL
10.2217/imt-2020-0266,33228440,results,2,NA,Covariates adjusted for/matched on in the indirect comparison,NA,NA,"Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease)",TRUE,NA,NA,JL
10.2217/imt-2020-0266,33228440,results,2,NA,Primary outcome: treatment effect contrast,NA,NA,HR,TRUE,NA,NA,JL
10.2217/imt-2020-0266,33228440,results,2,NA,Direction of the treatment effect contrast: IPD treatment is:,NA,NA,"Numerator if ratio, or left side if difference",TRUE,NA,NA,JL
10.2217/imt-2020-0266,33228440,results,2,NA,Primary outcome: unadjusted treatment effect,NA,NA,1.07,TRUE,NA,NA,JL
10.2217/imt-2020-0266,33228440,results,2,NA,"p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])",NA,NA,0.655,TRUE,NA,NA,JL
10.2217/imt-2020-0266,33228440,results,2,NA,Primary outcome: adjusted treatment effect,NA,NA,1.13,TRUE,NA,NA,JL
10.2217/imt-2020-0266,33228440,results,2,NA,"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])",NA,NA,0.419,TRUE,NA,NA,JL
10.2217/imt-2020-0266,33228440,results,2,NA,Sample size of the population of interest in the non IPD treatment arm,NA,350,350,FALSE,NA,NA,JL
10.2217/imt-2020-0266,33228440,results,3,NA,Initial sample size of the population of interest in the IPD treatment arm,NA,NA,543,TRUE,NA,NA,JL
10.2217/imt-2020-0266,33228440,results,3,NA,"Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC",NA,NA,206,TRUE,NA,NA,JL
10.2217/imt-2020-0266,33228440,results,3,NA,Reporting of a weights' distribution evaluation (MAIC),NA,NA,Not mentioned,TRUE,NA,NA,JL
10.2217/imt-2020-0266,33228440,results,3,NA,Reporting of the list of the covariates adjusted for/matched on,NA,NA,Yes,TRUE,NA,NA,JL
10.2217/imt-2020-0266,33228440,results,3,NA,Number of covariates adjusted for/matched on,NA,NA,12,TRUE,NA,NA,JL
10.2217/imt-2020-0266,33228440,results,3,NA,Covariates adjusted for/matched on in the indirect comparison,"Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Other(s)","Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Comorbidities and medical history (beside pathology/disease of interest in the comparison)","Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Other(s)",FALSE,NA,NA,JL
10.2217/imt-2020-0266,33228440,results,3,NA,Primary outcome: treatment effect contrast,NA,NA,HR,TRUE,NA,NA,JL
10.2217/imt-2020-0266,33228440,results,3,NA,Direction of the treatment effect contrast: IPD treatment is:,NA,NA,"Numerator if ratio, or left side if difference",TRUE,NA,NA,JL
10.2217/imt-2020-0266,33228440,results,3,NA,Primary outcome: unadjusted treatment effect,NA,NA,0.4,TRUE,NA,NA,JL
10.2217/imt-2020-0266,33228440,results,3,NA,"p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])",NA,NA,<0.001,TRUE,NA,NA,JL
10.2217/imt-2020-0266,33228440,results,3,NA,Primary outcome: adjusted treatment effect,NA,NA,0.35,TRUE,NA,NA,JL
10.2217/imt-2020-0266,33228440,results,3,NA,"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])",NA,NA,<0.001,TRUE,NA,NA,JL
10.2217/imt-2020-0266,33228440,results,3,NA,Sample size of the population of interest in the non IPD treatment arm,NA,125,125,FALSE,NA,NA,JL
10.2217/imt-2020-0266,33228440,results,4,NA,Initial sample size of the population of interest in the IPD treatment arm,NA,NA,542,TRUE,NA,NA,JL
10.2217/imt-2020-0266,33228440,results,4,NA,"Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC",NA,NA,211,TRUE,NA,NA,JL
10.2217/imt-2020-0266,33228440,results,4,NA,Reporting of a weights' distribution evaluation (MAIC),NA,NA,Not mentioned,TRUE,NA,NA,JL
10.2217/imt-2020-0266,33228440,results,4,NA,Reporting of the list of the covariates adjusted for/matched on,NA,NA,Yes,TRUE,NA,NA,JL
10.2217/imt-2020-0266,33228440,results,4,NA,Number of covariates adjusted for/matched on,NA,NA,12,TRUE,NA,NA,JL
10.2217/imt-2020-0266,33228440,results,4,NA,Covariates adjusted for/matched on in the indirect comparison,"Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Other(s)","Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Comorbidities and medical history (beside pathology/disease of interest in the comparison)","Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Other(s)",FALSE,NA,NA,JL
10.2217/imt-2020-0266,33228440,results,4,NA,Primary outcome: treatment effect contrast,NA,NA,HR,TRUE,NA,NA,JL
10.2217/imt-2020-0266,33228440,results,4,NA,Direction of the treatment effect contrast: IPD treatment is:,NA,NA,"Numerator if ratio, or left side if difference",TRUE,NA,NA,JL
10.2217/imt-2020-0266,33228440,results,4,NA,Primary outcome: unadjusted treatment effect,0.4,0.89,0.89,FALSE,NA,NA,JL
10.2217/imt-2020-0266,33228440,results,4,NA,"p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])",<0.001,0.549,0.549,FALSE,NA,NA,JL
10.2217/imt-2020-0266,33228440,results,4,NA,Primary outcome: adjusted treatment effect,0.35,1,1,FALSE,NA,NA,JL
10.2217/imt-2020-0266,33228440,results,4,NA,"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])",<0.001,0.987,0.987,FALSE,NA,NA,JL
10.2217/imt-2020-0266,33228440,results,4,NA,Sample size of the population of interest in the non IPD treatment arm,NA,126,126,FALSE,NA,NA,JL
10.2217/imt-2020-0266,33228440,results,5,NA,Initial sample size of the population of interest in the IPD treatment arm,NA,NA,543,TRUE,NA,NA,JL
10.2217/imt-2020-0266,33228440,results,5,NA,"Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC",NA,NA,416,TRUE,NA,NA,JL
10.2217/imt-2020-0266,33228440,results,5,NA,Reporting of a weights' distribution evaluation (MAIC),NA,NA,Not mentioned,TRUE,NA,NA,JL
10.2217/imt-2020-0266,33228440,results,5,NA,Reporting of the list of the covariates adjusted for/matched on,NA,NA,Yes,TRUE,NA,NA,JL
10.2217/imt-2020-0266,33228440,results,5,NA,Number of covariates adjusted for/matched on,NA,NA,7,TRUE,NA,NA,JL
10.2217/imt-2020-0266,33228440,results,5,NA,Covariates adjusted for/matched on in the indirect comparison,"Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Other(s)","Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease)","Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Other(s)",FALSE,NA,NA,JL
10.2217/imt-2020-0266,33228440,results,5,NA,Primary outcome: treatment effect contrast,NA,NA,HR,TRUE,NA,NA,JL
10.2217/imt-2020-0266,33228440,results,5,NA,Direction of the treatment effect contrast: IPD treatment is:,NA,NA,"Numerator if ratio, or left side if difference",TRUE,NA,NA,JL
10.2217/imt-2020-0266,33228440,results,5,NA,Primary outcome: unadjusted treatment effect,NA,NA,0.37,TRUE,NA,NA,JL
10.2217/imt-2020-0266,33228440,results,5,NA,"p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])",NA,NA,<0.001,TRUE,NA,NA,JL
10.2217/imt-2020-0266,33228440,results,5,NA,Primary outcome: adjusted treatment effect,NA,NA,0.42,TRUE,NA,NA,JL
10.2217/imt-2020-0266,33228440,results,5,NA,"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])",NA,NA,<0.001,TRUE,NA,NA,JL
10.2217/imt-2020-0266,33228440,results,5,NA,Sample size of the population of interest in the non IPD treatment arm,NA,240,240,FALSE,NA,NA,JL
10.2217/imt-2020-0266,33228440,results,6,NA,Initial sample size of the population of interest in the IPD treatment arm,NA,NA,542,TRUE,NA,NA,JL
10.2217/imt-2020-0266,33228440,results,6,NA,"Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC",NA,NA,393,TRUE,NA,NA,JL
10.2217/imt-2020-0266,33228440,results,6,NA,Reporting of a weights' distribution evaluation (MAIC),NA,NA,Not mentioned,TRUE,NA,NA,JL
10.2217/imt-2020-0266,33228440,results,6,NA,Reporting of the list of the covariates adjusted for/matched on,NA,NA,Yes,TRUE,NA,NA,JL
10.2217/imt-2020-0266,33228440,results,6,NA,Number of covariates adjusted for/matched on,NA,NA,7,TRUE,NA,NA,JL
10.2217/imt-2020-0266,33228440,results,6,NA,Covariates adjusted for/matched on in the indirect comparison,"Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Other(s)","Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease)","Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Other(s)",FALSE,NA,NA,JL
10.2217/imt-2020-0266,33228440,results,6,NA,Primary outcome: treatment effect contrast,NA,NA,HR,TRUE,NA,NA,JL
10.2217/imt-2020-0266,33228440,results,6,NA,Direction of the treatment effect contrast: IPD treatment is:,NA,NA,"Numerator if ratio, or left side if difference",TRUE,NA,NA,JL
10.2217/imt-2020-0266,33228440,results,6,NA,Primary outcome: unadjusted treatment effect,NA,NA,0.82,TRUE,NA,NA,JL
10.2217/imt-2020-0266,33228440,results,6,NA,"p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])",NA,NA,0.222,TRUE,NA,NA,JL
10.2217/imt-2020-0266,33228440,results,6,NA,Primary outcome: adjusted treatment effect,NA,NA,0.94,TRUE,NA,NA,JL
10.2217/imt-2020-0266,33228440,results,6,NA,"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])",NA,NA,0.738,TRUE,NA,NA,JL
10.2217/imt-2020-0266,33228440,results,6,NA,Sample size of the population of interest in the non IPD treatment arm,NA,240,240,FALSE,NA,NA,JL
10.3390/cancers12123648,33291810,general_information,NA,NA,Medical Condition of Interest Name,metastatic non small cell lung cancer,metastatic stage iv nsclc (non-small-cell lung carcinoma) with pd-l1 tumor proportion score (tps) ?1%.,XXXX,FALSE,NA,NA,JL
10.3390/cancers12123648,33291810,general_information,NA,NA,Countries of first author affiliations,NA,NA,usa,TRUE,NA,NA,JL
10.3390/cancers12123648,33291810,general_information,NA,NA,Countries of last author affiliations,NA,NA,usa,TRUE,NA,NA,JL
10.3390/cancers12123648,33291810,general_information,NA,NA,"Positions of study investigators (for any authors of the article, any that applies)",NA,NA,"Academic, Pharmaceutical Industry, Private Data Analysis Company",TRUE,NA,NA,JL
10.3390/cancers12123648,33291810,general_information,NA,NA,"At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company",NA,NA,Yes,TRUE,NA,NA,JL
10.3390/cancers12123648,33291810,general_information,NA,NA,Mentioned sources of funding,NA,NA,Pharmaceutical Industry,TRUE,NA,NA,JL
10.3390/cancers12123648,33291810,general_information,NA,NA,"Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article",NA,NA,Yes,TRUE,NA,NA,JL
10.3390/cancers12123648,33291810,general_information,NA,NA,Mention of a systematic review to find the studies to compare treatments of interest,NA,NA,Yes,TRUE,NA,NA,JL
10.3390/cancers12123648,33291810,study_information,NA,1,Patient-level data used,NA,NA,Yes,TRUE,NA,NA,JL
10.3390/cancers12123648,33291810,study_information,NA,1,Clinical Trial,NA,NA,Yes,TRUE,NA,NA,JL
10.3390/cancers12123648,33291810,study_information,NA,1,NCT (only for clinical trial registered on clinicaltrials.gov),NA,NA,NCT02039674,TRUE,NA,NA,JL
10.3390/cancers12123648,33291810,study_information,NA,1,Country where the clinical trial/observational study was conducted (international if more than one),unknown,NA,XXXX,FALSE,NA,NA,JL
10.3390/cancers12123648,33291810,study_information,NA,1,Phase of the clinical trial (clinical trial only),NA,NA,"1, 2",TRUE,NA,NA,JL
10.3390/cancers12123648,33291810,study_information,NA,1,Number of treatment arms (clinical trial only),NA,NA,2 or more,TRUE,NA,NA,JL
10.3390/cancers12123648,33291810,study_information,NA,2,Patient-level data used,NA,NA,Yes,TRUE,NA,NA,JL
10.3390/cancers12123648,33291810,study_information,NA,2,Clinical Trial,NA,NA,Yes,TRUE,NA,NA,JL
10.3390/cancers12123648,33291810,study_information,NA,2,NCT (only for clinical trial registered on clinicaltrials.gov),NA,NA,NCT02578680,TRUE,NA,NA,JL
10.3390/cancers12123648,33291810,study_information,NA,2,Country where the clinical trial/observational study was conducted (international if more than one),unknown,NA,XXXX,FALSE,NA,NA,JL
10.3390/cancers12123648,33291810,study_information,NA,2,Phase of the clinical trial (clinical trial only),NA,NA,3,TRUE,NA,NA,JL
10.3390/cancers12123648,33291810,study_information,NA,2,Number of treatment arms (clinical trial only),NA,NA,2 or more,TRUE,NA,NA,JL
10.3390/cancers12123648,33291810,study_information,NA,3,Patient-level data used,NA,NA,Yes,TRUE,NA,NA,JL
10.3390/cancers12123648,33291810,study_information,NA,3,Clinical Trial,NA,NA,Yes,TRUE,NA,NA,JL
10.3390/cancers12123648,33291810,study_information,NA,3,NCT (only for clinical trial registered on clinicaltrials.gov),NA,NA,NCT02775435,TRUE,NA,NA,JL
10.3390/cancers12123648,33291810,study_information,NA,3,Country where the clinical trial/observational study was conducted (international if more than one),unknown,NA,XXXX,FALSE,NA,NA,JL
10.3390/cancers12123648,33291810,study_information,NA,3,Phase of the clinical trial (clinical trial only),NA,NA,3,TRUE,NA,NA,JL
10.3390/cancers12123648,33291810,study_information,NA,3,Number of treatment arms (clinical trial only),NA,NA,2 or more,TRUE,NA,NA,JL
10.3390/cancers12123648,33291810,study_information,NA,4,Patient-level data used,NA,NA,No,TRUE,NA,NA,JL
10.3390/cancers12123648,33291810,study_information,NA,4,Clinical Trial,NA,NA,Yes,TRUE,NA,NA,JL
10.3390/cancers12123648,33291810,study_information,NA,4,NCT (only for clinical trial registered on clinicaltrials.gov),NA,NA,NCT02477826,TRUE,NA,NA,JL
10.3390/cancers12123648,33291810,study_information,NA,4,Country where the clinical trial/observational study was conducted (international if more than one),NA,NA,international,TRUE,NA,NA,JL
10.3390/cancers12123648,33291810,study_information,NA,4,Phase of the clinical trial (clinical trial only),NA,NA,3,TRUE,NA,NA,JL
10.3390/cancers12123648,33291810,study_information,NA,4,Number of treatment arms (clinical trial only),NA,NA,2 or more,TRUE,NA,NA,JL
10.3390/cancers12123648,33291810,methodology,1,NA,Treatment name 1,NA,NA,pembrolizumab + chemotherapy,TRUE,"Say that the ESS cannot be easily calculated because survival data, therefore use the number of patients at risk computed from the sum of weights was used
No detail about sample size of individual treatment arms and anchor: 
	N IPD=816  ESS=456 
	N nonIPD=793","Primary approach

Unadjusted treatment effect ==> From Supplementary Materials

Smoking status = others

N (2 arms) :
N non IPD = 793
N IPD = 816
ESS IPD = 456
",JL
10.3390/cancers12123648,33291810,methodology,1,NA,Study 'number(s)' for treatment 1,NA,NA,1;2;3,TRUE,NA,NA,JL
10.3390/cancers12123648,33291810,methodology,1,NA,Treatment name 2,NA,NA,nivolumab + ipilimumab,TRUE,NA,NA,JL
10.3390/cancers12123648,33291810,methodology,1,NA,Study 'number(s)' for treatment 2,NA,NA,4,TRUE,NA,NA,JL
10.3390/cancers12123648,33291810,methodology,1,NA,Type of population-adjusted indirect comparisons performed,NA,NA,MAIC,TRUE,NA,NA,JL
10.3390/cancers12123648,33291810,methodology,1,NA,Anchored comparison?,NA,NA,Yes,TRUE,NA,NA,JL
10.3390/cancers12123648,33291810,methodology,1,NA,Form of the indirect comparison,NA,NA,"Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate)",TRUE,NA,NA,JL
10.3390/cancers12123648,33291810,methodology,1,NA,Definition of a single primary outcome for the indirect comparison,NA,NA,"No primary outcome defined, or multiple primary outcomes without any clear distinction between them",TRUE,NA,NA,JL
10.3390/cancers12123648,33291810,methodology,1,NA,Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined),NA,NA,overall survival,TRUE,NA,NA,JL
10.3390/cancers12123648,33291810,methodology,1,NA,Primary outcome: variable type,NA,NA,Time-to-event,TRUE,NA,NA,JL
10.3390/cancers12123648,33291810,methodology,1,NA,Justification for selecting variables to be included in the adjustment model (in the main text),"Nothing mentioned, not reported","Statistical imbalanced between treatment groups (independently of the status of prognostic/effect modifier), A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion), Literature based (clinically or methodologically relevant to adjust on these variables based on the literature search conducted for this specific purpose)","Statistical imbalanced between treatment groups (independently of the status of prognostic/effect modifier), A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion), Literature based (clinically or methodologically relevant to adjust on these variables based on the literature search conducted for this specific purpose)",FALSE,NA,NA,JL
10.3390/cancers12123648,33291810,methodology,1,NA,Inclusion of prognostic factors in the adjustment/matching model,No discussion (in the main text) of the status of prognostic factors of the variables,No,No,FALSE,NA,NA,JL
10.3390/cancers12123648,33291810,methodology,1,NA,Inclusion of treatment-effect modifiers in the adjustment/matching model,No discussion (in the main text) of the status of treatment-effect modifiers of the variables,Yes,Yes,FALSE,NA,NA,JL
10.3390/cancers12123648,33291810,methodology,1,NA,"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)",NA,NA,No,TRUE,NA,NA,JL
10.3390/cancers12123648,33291810,methodology,1,NA,Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale),NA,NA,No,TRUE,NA,NA,JL
10.3390/cancers12123648,33291810,results,1,NA,Reporting of a weights' distribution evaluation (MAIC),NA,NA,Not mentioned,TRUE,NA,NA,JL
10.3390/cancers12123648,33291810,results,1,NA,Reporting of the list of the covariates adjusted for/matched on,NA,NA,Yes,TRUE,NA,NA,JL
10.3390/cancers12123648,33291810,results,1,NA,Number of covariates adjusted for/matched on,NA,NA,8,TRUE,NA,NA,JL
10.3390/cancers12123648,33291810,results,1,NA,Covariates adjusted for/matched on in the indirect comparison,NA,NA,"Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Other(s)",TRUE,NA,NA,JL
10.3390/cancers12123648,33291810,results,1,NA,Primary outcome: treatment effect contrast,NA,NA,HR,TRUE,NA,NA,JL
10.3390/cancers12123648,33291810,results,1,NA,Direction of the treatment effect contrast: IPD treatment is:,NA,NA,"Numerator if ratio, or left side if difference",TRUE,NA,NA,JL
10.3390/cancers12123648,33291810,results,1,NA,Primary outcome: unadjusted treatment effect,NA,NA,0.84,TRUE,NA,NA,JL
10.3390/cancers12123648,33291810,results,1,NA,"p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])",NA,NA,0.218,TRUE,NA,NA,JL
10.3390/cancers12123648,33291810,results,1,NA,Primary outcome: adjusted treatment effect,NA,NA,0.8,TRUE,NA,NA,JL
10.3390/cancers12123648,33291810,results,1,NA,"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])",NA,NA,0.152,TRUE,NA,NA,JL
10.3390/cancers13102406,34067521,general_information,NA,NA,Medical Condition of Interest Name,NA,NA,hepatocellular carcinoma,TRUE,NA,NA,JL
10.3390/cancers13102406,34067521,general_information,NA,NA,Countries of first author affiliations,NA,NA,italy,TRUE,NA,NA,JL
10.3390/cancers13102406,34067521,general_information,NA,NA,Countries of last author affiliations,NA,NA,italy,TRUE,NA,NA,JL
10.3390/cancers13102406,34067521,general_information,NA,NA,"Positions of study investigators (for any authors of the article, any that applies)",NA,NA,Academic,TRUE,NA,NA,JL
10.3390/cancers13102406,34067521,general_information,NA,NA,"At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company",NA,NA,Not mentioned,TRUE,NA,NA,JL
10.3390/cancers13102406,34067521,general_information,NA,NA,Mentioned sources of funding,None mentioned,This research received no external funding.,XXXX,FALSE,NA,NA,JL
10.3390/cancers13102406,34067521,general_information,NA,NA,"Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article",NA,NA,None,TRUE,NA,NA,JL
10.3390/cancers13102406,34067521,general_information,NA,NA,Mention of a systematic review to find the studies to compare treatments of interest,NA,NA,No,TRUE,NA,NA,JL
10.3390/cancers13102406,34067521,study_information,NA,1,Patient-level data used,NA,NA,Yes,TRUE,NA,NA,JL
10.3390/cancers13102406,34067521,study_information,NA,1,Clinical Trial,NA,NA,No,TRUE,NA,NA,JL
10.3390/cancers13102406,34067521,study_information,NA,1,Data source name (only if observational study or clinical trial without NCT),NA,NA,"retrospective cohort of patients affected by hcc who underwent surgical at the hepatobiliary surgery and liver transplantation unit, university of padua.",TRUE,NA,NA,JL
10.3390/cancers13102406,34067521,study_information,NA,1,Country where the clinical trial/observational study was conducted (international if more than one),NA,NA,italy,TRUE,NA,NA,JL
10.3390/cancers13102406,34067521,study_information,NA,2,Patient-level data used,NA,NA,No,TRUE,NA,NA,JL
10.3390/cancers13102406,34067521,study_information,NA,2,Clinical Trial,NA,NA,Yes,TRUE,NA,NA,JL
10.3390/cancers13102406,34067521,study_information,NA,2,NCT (only for clinical trial registered on clinicaltrials.gov),NA,NA,NCT01387503,TRUE,NA,NA,JL
10.3390/cancers13102406,34067521,study_information,NA,2,Country where the clinical trial/observational study was conducted (international if more than one),NA,NA,italy,TRUE,NA,NA,JL
10.3390/cancers13102406,34067521,study_information,NA,2,Phase of the clinical trial (clinical trial only),"2, 3",NA,XXXX,FALSE,NA,NA,JL
10.3390/cancers13102406,34067521,study_information,NA,2,Number of treatment arms (clinical trial only),NA,NA,2 or more,TRUE,NA,NA,JL
10.3390/cancers13102406,34067521,methodology,1,NA,Treatment name 1,padua surgical aggressive downstaging,padua downstaging protocol,padua surgical aggressive downstaging,FALSE,"Comparing hepatocellular carcinoma downstaging protocol before potential liver transplantation
Doesn't give a clear list of the variables adjusted on, could be guessed but sill with uncertainty
Doesn't give ESS
Compare rates, show the two different rates for the two studies, but doesn't give a rate difference or a rate ratio, and also don't give any pvalue, for adjusted or unadjusted. 
These peculiarities don't seem to be linked to the fact that the study compares protocols instead of treatments, relative outcomes differences/rates, and list of covariates adjusted for could have been produced anyway.","Les auteurs n'ont pas calculé de ""mesure statistique"" du ""downstaging failure"" :
Proportion de ""downstaging failure"" dans leur cohorte ajustée : 12%
Proportion de ""downstaging failure"" dans l'essai XXL  : 32%
effect size (d value) = |0.683|",JL
10.3390/cancers13102406,34067521,methodology,1,NA,Study 'number(s)' for treatment 1,NA,NA,1,TRUE,NA,NA,JL
10.3390/cancers13102406,34067521,methodology,1,NA,Treatment name 2,xxl protocol downstaging,xxl trial downstaging protocol,xxl protocol downstaging,FALSE,NA,NA,JL
10.3390/cancers13102406,34067521,methodology,1,NA,Study 'number(s)' for treatment 2,NA,NA,2,TRUE,NA,NA,JL
10.3390/cancers13102406,34067521,methodology,1,NA,Type of population-adjusted indirect comparisons performed,NA,NA,MAIC,TRUE,NA,NA,JL
10.3390/cancers13102406,34067521,methodology,1,NA,Anchored comparison?,NA,NA,No,TRUE,NA,NA,JL
10.3390/cancers13102406,34067521,methodology,1,NA,Form of the indirect comparison,NA,NA,Simple (ie treatments effects extracted from two studies),TRUE,NA,NA,JL
10.3390/cancers13102406,34067521,methodology,1,NA,Definition of a single primary outcome for the indirect comparison,NA,NA,Yes,TRUE,NA,NA,JL
10.3390/cancers13102406,34067521,methodology,1,NA,Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined),proportion of downstaging failure,downstaging failures,downstaging failures,FALSE,NA,NA,JL
10.3390/cancers13102406,34067521,methodology,1,NA,Primary outcome: variable type,NA,NA,Binary (eg rates),TRUE,NA,NA,JL
10.3390/cancers13102406,34067521,methodology,1,NA,Justification for selecting variables to be included in the adjustment model (in the main text),"Nothing mentioned, not reported
","Nothing mentioned, not reported","Nothing mentioned, not reported",FALSE,NA,NA,JL
10.3390/cancers13102406,34067521,methodology,1,NA,Inclusion of prognostic factors in the adjustment/matching model,NA,NA,No discussion (in the main text) of the status of prognostic factors of the variables,TRUE,NA,NA,JL
10.3390/cancers13102406,34067521,methodology,1,NA,Inclusion of treatment-effect modifiers in the adjustment/matching model,NA,NA,No discussion (in the main text) of the status of treatment-effect modifiers of the variables,TRUE,NA,NA,JL
10.3390/cancers13102406,34067521,methodology,1,NA,"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)",NA,NA,No,TRUE,NA,NA,JL
10.3390/cancers13102406,34067521,methodology,1,NA,Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale),NA,NA,No,TRUE,NA,NA,JL
10.3390/cancers13102406,34067521,results,1,NA,Sample size of the population of interest in the non IPD treatment arm,NA,NA,74,TRUE,NA,NA,JL
10.3390/cancers13102406,34067521,results,1,NA,Initial sample size of the population of interest in the IPD treatment arm,NA,NA,191,TRUE,NA,NA,JL
10.3390/cancers13102406,34067521,results,1,NA,Reporting of a weights' distribution evaluation (MAIC),NA,NA,Not mentioned,TRUE,NA,NA,JL
10.3390/cancers13102406,34067521,results,1,NA,Reporting of the list of the covariates adjusted for/matched on,NA,NA,No,TRUE,NA,NA,JL
10.3390/cancers13102406,34067521,results,1,NA,Primary outcome: treatment effect contrast,None,NA,None,FALSE,NA,NA,JL
10.2217/cer-2021-0216,35040693,general_information,NA,NA,Medical Condition of Interest Name,spinal muscular atrophy,ypes 1 spinal muscularatrophy,XXXX,FALSE,NA,NA,JL
10.2217/cer-2021-0216,35040693,general_information,NA,NA,Countries of first author affiliations,NA,NA,switzerland,TRUE,NA,NA,JL
10.2217/cer-2021-0216,35040693,general_information,NA,NA,Countries of last author affiliations,NA,NA,uk,TRUE,NA,NA,JL
10.2217/cer-2021-0216,35040693,general_information,NA,NA,"Positions of study investigators (for any authors of the article, any that applies)",NA,NA,"Pharmaceutical Industry, Private Data Analysis Company",TRUE,NA,NA,JL
10.2217/cer-2021-0216,35040693,general_information,NA,NA,"At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company",NA,NA,Yes,TRUE,NA,NA,JL
10.2217/cer-2021-0216,35040693,general_information,NA,NA,Mentioned sources of funding,NA,NA,Pharmaceutical Industry,TRUE,NA,NA,JL
10.2217/cer-2021-0216,35040693,general_information,NA,NA,"Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article",NA,NA,Yes,TRUE,NA,NA,JL
10.2217/cer-2021-0216,35040693,general_information,NA,NA,Mention of a systematic review to find the studies to compare treatments of interest,NA,NA,Yes,TRUE,NA,NA,JL
10.2217/cer-2021-0216,35040693,study_information,NA,1,Patient-level data used,NA,NA,Yes,TRUE,NA,NA,JL
10.2217/cer-2021-0216,35040693,study_information,NA,1,Clinical Trial,NA,NA,Yes,TRUE,NA,NA,JL
10.2217/cer-2021-0216,35040693,study_information,NA,1,NCT (only for clinical trial registered on clinicaltrials.gov),NA,NA,NCT02913482,TRUE,NA,NA,JL
10.2217/cer-2021-0216,35040693,study_information,NA,1,Country where the clinical trial/observational study was conducted (international if more than one),NA,NA,international,TRUE,NA,NA,JL
10.2217/cer-2021-0216,35040693,study_information,NA,1,Phase of the clinical trial (clinical trial only),NA,NA,"2, 3",TRUE,NA,NA,JL
10.2217/cer-2021-0216,35040693,study_information,NA,1,Number of treatment arms (clinical trial only),NA,NA,1,TRUE,NA,NA,JL
10.2217/cer-2021-0216,35040693,study_information,NA,2,Patient-level data used,NA,NA,Yes,TRUE,NA,NA,JL
10.2217/cer-2021-0216,35040693,study_information,NA,2,Clinical Trial,NA,NA,Yes,TRUE,NA,NA,JL
10.2217/cer-2021-0216,35040693,study_information,NA,2,NCT (only for clinical trial registered on clinicaltrials.gov),NA,NA,NCT02908685,TRUE,NA,NA,JL
10.2217/cer-2021-0216,35040693,study_information,NA,2,Country where the clinical trial/observational study was conducted (international if more than one),NA,NA,international,TRUE,NA,NA,JL
10.2217/cer-2021-0216,35040693,study_information,NA,2,Phase of the clinical trial (clinical trial only),NA,NA,"2, 3",TRUE,NA,NA,JL
10.2217/cer-2021-0216,35040693,study_information,NA,2,Number of treatment arms (clinical trial only),NA,NA,2 or more,TRUE,NA,NA,JL
10.2217/cer-2021-0216,35040693,study_information,NA,3,Patient-level data used,NA,NA,No,TRUE,NA,NA,JL
10.2217/cer-2021-0216,35040693,study_information,NA,3,Clinical Trial,NA,NA,Yes,TRUE,NA,NA,JL
10.2217/cer-2021-0216,35040693,study_information,NA,3,NCT (only for clinical trial registered on clinicaltrials.gov),NA,NA,NCT02193074,TRUE,NA,NA,JL
10.2217/cer-2021-0216,35040693,study_information,NA,3,Country where the clinical trial/observational study was conducted (international if more than one),NA,NA,international,TRUE,NA,NA,JL
10.2217/cer-2021-0216,35040693,study_information,NA,3,Phase of the clinical trial (clinical trial only),NA,NA,3,TRUE,NA,NA,JL
10.2217/cer-2021-0216,35040693,study_information,NA,3,Number of treatment arms (clinical trial only),NA,NA,2 or more,TRUE,NA,NA,JL
10.2217/cer-2021-0216,35040693,study_information,NA,4,Patient-level data used,NA,NA,No,TRUE,NA,NA,JL
10.2217/cer-2021-0216,35040693,study_information,NA,4,Clinical Trial,NA,NA,Yes,TRUE,NA,NA,JL
10.2217/cer-2021-0216,35040693,study_information,NA,4,NCT (only for clinical trial registered on clinicaltrials.gov),NA,NA,NCT02292537,TRUE,NA,NA,JL
10.2217/cer-2021-0216,35040693,study_information,NA,4,Country where the clinical trial/observational study was conducted (international if more than one),NA,NA,international,TRUE,NA,NA,JL
10.2217/cer-2021-0216,35040693,study_information,NA,4,Phase of the clinical trial (clinical trial only),NA,NA,3,TRUE,NA,NA,JL
10.2217/cer-2021-0216,35040693,study_information,NA,4,Number of treatment arms (clinical trial only),NA,NA,2 or more,TRUE,NA,NA,JL
10.2217/cer-2021-0216,35040693,study_information,NA,5,Patient-level data used,NA,NA,No,TRUE,NA,NA,JL
10.2217/cer-2021-0216,35040693,study_information,NA,5,Clinical Trial,NA,NA,Yes,TRUE,NA,NA,JL
10.2217/cer-2021-0216,35040693,study_information,NA,5,NCT (only for clinical trial registered on clinicaltrials.gov),NA,NA,NCT03306277,TRUE,NA,NA,JL
10.2217/cer-2021-0216,35040693,study_information,NA,5,Country where the clinical trial/observational study was conducted (international if more than one),usa,NA,XXXX,FALSE,NA,NA,JL
10.2217/cer-2021-0216,35040693,study_information,NA,5,Phase of the clinical trial (clinical trial only),NA,NA,3,TRUE,NA,NA,JL
10.2217/cer-2021-0216,35040693,study_information,NA,5,Number of treatment arms (clinical trial only),NA,NA,1,TRUE,NA,NA,JL
10.2217/cer-2021-0216,35040693,methodology,1,NA,Treatment name 1,NA,NA,risdiplam,TRUE,"Discuss the scale of the outcome **in the supplemental materials**
Exhaustive presentation of the methodology in supplemental materials
Separation of treatment effect modifiers and prognostic factors","MAIC

SMA1",JL
10.2217/cer-2021-0216,35040693,methodology,1,NA,Study 'number(s)' for treatment 1,NA,NA,1,TRUE,NA,NA,JL
10.2217/cer-2021-0216,35040693,methodology,1,NA,Treatment name 2,NA,NA,nusinersen,TRUE,NA,NA,JL
10.2217/cer-2021-0216,35040693,methodology,1,NA,Study 'number(s)' for treatment 2,NA,NA,3,TRUE,NA,NA,JL
10.2217/cer-2021-0216,35040693,methodology,1,NA,Type of population-adjusted indirect comparisons performed,NA,NA,MAIC,TRUE,NA,NA,JL
10.2217/cer-2021-0216,35040693,methodology,1,NA,Anchored comparison?,NA,NA,No,TRUE,NA,NA,JL
10.2217/cer-2021-0216,35040693,methodology,1,NA,Form of the indirect comparison,NA,NA,Simple (ie treatments effects extracted from two studies),TRUE,NA,NA,JL
10.2217/cer-2021-0216,35040693,methodology,1,NA,Definition of a single primary outcome for the indirect comparison,NA,NA,"No primary outcome defined, or multiple primary outcomes without any clear distinction between them",TRUE,NA,NA,JL
10.2217/cer-2021-0216,35040693,methodology,1,NA,Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined),event-free survival,event-free surviva,event-free survival,FALSE,NA,NA,JL
10.2217/cer-2021-0216,35040693,methodology,1,NA,Primary outcome: variable type,NA,NA,Time-to-event,TRUE,NA,NA,JL
10.2217/cer-2021-0216,35040693,methodology,1,NA,Justification for selecting variables to be included in the adjustment model (in the main text),NA,NA,"A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion), Literature based (clinically or methodologically relevant to adjust on these variables based on the literature search conducted for this specific purpose)",TRUE,NA,NA,JL
10.2217/cer-2021-0216,35040693,methodology,1,NA,Inclusion of prognostic factors in the adjustment/matching model,NA,NA,Yes,TRUE,NA,NA,JL
10.2217/cer-2021-0216,35040693,methodology,1,NA,Inclusion of treatment-effect modifiers in the adjustment/matching model,NA,NA,Yes,TRUE,NA,NA,JL
10.2217/cer-2021-0216,35040693,methodology,1,NA,"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)",No,Yes,Yes,FALSE,NA,NA,JL
10.2217/cer-2021-0216,35040693,methodology,1,NA,Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale),NA,NA,No,TRUE,NA,NA,JL
10.2217/cer-2021-0216,35040693,methodology,2,NA,Treatment name 1,NA,NA,risdiplam,TRUE,NA,"STC

SMA1",JL
10.2217/cer-2021-0216,35040693,methodology,2,NA,Study 'number(s)' for treatment 1,NA,NA,1,TRUE,NA,NA,JL
10.2217/cer-2021-0216,35040693,methodology,2,NA,Treatment name 2,onasemnogene abeparvovec,onasemnogeneabeparvovec,onasemnogene abeparvovec,FALSE,NA,NA,JL
10.2217/cer-2021-0216,35040693,methodology,2,NA,Study 'number(s)' for treatment 2,NA,NA,5,TRUE,NA,NA,JL
10.2217/cer-2021-0216,35040693,methodology,2,NA,Type of population-adjusted indirect comparisons performed,NA,NA,STC,TRUE,NA,NA,JL
10.2217/cer-2021-0216,35040693,methodology,2,NA,Anchored comparison?,NA,NA,No,TRUE,NA,NA,JL
10.2217/cer-2021-0216,35040693,methodology,2,NA,Form of the indirect comparison,NA,NA,Simple (ie treatments effects extracted from two studies),TRUE,NA,NA,JL
10.2217/cer-2021-0216,35040693,methodology,2,NA,Definition of a single primary outcome for the indirect comparison,NA,NA,"No primary outcome defined, or multiple primary outcomes without any clear distinction between them",TRUE,NA,NA,JL
10.2217/cer-2021-0216,35040693,methodology,2,NA,Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined),NA,NA,event-free survival,TRUE,NA,NA,JL
10.2217/cer-2021-0216,35040693,methodology,2,NA,Primary outcome: variable type,NA,NA,Time-to-event,TRUE,NA,NA,JL
10.2217/cer-2021-0216,35040693,methodology,2,NA,Justification for selecting variables to be included in the adjustment model (in the main text),NA,NA,"A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion), Literature based (clinically or methodologically relevant to adjust on these variables based on the literature search conducted for this specific purpose)",TRUE,NA,NA,JL
10.2217/cer-2021-0216,35040693,methodology,2,NA,Inclusion of prognostic factors in the adjustment/matching model,NA,NA,Yes,TRUE,NA,NA,JL
10.2217/cer-2021-0216,35040693,methodology,2,NA,Inclusion of treatment-effect modifiers in the adjustment/matching model,No,Yes,Yes,FALSE,NA,NA,JL
10.2217/cer-2021-0216,35040693,methodology,2,NA,"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)",NA,NA,No,TRUE,NA,NA,JL
10.2217/cer-2021-0216,35040693,methodology,2,NA,Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale),NA,NA,No,TRUE,NA,NA,JL
10.2217/cer-2021-0216,35040693,methodology,3,NA,Treatment name 1,NA,NA,risdiplam,TRUE,"Mentions that the matching was not successful, so limited interpreation for the results of this MAIC
","MAIC

SMA2/3",JL
10.2217/cer-2021-0216,35040693,methodology,3,NA,Study 'number(s)' for treatment 1,NA,NA,2,TRUE,NA,NA,JL
10.2217/cer-2021-0216,35040693,methodology,3,NA,Treatment name 2,NA,NA,nusinersen,TRUE,NA,NA,JL
10.2217/cer-2021-0216,35040693,methodology,3,NA,Study 'number(s)' for treatment 2,NA,NA,4,TRUE,NA,NA,JL
10.2217/cer-2021-0216,35040693,methodology,3,NA,Type of population-adjusted indirect comparisons performed,NA,NA,MAIC,TRUE,NA,NA,JL
10.2217/cer-2021-0216,35040693,methodology,3,NA,Anchored comparison?,NA,NA,Yes,TRUE,NA,NA,JL
10.2217/cer-2021-0216,35040693,methodology,3,NA,Form of the indirect comparison,NA,NA,Simple (ie treatments effects extracted from two studies),TRUE,NA,NA,JL
10.2217/cer-2021-0216,35040693,methodology,3,NA,Definition of a single primary outcome for the indirect comparison,NA,NA,"No primary outcome defined, or multiple primary outcomes without any clear distinction between them",TRUE,NA,NA,JL
10.2217/cer-2021-0216,35040693,methodology,3,NA,Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined),rulm change from baseline,the 12-month rulm (revised upper limb module) score change from baseline,the 12-month rulm (revised upper limb module) score change from baseline,FALSE,NA,NA,JL
10.2217/cer-2021-0216,35040693,methodology,3,NA,Primary outcome: variable type,NA,NA,"Continuous (count, mean, ...)",TRUE,NA,NA,JL
10.2217/cer-2021-0216,35040693,methodology,3,NA,Justification for selecting variables to be included in the adjustment model (in the main text),NA,NA,"A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion), Literature based (clinically or methodologically relevant to adjust on these variables based on the literature search conducted for this specific purpose)",TRUE,NA,NA,JL
10.2217/cer-2021-0216,35040693,methodology,3,NA,Inclusion of prognostic factors in the adjustment/matching model,NA,NA,Yes,TRUE,NA,NA,JL
10.2217/cer-2021-0216,35040693,methodology,3,NA,Inclusion of treatment-effect modifiers in the adjustment/matching model,NA,NA,Yes,TRUE,NA,NA,JL
10.2217/cer-2021-0216,35040693,methodology,3,NA,"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)",No,Yes,Yes,FALSE,NA,NA,JL
10.2217/cer-2021-0216,35040693,methodology,3,NA,Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale),NA,NA,No,TRUE,NA,NA,JL
10.2217/cer-2021-0216,35040693,results,1,NA,Sample size of the population of interest in the non IPD treatment arm,NA,NA,121,TRUE,NA,NA,JL
10.2217/cer-2021-0216,35040693,results,1,NA,Initial sample size of the population of interest in the IPD treatment arm,NA,NA,58,TRUE,NA,NA,JL
10.2217/cer-2021-0216,35040693,results,1,NA,"Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC",NA,NA,36.5,TRUE,NA,NA,JL
10.2217/cer-2021-0216,35040693,results,1,NA,Reporting of a weights' distribution evaluation (MAIC),NA,NA,"Yes, mentions that the weights distribution has been studied, and weights distribution reported in main article or supplemental materials",TRUE,NA,NA,JL
10.2217/cer-2021-0216,35040693,results,1,NA,Reporting of the list of the covariates adjusted for/matched on,NA,NA,Yes,TRUE,NA,NA,JL
10.2217/cer-2021-0216,35040693,results,1,NA,Number of covariates adjusted for/matched on,NA,NA,3,TRUE,NA,NA,JL
10.2217/cer-2021-0216,35040693,results,1,NA,Covariates adjusted for/matched on in the indirect comparison,NA,NA,"Age, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease)",TRUE,NA,NA,JL
10.2217/cer-2021-0216,35040693,results,1,NA,Primary outcome: treatment effect contrast,NA,NA,HR,TRUE,NA,NA,JL
10.2217/cer-2021-0216,35040693,results,1,NA,Direction of the treatment effect contrast: IPD treatment is:,NA,NA,"Numerator if ratio, or left side if difference",TRUE,NA,NA,JL
10.2217/cer-2021-0216,35040693,results,1,NA,Primary outcome: unadjusted treatment effect,NA,NA,0.24,TRUE,NA,NA,JL
10.2217/cer-2021-0216,35040693,results,1,NA,"p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])",NA,NA,[0.09;0.46],TRUE,NA,NA,JL
10.2217/cer-2021-0216,35040693,results,1,NA,Primary outcome: adjusted treatment effect,NA,NA,0.2,TRUE,NA,NA,JL
10.2217/cer-2021-0216,35040693,results,1,NA,"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])",NA,NA,[0.06;0.42],TRUE,NA,NA,JL
10.2217/cer-2021-0216,35040693,results,2,NA,Sample size of the population of interest in the non IPD treatment arm,NA,NA,22,TRUE,NA,NA,JL
10.2217/cer-2021-0216,35040693,results,2,NA,Initial sample size of the population of interest in the IPD treatment arm,NA,NA,58,TRUE,NA,NA,JL
10.2217/cer-2021-0216,35040693,results,2,NA,"Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC",NA,NA,58,TRUE,NA,NA,JL
10.2217/cer-2021-0216,35040693,results,2,NA,Reporting of the list of the covariates adjusted for/matched on,NA,NA,Yes,TRUE,NA,NA,JL
10.2217/cer-2021-0216,35040693,results,2,NA,Number of covariates adjusted for/matched on,NA,NA,2,TRUE,NA,NA,JL
10.2217/cer-2021-0216,35040693,results,2,NA,Covariates adjusted for/matched on in the indirect comparison,NA,NA,"Age, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease)",TRUE,NA,NA,JL
10.2217/cer-2021-0216,35040693,results,2,NA,Primary outcome: treatment effect contrast,NA,NA,HR,TRUE,NA,NA,JL
10.2217/cer-2021-0216,35040693,results,2,NA,Direction of the treatment effect contrast: IPD treatment is:,NA,NA,"Numerator if ratio, or left side if difference",TRUE,NA,NA,JL
10.2217/cer-2021-0216,35040693,results,2,NA,Primary outcome: unadjusted treatment effect,1.532,1.53,1.532,FALSE,NA,NA,JL
10.2217/cer-2021-0216,35040693,results,2,NA,"p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])",NA,NA,[0.721;2.665],TRUE,NA,NA,JL
10.2217/cer-2021-0216,35040693,results,2,NA,Primary outcome: adjusted treatment effect,0.936,0.94,0.936,FALSE,NA,NA,JL
10.2217/cer-2021-0216,35040693,results,2,NA,"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])",[0.033;4.064],[0.03;4.06],[0.033;4.064],FALSE,NA,NA,JL
10.2217/cer-2021-0216,35040693,results,3,NA,Sample size of the population of interest in the non IPD treatment arm,126,84,126,FALSE,NA,NA,JL
10.2217/cer-2021-0216,35040693,results,3,NA,"If anchored comparison, sample size of the population of interest in the non IPD treatment anchor arm",126,42,126,FALSE,NA,NA,JL
10.2217/cer-2021-0216,35040693,results,3,NA,Initial sample size of the population of interest in the IPD treatment arm,NA,NA,43,TRUE,NA,NA,JL
10.2217/cer-2021-0216,35040693,results,3,NA,"Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC",NA,NA,28.3,TRUE,NA,NA,JL
10.2217/cer-2021-0216,35040693,results,3,NA,"If anchored comparison, initial sample size of the population of interest in the IPD anchor arm",NA,NA,25,TRUE,NA,NA,JL
10.2217/cer-2021-0216,35040693,results,3,NA,"If anchored comparison, effective sample size after reweighting for MAIC; or sample size used in the regression model for STC in the IPD anchor arm",NA,NA,8.8,TRUE,NA,NA,JL
10.2217/cer-2021-0216,35040693,results,3,NA,Reporting of a weights' distribution evaluation (MAIC),NA,NA,"Yes, mentions that the weights distribution has been studied, and weights distribution reported in main article or supplemental materials",TRUE,NA,NA,JL
10.2217/cer-2021-0216,35040693,results,3,NA,Reporting of the list of the covariates adjusted for/matched on,NA,NA,Yes,TRUE,NA,NA,JL
10.2217/cer-2021-0216,35040693,results,3,NA,Number of covariates adjusted for/matched on,NA,NA,3,TRUE,NA,NA,JL
10.2217/cer-2021-0216,35040693,results,3,NA,Covariates adjusted for/matched on in the indirect comparison,NA,NA,"Age, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease)",TRUE,NA,NA,JL
10.2217/cer-2021-0216,35040693,results,3,NA,Primary outcome: treatment effect contrast,NA,NA,Means difference,TRUE,NA,NA,JL
10.2217/cer-2021-0216,35040693,results,3,NA,Direction of the treatment effect contrast: IPD treatment is:,NA,NA,"Numerator if ratio, or left side if difference",TRUE,NA,NA,JL
10.2217/cer-2021-0216,35040693,results,3,NA,Primary outcome: unadjusted treatment effect,NA,NA,-0.6,TRUE,NA,NA,JL
10.2217/cer-2021-0216,35040693,results,3,NA,"p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])",NA,NA,[-2.24;1.22],TRUE,NA,NA,JL
10.2217/cer-2021-0216,35040693,results,3,NA,Primary outcome: adjusted treatment effect,NA,NA,-0.49,TRUE,NA,NA,JL
10.2217/cer-2021-0216,35040693,results,3,NA,"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])",NA,NA,[-3.33;2.53],TRUE,NA,NA,JL
10.2217/cer-2021-0178,35068168,general_information,NA,NA,Medical Condition of Interest Name,parkinson's disease,parkinson’s disease ‘off’episodes,XXXX,FALSE,NA,NA,JL
10.2217/cer-2021-0178,35068168,general_information,NA,NA,Countries of first author affiliations,NA,NA,usa,TRUE,NA,NA,JL
10.2217/cer-2021-0178,35068168,general_information,NA,NA,Countries of last author affiliations,NA,NA,usa,TRUE,NA,NA,JL
10.2217/cer-2021-0178,35068168,general_information,NA,NA,"Positions of study investigators (for any authors of the article, any that applies)",NA,NA,"Pharmaceutical Industry, Private Data Analysis Company",TRUE,NA,NA,JL
10.2217/cer-2021-0178,35068168,general_information,NA,NA,"At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company",NA,NA,Yes,TRUE,NA,NA,JL
10.2217/cer-2021-0178,35068168,general_information,NA,NA,Mentioned sources of funding,NA,NA,Pharmaceutical Industry,TRUE,NA,NA,JL
10.2217/cer-2021-0178,35068168,general_information,NA,NA,"Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article",NA,NA,Yes,TRUE,NA,NA,JL
10.2217/cer-2021-0178,35068168,general_information,NA,NA,Mention of a systematic review to find the studies to compare treatments of interest,NA,NA,Yes,TRUE,NA,NA,JL
10.2217/cer-2021-0178,35068168,study_information,NA,1,Patient-level data used,NA,NA,Yes,TRUE,NA,NA,JL
10.2217/cer-2021-0178,35068168,study_information,NA,1,Clinical Trial,NA,NA,Yes,TRUE,NA,NA,JL
10.2217/cer-2021-0178,35068168,study_information,NA,1,NCT (only for clinical trial registered on clinicaltrials.gov),NA,NA,NCT02469090,TRUE,NA,NA,JL
10.2217/cer-2021-0178,35068168,study_information,NA,1,Country where the clinical trial/observational study was conducted (international if more than one),NA,NA,international,TRUE,NA,NA,JL
10.2217/cer-2021-0178,35068168,study_information,NA,1,Phase of the clinical trial (clinical trial only),NA,NA,3,TRUE,NA,NA,JL
10.2217/cer-2021-0178,35068168,study_information,NA,1,Number of treatment arms (clinical trial only),NA,NA,2 or more,TRUE,NA,NA,JL
10.2217/cer-2021-0178,35068168,study_information,NA,2,Patient-level data used,NA,NA,No,TRUE,NA,NA,JL
10.2217/cer-2021-0178,35068168,study_information,NA,2,Clinical Trial,NA,NA,Yes,TRUE,NA,NA,JL
10.2217/cer-2021-0178,35068168,study_information,NA,2,Country where the clinical trial/observational study was conducted (international if more than one),NA,NA,international,TRUE,NA,NA,JL
10.2217/cer-2021-0178,35068168,study_information,NA,2,Phase of the clinical trial (clinical trial only),NA,NA,3,TRUE,NA,NA,JL
10.2217/cer-2021-0178,35068168,study_information,NA,2,Number of treatment arms (clinical trial only),NA,NA,2 or more,TRUE,NA,NA,JL
10.2217/cer-2021-0178,35068168,study_information,NA,2,NCT (only for clinical trial registered on clinicaltrials.gov),NA,NCT02240030,NCT02240030,FALSE,NA,NA,JL
10.2217/cer-2021-0178,35068168,methodology,1,NA,Treatment name 1,NA,NA,apomorphine sublingual film,TRUE,"Very little discussion of the status of treatment effect modifiers in the main text, or of prognostic variables. Clearly includes variables that are neither one nor the other.",J'ai rempli la partie résultats avec les différences du score à 15/20 min vu que c'est le premier donné dans le tableau.,JL
10.2217/cer-2021-0178,35068168,methodology,1,NA,Study 'number(s)' for treatment 1,NA,NA,1,TRUE,NA,NA,JL
10.2217/cer-2021-0178,35068168,methodology,1,NA,Treatment name 2,NA,NA,levodopa inhalation powder,TRUE,NA,NA,JL
10.2217/cer-2021-0178,35068168,methodology,1,NA,Study 'number(s)' for treatment 2,NA,NA,2,TRUE,NA,NA,JL
10.2217/cer-2021-0178,35068168,methodology,1,NA,Type of population-adjusted indirect comparisons performed,NA,NA,MAIC,TRUE,NA,NA,JL
10.2217/cer-2021-0178,35068168,methodology,1,NA,Anchored comparison?,NA,NA,Yes,TRUE,NA,NA,JL
10.2217/cer-2021-0178,35068168,methodology,1,NA,Form of the indirect comparison,NA,NA,Simple (ie treatments effects extracted from two studies),TRUE,NA,NA,JL
10.2217/cer-2021-0178,35068168,methodology,1,NA,Definition of a single primary outcome for the indirect comparison,"No primary outcome defined, or multiple primary outcomes without any clear distinction between them",Yes,Yes,FALSE,NA,NA,JL
10.2217/cer-2021-0178,35068168,methodology,1,NA,Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined),change in updrs part iii score from predose to postdose,"the mean change in the updrs part iii score at week 12 from predose to the following timepoints postdose: 15 (apomorphine sublingual film) or 20 (levodopa),30 and 60 min.","the mean change in the updrs part iii score at week 12 from predose to the following timepoints postdose: 15 (apomorphine sublingual film) or 20 (levodopa),30 and 60 min.",FALSE,NA,NA,JL
10.2217/cer-2021-0178,35068168,methodology,1,NA,Primary outcome: variable type,NA,NA,"Continuous (count, mean, ...)",TRUE,NA,NA,JL
10.2217/cer-2021-0178,35068168,methodology,1,NA,Justification for selecting variables to be included in the adjustment model (in the main text),NA,NA,"Statistical imbalanced between treatment groups (independently of the status of prognostic/effect modifier), A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion)",TRUE,NA,NA,JL
10.2217/cer-2021-0178,35068168,methodology,1,NA,Inclusion of prognostic factors in the adjustment/matching model,No discussion (in the main text) of the status of prognostic factors of the variables,No,No discussion (in the main text) of the status of prognostic factors of the variables,FALSE,NA,NA,JL
10.2217/cer-2021-0178,35068168,methodology,1,NA,Inclusion of treatment-effect modifiers in the adjustment/matching model,NA,NA,Yes,TRUE,NA,NA,JL
10.2217/cer-2021-0178,35068168,methodology,1,NA,"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)",NA,NA,No,TRUE,NA,NA,JL
10.2217/cer-2021-0178,35068168,methodology,1,NA,Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale),NA,NA,No,TRUE,NA,NA,JL
10.2217/cer-2021-0178,35068168,results,1,NA,Sample size of the population of interest in the non IPD treatment arm,NA,NA,114,TRUE,NA,NA,JL
10.2217/cer-2021-0178,35068168,results,1,NA,"If anchored comparison, sample size of the population of interest in the non IPD treatment anchor arm",NA,NA,112,TRUE,NA,NA,JL
10.2217/cer-2021-0178,35068168,results,1,NA,Initial sample size of the population of interest in the IPD treatment arm,NA,NA,44,TRUE,NA,NA,JL
10.2217/cer-2021-0178,35068168,results,1,NA,Reporting of a weights' distribution evaluation (MAIC),NA,NA,Not mentioned,TRUE,NA,NA,JL
10.2217/cer-2021-0178,35068168,results,1,NA,Reporting of the list of the covariates adjusted for/matched on,NA,NA,Yes,TRUE,NA,NA,JL
10.2217/cer-2021-0178,35068168,results,1,NA,Number of covariates adjusted for/matched on,NA,NA,4,TRUE,NA,NA,JL
10.2217/cer-2021-0178,35068168,results,1,NA,Covariates adjusted for/matched on in the indirect comparison,NA,NA,"Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease)",TRUE,NA,NA,JL
10.2217/cer-2021-0178,35068168,results,1,NA,Primary outcome: treatment effect contrast,NA,NA,Means difference,TRUE,NA,NA,JL
10.2217/cer-2021-0178,35068168,results,1,NA,Direction of the treatment effect contrast: IPD treatment is:,NA,NA,"Numerator if ratio, or left side if difference",TRUE,NA,NA,JL
10.2217/cer-2021-0178,35068168,results,1,NA,Primary outcome: unadjusted treatment effect,NA,NA,0.57,TRUE,NA,NA,JL
10.2217/cer-2021-0178,35068168,results,1,NA,"p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])",NA,NA,0.818,TRUE,NA,NA,JL
10.2217/cer-2021-0178,35068168,results,1,NA,Primary outcome: adjusted treatment effect,NA,NA,0.15,TRUE,NA,NA,JL
10.2217/cer-2021-0178,35068168,results,1,NA,"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])",NA,NA,0.953,TRUE,NA,NA,JL
10.2217/cer-2021-0178,35068168,results,1,NA,"If anchored comparison, initial sample size of the population of interest in the IPD anchor arm",NA,37,37,FALSE,NA,NA,JL
10.2217/fon-2021-1509,35114819,general_information,NA,NA,Medical Condition of Interest Name,NA,NA,advanced systemic mastocytosis,TRUE,NA,NA,JL
10.2217/fon-2021-1509,35114819,general_information,NA,NA,Countries of first author affiliations,NA,NA,uk,TRUE,NA,NA,JL
10.2217/fon-2021-1509,35114819,general_information,NA,NA,Countries of last author affiliations,NA,NA,switzerland,TRUE,NA,NA,JL
10.2217/fon-2021-1509,35114819,general_information,NA,NA,"Positions of study investigators (for any authors of the article, any that applies)",NA,NA,"Pharmaceutical Industry, Private Data Analysis Company",TRUE,NA,NA,JL
10.2217/fon-2021-1509,35114819,general_information,NA,NA,"At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company",NA,NA,Yes,TRUE,NA,NA,JL
10.2217/fon-2021-1509,35114819,general_information,NA,NA,Mentioned sources of funding,NA,NA,Pharmaceutical Industry,TRUE,NA,NA,JL
10.2217/fon-2021-1509,35114819,general_information,NA,NA,"Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article",NA,NA,Yes,TRUE,NA,NA,JL
10.2217/fon-2021-1509,35114819,general_information,NA,NA,Mention of a systematic review to find the studies to compare treatments of interest,NA,NA,Yes,TRUE,NA,NA,JL
10.2217/fon-2021-1509,35114819,study_information,NA,1,Patient-level data used,NA,NA,Yes,TRUE,NA,NA,JL
10.2217/fon-2021-1509,35114819,study_information,NA,1,Clinical Trial,NA,NA,Yes,TRUE,NA,NA,JL
10.2217/fon-2021-1509,35114819,study_information,NA,1,NCT (only for clinical trial registered on clinicaltrials.gov),NA,NA,NCT02561988,TRUE,NA,NA,JL
10.2217/fon-2021-1509,35114819,study_information,NA,1,Country where the clinical trial/observational study was conducted (international if more than one),international,usa,XXXX,FALSE,NA,NA,JL
10.2217/fon-2021-1509,35114819,study_information,NA,1,Phase of the clinical trial (clinical trial only),NA,NA,1,TRUE,NA,NA,JL
10.2217/fon-2021-1509,35114819,study_information,NA,1,Number of treatment arms (clinical trial only),NA,NA,1,TRUE,NA,NA,JL
10.2217/fon-2021-1509,35114819,study_information,NA,2,Patient-level data used,NA,NA,Yes,TRUE,NA,NA,JL
10.2217/fon-2021-1509,35114819,study_information,NA,2,Clinical Trial,NA,NA,Yes,TRUE,NA,NA,JL
10.2217/fon-2021-1509,35114819,study_information,NA,2,NCT (only for clinical trial registered on clinicaltrials.gov),NA,NA,NCT03580655,TRUE,NA,NA,JL
10.2217/fon-2021-1509,35114819,study_information,NA,2,Country where the clinical trial/observational study was conducted (international if more than one),NA,NA,international,TRUE,NA,NA,JL
10.2217/fon-2021-1509,35114819,study_information,NA,2,Phase of the clinical trial (clinical trial only),NA,NA,2,TRUE,NA,NA,JL
10.2217/fon-2021-1509,35114819,study_information,NA,2,Number of treatment arms (clinical trial only),NA,NA,1,TRUE,NA,NA,JL
10.2217/fon-2021-1509,35114819,study_information,NA,3,Patient-level data used,NA,NA,No,TRUE,NA,NA,JL
10.2217/fon-2021-1509,35114819,study_information,NA,3,Clinical Trial,NA,NA,Yes,TRUE,NA,NA,JL
10.2217/fon-2021-1509,35114819,study_information,NA,3,NCT (only for clinical trial registered on clinicaltrials.gov),NA,NA,NCT00782067,TRUE,NA,NA,JL
10.2217/fon-2021-1509,35114819,study_information,NA,3,Country where the clinical trial/observational study was conducted (international if more than one),NA,NA,international,TRUE,NA,NA,JL
10.2217/fon-2021-1509,35114819,study_information,NA,3,Phase of the clinical trial (clinical trial only),NA,NA,2,TRUE,NA,NA,JL
10.2217/fon-2021-1509,35114819,study_information,NA,3,Number of treatment arms (clinical trial only),NA,NA,1,TRUE,NA,NA,JL
10.2217/fon-2021-1509,35114819,study_information,NA,4,Patient-level data used,NA,NA,No,TRUE,NA,NA,JL
10.2217/fon-2021-1509,35114819,study_information,NA,4,Clinical Trial,NA,NA,Yes,TRUE,NA,NA,JL
10.2217/fon-2021-1509,35114819,study_information,NA,4,NCT (only for clinical trial registered on clinicaltrials.gov),NA,NA,NCT00233454,TRUE,NA,NA,JL
10.2217/fon-2021-1509,35114819,study_information,NA,4,Country where the clinical trial/observational study was conducted (international if more than one),NA,NA,usa,TRUE,NA,NA,JL
10.2217/fon-2021-1509,35114819,study_information,NA,4,Phase of the clinical trial (clinical trial only),NA,NA,2,TRUE,NA,NA,JL
10.2217/fon-2021-1509,35114819,study_information,NA,4,Number of treatment arms (clinical trial only),NA,NA,1,TRUE,NA,NA,JL
10.2217/fon-2021-1509,35114819,methodology,1,NA,Treatment name 1,NA,NA,avapritinib,TRUE,Effective sample size only available in supplementary materials,"ESS and list of covariates ==> supplementary materials, but I have no access.

""Moreover, because the trials are single-arm trials, it was not possible to identify treatment effect modifiers, as relative treatment effects cannot be evaluated within trial for avapritinib or midostaurin.""  ==> effect-modifiers = No",JL
10.2217/fon-2021-1509,35114819,methodology,1,NA,Study 'number(s)' for treatment 1,NA,NA,1;2,TRUE,NA,NA,JL
10.2217/fon-2021-1509,35114819,methodology,1,NA,Treatment name 2,NA,NA,midostaurin,TRUE,NA,NA,JL
10.2217/fon-2021-1509,35114819,methodology,1,NA,Study 'number(s)' for treatment 2,NA,NA,3;4,TRUE,NA,NA,JL
10.2217/fon-2021-1509,35114819,methodology,1,NA,Type of population-adjusted indirect comparisons performed,NA,NA,MAIC,TRUE,NA,NA,JL
10.2217/fon-2021-1509,35114819,methodology,1,NA,Anchored comparison?,NA,NA,No,TRUE,NA,NA,JL
10.2217/fon-2021-1509,35114819,methodology,1,NA,Form of the indirect comparison,Simple (ie treatments effects extracted from two studies),"Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate)","Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate)",FALSE,NA,NA,JL
10.2217/fon-2021-1509,35114819,methodology,1,NA,Definition of a single primary outcome for the indirect comparison,"No primary outcome defined, or multiple primary outcomes without any clear distinction between them",Yes,Yes,FALSE,NA,NA,JL
10.2217/fon-2021-1509,35114819,methodology,1,NA,Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined),NA,NA,overall survival,TRUE,NA,NA,JL
10.2217/fon-2021-1509,35114819,methodology,1,NA,Primary outcome: variable type,NA,NA,Time-to-event,TRUE,NA,NA,JL
10.2217/fon-2021-1509,35114819,methodology,1,NA,Justification for selecting variables to be included in the adjustment model (in the main text),NA,NA,Status of prognostic factor/treatment effect modified assessed in the IPD dataset,TRUE,NA,NA,JL
10.2217/fon-2021-1509,35114819,methodology,1,NA,Inclusion of prognostic factors in the adjustment/matching model,NA,NA,Yes,TRUE,NA,NA,JL
10.2217/fon-2021-1509,35114819,methodology,1,NA,Inclusion of treatment-effect modifiers in the adjustment/matching model,No discussion (in the main text) of the status of treatment-effect modifiers of the variables,No,No discussion (in the main text) of the status of treatment-effect modifiers of the variables,FALSE,NA,NA,JL
10.2217/fon-2021-1509,35114819,methodology,1,NA,"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)",NA,NA,No,TRUE,NA,NA,JL
10.2217/fon-2021-1509,35114819,methodology,1,NA,Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale),NA,NA,No,TRUE,NA,NA,JL
10.2217/fon-2021-1509,35114819,results,1,NA,Sample size of the population of interest in the non IPD treatment arm,NA,NA,115,TRUE,NA,NA,JL
10.2217/fon-2021-1509,35114819,results,1,NA,Initial sample size of the population of interest in the IPD treatment arm,NA,NA,85,TRUE,NA,NA,JL
10.2217/fon-2021-1509,35114819,results,1,NA,Reporting of a weights' distribution evaluation (MAIC),NA,NA,Not mentioned,TRUE,NA,NA,JL
10.2217/fon-2021-1509,35114819,results,1,NA,Reporting of the list of the covariates adjusted for/matched on,Yes,No,Yes,FALSE,NA,NA,JL
10.2217/fon-2021-1509,35114819,results,1,NA,Primary outcome: treatment effect contrast,NA,NA,HR,TRUE,NA,NA,JL
10.2217/fon-2021-1509,35114819,results,1,NA,Direction of the treatment effect contrast: IPD treatment is:,NA,NA,"Numerator if ratio, or left side if difference",TRUE,NA,NA,JL
10.2217/fon-2021-1509,35114819,results,1,NA,Primary outcome: unadjusted treatment effect,NA,NA,0.54,TRUE,NA,NA,JL
10.2217/fon-2021-1509,35114819,results,1,NA,"p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])",NA,NA,[0.32;0.92],TRUE,NA,NA,JL
10.2217/fon-2021-1509,35114819,results,1,NA,Primary outcome: adjusted treatment effect,NA,NA,0.44,TRUE,NA,NA,JL
10.2217/fon-2021-1509,35114819,results,1,NA,"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])",NA,NA,[0.25;0.76],TRUE,NA,NA,JL
10.2217/fon-2021-1509,35114819,results,1,NA,Number of covariates adjusted for/matched on,3,NA,3,FALSE,NA,NA,JL
10.2217/fon-2021-1509,35114819,results,1,NA,Covariates adjusted for/matched on in the indirect comparison,"Age, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Race/ethnicity",NA,"Age, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Race/ethnicity",FALSE,NA,NA,JL
